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Foreword
The National Institute on Drug Abuse (NIDA) is pleased to publish in
its Research Monograph series the proceedings of the 48th Annual
Scientific Meeting of the Committee on Problems of Drug Dependence,
Inc. (CPDD). This meeting was held at Tahoe City, Nevada, in June
1986. The scientific community working in the drug abuse area was
saddened by the untimely death of one of its very productive and
active leaders: Joseph Cochin, M.D., Ph.D. Joe was a talented
scientist who was greatly admired by his students and colleagues.
For the past five years, Joe had served as the Executive Secretary
of the CPDD. This monograph includes papers from a symposium on
"Mechanisms of Opioid Tolerance and Dependence," dedicated to his
memory. These papers were presented by many of his friends and
colleagues, who took the opportunity to express their high esteem
for Joe.
The CPDD is an independent organization of internationally
recognized experts in a variety of disciplines related to drug
addiction. NIDA and the CPDD share many interests and concerns in
developing knowledge that will reduce the destructive effects of
abused drugs on the individual and society. The CPDD is unique in
bringing together annually at a single scientific meeting an
outstanding group of basic and clinical investigators working in the
field of drug dependence. This year, as usual, the monograph
presents an excellent collection of papers. It also contains
progress reports of the abuse liability testing program funded by
NIDA and carried out in conjunction with the CPDD. This program
continues to represent an example of a highly successful
government/private sector cooperative effort.
I am sure that members of the scientific community and other
interested readers will find this volume to be a valuable
"state-of-the art" summary of the latest research into the
biological, behavioral, and chemical bases of drug abuse.
Charles R. Schuster, Ph.D.
Director
National Institute on Drug Abuse
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In Memoriam: Joseph Cochin, M.D., Ph.D.
1916-1985
This volume is dedicated to the memory of Dr. Joseph Cochin,
whose death on October 19, 1985, saddened us all. Dr. Cochin
had a long and distinguished career as a research scientist and
teacher. His service to the Committee on Problems of Drug
Dependence as a member and for the past five years as Executive
Secretary was characterized by his patience and dedication. He
is survived by his wife, Renee, and three sons, Joshua, Joel and
Jesse.
His friends, colleagues, and family mourn the passing of this
distinguished scholar and gentle man. We will all miss him.
1
Presentation of
J. Michael Morrison Award
2
William L. Dewey
Ladies and gentlemen, I am pleased and honored to have the
opportunity to present the J. Michael Morrison Award for 1986.
Mike Morrison was a fine young man who worked diligently in
science administration to the benefit of science and therefore,
all of society. These qualities characterize this year's
awardee, Dr. Edward C. Tocus. He earned his master's and Ph.D.
degrees in Pharmacology at the University of Chicago. He worked
at Lederle Laboratories for the first six years of his profes-
sional career. The majority of his time at Lederle was spent in
endocrine research, but he also spent some time in toxicology.
He has been in the Division of Neuropharmacological Drug
Products at FDA since 1966. During that time, 50 different drug
scheduling actions have gone through his office. These drug
scheduling actions have been concerned with amphetamines,
rescheduling barbiturates, scheduling of benzodiazepines, PCP
and its analogs, cannabinoids and the narcotic agonist-antago-
nist, as well as many opiates. Equally important, during this
time significant drugs have been evaluated which have been
approved for the treatment of addiction. These include metha-
done and naltrexone. Other drugs with potential abuse potential
which have been approved during his tenure include the agonist-
antagonist analgesics, Nicorette, Delta-9-THC and Cismet for the
treatment of nausea and vomiting associated with cancer chemo-
therapy.
Ed Tocus has also contributed to issues important to the
Committee on Problems of Drug Dependence by serving on a number
of government committees and study groups. He served for a
number of years on the interagency committee on pain and discom-
fort. He worked with the SAODAP office in setting policy for
the treatment of narcotic-dependent patients. Throughout his
career he has served as a consultant to the World Health
Organization and the Pan-American Health Organization on matters
dealing with drug abuse treatment and control. He has served as
an advisor to Congressional committees and to various state drug
abuse authorities. His administrative expertise and his knowl-
edge of drug abuse related issues have been recognized by the
FDA by being chosen as their representative in the area of drug
abuse at meetings of the American Medical Association, Drug
Enforcement Agency, National Institute on Drug Abuse, as well as
nongovernmental scientific societies such as ACNP and CPDD. Dr.
Tocus was honored by the FDA in 1981 when he was presented with
their commendable service award for his contributions to the
therapeutic treatment of dependency disorders and to the sche-
duling of abused drugs.
One of the most important aspects of the contributions of Ed
Tocus is the manner in which he has carried out his duties. He
has a judicious and fair way of protecting the subjects but yet
allowing the evaluation of drugs to proceed.
Ed and his wife, Nora, who is earning her Ph.D. in psychology at
this time, have two grown sons.
It is a pleasure for me to present this award to Dr. Tocus. The
plaque is inscribed as follows:
In recognition of Outstanding Contributions in Science Admini-
stration, The J. Michael Morrison Award is presented to Edward
C. Tocus at the 48th Annual Meeting of the Committee on Problems
of Drug Dependence Tahoe City, California June 16, 1986.
AUTHOR
William L. Dewey, Ph.D., Medical College of Virginia, Virginia
Commonwealth University, Box 613, Richmond, VA 23298
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J. Michael Morrison Award Lecture,
1986
Edward C. Tocus
I am deeply honored to receive the third J. Michael Morrison
Award and join the previous distinguished recipients, Robert C.
Petersen now retired from the National Institute on Drug Abuse,
and Kay Croker of the American Society for Pharmacology and
Experimental Therapeutics. The award is for achievement as an
administrator in the drug field. I have listened to recipients
of various awards say how surprised they were and how they
wondered what it was that led to their selection. I can say
that I completely understand that reaction because it is pre-
cisely what I felt. This award represents the convergence of
several phases of my professional career which I will share with
you in the next several minutes.
The first phase was graduate training beginning in 1953. I like
to brag that I am a direct descendent fourth generation pharma-
cologist; that is, starting with the father of modern experi-
mental pharmacology, Oswald Schmiedeberg, whose student was John
Jacob Abel (father of U.S. pharmacology), whose student was
Eugene Maximillian Karl (EMK) Geiling, chairman of my Department
at the University of Chicago. Dr. Geiling was a contemporary of
Aldous Huxley, who wrote "Doors of Perception", an account of
taking hallucinogenic drugs. Dr. Geiling was with Dr. Huxley at
the time and took notes on the effects as they were experienced.
Through several class lectures, I was introduced to the world of
drugs of abuse including alcohol and narcotics. This exposure
included an initiation into the need for careful observations
and measurements in biological research. This characteristic of
"staying with the data" of a carefully planned and executed
study, in its broadest sense, has been a singular guiding
principle in all facets of my career.
The second phase of my career leading to this recognition is the
six years from 1960 to 1966 with a pharmaceutical company.
Those were the anti-Vietnam War years. They were years of
protests and marches against the government for social,
economic, political and environmental reasons. It was a time of
LSD. It was a time when I became disenchanted with both the
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pharmaceutical industry and the Federal Government. I believed
my future was destined in the international arena and, there-
fore, applied to several international health organizations for
a job. After a number of months of waiting, it became apparent
that you cannot get to an international health organization
directly from an industry position. With the conviction that
you cannot change government with marches and protests, but must
join it and work from within, and with a plan to go from a
federal to an international position, I applied to the FDA and
was accepted to be a reviewing pharmacologist in the Division of
Neuropharmacological Drugs.
That began in 1966, the third phase of my career, the bureaucra-
tic years. Because of my interest in the pharmacology of the
hallucinogenic substances, I requested and was assigned all of
the drugs of abuse along with all of the narcotic analgesics.
One of the first drugs which I evaluated and continued reviewing
until marketing was naloxone. Of course, LSD, marijuana, CME
(crude marijuana extract which later became delta-9-THC) were
all assigned to me as a reviewer. Although pentazocine was
available when I started, I had butorphanol and nalbuphine as my
drugs. Then came methadone. In about 1968, I began attending
the business and scientific meetings of the CPDD. I remember
one particular business meeting at the National Academy of
Sciences building in D.C. when Dr. Vincent Dole proposed estab-
lishing methadone treatment centers around the country for the
heroin addicts who were without any treatment. That caused a
flood of applications to the FDA, all of which were assigned to
me. By 1972, it was obvious this treatment was no longer
research and as a result, the methadone regulations were written
to handle the several hundred programs going at that time. In
1970, the Controlled Substances Act was written and the FDA now
had additional responsibilities in the drug abuse field. I was
also promoted to the supervisory pharmacologist in the Division
and all of the drug abuse work was too much, so we decided to
establish a Drug Abuse Staff within the Division. This was done
in 1971 with the agreement that I could continue to be responsi-
ble for my drug classes and the research in these classes. That
began the era of LAAM and Naltrexone, the endorphins and peptide
opiates, the cannabinols, and Nicorette chewing gum to name a
few of the projects you might recognize. Every investigator in
the country who studies a Schedule I substance in humans must
have an IND with the Drug Abuse Staff of the FDA.
Recognition with the Morrison Award means that joining the
government was the right choice, that my training, experience
and objectives converged. Luck put me in a position to follow a
class of drugs most pharmacologists rejected, drugs which my
naive artist friends in New York who -protested against the war
and nuclear bombs, and in support of civil rights and preserva-
tion of the environment were taking in spite of my advice. To
end the story, I have been able to work with the World Health
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and Pan American Health Organizations anyway, because of the
experience at the FDA. Thank you.
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Louis S. Harris
It gives me great personal pleasure to introduce this year's
recipient of the Nathan B. Eddy Award. Dr. Harold Kalant is a
native of Toronto, Canada. His formal education was at the
University of Toronto where, as a member of the Royal Canadian
Army Medical Corps., he earned an M.D. and B.Sc. in medicine.
He later received a Ph.D. degree in Pathological Chemistry from
the same institution. His post-graduate medical training was in
Canada and Chile, an early indication of his broad international
concern.
In the late 1950's he served as Biochemistry Section Head at the
Defense Research Medical Laboratories in Toronto where he began
his development of elegant analytical methods for the detection
of small amounts of hormones and drugs in body fluids. In 1959,
he began his association with the Department of Pharmacology of
the University of Toronto and the Addiction Research Foundation
of Ontario where he rose through the ranks to his present
position as Professor of Pharmacology and Director of Biobeha-
vioral Research. At the Addiction Research Foundation he began
his pioneering studies on the pharmacology toxicology and
mechanism of alcohol action, tolerance and dependence. It is
fair to say that the work of Dr. Kalant and his colleagues over
the past 25 years have provided much of the scientific basis for
our understanding of alcohol intoxication. These studies were
later extended to other drugs of abuse and form the scientific
basis for his selection for the Eddy Award.
Dr. Kalant has also served the medical and scientific community
by his service on numerous national and international commis-
sions and boards. Of particular note are his services to the
Committee on Problems of Drug Dependence, the Expert Panel on
Drugs of Dependence of the World Health Organization and the
National Institute of Alcoholism, and Alcohol Abuse, where he
currently is Chairman of the Board of Scientific Counselors.
His distinguished career has earned him numerous honors. These
include the Jellinek Memorial Award for Research on Alcoholism
(jointly with R.E. Popham), the Raleigh Hills Foundation Inter-
national Gold Medal, and the Upjohn Award of the Pharmacological
Society of Canada. In 1983, he was elected as a Fellow of the
Royal Society of Canada.
Dr. Kalant is a brilliant but modest man whose career may be
summed up by the following citation. "Harold Kalant distin-
guished scientist, gentle man. Your research on alcohol,
alcoholism and other drugs of abuse has greatly benefited
mankind."
The Committee on Problems of Drug Dependence is honored to name
you the 1986 recipient of the Nathan B. Eddy Award.
AUTHOR
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Nathan B. Eddy Memorial Award
Lecture: Tolerance and its
Significance for Drug and Alcohol
Dependence
Harold Kalant
Tolerance has always been considered as one of the cardinal signs
of addiction, whether to alcohol or other drugs, yet the reason
for the importance attached to it has seldom been explained.
Why, indeed, does tolerance really matter? The answer is not
readily apparent from the research literature on this subject.
Early in the course of investigation of tolerance, a metabolic or
pharmacokinetic variety was recognized, resulting from an
increased rate of biotransformation of the administered drug
(Pringsheim 1908). There are many examples of pharmacokinetic
tolerance, affecting virtually all types of psychoactive drug.
If tolerance is measured as a decrease in the duration of drug
effect, pharmacokinetic factors may be of considerable
importance, especially in relation to tests of long duration
(e.g., duration of loss of righting reflex in rats or mice after
administration of ethanol or other hypnotic-sedative drugs).
However, for most experimental purposes it is much more common to
express tolerance in terms of a reduction in the maximum
intensity of response, or of increase in the dose required to
achieve a given effect, such as increase in ED50 (Fernandes et
al. 1977). Most test responses reach their maximum levels quite
early after parenterial administration of drugs, or even in some
cases after oral ingestion. Pharmacokinetic tolerance is of
little importance under these circumstances, and one is dealing
then with functional or pharmacodynamic tolerance (Kalant et al.
1971; Cicero 1980).
The traditional view has been that pharmacodynamic tolerance
represents a physiological homeostatic adaptation to the direct
pharmacological action of the drug, occurring at the molecular
level (e.g., Collier 1965; Goldstein and Goldstein 1968). Such a
homeostatic process is also generally presumed to underlie
physical dependence: tolerance is shown by normal function in
the presence of the drug, while withdrawal of the drug then
unmasks the adaptive change which constitutes the basis of the
withdrawal reaction. Since, in this view, tolerance is
essentially a physiological adaptive process, it has been
generally held to be specific for the type of drug used,
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according to the mechanism of action of the drug. Thus, for
example, tolerance to a drug such as morphine, which acts via
stereospecific receptors, has been conceived as a different
process from tolerance to ethanol, which acts by non-specific
interaction with lipids and proteins of the cell membrane.
According to this view, therefore, transfer of tolerance and of
dependence between alcohol and opiates would be most improbable.
The relation of such postulated homeostatic change to continued
drug-taking or drug dependence is seldom explained, except for the
unproven assumption that the tolerant individual needs to increase
the dose of the drug in order to achieve the euphoric or other
desired effect of the drug, and for the more clearly proven
observation that drug-taking may become, in part, a self-
medication for the relief of withdrawal symptoms. Apart from
these two possibilities, the question remains unanswered: why
does tolerance really matter? Before attempting to answer it, one
should examine carefully what tolerance really is, and how well or
poorly the classical theories really explain it.
The traditional view of tolerance has been seriously challenged by
a number of findings beginning over 20 years ago. Irwin (1963)
observed that tolerance to phenothiazines developed more rapidly
when the subjects were submitted to arousal stimuli during the
course of drug action. Chen (1968) reported that animals which
were obliged to perform a test daily under the influence of
alcohol developed tolerance, whereas those which received the same
dose of alcohol after the daily test performance did not become
tolerant. Kayan et al. (1969) observed similarly that animals
subjected repeatedly to tests of nociception under the influence
of morphine developed a high degree of tolerance, while those
receiving the same chronic dosage without the repeated tests
developed less or none. From such observations, there arose the
view that tolerance is essentially a learning process, rather than
a physiological adaptation, and it has even been asserted that no
tolerance occurs unless the drug-treated subject experiences test
performance while in the drugged state (Wenger et al. 1981).
This view of tolerance as a learning process is consistent with a
number of observations of formal resemblances between tolerance
and learning. For example, when rats were exposed to repeated
cycles of chronic alcohol exposure and withdrawal, they reacquired
tolerance on the later cycles more rapidly than they had acquired
it the first time (Kalant et al. 1978). The administration of
cycloheximide, during the course of chronic ethanol
administration, prevented the development of ethanol tolerance
(LeBlanc et al. 1976) just as it had been previously observed to
inhibit the acquisition of new learning. However, it is
noteworthy that repeated cycles of alcohol exposure and withdrawal
also enhanced the rate of development and intensity of expression
of a withdrawal reaction (Branchey et al. 1971; Clemmesen and
Hemmingsen 1984). The concept of tolerance as a learned
compensation for drug effects does not offer any obvious
explanation of such a facilitation of physical dependence.
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Nevertheless, further support for the idea that tolerance involves
learning of some type was provided by a variety of studies on both
operant and classical (Pavlovian) conditioning. In studies of the
effects of various drugs on operant behavior, it was observed
repeatedly that drug effects which resulted in a loss of
reinforcements resulted in more rapid development of tolerance.
One of the earliest such observations was that by the Lexington
group (Fraser 1957), that tolerance to barbiturates in human
subjects was seen first on cash-rewarded tasks in which the drug
effects caused a loss of earnings. Subsequently, the same
phenomenon was observed in rats, in relation to the effects of
amphetamine (Schuster et al. 1966) and of tetrahydrocannabinol
(Elsmore 1976) on food-rewarded bar-pressing tasks. We were later
able to confirm this with cocaine in a different type of operant
procedure (H. Kalant and N. Woo, unpublished studies), and with
ethanol and chlormethiazole (Kalant et al. 1986).
Siegel, in a thorough and systematic series of experiments
beginning in the mid-1970's (Siegel 1975), has drawn attention to
the role of Pavlovian conditioning of environmental cues in the
development and expression of tolerance and physical dependence in
rats treated with morphine. When animals were tested in the same
environment in which they were treated with morphine daily, they
developed increasingly rapid expression of tolerance to the
analgesic and hypothermic effects, But when they were tested in a
different environment, the manifestation of tolerance was markedly
decreased or abolished. When they were treated with saline in
place of morphine in the morphine-linked environment, they
presented an overt withdrawal reaction. Similar findings have
been obtained with respect to the hypothermic effect of ethanol
(Lê et al. 1979; Crowell et al. 1981) and other drugs. The
suggested explanation is that an innate (unconditional) adaptive
response to the acute effect of the drug becomes linked
conditionally to the specific environmental stimuli, so that
subsequent exposure to those stimuli initiates the adaptive
response as a conditioned response, beginning even before the
administration of the drug. There have been numerous
confirmations of the functioning of this mechanism, and its
importance has been demonstrated in certain examples of
cross-tolerance. For example, both ethanol and hydralazine
produce hypothermia, but no cross-tolerance between ethanol and
hydralazine effects on body temperature is seen (Rigter et al.
1980) unless the animals receive hydralazine in the same
environment in which they have previously been made tolerant to
ethanol (Lê et al. 1986c).
Further indirect support for the concept of learning as an
integral part of tolerance is provided by observations of the
effects of certain neuropeptides on ethanol tolerance. DeWied and
his collaborators, in a long series of studies beginning in the
196Os, had observed that vasopressin, and the desglycinamide8
derivative of it (DGAVP) which is almost devoid of peripheral
endocrine action, were able to maintain a learned avoidance
behavior in the rat under conditions in which extinction would
11
otherwise have occurred (deWied and Bohus 1979). Similar doses of
these hormones were found to maintain ethanol tolerance after the
end of a period of chronic alcohol administration (Hoffman et al.
1978; Rigter et al. 1980; Lê et al. 1982). This effect of the
peptide was demostrable only in the presence of an intact
serotonergic pathway from the median raphe nucleus to the
hippocampus (Lê et al. 1982; Speisky and Kalant 1985). It had
previously been observed that lesioning of these pathways would,
by itself, impair the acquisition of tolerance (Lê et al. 1981).
While the specific involvement of a hippocampal pathway in the
development and retention of tolerance can scarcely be considered
proof of a learning process, it is at least compatible.
Despite all this evidence implicating a role of learning of
various types in the development of alcohol and drug tolerance, it
is nevertheless possible to produce tolerance in circumstances in
which no opportunity for learning under drug influence is
apparent. For example, continuous exposure of rats or mice to
morphine, released from a subcutaneously implanted pellet, results
in tolerance to the analgesic effects of morphine when the animals
are tested for the first time after removal of the pellet.
Similar results have been obtained with subcutaneous implantation
of barbiturate pellets, or with continuous administration of
various drugs from subcutaneously implanted osmotic minipumps. In
analogous fashion, ethanol tolerance and dependence can be
produced by continuous exposure to ethanol vapor in a closed
chamber (Goldstein 1972), or by continuous administration of
ethanol in a liquid diet modified from that of Lieber et al.
(1965) (Khanna et al. 1979).
Does this mean that different types of tolerance exist, in
learning and non-learning situations? At present, the answer can
only be "not necessarily". There is no feature of the tolerance
produced by these methods that distinguishes it from tolerance
produced by the techniques which involve learning opportunities.
In the studies referred to above, involving repeated cycles of
alcohol exposure and withdrawal, a crossover between the first and
second cycles from a learning to a non-learning model of tolerance
does not interfere with the facilitation of tolerance seen in the
second cycle (Kalant et al. 1978). On the other hand, tolerance
to ethanol is accompanied essentially by a parallel shift of the
dose-response curve, while tolerance produced by chronic high-dose
treatment with morphine (Mucha and Kalant 1980) or of
chlordiazepoxide (Lê et al. 1986a) gives rise to a flattening of
the dose response curve rather than a parallel shift. Cross-
tolerance between ethanol and chlordiazepoxide is therefore
asymmetrical, involving only the "parallel shift" component (Lê et
a l . 1986c). Further, development of tolerance to ethanol is
accompanied by cross-tolerance to barbital but not to
pentobarbital, on a number of different tests (Gougos et al.
1986). These findings, which are suggestive of differences
relating to the different molecular mechanisms of action of these
drugs, leave open the possibility that there may in fact be more
than one mechanism of tolerance.
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However, the most economical hypothesis to account for the
differences in tolerance produced by the same drug on the same
test, under different behavioral or environmental circumstances,
is that the stimulus to the development of tolerance is not the
presence of the drug per se, or its direct molecular interaction
with a specific receptor or other cell component, but rather, that
the stimulus is the functional impairment produced by the drug by
whatever means through which it acts. Clearly, the type and dose
of drug will have an important bearing on the functional
disturbance, but the latter can also be enhanced by environmental
or behavioral circumstances. For example, ethanol impairs
thermoregulation, and thus can give rise to hypothermia at low
ambient temperatures or to hyperthermia at high temperatures.
When rats are treated with ethanol repeatedly at an ambient
temperature (Ta) of 4°C, which results in marked hypothermia,
they develop a high degree of tolerance to the hypothermic effect
of ethanol tested at normal room temperature. In contrast, rats
of the same strain, receiving the same dosage of ethanol at Ta
of 36°, do not develop tolerance to the hypothermic effect at room
temperature (Lê et al. 1986b). When rats of different strains,
differing in initial sensitivity to the hypothermic effect of
ethanol, are treated chronically with ethanol, the strains which
were most sensitive initially show the greatest acquisition of
tolerance, so that they may ultimately reach the same level of
response as the more resistant strains (Riley and Lochry 1977;
Khanna et al. 1985). The cross-tolerance between ethanol and
morphine, which has been observed in vivo and in vitro (Khanna et
al. 1979; Mayer et al. 1980) is most easily explained the basis
of tolerance to the same functional disturbances that are produced
by both drugs. The same principle can be observed to apply even
to relatively simple response systems. Tolerance to the effect of
ethanol on post-tetanic potentiation in the abdominal ganglion of
aplysia is observed only if the afferent fibres to the ganglion
are stimulated repeatedly during the exposure to alcohol (Traynor
et al. 1977). Tolerance to the effect of ethanol on a spinal
reflex in the spinally transected rat is seen only when the reflex
is elicited repeatedly during alcohol exposure (J rgensen and
Hole 1984). One may conjecture that neurons or synapses, in an
altered state associated with functional activity, are more
sensitive to the effects of ethanol and other drugs and therefore
experience a greater stimulus to adapt to these effects.
This view of tolerance carries several important implications.
The first is that tolerance is not a global state of resistance to
the drug in question, but a delimited state that applies under
certain circumstances and not others. In experimental terms, this
implies that tolerance may be a test-specific phenomenon,
especially at low doses of drug which do not necessarily affect
all functions of the organism. Thus one sees, for example, that
rats subjected to daily gavage with ethanol in a dose of 2 g/kg
show substantial tolerance to the hypothermic effect of ethanol,
and to its impairment of operant responding for food reward, but
no tolerance on a test of motor impairment (Lê et al. 1984). At
higher doses, which impair many basic physiologial-functions, one
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is more likely to see generalized tolerance simply because almost
all of the animal's normal activities will have been affected even
in the absence of specific tests, and therefore an adequate
stimulus to tolerance development will have arisen in most
neuronal pathways. Another implication is that any proposed
molecular basis for tolerance must be able to account for the
interaction of the drug, the behavioral state and the
environmental context in which the drug is presented. Any
theory of tolerance based exclusively on molecular mechanisms such
as receptor change, altered membrane composition or function, is
likely to be overly simple unless it includes some postulated
means by which the level of CNS arousal or the impact of incoming
neuronal stimuli can modify the drug effect at a particular
locus.
Another implication of this concept of tolerance is that the
relationship of tolerance to physical dependence is not
necessarily constant. In most purely pharmacological studies, in
which large doses of morphine, alcohol, barbiturate or
benzodiazepine, for example, are given regularly by intubation or
by intraperitoneal injection, and a global tolerance is produced
on the basis described above, physical dependence does usually
develop in parallel with tolerance and is manifested as a
spontaneous or evoked withdrawal reaction when the drug is
stopped. However, when tolerance is produced by lower doses of
drug, in a model involving a substantial role of environmental
conditioning, this does not necessarily apply. For example,
Siegel (1975) found no withdrawal symptoms in morphine-tolerant
rats until they were exposed to the same environmental stimuli
after injection with saline instead of drug. One may well ask
whether such a subject is indeed dependent. Cochin and Kornetsky
(1964) described very long-lasting tolerance in rats to which no
morphine had been given for many months, but which still showed
reduced antinociceptive effect of morphine when tested in the same
test environment as before. This is clearly suggestive of a
conditioned tolerance that has persisted because no extinction
trials have been carried out. Is this possibly related to what
has been described as "protracted abstinence"? Does this have
implications for treatment of addiction in humans? Perhaps the
withdrawal-like symptoms and craving experienced by addicts on
returning to the environment of their habitual drug use is in fact
the same phenomenon, as suggested many years ago (Wikler 1948;
Ludwig and Wikler 1974). Should treatment normally include
deliberate extinction trials in order to eliminate this
potentially important cause of relapse?
A final question concerns the relationship of this complex and
multi-faceted pattern of tolerance to reinforcement of drug
intake. An individual who is exposed for the first time to the
action of a drug is likely to experience a variety of effects,
some pleasurable or reinforcing and others unpleasant or aversive.
The relative balance between the aversive and reinforcing effects
presumably determines whether or not drug consumption is likely to
be repeated on other occasions. The aversive effects include most
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of those which are used as common laboratory measures of drug
action, such as hypothermia or impaired intestinal motility with
morphine, dizziness or motor incoordination with ethanol, or
appetite suppression by amphetamine or cocaine. Even the
antinociceptive effect of morphine, which is a therapeutically
desirable effect in patients experiencing pain, is linked to
aversive effects in the healthy volunteer subject. The
reinforcing effects, designated in humans by subjective terms such
as euphoria and "high", must be inferred in experimental animals
from objectively measured behaviors such as drug self-
administration, or conditioned taste or place preferences.
Tolerance can be shown to develop readily to all of the aversive
effects. In contrast, there is little or no evidence that
tolerance develops to the reinforcing effects. In animal
experiments involving intravenous self-administration of morphine
or cocaine, for example, prolonged experience with a fixed drug
dosage does not result in extinction of responding, as would be
expected if the animal failed to experience the reinforcing effect
as a result of tolerance. Many investigators have suggested that
the reinforcing effects of drugs such as morphine, amphetamine, or
low doses of sedative drugs are linked to their stimulant effects,
including increased arousal, exploratory activity and elevated
body temperature. Though there are a few reports of the
development of tolerance to morphine-induced hyperthermia, for
example, most investigators have failed to find clear-cut
tolerance to these excitatory or stimulant effects. This may be
considered perhaps as indirect evidence supporting the view that
little or no tolerance occurs to reinforcement by drugs. In that
case, the development of tolerance would mean essentially
tolerance to the aversive effects, so that the preponderance of
reinforcement over aversive consequences of the drug would be
increased (Cappell and LeBlanc 1981). This should substantially
increase the strength of the behavioral dependence. One may
wonder whether an intuitive grasp of this relationship may have
been responsible for the importance which has been traditionally
attached to tolerance as a component of drug addiction. If this
picture is correct, it raises an important goal for new
therapeutic efforts in the treatment of drug dependence. This
objective would be to develop methods of diminishing the relative
strength of reinforcement, either by reversing the tolerance to
the aversive effects, or devising some strategy for producing
tolerance to the reinforcing properties. How such an objective
might be attained is a subject for future recipients of the Eddy
Award to discuss.
The history of the study of tolerance and drug dependence is full
of examples of important observations which have been made,
forgotten, and rediscovered years later. A few examples are
sufficient to illustrate the point. Pringsheim (1908) reported
clearly the development of pharmacokinetic tolerance to ethanol in
rats subjected to daily intubation with large doses; this finding
was reported nearly 60 years later by our own group (Hawkins et
al. 1966), who performed experiments which we would not have had
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to do if we had known of Pringsheim's work in time. Fraser et al.
(1957) described clearly the pattern of "learned tolerance" which
was rediscovered independently by Chen in 1968 and again by Wenger
et al. (1981) and others later. Himmelsbach (1943) described the
increased rate of development of tolerance on repeated cycles of
exposure to meperidine, which our own group observed over 30 years
later in relation to ethanol. Many other examples can easily be
found in the present-day literature.
Purposeful repetition of earlier work is often necessary or
desirable, because earlier methods are later shown to be
unreliable, or because the work was not given a theoretical
context which a modern repetition can provide. In many cases,
however, the people who rediscover the phenomenon are not even
aware after the fact that it had already been described years
earlier by other investigators. This loss of continuity of
knowledge is probably due to at least two factors. The first is
the excessive and increasing tendency toward compartmentalization,
so that what one investigator discovers with an opiate is not read
by another investigator working with ethanol or benzodiazepines.
The second is excessive preoccupation with what is most recent,
leading many investigators to carry their reviews of the
literature no farther back than five or at most 10 years. The
argument is often advanced that anything older than that has been
done with antiquated techniques, and is therefore not worthy of
further consideration. I should like to close with a plea for a
more general awareness of the need, in this as in other fields of
research, for scholarship and not only for technology. Knowing
what has been done in the past, and formulating the right
questions on the basis of that knowledge, are at least as
important as applying the most modern and sophisticated methods.
FOOTNOTE
1This paper is dedicated to the memory of the late Dr. Joseph
Cochin, a pioneer in research on drug tolerance.
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Early Studies of Tolerance to
Morphine
Conan Kornetsky
I believe it is most appropriate that the Committee on Problems of
Drug Dependence have this special symposium in honor of Joseph
Cochin. As all of you know, Joe invested a great deal of his
energy in this organization. And the topic of this special
symposium, Tolerance and Dependence is one that was the subject of
his scientific career. Although Joe’s death was a sad occasion for
us all, we are not here to mourn his death but we are here to
applaud his life.
Joseph Cochin was born the 21st of July 1916 in Winnipeg, Canada;
however, his family moved to Detroit where he attended secondary
school and Wayne University, receiving his B.S. in chemistry in
1937. He worked as a chemist from 1937 to 1939 at an oil refining
company. However, in 1940 he received a teaching certificate from
the state of Michigan and taught in the Detroit public schools
from 1940 to 1942. He served in the U.S. Army from 1942-1946 with
considerable duty in the South Pacific. After leaving the Army he
became a graduate student in the Department of Pharmacology as
well as a medical student at the University of Michigan at Ann,
Arbor. He received his M.D. degree in June 1953 and his Ph.D. the
following year. Joe’s first choice was biochemistry, but due to
an error in interpreting his undergraduate point average he was
not admitted to the program in biochemistry. However, the
Pharmacology Department at Michigan accurately interpreted his
point average and admitted him. Biochemistry’s loss was
pharmacology’s gain.
As many of you know, Joe was very loyal to the University of
Michigan. He took almost as much pleasure with every win of its
football team as with every publication from the Pharmacology
Department. He would use the metaphor that Michigan was the
“Harvard of the West” - I pointed out to him that he was somewhat
incorrect, the metaphor really was that Harvard was the Michigan of
the East.
Joe had a strong attachment to the University of Michigan. In
1958 the ASPET meeting was at Ann Arbor. It was the year that the
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Pharmacology Department moved to new quarters. Although the
building was empty he dragged me to it so that I would see the
house built by John Jacob Abel, and he, like many other former
Michigan pharmacology students, picked up a piece of the building
as a memento. I believe he took a thermostat off of the wall.
Joe’s Ph.D. dissertation was on the chemical determination of
morphine and its biological fate. His doctoral committee was
comprised of Associate Professor Lauren A. Woods as chairman,
Instructor Theodore M. Brody, Associate Professor Joseph P.
Chandler, Assistant Professor Edward F. Domino and Professor
Maurice H. Seevers. The first paragraph of the abstract of his
dissertation outlined the aims of the research and it was Joe’s
first but not last study designed to determine the variables
accounting for tolerance and physical dependence.
The metabolic fate of morphine and its possible
interrelationship with the problems of tolerance
and physical dependence have long been a matter of
great interest. It is the aim of this study to
attempt to elucidate the fate of the alkaloid in
the animal organism and to investigate the changes,
if any, which take place in the excretory pattern of
morphine in the dog during chronic administration of
the drug. (Cochin 1954, p. 1 Abstract).
This work was published in May 1954 in the Journal of Pharmacology
and Experimental Therapeutics. (Woods et al. 1954; Cochin et al.
1954).
FIGURE 1
Title page of Joe’s published dissertation. Copyright 1954,
Williams and Wilkins Company.
Figures 1 and 2 are reproductions of the first page and a summary
table, respectively from Cochin et al. (1954). Figure 2 clearly
shows that there was not a significant difference in the metabolic
fate between the morphine tolerant and nontolerant animal. As
the authors pointed out the slight but not significant difference
between the two groups are of "little importance in explaining the
marked tolerance developed to morphine . . ." Joe, as always, was
very conservative in his interpretation for he added, “in the
dog,” to the statement.
2 1
Summary table of the results from the dissertation publication
(Cochin et al. 1954). Copyright 1954, Williams and Wilkins
Company.
FIGURE 2
A minor historical note is that in the footnote of this paper the
word statistically is spelled incorrectly. I am not sure Joe ever
noticed the error but it clearly points out to me a flaw in a
Michigan education.
This paper, I believe, put to rest the hypothesis that alteration
in the pattern of morphine excretion accounts for the development
of tolerance and physical dependence. In order for Joe to make
that simple statement it was first necessary for him to develop a
sensitive, reliable and practical method for the quantitative
determination of morphine in plasma and urine, not an easy task.
Joe left Michigan in the Fall of 1954 where he became a member of
the Laboratory of Nathan Eddy in the National Institute of
Arthritis and Metabolic Diseases in Bethesda. Here Joe did
clinical studies on the efficacy of various new drugs in the relief
of pain. It was in Bethesda that I met Joe. We collaborated on
two series of experiments. The first of these was not directly
related to the phenomenon of tolerance. The second series of
experiments developed from Joe’s interest in tolerance and
dependence. We set out to study the time course for the develop-
ment and disappearance of tolerance to morphine in the rat using
both the “hot plate” and swimming speed, a simple test of motor
effects.
This seemed like a fairly simple thing to do. We measured the
response of the same animals to the hot plate” and speed of
swimming in a 15 foot long water trough. Figure 3, taken from
that paper (Cochin and Kornetsky 1964) clearly shows the rapid
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development of tolerance to a 20 mg/kg test dose. Daily dose
started at 20 mg/kg twice daily increasing to 20 mg/kg twice daily
so that by the 5th day the total daily dose was 200 mg/kg. They
Figure 3
The development of tolerance
in the same animals to 20
mg/kg of morphine in the rat
on the “hot plate” and a
swimming test (Cochin and
Kornetsky 1964). Copyright
1964, Williams and Wilkins
Company.
were then maintained on this dose until the end of the chronic drug
period. We then abruptly withdrew the animals and hoped to see a
rapid loss tolerance. To our surprise no rapid recovery was
forthcoming.
Figure 4 summarizes the results from this experiment. There were
two groups of animals, those that received the daily injections of
morphine and a control group that received a single injection at
the same time that the experimental animals were administered their
first dose and then they were not given a second dose until 68
days later. Each animal was tested on both the “hot plate”
procedure as well as speed of swimming. As can be seen there were
& 3 depict the performance of
the control group. Copyright
1964, Williams and Wilkins
Company.
clear differences in loss of tolerance in the animals on the two
procedures. Striking was the marked attenuation of morphine effect
in the control animal’s response on the "hot plate". Their
response was only 40% of their original response to morphine. The
of the experimental group on
the “hot plate” and swimming
test, respectively. Groups 2
of sensitivity to 72 days of
daily morphine administration
in the rat on the “hot plate”
and the swimming test. Group
1 & 2 depict the performance
A comparison of recovering
Figure 4
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experimental animals only reached the level of the control animals
on day 300 of withdrawal where both groups still showed a response
that was less than 40% of their original response. This phenomenon
was not observed in the swimming procedure, a simple test of motor
performance. However, even here recovery of sensitivity to the
level of the control animals did not occur until somewhere between
150 to 250 days post-withdrawal. One problem that we immediately
became aware of was that in order to test for tolerance we were in
fact priming the tolerance.
In order to determine whether priming played a role we designed
an experiment where animals would be tested for tolerance only
once. In order to determine the time necessary to lose tolerance
to morphine different groups of animals were used, each to be
tested only once at a specified time period. The results of this
experiment are illustrated in figure 5. What was striking in this
experiment was that the control animals that only received morphine
once at the start of the experiment, once 2 months later, and then
approximately once every two months (groups Cl), seemed to develop
what appears to be tolerance. Group Al, the experimental group who
received daily doses of morphine for the first 60 days also showed
Figure 5
A comparison of  "primed" and
"unprimed" animals recovery
of sensitivity to morphine
after chronic administration
doses (groups A1-5) or after
an initial acute dose 68 days
prior (groups C1-6). Points
N1 & N2 are the response of
two groups of naive animals
to the test dose of morphine
response is expressed as a
percent of the initial
response to the morphine of
the experimental and control
groups. Copyright 1964,
Williams and Wilkins Company.
little evidence of recovery of sensitivity to morphine. The C2-6
and A2-5 animals were only tested once after the second month after
the first injection of morphine. The results using the "hot
plate," shown here, were clearly different from that of the swim-
ming animals (not shown). The latter once again showed recovery of
sensitivity and it was the same for primed and unprimed animals.
What is most interesting in this figure is the control animal
curves (C1, etc) suggesting that a single dose of morphine might
have profound lasting effects.
Subsequently we (Kornetsky and Bain 1967) looked at the effect of
a second dose of morphine on a foot shock titration analgesic
24
procedure. The results of this experiment are shown in figure 6.
In this study all animals were tested only on the designated test
day with half of them receiving saline on the 1st day. The
indicated control level is the response of the saline animals to
their first dose of morphine on the designated day. The response
of the other animals is the effect of their 2nd dose but first
Figure 6
a subsequent 5 mg/kg test dose
on a foot-shock attention
procedure. Scores are ex-
pressed as a percent of the 
control group of animals who
originally received saline
rather than morphine (From
Cochin and Kornetsky 1968
effect of morphine in a 
based on Kornetsky and Bain
1967).  Copyright 1968,
Williams and Wilkins Company.
The effect of a single injec-
tion of 10 mg/kg of morphine
in the rat on the effects of
time tested with morphine. This experiment is not dissimilar from
one reported in 1953 by Nathan Eddy who showed that in mice the
effects of a second dose of morphine given 24 hours following the
first dose will not be influenced by the first dose, but if 72 or
92 hours intervenes the effect of the second injection is
significantly altered.
The interesting thing that this experiment shows is that when only
one day intervened between doses of morphine tolerance was slight.
It is as if there must be some sort of consolidation, much like
what is seen for short term memory. Only here we have the time
period spread out and that a given dose immediately after the
first, one day in this case, does not give the cell sufficient time
for the consolidation of the receptor to the opiate molecule.
Feinberg and Cochin (1972) reported that cycloheximide, a potent
inhibitor of protein synthesis, which will prevent consolidation of
short term memory, will also block the development of tolerance if
given one hour prior to the morphine administration in the mouse.
In the 1964 paper (Cochin and Kornetsky) in which we demonstrated
single dose tolerance, we suggested that "one of the possible
explanations may be the induction of some sort of immune mechanism
by the administration of morphine." This concept had been pre-
viously considered by others, Gioffredi in 1897 and 1898 (as
reported by Krueger et al. 1941) reported that injection of serum
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from tolerant animals into naive animals protected the naive
recipients from the effects of an otherwise lethal dose of
morphine. Later investigators were not able to replicate these
findings and it was generally concluded that the evidence is
against the presence of any specific antibody as a mechanism for
tolerance. These earlier investigators mainly studied the lethal
effects of morphine and did not determine the effects of passive
transfer on sub-lethal doses.
The first experiment in which we attempted to passively transfer
tolerance was done with the dog as the donor animal (Kornetsky and
Kiplinger 1963). Dogs were given gradually increasing daily doses
of morphine for two weeks. The drug was abruptly withdrawn and 48
hrs later blood was taken and serum prepared from these animals as
well as comparable controls. Serum from the morphine-tolerant
donors and from control donor animals was injected into two
separate groups of rats and the effects of a test dose of morphine
on the time needed to swim a straight alley was measured 48 hours
after the injection of either control serum or serum from tolerant
animals. To our surprise we observed a potentiation of the
morphine effect that was subsequently replicated by Kiplinger in
another laboratory using the “hot plate as a measure of effect
(Kiplinger and Clift 1964).
Joe and I decided that we would pursue this work first using the
rabbit as the donor animal and the mouse as the test animal
(Cochin and Kornetsky 1968). Figure 7 shows the results of one of
these experiments. Serum was collected one week after withdrawal
and the effects of a test dose of 10 mg/kg in the mouse, given at
Figure 7
Effect (x ± SEM) of serum
obtained from morphine-
tolerant (T) and nontolerant
(V) donor rabbits on the “hot
plate” response of mice to
10 mg/kg of morphine.
Copyright 1968, Williams and
Wilkins Company.
various time periods after the injection of the serum, were tested
using the “hot plate.” The ordinate is the latency of response
to the 10 mg/kg dose. As can be seen the animals receiving serum
from the morphine tolerant animals showed significant reduction in
effect at 24 and 48 hours and one week after the serum administra-
tion. We had similar results when the rat was the donor animal
and the mouse the test animal (Cochin and Kornetsky 1968).
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We continued this line of work attempting to see if we could
replicate the Kiplinger and Clift findings and our previously
mentioned findings unfortunately none of the results were as
robust as previously reported. However, there was a trend in that
either we found no differences or differences in the direction
previously reported, that is, serum from dogs chronically treated
potentiated the effects of morphine on the test procedure whereas
those results in which the donor animal was the rabbit the trend
was in the direction of an attenuated response in the test
animals.
Friedler, in her dissertation under the direction of Joe Cochin
(1968), tested the hypothesis of a possible immune factor in
tolerance by removing the thymus within 24 hours after birth and
then subsequently testing the mouse on the “hot plate” procedure.
Although no difference was found between these two groups, she did
make an important observation in that offspring of mothers treated
with morphine prior to mating at 4-5 weeks of age showed a
depression in the “hot plate” response to an initial dose of
morphine, suggesting in some way that tolerance was passed from the
mother to the offspring (Friedler and Cochin 1972). It should be
noted that if the offspring were exposed to morphine in utero it
could only be to trace amounts since the mothers were not bred for
at least 4 or 5 days after drug withdrawal. This has led to a
series of experiments by Friedler demonstrating that not only can
pregestational treatment of the dam with morphine affect the
offspring but the even more surprising finding, that the pregesta-
tional treatment of the sire will also affect the offspring
(Friedler 1985).
Although these experiments did not lead to a clear demonstration
of a immunological mechanism they did indicate that morphine and
possibly other drugs may have profound effects months after the
administration of morphine and further that these effects may be
passed on to the offspring.
Joe added much to our understanding of the phencmenon of tolerance
and physical dependence. I have described, for the most part,
only those experiments that he and I worked on together or
specifically related experiments. The legacy that Joe left to us
is not only the answers but also the questions that he asked
concerning the phenomenon of tolerance and physical dependence.
We will miss him.
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Acute and Chronic Tolerance:
Relevance for Clinical Practice
Carl Rosow
INTRODUCTION
Joe Cochin devoted much of his scientific career to the char-
acterization of opioid tolerance and physical dependence in
various animal models. He never forgot his clinical "roots",
and we discussed the potential clinical relevance of his work on
a number of occasions. He pointed out that a great deal of the
human data on tolerance and physical dependence was obtained in
drug abusers, particularly those at the Addiction Research
Center in Lexington. It was never clear to him just how much of
this information was applicable to patients receiving opioids
for pain.
There is no general consensus on the importance of opioid
tolerance in "normal" patient populations. In 1982 Abbott et
al. published a study of opioid tolerance using an animal model
of chronic pain. They concluded that"... the degree of toler-
ance seen is consistent with clinical reports that tolerance is
not an important consideration in the management of prolonged
pain.” Twycross (1974) has stated that tolerance is not much of
a practical problem in 85 - 90% of patients receiving heroin for
pain of terminal cancer. Isbell et al. (1947) were able to use
methadone in a surgical population 3 to 5 weeks without
substantial dose escalation. These clinical anecdotes are
certainly at odds with the preclinical literature which suggests
that profound opioid tolerance can be produced in a very short
period of time.
Why worry about tolerance? As long as we give the appropriate
dose of medication, is the tolerant patient compromised in any
way? As a clinician, I might worry about tolerance for several
reasons:
1. Opioid tolerance frequently manifests initially as a
decrease in duration of analgesic effect. This exacerbates the
"pain cycle" with increasing pain and anticipation of pain
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before each round of medication. Increasing the frequency of
injections to compensate means more discomfort and inconvenience
for the patient and a greater burden on the nursing staff.
2. Tolerance develops most rapidly to depressant opioid
effects like analgesia, so stimulant effects like constipation
become proportionately more of a problem.
3. Very high levels of tolerance may actually lead to receptor
desensitization and flattening of the dose-response curve.
(This was discussed earlier by Dr. Kalant). Some patients may
not get sufficient relief of pain with any dose of opioid.
Although I am unaware of any prospective trials to assess the
impact of tolerance in ordinary clinical practice, there are
clues to be found in the medical literature: First, acute and
chronic tolerance have both been demonstrated in "normal"
patient populations. Second, the clinical use of opioids has
undergone some radical changes during the last five to ten years.
Opioids are now being administered in ways which appear to
maximize the chances for tolerance to develop--if one believes
the animal data. Finally, profound opioid tolerance has been
described repeatedly in man, and the frequency of clinical
reports suggests that it will become more of a problem in the
future. In the remainder of this brief presentation I would
like to elaborate on these three points.
ACUTE TOLERANCE
Let us consider first two phenomena described in the experi-
mental literature, "acute" tolerance and "single-shot" toler-
ance. In animals, sufficient doses of opioids will produce the
rapid onset of tolerance (usually within hours) to a second
dose. This has been demonstrated with respect to morphine-
induced hypothermia, hypotension and analgesia as well as
levorphanol-induced lenticular opacification. This "acute" form
of tolerance may require a high degree of receptor occupancy by
agonist, while so-called "chronic" tolerance ma
relatively low doses. Cochin and Kornetsky (1964) demonstrated
occur after
that long-term tolerance to hot-plate analgesia can be produced
by one large injection of morphine. This phonomenon of "single-
shot" tolerance develops over time and is easily demonstrable
months after the initial injection.
I need look no further than my own specialty of anesthesiology
to find a human model for acute tolerance. In 1969, Lowenstein
described the use of high doses of morphine for anesthesia in
open-heart surgery. It has now become common clinical practice
to administer very high doses of opioid (usually fentanyl or one
of its new congeners) to produce hypnosis and profound analgesia
during cardiac surgery. Some representative drugs and doses are
listed in Table I.
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TABLE 1: Opioid doses of cardiac surgery
Drug Analgesic Potency Dose
(Morphine = 1) (mcg/kg)
Fentanyl 100 50-150
Sufentanil 1000 10-30
Alfentanil 30 100-200
Based upon its relative analgesic potency, 30 mcg/kg of
sufentanil is comparable to 30 mg/kg of morphine given as a
single dose (2.1 grams/70 kg). Patients given these enormous
doses of sufentanil usually require ventilation for 18-24 hours.
Doses of fentanyl and alfentanil are comparably high.
Bovill et al. (1983) have demonstrated the development of acute
tolerance to the hypnotic effect of alfentanil when it is used
in this manner. They showed a strong positive correlation (r =
0.94) between the total dose of alfentanil administered during
surgery and the plasma level of alfentanil measured at the point
the patient regained conciousness. Acute tolerance to thiobar-
biturates has been demonstrated in man and animals using a
similar approach (Maynert and Klingman (1960). I am not aware
of any descriptions of acute tolerance to the analgesic or
respiratory depressant effects of alfentanil, although tolerance
could well be overlooked in this clinical setting.
It is entirely speculative whether single-dose tolerance could
be demonstrated in man. The cardiac surgical patients I de-
scribed actually received larger absolute doses of opioid than
those used by Cochin and Kornetsky in their animal experiments.
No one knows how these cardiac patients respond to opioids six
months after operation. If any differences have been noted,
they have not been sufficiently striking to be reported.
CHRONIC TOLERANCE
The long-term or chronic tolerance which occurs upon repeated
administration of opioids has much more obvious parallels in
clinical practice. Cochin and others have demonstrated some
rather distinctive features of chronic tolerance in animals
(Cochin 1970). It can occur after low doses, requires time to
develop, and the rate of tolerance development
the pattern of dosing. Mushlin et al. (1976) showed that the
is influenced by
degree of tolerance to a second dose of morphine is approxi-
mately the same whether the doses are spaced 1 day apart or
three weeks apart. In contrast, continuous parenteral adminis-
tration (e.g. by subcutaneous implantation of a morphine pellet)
was found to produce a very high degree of tolerance within one
to three days (Way et al., (1969).
It therefore appears that continuous low plasma levels produced
by frequent small doses or infusions may be more effective in
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initiating tolerance than intermittent high doses. This is an
important point, since maintenance of constant plasma opioid
levels by frequent injections seems to be a very good way to
control clinical pain (Stapleton et al., 1979). Many clinicians
have lamented the inadequacy of our traditional methods of pain
control (Angell 1982). Large doses of opioid prescribed "prn"
tend to produce cycles of pain followed by oversedation. If the
analgesic is given at regular intervals by the clock, patients
are kept more comfortable since the drug is given in anticipa-
tion of pain rather than in response to pain. In these cases
blood levels may fluctuate, but they tend to be maintained at or
above therapeutic levels.
An even more effective treatment modality is the PCA or Patient
Controlled Analgesia device which allows the patient to push a
button for a small intravenous bolus of opioid (Bennett and
Griffen 1983). Patients generally establish very stable blood
levels of analgesic (approximating a continuous infusion) and
reportedly achieve very good pain relief using relatively low
total doses. Patient satisfaction is very high with this tech-
nique, and the incidence of oversedation and respiratory embar-
rassment is reported to be quite low.
Continuous intravenous infusion of opioid is becoming increas-
ingly popular, especially in the intensive care unit. The most
common indication is a need for sedation and suppression of
airway reflexes in a patient who is artifically ventilated.
Continuous infusion is also utilized in pain of terminal malign-
ancy when intramuscular injections are not feasible or not
effective.
The newest form of opioid analgesia involves direct instillation
into the central nervous system. Opioids may be given intermit-
tently or continuously through lumbar epidural or intrathecal
catheters. This produces a dense segmental analgesia without
other motor or sensory deficits. Morphine may also be adminis-
tered by intracerebroventricular injection in selected cases.
The profound and long-lasting analgesia produced this way is due
to the immense concentration of opioid at a central nervous
system receptor sites. This would be difficult--if not impossi-
ble--to achieve by intravenous injection.
One would predict that these trends in clinical analgesia might
produce high levels of tolerance, and this does seem to be the
case for some patients. Consider the following examples:
---Woods and Cohen (1982) described a patient with hip pain
secondary to metastatic cervical cancer who required daily doses
of methadone (90 mg p.o.) to supplement an i.v. infusion of
morphine (280 mg per 24 hours). She was changed to epidural
morphine, and she initially obtained adequate analgesia from 2.5
mg by this route. Within ten days she required an epidural
infusion of 10 mg per hour. This heroic dose of morphine
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produced no sedation or respiratory depression and barely
adequate analgesia.
---Greenberg et al. (1982) describe a similar patient who
required a ten-fold increase in
over a one week period. Increasing tolerance and progression of
her dose of intrathecal morphine
her tumor led to large increases in morphine dose over the next
three months. Shortly before her death the patient was receiv-
ing up to 150 mg of intrathecal morphine per day supplemented by
20-30 mg of oral levorphanol. She experienced no sedation or
respiratory depression at these doses.
---Coombs et al. (1985) report a patient with metastatic adeno-
carcinoma of the rectum who developed complete tolerance to
morphine. She experienced no sedation, no respiratory depres-
sion, and no analgesia after the injection of 17.5 mg of
morphine directly into the lateral cerebral ventricle (!)
How can we account for such profound changes in some individu-
als? Why don't more patients get into trouble like this? Which
environmental or physiological factors might identify those
patients at risk? Unfortunately, these case reports show that
the issue is of more than theoretical importance. The patient
who has been made refractory to opiates finds himself with a
sadly diminished set of therapeutic options.
Joe Cochin would have found more than a touch of irony in all of
this. He spent more than thirty years lecturing medical stu-
dents on the evils of underprescribing opiates for pain. I am
sure he would agree that the development of tolerance is a
modest risk associated with the compassionate use of opiate
analgesics--but it is a risk that should not be taken lightly.
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Recent Studies on Heterogeneity
and Isolation of Opioid Receptors
3 5
Eric J. Simon
I am very honored to be invited to be a speaker at this
fine symposium in honor of the memory of Joe Cochin. I
am sure that my being here has more to do with my
friendship and love for Joe than with the relevance of
my topic to this symposium, which is, of course, as it
should be. I should add that Joe had a very keen
interest in the biochemical pharmacology of opioid
receptors and their endogenous ligands.
CPDD will not be the same without Joe, but then many
things will not be the same. His impact was felt in so
many areas. I would like to mention some that have not
been mentioned by the other speakers. I had the privi-
lege of serving on the NIDA Study Section with Joe. I
do not remember anyone who was a more thorough and
fairer reviewer of research grants than he. It was a
pleasure to work with him and to spend our leisure
hours together. I also had much contact with him in his
role as Field Editor for JPET and, as Eve Killam will
tell you, he was an exceptional one. He handled 70-80
reviews a year, twice as many as the other Field Edi-
tors, yet he managed to call every reviewer on the
telephone before sending him or her the paper. As has
been said many times, Joe was an outstanding pharmaco-
logist, but, above all, he was a wonderful, warm human
being with a great sense of humor and an astonishing
range of interests and knowledge. This included the
ability to find the best restaurants no matter where we
were, Rockville, MD or Milan, Italy. We had many unfor-
gettable dinners together and several of the partici-
pants today were often with us. Sometimes our wives
were with us, including Renee, who due to the pressures
of her own work was not able to travel with Joe as
often as she would have liked. I am very happy that she
is able to be here today to see first hand how we feel
about Joe. We will miss him enormously. It was a privi-
lege to have been his friend.
I plan to summarize for you some recent results from my
laboratory concerning our efforts to understand the
molecular basis of opioid receptor heterogeneity. I
shall list only the most pertinent references to the
work to be discussed. For more complete literature
citations please see references listed at the end of
this paper.
Before beginning, a word is in order concerning the
relation of my topic to tolerance and dependence. The
discovery of opioid receptors and their putative natu-
ral ligands, the endogenous opioid peptides, have re-
sulted in enormous research activity and given rise to
many useful and important findings. The one disappoint-
ment has been that the expected resolution of the
biochemical mechanism of the long term effects of
opiates has not yet occurred. However, many of the
physiological effects in which the endogenous opioider-
gic system seems implicated bear a close resemblance to
the acute pharmacological effects of opiate narcotic
analgesics. It is therefore expected by most workers in
this field that this system will prove to be involved
in tolerance and dependence and that a thorough under-
standing of it will lead to the elucidation of the
molecular basis of these phenomena. It would indeed be
surprising if the CNS had an opioidergic system and it
had nothing at all to do with the chronic action of
opiates.
This wishful thinking is supported by several types of
evidence. I will just mention two. One is the finding
that tolerance can develop to pharmacological quanti-
ties of opioid peptides. The other is the recent
finding that it is possible to produce selective to1e-
rance to the separate types of opioid receptors.
The existence of multiple types of opioid receptors
seems firmly established now. The major types are mu,
kappa and sigma, first postulated by Martin, and the
delta receptor, which has a preference for enkephalins,
first suggested by Kosterlitz. There may be many other
receptor types as well as subtypes, and a considerable
number has already been postulated in the literature,
but the evidence for these is currently less
compelling. The question to which the answer is not yet
known is what is the molecular basis of this receptor
heterogeneity. To put it simply: are the various recep-
tor types separate molecular entities or are they
different conformations of a single receptor molecule?
Our studies are aimed towards an answer to this
question. Many experiments have been done in a number
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of laboratories, including our own, using membrane
binding and pharmacology to establish the existence and
characteristics of the various types of opioid binding
sites, but these studies, while extremely important,
cannot shed light on their molecular basis. This is
best approached by attempting physical separation of
receptors and their subunits. Ultimately, it will be
necessary to purify each receptor type and elucidate
its structure. My summary will address these
approaches.
In our laboratory Dr. Y. Itzhak was able to separate
kappa sites from mu and delta sites. This was done by
using a technique called sucrose density centrifugation
on extracts of guinea pig brain, which retained their
receptor binding activity. Such physical separation,
also achieved by Dr. R.S. Zukin using a column separa-
tion, strongly suggests that the kappa site is on a
separate molecule from the others. All attempts to
achieve a similar separation of mu from delta sites
were unsuccessful.
We therefore resorted to a different approach. These
experiments were carried out by several people in my
laboratory, most notably, my graduate student Andrew
Howard. Iodine-labeled beta-endorphin, able to bind to
opioid receptors with high affinity, had just become
available. Using crosslinking reagents (double-headed
reagents available commercially) it was possible to
link this ligand covalently to cell membrane
preparations from different brain regions and from
neuroblastoma x glioma hybrid cell cultures (NG108-15).
Beta-endorphin has high affinity for both mu and delta
sites but very low affinity for kappa sites. This
therefore provides a method for linking beta-endorphin
irreversibly to these two types of receptors in the
same membranes and to determine labeling patterns in
tissues with widely varying ratios of mu to delta. The
covalently labeled binding sites were extracted with
the detergent SDS and run on SDS-polyacrylamide gel
electrophoresis (SDS-PAGE). This technique separates
different protein subunits by size and permits one to
see whether the subunits of mu and delta sites are the
same or different. The bands on the gel are visualized
by autoradiography, a technique which allows the
radioactive particles to expose an x-ray film. The
results of this research gave strong support to the
idea that the major binding proteins of mu and delta
receptors are of different molecular size. The first
evidence was that a protein of MW 65000 occurred in
tissues enriched in mu sites but not in NC-108-15
cultures known to contain only delta receptors.
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A protein of MW 53000 was observed in the cell cultures
and in tissues rich in delta sites but not in tissues
containing mainly mu sites, such as the rat thalamus.
To prove more conclusively the nature of these binding
proteins, the binding and crosslinking of 125-I-beta-
endorphin to brain and cultured cell membranes was run
in the presence of the highly selective mu ligand,
DAla2-MePhe4-Gly-ol5-enkephalin (DAGO) and the equally
selective delta ligand, Pen2-Pen5-enkephalin (DPDPE). It
is noteworthy that both are peptides related to
enkephalin but the modifications made have resulted in
markedly different receptor selectivity for these two
peptides. It was found that the labeling of the 65000
MW protein was selectively suppressed by DAGO, while
the 53000 MW protein was no longer labeled when DPDPE
was present during beta-endorphin binding and
crosslinking to membranes. These results, taken
together, provide strong evidence that mu and delta
receptors have binding subunits that differ from each
other in size and suggest that these two receptors are
likely to be separate molecular species.
As stated earlier, the ultimate goal is to purify to
homogeneity all separable types of opioid receptors and
to obtain their complete amino acid sequence,
carbohydrate and lipid composition and tertiary
structure. Progress towards purification of receptors
has been made in several laboratories, notably those of
Abood, Barnard, Klee, Loh, and Zukin, as well as in our
own. Only our own work will be summarized but
references to the other studies will be found at the
end of this paper.
The solubilization of opioid receptors in active form
from mammalian brain membranes was accomplished by
Richard Howells as part of his graduate research. This
method, which involves the use of digitonin in the
presence of a high concentration of sodium chloride, is
still the preferred method used in our laboratory and
in several others. For purification, opioid receptors
were solubilized from bovine striatum. The method of
purification to be described was developed by A.
Howard, T.L. Gioannini and J.M. Hiller in my
laboratory. The soluble receptor is purified in two
major steps. The first involves affinity
chromatography. A derivative of naltrexone is
covalently bound to Sepharose beads. The receptor is
selectively retained on columns of this material due to
its affinity for the opioid ligand, while other
proteins pass right through. The receptor can be eluted
by high concentrations of an opioid such as naloxone.
Purification of 3000-5000-fold was achieved in this
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single step. The second purification step involves a
column of wheat germ agglutinin (WGA) bound to agarose
beads. This is a lectin which retains glycoproteins
that contain the sugar, N-acetylglucosamine. Since we
found that the opioid receptor is such a glycoprotein
it can be purified by retention on WGA-agarose and
elution by N-acetylglucosamine. This results in another
15-20-fold purification. The final product has a
specific binding activity of ca. 13000 pmol/mg protein,
close to the theoretical value for a pure protein of MW
65000. It gives a single band of that MW on SDS-PAGE.
Considerable evidence has been accumulated that the
protein purified from cow striatum is the binding
subunit of the mu receptor. We are currently purifying
large amounts (several hundred picomoles) of this
receptor in order to obtain a partial amino acid
sequence. This task has been made significantly more
difficult because the amino terminal of the protein is
not free. Free amino terminals must therefore be
generated by fragmentation and purification of the
resulting peptides before sequencing is possible. Once
a suitable sequence is obtained it will be used to
synthesize oligonucleotide probes. Such probes will be
used to isolate the cDNA corresponding to receptor mRNA
from a brain cDNA library. This cDNA will then be
cloned to obtain large quantities for total sequencing.
The nucleotide sequence will provide the amino acid
sequence of the entire protein. This seemingly involved
method is far more rapid than the direct sequencing of
a large protein. This research is being done in
collaboration with Dr., S. Udenfriend at Roche Institute,
in whose laboratory two of my former students, R.
Howells and A. Howard, are doing post-doctoral training.
A final word is in order about the significance of all
this work. In the forseeable future the full structures
of the major types of opioid receptors will be known.
This will furnish the final proof as to which types of
receptors are different molecules. We will also know
whether differences in receptor type reside in the
protein chain or in other parts of the molecule, such
as the carbohydrate or lipid portion. The latter would
mean that the same gene codes for them and that the
variation is due to post-translational modification.
The former would suggest different genes. The presence
of considerable homology between reeceptor genes would
suggest that they originated from a common ancestor
gene. It will then also become possible to probe
receptor function on the molecular level. This is done
with a variety of techniques, e.g. reconstitution into
membranes and recoupling of binding sites to other
proteins such as the G-proteins and the enzyme
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adenylate cyclase. Site-directed mutations can be
produced and their effect on function studied. It will
also become easy to make highly specific antibodies to
various portions of the receptor molecules. These can
be used for fine mapping of receptor distribution and
they will facilitate isolation. The availability of
cDNA probes will make it much easier to test for subtle
differences in receptor level or turnover during the
development of tolerance and dependence.
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Role of the Spinal Cord in the
Development of Opiate Tolerance
and Dependence
A. E. Takemori, Gary E. DeLander, and P. S. Portoghese
INTRODUCTION
W ikler  and Frank (1948) were among the f i rs t  to  suggest  the
importance of the spinal cord in tolerance and dependence by
demonstrating in chronic spinal dogs that supraspinal influences were
not necessary for the development of these adaptive phenomena.
These findings have been confirmed and extended in spinal dogs
(Martin and Eades, 1964) and in spinal rats (Berge and Hole, 1981).
Yaksh and coworkers (1977; 1981) showed that tolerance and physical
dependence could be induced in rats and other species by repeated
injections of morphine via an indwelling spinal catheter. Participation
of the spinal cord in analgesia induced by systemically administered
opiates has also been demonstrated (Yeung and Rudy, 1980a,b).
Thus it was of interest to study the role of spinal sites and opioid
receptor type which are responsible for the development of tolerance
and dependence to systemically administered opiates.
In this study, we have taken advantage of the use of two of our newly
developed affinity labels for opioid receptors, ß-chlornaltrexamine (ß-
CNA, Por toghese et al . ,  1978) and ß- funal t rexamine (ß-FNA,
Portoghese et al., 1980). ß-CNA is the nitrogen mustard derivative of
naltrexone and is a highly selective, irreversible antagonist for opioid
receptors in general. ß-FNA is the fumaramate methyl ester derivative
of naltrexone and is an irreversible opioid antagonist but in contrast to
ß-CNA, it is highly selective for opioid receptors of the mu type. Opioid
receptors of the mu type have already been shown to be the main type
in the central nervous system that are responsible for the development
of physical dependence both in rats (Aceto et al., 1986) and monkeys
(Gmerek and Woods, 1985; Aceto et al., 1986).
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METHODS
Rats were given saline or the irreversible antagonists, ß-CNA or ß-FNA
through indwelling spinal catheters 24 hr before inducing tolerance
and dependence by implanting s.c. 3 morphine (50 mg base) pellets.
Tolerance was assessed 72 hr later by determining the ED50 values
for morphine using the tail fl ick and hot plate analgesic assays.
Physical dependence was assessed by noting several characteristic
signs after withdrawal was precipitated by injections of various doses of
naloxone.
RESULTS AND DISCUSSION
ß-CNA and ß-FNA not only inhibited slightly morphine-induced
analgesia 72 hr after i.t. administration but they appeared to block
completely the development of analgesic tolerance as seen by the lack
of change in the ED50 of morphine 72 hr after implantation of morphine
pellets. Lack of change in the ED50 value does not necessarily mean
that tolerance did not develop. It has been shown previously that
pretreatment of animals with moderate doses of morphine several
hours before analgesic testing does not change the ED50 of morphine
but these animals had much higher levels of morphine in their brain
indicat ing that  some degree of  centra l  to lerance had occurred
(Contreras and Takemori, 1981). This may merely mean that the usual
analgesic assays are not sensitive enough to detect the development
of low degrees of tolerance. The activities of the alkylating antagonists
were presumed to be due solely to spinal effects because neither drug
affected the analgesia induced by morphine given i.c.v. Although ß-
CNA and ß-FNA were localized in the lumbar-sacral region of the
spinal cord, the tolerance observed by testing morphine given i.c.v. was
also inhibited suggesting a supra-spinal interaction.
Rats pretreated with either ß-CNA or ß-FNA were significantly less
dependent than control rats when the withdrawn rats were observed for
mastication, ear blanching, abnormal posturing, diarrhea, wet dog
shakes, jumping and hypothermia. The amount of naloxone required
to elicit the withdrawal signs was significantly greater in the ß-CNA- or
ß-FNA-treated animals than in the control dependent rats.
CONCLUSIONS
We can conclude with the use of ß-CNA that spinal opioid receptors
play a prominant role in the development of analgesic tolerance and
physical dependence to systemically administered morphine. The use
of ß-FNA allows us to conclude that the mu type opioid receptors in
particular are important in these adaptive changes. The results also
indicate that the development or expression of tolerance depends on
the interaction of spinal and supraspinal sites
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Neural Substrates of Opioid
Tolerance and Dependence
George F. Koob
CONCEPTUAL ISSUES
Opiate dependence has been a subject of significant interest not
only because it has served as a prototype for chemical dependency
in general, but also because it presumably reflects an important
biological plasticity, a large extent of which is hypothesized to
be located in the central nervous system. For the present, our
approach is a "top-down" approach where we operationally define
behavioral phenomenon and then seek to identify brain sites and
neurochemical substrates for these phenomenon (Koob and Bloom,
1983). Here, opioid agonists or antagonists are administered to
animals and underlying substrates are identified by alterations
in behavior that reflect physical dependence or alterations in
drug self-administration. Clearly integration of this
information with evidence produced by the opposite approach of
developing evidence at the molecular level for those cells likely
to release and respond to opiates ("bottoms up") will ultimately
be necessary for a multidisciplinary understanding of opiate
dependence,
An important influence on my thinking in this area was a 1970
review paper of Dr. Joe Cochin (Cochin, 1970). While the subject
of this paper was largely, or at least ostensibly, opiate
tolerance, the principles outlined apply almost equally well to
the phenomenon of dependence. One of the objectives of this
paper was an attempt to describe the different hypotheses that
had been used to explain opiate tolerance and dependence. The
hypotheses that were discussed included altered metabolic
disposition, prevention of access of drug to the site of action,
occupation and saturation of receptor sites, and cellular
adaptation. Dr. Cochin elaborated on the fourth hypothesis which
was the cellular adaptation hypothesis. Here a biochemical
transformation or an immune-like reaction was hypothesized to be
the substrate for tolerance and dependence to opiate compounds.
Dr. Cochin went even further to describe the current cellular
adaptation theories that had been described at that time. There
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was a dual-action theory by Seevers and Woods (1953), a
depression theory by Shuster (1961), and a receptor induction
theory of Collier (1965) that was already alluded to in this
symposium. But my favorite part of Dr. Cochin's paper was the
following quote: "One of the common features of the two theories
is that there is a neurohumor, C, that is affected by chronic
opiate administration."
It is this premise upon which a number of us have continued to
work. What is the neurohumor, and what is the neural substrate
in the brain for opiate dependence? Rephrasing the question,
what are the neurobiological sites that are most important for
opiate dependence?
NEURAL SUBSTRATES OF PHYSICAL DEPENDENCE
Physical dependence is classically defined as "intense physical
disturbances (that result) when the administration of a drug is
suspended" (Eddy et al., 1965). In an early study on neural
substrates of precipitated withdrawal, crystalline naloxone was
injected into different loci in an attempt to precipitate a
withdrawal syndrome in dependent rats (Wei et al., a 1973). The
withdrawal syndrome was characterized by escape behavior and wet
dog shakes. Two major areas that elicited naloxone-induced
precipitated withdrawal were the medial thalamus and an area
which was described as the mesencephalic-diencephalic junction.
This study suggested a site-specific brain location for opiate
withdrawal, and by extension, opiate dependence. More recent
work, however, suggests that the conclusion that these sites in
the medial thalamus and the mesencephalic-diencephalic junction
may be important substrates for an "abstinence syndrome" may have
been overstated. For example, large lesions of these substrates
in the rat do not abolish the "abstinence syndrome" produced by
injection of systemic naloxone in dependent rats (Adler et al.,
1978).
A more recent study took a conceptually similar but experi-
mentally quite different approach (Bozarth and Wise, 1984).
Here, dependence was induced by the infusion of small amounts of
morphine directly into different regions of the brain using a
minipump. Dependence again was measured by escapes from a small
container, precipitated by a systemic injection of naloxone.
Perfusion of morphine into the periventricular gray region, the
area around the central gray, produced increased escape when
those animals received systemic injections of naloxone. The
ventral tegmental area, an area at the base of the midbrain which
has been implicated in opiate, stimulant and reinforcing actions
and which is the source of the mesolimbic dopaminergic cell
bodies, did not produce this manifestation of physical
dependence. Indeed, the authors found instead that non-dependent
animals readily self-administered morphine into the ventral
tegmental area but not the periventricular gray (Bozarth and
Wise, 1981; Bozarth and Wise, 1984).
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NEURAL SUBSTRATES OF PSYCHOLOGICAL DEPENDENCE
"Psychic" dependence, as it was classically defined, is a
condition in which a drug produces "a feeling of satisfaction and
psychic drive that requires periodic continuous administration of
the drug to produce pleasure or to prevent or avoid discomfort"
(Eddy et al., 1965). Our recent work has been directed at
identifying the neurosubstrates that might be involved in opiate
dependence from the psychic dependence point of view. The animal
model used in these studies involves intravenous self-
administration of heroin in non-physically dependent rats. Rats
in these studies are allowed three hours access a day to heroin,
and no more. By all measures that are classifically used to
define physical dependence in the rat, these rats are not
physically dependent. They do not show precipitated withdrawal
whether they are injected with naloxone before the session or
even immediately after the session (Table I). The rats inject
0.06 mg/kg of heroin per injection intravenously on a continuous
reinforcement schedule. Responding is very stable from day to
day, and when an animal has established a baseline, the animals
vary less than 10% from day to day. The inter-injection interval
becomes very regular and very stereotyped, and in this animal
model of "chipping," the rats do not show tolerance in that they
do not increase the amount of heroin taken over time. Injections
increase during the first two weeks and then level off to a
stable number self-administered injections a day and stay at that
level (Figure 1).
Heroin Self-Administration
FIGURE 1. Representative response records for 2 rats self-
administering heroin. Test sessions were 3 hours in duration.
Each mark represents a response/infusion of intravenous drug.
However, if the rats are allowed continuous 24 hour access to, 
heroin for 30 days, then they will continually increase over the
30 day period (responses/24 hour were 62.6 ± 8.9 for days 1-5 and
135.5 ± 25.0 for days 26-30 for 4 rats). Injections of naloxone
at this point will produce precipitated withdrawal (Table I).
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TABLE I Naloxone precipitated withdrawal in dependent and non-
dependent rats
Daily 3 Hour
Access
23 Hour
Access
Rearing
Teeth chattering
Weight loss
(3 hours)
Values represent mean ± S.E.M.
9.8 ± 2.5 12.8 ± 3.7
6.5 ± 1.2 13.0* ± 2.2
5.3 gms ±  1.8 17.0 gms* ± 2.9
Values represent number of rats
showing the presence of a response
over the total rats/group
Ptosis 1/4 3/4
Diarrhea 0/4 4/4*
*Significantly different from 3 hour group, information statistic
or Students t-test.
Measures of naloxone-precipitated withdrawal signs for 10 minutes
in the home cage of rats with limited access to heroin (n = 4)
and in rats allowed continuous access 23 hours/day (n = 4). Rats
were tested in their self-administration cage after 3 hours
access to heroin on a CRF schedule. Four mg/kg naloxone was
injected S.C.
In the non-dependent, restricted access studies, there is an
inverse dose effect function. Increasing the dose decreases the
number of self-injections and increases the inter-injection
interval; decreasing the dose increases the number of self-
injections and decreases the inter-injection interval (Ettenberg
et al., 1982; Koob et al., 1986). Thus, pharmacological
antagonism is reflected as a shift to the right of the dose-
effect function, and what one would predict at a dose in the
middle of the function is an increase in the self-administration
of heroin (Koob et al., 1986). Indeed, systemically administered
naloxone increases the number of injections taken during a
session. Similar effects have been observed by injecting
methylnaloxonium, a quaternary derivative of naloxone that does
not readily cross the blood-brain barrier, directly into the
central nervous system in an attempt to block the effects of
heroin self-administration. Intraventricular injection of
methylnaloxonium hydrochloride produced a dose-dependent increase
in the amount of heroin the animals would self-administer in a
three-hour session (Vaccarino et al., 1985a). The threshold here
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was approximately 1 µg of methylnaloxonium injected intra-
ventricularly.
Injections of methylnaloxonium into the ventral tegmental area
produced basically the same dose effect function observed after
intraventricular injection. However, injections of methyl-
naloxonium in small quantities into the area of the nucleus
accumbens produced at least an 8 to 10-fold shift to the left of
the dose-effect curve of methylnaloxonium compared to
intraventricular injections of methylnaloxonium (Vaccarino
et al., 1985b).
Thus, methylnaloxonium was much more effective when injected
directly into the nucleus accumbens than into the lateral
ventricle. Based on that study and other observations examining
the neural substrates for stimulant-type effects of opiates in
non-dependent rats (Amalric and Koob, 1985; Vaccarino et al. ,
1986), these data suggest the region of the nucleus accumbens
might be an important substrate for opiate reinforcement. The
nucleus accumbens receives significant information from limbic
structures and as a part of the ventral striatum is situated in
an important position to influence motivated behavior (Kelley and
Stinus, 1984). There are important inputs from the amygdala, the
hippocampus, the prefrontal cortex and of course, the
dopaminergic system which profoundly innervates this area, and
the present thesis is that this might be an important substrate
for the reinforcing actions of opiates.
SUMMARY AND CONCLUSIONS
Opiate dependence is not represented by a single neuronal
substrate but probably reflects actions at multiple functional
sites in the central nervous system. Classical measures of
opiate dependence such as escape reactions and wet dog shakes may
be elicited by neural substrates in the medial thalamus and
periaqueductal gray. Our work and others suggests that the
region in the nucleus accumbens and its afferent and efferent
connections may be an important substrate to reinforcing
properties of opiates. The nucleus accumbens is also an
important substrate for the reinforcing properties of stimulant
drugs. These data suggest that opiate dependence may represent
functional changes not only in neural substrates responsible for
physical dependence, but also in brain sites responsible for the
reinforcing actions of opiates.
It should be noted that there was inability in the early days
when the endorphins first came to the forefront, to show correla-
tions between changes in opiate binding and endorphin levels
associated with dependence. This may be due to a failure to
identify functionally significant substrates that may be
implicated from what one would call the top-down approach.
Perhaps the "neurohwnor" that Dr. Cochin was thinking about is an
opioid peptide located in brain regions high in opiate receptors
and functionally sensitive to opiate antagonists. New work
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isolating particular loci for opiate actions may point to
potential sites and neurochemical substrates for opiate
dependence.
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Tolerance and Dependence: Impli-
cations for the Pharmacological
Treatment of Addiction
Mary Jeanne Kreek
Dr. Joseph Cochin was a highly respected scientist, whose
research papers teach the important fundamentals about the
actions of exogeneous opiates and therefore by inference also
about the endogenous opioids. I was first introduced to the
works of Dr. Joseph Cochin by one of my early mentors, Professor
Vincent P. Dole, who, in 1964, first introduced me to these
teachings. I first met Dr. Cochin when he was a very kind and
compassionate, though rigorous, site visitor on my first grant on
a narcotics related topic. We then become very good friends as
fellow scientists, working in areas related to narcotic
pharmacology and the biology of the addictive diseases. Later I
also had the priviledge of becoming a close working colleague
with Dr. Cochin on this Committee on Problems of Drug Dependence.
Dr. Cochin's own teachings concerning the development of
tolerance to narcotics and also the long-term persistence of
these narcotic effects, made a very significant impact upon the
concept of the development of a pharmacological treatment of
narcotic addiction using an orally effective, long-acting
narcotic, as presented by Dr. Vincent Dole and Dr. Marie
Nyswander whom I had the priviledge of joining at The
Rockefeller University at the initiation of their research work
on the pharmacological treatment of narcotic addiction in 1964.
Dr. Cochin's teachings also has had an important impact on the
development of our concept of narcotic addiction as a metabolic
disease.
Dr. Marie Nyswander, who was also a close friend of Joe Cochin,
died two months ago on April 20, 1986. Therefore, my comments are
presented in memory of both Joe and Marie, two great leaders in
this field.
The problem of narcotic addiction remains an enormous one and is
growing. In the United States it is estimated that there are
at least 500,000 "hard core" narcotic addicts ("hard core"
defined as multiple opioid injections each day with opiate
dependency). It has also been estimated that there may be four
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times this number of intermittent use narcotic abusers. These
numbers are devastating in societal terms, in health care terms,
and also now with the epidemic of AIDS growing especially
important with respect to that new medical problem.
The stages of narcotic addiction can be briefly summarized: acute
exposure to narcotics may lead to chronic narcotic use which,in
turn, will lead to development of tolerance and development of
physical dependence (which means, by definition, abstinence
syndrome on drug withdrawal); protracted abstinence which may be
detected much longer than acute withdrawal symptoms; and
persistent drug hunger, with resultant return to narcotic use; or
alternatively, use of other drugs or alcohol on the way to return
to narcotic use. The acute effects of short or long acting
narcotics, in man, are well known: analgesia, somnolence, and
euphoria, sometimes preceded by dysphoria, as well as respiratory
depression, pupillary constriction, urinary retention,
constipation and a variety of alterations in endocrine function.
The well known important desired effects are analgesia or
euphoria; the other effects are not usually the desired effects.
Tolerance develops during chronic use of narcotics in humans.
Tolerance develops to most, but not all, of the acute narcotic
effects, whether caused by short-acting or long-acting narcotics,
although tolerance develops at varying rates for the different
effects.4 These profound differences in the rates of development
of tolerance to the specific narcotic effects are of interest
because they can be observed to occur in humans during constant
dose therapy with the same pharmacokinetically long-acting
narcotic drug, with the person exposed to the same environment on
a daily basis. Thus, here we are able to observe and consider the
biochemical and physiological factors which may contribute to the
development of tolerance and which are different from some of the
factors of conditioning or learning which were discussed in
preceeding presentations. Multiple opiate receptor subtypes,
with specific subtype(s) responsible for any given effect, may be
in part the explanation, with varying affinities of receptors for
different ligands at specific sites of action. possibly,
according to recent intriguing data, different transducers and/or
second messenger systems, my be operative in response to
different ligands, or at different receptor subtypes, or within
different tissues or organs. Also, diverse neural networks, and
different varieties of neurotrasmitter/hormone modulators at
different sites of action, in addition to differences in local
concentrations of drugs, may also contribute to the varying rates
for development of tolerance to different narcotic effects.
Because of the development of tolerance, the amount of narcotics
which must be used, either administered or self-administered, to
achieve the desired effect, either analgesia or euphoria, usually
have to be increased. The doses of narcotic also usually have to
be increased to prevent sighs and symptoms of narcotic
abstinence in an individual who is physically dependent.
Drug-seeking behavior may result, in part, from real or perceived
symptoms of relative opiate withdrawal, and in part, as a
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continuing response to some unidentified alteration in normal
physiology which, as reported by Cochin and Kornetsky in 1964,
may persist long after even a single narcotic administration, or
could be permanent cessation of chronic regular
exposure to narcotics.
Hypotheses, which we have formulated as a basis for some our work
are: (1) A narcotic drug must be available to specific receptors,
(i.e., opiate receptors) exerting biological activity for a
finite and definable period of time for tolerance and physical
dependence to develop. (2) Drug-seeking behavior may follow as a
natural consequence when the signs and symptoms which result when
drug (narcotic) is withdrawn from the tolerant and physically
dependent individual are identified as related to drug
withdrawal, and are relieved by re-administration of drugs. (3)
Constant availability of drugs to specific receptors is essential
for steady state maintenance of the tolerant and dependent state,
and it is this constant availability of the drug to specific
receptors, resulting in a steady state, which has been essential
for the pharmacological, physiological and thus clinical efficacy
of methadone maintenance treatment.  (4) Finally, availability
of drug to specific receptor sites may be affected by host
response and other exogenous factors, that is, any factors which
may affect overall distribution, metabolism, and excretion of the
drug.
Many of the pharmacological as well as physiological effects of
heroin when used on a chronic basis may be explained by its
pharmacokinetic properties. The heroin addict must use muiltiple
heroin injections each day, first to achieve euphoria or "high",
and, with the development of tolerance, simply to prevent the
onset of narcotic withdrawal, or "sick" state. Readministration
of drug prevents withdrawal. Because of the short-acting
pharmacokinetic properties of heroin, (or morphine), several
daily injections are necessary to either get the desired effect
of euphoria (or analgesia), or simply to prevent narcotic
withdrawal symptoms. Methadone is a synthetic opioid drug, which
we are know acts primarily at mu opioid receptors but possibly
also in part at other receptor subtypes. When given in high
dosages to narcotic tolerant individuals, the effects of heroin
and methadone, are very different from each other. Heroin, to be
fully effective must be administered intravenously, because of
extensive "first pass" hepatic biotransformation after oral
administration, whereas methadone can be administered orally,
since its absorption from the gastointestinal tract is
essentially complete, its initial hepatic uptake extensive (around
90%) but release from hepatic binding (storage) sites also
extensive and biotransformation gradual.15 The onset of action
of heroin when given intravenously is immediate, whereas
methadone has a 30 minute onset action time after oral
administration.6 Duration of action of heroin is 3 to 6 hours,
whereas the duration of action of a moderate to high dose (30 to 
120 mg./day) of methadone is 24 to 36 hours.5,12,13,20,24
Euphoria will be experienced during the first 1 to 2 hours after
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heroin administration if a large enough dose is self-administered
to prevent narcotic withdrawal symptoms for six hours, whereas, if
the proper dose of methadone is administered, with strategy
that the dose given should be less than to which a person
has become tolerant, then no euphoria, and no narcotic affect of
any kind can be perceived by the patient, or observed or measured
by the physician or scientist will occur, and withdrawal symptoms
will not appear until 24 hours or more, unless there is some
factor affecting overall drug dispostion.10,12,22 Therefore,
when moderate to high daily doses of methadone, (30-120mg/d), are;
given, as single oral daily dose, one can achieve a stabilized
state, a functional state, which is described as "straight", or
normal, with no euphoria and no abstinence symptoms. Because of
the very high degree of tolerance which is developed when
moderate or large doses of methadone are administered daily, (80
mg/d studied extensively), if a dose of heroin is superimposed,
administered in a research setting on a double binded basis, or
self-administered on the street, then no euphoria and no
subjective effects of a superimposed narcotic may be perceived by
the patient nor observed or measured by the
scientist because of narcotic cross-tolerance.
physician or
When we
developed specific and sensitive analytical methods for
measurements of methadone, and its metabolites in blood and other
body fluids, we were able to show that this functional state was
closely paralleled by the plasma levels and,' therefore, it is
assumed, receptor levels of drug, with very small peak levels,
(barely a doubling of the nadir or sustained plasma level at the
end of a 24 hour dosing interval), along with a sustained
steady-state plasma level of drug over a 24 hour dosing
interval.5,8,9,13,20 Using a variety of techniques primarily
stable isotope trace, technology, and chemical ionization mass
spectometry with selected ion monitoring, we now know that the
apparent terminal half-life of the racemic methadone, is around
24 hours, whereas that of the active levo (-R)- enantiomer is
48 hours.5,13,20 We also have learned that methadone is
essentially completely absorbed after oral administration, and is
secreted into bile and excreted in feces almost exclusively as
metabolites, but in urine partially as unchanged methadone and
that steady state levels of methadone in cerebralspinal fluid are
achieved by daily oral dosing.8,9,14 Methadone maintenance
treatment for narcotic addiction has now been carried out in over
150,000 heroin addicts; approximately 100,000 are currently in
treatment. Voluntary retention in treatment for more than 2
years is greater than 50%, ranging from 55% to 80%, depending
upon the clinic arid the methadone treatment modality, with the
highest retention rate apparently in those treatment programs
which combine pharmacological treatment with the best features of
a health maintenance organization and of a drug-free environment
(counseling, general health care, mental health care along with
various kinds of special groups, rehabilitation and education
services being offered as well). Illicit narcotic (heroin) abuse
during treatment is less than 10%. Recidivism after cessation of
methadone treatment, however, is essentially the same as
recidivism after exit from incarceration or from residential
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drug-free treatment, or discharge from drug-free or
"detoxification" programs employing short-term methadone
treatment or other pharmacolcgical agents. Only 20 to 30 percent
of former "hardcore" heroin addicts are found to stay narcotic
free for three years or more. Seventy to eighty per cent of
drug-free former, rehabilitated methadone-maintained patients
will return to narcotics use following voluntary or involuntary
discharge from treatment, whereas less than 10% will use illicit
narcotics during treatment, and most will prefer to stay in
methadone maintained treatment, if that is allowed. The actions
of chronic methadone treatment, are to prevent withdrawal
symptoms, prevent so-called "drug hunger", whatever the basis of
that is chronic methadone treatment also "blocks", by
cross-tolerance, the euphoric effects of other short acting
narcotics. The mechanism of action of methadone is that this
long-acting narcotic provides steady levels of opioid at opiate
receptor sites thus allowing normalization of most, if not all,
physiological processes which are disrupted and become abnormal
during chronic heroinuse.
There has been one very intriguing yet unexplained observation
with respect to chronic methadone maintenance treatment.
Discussed earlier in this symposium was the problem of increasing
tolerance which develops in chronic pain patients when the
analgesia is the desired effect. It has been of great interest
to us that, as we have now been able to observe and follow
prospectively patients in methadone maintainence treatment for
over 20 years, with a constant single daily dose of methadone
administered orally, there is no tolerance developed to the
narcotic-withdrawal prevention effect of that dose, and no
tolerance to "drug-hunger" prevention by that dose. Yet when, on
a double-binded basis, one significantly reduces that methadone
dose abruptly, the full spectrum of narcotic withdrawal signs and
symptoms along with neuroendocrine changes, which will be
discussed briefly, may be observed and documented. Therefore, by
steady perfusion of opiate receptors, possibly both mu and other
sub-types, we are not seeing the development of increasing
tolerance to the abstinence-preventing effect or drug-hunger
preventing effect when this long-acting synthetic narcotic
methadone is used.
Metabolic bases for addiction has been proposed by us and by many
others. Those metabolic bases for addiction may include factors
associated with genetics, pharmacology, but also pharmacology
intersecting with physiology which was an early teaching of
Cochin. Variable outcome following drug exposure may be due in
part to host response differences, due to coexistent disease or
altered physiological states, or drug interactions which play of
course an enormous role in this treatment of the user.7,14,12
Short-acting narcotics have "on-off" effects at specific receptor
sites of action, simply because of their pharmacokinetic
properties. With heroin, 3-4 cycles a day of receptor action can
be observed as the heroin is administered 3-4 times a day with
the peak plasma level followed by a nadir level, a peak and a
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sharp decline, giving this "on-off" effect at receptor sites.
Although tolerance develops to the acute opioid effects and
physical dependence also develops, the physiological effects are
the net result of intermittent opiate effect, followed by
relative opioid withdrawal, two or three times a day. Contrasted
with this are the effects of a long-acting narcotic such as
methadone or levo-alpha-acetylmathadol. When methadone is
administered orally, there is a sustained action at specific
receptor sites, again simply because of the pharmacokinetic
properties of the drug, with one cycle a day, one dose
administration a day.2 A high degree of tolerance develops to
all of the various acute opioid effects and this degree of
tolerance is sustained; the physiological effects are the result
of a constantly steady state opioid effect, without any
intermittent opioid withdrawal.
Acutely, short-acting or long-acting opioids have a variety of
effects on endocrine functions. Most of these effects persist
during chronic administration of short acting narcotics with
resultant chronic alterations in neuroendocrine function. However,
during chronic  treatment with the long-acting narcotic methadone,
these abnormalities slowly disappear with resultant normalization
of endocrine or neuroendocrine function.4,11,16,18,19,23 They
include, in man, inhibition of release of FSH, LH, and
suppression of LHRM with resultant changes in testosterone
production and in ovulation, inhibition of release of ACTH and
beta-endorphin which comes from the same parent peptide
precursor,proopiomelanocortin, along with suppression of adrenal
cortical production of glucocorticoids (cortisol in man).
Abnormalities in the circadian rhythm of release of these
peptides and steroid hormones also results from such acute
narcotic administration. Increase in release of antidiuretic
hormone, and increase release of prolactin are also observed. We
have had the opportunity to follow patients maintained on a
single dose of methadone administered orally, and have shown that
prior to the development of full tolerance to narcotics one can
observe all of the abnonmlities, described above, and in
addition an abnormal metyrapone response, which is a test of
hypothalamic reserve to stress, the failure of the hypothalamus.
and pituitary to respond to chemically induced stress, is
observed during the first 2 to 3 months of chronic methadone
treatment.4,6,11 However, after 12 months or more of steady dose
methadone treatment normalization of most induced neuroendocrine
functions occur.6,16,19 However, we have also shown that minimal
tolerance develops to the prolactin releasing effect on a peak
level of opioid. When methadone is administered orally, the peak
level occurs at around 4 hours after dose administration; and
peak level of prolactin, although not elevated above normal
levels, occurs at about that same time, rather than in the early
morning hours. Since prolactin is usually under tonic inhibitory
control by dopamine, these findings suggest that there is no full
tolerance developed to the opioid effect on prolactin releases
even when increased amounts of opioid are present on the
sustained basis at receptor sites.
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The roles of the endogenous opioids ("endorphins") in addiction
remains unknown. However there have been three very different
hypotheses proposed which have been that 1) narcotic addiction
could be a disease of endorphin deficiency; 2) a disease of
endorphin excess with failure to respond to endorphins; or 3) a
disease in which there may be an altered feedback control of
synthesis, release or degradation of one or more of the classes
of endogenous opiates, or altered receptor response. The latter
seems most likely.
We have developed and modified various techniques for qualitative
and quantitative analyses of sane endogenous opioids.16, 18, 19, 25
We have now been able to look at one simple question of: a) are
there any age related changes in plasma levels of beta-endorphin
in man, using a highly sensitive and specific radioimmunoasay for
measurement in beta-endorphin levels. Levels were all measured
in the early morning level; morning, when the levels have been
shown to be the highest, following the circadian rhythm of ACTH
release. One rather intriguing observation which we have made, is
that be appears to be an increase in the morning resting level
of beta-endorphin with age.25
Also, using this technology as wall as other technologies for
peptide analyses we have been able to address more directly than
in our earlier studies some other questions. Acute and chronic
use of short acting narcotics in man with three or four doses
administered each day cause chronic alterations in neuroendocrine
functions, including chronic suppression of levels of release of
ACTH, cortisol, and probably beta-endorphin. Although tolerance
develops to many narcotic effects, tolerance, or at least
adaptation, does not develop to the intermittently high and low
levels of narcotic. During chronic use of methadone which is a
long-acting opioid we propose that we would see normalization of
most aspects of neuroendocrine function which could occur because
of the long acting properties of the drug giving steady state
perfusion of opioid at receptor sites. Normally one of the most
important stress response mechanisms in man is that of release of
ACTH, from the anterior pituitary which in turn is followed by
the release from the adrenal cortex of cortisol. The hypothalamus
plays an important role by releasing corticotropin releasing
factor, which in turn causes release of peptides from the
porrpiomelano cortin presursor peptide from the antuary
pituitary. There is a negative feedback control mechanism
effected by cortisol released by its adrenal cortex in response
to increased circulating levels of ACTH which may be operative
both at hypothalamic sites and directly at anterior pituitary
sites. When plasma cortisol levels go up there is a decrease in
release of the control peptide hormones, including adrenal ACTH
and also beta-endorphin release. In the chronic heroin addict
and in the methadone maintained patient who is in the first one
or two months of treatment, at a time when doses of methadone are
being increased and tolerance has not been developed, abnormal
plasma levels and patterns of release of beta-endorphin ACTH
and abnormalities in cortisol are observed.4,6,11  However in a
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chronic methadone maintained patient there are normal plasma
levels of beta-endorphin, with a normal circadian rhythm (highest
levels in the morning, lowest in the evening) normal levels of
ACTH, arid nod levels of cortisol.16,18,19 When metyrapone, a
compound which blocks the 11 beta-hydroxylation of the precursor
of cortisol, thus preventing cortisol production, by the adrenal
cortex, which therefore interrupts the normal negative feedback
signal for control at hypothalamic and pituitary sites of tropic
peptide hormone release, an abnormal response is seen in the
heroin addict which is an inability to release increased amounts
of ACTH and an inability to release increased amounts of
beta-endorphin in response to this chemically induced stress. A
similar abnormal response is observed in patients during the
first me to three months of methadone maintainence treatment,
during which time the doses of methadone are being increased and
stabilized, and full tolerance is developing.4,6 In the chronic
methadone maintained patient who has been in treatment for one
year or more, after cortisol levels are dropped abruptly by
metyrapone administration, an absolutely normal ability to
increase release of tropic peptides hormones, as reflected by
increases in plasma levels of ACTH and beta-endorphin. Thus the
normalization of the hypothalamic-pituitary-adrenal axis function
as reflected by normal levels and circadian rhythm of release of
hormones, along with normalization of responses to chemically
induced stress is achieved through this long term, steady state
methadone maintenance treatment of heroin addicts. It is of
interest that this normalization comes around the time when there
is normalization of functional status and behaviors. Other
scientific groups are studying the possible relationships between
these and other stress hormones in the brain and periphery, along
with patterns of release of stress hormones, with abnormal
behavior.
We are also now studying the neuroendocrine status of the
drug-free former heroin addict and the drug-free former methadone
maintained patient. Some of our early studies lead us to believe
that for a very long period of time, following restoration of a
drug-free state, several neuroendocrine responses are abnormal,
and that these abnormalities may indeed contribute to the
behavior of drug seeking.
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Mechanisms of Opioid Tolerance
and Dependence: Symposium
Summary
Martin W. Adler
Because this symposium is dedicated to Joe Cochin's
memory, I would like to say a word about the
relationship that I had with him, aside from our close
friendship. Joe got me into this field over 15 years
ago when he urged me to switch from studying the
effects of brain damage in animals on brain
excitability to looking at the effects of brain damage
on narcotic dependence and determining what brain sites
might be involved in producing dependence. At the
time, I was (as the euphemism goes) between grants, and
it seemed like a very good idea. Because I was a young
investigator at that time, I find it particularly
fitting that the award being established by the CPDD in
Joe Cochin's memory is for a young investigator. With
those few comments, I would like to turn to the
symposium.
We heard an excellent overview from Dr. Harold Kalant
about the field of tolerance, with particular emphasis
on the role of conditioning and learning. He discussed
some of the factors, including pharmacokinetics,
environment, and very importantly, the test being used,
that enter into the development of tolerance with a
number of drugs of abuse. It should be remembered that
although we usually focus on alcohol or on opioids when
we talk about tolerance and dependence, we are really
dealing with a wide variety of substances, each of
which has very specific pharmacodynamic properties and
very specific pharmacokinetic properties associated
with its use. The characteristics of dependence and
tolerance and the sites of action probably vary with
these different compounds although there may be some
commonality, an issue I will address again at the end.
Dr. Kalant pointed out that tolerance is not global, it
can be test-specific, and the quantitative relationship
between tolerance and dependence is not constant,
especially at low doses. A particularly important
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corollary to this point is that without a complete
dose-response curve when looking at phenomena like
tolerance and dependence, one can be led down the
garden path very easily. One of the most critical
questions raised by Dr. Kalant was why is tolerance
important. There are many answers, or at least partial
answers, as we have heard during the course of this
symposium. Dr. Kalant pointed out that tolerance
develops earlier to the aversive effects than to the
stimulatory effects; since stimulatory effects may
include the reinforcing effects, there could be a shift
towards the so-called desired effects with chronic use
of a substance. Despite the fact that most textbooks
state that tolerance does not develop to the
stimulatory effects, it is now known that it does. We
and others, for example, have demonstrated that
tolerance develops to the pupillary effects of opioids
(Adler et al., 1980; Adler et al., 1981; Higgins et
al., 1985; Tress et al., 1978).
Dr. Conan Kornetsky spoke about the duration of
tolerance that even single doses of a drug can produce
and I think that this is particularly important not
only in human but also in animal studies. If one gives
a dose of a drug and then waits a period of time,
several days or even a week or two in some studies, we
make the assumption (probably incorrectly in many
cases) that we are not seeing any long-lasting effect
since the drug itself has been eliminated from the
body. One of the problems that those of us doing
animal studies encounter is that in order to do them
properly we either have to resort to sophisticated
cross-over designs or we have to use large numbers of
naive animals in order to avoid the possibility of
confounding the interpretation of results with
long-lasting effects such as those discussed by Dr.
Kornetsky.
Dr. Carl Rosow talked about some of the reasons why
tolerance is important clinically. I might sum up part
of his talk by saying that he demonstrated that as the
duration of the effect diminishes, one must give
injections more frequently. As shown in a number of
animal studies, tolerance develops to different effects
at different rates and physical dependence can be
produced by regimens of frequent drug administration.
Profound tolerance leads to a lessening of the maximal
analgesia produced by the drug. A particularly
important point that he made is that we may be doing
exactly the wrong thing with the current procedures for
administering drugs to patients for chronic pain or to
relieve acute episodes of pain. If we can extrapolate
our findings in animals to human therapeutics, then
giving patients the drugs almost continuously might be
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expected to result in the more rapid development of
tolerance and dependence. Dr. Rosow mentioned the
possibility of trying different regimens. I think that
we may eventually find that the most preferable
regimens are those that lie between a continuous
infusion and an intermittent administration - something
akin to the drug holidays that were used with
psychotropic agents - in order to minimize the
development of tolerance and dependence.
The next speaker was Dr. Eric Simon. Although he said
that his work with the opiate receptor might not appear
to pertain directly to tolerance and dependence, I
believe that it does. If we do not understand the
interplay between receptors and their endogenous
ligands, we are not going to understand very much about
the processes involved in these phenomena. Dr. Simon's
work on the chemical characterization of mu and kappa
receptors has important implications for understanding
many of the effects of opioids, including tolerance and
dependence.
Dr. Akira Takemori focused on the spinal cord in terms
of the development of tolerance to the analgesic
effects of morphine. He drew our attention to the
ability of two long-lasting antagonists that he and his
colleagues developed, ß-CNA and ß-FNA, to block the
development of tolerance. In addition, he showed that
tolerance depends on the interaction of spinal and
supraspinal sites. That is an important concept, not
only for analgesia, but for a number of effects of
opioids. It appears more and more likely that we are
going to see the implications of the interactions at
different levels since we know that the opioid
receptors are located both peripherally and centrally.
Dr. George Koob talked about dependence and its neural
basis, one of the crucial areas of study in the field
of centrally acting drugs. He asked the question of
what are the neural biological sites that are most
important for opiate dependence and said that we can
raise the question of whether there is a single locus
in the brain responsible for dependence and the
abstinence syndrome. I do not believe that a single
site is involved. There are so many different aspects
to tolerance and dependence and to the expression of
abstinence that it appears highly unlikely that there
is one primary site. More probable is that the site
depends on the particular sign that we are observing.
Eddie Wei and his colleagues, using implantation of
naloxone crystals into different brain areas, came to
that conclusion a number of years ago (Wei et al.,
1972). On the basis of brain lesion experiments (Adler
et al., 1978), we also concluded that there was not one
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site; rather, specific sites were associated with
specific signs. Dr. Koob found that, for
self-administration, the medial thalamus and the
periaqueductal grey may be of great importance, while
the nucleus accumbens may be critical for
reinforcement. His studies are vital for an
understanding of reinforcement and the reason that
people continually seek to use drugs. Identifying the
sites of action with some of the techniques that Dr.
Koob discussed will certainly play a role in our
understanding of the use of abused drugs, and
potentially in treatment methods for patients in the
future.
Finally, the studies reported by Dr. Mary Jeanne Kreek
brought together information about pharmacodynamic and
pharmacokinetic factors for treating addicts with
methadone. She also showed that tolerance to some of
the neuroendocrine effects of methadone developed
rapidly while tolerance developed more slowly to some
other endocrine effects. Furthermore, she pointed out
that normalization of the hypothalamo-pituitary-adrenal
axis functions may be important. We seem to be dealing
here with some of the compensatory mechanisms that
occur and that are important in terms of the signs
associated with chronic use of a number of drugs,
including methadone.
I would now like to indicate a few of my own thoughts
on tolerance and dependence. I can do that by focusing
on one of the effects that Joe Cochin studied and in
which he was very interested - the effects of opioids
on body temperature. I believe that the evidence is
accumulating that mu and kappa receptors play a vital
role in thermoregulation itself. Dr. Cochin and his
colleagues (Rosow et al., 1982) found that 10 mg/kg of
morphine given ip to mice at 20 or 25°C ambient results
in a small drop in body temperature. Upon chronic
administration of that dose, the effect gradually
reverses and one sees an increase in body temperature.
This reversal becomes even more apparent as the dose of
morphine is increased. These studies, as well as
others in which ambient temperatures were altered led
to the conclusion that there was marked tolerance to
some of the temperature effects of opioids but not to
others. In fact, there was an enhancement of some
effects. To bring in drugs other than the opioids, one
merely has to look to cocaine and amphetamine to see
not only tolerance to some effects, but what has been
called "reverse tolerance" or an actual increase in
sensitivity to others. This phenomenon has been seen
with opioids, as well, but has not been recognized
until fairly recently. The study of tolerance
mechanisms is not restricted to just those methods that
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have been discussed at this symposium. For example,
studies by Klee et al. (1984), Law et al. (1984) and
others used neuroblastoma clonal cell lines to show
that receptor desensitization, receptor downregulation,
and an increase in adenyl cyclase occurred during
chronic opiate treatments. Their work indicates that
tolerance and dependence are separate cellular
adaptation processes, something that a number of
investigators have concluded using in vivo approaches
in addition to in vitro ones. Work by Cochin and
Kornetsky (1964) on the idea that there may be some
involvement with the immune system is pertinent to what
we are finding today. They suggested that aspects of
tolerance and dependence might be due to the induction
of an immune mechanism. That idea is particularly
intriguing because we now know that opioids can affect
some parts of the immune system, as will be discussed
at a later session of this meeting by Dr. Arthur Falek
and his group. Even more intriguing are the findings
that opioid receptors exist in several components of
the immune system.
Although we do not yet know the basic mechanisms that
underlie tolerance and dependence, a number of
discoveries in the past few years have obvious
implications for our understanding of these states.
These findings include the discovery of the opioid
receptor, the realization that multiple opioid
receptors are present in vivo, the discovery of three
families of endogenous opioid peptides, the anatomical
localization of the receptors and the peptides, and the
gradual elucidation of the functional roles of the
receptors and the peptides. The relevance of our
findings with opioids bears more than a tenuous
relationship to other drugs of abuse. Not only does
there appear to be some commonality among the pathways
and the factors that influence reinforcement, but the
interactions of the various drugs of abuse with
neuropeptides might have some similarities. This is an
area of research that is just beginning. On the other
hand, it still seems that there are specific
characteristics associated with the different drug
classes. The advances in the opioid field have played
a significant role in opening the neuropeptide field in
general; thus, the study of opioids, although not yet
providing an answer to the question of the basic
mechanisms involved in tolerance and dependence, have
succeeded in opening new vistas in understanding the
interplay among numerous chemicals and receptors in the
brain and elsewhere. In the long run, the lasting
legacy of research on tolerance and dependence may be
in our overall understanding of brain mechanisms.
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Morphine Antinociception in the
Chronic Spinal Rat
C. Advokat, J. Suiciak, and P. Burton
Spinal opiate administration produces potent, selective and long-lasting analgesia
in a variety of acute and chronic pain states. Recent evidence, however, indicates
that the efficacy of spinal morphine does not decline during chronic exposure,
suggesting that the spinal cord does not exhibit tolerance. To examine directly
the spinal contribution to opiate analgesia and tolerance we studied opiate anti-
nociception in spinally transected rats.
Spinal transections (T6-T9) and catheterizations were performed under ether
anesthesia on male albino rats (250-400g). At various intervals after transection
the latency of tail withdrawal (flick) to a high intensity thermal stimulus was
determined. Individual groups of intact and spinal rats were then injected with
morphine sulfate, either, subcutaneously (sc, 0.75 mg/kg - 6.0 mg/kg) or intra-
ethecally (ith, 0 ug - -15 ug) and retested 40 m. later.
Within one day after transection the dose response curve to sc morphine was
shifted to the right of the curve obtained in unoperated control rats. At intervals
of 3, 10 and 20-30 days, this shift was more pronounced. The ED50 of chronic spinal
rats increased progressively during the first three weeks after transection.
To determine whether the decrease in opiate sensitivity was a direct function of
changes within the spinal cord the effect of ith morphine was determined in
intact and spinal rats. In contrast to the results of SC administration, the ith
dose response curve of acute, 24 h. spinal rats was not different from that of
intact rats. However, the intact and spinal rats differed in the distribution of
their antinociceptive scores. Intact rats showed a graded increase in reaction
as a function of increasing dose. Spinal rats showed an all-or-nothing response
to ith morphine; either no change in latency, or a maximum response at each dose.
Additional experiments investigated the reason for this difference between intact
and spinal rats. It was found that the dose-response curve of intact rats to
ith morphine could be modified by experience with the nociceptive test: Their
response to a second ith injection was significantly reduced by the interpolation
of additional tail flick tests, but not by the passage of time alone. This result
suggested that the effect of spinal morphine could be modified by nonpharmacological
processes, such as arousal and habituation to the experimental context.
Department of Pharmacology, University of Illinois College of Medicine, Chicago, IL
(Supported by NIDA grant 02845)
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lntrapartum Resuscitation of
Infants Born to Drug Dependent
Women
Barbara Berger, Saundra Ehrlich, Theresa Matteucci, and
Loretta P. Finnegan
A study was undertaken to investigate the effects of
maternal drug use on neonatal resuscitation. Infants
of drug dependent women (n=56) were compared to a
drug-free control group (n=63). Drugs of abuse for
the drug dependent women included both opiates and
non-opiates (57%) or non-opiates only (43%). Socioe-
conomic status, gestational age and parity were simi-
lar in both groups. A high incidence of low birth
weight was seen in the infants born to drug dependent
women: 13 infants versus 7 infants in the control
group. Resuscitation was divided into four levels
with increasing degrees of complexity: Level I-suc-
tion bulb and/or suction catheter only: Level II-oxy-
gen inhalation and/or positive pressure inhalation in
addition to suction: Level III-intubation and visual-
ization of the cords in addition to suction and oxygen
administration: Level IV-external cardiac massage.
Infants born to drug dependent women had a higher in-
cidence of Level III and Level IV resuscitation. This
was found despite the overwhelming number of black in-
fants in the comparison group (black infants are
thought to require more intervention possibly due to
lower birthweights and a negative response to perina-
tal stress). Levels I and II were similarly adminis-
tered to the two groups of infants. The type of anal-
gesia or anesthesia received by the mothers during the
intrapartum course was not related to the level of re-
suscitation required by the infants. The results of
these data suggest that the risk of requiring in-
creased levels of resuscitation at birth is greater
for infants born to drug dependent women. In the ap-
plication of this data to current practice, medical
facilities which provide care for pregnant drug depen-
dent women should anticipate problems in the delivery
room, and establish appropriate emergency procedures
in order to provide optimal care for this high-risk
population.
Jefferson Medical College of Thomas Jefferson
University, Department of Pediatrics, Phila., PA
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Adinazolam: Comparative
Evaluation of Acute Behavioral
and Subjective Effects
George E. Bigelow, Roland R. Griffiths, Frank Funderburk,
and Ira A. Liebson
Adinazolam is a new triazolobenzodiazepine compound showing
anti-depressant as well as anxiolytic activity. This paper
reports results of a clinical laboratory evaluation of the
acute behavioral and subjective effects of adinazolam in
comparison to the standard benzodiazepine anxiolytic
lorazepam. The purpose of the study was to assess the
relative abuse liability and performance impairing effects of
the compounds, and to assess the utility of the test
procedures for differentiating among benzodiazepines. Twenty-
four volunteers with histories of "recreational" sedative use
were randomized to receive each of four dose levels of either
adinazolam (0, 15, 30, and 50 mg) or lorazepam (0, 1.5, 3, and
5 mg) in a mixed order and under double-blind procedures.
Throughout each 8-hr session repeated measures were made of
subjective and behavioral indices, including: subject and
observer ratings of drug effect and drug liking, Addiction
Research Center Inventory, Profile of Mood States, digit
symbol substitution performance, eye-hand coordination, short-
term memory, choice reaction time, and tracking performance.
Results showed both similarities among and differences between
the two study drugs. Both adinazolam and lorazepam showed
qualitatively similar effects indicating significant dose-
related sedation on both subjective and performance indices.
However, significant between-drug differences and/or drug x
time interactions on measures of eye-hand coordination,
tracking performance, and digit symbol substitution
performance indicated that adinazolam tended to produce a
lesser magnitude and/or a lesser duration of psychomotor
performance impairment than did lorazepam. These data
indicate that the test procedures can differentiate among
benzodiazepines, suggest that subjective effects and
performance-impairing effects of benzodiazepines may be
dissociated, and suggest that adinazolam may present a reduced
risk of behavioral impairment.
Authors' affiliation: The Johns Hopkins University School of
Medicine; Francis Scott Key Medical Center, Baltimore, MD
21224.
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Water Soluble Tetrahydrocanna-
binoids: Pharmacological and
Radioligand Binding Studies
David R. Compton, Patrick J. Little, and Billy R. Martin
The mechanism of action of the cannabinoids is believed to to be mediated either
by general membrane perturbation or through an interaction with a specific
receptor. Binding site assays with cannabinoids are hindered by the extreme
lipophilicity of these compounds. Therefore, attempts have been made to evaluate
water  soluble  THC analogs [morpholinobutyric  acid ester  (MB) and
trimethylammonium (TMA) derivatives of 8-THC] in ligand binding and
pharmacological assays. The radioligand binding studies using either 10 or 100
nM 3H-MB- 8-THC (37°C, 1 mg prot/ 5 ml TES-NH4OH buffer, pH 7.0) failed
to find any evidence of a specific, saturable binding site for the cannabinoid class
of drugs. These data are similar to those previously reported for 3H- 8-THC
binding to brain tissue (Harris et al., 1978). The results from radioligand binding
studies using 75 pM 3H-TMA- 8-THC are not similar to data published
previously (Nye et al., 1985). Binding studies with fresh tissue indicate a large
degree of unsaturable binding, plus a small amount of saturable binding (KD = 26
nM, Bmax = 33 pmol/ mg prot). However, 3H-TMA- 8-THC also bound to heat
denatured (95°C, 1 hr) tissue in a saturable manner (KD = 771 nM, Bmax = 3.02
nmol/ mg prot). The pharmacological effects of MB- 8-THC on several
parameters (hypoactivity, hypothermia, analgesia) suggests that it is less potent
(0.3-0.1) than 9-THC. Values obtained with
9-THC on these parameters are
similar to those previously reported; also the
MB- 8-THC are similar to those obtained for 8-THC (Martin et al., 1984). The
potency range for the effects of
partition coefficient obtained for 9-THC (12,898 ± 550) is more like the 6,000
value obtained by Gill and Jones (1972) than the 60,000 value obtained by Roth
and Williams (1979). The extremely low coefficient obtained for TMA- 8-THC
(13 ± 1) indicates it is very water soluble. Zitko et al. (1972) reported
MB- 8-THC to be freely soluble in water (at approximately mM levels), yet at the
µM levels being used in these binding studies it was necessary to prepare
solutions in ethanol in silanized glassware, which suggests limited hydrophilicity.
The coefficient obtained for MB- 8-THC (526 ± 27) supports this contention,
These data suggest that the 3H-TMA- 8-THC site is probably not responsible for
the behavioral effects of the cannabinoids. Secondly, although MB- 8-TI-IC is
active behaviorally, this cannabinoid did not exhibit saturable binding, which may
be due to the fact that MB- 8-THC is only partially water soluble, suggesting
other water soluble analogs should be investigated.
AUTHORS: D.R. Compton; P.J. Little; B.R. Martin; Med.Coll.Va./ Va.
Commonwealth Univ., Rich., VA. Supported by NIDA Grants DA-03672,
DA-07020, and a CPDD Postdoctoral Travel Grant.
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Carbon Monoxide for Assessing and
Treating Tobacco Dependence in
COPD
Thomas J. Crowley, A. E. Andrews, J. Cheney, G. Zerbe, and
T. L. Petty
Cigarette-induced chronic obstructive pulmonary disease (COPD)
kills about 60,000 Americans each year. Continued smoking by
severely handicapped COPD patients testifies to the strength of
their tobacco addiction. Tobacco abstinence slows COPD's
progression, but clinicians often doubt the veracity of patients'
self-reported abstinence. Among 182 COPD patients attending the
Chest Clinic of the Denver V.A. Hospital, we measured breath carbon
monoxide (CO) with the Minico Monitor to assess smoking prevalence,
seeking correlations with self-reported tobacco abstinence. Of
these patients, 72% received home oxygen therapy, and the mean FEV1
for the group averaged 40% of predicted normal. When confronted
by the monitor, 37% of patients admitted recent smoking. Of those
who admitted smoking, 93% exceeded 8 parts per million (PPM) CO in
breath; of those who denied smoking, 92% had breath CO at or below
8 PPM. Those who admitted smoking had a mean CO of 23.1 PPM; those
who denied smoking had a mean CO of 5 PPM.
We assessed decay rates of breath CO among twelve patients who
smoked, monitoring them hourly from immediately after a last
cigarette through 8 hours of abstinence. The group mean CO declined
from 32.2 PPM to 17.2 PPM over 8 hours; this is 55.9% of the possible
fall, assuming an asymptote of 5 PPM. Exponential fits to the data
of each of the 12 patients produced half-life estimates ranging
among patients from 2.7 to 12.7 hours (mean 6.5 ± 0.81 s.e.m. hours).
Finally, we have attempted to shape reduced smoking by reinforcing
reduced CO levels among COPD patients. Breath CO samples were
assessed at subjects' homes 3 times per week for month. In the
last 2 weeks, subjects were paid Colorado lottery tickets (on a
sliding scale) for reductions in breath CO below baseline levels.
Three patients have now completed this protocol, and the final
measured values are approximately l/3 lower than initial values.
CO measurement appears valuable for providing reasonably valid,
inexpensive, and instantaneous information on smoking behavior to
pulmonary patients and their clinicians. Reinforcement of reduced
CO levels may be a practical way of encouraging abstinence in these
severely addicted, tobacco-dependent patients.
AUTHORS: T.J. Crowley, A.E. Andrews, T.L. Petty, G. Zerbe, J.
Cheney; Departments of Psychiatry, Medicine, and Preventive
Medicine and Biometrics, University of Colorado School of Medicine,
Denver, Colorado 80262. Support from MDA: DA03961
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Effects of MDA and MDMA on
Neurotensin and Substance P
Systems in Rat Basal Ganglia
G. R. Hanson, K. Merchant, A. A. Letter, D. M. Stone,
and J. W. Gibb
Considerable public attention has been focused recently on the actions of
amphetamine-like designer drugs such as 3,4mthylenedioxyanphetmine (MDA) and
its congener, 3,4 methylenedioxymethamphetamine  (MDMA, ecstasy). We (Stone, D.
et al., FASEB abstracts, 1986) and Ricaurte et al. (Science 229, 1985) have
found that these compounds exert profound biochemical changes in CNS seroton-
ergic pathways while apparently having lesser impact on CNS dopaminergic pro-
jections. However, prior to the present report, there have been no studies
which have examined the influence of MDA and MDMA on neuropeptide pathways.
Rats were given 5 subcutaneous injections (6-h intervals) of saline MDA (10
mg/kg/dose), MDMA (15 mg/kg/dose) or METH (15 mg/kg/dose) and sacrificed 18 h
following the final injection. In some experiments the dopamine D-2 antagonist,
sulpiride (80mg/kg/dose), or the 5HT-2 antagonist, ritanserin (1 mg/kg/dose),
were given either separately or concurrently with the designer drugs or METH.
Neurotensin-like (NTLI) and substance P-like (SPLI) immunoreactivity were
determined by RIA in the striatum and substantia nigra employing highly specific
antiserum.
We found that concentrations of striatal NIL1 were similarly elevated by treat-
ment with MDA, MDMA or METH (200% of control). Increases of striatal NTLI also
were seen following sulpiride administration, an effect which was additive with
that of the designer drugs and METH However, while each of these stimulants
also increased nigral NTLI concentrations (200% of control), D-2 blockade, by
itself, did not have an effect and in combination it attenuated the METH effect
in this tissue, but did not alter the changes induced by MDA and MDMA. In
contrast, 5HT-2 blockade had no effect on NTLI concentrations either alone or in
combination in striatal or nigral tissues.
The substance P systems responded somewhat  differently in that SPLI concentra-
tions were elevated in the striatum following treatment with both MDA and MDMA,
but nigral levels of SPLI were only elevated by MDA treatment.
These findings demonstrate that the designer drugs MDA and MDMA, can have
profound effects on the neurotens in and substance P systems associated with the
basal ganglia. Some of these effects appear to be related to dopaminergic, but
hot serotonergic activity, although other mechanism are definitely involved.
(Supported by USPHS grants DA 00869 and MH 40175)
Affiliation: University of Utah, Salt Lake City, UT
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Human Coffee Drinking: Rein-
forcing and Physical Dependence-
Producing Effects of Caffeine
Roland R. Griffiths, George E. Bigelow, and Ira A. Liebson
In a residential research ward, coffee drinking was studied in 9
volunteer human subjects with histories of heavy coffee drinking.
The presence or absence of caffeine in the coffee was manipulated
under double-blind conditions by using caffeinated (CAF) or
decaffeinated (DECAF) coffee. When subjects were alternately
switched for 10 or more consecutive days between CAF and DECAF,
the daily number of cups consumed tended to be relatively stable.
In a different experiment, preference for CAF vs. DECAF was
assessed. After experimenter-scheduled exposures, subjects were
given choices between CAF and DECAF. When subjects were presum-
ably caffeine tolerant/dependent, CAF was better liked than DECAF
and was reliably preferred to DECAF in choice tests. When sub-
jects were not caffeine tolerant/dependent, CAF was not reliably
preferred to DECAF, nor were there pronounced differences in
liking. Under these conditions, some subjects preferred DECAF
to CAF, citing adverse symptoms (suggesting caffeine toxicity)
as reasons for avoiding CAF. The effects of caffeine withdrawal
were studied by abruptly substituting DECAF for CAF for 10 or
more days. This resulted in an orderly withdrawal syndrome,
having an onset latency of 19 hours, peaking on days 1 or 2, and
progressively decreasing over the next 5 or 6 days. The with-
drawal syndrome, which was detected on subject-rated, staff-
rated, and objective behavioral measures, was characterized by
increased headache, sleepiness and laziness, and decreased
alertness and activeness. The present study provides the first
unequivocal demonstration of the reinforcing effects of caffeine
in humans and also documents the severity of the caffeine with-
drawal syndrome. It is concluded that caffeine has the cardinal
features of a prototypic drug of abuse.
AUTHORS: R. R. Griffiths, Ph.D.; G. E. Bigelow, Ph.D.: I. A.
Liebson, M.D.; Department of Psychiatry and Behavioral Sciences,
Johns Hopkins/Key Medical Center, Baltimore, MD. Supported in
part by N.I.D.A. grant DA03890.
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Subjective Effect of Diazepam
Withdrawal: Severity Depends on
Chronic Diazepam Dose
M. Emmett-Oglesby, D. Mathis, S. Idemudia, H. Lal, and
C.Harris
The subjective effect of withdrawal from diazepam has
been measured in an animal model for anxiety, the
pentylenetetrazol (PTZ) discrimination paradigm (La1
and Emmett-Oglesby, Neuropharmacology 22:1422, 1983).
In this paradigm rats are trained (with food re-
inforcement) to press one lever after injections of
the anxiogenic drug PTZ, and to press an alternate
lever after saline. In previous studies, the stimu-
lus effect of Ro 15-1788 (given to precipitate with-
drawal) substituted in a dose-dependent manner for
the PTZ stimulus. The present study was conducted to
determine the relationship between dose of diazepam
(given chronically) and degree of PTZ-lever selection
precipitated by Ro 15-1788. Prior to chronic diaze-
pamI rats selected the PTZ-appropriate lever after
PTZ, and the PTZ stimulus was blocked by diazepam,
indicating reliable control of behavior by drug
stimuli. Rats were then injected intraperitoneally,
at 8-hour intervals, with diazepam, 20, 40, or 80
mg/kg. After 6 days of chronic diazepam all rats
were given an injection of diazepam, 20 mg/kg, fol-
lowed 15 min later by Ro 15-1788, 40 mg/kg. They
were tested for lever selection 15 min after the
second injection. The percent of rats selecting the
PTZ-lever increased from 20 to 86% over the dose
range from 20 to 80 mg/kg, tid. (7-12 rats per
group). These data indicate that, as with overt
withdrawal signs, the severity of the subjective ef-
fect of withdrawal is also directly related to the
dose of chronic diazepam. These results further
characterize PTZ discrimination as a sensitive assay
for a subjective effect of diazepam withdrawal.
AUTHORS: M.W. Emmett-Oglesby, Ph.D.; D.A. Mathis;
S.O. Idemudia, Ph.D.; H. Lal, Ph.D.; and C.M. Harris,
Ph.D.; Department of Pharmacology, Texas College of
Osteopathic Medicine, Fort Worth, TX. Supported by
N.I.D.A. Grant DA-03521A.
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Kappa and Mu Opiate Effects
on Information Processing
Ronald I. Herning, Wallace B. Pickworth, and Karen Kumor
In drug abusers morphine, a mu agonist, and ketocyclazocine, a
kappa agonist, produced different profiles of subjective,
physiologic, and discriminative effects. Subjects reported
euphoria after morphine and dysphoria and LSD-like effects after
ketocyclazocine. Event related potentials (ERPs) provide a means
of assessing the effects of drugs on sensory and cognitive function
in humans. We used an ERP measure to distinguish mu and kappa
opiate effects on human cognition.
Twelve male volunteers with drug experience participated in an
inpatient study. They received: placebo, naloxone (210 mg),
morphine (30 mg) or ketocyclazocine (1.2 mg) in a double-blind
randomized experiment. The subject performed the oddball ERP task
before, 60 and 300 minutes after drug administration by listening
to rare and frequent tones and counting the rare tones. The EEG
was recorded from five scalp locations. The peaks and latencies of
the N100 and P300 components of the average ERP were determined for
the rare and frequent tones. The NlOO amplitude to the rare tone
was reduced only by ketocyclazocine (p < .05). Morphine,
ketocyclazocine and naloxone reduced P300 amplitude to the rare
tone (p <.05); only morphine increased P300 latency (p < .05).
The decrease in N1OO amplitude with ketocyclazocine indicates a
deficit in selective attention and is consistent with a previous
report of perceptual alterations in humans. During morphine-induced
euphoria and ketocyclazocine-induced dysphoria the P300 amplitude
is reduced. The effect is not specific to opiates since P300
amplitude is also reduced by alcohol and cocaine. The reduction in
P300 amplitude reflects an inability to update working memory
during the psychoactive effects of these drugs. This inability may
be a direct drug effect or a consequence of the euphoria or
dysphoria produced by abused drugs. The increase in P300 latency
produced by morphine suggests a delay in processing the target
stimuli. This delay was not observed with ketocyclazocine. Thus,
mu and kappa agonists, cause differential effects on sensory
information processing in drug abusers.
Authors Affiliation: NIDA Addiction Research Center
P.O. Box 5180, Baltimore, MD 21224
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The Effects of MDMA (Ecstasy)
on Brain-Stimulation Reward
and Detection Thresholds
Michael P. Bird, Carol B. Hubner, Stefanie Rassnick,
and Conan Kornetsky
Methylendioxymethamphetsminne (MDMA) is a psychoactive compound
having structural similarities to both amphetamine related
sympathomimetics and hallucinogens like mescaline. It is
reported to produce profound pleasurable effects including
acute euphoria and longer lasting positive changes in attitude
and self-confidence, and recent reports indicate extensive
recreational use.
In this study the abuse potential and behavioral effects of
rscemic 3.4-MDMA were assessed by brain-stimulation reward and
detection, respectively. Increased sensitivity (a lowering of
threshold) for rewarding brain stimulation has been used as an
animal model of drug-induced euphoria and is thought to be
predictive of abuse liability in man. A raising in the detec-
tion threshold suggests a disruption in attentional and percep-
tual capacities. In both procedures, a bipolar electrode was
stereotaxically implanted in the medial forebrain bundle-
lateral hypothalamic (MFB-LH) area of male CDF rats. Reward
and detection thresholds were determined using a modification
of the psychophysical method of limits. Subjects were trained
to turn a wheel manipulandum to obtain electrical stimulation
to the MFB-LH. In the reward procedure the animal learns to
respond only to stimuli which are rewarding, while in the
detection procedure the animal is motivated to respond to the
lowest intensity cue it can detect.
MDMA significantly lowered the reward threshold at doses (l.O-
2.0 mg/kg. SC) which did not alter the detection threshold.
Higher doses (4.0-8.0 mg/kg. SC), however, did not lower the
reward threshold but did significantly raise the detection
threshold and increased nonreinforced responding. These find-
ings suggest that MDMA has euphorigenic properties that can be
dissociated from its attentional and motor effects. The close
correspondence between high doses which fail to lower the
reward threshold and the minimally effective dose that raises
the detection threshold illustrates the influence of attention-
al and perceptual effects of MDMA in disrupting the animal's
ability to perform in the reward procedure.
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Contribution of Personality
Variables to the Subjective
Effects Produced by
Methaqualone and D-Amphetamine
Martin lonescu-Pioggia, George S. Welsh, and
Jonathan O. Cole
Welsh (Creativity & Intelligence, Chapel Hill, NC: IRSS, 1975) proposed a
personality model employing two independent dimensions: origence (OR) and
intellectence (IN). OR lies on the vertical dimension and IN on the horizontal.
Continuous scores can be obtained on both dimensions which are orthogonal and
also yield four distinct personality types. Low OR subjects prefer structure, while
high scorers favor unstructured and unconventional experiences. Low IN subjects
prefer concrete experiences, while high scorers are more comfortable with the
abstract. If a relationship between personality and substance use exists, then
acute drug-induced subjective effects may vary as a function of subjects’ scores on
OR and IN.
MMPI-derived OR (M-OR) and IN (M-IN) scores were obtained from 23 males and
20 females who met provisional criteria for recreational substance use: 1) use of
psychoactive substance (excluding etoh or marijuana at least 4 times); 2) does
not meet DSM-III criteria for a substance abuse disorder; 3) use of a substance
primarily for relaxation or experiencing novel mood states; and, 4) MMPI profile T
scores generally <70.
Twenty-two subjects received 200 and 400 mg of methaqualone, and 21 subjects 15
and 30 mg of d-amphetamine under placebo-controlled double-blind conditions.
Each experiment consisted of three sessions during which subjective states were
measured pretreatment, and at 4 one-hour intervals posttreatment, using an
abbreviated version of the ARCI.
ARC1 scale scores were predicted from M-OR and M-IN using multiple linear
regression. For methaqualone, high M-IN scores were associated with high scores
on the Sedation scale (R2= .31, p.< 05). For amphetamine, high M-OR scores were
associated with high scores on the Amphetamine (R2=.43, p<.05) and Euphoria
scales (R2= .16, p<.O5); in one case, a low M-IN score was associated with a low
score on the Euphoria scale (R2=.31,p<.05).
M-OR and M-IN scores were used to classify recreational substance users into one
of Welsh’s four personality types. A significant proportion of subjects (28/42) fell
within the type characterized by high scores on both OR and IN. In addition, a
significant proportion of subjects (32/43) also had peak MMPI profiles involving
some combination of scales 4/Pd and/or 9/Ma (p < .01).
Results suggest that personality variables can be used as preditors of acute drug-
induced subjective states. While substances may have a uniform effect, its
perception, and hence the estimate of abuse potential, is partially mediated by
individual differences. This subgroup of substance users was characterized by
high scores on both OR and IN, and by MMPIs on scales 4/Pd and/or 9/Ma.
AUTHORS: M. Ionescu-Pioggia, Ph.D.1,2,3; G.S. Welsh, Ph.D.1, J.O. Cole, M.D.2;
1) University of North Carolina at Chapel Hill, 2) McLean Hospital-Harvard
Medical School, 3) Burroughs Welcome Co., Research Triangle Park, NC 27709.
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Opioid Profile of BW942C in Man
Rolley E. Johnson and Donald R. Jasinski
BW942C is a chemically novel enkephalin-like pentapeptide under
evaluation fox the treatment of acute non-specific diarrhea.
BW942C exhibits naloxone reversible opioid activity in the guinea
pig ileum and animal antitussive model. Parenterally, BW942C is
three to six times more potent than morphine in producing
analgesia in rats and mice. The oral dose required to produce
antidiarrheal effects is reported to be thirty to sixty-two
hundred times less than the oral dose required to produce
analgesia. This wide separation between apparent central nervous
system and peripheral activity provides a rationale for the
efficacious use of BW942C without abuse liability.
The high water solubility allowing for possible parenteral
administration and reports of euphoria, and naloxone reversible
opioid effects led us to assess the drug for morphine-like
subjective effects, miosis and abuse liability in nine opioid
abusers using a double-blind, randomized, crossover design.
Comparisons of physiological and subjective effects were made
between intramuscularly administered morphine (7.5, 15, and 30
mg), BW942C (0.5, 1.0, and 2.0 MG) and placebo. Although both
drugs constricted pupils, only morphine constricted pupils in a
dose dependent manner. Neither drug significantly affected
respiration, blood pressure, or temperature. Subjective effects
were measured using the Single-Dose Opiate Questionnaire (Feel
Drug, Drug Identification, Opiate Symptoms and Liking scales) and
a short form of the Addiction Research Center Inventory (MBG,
PCAG, and LSD scales). Both drugs were psychoactive as measured
by the Feel Drug scale; however, responses were monotonic for
BW942C and dose dependent for morphine. BW942C did not increase
Liking scores while morphine increased Liking scores in a dose
responsive manner. Only morphine at the high dose significantly
(p< 0.05) increased the MBG (euphoria) scale score. Only BW942C
at the high dose significantly (p< 0.05) increased the PCAG
(apathetic sedation) and LSD (dysphoria) scale scores; effects
which are consistant with nalorphine-like agonists. A dose
responsive increase in "dope" identification was observed with
morphine but not BW942C.
From this data, it is concluded that BW942C is not a typical
morphine-like drug and is not likely to be abused.
Authors: R.E. Johnson, Pharm.D.; D.R. Jasinski, M.D.; The
National Institute on Drug Abuse, Addiction Research Center
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A Calorimetric Analysis of Body
Temperature Changes Produced in
Rats by Morphine, Methadone,
and U50,488H
Thomas J. Lynch, Rebecca P. Martinez, Michael B. Furman,
Ellen B. Geller, and Martin W. Adler
selective kappa agonist, U50-488H (Upjohn). A gradient-layer
calorimeter with semiconductor, heat flux sensors permitted
measurement of whole-body Q, while VO2 was calculated from the
p02 deficit measured in the calorimeter. Calorimeter temper-
ature was 20°C.
Continuous chart traces of body temperature (Tb), O2 consumption
(VO2) and heat loss (Q) from Sprague-Dawley rats were obtained
before and after s.c. injection of morphine, methadone or the
Control and saline-injected rats showed only slight changes in
Tb, Q and VO2 and these were in parallel. However, increasing
Tb, was consistently correlated with a decreasing Q/VO2, ratio
(calories per ml O2) and vice versa.
further.  Within minutes Tb began an exponential recovery with a
hypothermia, but very different during recovery.
(40 mg/kg) changes in Tb, VO2 were similar during the onset of
A low dose of morphine sulfate (4 mg/kg) caused a small increase
in both Q and V02, accompanied by hyperthermia of 0.5-1.0ºC
lasting about min. The hyperthermia conincided with a Q/V02
decrease of 0.2-0.4 cal/ml. Injection of 8 mg/kg caused slight
hypothermia in some cases and greater hyperthermia in others.
The relationship between changes in Tb and Q/VO2, with 8 mg/kg
was similar to that with 4 mg/kg only more clear.
A high dose of morphine (64 mg/kg) caused hypothermia of 4-5°C
within 4 hr. The drop in Tb was initiated, typically, by a 0.7
cal/ml increase in Q/V02 within 1 hr.
continuously until Tb stabilized at a low level between 2 and 4
After 1 hr, Q/V02 dropped
hr post-injection. The start of recovery was signalled by a
sharp increase in VO2 while Q remained steady or dropped even
time constant of 30-60 min.  With the kappa agonist, U50-488H
Since Q and VO2 both decrease during the onset of hypothermia
induced by all three drugs, the apparent cause of hypothermia is
decreased metabolism rather than an absolute increase in heat
loss. We don't know if the drop in Q/V02, suggesting peripheral
thermoregulation, would occur faster in native rats during a
similar decrease.
Temple University, Philadelphia, PA
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Interactions Between Naloxone and
T-Lymphocytes: Do They Indicate
the Presence of Specific Opiate
Binding Sites?
J. J. Madden, R. M. Donahoe, J. Zwemer-Collins, and A. Falek
Opiates have been reported to modulate various biological
functions of T lymphocytes when administered either in vivo or
in vitro. Lymphocytes from opiate addicts, for example, exhibit
diminished capacity for DNA repair, increased cytogenetic
damage, and decreased E-rosette forming ability and mitogen-
stimulated blastogenesis. However, the mechanism(s) by which
opiates modulate these lymphocyte functions has not yet been
determined although the hypothesis has been advanced that T
lymphocytes have specific opiate binding sites.
Naloxone, the opiate antagonist, binds specifically to highly
enriched, unstimulated peripheral T lymphocytes that are rela-
tively platelet (<20%) and monocyte free (<2%). Platelets and
monocytes interfere with the measurement of specific binding for
lymphocytes because they take up large quantities of labeled
compound yielding high non-specific binding values. The specific
binding of naloxone to the lymphocytes is media dependent. It
can be demonstrated in a minimal buffer like Hanks Balanced Salt
Solution (GIBCO) but not a highly enriched medium like RPMI 1640
(GIBCO) with or without fetal bovine serum. The inhibition of
specific binding by RPMI 1640 is not a function of ionic strength,
pH, the presence of reducing agents (glutathione), or of adenine-
containing compounds (NAD+ and nicatimamide). Specific binding
can also be demonstrated in sonicates of lymphocytes particular-
ly if the soluble material is first removed from the active
membrane particulates by high speed centrifugation. The superna-
tant apparently contains a factor(s) which inhibits specific
opiate binding. The specific binding to whole lymphocytes is
saturable at approximately 100nM, although this varies between
individuals.
AFFILIATION:
Emory University, Atlanta, GA and Georgia Mental Health
Institute, Atlanta, GA.
Funded in part by NIDA grant #01451
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Discriminative Properties of Flupirtine, a New
Centrally Acting Analgesic, in Rats
Bernd Nickel, Suzanne E. Schell, Harlan Shannon, and
Michael Swedberg
Flupirtine (FPT), ethyl-N-[2-amino-6-(4-fluor-phenylmethyl-amino)-
pyridin-3-yl]carbamate, a new analgesic has been shown to be as
effective clinically as pentazocine (PENT) and codeine in relief of
severe pain. No significant difference was observed in overall
analgesic effect assessed by a verbal rating system yet a fairly
pronounced sedative-type effect was found with FPT. Preclinical
pharmacological studies confirm these findings but little is known
about the possible mechanisms by which FPT may exert this activity or
about its subjective effects.
In view of this, studies were initiated in an animalmodel to identify
discriminative effects of drugs (Shannon, JPET 216(3):543-551, 1981).
Male F344 rats were trained in a two-choice, FR5 shock termination
task. Studies were conducted to determine if animals could be trained
to discriminate between FPT (10mg/kg i.p., 30 minutes pre-test) and
vehicle. Following some 64 sessions in which FPT was administered 30
minutes before the start of the training session, the level of drug
appropriate responding did not reach the pre-established criterion for
acquisition. When the pretreatment time was decreased to 10 minutes,
the training criteria were met. However, performance in individual
animals was not always reliable. In addition doses of FPT (0.3to 10
mg/kg) were evaluated in rats trained to discriminate between vehicle
and 10 mg/kg of PENT. PENT alone produced dose related increases in
responding on the PENT lever (nearly 100%). In animals tested with FPT
responses on the PENT lever remained at or near zero at all dosage
levels. FPT was also compared with tramadol, another analgesic widely
used in Europe. As in other test procedures, FPT showed behavioral
effects clearly different from those exhibited by tramadol in these
studies. That is, tramadol substituted for PENT whereas FPT did not.
Since sedative-like properties had been seen with FPT, the compound was
also tested in a separate group of rats trained to discriminate between
lorazepam (LZP) (0.3 mg/kg) and vehicle. Rats trained on and tested
with LZP responded on the drug appropriate lever nearly 100% of the
time. In contrast, when FPT was the test drug, responding on the LZP
appropriate lever remained at or near zero.
Thus, the profile of behavioral activity FPT exhibits appears to be
somewhat unique compared to that shown by other strong centrally acting
analgesics in these testing procedures. Additionalwork is ongoing to
further describe its discriminative properties.
AUTHORS: Bernd Nickel, rer.med.*; Sue Schell; Harlan Shannon, Ph.D.;
and Michael Swedberg, Ph.D.; *Homburg Degussa Pharma Gruppe,
Biological Research, D-6000 Frankfurt/Main, Federal Republic of
Germany; and Addiction Research Center, National Institute on Drug
Abuse, Baltimore, MD USA
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Flupirtine, a New Analgesic With
a Novel Profile of Activity
Bernd Nickel, Karen L. McCullough, and Bruce Vaupel
Early results with flupirtine (FPT) strongly suggested a novel profile of
pharmacological activity. FPT demonstrated relatively high potency as an
analgesic but did not show signs in common with opiates or other potent
analgesics. Studies of tolerance, physical dependence and self-adninistration
as we11 as binding to opiate receptors ware negative.
To further examine the profile of activity FPT demonstrates, the chronic spinal
dog preparation, previously shown to provide valuable insight into the compar-
ative spectra of activity of a large number of centrally acting agents, was
used. Studies were conducted comparing three (0.31, 1.25, and 5.0 mg/kg) doses
of pentazocine (PENT) and four doses (0.31, 1.25, 5.0, and 10.0 mg/kg) of FPT.
I.v. administered PENT and FPT were evaluated for effects on two nociceptive
reflexes, the flexor (spinal) and the skin twitch (supraspinal), as well as on
respiration, heart rate, pupillary diameter, nictitating membrane width, rectal
temperature, and behavior over a 150 minute period (Vaupel et al., Drug Alc.
Dependence 2:45-63, 1977).
PENT was clearly more effective than FPT in depressing the amplitude of the
flexor reflex. Both drugs produced increases in the latency of the skin twitch
reflex with pentazocine being apparently more efficacious. PENT and FPT-induced
antinociception determined with the skin Witch reflex peaked within the first
10 minutes of administration; however, the effect of PENT was sustained over 150
minutes. FPT and PENT produced comparable miotic and hypothermic effects. The
profile of FPT is characterized by hypothermic antinociception, miosis, slight
hypothermia, and decreased behavioral arousal. Notably dogs which appeared to
be sleeping were easily awakened. PENT produced a profile characterized by
supraspinal and spinal antinociceptive properties, miosis, and slight hypo-
thermia.
In summary, these studies are in agreement with earlier results suggesting that
FPT may exhibit a profile of activity distinctly different from classical
centrally acting analgesic and other centrally acting compounds previously
characterized in the spinal dog preparation. More work is underway to elaborate
on the mechanisms which may underlie the compound's activity.
Affiliation: Homburg Degussa Pharma Gruppe, Addiction Research Center and
National Institute on Drug Abuse
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The Effect of Chronic Maternal
Drug Addiction on Placental Drug
(Xenobiotic) Metabolism
Enrique M. Ostrea, Jr., Thomas Porter, and James N. Wardell
The human placenta (plac.) is normally incapable of xenobiotic
biotransformation, although there are circumstances such as
in maternal cigarette smoking, where specific placental xenobiotic
monoxygenase activity has been induced. The aim of this study
was to establish if chronic drug addiction during pregnancy
would induce placental metabolism of drugs, as well. Microsomes
(105,000 g pellet) were prepared from tissue homogenates of
placentas obtained from 4 control and 5 drug dependent (DD)
women and from the liver of 3 non-drug dependent fetuses (22-24
weeks). The microsomal mixed function oxidase reactions
(hydroxylation and dealkylation) and conjugation were assayed
as follows: A. hydroxylation of aniline (assayed as Drug
p-aminophenol formed/mg protein). B. demethylation of aminopyrine
(assayed as nmol HCHO formed/mgprotein) and C. conjugation
of bilirubin (assayed as µg conjugated bilirubin formed/mg
protein). The liver from an adult Sprague-Dawley rat was used
during each assay to control for enzyme activity. The
concentration of products formed were plotted against time and
from the slope of the regression line, the enzyme activity was
calculated as products formed/mg protein 160 minutes.
RESULTS (enzyme activity)
Control Plac. DD Plac. Liver (fetus) Liver (fetus)
A. 0.93 0.28 3.12 44.76
B. 2.05 2.97 6.21 30.49
c. 0.18 0.25 0.14 1.39
CONCLUSION
Despite chronic addiction, the placenta of the DD mother shows
no enhancement of its xenobiotic biotransformation activity
and therefore does not offer the fetus who also has limited
hepatic drug biotransforming capability, any protection from
drugs.
AUTHORS: E. M. Ostrea, Jr., M.D., T. Porter, B.S.; J. N. Wardell,
M.D.; Wayne State University, Hutzel Hospital, Departments of
Pediatrics and Obstetrics/Gynecology, Detroit, MI
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Infants with Slit-Like Ventricles:
Incidence, Perinatal Factors,
Birth Weight, and Neonatal
Abstinence
Matthew E. Pasto, Saundra Ehrlich, and Loretta P. Finnegan
Infants exposed to narcotic agents in-utero show a
higher incidence of slit-like ventricles (SLV) than
infants born to drug-free control mothers. Seventy-
three infants were studied at birth, one month, and
six months (43 drug-exposed and 30 control infants).
As in previous studies, a persistently high percentage
of SLV were seen in the drug-exposed group; 93% at
birth, 72% at one month and 26% at six months in com-
parison to the control group which had 37%, 17%, and
3% at similar time intervals. Grouping both the drug
exposed and control infants together, SLV were more
likely to occur in white infants (87%) than in black
infants (62%). SLV were also more likely to occur and
persist in infants with lower birth weights (2992.5
gms. vs. 3130.2 gms.) and in those who required treat-
ment for neonatal abstinence (p=<.05). Although the
frequency of SLV in infants decreased between birth
and six months of age, an increasing percentage of
treated infants continued to show slit-like ventricles
- 65% at birth, 68% at 1 mo. and 72% at 6 months.
Though these infants had severe symptoms of abstinence
(on assessment with the Finnegan Neonatal Abstinence
Score) , these findings do not exclude the possibility
that the pharmacotherapy required for abstinence in-
fluenced the persistence of SLV. For drug-exposed in-
fants, there were no significant differences between
infants with slit-like and normal ventricles in number
of days to control and treat abstinence or maternal
methadone dose during pregnancy. For infants with
SLV, no differences were found in age of mother, ges-
tational age, or infant head circumference. In con-
clusion, factors which may possibly play a role in the
occurrence and incidence of SLV are: 1) race, 2) low
birth weight, 3) drug exposure in-utero, 4) neonatal
abstinence, and possibly 5) pharmacotherapy for absti-
nence.
Jefferson Medical College of Thomas Jefferson
University, Department of Radiology, Phila., PA.
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THC Plasma Distribution in
Rhesus Monkey Mother and Fetus
Near Term
Merle G. Paule, John R. Bailey, and W. Slikker, Jr.
In order to quantify the placental transfer of delta-9-tetrahy-
drocannabinol (THC, the major psychoactive component of mari-
juana) to the fetus, three late term (146-151 day! rhesus mon-
keys (Macaca mulatta) were given 0.3 mg/kg THC iv (maternal
radial vein). With the use of an intraplacental cannulation
technique, simultaneous blood samples were obtained from a
maternal uterine vein and an intraplacental artery at 0, 1, 3,
6, 15, 30, 60, 120 and 180 min after dosing. Plasma samples
were analyzed by radioimmunoassay for THC and a major metabolite
11-NOR-9-carboxy-THC (11-NOR). Peak plasma THC values were
obtained 15 min after dosing in the fetus and demonstrate that
THC rapidly crossed the placenta into the fetal circulation.
The concentration difference between maternal and fetal plasma
THC, which was striking over the first 15. min, decreased rapidly
and after 3 hrs, maternal and fetal levels were equal (37
ng/ml), indicating that fetal THC exposure after maternal admin-
istration is substantial. Maternal concentrations of THC were
greater than maternal ll-NOR concentrations at all time points
examined. 11-NOR was virtually undetectable in fetal plasma
which suggests 1) this metabolite that is formed by the mother
does not readily cross the placenta and 2) the fetus does not
readily metabolize THC to 11-NOR. In another group of animals
it was determined that plasma THC areas under-9 the concentration
versus time curves (AUCs, as ng-min/ml x 10-2 15-300 min after
injection of 1.0 mg/kg THC iv, did not differ significantly
between pregnant (n=6, AUC=7041 and nonpregnant (n=3, AUC=876)
females indicating that pregnancy did not appear to alter
maternal disposition of parent compound after THC administra-
tion.
AUTHORS: Merle G. Paule1,2, Ph.D.; John R. Bailey1, M.S.;
William Slikker, Jr.1,2, Ph.D.; 1Primate Research Facility,
Division of Reproductive and Developmental Toxicology, National
Center for Toxicological Research, Jefferson, AR 72079, and
2Department of Pharmacology, University of Arkansas for Medical
Sciences, Little Rock, Arkansas 72205. (Supported, in part, by
NIDA IAG 224-83-0005.)
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Local Cerebral Glucose Utili-
zation Following Intravenous
Cocaine Administration
L. J. Porrino; F. R. Domer; A. Crane, and L. Sokoloff
Behavioral studies have shown cocaine to be a potent reinforcing
stimulus. As with other psychomotor stimulants cocaine admini-
stration also increases locomotor activity. Both the locomotor
and reinforcing effects of cocaine are thought to be mediated by
its actions at dopaminergic synapses, particularly those of the
mesolimbocortical system. We have used the quantitative auto-
radiographic 2[14C]deoxylglucose (2-DG) method to determine the
anatomic distribution of alterations in metabolic activity in
this system as well as other portions of the CNS that are pro-
duced by cocaine in rats. Rates of local cerebral glucose
utilization (LCGU) were measured according to the standard
protocol in four groups of male adult Sprague-Dawley rats to
which 0.5, 1.0 and 5.0 mg/kg cocaine or vehicle alone was admin-
istered i.v. 5 minutes prior to the initiation of the experi-
mental procedure. Locomotor activity was measured concurrently
with the 2-DG procedure. Cocaine administration resulted in
discrete changes in LCGU at all doses. Significant dose-depen-
dent increases were observed in the medial prefrontal cortex,
nucleus accumbens and lateral septum. At the lower doses, those
which rats will self-administer, LCGU alterations were mainly
restricted to these portions of the mesolimbocortical system. At
the highest dose widespread increases were also found in struc-
tures of the extrapyramidal motor system including the caudate,
globus, subthalamic nucleus and the substantia nigra, and a
significant decrease was observed in the lateral habenula.
Locomotor activity positively correlated with LCGU in the cau-
date, globus pallidus, substantia nigra and inversely in the
lateral habenula. The rate of glucose metabolism in the nucleus
accumbens, a structure thought to have a role in stimulant-pro-
duced locomotor activity, did not correlate with locomotor
activity in the present study. These data are consistent with
the view that portions of the mesocorticolimbic system, in
particular the medial prefrontal cortex and the nucleus accumbens
are a part of the neural circuitry subserving the behavioral
response to cocaine. The locomotor stimulatory effects of
cocaine, however, appear to be mediated by the extrapyramidal
motor system.
Affiliations: NIDA-ARC, Baltimore, MD; Tulane University, New
Orleans, LA. and NIMH, Bethesda, MD
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Induction of Midazolam Depen-
dence in the Rat
Gary M. Samoriski, Norman R. Boisse, Nicholas Quaglietta,
and John J. Guarino
Midazolam (MID) is a new benzodiazepine currently marketed in the
U.S. for preoperative sedation and induction of anesthesia. MID
is the most fat soluble, rapidly acting and short acting benzod-
iazepine. Among a group of benzodiazepines Studied (self-adminis-
tration), MID had the highest abuse liability. Despite this, a
withdrawal syndroma has not been demonstrated. Accordingly, ex-
perimantal investigations of physical dependence to MID in the
rat were performad under different schedules of administration.
Acute dose response and time action for CNS depression (overt in-
toxication) were evaluated by gross neurological testing to guide
design of treatments (Tr). Signs of withdrawal (WD) were monit-
ored by 2-3 Tr blind, independent raters. Tr-I, 120 mg/kg, p.o.,
g.i.d., which produced continuous CNS depression, was stopped at
72 hrs. and testing for WD began. WD emerged after 1.5 days, pe-
aked at 3.8 days with recovery by day 5. The long latency for WD
suggested saturation of body and/or metabolism. Tr-
II, 120 mg/kg, p.o., b.i.d. x 3 weeks, produced a 28% more severe
WD than Tr-I. Onset was more abrupt, less than one day, and pe-
aked. at 2.2 days with recovery by day 9. Tr-III, MID 120 mg/kg,
p.o. chronically escalating to 180 mg/kg, b.i.d. x 5 weeks, pro-
duced the most severe WD (19% more than Tr-II) and was quickest
to peak (1.8 days). Treatments I-III produced tolerance to gross
intoxication. In Tr-IV, (a single 120 mg/kg, p.o.) MID showed no
evidenceof spontaneous withdrawal. These results provide evid-
ence for the intrinsic potential of midazolam to induce chronic
dependence; acute dependence seems to be absent perhaps because
of MID's extremaly short duration of action. Further study is
needed to rigorously compare MID to other benzodiazepines for
relative dependence potential. Nevertheless, MID withdrawal was
no more severe than for the long acting historical standard of
maximal chlordinzepoxide dependence (JPET 226: 100, 1983).
AUTHORS: Gary M. Samoriski, Norman R. Boisse, Nicholas
Quaglietta arid John J. Guarino, Sect. of Pharmacology North-
eastern University, Boston, MA 02115
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Genetic Differences in the
Development of Physical
Dependence on Pentobarbital
in Four Inbred Strains of Rats
Tsutomo Suzuki, Yoko Koite, Saizo Yanaura,
Frank R. George, and Richard A. Meisch
The purpose of the present study was to systematically investi-
gate physical dependence on pentobarbital (PB) in four inbred
strains of female rats, Fischer 344 (F344), Lewis (LEW), Sponta-
neously Hypertensive (SHR) and Wistar Kyoto (WKY), and to inves-
tigate the possible relationship between degree of motor incoor-
dination during PB treatment and severity of withdrawal.
Rats were chronically fed food containing PB on an escalating
drug dosage schedule (1 to 16 mg/kg of food) over a period of 47
days. Motor incoordination was elevated by a rotarod performance
test. Withdrawal was conducted by substituting normal food for
PB-admi!xed food. Withdrawal signs were observed for 48 hrs after
termination of drug treatment.
During treatment, the growth curve of the LEW, SHR and WKY rats
was suppressed as compared with respective controls. The ranking
of the motor incoordination was as follows: WKY > LEW > SHR >
F344. After withdrawal, various signs of PB withdrawal occurred.
The withdrawal signs from PB in F344, LEW and SHR rats were mild
as compared with those in WKY rats. The order of the severity of
withdrawal signs in the four inbred strains was parallel to that
for motor incoordination.
The results of this study emphasize the important role of genetic
factors as determinants of both response to chronic drug treat-
ment and degree of withdrawal severity. These results suggest
that the differences between strains in withdrawal can be attrib-
uted to differences in the degree of chronic CNS depression.
AUTHORS: T. Suzuki, Ph.D.; Y. Koike, Ph.D.; S. Yanaura, M.D.
F.R. George, Ph.D. and R.A. Meisch, M.D.
Affiliation: Hoshi University, Toyoko Japan; University of
Minnesota, Minneapolis; University of Maryland, Baltimore;
National Institute on Drug Abuse, Addiction Research Center,
Baltimore, Maryland
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Tripelennamine Potentiation of
Opioid Reinforcement (T’s and
Blues)—Mediation by Central
Histamine?
Ellen M. Unterwald and Conan Kornetsky
In recent years, the abuse of pentazocine combined with tripelennanine (street
name "T's and Blues") has become widespread. This combination is frequently
substituted for heroin and apparently gives the user a more heroin-like effect
than is experienced with pentazccine alone. The mechanism by which tripellenanine
enhances the euphoric properties of pentazocine is poorly understood. We have
previously reported that pentazccine lowers the threshold for rewarding brain
stimulation and that tripelennanine potentiates this lo&ring effect (Unterwald
and Kornetsky, Pharmacol. Biochem. Behav. 21:961-964, 1984). A lowering of
reward threshold appears to reflect drug-induced euphoria and hence is predictive
of abuse liability (Kornetsky et al., Arch. Gen. Psycriat. 38:289-292, 1979).
Tripelennanine has several pharmacological actions including antihistrminic and
local anesthetic effects. The present study was undertaken to determine which of
these actions is responsible for tripelennanine's ability to enhance euphoria.
Bipolar stimumlating electrodes were implanted in the medial forebrain bundle-lateral
hypothalmus of male rats. A rate-independent procedure was used to determine the
reward threshold and involved varying the current intensity of the stimulation
according to a modification of the psychophysical method of limits. The effects of
diphenhydranine, an antihistamine, and procaine, a local anesthetic, on the threshold
for reinforcing brain stimulation were determined. In addition, their ability to
potentiate the effect of pentazocine was also tested.
Results indicate that acute administration of diphenhydranine produced a significant
although modest, lowering of reward threshold. When a low, ineffective dose of
diphenhydranine was co-administered with an ineffective dose of pentazocine, a
significant lowering of reward threshold was seen. Procaine, over a wide range
of doses, produced no significant effect alone or in combination with pentazocine.
Therefore, it appears that diphenhydranine, but not procaine, has weak reinforcing
activity. These results suggest that antihistamines can increase the euphoric
quality of opioids and that the reinforcing property of tripelennamine is
mediated at least in part through its effect on central histanine systems.
AUTHORS: E. M. Unterwald and C. Kornetsky, Laboratory of Behavioral Pharmacology,
Boston university School of Medicine
Boston, Massachusetts
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Effect of Cigarette Rod Length
on Smoking Topography
Phillip P. Woodson and Roland R. Griffiths
Nine habitual smokers smoked their preferred brand cigarette
under three conditions. In the "Full-Length Condition" (FLC),
one puff was taken from each of eight full length cigarettes
while in the "Butt-Length Condition" (BLC), one puff was taken
from each of eight butt length cigarettes prepared by clipping
off all but 5 mm of burnable tobacco rod distal to the filter.
In the third "Whole-Length Condition" (WLC), one cigarette was
smoked (eight puffs) progressively down the burning rod to within
5 mm of the filter. Carbon monoxide (CO) boost after each
condition was used as an indice of smoke exposure.
The BLC produced a smaller CO boost than did the FLC and WLC.
The lower draw-resistance level of the BLC may partially account
for this in that it generated a more intensive puff (i.e.,
shorter latency to maximum flow and higher maximum flow). This
should make the combustion process more efficient; resulting in
less CO production. The more intensive puff profile of the BLC
may also explain the finding that even though BLC puff durations
were shorter than those of the FLC, BLC puff volumes were only
marginally less (p .1) than those of the FLC. The CO findings
may also be a function of the smaller smoke inhalation volume
(i.e., shallower inhaling) and slower smoke inhalation rate of
the BLC. BLC smoke was rated as hotter than the other two
conditions, suggesting that the less intense inhalation pattern
may be a defensive mechanism.
AUTHORS: P. P. Woodson, Dr.,sc.nat.
R. R. Griffiths, Ph.D.
Department of Psychiatry and Behavioral Sciences
The Johns Hopkins University School of Medicine
Baltimore, Maryland 21224
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An 11-Year Study of Mortalities
in Methadone Patients: The
Growing Impact of AIDS
Warren K. Bickel, William F. Knight, Ira Marion, and
Joyce H. Lowinson
Many heroin addicts upon entering methadone treatment show good
therapeutic gains, discontinue drug use, and generally lead a
productive and useful life. Unfortunately, a certain number of
methadone patients do not make therapeutic improvement, but
instead continue their drug use and continue to engage in the
concominant lifestyle. Consequently, it is not surprising that
methadone patients have increased rates of mortality resulting
from drug related accidents and violence, overdoses, and a
variety of medical problems stemming from substance abuse.
A study was done in order to characterize the mortalities that
occurred in a large methadone program serving 2400 patients in
the Bronx borrough of New York City during the period of 1975 to
1985. Medical records and death reports were reviewed in order
to obtain the exact cause of death. Mortalities were classified
as follows: drug overdose, AIDS, medical, alcohol related,
violent and accidental, suicide and unknown.
A total of 263 persons died over an 11 year period while
enrolled in the methadone program. The overall death rate has
risen from 8.35/1000 in 1975 to 19.34/1000 in 1985. Although
the numbers have been increasing, the contribution of the
various causes to the overall mortality have been changing.
There is evidence that over time the impact of overdoses,
violent and accidental deaths are waneing while the impact of
medically related deaths and AIDS are coming to the fore. In
1982, AIDS accounted for 4.6% of all mortalities; by 1985 AIDS
was responsible for 38.6% of the mortalities. Clearly, AIDS is
becoming the most significant factor in the mortalities en-
countered in methadone treatment; if the present trend continues,
in 1986 AIDS will be the single largest cause of death in our
program.
AFFILIATION:
Einstein College of Medicine, Division of Substance Abuse, 1500
Waters Place, Bronx, NY 10461
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Effects of Diazepam on Human
Laboratory Aggression:
Correlations with Alcohol Effects
and Hostility Measures
D. R. Cherek, J. L. Steinberg, and T. H. Kelly
Clinical studies have typically reported that diazepam
(Valium) reduced aggressive behavior of patients (e.g.,
Cherek and Steinberg, 1986). However, diazepam resulted in
"paradoxical” increased aggressive behavior in some patients
(Hall and Zizook, 1981), and increased reports of hostility
in subjects residing on a research ward (Griffiths, et. al.,
1983). The following experiment was undertaken to determine
the effects of acute diazepam administration on aggressive
responding of normal males in a laboratory setting.
METHOD
Subjects
Seven males have participated after giving their informed
consent. Volunteers were recruited by advertisements
soliciting participation in behavioral research projects.
The advertisements and consent forms did not mention
aggressive behavior, since we did not want to imply that the
research subjects must respond aggressively to participate in
the experiment or to earn monetary payments.
All subjects were given a complete physical exam and
structured psychiatric exam prior to drug administration. To
avoid problems associated with drug usage, daily breath
alcohol measures were taken and urine samples were obtained
for complete drug screen analysis.
PROCEDURE
Subjects were told that they would be randomly paired with
other people participating in the research project at the
same time, but in a different location. The situation was
described as one in which they could influence the amount of
money earned by these other individuals by subtracting money
from them. Subjects were told that people with whom they
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were paired could choose to subtract money from them at any
time during the experimental sessions.
All subjects came to the medical center for daily fifty (50)
minute sessions five days per week (Mon. thru Fri.).
Subjects were required to swallow two #00 gelatin capsules
thirty (30) minutes prior to the session. These capsules
contained either placebo or 2.5, 5 or 10 mg of diazepam per
70 kg of body weight. Successive drug doses were separated
by at least 96 hours, and were administered if preceding
placebo session responding was within variability ranges
established prior to drug administration.
The response console contained two response manipulanda,
response button A and button B. Pressing button A was
maintained by a fixed ratio (FR) 100 schedule of point
presentation. Each point delivery was Indicated by
incrementation of a counter mounted directly adjacent to
button A and was equivalent to ten cents. Pressing button B
ostensibly delivered an aversive stimulus to another person
and was defined as aggressive. The completion of each fixed
ratlo (FR) 10 on button B resulted in the ostensible
subtraction of one point, i.e., ten cents from the other
person.
Aggresslve responding was elicited by subtracting money from
the subjects, which was attributed to the other
participants. Point subtractions (provocations) were
scheduled to occur at random points throughout the session.
In the absence of aggressive responding, subjects were
scheduled to receive 40 provocations (point subtractions) per
session. In addition to ostensibly subtracting a point from
the other person, ten responses on button B also Initiated a
provocation-free Interval (PFI) during which point
subtractions were not presented. PFI durations were either
125 or 500 seconds. Subjects were able to initiate a PFI
only following at least one point subtraction, i.e., an
escape contingency. When the PFI elapsed, point subtractions
were again presented randomly.
Following the completion of the diazepam dose-response curve,
subjects participated in additional sessions and were
administered placebo drinks or a single alcohol drink
containing 0.5 g/kg of alcohol thirty (30) minutes prior to
these additional sessions.
Subjects completed the Profile of Mood States (POMS)
questionnaire and were evaluated for clinical signs of
intoxication after each session. Subjects also completed the
Buss-Durkee Hostility Questionnaire at the end of the study.
Subjects were not actually paired with another person during
the experiment, and they were debriefed and informed of this
at the end of the experiment.
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RESULTS
Aggressive responding usually occurred immediately following
provocations i.e., point subtractions. The effects of
placebo and the three doses of diazepam on the number of
aggressive responses per session are shown in Figure 1.
Dose-response curves at PFI values of 500 seconds are shown
in the top half of the figures, and those at PFI values of
125 seconds are shown in the bottom half. The dose-response
curves are expressed as percent changes from placebo baseline
set at zero, in order to compare effects upon different
frequencies of aggressive responding. The frequency of
provocation was relatively low (5-10 per session) at a PFI of
500 seconds (top half of figure). and higher (16-25 per
session) at a PFI of 125 seconds (bottom half of figure).
Aggressive responding was maintained by escape from scheduled
provocations as previously discussed.
One subject (S-173) increased aggressive responding following
the administration of 10 mg of diazepam per 70 kg. The
effect was first observed at a high frequency of provocation
(lower left curve), and then replicated at a low frequency of
provocation (upper left hand curve). Increased aggressive
responding in this subject typically represented aggressive
responding in the absence of provocation which did not occur
under placebo conditions. No other subjects evidenced this
effect.
Diazepam had no effect upon the aggressive responding of
subject S-178. All other subjects had reduced aggressive
responding following the administration of the highest
diazepam dose. Three subjects had decreased aggressive
responding following the administration of the 5 mg per 70 kg
diazepam dose.
Figure 2 shows the effects of placebo and the three diazepam
doses on non-aggressive monetary reinforced responses.
Dose-response curves are again expressed as percent of
placebo controls. Diazepam produced slight and
dose-dependent decreases in non-aggressive responding in most
subjects. Some subjects evidenced slight increases in
non-aggressive responding.
The large increased aggressive responding observed in subject
S-173, cannot be attributed to a non-specific or generalized
stimulant effect since non-aggressive responses are not
affected or slightly decreased. The decreased aggressive
responding observed in most of the subjects appears to be
selective. Both aggressive and non-aggressive responding
were decreased, but decreases in non-aggressive responding
were less than ten percent, while decreases in aggressive
responding were 25 to 50 percent. Diazepam effects on
aggressive and non-aggressive responding were poorly
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Figure 1. The effect of placebo (0) and three doses of
diazepam 2.5, 5 and 10 mg per 70 kg on aggressive responses.
Data points are expressed as percent changes from the mean
placebo session values set at zero. Drug data points
represent the mean of three different sessions. Vertical
lines at all data points represent 1 SEM. Subjects assigned
to PFI durations of 500 seconds are shown in the top half of
the figure, and those assigned to PFI durations of 125
seconds are shown in the bottom half of the figure.
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Figure 2. The effect of placebo (0) and three doses of
diazepam 2.5, 5 and 10 mg per 70 kg on non-aggressive
monetary reinforced responses. Data points are expressed
as percent changes from the mean placebo session values set
at zero. Drug data points represent the mean of three
different sessions. Vertical lines at all data points
represent 1 SEM. Subjects assigned to PFI durations of 500
seconds are shown in the top half of the figure, and those
assigned to PFI durations of 125 seconds are shown in the
bottom half of the figure.
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correlated (r = -0.09). Subjects S-178 had substantial
decreases in non-aggressive responding while aggressive
responding was unchanged; Subject S-198 had slightly
increased non-aggressive responding while aggressive
responding was markedly reduced.
The Profile of Moods State (POMS) questionnaire was completed
by all subjects at the end of each session. Scores from the
POMS were combined into six categories: tension, depression,
confusion, anger and fatigue. The anger scores as well as
all other categories of the POMS were essentially unchanged
following diazepam administration.
Subjects completed the Buss-Durkee Hostility Questionnaire at
the end of the study. This questionnaire consisted of 75
true-false items. The scale contains both objective and
subjective items regarding aggression and hostility. The
categories of this scale are: assault, indirect hostility,
irritability, negativism, resentment, suspicion, verbal
hostility and guilt. The total hostility score is the sum of
the scores of all of these categories. Subject S-173 who had
marked increases in aggressive responding following the
administration of the highest diazepam dose, had higher
scores on the assault (a measure of physical violence against
others) and verbal hostility scale. Subject S-173 overall
hostility score was 46 and was much higher than scores of any
of the other subjects (17-25).
Discussion
Our preliminary findings indicate that “paradoxicaltt
increases in aggressive responding were observed in a single
subject in a laboratory. Reports of paradoxical increases in
aggressive behavior have been observed in patients
administered certain benzodiazepines in a therapeutic
context. The present experiment indicates that increased
aggressive behavior can occur in normal males following the
administration of diazepam at a dose of 10 mg per 70 kg.
However, the acute administration of diazepam resulted in a
relatively selective suppression of aggressive behavior in
all other subjects, validating the “aggressive” effects
of diazepam that have been reported clinically and in
laboratory studies with non-humans.
The correlation between the effects of diazepam and the
effects of alcohol on aggressive responding was highly
significant (r=0.918, p<.001). In addition, the total
hostility scores on the Buss-Durkee Hostility Scale and the
effects of diazepam on aggressive responding were also
significantly correlated (r=0.823,  p<.025). Our preliminary
data indicate that high scores of self-reported hostility and
increased aggressive responding following alcohol
administration may predict paradoxical increases in
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aggressive behavior following diazepam administration.
However, the typical response to diazepam administration is a
rather selective decrease in aggressive responding and little
or no effect on non-aggressive responding.
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The Role of Temptation in
Reactivity to Alcohol Stimuli
Eric Corty, Charles P. O’Brien, and Stephan Mann
Relapse may be the major problem in the treatment of addictive
behaviors. While treatment can detoxify patients from alcohol
and/or drugs, one of the diagnostic hallmarks of this class of
disorders is the resumption of substance use in the absence of
physiological withdrawal. Wikler (1965) noted that some addicts,
after months or years of abstinence, returned to drug use when
they returned to an environment where they had previously used
drugs. This relapse appeared to be motivated by the reappearance
of withdrawal symptoms. Wikler postulated that classical
conditioning of a specific environment and withdrawal symptoms
occurred via repeated associations. The instrumental activity of
drug seeking and drug use was then reinforced by the alleviation
of withdrawal symptoms when the drug was used. Finally, upon
return to the environment withdrawal symptoms ware re-elicited and
subsequent drug use became more probable.
There is some support for this model in the area of alcohol
dependence. Kaplan et al. (1983) found that cues associated with
alcohol led to physiological and cognitive responses that
correlated with an increased probability of drug seeking behavior.
Others have also shown in humans that alcohol cues affect the
physiological effects of alcohol (Dafters and Anderson, 1982) and
affect craving, physiology, and behavior (Ludwig et al., 1974).
Pomerleau et al. (1983) measured cognitive and physiological
responses in a group of alcoholics and a group of control subjects
who sniffed cedar chips and alcohol. Alcoholics significantly
differed by reporting more craving for alcohol and by swallowing
more frequently when sniffing alcohol. Pomerleau et al.
considered swallowing to be a conditioned response and suggested
that such conditioned responses may be an effective way to assess
desire to drink and to predict relapse.
The present studies replicated and extended the Pomerleau et al.
study. The first study was a replication with several
methodological changes. Notably, salivation rather than
swallowing was the dependent variable, the order of the stimuli
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was counterbalanced, and a caloric control stimulus was used. In
the second study, a series of case reports, the role of cognitive
set in conditioned reactions to drug cues was explored.
STUDY I: Exposure to Alcohol Cues
Subjects. Ten subjects who had completed detoxification at the
Philadelphia VA Medical Center and ten nonalcoholic control
subjects (recruited via signs posted at the VA) were used.
Informed consent was obtained and subjects were reimbursed $5 for
their participation. The alcoholic subjects ware 90% black, had a
mean age of 40.7 (s.d. = 11.7), had their first drink at a mean
age of 14.2 years (s.d. = 4.6), had been heavy drinkers for a
mean of 14.0 years (s.d. = 12.0), had a mean score on the MAST
(Selzer, 1971) of 35 (s.d. = 12.2), had been in treatment for
alcoholism a mean of 2.8 times (s.d. = 2.2) and drank a mean of
8480 ml. of ethanol (s.d. = 8600) over a mean of 17.9 (s.d. = 9.9)
of the last 30 days. In contrast, the nonalcoholic subjects ware
50% black, had a mean age of 35.7 (s.d. = 10.5), had their first
drink at the mean age of 19.3 (s.d. = 7.5), had a mean score of
1.0 (s.d. = 1.2) on the MAST, and drank a mean of 90 ml of ethanol
(s.d. = 100) over a mean of 2.7 (s.d. = 2.1) of the last 30 days.
Procedure. The experimental session always began at the same time
of day. Each session began with a ten minute baseline period. The
subject then placed three dental rolls in his mouth to collect
saliva. After the dental rolls had been placed, the subject opened
the door to a cupboard, removed the container that had been placed
there, and began to sniff the contents of the container. After
five minutes the subject was told to remove the dental rolls and
to replace the container. Fifteen minutes later the procedure was
repeated and subject found a different stimulus to be sniffed in
the cupboard. Fifteen minutes after this second trial the
procedure was repeated a third time with yet a third substance to
be sniffed. Ten minutes later the session was terminated.
The order of the substances found in the cupboard varied. The
first substance that all subjects sniffed was cedar chips. The
second substance was either a cup containing 60 ml of an orange
flavored drink or the smallest available bottle of their preferred
alcoholic beverage. The orange beverage and the alcoholic beverage
were sniffed in a predetermined random order. Subjects were told
that they could not consume any of the substances.
Finger temperature, skin resistance level, and heart rate were
measured continuously. The other dependent variables, salivation,
blood pressure, and self-reported urge to drink alcohol, were
measured at each of the stimulus periods.
Results. Repeated measures ANOVAs ware used to examine all
dependent variables. The design was group (alcoholic vs.
nonalcoholic) by order (cedar, alcohol, orange vs. cedar, orange,
alcohol) by time (baseline vs. stimulus I vs. stimulus II). A
significant group x order x time interaction would show that
alcoholics and nonalcoholics reacted differentially to the
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different stimuli. However, no such significant interactions ware
found. For most of the variables, the only significant effect
found related to time. Both heart rate and finger temperature
decreased significantly over the experimental session (F (2,32) =
20.23, p < .001 and F (2,32) = 12.11, p < .001, respectively).
Both measures of blood pressure evidenced time x group
interactions (F (2,28) = 3.9, p < .05 and F (2,28) = 5.93, p <
.01, for systolic and diastolic respectively). Salivation showed a
significant group x order interaction (F (1,16) = 5.06, p < .05)
with the alcoholics salivating less overall when the stimuli they
sniffed were in the order of cedar chips, then orange beverage,
then alcohol. For the other two dependent variables, skin
resistance and reported urge for a drink of alcohol, no
significant effects were found.
Discussion. Group data from this study do not support the
conditioning mode1 of alcoholism. That is, Study I failed to show
that alcoholics and nonalcoholics react differentially to alcohol
stimuli. Though this may be because the conditioning model of
alcoholism is invalid, the failure to reject the null hypothesis
may also be due to procedural factors. If the procedure is at
fault then it is likely that the phenomenon of conditioned
responses to alcohol stimuli is not robust. That is, the
phenomenon might only be elicitable under certain, specified
conditions and only be measurable by certain, specified variables.
Two procedural differences seem most important. Hodgson et al.
(1979) found that severely dependent subjects exhibited a greater
degree of craving than did moderately dependent subjects. Though
the alcoholic subjects in the present study all had diagnoses of
alcohol dependence, none of them had a SADQ score high enough to
be placed in the severely dependent range (Stockwell et al.,
1983). Thus, it is possible that evidence supporting the
conditioning model of alcoholism would be found with more severely
dependent subjects.
In the present study, subjects were told that though they would be
asked to sniff various substances they would not be asked to and
would not be allowed to consume any of them. Pomerleau (1984)
reported that he kept instructions to subjects deliberately vague
as to the possibility of consumption. Different settings,
environmental and/or cognitive, may be more or less conducive to
the elicitation of conditioned responses or urges. That is, being
faced with a beverage that one knows one will not be allowed to
consume may be phenomenologically different from confronting a
drink that one could actually consume.
Evidence supporting this notion can be found in Kaplan et al.,
(1984). Alcoholics were asked to sniff a malt beverage that they
knew may or may not contain alcohol before consuming it. After
consumption the subject was asked whether he thought the beverage
contained alcohol. Subjects who reported believing the beverage to
be alcoholic showed a significantly greater skin conductance level
change to the presentation of the beverage. Thus, cognitions
appear to play a role in what could be considered a conditioned
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reaction to alcohol related stimuli.
STUDY II: Exposure to Alcohol Cues with Permission to Drink
Study II was designed to explore the role that expectations (or
cognitions, or setting) nay play in eliciting conditioned
responses to alcohol relevant stimuli, In addition to changing the
setting, we also changed the salience of the stimulus, the order
of presentation, and selected as subjects extremely dependent
alcoholics. Study II was designed as a series of case studies.
Subjects. As this study was going to involve the ingestion of
alcohol by alcoholics, the inclusion/exclusion criteria ware
stringent. over a six month period only 11 subjects volunteered
for this study and only three of these met the following screening
criteria. In order to participate, volunteers had to be between
age 25 and 50 and had to have a DSM III diagnosis of alcohol
dependence. They had to report at least a five year history of
heavy drinking; during the past 30 days they had to report
drinking at least 250 ml. of ethanol on at least 20 days. Subjects
had to have an SADQ score of greater than 30. Subjects had to
agree to enter into treatment for alcoholism at the conclusion of
the study. subjects were eligible to earn $50 if they completed
five days of alcoholism treatment at the conclusion of the study.
(All three subjects earned the $50.) And, of course, subjects had
to sign statements of informed consent.
Subjects were excluded if they had any systemic condition that was
caused or worsened by alcohol. In addition they were excluded for
the following psychiatric reasons: any psychotic condition, major
affective disorder, sociopathy, organic mental syndrome or
dementia, and retardation. Subjects had to be free of any other
major substance abuse in the past six months. And finally,
subjects could not be taking any medication with the ability to
alter the psychophysical dependent variables.
Subject 1 (S1) was a 30 year old black male with a seven year
history of heavy drinking and an SADQ score of 36. Prior to
admission for detoxification he reported drinking 30 days per
month, consuming a mean of 310 ml. of ethanol per drinking day.
Subject 2 (S2) was a 26 year old black male with a seven year
history of heavy drinking and an SADQ score of 50. S2 reported
drinking 29 out of 30 days, consuming an average of 440 ml. of
ethanol per drinking day. Subject 3 (S3) was a 32 year old black
male with a 15 year history of heavy drinking and an SADQ score of
45. He reported drinking 30 days in the month prior to admission,
consuming 496 ml. of ethanol per day.
Procedure. The procedure was aimed at getting subjects to believe
that when the researcher offered them a drink of alcohol and told
them that they could drink it, that they actually would be allowed
to consume it. This was deemed vital, for we believed that the
stimulus would elicit a conditioned reaction only if the subject
was tempted by it. To this end, we designed the study to take
several days. The first two days set the stage for day 3, the
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test day.
Subjects were admitted into the hospital on a Friday and began the
study on Monday. At the completion of the study the subject stayed
in the hospital for two more days in order to make sure that the
alcohol withdrawal syndrome had not been re-instituted. After this
the subject was discharged and began alcohol rehabilitation
treatment.
Day 1 and Day 2. On each of these days the subject was seated in
the experimental chamber and had electrodes attached. After a 20
minute baseline period the subject drank either alcohol (0.6 ml/kg
of body weight) mixed one part to five with tonic water or a
similar quantity of water mixed one part to five with tonic water.
The alcohol was calculated to raise blood alcohol level to 0.05%.
subjects were told that on different days they would consuming
different amounts of alcohol. Both subjects and experimenters
were blind as to the amount of alcohol received on each day.
Sixty minutes after the ingestion of the alcohol the session
concluded.
Day 3. was the test day and consisted of two sessions Day
separated by a 45 minute break. Each session had a 20 minute
baseline period during which the first measures of salivation and
physiological responses were taken. After baseline the subject
retrieved a glass containing the stimulus beverage and an opened
manufacturer's bottle of the beverage from the cupboard. The
subject sniffed this for five minutes. During this time
physiological recordings were made and the subject was asked if he
had any urge for a drink of alcohol. Also during this time the
subject watched an audio-video tape that consisted of stimulus
relevant material. After the five minutes were up, the subject was
told that he could consume the beverage if he wanted. All of
these directions were contained in the audio-video tape in order
to minimize experimenter influence. The session continued for
another 25 minutes.
Session I on day 3 always consisted of the non-alcoholic stimulus.
The beverage was a cola and the audio-video tape showed pictures
of soft drinks and soft drink dispensers with a soundtrack from
advertisements. Session II always consisted of the alcoholic
stimulus. The beverage was the subjects' favorite alcoholic
beverage in the form that the subject preferred (e.g., straight or
mixed). The audio-video tape showed pictures of alcoholic
beverages and containers and had footage of a person buying
alcohol in a liquor store and drinking in a bar. Again, there was
a soundtrack from relevant advertisements.
Results and Discussion. The only physiological variable presented
will be salivation as this variable has been found to be relevant
in other studies. We would also like to stress that these results
are based on three case studies.
For both stimuli, the cola and the alcohol, the subjects ingested
the stimulus drink. Thus it seems that subjects believed that the
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beverages could be consumed and found the beverages attractive.
Subjects' reported urges for a drink of alcohol did not vary much
with the stimulus presented. Subject 1 reported no urge for
alcohol in either situation and Subject 3 reported a slight urge
in both situations. only for Subject 2 was there an increase from
a moderate urge for a drink of alcohol when confronted with the
cola stimulus to a considerable urge when confronted with the
alcohol stimulus. On several grounds self-report of urge does not
seem to be adequate in assessing urge. First, it does not show
the variability across situations that one would expect and second
a subject who reports no urge for a drink still consumed a drink.
We calculated a change score for salivation. A change score of
100% indicates no increase in salivation to the stimulus over the
baseline period. Salivation data are shown in Table 1.
Table 1. Individual subjects' salivation and change scores during
cola and during alcohol stimulus periods.
Sl:
Baseline Salivation Change Score
Cola Alcohol Cola Alcohol
1.96 2.61 162% 163%
s2: 1.22 .74 134% 240%
s3: 1.78 1.43 136% 233%
Note: Baseline salivation measured in grams.
Change score = salivation to stimulus as a % of baseline.
All subjects in all conditions evidenced a change score greater
than 100%. Thus it seems that the presentation of a stimulus
beverage with the presentation of ancillary stimulus material and
under a condition where the subject knows that he can consume the
beverage elicits increased salivation.
In two subjects, the change score for the alcohol condition was
considerably greater than it was for the cola condition. Thus, it
seems that for these conditions and for these subjects the
presentation of the alcohol stimulus elicited a greater increase
in salivation.
Overall Discussion. Study I failed to show that conditioned
reactions to alcohol stimuli can be elicited in alcoholics. Study
II suggested that such reactions can be found under certain
conditions and with certain subjects. Thus, at present it seems
safe to conclude that such conditioned reactions do exist but that
their prevalence is unknown and that the parameters under which
they can be elicited are not well known.
Our impression is that the most important parameter for the
elicitation of such a conditioned reaction is a setting in which
the temptation is real. The stimulus must be available and the
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subject must truly believe that it may be consumed. Both the
cognitive and the physical settings are important. This impression
is based on the differences in results between the two studies.
Many parameters beside temptation were varied from one study to
the next and the second study is based on only a small number of
subjects. Nonetheless, we hold that without a tempting stimulus
(one that is available and that the subject believes could be
consumed) the second study would have shown no conditioned
reactions to alcohol related stimuli.
This need for temptation may limit the utility in treatment of the
conditioned reactions to alcohol related stimuli. Initially it
was hoped that this methodology could be used to assess craving
and/or relapse potential during treatment (Pomerleau et al., 1983)
or that it could be used as an active component of treatment for
heroin or cocaine dependence (Childress et al., 1985).
Unfortunately, when actual temptation with the possibility of
consumption is present, the presentiment that assessment or
treatment may contribute to relapse occurs. Although data do not
support the notion that one drink leads to a drunk (e.g., Paredes
et al., 1973), the tenor of the times (e.g., Pendery et al., 1982)
may make it difficult to support the research that would determine
whether the integration of a temptation extinction component into
a comprehensive treatment program would decrease the rate of
relapse. We feel, given the relatively low rates of success in
treatment, that research on conditioning factors in alcoholism is
necessary and should be undertaken.
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Alcohol Effects on Human
Aggressive Behavior: Influence
of Concurrent Fixed-Ratio
Reinforcement Contingencies
Thomas H. Kelly, Don R. Cherek, and Joel L. Steinberg
When humans are provoked in a laboratory setting, they respond in
a manner that presents noxious stimuli, such as electric shock,
loud noise, or monetary point subtractions, to other persons.
This behavior has been investigated because of its functional
similarity to human aggression. Several research groups have
reported that alcohol increases the probability of these
aggressive responses. Recent reviews of these findings have
stressed the importance situational factors in determining the
effects of alcohol on aggressive responding (Taylor and Leonard
1983: Cherek and Steinberg 1986). Clinical evidence also
confirms the situation-dependent nature of alcohol effects on
aggression. This paper presents evidence suggesting that
concurrent reinforcement contingencies influence the effects of
alcohol on human aggressive behavior.
Several studies using various procedures have demonstrated the
role of concurrent reinforcement contingencies in controlling
probabilities of aggressive responding. For example. aggressive
behavior increases in probability during extinction of previously
reinforced behavior (e.g., Azrin et al., 1966; Thompson and Bloom
1966: Kelly and Hake 1970; Harrell 1972). The probability of
aggressive responding is also functionally related to
presentation of other reinforcers (e.g., Hutchinson et al., 1968;
Flory 1969). Drugs such as delta-9 tetrahydrocannibinol,
produce selective effects on aggressive responding that is
maintained by concurrent reinforcement schedules (Cherek and
Thompson 1973: Cherek et al., 1980). Neither the effects of
concurrent reinforcement schedules on human aggressive behavior
or drug effects on these behaviors have been investigated.
M E T H O D
Subjects: Four subjects between the ages of 18 and 40, in good
physical health and devoid of any major psychiatric condition
completed the study. They were recruited with newspaper
advertisement for part-time employment. No mention of drugs or
aggression was included in advertisements to avoid bias in the
109
responding population. All gave informed consent prior to
participation. Subjects were asked to refrain from caffeine and
nicotine consumption for one hoar prior to each session and
illicit drug use throughout the study. Urine samples were
collected at the first session and periodically throughout the
study to monitor drug usage, and breath alcohol levels were
measured daily. Repeated alcohol detection prior to sessions and
any incident of illicit drug consumption were exclusion criteria.
Apparatus: Before sessions, subjects were seated in front of a
human response console equipped with two illuminating response
buttons, an add/subtract counter, pseudo-thermistor and speaker.
The thermistor was taped to the middle finger of the left hand
prior to each session, and subjects were informed that body
temperature, pulse rate and pulse pressure were being monitored.
These instructions were used to minimize the importance of
aggressive responding as a primary dependent variable. No
mention of aggressive responding was offered during initial
instructions.
Procedure: Subjects were exposed to a three component
reinforcement schedule. A and B buttons were illuminated during
components. Responses on the A button intermittently increased
point totals on the counter. Point increases produced an audible
click, and a 0.5 second flash of a green light occurred. A and B
buttons were dark during this time. Each point was exchanged for
ten cents following sessions. During separate components, 50,
200 or 500 responses produced a point. The three components were
presented in a random order twice per session. Components
changed following the first point delivery nine minutes after the
start of a component, or after eleven minutes (i.e., 2 minute
limited hold). A 5 second timeout, during which A and B buttons
were dark, separated components. Session time averaged 56
minutes.
Human response rate during fixed ratio reinforcement
contingencies is typically greater than 4.5 responses per second
and independent of response requirement. Responses occurring
less than  seconds following a previous response (IRT <.2
seconds) were counted but had no effect on response
requirements. Approximately 20% of responses were emitted with
IRT's less than .2 seconds. The added IRT contingency maintained
stable reinforcement density when response rates changed.
Periodically throughout sessions, points were subtracted from
subjects. Point subtractions produced an audible click, and a
0.5 second red light flash occurred. Subjects were told that
they were paired with another participant selected at random from
a group of participants and that this participant would control
point subtractions. In reality, points were subtracted according
to a variable-time schedule throughout the first nine minutes of
each component. No points were subtracted daring the 2 minute
limited hold.
Subjects were informed that they could also subtract points from
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the other participant throughout each session. 10 responses on
the second, or B button darkened the A and B buttons for 0.5
seconds and ostensibly subtracted a point from the other
participant. A 5 second change-over-delay reduced contiguity
between B button responses and point delivery following A button
responses.
Subjects were initially exposed to a minimum of one session with
no provocations. Next, provocations were presented every 75
seconds, on average. Each ratio completed on the B button
delayed subsequent provocations for 500 seconds. A minimum of
three sessions with this avoidance contingency were presented.
Finally, provocations were presented every 300 seconds, on
average. No avoidance or escape contingencies were in effect
during the final schedule. As such, changes in aggressive
responding produced no change in provocation density during
subsequent dose-response determinations. When performance became
stable, alcohol dose-response curves were measured.
Drug Administration: Prior to each session subjects were given
twenty minutes to consume a cocktail containing 16 a of a ginger
ale-ethanol mixture, using 95% ethanol, four drops of peppermint
oil and crushed ice. with 1 ml of ethanol floated on top.
Sessions began 30 minutes after receiving the cocktail. Breath
samples were collected before and after each session to document
blood-alcohol levels. Ethanol doses of 0.125, 0.25 and 0.5 g/kg
were administered double-blind in an ascending/random sequence
until three replications per dose were recorded. Drug
administration was separated by a minimum of forty eight hours
and delivered when preceding placebo session values were within
variability ranges established prior to drug administration.
After completing the study, subjects responded to open-ended
questions designed to solicit information about the validity of
the cover story.
RESULTS
Blood alcohol levels were estimated by breath analysis
immediately before and after each session. The smallest dose
produced negligible blood levels prior to sessions (0.1 g/dl or
less), and no alcohol was detected following sessions. The
moderate dose produced slightly higher presession alcohol levels
(approximately .03 g/dl) which decreased to negligible levels
following the session. The highest dose (0.5 g/dl) produced
higher presession levels (.04 to .08 g/dl) that remained
slightly elevated following sessions.
The effects of alcohol on aggressive responding averaged over an
entire session are presented in figure 1. Low doses of alcohol
produced slight increases on aggressive responding in three of
four subjects which is consistent with previously reported
results. No systematic changes were observed on point-maintained
responding following alcohol administration.
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The relationship between concurrent fixed-ratio response
requirement and aggressive responding was analyzed during control
sessions. Figure 2 presents the number of aggressive responses,
adjusted for provocation, emitted during fixed-ratio 50, 200 and
500 components (open circles). Three of four subjects emitted
significantly more aggressive responses per provocation as
concurrent response requirements were increased.
The effects of alcohol on aggressive responding were also
analyzed as a function of concurrent fixed-ratio response
requirement. Data in figure 2 suggest that the behavioral
effects of the highest dose (0.5 g/kg) were enhanced as
concurrent ratio response requirements increased in two subjects.
Written responses on a poststudy questionnaire and verbal
responses during debriefing indicated that all subjects accepted
the validity of the initial cover story.
FIGURE 1. Aggressive responses per provocation as a function of
the log dose of alcohol (g/kg). Vertical lines represent ± 1
S.E. Each point represents the mean of at least 3 sessions, and
points above 0 g/kg represent the mean of at least 9 sessions.
112
DISCUSSION
Alcohol increased the tendency for subjects to respond
aggressively when provoked. Alcohol had little effect on or
decreased nonaggressive responding at these same doses,
suggesting that the effects of the drug on aggressive responding
were not produced by nonselective stimulation. Density of both
point presentations and point subtractions remained constant
across alcohol doses; therefore, the effects of provocations were
not altered by drug-induced changes in responding. Running rate
and pattern of responding were similar on point-maintained and
aggressive response options, suggesting that the differential
alcohol effects observed were not related to differences in
control responding (Cherek et al., 1985). Instead, the relative
probabilities of responding on the aggressive response option
increased following alcohol administration.
FIGURE 2. Aggressive responses, adjusted for number of
provocation, emitted during three separate components of a mixed
reinforcement schedule at four alcohol conditions. Open circles
represent control sessions, open squares represent 0.125 g/kg,
closed circles represent 0.25 g/kg, and closed squares represent
0.5 g/kg. Vertical lines represent ± 1 S.E. Each point
represents the mean of at least 3 sessions. and control points
represent the mean of at least 9 sessions.
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Small doses were studied to produce blood-alcohol levels below
socially-determined levels of intoxication (see also Cherek et
al., 1985). Other researchers (e.g., Taylor et al., 1976:
Zeichner and Pihl 1979) have demonstrated the aggression-
enhancing effects of high alcohol doses in a laboratory setting.
The probability of aggressive responding was linearly related to
concurrent fixed-ratio response requirements. Hutchinson and
co-workers (1977) studied the relationship between jaw clenching,
a correlate of human anger, and concurrent fixed-ratio response
contingencies. Their data also revealed a positive relationship
between fixed-ratio response requirements, up to 500, and jaw
clenches. As ratio requirements were increased beyond 500,
however, jaw clenching decreased in intensity, resulting in an
overall inverted-U shaped relationship between fixed-ratio
response requirement and jaw clenches. Jaw clenches were also
related to the temporal characteristics of point-maintained
responding, closely paralleling the relationship between nonhuman
adjunctive behavior and concurrent inducing schedules. This
finding along with the results of the current study suggest that
concurrent schedule contingencies influence the emotional and
behavioral response to aversive stimuli. In the present study,
concurrent reinforcement commodities (points on a counter) were
also used as provoking stimuli. As such, the results should be
related to the schedule-induction literature with caution.
Alcohol effects on aggressive responding were influenced by
concurrent fixed-ratio. response requirements in two subjects.
Concurrent reinforcement contingencies appear to be one factor
determining the situation-specific nature of alcohol effects on
human aggressive behavior.
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Naltrexone Stimulation of Pituitary,
Adrenal, and Gonadal Hormones During the
Luteal Phase of the Menstrual Cycle:
Acute Effects of Alcohol
Jack H. Mendelson, Nancy K. Mello, Ulrike Lange,
Siew Koon Teoh, Alice S. T. Skupny, Susan Palmleri, and
James Ellingboe
Derangements in menstrual cycle and reproductive function of
women are frequently associated with chronic alcohol abuse
(Hugues et al. 1980; Ryback 1977; Moskovic 1975). Experimental
animal studies have shown that chronic ethanol administration
may adversely affect pituitary and gonadal hormone function (Van
Thiel et al. 1978; Cicero 1980; Gavaler et al. 1980; Van Thiel
and Gavaler 1982; Mello et al. 1983). However, studies of acute
administration of alcohol to normal women and female rhesus
monkeys did not produce any significant changes in plasma levels
of luteinizing hormone (LH) or 17 beta estradiol (E2)  (Mendelson
et al. 1981; McNamee et al. 1979; Välimäki et al. 1983; Mello et
al. 1984). The absence of any acute alcohol effects on female
pituitary gonadotropins and gonadal steroid hormones in these
studies may have been related to relatively low and stable
hormonal levels during the early follicular and mid-luteal
phases of the menstrual cycle. The present study was undertaken
to determine acute alcohol effects on pituitary, adrenal and
gonadal hormones following perturbation by administration of the
opioid antagonist Naltrexone.
We have recently reported that Naltrexone may be a safe and
effective drug for assessing function of the hypothalamic-
anterior-pituitary axis in women (Mendelson et al. 1986). We
observed that Naltrexone induced an increase in plasma luteiniz-
ing hormone (LH), prolactin, ACTH and cortisol during the early
follicular phase of the menstrual cycle. Naltrexone administra-
tion also induced stimulation of pituitary, adrenal and gonadal
hormones during the luteal menstrual cycle phase. The purpose
of this study was to determine if acute alcohol administration
modified or attenuated Naltrexone stimulated anterior pituitary,
adrenal and gonadal hormones in healthy normal cycling women
during the luteal phase of the menstrual cycle.
METHODS
Ten healthy women between the ages of 22 and 33 (mean age 26)
provided informed consent for participation in these studies.
All women had normal physical and mental status examinations.
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The women also had normal blood chemistry, blood hemogram and
urinalysis studies. All women had normal menstrual cycle
function, none were pregnant and none used contraceptive
medication. Urinalysis for drug screening carried out when
subjects were initially evaluated for participation in the study
as well as on each study day were negative for opioids,
barbiturates, benzodiazepines, cocaine and other stimulant,
depressant, psychoactive and psychotropic drugs. No women had
any past or current history of alcohol or drug abuse.
Each woman was studied on two occasions one day apart. Each
subject received both alcohol and alcohol placebo (as described
below) in a randomized counter-balanced, double-blind procedure.
Half of the subjects received alcohol on the first study day,
the other half received alcohol on the second study day.
Subjects reported to the Clinical Research Facility at 9 a.m. on
each study day following a 12 h fast. An intravenous catheter
was placed in the antecubital vein and connected to a slow
infusion of physiologic saline. Subjects remained recumbent
throughout the study and were not permitted to smoke.
Following collection of blood samples over a 30 min interval,
subjects swallowed a 50 mg Naltrexone tablet. After collection
of two more consecutive blood samples (at 30 min intervals),
subjects drank either an alcohol or an alcohol placebo solution
over a period of 15 min. The alcohol solution consisted of 1 ml
of 95% ethanol/kg of body weight diluted in a total volume of 12
ozs. of ice cold fruit juice. Blood samples were collected at
15, 20, 25, 30, 45, 60, 90, 120, 150, and 180 minutes following
initiation of alcohol or placebo intake. Both the ethanol
solution and placebo alcohol were administered with a new device
which has been described previously (Mendelson et al. 1984).
RESULTS
There were no significant differences in progesterone values for
subjects during the two conditions. Naltrexone administration
did not significantly affect plasma progesterone levels.
Administration of alcohol or placebo did not produce any
significant alterations in plasma progesterone values. A
statistically significant increase in LH levels was found after
both Naltrexone and placebo administration (P <.001) and
Naltrexone and alcohol administration (P <.001). A significant
increase in prolactin levels over baseline values was found for
both the placebo (P <.04) and the alcohol (P <.001) conditions
(Fig. 1). Plasma cortisol levels increased significantly
following Naltrexone and placebo intake (P <.001) (Fig. 2).
After Naltrexone and alcohol intake, a significant increase in
plasma cortisol levels (P <.01) was found (Fig. 2). Plasma
estradiol levels did not increase significantly following
Naltrexone and placebo administration. However, plasma
estradiol levels were significantly elevated following
Naltrexone and alcohol intake (P <.001). Data from
117
representative subjects are shown in Figures 1, 2, and 3.
DISCUSSION
Naltrexone induced stimulation of the hypothalamic-pituitary-
adrenal-gonadal axis observed in previous studies with women
during the early, mid and late follicular phase of the menstrual
cycle (Mendelson et al. 1986) was also found in this study
carried out during the luteal phase of the menstrual cycle. The
magnitude of LH stimulation was smaller in women studied during
the mid-luteal phase of the menstrual cycle than those
administered the drug during the early follicular phase.
However, the magnitude of Naltrexone induced prolactin and
cortisol stimulation during the mid-luteal phase of the
menstrual cycle were the same as those observed in women studied
during the early follicular phase.
Naltrexone administration did not alter progesterone levels
during either placebo or alcohol conditions. Naltrexone
administration did not induce any changes in plasma estradiol
levels during the placebo condition. However, Naltrexone
followed by alcohol administration resulted in a significant
sustained elevation in plasma estradiol levels. This observa-
tion is consistent with findings we obtained in previous studies
of acute alcohol administration following naloxone infusion to
women during the mid-luteal phase of the menstrual cycle.
Acute alcohol intake alone had no effect on basal LH levels in
women and Macaque monkeys (Mendelson et al. 1981; McNamee et al.
1979; Välimäki et al. 1983; Mello et al. 1984). The absence of
an acute alcohol effect on LH following Naltrexone administra-
tion is consistent with previous studies we have carried out
with concurrent naloxone and alcohol administration to women.
These data are also consistent with previous findings obtained
in studies with male Macaque monkeys where alcohol (BAL levels
250-350 mg/dl) did not effect naloxone induced stimulation of LH
and T (Mello et al. 1985). Alcohol administration also did not
suppress naloxone stimulated LH in rat when naloxone was admin-
istered in doses of 1-4 mg/kg (Cicero et al. 1982). However,
following low-dose naloxone administration (0.75 mg/kg) alcohol
(90 mg/dl) suppressed LH stimulation (Cicero et al. 1982).
Since naloxone is postulated to directly stimulate hypothalamic
secretion of LHRH (Yen et al. 1985) these data suggest that
alcohol does not impair hypothalamic regulation of LHRH secre-
tion over the dose range studied. These findings, considered in
the context of previous studies of alcohol effects on synthetic
LHRH stimulation of pituitary release of LH, suggest that both
hypothalamic and pituitary function may be resilient to the
effects of acute alcohol administration. In female rhesus
monkey, blood alcohol levels of 180 to 270 mg/dl did not
suppress LHRH stimulated LH (Mello et al. 1986). Alcohol also
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did not suppress LHRH stimulated LH in intact male rodents
(Cicero et al. 1978) or normal males (Ylikahri et al. 1978).
These studies of acute alcohol effects on LH under basal or
naloxone or synthetic LHRH stimulation are discordant with
studies of chronic alcohol effects where suppression of LH has
been observed in alcoholic women (Hugues et al. 1980; Moskovic
1975; Välimäki and Ylikahri 1981). This suggests that repeated
or sustained episodes of alcohol intoxication are required to
suppress pituitary gonadotropin secretory activity in females.
Alcohol Effects on Naltrexone Stimulated Estradiol
After placebo control administration, estradiol levels were
unchanged by Naltrexone administration. Lack of a Naltrexone-
related increase in plasma E2 following the placebo control is
consistent with the finding that a single dose of synthetic
LHRH, sufficient to stimulate an eight to tenfold increase in
plasma LH, did not raise plasma levels of E2 in normal women who
were studied during the follicular phase of the menstrual cycle
(Kletzky et al. 1982).
The significant and sustained elevation of plasma E2 levels
after concurrent administration of both alcohol and Naltrexone
was unexpected. Although increased LH secretion would be
expected to enhance gonadal steroidogenesis, one should not
observe increased plasma E2 levels unless E2 metabolism were to
become rate limiting. No alcohol-related changes in plasma E2
have been observed in previous studies with normal, healthy
women (Välimäki et al. 1983; McNamee et al. 1979; Mendelson et
al. 1981) or female Macaque monkeys (Mello et al. 1984).
However, basal E2 levels but not Naltrexone stimulated E2 was
measured in these studies.
The rapid increase in plasma E2 following concurrent Naltrexone
and alcohol administration could be the consequence of increased
E2 production and/or decreased E2 metabolism. Increased
synthesis of E2 from testosterone is probably not the
explanation, because alcohol induction of aromatase activity has
been demonstrated only during the long-term ingestion of alcohol
(Gordon et al. 1976). A more plausible mechanism is that the
decrease in NAD/NADH ratio, known to be caused by metabolism of
ethanol in the liver (Forsander et al. 1958), might reduce the
rate of oxidation of E2
for other 17-hydroxy/l7-ketosteroid pairs
to estrone, a shift in equilibrium that
has been demonstrated
in plasma and gonadal tissue (Cronholm and Sjovall 1968, 1969;
Murono and Fisher-Simpson 1984, 1985).
The biologic significance of increased plasma estradiol levels
following alcohol intake during Naltrexone induced gonadotropin
stimulation remains to be determined. Since an increase in
endogenous levels of estradiol during the late follicular phase
of the menstrual cycle is necessary for the normal periovulatory
LH surge, it is possible that acute ethanol intake just prior to
ovulation could effect the time of onset or duration of the LH
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surge. Anovulatory cycles and luteal phase inadequacy are
frequent concomitants of alcohol abuse in women (Hugues et al.
1980; Moskovic 1975).
Whether or not recurrent episodes of alcohol intoxication may
change plasma estradiol levels during early pregnancy also
remains to be determined. Such studies are currently in
progress.
Alcohol and Naltrexone Induced Stimulation of Prolactin
Naltrexone induced stimulation of prolactin levels in women
observed in this study was consistent with recent reports of
naloxone stimulation of prolactin secretion (Snowden et al.
1984; Yen et al. 1985; Cetel et al. 1985). Naltrexone
stimulation of prolactin during the placebo condition study was
probably due to Naltrexone stimulation of gonadotropin releasing
hormone (GnRH). Braund et al. (1984) reported increased
prolactin levels following GnRH administration during the luteal
phase of the menstrual cycle.
The large increase in prolactin levels following Naltrexone and
concurrent ethanol administration was not anticipated since
acute ethanol intake alone did not produce any significant
changes in plasma prolactin levels in women studied during the
follicular phase of the menstrual cycle (Mendelson et al. 1981).
Alcohol induced increases in plasma E2 levels during concurrent
Naltrexone stimulation of LH could facilitate Naltrexone induced
stimulation of prolactin release. Estrogens have been reported
to increase prolactin secretion in experimental animals (Neil1
1974; Clemens and Meites 1977; Quadri et al. 1979) and humans
(Frantz et al. 1972; Yen et al. 1974). Diefenbach and his
associates (1980) have reported that E2 treatment significantly
increased the prolactin response to TRH in intact, ovari-
ectomized and stalk-sectioned female rhesus monkeys.
A modulating effect of 17 -estradiol on prolactin secretion is
believed to occur at both hypothalamic and pituitary levels
(McCann et al. 1968; Dufy et al. 1979). Direct action of
estrogens on prolactin secreting cells has shown to be related
to specific estrogen cytoplasmic receptors and transport
mechanisms (Hang et al. 1978). Estrogens stimulate
incorporation of precursors in prolactin biosynthesis (Stone et
al. 1977; Lieberman et al. 1980), and there is also evidence
that estrogens decrease sensitivity of prolactin cells to
dopaminergic inhibition (Gala and Boss 1975; Labrie et al. 1978;
Beaulieu et al. 1979; Ferland et al. 1979).
Cetel and co-workers (1985) have concluded that "a common
neuroendocrine mechanism is involved in the opioidergic control
of prolactin and LH secretion and that this effect of naloxone
is manifested only during high ovarian steroid environments."
Data obtained in this study are consistent with the hypothesis
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that Naltrexone induced prolactin secretion is enhanced under
conditions when E2 levels are elevated. Further studies are
necessary to determine the biologic significance of ethanol
induced increases in plasma prolactin levels during concurrent
gonadotropin stimulation.
Alcohol and Naltrexone Induced Stimulation of Cortisol
Alcohol administration following Naltrexone was associated with
a prompt increment in plasma cortisol levels. The rate of
increment as well as the peak plasma cortisol levels following
Naltrexone and ethanol administration was significantly greater
than after Naltrexone and placebo intake (P <.01). Acute alco-
hol administration alone has been found to induce an increase in
plasma cortisol levels (Mendelson et al. 1971). Ethanol induced
enhancement of Naltrexone stimulation of plasma cortisol levels
is probably due to a direct effect of ethanol and Naltrexone on
ACTH release from the pituitary since we have shown, in previous
studies, that Naltrexone administration produces a prompt
increase in plasma ACTH levels which is followed by subsequent
increases in plasma cortisol (Mendelson et al. 1986).
In summary, the findings obtained in this study indicate that
Naltrexone stimulates LH, prolactin and cortisol secretion in
normal cycling women during the mid-luteal phase of the
menstrual cycle. Naltrexone did not alter basal plasma levels
of progesterone or estradiol. However, a significant increment
in estradiol levels occurred following concurrent Naltrexone and
ethanol administration. The mechanisms underlying this
phenomena are probably due to ethanol's effects on hepatic bio-
transformation of estrogens following gonadotropin stimulation.
The enhanced levels of anterior pituitary, gonadal and adrenal
hormones following naloxone administration and ethanol suggests
that acute alcohol intake stimulates rather than depresses the
hypothalamic-pituitary-gonadal axis and the hypothalamic-
pituitary adrenal axis. Although depression of pituitary,
adrenal and gonadal function may occur after chronic alcohol
intake or alcohol abuse, we conclude that ethanol has a
biphasic, dose related effect on hypothalamic, anterior-
pituitary, adrenal and gonadal hormones.
FIGURE LEGENDS
FIGURE 1. Plasma prolactin levels for a representative subject
prior to and following Naltrexone (N) and placebo (P)
administration (top panel), and Naltrexone (N) and alcohol (A)
administration (bottom panel).
FIGURE 2. Plasma cortisol levels for a representative subject
prior to and following Naltrexone (N) and placebo (P)
administration (top panel), and Naltrexone (N) and alcohol (A)
administration (bottom panel).
FIGURE 3. Plasma estradiol levels for a representative subject
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prior to and following Naltrexone (N) and placebo (P)
administration (top panel), and Naltrexone (N) and alcohol (A)
administration (bottom panel).
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Alcohol Enhances LHRH-Stimulated
LH in Ovariectomized Female
Rhesus Monkeys
Nancy K. Mello, Jack H. Mendelson, Mark P. Bree, and
Alice S. T. Skupny
INTRODUCTION
It is well-established that chronic alcohol abuse is associated
with menstrual cycle abnormalities (persistent amenorrhea,
anovulation and luteal phase defects) (Hugues et al. 1980;
Moskovic 1975; Välimäki and Ylikahri 1981; Mello et al. 1983).
But it has been difficult to determine if the toxic effects of
alcohol occur primarily at the hypothalamus, the pituitary, or
the ovary, or all in combination. Synthetic luteinizing hormone
releasing hormone (LHRH) stimulates release of anterior pituitary
gonadotropins, luteinizing hormone (LH) and follicle stimulating
hormone (FSH), and can be used to assess pituitary function. We
recently reported that alcohol (2.5 and 3.5 g/kg) prevented LHRH
stimulation of FSH in normal female rhesus monkeys studied during
the follicular phase of the menstrual cycle (Mello et al. 1986).
However, alcohol did not prevent a significant increase in LH
following LHRH stimulation. Under sucrose control conditions,
LHRH-stimulated significant increases in both LH and FSH within
30 and 80 min, respectively (Mello et al. 1986).
A selective alcohol blockade of LHRH stimulated FSH is consistent
with the hypothesis that FSH release is controlled by an inter-
action between endogenous LHRH stimulation and suppression by a
gonadal peptide, inhibin (McCann et al. 1983; Channing et al.
1985). The differential effect of alcohol on LH and FSH during
the follicular phase of the menstrual cycle suggested that FSH
secretory cells may be more sensitive to alcohol than LH
secretory cells. Because FSH is essential for normal follicular
development and maturation (Goodman and Hodgen 1983; Ross 1985).
an alcohol related inhibition of FSH could result in some
menstrual cycle irregularities commonly seen in alcohol dependent
females. Suppression of FSH could delay follicle maturation and
ovulation or result in luteal phase dysfunction after timely
ovulation (DiZerega and Hodgen 1981; Goodman and Hodgen 1983).
Since the release of pituitary gonadotropins in normal females,
under basal or artificially stimulated conditions is necessarily
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influenced by the ovarian steroid milieu, it seemed important to
reexamine alcohol effects on LH and FSH in ovariectomized
females. If alcohol also suppressed LHRH stimulated FSH, but not
LH in ovariectomized females, this would indicate a primary
effect of alcohol at the level of the pituitary. Alternatively,
if alcohol's effects on pituitary hormones were different in
ovariectomized and normal females, this would indicate that
ovarian steroid or peptide modulation of the hypothalamic-pitui-
tary-gonadal axis is one important determinant of alcohol's
effect on FSH and LH. This study examined the acute effects of
alcohol (2.5 and 3.5 g/kg) and an isocaloric control solution on
LHRH stimulated LH and FSH in bilaterally ovariectomized monkeys.
METHODS
Subjects: Five sexually mature, bilaterally ovariectomized
female rhesus monkeys (7.4 +1.1 kg) were studied. These monkeys
had been ovariectomized for-over 440 days ( = 558 +105 days).
Two monkeys were alcohol-naive and three monkeys had a history of
low dose alcohol self-administration but had been alcohol-free
for over 18 months when these studies began. Monkeys were main-
tained on ad lib food and water; monkey chow was supplemented
daily with fresh fruit, vegetables and multiple vitamins. A 12-h
light-dark cycle (7 a.m. to 7 p.m.) was in effect.
Animal maintenance and research was conducted in accordance with
the guidelines provided by the Committee on Care and Use of
Laboratory Animals of the Institute of Laboratory Animal Re-
sources, National Research Council. The facility is licensed by
the U. S. Department of Agriculture. The health of the monkeys
was periodically monitored by a consultant veterinarian from the
New England Regional Primate Research Center.
Sequence of Conditions and Integrated Plasma Sample Collection:
Acute effects of alcohol and sucrose control solutions on LHRH
stimulated LH and FSH were evaluated in the same subjects under
identical conditions. Basal levels of LH and FSH were measured
for 80 min before alcohol or sucrose was administered. LH and
FSH were measured for an additional 120 min before LHRH was
administered, and for 180 min after LHRH administration. Samples
were collected at 20 min intervals except during the first hour
after LHRH administration when samples were collected at 15 min
intervals to more accurately follow the timecourse of LHRH stimu-
lated LH and FSH activity.
Details of the integrated plasma sample collection procedures
have been reported previously (Bree et al. 1982). A complete
description of the radioimmunoassay procedures for LH and FSH
analysis and the enzymatic method used for plasma alcohol analy-
ses appears in Mello et al. 1986. The LH assay sensitivity was
7.2 ng/ml. Intra- and inter-assay coefficients of variation were
6.4 and 7.1 percent, respectively. The FSH assay sensitivity was
a2.0 ng/ml. Intra- and inter-assay coefficients of variation were
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9.4 and 14.5 percent, respectively. The plasma alcohol assay
sensitivity was 20 mg/dl. Intra- and inter-assay coefficients of
variation were 2.7 and 3.8, respectively.
Alcohol Administration: Alcohol (2.5 and 3.5 g/kg), prepared as
a 25 percent solution, was administered through a pediatric grade
nasogastric tube. Alcohol effects were compared with a sucrose
control solution, isocalorically equivalent to 2.5 g/kg alcohol.
Monkeys were fasted for 18 to 20 h to ensure uniform absorption
of alcohol.
LHRH Administration: Synthetic LHRH (Gonadorelin hydrochloride;
Factrel®) (100 mcg i.v.) was injected into the saphenous vein 120
min after alcohol administration. LHRH was administered during
the ascending phase of the blood alcohol curve to ensure that the
maximal effects of LHRH stimulation occurred when blood alcohol
levels exceeded 150 mg/dl.
Statistical Analysis: The effects of sucrose, alcohol and LHRH
on pituitary hormones were evaluated with Analysis of Variance
(ANOVA) and Least Square Difference (LSD) followup tests. If
ANOVA revealed a significant main effect, the significance of
group mean values at each sample period were compared with
baseline means using Dunnett's test for comparison of multiple
experimental groups with a single control group.
RESULTS AND DISCUSSION
LH levels were equivalent before and after administration of a
sucrose control solution. Synthetic LHRH administration
significantly increased LH levels (P < .001) as evaluated by
ANOVA. LH increased significantly within 30 min after LHRH
administration and remained above baseline levels for 105 min
(P< .01). FSH levels were also equivalent before and after
sucrose control administration. Synthetic LHRH stimulated a
significant increase in FSH within 60 min (P < .01).
Acute Alcohol Administration Did Not Change Basal LH and FSH:
Basal LH levels were lower after alcohol but these changes were
not statistically significant. The pre-alcohol baseline LH
values averaged 168 (±6) ng/ml and 162 (±8) ng/ml, respectively.
After administration of 2.5 g/kg alcohol, LH averaged 142 (±6)
ng/ml and after administration of 3.5 g/kg of alcohol, LH
averaged 150 (+6) ng/ml.
These data are consistent with previous studies of acute alcohol
effects on LH in post-menopausal women (Mendelson et al. 1985)
and in normally cycling women (Mendelson et al. 1981; McNamee et
al. 1979; Välimäki et al. 1983) and female Macaque monkeys (Mello
et al. 1984). However these findings are at variance with data
obtained in ovariectomized female rats where alcohol (3.0 g/kg
I.G.) suppressed LH but not FSH under basal (non-stimulated)
conditions (Dees et al. 1985).
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Basal FSH levels were unchanged by alcohol administration. Base-
line FSH values averaged 48 (24) and 66 (±2.2) ng/ml, respec-
tively. After administration of 2.5 and 3.5 g/kg alcohol, FSH
averaged 49 (±3) ng/ml and 61 (±1.5) ng/ml, respectively.
These data are consistent with reports of unchanged FSH levels
after acute alcohol administration in human males (Välimäki et
al. 1984). But in human females, acute alcohol administration
has been associated with a significant decrease in FSH over time
(Välimäki et al. 1983).
Acute Alcohol Administration Enhanced LHRH Stimulated LH: L H R H
stimulated a significant increase in LH (P < .001) after adminis-
tration of 2.5 and 3.5 g/kg of alcohol. LH increased signifi-
cantly within 30 min after LHRH administration (P < .01) when
blood alcohol levels averaged 242 (±26) and 296 (±20) mg/dl. The
magnitude of the LHRH stimulated increase in LH after alcohol was
significantly greater than after sucrose administration (P < .01,
.001). Moreover, there was an alcohol dose-dependent enhancement
of LHRH stimulated LH. After 3.5 g/kg alcohol, LHRH stimulated
LH levels were significantly higher than after 2.5 g/kg alcohol
(P < .001) or sucrose control administration (P < -001).
Baseline LH values were equivalent under all three conditions.
The alcohol related enhancement of LHRH stimulated LH in com-
parison to control conditions is clearly shown in data from a
representative individual monkey (Fig 1). It is apparent that
the rate of onset, magnitude and duration of the LH response to
LHRH was greater after alcohol (closed squares = 2.5 g/kg; closed
circles = 3.5 g/kg) than after sucrose control (open triangles)
administration.
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It is difficult to account for the significant alcohol dose-
related increase in LHRH stimulated LH observed in these
ovariectomized monkeys. Increased pituitary sensitivity to LHRH
stimulation following alcohol administration could reflect
alcohol's effects on endogenous LHRH or on other hormones known
to modulate pituitary sensitivity to LHRH, such as estradiol.
Ovariectomy reduces circulating estradiol by approximately 60
percent, but estrogens are produced in the adrenal and through
peripheral conversion of androgens to estrogens (Ross 1985).
Under LHRH stimulation conditions, increased estradiol could
enhance the LH response, just as the mid-cycle LH surge in
normally cycling rhesus females is dependent upon the peri-
ovulatory increase in estradiol (Karsch et al. 1973). Two lines
of evidence are consistent with the hypothesis that alcohol-
induced changes estradiol may increase pituitary sensitivity
to LHRH stimulation.
First, we found that alcohol significantly increased plasma
estradiol levels in comparison to control (P < .004) following
gonadotropin stimulation by naloxone in normally cycling women
(Mendelson et al. 1986). We speculated that alcohol might
increase estradiol production and/or decrease estradiol
metabolism. Since intrahepatic ethanol metabolism decreases NAD
availabililty for other coupled oxidative reactions (Cronholm and
Sjovall 1968; Cronholm et al. 1969; Murono and Fisher-Simpson
1984, 1985), this in turn might reduce the rate of oxidation of
estradiol to estrone and result in elevated estradiol levels
(Mendelson et al. 1986). Alcohol also increases estradiol levels
in ovariectomized rats (Gavaler et al., 1986).
Second, the sustained significant elevation in LHRH stimulated LH
after alcohol (165 min) in comparison to control (105 min) is
consistent with earlier studies of estradiol pretreatment in
ovariectomized monkeys (Krey at al. 1973). Although chronic (13
day) estradiol treatment decreased the amplitude of the LH
response to LHRH stimulation, LH remained elevated for over 3
hours whereas in untreated ovariectomized and intact rhesus
females, LH levels decreased within 30 min (Krey et al. 1973).
There is also evidence that estradiol pretreatment increases
pituitary sensitivity to LHRH stimulation in normal and hypo-
gonadal women (Jaffe and Keye 1974; Lasley et al. 1975).
Estrogen pretreatment also increased pituitary responsivity to
LHRH stimulation in the intact diestrous rat (Arimura and Schally
1971). Consequently, it is possible that if alcohol did increase
estradiol, this could have sensitized the pituitary to produce an
augmented LH response to LHRH stimulation. Unfortunately, we
were unable to measure estradiol in ovariectomized females in
these studies. Therefore, we cannot provide direct evidence to
confirm or refute the hypothesis that alterations in steroid
biotransformation, associated with intrahepatic ethanol
catabolism, may have increased plasma estradiol and further
sensitized pituitary sensitivity to LHRH stimulation.
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Acute Alcohol Effects on LHRH Stimulated FSH: After administra-
tion of 2.5 and 3.5 g/kg alcohol, FSH increased significantly (P
< .01) within 45 min after LHRH administration. Although FSH
levels were significantly higher after 3.5 than 2.5 g/kg alcohol
(P < .001), this probably reflects significant differences in
both baseline and post-alcohol FSH levels (P < .001).
In contrast to parallel studies in normally cycling female rhesus
monkeys (Mello et al. 1986), there was no differential effect of
alcohol on LHRH-stimulated FSH and LH in these ovariectomized
females. These data suggest that in the absence of antecedent
ovarian steroid modulation, pituitary FSH secretory cells are
more resistent to the acute effects of alcohol. In normally
cycling females, ovarian steroid hormones exert a negative
feedback effect on both LH and FSH during the early follicular
phase. Yet after LHRH stimulation, alcohol had no suppressive
effect on LH in normals or in ovariectomized females, and
suppressed FSH only in intact, not in ovariectomized females.
Further studies will be required to clarify the contribution of
ovarian steroids or peptides (inhibin) to these effects.
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Psychophysiological Effects of
Alcohol-Related Stimuli
Mary E. McCaul, Jaylan S. Turkkan, and Maxine L. Stitzer
When the physiological and subjective effects of a drug such as
ethanol are repeatedly paired with stimuli in the natural environ-
ment, drug-related conditioned responses may come to be elicited
by these previously neutral stimuli. Such conditioned responses
are thought to play an important role in triggering craving and
precipitating relapse to drug use following periods of abstinence.
While much of the objective evidence of conditioning during re-
peated drug administrations has been obtained in animal studies,
there have been several demonstrations of the operation of condi-
tioning in humans.
Conditioned responses to naturally occurring drug-related stimuli
have been demonstrated in humans when slides and videotapes de-
picting drug rituals have been presented to opiate addicts (Teas-
dale, 1973; Ternes et al, 1980) or when drug addicts have been
allowed to perform drug preparation and injection rituals (O'Brien
et al, 1980). In alcoholics, differences in heart rate, skin con-
ductance and subjective response measures were found when alco-
holic subjects were given controlled exposure to the taste of al-
coholic versus nonalcoholic beverages in doses that were insuffi-
cient to produce direct drug effects (Baker and Cannon, 1979;
Cannon and Baker, 1981; Kaplan et al, 1985).
The present study extends previous research on physiological and
subjective responses to naturalistic alcohol-related stimuli, i.e.
tastes, sight and smell of liquor. First, it includes two com-
parison stimuli; one that is similar in gustatory intensity to
whiskey and one that is a neutral gustatory stimulus. Second, it
characterizes the components and magnitude of alcohol-related re-
sponses in subjects with different drinking histories, that is,
social drinkers and alcoholics.
METHODS
Subjects. Twelve male volunteers participated in the study: six
reported histories of alcohol abuse and six were moderate
drinkers. Alcoholics met the following criteria for participa-
tion: five or more years heavy alcohol use, 10 or more drinks
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daily (approximately 3 - 7 days per week), one or more dependence
symptoms such as tremor, morning drinking or blackout, and either
prior treatment for alcohol abuse or alcohol-related social, legal
or employment problems. Social drinkers did not exceed four to
six drinks daily (approximately 2 - 5 days per week) and reported
no dependence symptoms, withdrawal or drinking-related problems.
Subjects were excluded from the study if they reported recent reg-
ular use of any substance other than alcohol, caffeine or ciga-
rettes.
All subjects were 25 - 40 years old; mean ages of social drinkers
and of alcoholics were 29.5 and 30.8 years old, respectively.
Mean years of regular alcohol use was not significantly different
for the two groups; social drinkers had been drinking regularly
for 12.2 years and alcoholics for 14.3 years. Average daily alco-
hol consumption and average number of drinking days per week were
significantly different for the two groups. Alcoholics drank an
average of 18.8 ounces of alcohol on 6.7 days per week, whereas
social drinkers consumed an average of 5.6 ounces of alcohol on
3.3 days per week.
All subjects provided written informed consent prior to participa-
tion in the study. Subjects were paid $40 for the single day ses-
sion.
Procedures. Subjects participated in a single outpatient ex-
perimental session of 4 hours duration. Subjects were checked for
blood alcohol level and a urine specimen was obtained for later
drug screening before the start of the session. Subjects were not
allowed to smoke or drink caffeinated beverages for at least one
hour before the start of the session.
Throughout the experimental session, subjects remained seated in a
quiet laboratory room with the research technician. After sub-
jects were instrumented, a 25-minute physiological stabilization
period began; during this period, subjects received a practice
stimulus presentation trial to acquaint them with the experimental
procedures. For the remainder of the session, twelve four-minute
stimulus presentation trials were conducted; trials were separated
by a variable inter-trial interval averaging 10 minutes.
The three types of stimulus trials were alcohol, hot-pepper juice
and water. Alcohol stimuli included a 2 ml sample of diluted
whiskey to sniff and taste and a "Jack Daniels" whiskey bottle for
visual display. Hot-pepper juice stimuli included a 2 ml sample
of diluted pepper juice and an empty "Sons of Italy" peppers jar.
Water stimuli consisted of 2 ml water and a pitcher for display.
Each 2 ml sniff/taste stimulus was delivered in a test tube which
the subject held under his nose for two minutes, after which he
was instructed to drink. Stimuli were presented in a randomized
block design; each type of stimulus was presented four times
during the session.
Dependent Measures. Physiological measures included: heart rate,
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continuously monitored using chest EKG electrodes; and skin tem-
perature, continuously monitored from a skin surface thermister
taped to the index finger of the left hand. Data were averaged
over 10 second intervals for one minute following each stimulus
presentation.
Subjective effect questions were displayed on a computer screen; a
joy box next to the subjects' right hand was used to move a screen
cursor arrow to respond to each self-report item. When subjects
had moved the arrow to the desired position, they pushed a button
on the joybox to advance to the next item. Analog questions in-
cluded ratings of stimulus intensity, liking, feeling different,
feeling high, feeling hungover, and craving for alcohol. Physio-
logical and subjective data were analyzed using a repeated mea-
sures analysis of variance.
RESULTS
Subjects rated the alcohol and pepper juice stimuli as similar in
intensity; both were rated as significantly more intense than
water. Thus, subjects' ratings confirmed the stimulus selection
of pepper juice as a control for the gustatory intensity of alco-
hol.
Figure 1 presents the effects of water, pepper juice and alcohol
on mean heart rate for social drinkers and alcoholics. There was
a significant effect of stimulus type (p<.0001) as well as a
stimulus type X group interaction (p<.02) on heart rate. For both
groups, heart rate was higher following pepper juice and alcohol
presentations than following water. This increase was greater in
FIGURE 1. Mean heart rate during stimulus presentation trials as
a function of stimulus type. Each point is an average of four
stimulus presentation trials, averaged over six subjects. Trials
were one-minute averages, pooled from six 10-second intervals fol-
lowing stimulus presentation.
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FIGURE 2. Mean scores for three subjective report items as a
function of stimulus type. Scores were obtained one minute after
the start of each stimulu presentation trial. Each point is an
average of four stimulus presentation trials, averaged over six
subjects.
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social drinkers, who showed an average difference of 3.5 bpm be-
tween water and alcohol stimuli, than in alcoholics, who showed an
average difference of approximately 1.0 bpm. There was no signi-
ficant effect of stimulus type or of group on skin temperature.
There was a significant effect of stimulus type on three of the
five subjective report items. On all three items, subject ratings
were highest following alcohol stimuli and less following pepper
juice and water. Figure 2 (top panel) presents the effects of
stimulus type on mean analog high score for social drinkers and
alcoholics. The effect of stimulus type on high ratings was high-
ly significant (p<.006), with subjects reporting feeling higher
following alcohol stimuli than following pepper juice and water
stimuli.
As shown in Figure 2 (middle panel), there was a similar pattern
in alcoholics' responses to the analog question "Do you feel any
different now than before the stimulus"; that is, mean score was
significantly higher following alcohol stimuli than following pep-
per juice and water (p<.021) However, social drinkers did not
respond differently on this item to any of the three stimuli.
Finally, Figure 2 (bottom panel) shows that there was a signifi-
cant effect of stimulus type and of group on craving, specifically
"How badly do you want an alcoholic drink right now." Subjects in
both groups reported significantly higher craving scores following
alcohol stimuli than following pepper juice or water stimuli
(PC.021) Alcoholics reported significantly higher craving fol-
lowing all three stimuli than did social drinkers (p<.051) There
were no significant effects of stimulus type or group for analog
questions on hangover and stimulus liking.
DISCUSSION
In summary, heart rate increases appeared to be determined by the
intensity of the stimulus rather than by the stimulus relationship
to alcohol; that is, heart rate was higher following the more in-
tense stimuli of pepper juice and alcohol than following water.
In contrast, subjective responses appeared to be determined by
stimulus type rather than by intensity; high, feeling different
and craving all were reported as higher following alcohol stimuli
than following pepper juice and water stimuli. Generally, re-
sponses to the three stimulus types were similar in alcoholics and
social drinkers; craving was the only measure on which significant
group differences were evident.
Our findings for heart rate are in contrast with previous reports
of differential responses of alcoholics to alcohol-related vs.
alcohol-neutral stimuli (Kaplan et al, 1985). These differences
may stem from the failure to control for stimulus intensity in
some earlier research. However, our findings for the subjective
analog measures are similar to other research that has reported
magnitude of subjective responses to be a function of the stimulus
relationship to alcohol (Kaplan et al, 1985; Pomerleau et al,
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1983). Our findings suggest a divergence in physiological and
subjective measures of conditioned responses to alcohol and demon-
strate the importance of appropriate controls in understanding
this research area. Further investigations on a number of vari-
ables including environmental context, length of pre-session alco-
hol abstinence and expectation of alcohol availability are cur-
rently in progress in this laboratory.
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Mood States Can Elicit
Conditioned Withdrawal and
Craving in Opiate Abuse Patients
Anna Rose Childress, A. Thomas McLellan, Michael Natale,
and Charles P. O’Brien
In the course of clinical work with opioid abusers, we and others have often
noted the apparent association between negative mood states (e.g.,
depression, anxiety) and subsequent drug use (Woody et al. 1975; Dorus
and Senay 1980; Rounsaville et al. 1982). Most explanations of this
association have focused on the ability of opioids or other drugs to reduce
or temporarily “medicate” the patient’s symptoms (Khantzian et al. 1974;
Wurmser 1979). We have recently become aware of another, perhaps
equally important, way in which moods and drug use may be linked. While
studying the ability of drug-related stimuli to elicit conditioned craving and
withdrawal-like responses in opioid abusers (Childress et al. 1984, 1985),
we noticed that the effectiveness of our stimuli often seemed to vary as a
function of the patient’s mood: if angry or depressed, patients would
sometimes report a stronger subjective response of craving or withdrawal.
We began to suspect that the repeated pairing of certain mood states with
drug administration (perhaps through attempts at self-medication) had
caused the mood states themselves to become conditioned stimuli,
capable of eliciting the conditioned phenomena associated with opioid
use, particularly conditioned craving and withdrawal-like responses
(O’Brien 1975).
Our own work and that of others has shown that external drug-related
stimuli (e.g., drug paraphernalia, drug talk, etc.) which have been
repeatedly paired with drug administration can become conditioned stimuli
capable of eliciting high-like, craving or withdrawal-like symptoms in
opioid abusers (Teasdale 1973; Ternes et al. 1979; Sideroff and Jarvik
1980; Childress et al. 1984, 1985). The current study extends these earlier
findings by investigating the ability of internal stimuli such as mood states
to become conditioned stimuli capable of eliciting conditioned high-like,
craving and withdrawal-like symptoms. If the link between mood states
and these conditioned responses can be demonstrated, it would mean that
problem moods in drug patients can lead to drug use in at least two ways:
1) by prompting self-medication of the uncomfortable mood symptoms
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(negative reinforcement) and 2) by directly eliciting (through classical
conditioning) responses such as conditioned craving and withdrawal
which, in turn, trigger drug use. These two ways are, of course, not
mutually exclusive and may even be mutually enhancing.
BACKGROUND
During the course of an earlier treatment study (Childress et al. 1984,
1985) attempting to extinguish conditioned craving and withdrawal-like
responses in opioid abuse patients, we encountered a methadone
outpatient, “Mr. B,” who had received a series of 22 repeated exposures to
drug- related stimuli, including 6 or more cook-up rituals. In the course of
these treatment sessions, the drug-related stimuli had gradually become
less evocative for this patient, as shown in Figure 1 (See sessions 16
through 22). Prior to session 23, Mr. B had been ejected from the hospital
canteen for loitering and had engaged in an angry exchange with hospital
security officers. Upon subsequently performing a cook-up ritual, the
patient began to experience a cluster of withdrawal-like symptoms,
including yawning, rhinorrhea, lacrimation, sweating, hot flashes and a
bad (withdrawal-like) taste in his mouth. The patient himself was surprised
at the number of symptoms he experienced commenting “Boy, Doc, this is
the worst session we’ve had - I guess all my troubles are getting to me ...”
Across the next sessions (24 - 30) the patient, no longer acutely angry,
exhibited minimal response to the extinction stimuli.
Figure 1. C H A N G E I N S Y M P T O M S
O V E R S E S S I O N S
This case and others like it led us hypothesize that mood states, alone or in
conjunction with other drug-related stimuli, could be important triggers for
drug craving, conditioned withdrawal and potentially, drug use. We chose
to study three negative affective states common in our patients:
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depression, anxiety and anger -- and, for comparison value, one positive
affective state, euphoria.
METHOD
The subjects for this study were seven male veteran opioid dependent
patients receiving inpatient detoxification. These patients were clinically
screened to rule out diagnoses of schizophrenia or organic brain
syndrome. The mean age of this patient sample was 38 years, with an
average of 14 years of opioid use and 4 years of methadone treatment.
After screening, patients were admitted to the inpatient detoxification unit
for a four-week stay. Methadone dose was 25 mg on admission and dose
was reduced to 20 mg the day after admission. Subsequent dose
reductions were scheduled such that detoxification was completed by the
end of the third week post-admission.
Prior to the initiation of treatment, patients were given two sessions which
introduced psychotherapy and offered basic training in guided self-
hypnosis. Guided self-hypnosis training was provided by two licensed
doctoral-level psychologists according to the methods of Spiegel &
Spiegel (1978). This technique enabled patients to briefly re-experience
feelings of anger, euphoria, anxiety, depression or deep relaxation by
recalling, in vivid sensory detail, a scene associated with those feelings.
Before treatment began, patients were asked to select and to describe
scenes associated with each of these mood states.
Each treatment session began with 30 minutes of cognitive-behavioral
psychotherapy. Following therapy, patients entered a state of focused
relaxation through guided self-hypnosis. After becoming relaxed (giving a
self-rating 6 on a 1-10 scale) patients were then asked to shift their
focused concentration to a predetermined mood scene. Patients remained
focused on this particular mood scene until they re-experienced the
feelings associated with the scene. After reaching sufficient
absorption/involvement in a given mood (a self rating of 6 on a 1-10
scale), the patient was asked to open his eyes and proceed with a cook-up
ritual. Following the cook-up, the session ended with a final period of deep
relaxation. Each of the 4 mood states was induced on 4 separate,
randomized occasions using a Latin square design.
Measures
Data were based on the subjective ratings of overall high, craving, and
wifhdrawal using a 1-10 scale for each rating. In addition, the type and
intensity of symptoms was probed through an accompanying list of 24
withdrawal- like and 24 high-like symptoms. Examples of
withdrawal-like symptoms included “watery eyes,” “runny nose,” “pounding
heart,” “chills,” etc. Examples of high-like symptoms included “skin itchy,”
“drowsy, ” “coasting,” etc. The intensity of each symptom was rated by the
139
subjects on a 4 point scale, yielding total scores for withdrawal and high
symptoms. Measures were collected 1) at Baseline, 2) after
mood-induction (Post-Mood), and 3) after cook-up ritual (Post-Cook-Up).
RESULTS
Mean values for subjective high, craving, withdrawal, ratings as well as
high and withdrawal symptom scores were derived for each of the four
mood states, at each rating interval (Baseline, Post-Mood, Post-Cook-up).
Two-way analyses of variance (patient x mood) were performed, using
difference scores to directly assess the impact of the induced mood
(Baseline to Mood), the additional impact, if any, of the cook-up ritual
(Mood to Cook-Up), and finally, the net effect of mood induction and the
cook-up ritual (Baseline to Cook-Up).
Effect of Mood Alone as a Conditioned Stimulus - The analyses assessing
the effect of mood as a conditioned stimulus showed a direct main effect of
mood state on both subjective withdrawal and the withdrawal symptom
score (p<.024). Further paired comparisons (Bonferaroni t-test) showed
the main effect of mood was due largely to the significant difference (p<.05)
between euphoria and depression. induction of euphoria actually reduced
withdrawal responses from baseline values, while depression triggered
overall increases in both withdrawal measures. Though induced anger
was a powerful elicitor of withdrawal symptoms in one study patient, there
was no consistent effect of anger on withdrawal across the patient sample.
The differential effect of the other induced mood states on withdrawal
symptoms is illustrated in Fig. 2, using data from Pt. MOB, whose pattern of
response parallels that of the group as a whole. In general, mood effects
on craving were less consistent and less prevalent than the effects of
mood on withdrawal, though the pattern was similar: euphoria reduced
craving in a few patients, while the negative affective states, depression,
anger and particularly, anxiety tended to increase subjective craving.
There was essentially no effect (p>10) of mood on either the high rating or
high symptom score.
Effect of Adding Cook-up Ritual - Assessment of Post Mood to Cook-Up
difference scores yielded no further statistically significant changes in
either craving or withdrawal as a function of the added cook-up ritual.
Cook-up tended to further increase withdrawal symptoms when preceeded
by induction of anxiety (in four of six patients), but the extent of change fell
short of producing either a significant main (p<.127) or interaction effect
(p<.253) of cook-up beyond mood. There were statistically significant main
and interaction effects upon subjective high and high-symptoms, but these
effects were due almost entirely to the contribution of one patient. In this
patient, cook-up reversed both the euphoria-induced increase and the
depression induced decrease in high/high symptoms.
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Figure 2. Differential responsivity to drug-related stimuli (cook-up ritual)
under different mood states in a methadone patient undergoing
detoxification. Each bar represents the mean withdrawal symptom score
for four stimulus presentations.
Net Effect of Mood Induction Plus Cook-Up - Analyses of Baseline to
Cook-Up difference scores yielded a significant main effect of patient
(p<.012) and a significant (patient x mood) interaction effect (p<.043) of the
net procedure (mood induction plus cook-up) on the craving rating and
withdrawal symptoms. For most patients, the net effect of negative mood
induction plus cook-up was to increase subjective ratings of craving and
withdrawal and withdrawal symptoms above baseline values. When
cook-up followed euphoria induction, however, both subjective withdrawal
and withdrawal symptoms decreased in all five subjects who had
withdrawal symptoms at baseline. There were no significant effects of the
total procedure on either subjective high or high symptoms.
SUMMARY AND DISCUSSION
From these results, it is apparent that:
1) Certain negative mood states, particularly anxiety and depression,
can act as reliable ‘triggers’ or CSs for conditioned withdrawal and craving
in opiate abuse patients.
2) Approximately two-thirds of this small patient sample were “mood
responders,” showing relatively systematic changes in withdrawal and/or
craving to one or more of the induced mood-states. This finding suggests
that treatment programs featuring extinction should address both internal
and external CSs in order to be maximally effective.
3) These internal mood states do not require the presence of external
drug-related stimuli in order to exert their effects. In fact, with the present
procedures, mood induction alone accounted for most of the changes in
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withdrawal and craving. Addition of the cook-up ritual did not cause further
significant change in either the magnitude or the direction of the
conditioned responses.
4) Induction of the positive mood state, euphoria, actually tended to
reduce the baseline withdrawal and craving.
Our interpretation of these data has been cast in terms of the ability of
certain mood states to elicit conditioned opioid-related phenomena. It
could, however, be argued that induction of certain moods may produce
symptoms which resemble opioid withdrawal, but which in reality, reflect
the basic profile of arousal, associated with the mood itself. Induction of
anxiety for example, might cause “palpitations” or “restless, nervous
feelings” which also occur in opioid withdrawal. This explanation,
however does not explain the present pattern of results. For example,
there is little overlap between the symptoms of opioid withdrawal and
those of depression, yet depression was a potent elicitor of opioid
withdrawal symptoms. Anger, on the other hand, can cause considerable
sympathetic arousal, but it did not systematically produce increased
reports of withdrawal. Euphoria, which can be associated with increased
arousal, palpitations, etc. actually caused a reduction in reported
withdrawal. Finally, symptom items associated more specifically with
opioid withdrawal, such as stomach cramps, chills, nausea, watery eyes
etc., were endorsed as often as the relatively non-specific items, e.g.,
“palpitations,” “nervousness,” etc. Given these patterns, we feel that most
of the withdrawal symptoms experienced by these patients are a function
of the conditioned association between certain moods and subsequent
drug use, not just a mis-labeling of arousal associated with the mood itself.
The readiness with which most of these detoxifying patients experienced
and labeled withdrawal symptoms is greater than we have found in either
methadone-maintained or abstinent populations (Childress et al. 1984,
1986). This difference may be due to the ongoing detoxification procedure
in the present sample, which may have increased the probability of
experiencing conditioned withdrawal, and almost certainly increased the
likelihood of noticing and labeling symptoms: most detoxifying patients are
quite attuned to signs of withdrawal. These data would suggest that
detoxifying patients may be particularly vulnerable to the “trigger” effect of
negative mood states on withdrawal symptoms.
We are impressed that the impact of mood states on withdrawal and
craving is robust enough, and systematic enough, to be evidenced even in
this small subject sample under these artificial conditions. Given the
variability in hypnotizability and in the mood induction procedure itself, less
systematic results or even the lack of effects across subjects would not
have been too surprising. Instead, these consistent results suggest that
mood states are powerful “real life” modulators of craving and withdrawal
for many patients and, as such, demand treatment attention.
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From a therapeutic standpoint, two treatment approaches may be useful.
First, professional psychotherapy focused on increased understanding
and control over the frequency of negative moods has been shown to be
helpful. and mood-related extinction, involving repeated exposure to the
“trigger” mood(s) (with or without relevant drug-stimuli), not followed by
drug. Second, since induction of euphoria through guided self-hypnosis
helped alleviate baseline withdrawal symptoms in all patients who had
such symptoms, self-guided positive mood induction could also be a useful
tool for the detoxifying patient, as an adjunct to, or even a partial
replacement for, the medications used to ease opioid withdrawal.
Fortunately, these methods are not mutually exclusive and might very well
be mutually enhancing. We are currently conducting a treatment-outcome
protocol in abstinent opioid abusers which employs both these features
(Childress et al. 1986).
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Abuse Liability Assessment of
Buprenorphine-Naloxone
Combinations
George E. Bigelow, Kenzie L. Preston, and Ira A. Liebson
Buprenorphine is an opioid analgesic with partial agonist
activity. Previous studies with buprenorphine in a post-
addict population showed that while buprenorphine produced
morphine-like subjective effects, it had lower intrinsic
activity than morphine and produced a lesser degree of
physical dependence than morphine (Jasinski et al., 1978).
These investigators suggested that buprenorphine has the
potential to be abused but that this potential is less than
that of morphine.
One strategy used to decrease the abuse of opioid analgesics
has been to combine the opioid analgesic with an opioid
antagonist. Examples of combinations which have been
investigated include: morphine and nalorphine (Fraser et al.,
1956), methadone and naloxone (Nutt and Jasinski, 1974) and
pentazocine and naloxone (Legros et al., 1984). The later
combination, pentazocine and naloxone, is currently being
marketed in the United States.
The purpose of this study was to evaluate the effects of
combining naloxone with buprenorphine. This was done by
assessing the combination product as well as buprenorphine
alone in relation to two reference compounds, hydromorphone
and naloxone, in opioid-dependent human volunteers.
Measurements included both morphine-like effects and opioid
abstinence signs and symptoms. Compounds which show a
morphine-like profile of effects are viewed as possessing
morphine-like abuse potential; this is a methodology which has
received extensive use and validation (Jasinski, 1977).
Measures of opioid abstinence were derived from those
developed by Kolb and Himmelsbach (1938) and from other
documented opioid abstinence signs and symptoms.
METHODS
The subjects were 6 adult male volunteers who were maintained
on methadone HCl 30 mg/day. Methadone doses were administered
once every 24 hours, approximately two hours after the
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experimental session. On the basis of physical examination,
history, and laboratory chemistries, subjects were found to be
without significant medical or psychiatric disturbance other
than their drug abuse. Subjects gave their written informed
consent prior to beginning the study and were paid for their
participation. Subjects participated while residing in an 8-
bed behavioral pharmacology research ward.
Seven drug conditions were tested in randomized order for each
subject: placebo, hydromorphone HCl 6 mg; naloxone HCl 0.2 mg;
buprenorphine 0.2 and 0.3 mg; buprenorphine 0.2 mg plus
naloxone HCl 0.2 mg; and buprenorphine 0.3 mg plus naloxone
HCl 0.2 mg. Commercial preparations of hydromorphone HCl and
naloxone HCl were used. Buprenorphine HCl was supplied by
Reckitt and Colman Pharmaceutical Div in ampules in the
concentration of 0.2 and 0.3 mg (base) in 1 ml normal saline.
The appropriate volume of drug solution from ampules was
diluted to 1.5 ml with 0.9% normal saline. Normal saline (1.5
ml) served as placebo. All doses were given subcutaneously as
two 0.75 ml injections, one in each upper arm, under double-
blind conditions. Hydromorphone and naloxone doses were
calculated on the basis of the salt. Buprenorphine doses were
calculated on the basis of the drug base.
Each subject participated in 7 experimental sessions.
Sessions were run at the same time of day for each subject and
were separated by at least 48 hours. All subjective effect
and psychomotor performance measures were presented on a
computer screen. Subjects used a key pad and joy stick to
respond to subjective effect questions and to perform the
psychomotor tasks. The subject was seated in an experimental
testing room for each 2.5 hour session. After a 15 min
stabilization period, 10 min of baseline physiological
recording was taken; a pupil photo was taken, and the subject
answered subjective effect questionnaires and performed two
psychomotor tasks. Approximately 30 min after the start of
the physiological recording; subjects received subcutaneous
injections of saline or active drug. The session continued in
the testing room for 2 hours after drug administration.
Physiological measures, except for pupil diameter, were
monitored continuously throughout the session. Self-report,
behavioral, and pupil diameter were collected at 15, 30, 45,
60, 90, and 120 min after drug administration.
Four physiological measures were monitored continuously: heart
rate, blood pressure, skin temperature, and respiration. Data
for each measure were collected and stored in one-minute
intervals using a microcomputer. Pupil diameter was
determined from photographs taken in ambient room lighting
using a Polaroid camera with a 3X magnification. Subjective
effect measures included visual analog scales, a
pharmacological class questionnaire, and an adjective rating
questionnaire. On the visual analog scales, the subject rated
his current degree of "high" and "sick" and the degree of "any
drug effect," "good effects," "bad effects," and "liking" of
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the drug effects by placing a mark along a 10 cm line marked
at either end with "none" and "extremely." On the
pharmacological class questionnaire, the subject categorized
the drug effect as being most similar to one of ten classes of
psychoactive drugs; the questionnaire provided descriptive
titles for and examples of each of the following classes:
placebo, opiate, opiate antagonists, phenothiazines,
barbiturates and sleeping medications, antidepressants,
hallucinogens, benzodiazepines, stimulants, and other. The
adjective rating questionnaire consisted of 40 items which the
subject rated on a 5-point scale from 0 (no effect) to 4
(maximum effect). The items in the rating scale were divided
into 3 subscales: the Fraser scale [adjectives previously
shown by Fraser et al. (1961) to be sensitive to opioid
effects], an opioid agonist-like scale [adjectives in the
Fraser scale plus additional adjectives associated with
morphine-like effects], and a withdrawal scale [adjectives
derived from the Himmelsbach abstinence rating scale
(Jasinski, 1977) plus other adjectives decribing withdrawal
symptoms]. The subject was instructed to give answers
describing how he felt at the time he filled out the
questionnaires. Observer ratings were completed by a research
technician who rated the subject's drug effect at the same
times and using the same adjective list as the subject
himself.
Data were converted to change from pre-drug baseline and were
analyzed by analysis of covariance with repeated measures over
time and as areas under the time course curves. Duncan's
Multiple Range test was used to assess differences of the
active drug conditions from placebo.
RESULTS
On the pharmacological class identification questionnaire
subjects identified placebo as a blank in 100% of
opportunities. Hydromorphone was identified as an opioid in
50% of opportunities. When given alone both doses of
buprenorphine were typically identified as being placebo (78
and 86% of opportunities) with only occasional identifications
as an opioid or other. Naloxone alone was identified
primarily (67% of opportunities) as an opioid antagonist, as
were both buprenorphine-naloxone combinations (81 and 67% of
opportunities).
On the visual analog scales hydromorphone produced significant
increases on the "liking," "good effects," "high" and "any
drug effects" scales of the visual analog scales.
Buprenorphine given alone had no significant effects on any of
the visual analog scales. Naloxone and the buprenorphine-
naloxone combinations increased the "any drug effects," "bad
effects" and "sick" scales. On the subject-rated adjective
scales hydromorphone produced increases in both the subject-
rated Fraser and agonist adjective rating scales, but had no
significant effects on the withdrawal scale. Naloxone alone
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and in combination with buprenorphine produced little or no
changes in the agonist scale. Naloxone alone produced
significant increases in the withdrawal scale score. The
withdrawal scale scores produced by the naloxone-buprenorphine
combinations, though elevated, were not significantly
different from placebo; these scores, however, were also not
significantly different from naloxone. Buprenorphine alone
produced no significant changes in scores on any of the
subject-rated adjective rating scales.
On the observer-rated adjective rating scales, neither
hydromorphone nor buprenorphine produced significant changes
on any scale. Naloxone given alone and given in combination
with buprenorphine significantly increased withdrawal scale
scores.
On the physiological measures hydromorphone produced
significant decreases in pupillary diameter and respiratory
rate. Naloxone and naloxone plus buprenorphine increased
pupil diameter and decreased skin temperature. Hydromorphone,
naloxone and the buprenorphine-naloxone combinations all
produced significant increases in blood pressure. None of the
physiological measures were changed following either dose of
buprenorphine tested as compared to placebo.
DISCUSSION
The results of this study, which compared hydromorphone,
naloxone, buprenorphine, and two buprenorphine-naloxone
combinations, show that hydromorphone produced increases in a
number of opioid-sensitive subjective effect measures,
decreases in pupil diameter and respiratory rate, and
increases in blood pressure. At the doses tested,
buprenorphine given alone had no significant effects on any
subjective, behavioral, or physiological measure. Naloxone
produced increases in subjective effect and behavioral scales
indicating opioid abstinence effects and produced decreased
skin temperature and increased blood pressure and pupil
diameter. Both buprenorphine-naloxone combinations produced
changes in the subjective, behavioral, and physiological
effects which were in the same direction as those produced by
naloxone, indicating that the combinations had qualitatively
naloxone-like properties.
The purpose of combining buprenorphine and naloxone is to
discourage diversion of buprenorphine for substitution for an
opioid agonist in opioid-dependent abusers. The results of
the present study showed that, in subjects maintained on a low
dose of methadone (30 mg), clinically useful doses of
buprenorphine plus naloxone 0.2 mg produced significant
abstinence symptoms which were similar to those produced by
naloxone 0.2 mg alone and which were perceived by subjects as
being quite unpleasant. In our opinion, these combinations of
buprenorphine and naloxone have a low potential for abuse in
an opioid-dependent population.
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Effects of Passive Exposure to
Marijuana Smoke
Edward J. Cone, John D. Roache, and Rolley E. Johnson
INTRODUCTION
millions of screening tests for
society to determine if recent active
At the present time,
cannabinoids in urine are being administered to members of a
large cross-section of our
use of marijuana has occurred. The confirmed finding of a
positive result can lead to severe legal and professional
consequences for the individual tested. Recently, it has been
reported that the passive inhalation of marijuana smoke can
result in the production of urines which test weakly positive
for cannabinoids and also result in low blood levels of
delta-9-tetrahydrocannabinol (THC) immediately after exposure
(Law et al., 1984; Mason et al., 1983; Morland et al., 1985;
Perez-Reyes et al., 1983). It is not clear from these studies
if longer periods of passive exposure or more intense exposures
to marijuana smoke increase the likelihood of individuals to
test positive for cannabinoids.
We assessed the effects of passive inhalation of sidestream
marijuana smoke in a group of 5 experienced, but drug-free male
marijuana users. A similar but more limited study was performed
with two male staff members without a history of marijuana use.
These studies addressed the following questions regarding the
passive inhalation of marijuana smoke:
1. Under standardized conditions, does increased smoke
exposure lead to increased frequency of "positive"
specimens?
2. Do multiple passive exposures lead to accumulation?
3. Are acute behavioral, physiological and hormonal effects
produced?
4. Do marijuana-naive subjects produce more or fewer
"positive" specimens?
5. How does this study relate to the conditions of the
"real world" in which marijuana is smoked?
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METHODS
Subjects: Five subjects (A-E) were healthy, drug-free males
with a history of marijuana use. Criteria to enter the study
included a documented period of 14 consecutive days of
cannabinoid "negative" urines. During the study, subjects were
housed on a closed ward under close surveillance. Two
additional male subjects (F,G) from the staff with no history of
marijuana use participated in one phase of the exposure
studies. The studies were conducted under the guidelines for
the protection of human subjects (45CFR46).
Passive Exposure Conditions. Subjects A-E were passively
exposed under double-blind conditions to sidestream smoke from
16 standard marijuana cigarettes (2.8% THC) for one hour each
day (0830-0930 hr) for 6 consecutive days. Smoke exposure was
carried out at the same time each day. Preceding and following
the days of marijuana smoke exposure, the subjects were exposed
for two days to the smoke of 16 placebo cigarettes (0% THC).
During exposure, the subjects wore goggles and sat quietly in a
small unventilated room (2.1 m x 2.5 m x 2.4 m). The
approximate volume after adjustment for contents was 12,225
liters. One-half of the cigarettes were burned at the start of
the session (O-12 min) and the remainder were burned 30-42 min
into the exposure session. The cigarettes were burned in a
smoking apparatus designed to release only sidestream smoke.
Room air samples were analyzed at timed intervals for THC and
carbon monoxide (CO). A second exposure study was performed
with the subjects A-E for 6 days under similar conditions with 4
marijuana cigarettes (2.8% THC) but preceded and followed by
only one day of placebo smoke exposure. A third exposure study
was performed with 2 subjects F and G for six days to the smoke
of 16 marijuana cigarettes (2.8% THC) but without blind
conditions and without exposure to placebo smoke.
Collection and Assay of Biological Samples. All urine specimens
were collected from the SubJects during their participation in
the dies. All urines were screened with the EMITA
d.a.u.™ Cannabinoid 20 Assay (Syva Co) with a 20 ng/ml low
calibrator (EMIT 20). Specimens with rates greater than that of
the medium calibrator (75 ng/ml) were assayed by EMITR
d.a.u.™ Cannabinoid Assay which employs a 100 ng/ml low
calibrator (EMIT 100). Venous bloods were collected from
subjects A-E 30 minutes prior and 20-30 minutes following each
exposure session with 16 cigarettes. Only subject D was
eligible to donate blood samples during the 4 cigarette exposure
study. Analysis for THC was performed by radioimmunoassay.
Analyses for hormones were performed with commercial kits.
Behavioral and Physiological Measures. Behavioral and
physiological effects were assessed at 1 hr (0730) and 0.5 hr
(0800) before smoke exposure and following exposure at 0930,
1030, 1130 and 1230. Subjective effects were measured with
subscales of the Addiction Research Center Inventory (MAR 15,
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MBG, LSD, PCAG), Single Dose Questionnaire (Feel Drug, Drug
Identification, Symptoms, Liking) and a visual analog scale
(VAS). The latter scale consisted of a 200 mn line on which
subjects rated the "high" or positive effects and "bad" or
negative effects of the test conditions. Psychomotor
performance was measured by the circular lights task (CLT) and a
computerized version of the digit-symbol-substitution task
(DSST). Behavioral and physiological responses were analyzed as
differences between the responses after smoke exposure and the
mean of the two control responses prior to smoke exposure. Area
under the curve (AUC) for the response over time was calculated
by the trapezoidal rule. If the analysis of variance of AUC
data showed a significant (p< 0.05) effect of study days, a
Tukey test was applied to determine which marijuana smoke
exposure days were different than the placebo day preceding
marijuana smoke exposure.
RESULTS
Chemical Evidence for Passive Absorption of THC. Specimen
screening by EMITR assay revealed a large number of "positive"
urines with rates exceeding the 20 ng/ml calibrator (EMIT 20)
during the 24 hour period following passive exposure to the
smoke of 16 marijuana cigarettes (Table 1). A much smaller
number of the EMIT 20 positive specimens for subjects A-E also
exceeded the 100 ng/ml calibrator (EMIT 100). EMIT 20 positive
urines also were obtained following exposure to the smoke of 4
marijuana cigarettes with 4 of 5 participating subjects
producing at least one positive urine. The assay rates for
these specimens were consistently below that of the 75 ng/ml
calibrator of the EMIT 20 assay.
The time course for the appearance and disappearance of
cannabinoids in urine was similar for most subjects. Generally
the urines obtained during the subsequent 4 hours after exposure
were the most likely specimens to test positive and exhibited
the highest reaction rate. Also, the specific gravity of the
specimen appeared to be directly related to the number of
"positive" specimens produced at the higher exposure level.
EMIT 20 positive urines were not detected later than 24 hours
following the 4 marijuana cigarette exposure for subjects A-E
and with one exception (subject F), no later than 48 hours
following the 16 marijuana cigarette exposure. Subject F
produced occassional EMIT 20 positive specimens for 5 days
following passive exposure.
Daily mean plasma levels of THC for subjects A-E following
exposure to the smoke of 16 marijuana cigarettes ranged from 2.4
to 7.4 ng/ml. The highest mean concentration of MC was found
to occur on the last day (sixth day) of exposure to active
marijuana smoke. The individual peak concentration also
occurred on this day (Subject E, 18.8 ng/ml). For the one
subject who donated blood during the 4 marijuana cigarette
exposure sessions, THC ranged from 0.8 - 2.5 ng/ml. Plasma
samples obtained from subjects A-E before and after passive
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Table 1 Room Air THC Levels, Breath Carbon Monoxide Levels and EMITR Assay of Specimens After Passive
Marijuana Smoke Exposure.
1Room Air THC concentration at end of 1-hour exposure session. 2Mean breath CO levels obtained after 45
minutes of smoke exposure. 3Second day of Placebo exposure only following 16 cigarette treatment.
4Urines collected only from subject F.
exposure to the smoke of 16 marijuana cigarettes over the 10 day
exposure study showed no significant changes in levels of
cortisol, prolactin, growth hormone, testosterone, luteinizing
hormone or follicle stimulating hormone. Breath and room air CO
levels and room air levels of THC were dose-related to the
number of marijuana cigarettes burned during exposure. Room air
THC levels appeared to be inversely related to the number of
people present in the room during exposure.
Behavioral and Physiological Effects. Elevated responses were
obtained on the MAR 15 LSD PCAG VAS, Feel Drug and Liking
scales after exposure to marijuana smoke (Table 2). These
responses reached significance on all but the PCAG scale after
16 marijuana cigarette exposure. Responses were slightly
depressed with CLT and DSST after 16 marijuana cigarette
exposure but were not significant. Responses on most scales
were time-related with peak effects occurring immediately after
passive exposure to marijuana smoke.
Physiological measures were highly variable under both the 4 and
16 marijuana smoke exposure conditions. Supine pulse was
elevated after both test conditions but reached significance
only on one day of the 4 marijuana smoke exposure sessions and
did not reach significance during the 16 marijuana smoke
exposure sessions. Standing pulse was significantly elevated on
the second day of exposure to the smoke of 16 marijuana
cigarettes but was significantly depressed on the sixth day of
exposure. Other measures generally showed no effects from
passive inhalation at either exposure level.
Table 2. Behavioral and Physiological Effects of Passive
Exposure to Marijuana Smoke
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Does Greater Passive Marijuana Smoke Exposure Lead To An
Increased Frequency Of "Positive" Urine Specimens?
Unquestionably our results indicate that as the intensity of
marijuana smoke increases, passive absorption of cannabinoids
increases with a subsequent increase in the excretion of urinary
cannabinoids. An increase also occurred in the degree of
positivity of specimens and in the length of time positive
specimens could be detected after passive smoke exposure. It
also appeared that passive exposure to the smoke of 4 marijuana
cigarettes for one hour approximated the "threshold" level of
exposure necessary for the production of cannabinoid urinary
metabolites detectable by the EMIT 20 assay.
DISCUSSION
Do Multiple Passive Exposures Lead To Accumulation?
Room air concentrations of THC during the first exposure session
was generally less than those found on subsequent exposure days.
Thus, accumulation does not account for the initial increase in
number of positives specimens produced by subjects A-E during
the 16 marijuana smoke exposure sessions. Over the remaining
six days of exposure with 16 marijuana cigarettes, reaction
rates for subjects C, D and E increased with exposure indicating
some accumulation was occurring; however, this was not evident
for subjects A and B. No accumulation was evident following
exposure to the smoke of 4 marijuana cigarettes by any subject.
Are Acute Behavioral, Physiological And Hormonal Changes
Produced by Passive Inhalation of Marijuana Smoke?
Significant subjective effects were produced by exposure to the
smoke of 16 marijuana cigarettes. The magnitude of these
effects approximated those observed when the same subjects (A-E)
actively smoked one marijuana cigarette (2.8% THC)(Data not
reported here). Exposure to the smoke of 4 marijuana cigarettes
produced lesser but qualitatively similar effects. Also, a
slight but non-significant performance impairment was observed
with the CLT and DSST following exposure to the smoke of 16
marijuana cigarettes. These latter tasks have been shown to be
sensitive measures of drug-induced. performance impairment by
sedative/tranquilizer drugs. All of the behavioral effects were
time related and had returned to baseline within four hours
after exposure. Consistent with these observations of
behavioral effects were the detection of blood levels of THC
following exposure which occasionally exceeded the arbitrary
limit of 10 ng/ml which has been suggested as evidence of
functional impairment. Physiological and hormonal effects after
exposure to marijuana smoke were highly variable and showed no
clear trends at any exposure level.
Do Marijuana-Naive Subjects Produce More Or Fewer Positive
Specimens Than Experienced Users?
Following exposure to the smoke of 16 marijuana cigarettes,
subjects F and G produced a total of 48 and 23 EMIT 20 positive
specimens. This closely overlaps the range of positive
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specimens produced by subjects A-E (27-49 positive specimens).
Also, subject F generally had the lowest EMIT 20 reaction rates
and subject G had the highest reaction rates of the 7 subjects
tested. These data appear to indicate no differences between
these groups in the degree of absorption and excretion of
cannabinoids following passive marijuana smoke exposure.
How Does This Study Relate To The Conditions Of The "Real World"
In Which Marijuana Is Smoked? This study was conducted in a
small unventilated room in which marijuana cigarettes were
burned producing only sidestream smoke. Comparisons with "real
world" conditions are purely speculative, however the following
points can be made: 1) the factor which limits the
acceptability of passive smoke exposure may be smoke irritation
of mucous membranes and the eyes; 2) adequate room ventilation,
regardless of room size, would greatly reduce the amount of
cannabinoids passively absorbed and consequently the excretion
of cannabinoid "positive" urine specimens; 3) the amount of
cannabinoids in roan air available for passive absorption
appears to be inversely related to the number of people present
in the room; 4) subjects receiving approximately equivalent
doses of passive marijuana smoke exposure can show great
variations in the manner in which they excrete cannabinoid
metabolites. The most critical factor in producing positive
specimens following "threshold dose" exposure appears to be the
specific gravity of the urine. These studies emphasize the need
for caution regarding individuals who could potentially be
exposed to heavy marijuana smoke environments and also caution
regarding the interpretation of urine screening results.
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Butorphanol-Precipitated
Withdrawal in Opioid-Dependent
Human Volunteers
Kenzie L. Preston, George E. Bigelow, and Ira A. Liebson
Butorphanol is an opioid analgesic with agonist/antagonist
activity (Pircio et al., 1976). It is a potent analgesic
[5 to 8 times more potent than morphine (Houde 1979; Pircio
et al., 1976)], but has been found to have mild antagonist
effects in morphine-dependent subjects. In 14 hour withdrawn
morphine-dependent rhesus monkeys, at low doses butorphanol
failed to suppress withdrawal and, at higher doses, produced a
mild exaccerbation of withdrawal signs (Woods and Gmerek 1985).
Butorphanol produced only mild suppression of abstinence signs
(not statistically significant) in withdrawn morphine-dependent
humans, and, in doses up to 8 mg, butorphanol precipitated only
mild, non-dose related abstinence signs (equivalent to nalor-
phine 1.5 mg) in non-withdrawn subjects (Jasinski et al.,
1975).
In the present study the effects of butorphanol in opioid-
dependent humans were re-evaluated using methadone-dependent
human volunteers. The effects of butorphanol were evaluated in
relation to two reference compounds, hydromorphone and naloxone.
METHODS
The subjects were 5 adult male opioid-dependent volunteers with
histories of narcotic drug abuse. Subjects were maintained on
methadone HCl 30 mg/day, given once every 24 hours approximately
two hours after the experimental session. On the basis of
physical examination, history, and laboratory chemistries,
subjects were found to be without significant medical or
psychiatric disturbance other than their drug abuse. Subjects
gave their written informed consent prior to beginning the study
and were paid for their participation. Subjects participated
while residing on a behavioral pharmacology research ward.
Drug conditions tested were: placebo, hydromorphone HCI 4 and 8
mg, naloxone HCl 0.1 and 0.2 mg, and butorphanol tartrate 0.375,
0.75, 1.5, 3 and 6 mg. Drug conditions were presented in a mixed
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order. Saline placebo, hydromorphone doses, and naloxone doses
were scheduled in random order; butorphanol sessions were also
scheduled at random positions in the experimental sequence, but,
as a precaution, since the appropriate dose, range of butorphanol
was not known, doses of butorphanol were presented in an ascend-
ing series. Neither the research technician conducting the study
nor the subjects were aware of this dose schedule. Commercial
preparations of hydromorphone, naloxone, and butorphanol were
used. The appropriate volume of drug solution from ampules was
diluted to 3 ml with 0.9% normal saline. Normal saline (3 ml)
served as placebo. All doses were given intramuscularly as two
1.5 ml injections, one in each upper arm, under double-blind
conditions. Doses were calculated on the basis of the salts.
Experimental sessions were run at the same time of day for each
subject and were separated by at least 48 hours. Data were
collected in a quiet experimental testing room separated from
the ward. The subject was seated in the experimental testing
room for a 2.5 hour session. After a 15 min stabilization
period, 10 min of baseline physiological recording was taken;
a pupil photo was taken, and the subject answered subjective
effect questionnaires. Subjective effect questions were
presented on a computer screen, and subjects used a key pad
and joy stick to respond. Drugs were administered approximately
30 min after the start of the physiological recording. The
session continued in the testing room for 2 hours after drug
administration. Physiological measures, except for pupil
diameter, were monitored continuously throughout the session.
Subjective effect and pupil diameter measures were collected
at 15. 30, 45, 60, 90, and 120 min after drug administration.
Four physiological measures were monitored: heart rate, blood
pressure, skin temperature, and respiration. Data for each
measure were collected and stored in one-minute intervals
using a microcomputer. Pupil diameter was determined from
photographs taken in ambient room lighting using a Polaroid
camera with a 3X magnification. Subjects completed three
questionnaires: visual analog scales, a pharmacological class
questionnaire, and an adjective rating questionnaire. On the
visual analog scales, the subject rated his current degree of
"high" and "sick" and the degree of "any drug effect,"
"good effects,"  "bad effects," and "liking" of the drug effects
by placing a mark along a 10 cm line marked at either end with
"none" and "extremely." On the pharmacological class question-
naire, the subject categorized the drug effect as being most
similar to one of ten classes of psychoactive drugs; the
questionnaire provided descriptive titles for and examples of
each of the following classes: placebo, opiate, opiate
antagonists, phenothiazines, barbiturates and sleeping
medications, antidepressants, hallucinogens, benzodiazepines,
stimulants, and other. The adjective rating questionnaire
consisted of 40 items which the subject rated on a 5-point
scale from 0 (no effect) to 4 (maximum effect). The items
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in the rating scale were divided into 3 subscales: the Fraser
scale [adjectives previously shown by Fraser et al. (1961)
to be sensitive to opioid effects], an opioid agonist-like scale
[adjectives in the Fraser scale plus additional adjectives
associated with morphine-like effects], and a withdrawal scale
[adjectives derived from the Himmelsbach abstinence rating scale
(Jasinski 1977) plus other adjectives decribing withdrawal
symptoms]. The subject was instructed to give answers describing
how he felt at the time he filled out the questionnaires.
Data were analyzed by analysis of covariance with repeated
measures for areas under the time course curves for individual
drugs.
RESULTS
There were large individual differences in sensitivity to the
effects of butorphanol. Two subjects received the 6 mg dose of
butorphanol. One subject showed an intense response to
butorphanol 3 mg and, therefore, did not receive the 6 mg dose.
Two subjects showed signs of intense abstinence signs and symp-
toms following the administration of butorphanol 1.5 mg; higher
doses of butorphanol were omitted. The intensity of the effects
of the highest dose of butorphanol administered to each subject
was approximately equivalent. Therefore, doses of butorphanol
were analyzed as low, medium and high doses with the high dose
being the highest dose each subject received, the medium dose
being one half the high dose, and the low dose being one
quarter of the high dose.
In the pharmacological class identification questionnaire
subjects identified placebo as a blank in 70% of opportunities.
Naloxone 0.1 and 0.2 mg were identified primarily (50 and 67% of
opportunities, respectively) as an opioid antagonist. Butorpha-
no1 produced dose related increases in opioid antagonist
identifications (low dose- 7%, medium dose- 47% and high dose-
63% of opportunities). Hydromorphone 4 and 8 mg were identified
as an opioid in 30 and 13% of opportunities (respectively).
Both doses of hydromorphone were identified as placebo in
approximately 50% of opportunities.
On the visual analog scales, naloxone and butorphanol increased
the "any drug effects,"  "bad effects" and "sick" scales while
hydromorphone produced no significant changes on any of the
scales. Hydromorphone also produced no significant changes on
any of the adjective rating scales. Naloxone and butorphanol
produced little or no changes in the agonist scale. Butorphanol
produced significant increases in the withdrawal scale score.
The withdrawal scale scores produced by naloxone, though elevated,
were not significantly different from placebo.
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On the physiological measures naloxone and butorphanol
significantly increased pupil diameter and decreased skin
temperature. Naloxone and butorphanol produced increases in
systolic and diastolic blood pressure though only the increases
produced by butorphanol rearched statistical significance.
Hydromorphone produced significant decreases in pupillary
diameter and respiratory rate.
DISCUSSION
The results of this study, which compared butorphanol. naloxone
and hydromorphone, showed that hydromorphone produced decreases
in pupil diameter and respiratory rate, but had little or no
effects on subject-rated measures in these methadone-dependent
and tolerant subjects. Naloxone produced decreased skin
temperature, increased pupil diameter and increases in subjective
effect scales indicating opioid abstinence symptoms.Butorphanol
produced changes in subjective and physiological measures which
were in the same direction as those produced by naloxone, indica-
ting that butorphanol precipitated opioid abstinence in metha-
done-dependent humans.
Qualitatively the abstinence signs and symptoms produced by
butorphanol and naloxone were quite similar though there were
some differences between naloxone and butorphanol in the
specific items of the withdrawal adjective rating scale which
each affected. Anecdotally, some subjects claimed to be able
to discriminate between the effects of the two antagonists.
In general, subjects found the effects of butorphanol to be
less tolerable than those of naloxone. Further work is needed,
however, to determine whether there are real differences
between the abstinence syndromes produced by these two drugs
or whether differences in duration of action and/or magnitude
of effects of the doses compared account for the minor dif-
ferences seen here.
In previous studies conducted in morphine-dependent humans and
monkeys, only mild abstinence symptoms and/or signs have been
produced by butorphanol. The reason for difference between the
results of these previous studies and the present study are un-
clear. The most apparent difference is that subjects in the
present study were physically dependent on methadone while the
other studies used morphine-dependent subjects. There may be
other, less-apparent differences between study procedures which
account for the disparity.
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Altered Dose Incentive Procedures:
Effects on Polydrug Use Among
Methadone Maintenance Patients
Maxine L. Stitzer, Warren K. Bickel, and George E. Bigelow
Some methadone maintenance patients continue to abuse an
assortment of sedative drugs while enrolled in treatment (Stimmel
et al., 1978; Stitzer et al., 1981). These patients are
typically denied take-home and other program privileges while
counselors attempt to dissuade them from continuing their polydrug
use. If drug use does continue, a treatment termination contract
may be presented which specifies a standard of improvement needed
for continued treatment participation. Recent studies have shown
that treatment termination contracting can be effective strategy
for dealing with continuing illicit drug supplementation among
methadone patients (Dolan et al., 1985; McCarthy and Borders
1985).
Methadone dose alterations might also be effectively used to
promote reduced supplemental drug use among maintenance patients.
Since the daily methadone dose acts as a mild reinforcer (McCaul
et al., 1982), partial dose reductions could be scheduled as an
aversive consequence of continued drug use. Alternatively, the
opportunity to receive dose increases might be used as a positive
incentive for evidence of improved behavior. The purpose of the
present study was to compare the effects of a positive and a
negative dose alteration incentive procedure on polydrug
supplementation among a group of chronic abusers. In the
positive incentive procedure, subjects were offered the chance to
raise their methadone dose over its original stable level by
providing drug-free urine samples. Drug-positive samples reduced
the dose back to its original stable level but the dose could not
decrease below this level. In the negative incentive procedure,
drug-positive urine samples resulted in partial dose decrements.
Drug-free samples resulted in gradual restoration of the original
dose, but the dose could not increase above its original stable
level. Results of the present study may shed light on the
relative efficacy of positive versus negative incentive
procedures and may have practical importance for developing
optimal treatment procedures at methadone clinics.
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METHODS
Subjects. All patients enrolled in our treatment research
clinic signed informed consent at program entry which stated
that incentive programs would at times constitute an important
part of their treatment plan and that during these programs,
clinic privileges and treatment parameters including the size of
their methadone dose might be determined by their drug use and
other behaviors. The seventeen patients selected for
participation in this study delivered more than 50% drug-
positive urine samples during a 10-week baseline evaluation
period, with benzodiazepine tranquilizers being the most
frequently detected drug type. Five study subjects were female
and 12 were male. Average age was 32.7 years (range = 23 - 43
years). Extensive histories of methadone treatment were common,
with an average of 3.2 prior treatment admissions. Subjects had
been enrolled at the present clinic for an average of 12.4
months (range = 2 - 23 months) prior to the start of the study
intervention with an average pre-study daily methadone dose of
51.5 mg (range = 40 - 60 mg).
General procedures. Urine samples were collected three times
weekly, on Monday, Wednesday and Friday. All samples were
analyzed at an outside testing laboratory using thin layer
chromatography which detects a wide variety of opiate and
nonopiate drugs including morphine, codeine, hydromorphone,
propoxyphene, diazepam, lorazepam, oxazepam, barbiturates,
phenothiazines, hydroxyzine pamoate (Vistaril), ethchlorvynol
(Placidyl), and amitriptyline (Elavil). Following a 10-week
baseline evaluation period, subjects were randomly assigned to
one of the two dose incentive procedures described below and
previously approved by the FSK Institutional Review Board for
Human Research. The procedures were implemented after a two
week warning period, and subjects were followed for 18 weeks.
Dose incentive procedures. Urine test results were received
from the outside testing laboratory by Thursday afternoon for
samples collected on Monday of that week and on Friday and
Wednesday of the previous week. Doses were altered each Monday
based on these three most recent test results (Wed, Fri, Mon).
Thus, the delay between sample collection and the altered dose
consequence was 1 - 1-1/2 weeks. Each urine sample that
contained detectable quantities of any drug besides methadone
(quinine positives excluded) resulted in a 5 mg dose decrease,
while samples free of all supplemental drugs resulted in a 5 mg
dose increase. Shown below are the dose changes that could be
earned each week by all study participants.
163
ALTERED DOSE CALCULATION
Drug-free Drug-positive Net dose change (mg)
specimens specimens
0 3 -15
1 2 - 5
2 1 + 5
3 0 +15
Subjects in the positive incentive condition could raise their
dose to 160% of its original value by providing drug-free
urines. Dose increases were lost drug-positive specimens
were obtained, but the dose could not decrease below its
original stable value. Subjects in the negative incentive
condition could lower their dose to 48% of its original stable
value by providing drug-positive urines. The dose could be
restored with drug-free urines but could not increase above its
original stable level.
RESULTS
As shown in Figure 1, the average percentage of drug-free
samples during baseline was similar for the two study groups and
did not exceed 20% drug-free samples during any two-week pre-
study baseline period.
Both interventions resulted in improved rates of drug-free
sample delivery, with the average increasing to about 44% drug-
free samples during the intervention [repeated measures analysis
of variance, F(1,15) = 16.2, p < 0.0011. It is clear from
Figure 1 that there was no difference between the two incentive
procedures as far as the overall extent of improvement in drug
use was concerned. Figure 1 shows that improvements occurred
early in the incentive program, in some cases during the pre-
intervention announcement weeks, and were generally sustained
throughout the 18-week followup. One subject in the decrease
incentive condition relapsed during study week 11, however,
resulting in a lowered percentage of drug-free samples for that
group during subsequent weeks.
Individual subject differences in study outcome were apparent.
About half of the subjects in each group improved sufficiently
to deliver 50% or more drug-free urine specimens on average
during the intervention period. An interesting qualitative
difference in outcomes for the two groups was also apparent.
Four subjects exposed to the negative incentive condition
dropped out of the study by the fifth intervention week (on-
going treatment was arranged for these patients at this clinic
or at another clinic), while no subjects assigned to the
positive incentive condition dropped out of the study. Rather,
164
some positive incentive subjects stayed at the clinic and
continued to abuse supplemental drugs.
FIGURE 1. Percent drug-free urine samples delivered during
successive study weeks by methadone maintenance patients
assigned to a dose increase  (N = 9) or a dose decrease (N- = 8)
incentive procedure. Drug-free classification of urine samples
is based on TLC testing that detects a wide variety of opioid
and nonopioid drugs. Missing data from study dropouts have been
replaced by average baseline percent of drug-free urines.
DISCUSSION
This study showed that polydrug abuse among methadone
maintenance patients could be influenced by a program in which
the size of the daily methadone dose was determined by recent
urinalysis test results. Average percentage of drug-free urine
reports increased about 30% -- from 13% during baseline to 44%
during the period when the altered dose consequence was in
effect. Previous research suggests that methadone dose
alteration may in fact be a less potent reinforcer for methadone
maintenance patients than take-home reinforcers (Stitzer,
Bigelow and Liebson 1979) or menus offering a choice of
reinforcers (Stitzer et al., 1982). Nevertheless, the present
study suggests that interventions involving the methadone dose
might be usefully applied in clinics where there is reluctance
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to grant take-home privileges or other tangible rewards to
patients with a history of chronic polydrug abuse.
Baseline data for these study subjects highlight the poor
performance that can occur when no consequences are attached to
urine results, while the improvement noted during the study
intervention suggests that systematic consequences attached to
urine results are desirable. That two different procedures
involving methadone dose appeared equally effective, suggest
that the specific content of the intervention used may be less
relevant than the fact that some consequence is attached to
urinalysis test results. Consistent with this notion is a
recent report by McCarthy and Borders (1985) where improved
treatment outcomes were obtained using a very simple set of
structured consequences that required patients to be drug-free
for at least 1 out of every 4 treatment months.
About half the subjects in each group showed marked improvement,
delivering 50% or more drug-free urines during the intervention
while the remaining subjects either left the clinic or showed
only marginal improvement at best. These individual differences
in outcome are consistent with other recent reports concerning
effects of contingency management interventions including
treatment termination contracting (Dolan et al., 1985) and take-
home incentive procedures (Stitzer, Bigelow, Liebson and
Hawthorne 1982). In general, it appears that substantial
improvement can be expected in about half the subjects exposed
to such interventions.
In the present study, a positive and a negative incentive
procedure had differential effects on patient retention.
Specifically, the negative incentive procedure involving dose
decreases promoted study dropout, which in a nonresearch clinic
might translate into treatment dropout. It is likely that
treatment dropouts will have worse outcomes on measures of drug
use, crime and mortality than patients who remain in methadone
treatment. Results of the present study therefore support the
use of positive as compared With negative incentive procedures
since equivalent results may be obtained in those patients who
will respond to contingency management interventions while
treatment dropout among nonresponders will be avoided.
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Double-Blind Comparison of
Parenteral Meptazinol and
Morphine in Postoperative Pain
Abraham Sunshine, Howard Richman, Robert Cordone,
Napoleon Estrada, Norma Robissa, and Nancy Olson
Maptazinol, m-(3-ethyl-l+ethyl-hexahydro-1-H-azepin-3-yl)
phenol hydrochloride is a centrally active opioid analgesic
with specificity for the mu-1 receptor1. Houde et al com-
pared the effectiveness and safety of i.m. meptazinol (50,
100, and 200mg) to i.m. morphine (4,8 and 16mg) in cancer
patients with moderate to severe postoperative pain and found
meptazinol to be 1/15th to 1/20th as potent as morphine, and
to provide a more rapid onset than morphine. Relative
potencies for the hourly parameters were not presented, only
those for time to Peak and the summary variables. Sleepiness
was the most common side effect on morphine, while nausea was
most common on meptazinol2. Forrest compared the same three
dose levels of meptazinol to morphine 5 and 10mg in patients
with moderate or severe general postoperative pain3. A valid
bioassay was reported showing that 100mg of meptazinol is ap
proximately eguivalent to 8mg of morphine for peak effect.
The present clinical trial was designed to assess the anal-
gesic efficacy and safety of meptazinol (5Omg and 100mg) in
comparison to morphine (5mg and 10mg) when administered
parenterally for the treatment of postoperative pain. In ad-
dition to the relative potency estimates of meptazinol to
morphine for the usual summary variables, hourly parameters
were also assessed.
METHODS
Selection of patients: Adult male and female inpatients from
the surgical services at New York Infirmary-Beekman Downtown
Hospital in New York City who had moderate or severe pos-
toperative pain and who required parenteral medications were
subjects of this study. All patients were informed of the
nature of this study and all gave written informad consent
indicating their willingness to participate.
Study Design: This study utilized a double-blind, parallel
group, single-dose design. Patients were randomly assigned
to either morphine sulfate 5 or 10mg or meptazinol hydroch-
loride 50 or 100mg. When the patient's postoperative pain
was moderate or severe, study medication was administered by
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the research nurse as a single injection in the upper outer
quadrant of the gluteal muscle. Pain intensity, relief, side
effects, and concomitant medications were obtained by the re-
search nurse at 1/2, 1 hour, and hourly thereafter for a to-
tal of 6 hours. If asleep at a scheduled interview, the
patient was awakened. At each observation, patients were
asked to rate their pain intensity on a four point scale
using 0 = no pain; 1 = slight pain; 2 = moderate pain; and 3
= severe pain. At all but the baseline interview, they were
also questioned to determine their percent relief from the
initial pain. Relief was coded on a five point scale: 0 =
no relief, 1 = 25% relief, 2 = 50% relief, 3 = 75% relief or
4 = 100% relief. Side effects reported by the patient or ob-
served by the nurse were evaluated and reported. In order to
obtain the patient's subjective estimate of the time to onset
of drug effect each patient was asked to determine how long
it took for the medication to provide them meaningful relief
of pain. In addition, at the last interview, the patient was
asked to assess his overall improvement and his overall
rating of the test medication. These were respectively quan-
tified on a seven-point scale ranging from: 1 = very much
worse to 7 = very much better, and on a four-point scale: 0
= no help; 1 = fair; 2 = good; 3 = excellent.
Statistical Methods: Several measures of analgesia were
derived from the interview data4. Pain Intensity Difference
(PID) is the difference between the pain intensity score at
an observation point and the baseline intensity. The sum of
the Pain Intensity Difference (SPID) is the sum of the PID
saxes, weighted by the time interval between observations
and is an estimate of the area under the time-effect curve of
the treatment. Percent SPID (%SPID) is defined for each
patient to be the ratio of the patient's SPID score to the
maximum possible SPID (depending on the baseline intensity)
times 100. TOTAL is the sum of the relief values also
weighted by the length of the time interval between observa-
tions. Time to Peak is defined for each patient as the time
after drug administration that maximum PID occurs.
Univariate bioassay analyses were done for each of the vari-
ables and yielded estimates of the relative potency of mep-
tazinol to morphine with 95% confidence limits. The validity
assumptions of parallelism of the log dose response lines,
equality of the mean responses of the two test treatments and
non-zero regression were tested in analysis of variance
(ANOVA). Deviations from linearity could not be tested be-
cause no treatment was at three different dose levels. The
statisical techniques for bioassay have been described by
Finney5 a comparison was made among the four treatments
using a univariate one way analysis of variance to test the
hypothesis of no difference between treatments for all
parameters. When the ANOVA was significant at the 0.05
level, tests were performed to investigate pairwise dif-
ferences between treatment using Peritz's modification of
the Neuman Keuls procedure6 and Fisher's protected least sig-
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nificant difference test (LSD)7.
RESULTS
Table 1. Relative Potency Estimate of Meptazinol to Morphine
One hundred and eighteen patients were enrolled in the study
but one patient in the meptazinol 100mg group was dropped
from the analysis because of adverse reactions which required
treatment. The mean response for the hourly and sumnary
variables and an indication of significant treatment dif-
ferences are shown in Table 2. The time effect curve (Fig.
1) for pain intensity difference shows that the two doses of
meptazinol are similar, with the higher dose resulting in
more analgesia; the peak effect occurs at 30 minutes and
thereafter there is a rapid decline in analgesic effect for
both doses. The time effect curves for morphine are similar
to each other but quite different from those of meptazinol in
that the peak effect occurs at one hour, but the analgesic
effect begins to decline thereafter at a far slower rate than
is seen with meptazinol.
Dose response Lines of Meptazinol and Morphine: Statisti-
cally significant dose response lines and no significant
deviations from parallelism were observed for most variables
including SPID, %SPID, TOTAL, and Time to Peak as shown in
Table 1. Relief variables at hour 4, 5, and 6, and PID vari-
ables at hour 2, 3, 4, 5, and 6 did not have a significant
dose response.
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Relative potency of Meptazinol to Morphine: Tests for the
validity of the underlying assumptions necessary to estimate
the relative potency of the two drugs were made in the
analysis of variance. Estimates of the relative potency of
meptazinol to morphine were 0.04, 0.03, 0.04, and 0.25 for
SPID, % SPID, TOTAL and Time to Peak respectively and all had
finite 95% confidence limits as shown in Table 3. For the
summary variables SPID, %SPID, and TOTAL, 100mg of meptazinol
is approximately equivalent to 4mg of morphine. The relative
potency of meptazinol compared to morphine at 1/2 hour was
.23 for PID and .19 for relief. At 1 hour, it was .13 for
PID and .12 for relief. This would indicate that 100mg of
meptazinol is approximately equivalent to 20mg of morphine
when evaluated at 1/2 hour and approximately equal to 13mg of
morphine at the first hour. By the second hour, 100mg of
meptazinol is approximately equivalent to 6mg of morphine.
Table 2. Mean Values for Measures of Analgesic Efficacy
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M = Significantly better than morphine 5mg, p < 0.05
L = Significantly different than meptazinol 50mg, p < 0.05
H = Significantly better than meptazinol l00mg, p < 0.05
S = Significantly better than morphine l0mg, p < 0.05
Differences Between The Two Doses of Morphine: A dose
response was seen between the low dose and high dose of mor-
phine with the high dose having better mean efficacy scores
for all efficacy variables. Statistically significant dif-
ferences between the two dose levels were seen for pain
relief and PID at 1 hour, relief at 3 hours, and for the sum-
mary variables, TOTAL Relief, Patient's Subjective Onset of
Relief, and Peak %. The two global assessments, i.e.
patient's overall improvement and patient's rating of the
test medication, also indicated that morphine 10mg was sig-
nificantly more efficacious than morphine 5mg.
Differences Between The Two Doses of Meptazinol: A dose
response was also seen between the two dose levels of mep-
tazinol with the higher dose having overall better mean ef-
ficacy saxes; however, significant pairwise differences be-
tween the 50 and 100mg dose were seen only for relief scores
at 1/2 and 1 hour, Peak %, and the patient's global assess-
ment of the medication.
Differences Between Maptazinol and Morphine: In general,
morphine 10mg was the most effective treatment and meptazinol
5Omg was the least effective. Meptazinol 100mg was the most
effective in terms of mean efficacy scores at 1/2 and 1 hour,
patient's subjective onset of relief and Time to Peak. Mep-
tazinol 1OOq was significantly superior to morphine 5mg for
relief and PID at 1/2 and 1 hour, patient's subjective onset
of relief, and Time to Peak. In addition, meptazinol 100mg
was significantly better than morphine 10mg for PID at 1/2
hour. Morphine 10mg was significantly more efficacious than
both dose levels of meptazinol for the hourly PID and relief
scores beginning with the second hour for the low dose, and
the third hour for the high dose and continuing throughout
the sixth hour. Morphine 10mg was also significantly supe-
rior to the two levels of meptazinol for SPID, %SPID, TOTAL
and the patient's assessment of overall improvement. In ad-
dition, morphine 10mg was significantly better than the low
dose of meptazinol for Peak % and for the patient's global
rating of the medication.
Morphine 5mg was significantly more effective than meptazinol
50mg for for relief at hours 4, 5, and 6, PID at hours 3, 4, 5,
and 6, %SPID, and TOTAL. In addition, morphine 5mg was sig-
nificantly better than meptazinol 100mg for relief at hours 4
and 5, and PID at hours 4 and 6.
Adverse Reactions: Twenty patients reported adverse reac-
tions, of which 9 received meptazinol 100mg, 6 received mor-
phine 10mg, 3 received meptazinol 50mg and 2 patients
received morphine 5mg. One patient in the meptazinol 100mg
group became diaphoretic and nauseated 1/2 hour after study
drug administration, was administered Benadryl 50mg and was
discontinued from the study. Meptazinol 100mg had the
greatest incidence of adverse effects followed by morphine
172
10mg. Some adverse effects reported with meptazinol 100mg
include apprehension, diaphoresis, dizziness, lightheaded-
ness, nausea, and vomiting. Some adverse effects reported
with morphine 10mg include dizziness, drowsiness, sleepiness
and flushing.
Figure 1: Time effect curve for mean PID scores are calcu-
lated by subtracting the mean pain intensity score for each
observation point from the pain intensity at O-hour.
DISCUSSION AND CONCLUSION
The estimate of the relative potency of meptazinol to mor-
phine for SPID and TOTAL were 0.04, while for Time to Peak it
was 0.25. Thus 100mg of meptazinol is approximately equiv-
alent to 4mg of morphine based on the summary variables SPID
and TOTAL. However, based on the Time to Peak variable,
100mg meptazinol is approximately equivalent to 25mg of nor-
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phine. In addition, the relative potency estimates were
greatest at the 1/2 and 1 hour points; thereafter, they
decreased considerably, so that by the third hour 100mg of
meptazinol was approximately equivalent to 4mg of morphine.
In summary, meptazinol 100mg is an effective, rapidly acting
analgesic of short duration. It could be of great value in
ambulatory outpatient surgical procedures including endoscopy
and colonoscopy, where the pharmacological effects are
required for only a brief period and the patient then goes
home. It's non-sedating effect make it safer in ambulatory
patients and in debilitated patients such as those with pul-
monary disease. The percentage of patients with adverse ef-
fects reached 32% for the 100mg dose of meptazinol. It would
be of interest to study the 75mg dose for efficacy and ad-
verse effects.
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Treatment Effectiveness: Medi-
cal Staff and Services Provided
to 2,394 Patients at Methadone
Programs in Three States
John C. Bail, Eric Corty, S. Paul Petroski, Henrietta
Bond, Anthony Tommasello, and Harold Graff
INTRODUCTION
Daily intravenous heroin use and addiction continues to be a
major social and medical problem in the United States with some
500,000 addicts concentrated in metropolitan areas. The major
treatment modality serving this addict population is methadone
maintenance therapy which currently treats some 75,000 patients.
The issue of whether this relatively new mode of treatment should
be expanded, maintained or restricted continues to be a subject
of controversy both within the medical community and the public
arena.
The controversy about methadone maintenance treatment not only is
beset with the uncertainties and ambiguities which tend,
generally, to accompany new modes of treatment, but it involves a
fundamental ambivalence about the role of medicine in the
rehabilitation of intravenous opiate addicts. This ambivalence
about how the contemporary problem of opiate addiction should be
addressed is reflected in the spectrum of opinions found in the
scientific and medical literature (Musto, 1973; Eddy, 1973; Ball
and Graff, 1975; Dole and Joseph, 1978; Lowinson, 1981; Trebach,
1982; McLellan et al., 1982; Woody et al., 1983; Wilson and
Herrnstein, 1985).
METHOD
A comprehensive evaluation of methadone maintenance treatment
involves description and measurement of four fundamental
entities: (1) the patients and their presenting problems, (2) the
programs that provide treatment, (3) the treatment provided and,
(4) the desired goal or outcome of treatment. (Meyer, 1983;
Jaffe, 1984; Tims and Holland, 1984).
The present paper addresses the question of what constitutes
methadone maintenance treatment. Specifically, we address the
issue of what specific types of medical services are provided to
patients in methadone maintenance treatment. (A collateral paper
describing counseling and other non-medical services is in
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preparation.)
In the summer and fall of 1985, a research team from the
Methadone Research Project interviewed the entire treatment staff
at the seven selected programs. The interviews in each program
took place on a single day during a designated week. The
interviewers collected data about employment, demographics,
treatment duties, and actual services provided to patients in the
prior week. It is these data that make up the basis of the
present paper.
THE MEDICAL STAFF AT THE 7 METHADONE PROGRAMS
The medical staff at these seven methadone maintenance programs
are divided into four categories. (Table 1) These are, A)
physicians, B) nurse practitioners and physician's assistants, C)
nurses and, D) pharmacists. All programs have at least one
physician; these seven programs are served by a total of 15
physicians. However, the actual amount of time that these
programs are served by the physicians range from .23 FTE to 2.52
FTE. (An FTE is a Full Time Equivalent and represents from 35 to
40 hours per week, depending upon the program:) The average
program has a mean of .84 FTE of physician coverage per week.
Two programs are served by physician's assistants (PAS) and two
by nurse practitioners (NPs). Two of these programs have two
full time PAs/NPs; the other two have only part time coverage.
For the four programs, there is a mean of 1.12 FTE of NP/PA
coverage per week.
All but two of the programs have coverage by dispensing nurses.
These two programs ('P' and 'E') have coverage by pharmacists.
Nurses comprise the largest category of medical staff with a
total of 21 RNs and LPNs. The five programs with nurses have from
three to six nurses on staff with total FTE ranging from 2.60 to
5.13. For the five programs, there is a mean of 3.48 of nurse
FTE per week. The seven pharmacists are split between two
programs with the total FTE ranging from 1.68 to 3.0. Thus, for
the two programs there is a mean of 2.34 pharmacist FTE per week.
Role and Medical Services Provided by the 21 Nurses
The principal role of nurses in most of the programs was to
dispense methadone to patients. Thus, in the five programs which
employed nurses for this purpose (two employed pharmacists) most
of their time was devoted to this task. At the same time, most
of the nurses also provided general medical care to patients.
Thus, the 21 nurses provided treatment to 288 patients during the
designated week. The nurses, then, commonly had a dual treatment
role in the programs - dispensing methadone and providing medical
care. Each of these roles can be briefly described.
The dispensing role of the nurses usually involved continuous
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dose preparation, record keeping, checking patients for
intoxication, keeping attendance, urine scheduling and similar
tasks. Sometimes, the nurses also collected urine specimens and
collected fees.
The second role of nurses was to provide general medical care. In
this role, nurses tested patients (e.g., for alcohol
intoxication), provided liaison to physicians and other staff,
gave medical advice and education and otherwise assisted patients
in numerous ways. Although the role of nurses in particular
programs varied somewhat, in most cases they fulfilled both the
dispensing and treatment roles.
Role and Services Provided by Physicians Assistants and Nurse
Practitioners
The role of the 3 physicians assistants and 3 nurse practitioners
was quite different from that of the dispensing nurses as these
staff did not engage in dispensing. Their role, therefore, was
principally devoted to providing general medical care. These
medical services included intake and other physical examinations,
determination or recomnendation of methadone dosage change (as
well as that of other medication), case management, treatment
referrals both within and outside the program and other related
duties. In general, these PA and NP staff worked closely with
the staff physicians.
With respect to output of medical services, the PA/NP staff saw
more patients and provided more services per FTE than the nurses,
but this was to be expected as they did not have a dispensing
role along with a medical care role.
It is pertinent to note that only four of the seven methadone
maintenance programs had either physician assistants or nurse
practitioners on the staff. Furthermore, these highly trained
medical staff were only in full-time status at two programs.
The Role of Pharmacists in the Methadone Programs
Two of the seven programs employed pharmacists rather than nurses
to dispense methadone. The role of the seven pharmacists was
primarily to dispense methadone. They provided, for the most
part, little other medical service to patients. Indeed, one of
the notable differences between the pharmacists and nurses was
that the latter group also provided general medical care and
education to patients.
Of the two programs which employed pharmacists to do the
dispensing of methadone, one also employed two full-time nurse
practitioners while the other had no nursing staff. Thus, one
program had neither dispensing nurses, nor nurse practitioners
nor physicians assistants.
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Role and Medical Services Provided by Physicians in the Methadone
Programs
All fifteen of the staff physicians provided medical care to
patients in the methadone maintenance programs. Although the
nature of this care varied somewhat from program to program,
especially where psychiatrists were employed, in general the
physicians provide general medical coverage through physical
examinations, case reviews, direct patient care, consultation and
referral to outside medical facilities. Other services provided
included psychiatric evaluation and therapy, dosage change,
admission screening and examination, advice on rehabilitation,
legal and family problems as well as medical education of various
kinds.
In analyzing the extent of medical services provided by
physicians in the seven programs, it was evident that there ware
marked differences in the amount of treatment available and
provided. Thus, physicians in some programs treated ten times
more patients per week than in others; the range in number of
patients treated per week was from 8 to 94. Similarly, there were
comparable variations in the percentage of patients seen by
physicians in the programs on a weekly basis - from a high of
25.4 percent of the patient population to a low of 3.1 percent of
the patient population. (Table 2).
These marked differences in the amount of medical services
provided by physicians in the different programs ware partly due
to variation in the availability of staff. Thus, when the above
differences in services provided (i.e., patients treated) were
analyzed with regard to full-time physician equivalents, the
variation was greatly diminished. Thus, the range in number of
patients seen by physicians per week was from 27.6 to 90.0, with
four of the programs treating over 50 patients per full-time
physician equivalent.
Still, two points seem noteworthy with regard to the medical
services provided by the physicians at these programs. First,
and most significant, there ware vast differences in the medical
coverage provided by physicians. Thus, ten times more patients
were seen by physicians in some programs than others. Also, in
some programs only 3 or 5 percent of the patients ware seen by
physicians during a week.
Second, it is important to note that the major reason why
patients in some programs receive treatment from physicians while
others in different programs do not is that there are
extraordinary differences in the staffing patterns in these
methadone maintenance programs. Thus, it has been found that
some programs have ten times more coverage by physicians than
others.
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Medical Services Provided Per Week By the Staff Groups Combined
In order to ascertain the overall extent of medical services
provided patients in these seven methadone maintenance programs,
it is efficacious to combine the separate services provided by
dispensing nurses, physicians assistants-nurse practitioners and
physicians. When this is done, it may be seen that there are
still considerable variations in the provision of medical care.
Thus, the number of patients seen per week by the medical staff
varies from 36 to 185 in the seven programs. Although this
figure involved some duplication (as some few patients are seen
by more than one type of medical staff), it does reflect the
number of treatment sessions and it is a rather accurate
enumeration of the extent of medical services actually provided
on a weekly basis.
It is relevant to analyze how the available medical staff provide
services on a comparative basis; that is, on the basis of
full-time staff equivalents (FTEs). When this is done (Table 3,
column 5), some of the prior differences dissipate. Although the
number of patients seen in the seven programs per full-time staff
(FTE) varies from 9.7 to 38.5, in 5 of the 7 programs each
full-time staff treats from 22 to 32 patients per week. But, the
program with the fewest medical staff sees the most patients per
FTE. Therefore, the main reason for marked differences in
treatment services provided is that some programs have more
treatment staff than others.
Analysis of the provision of treatment services can be undertaken
with respect to the percentage of the patient population seen per
week by medical staff. These figures show notable differences
among the seven programs. Thus, the range in percentage of
patients who received medical services is from 14 to 53 percent
on a weekly basis. Thus, patients in some methadone programs are
three times as likely to receive medical services as those in
others.
CONCLUSION
In this report, we have investigated the type and frequency of
medical services provided to 2,394 patients by 49 medical staff
in seven methadone maintenance programs. Data were collected by
a four person research team at each site by means of face-to-face
interviews with the entire treatment staff.
The research findings lend support to four major conclusions.
First, it is evident that there are marked differences in both
the number and type of medical staff which serve these methadone
programs. Some programs have continuous daily medical coverage
by physicians, others have only part-time coverage on certain
days with no coverage on other days. Some programs have highly
qualified full-time physicians assistants or nurse practitioners,
but some do not. Most of the programs have nurses, but not all.
Two programs have pharmacists, but five do not. So, we have
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found notable differences in the medical staff available to
provide treatment.
Second, we have found considerable variation in the medical
services provided patients in these seven programs. In some
programs, less than 10 percent of the patients see a physician on
a weekly basis, while in others 20 percent or more see a
physician. Similar variations in the frequency of treatment were
observed for the entire treatment staff.
Third, it was found - as might be expected - that the provision
of medical services to patients was related to the number and
type of available staff. This finding is important. For it
indicates that the available staff - whatever this is - is
actively engaged in providing medical services to these needy
patients. It is not that patients fail to seek these services.
Rather, the findings indicate that there is a pressing demand for
medical treatment in these programs.
Lastly, from an evaluation perspective, this analysis of medical
staff and the treatment services they provide is only a first
step. Next, we need to investigate whether the provision of these
and other treatment services in methadone maintenance programs
are related to patient improvement and rehabilitation. How, for
example, does length, type and intensity of methadone treatment
affect patient outcome?
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TABLE 1
Medical staff at seven methadone maintenance programs and patient population of
and during designated week*
* Patient census is presented by range in order to maintain confidentiality.
Calculated values, however, are derived from  the actual figures.
TABLE 2
Medical services provided by physicians at seven methadone maintenance
programs during designated week.
TABLE 3
Patients seen by the total medical staff of each program during
designated week
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A Clinical Trial of Buprenorphine: I. Com-
parison with Methadone in the Detoxification
of Heroin Addicts II. Examination of its
Opioid Blocking Properties
Warren K. Bickel, Rolley E. Johnson, Maxine L. Stitzer,
George E. Bigelow, Ira A. Liebson, and Donald R. Jasinski
A new synthetic opioid, buprenorphine, has shown promise as a
treatment drug for opioid addiction that possesses many of the
benefits of the standard agonist and antagonist treatments
methadone and naltrexone) while possessing few of their
liabilities (Jasinski et al 1978). Like methadone and
naltrexone, buprenorphine has a long duration of action.
Buprenorphine, in a fashion similar to methadone, supports drug
self-administration and therefore may be associated with good
treatment retention (Lukas et al., 1983; Mello et al., 1981).
Like naltrexone, buprenorphine is very safe across a broad range
of doses (Lewis et al., 1982). Moreover, buprenorphine produces
only a minimal degree of physical dependence which may permit
rapid detoxification (Lukas et al., 1984). The limited with-
drawal associated with the discontinuation of buprenorphine
treatment may render buprenorphine as the preferred pharmaco-
therapy for opioid detoxification. Additionally, buprenorphine
via the mechanism of pharmacologic blockade reduces opioid
self-administration (Mello et al., 1982). Although the dose-
effect relation of buprenorphine's blockade has yet to be
determined, pharmacologic blockade has been demonstrated in man
(Jasinski et al., 1978 Thus, buprenorphine has many
properties that may be beneficial in the treatment of opioid
addiction.
One undesirable feature is buprenorphine's ability to
precipitate withdrawal in opioid-dependent individuals in a
fashion similar to that of naltrexone. For example, Lukas et
al. (1984), found that subjects maintained on methadone when
abruptly placed on buprenorphine maintenance exhibited mild
withdrawal signs and symptoms lasting from three to five days.
Buprenorphine's withdrawal producing properties may result in
poor retention during treatment induction and may represent its
greatest impediment as a treatment of opioid addiction.
The purpose of the present study was to conduct, what is to the
authors' knowledge, the first controlled clinical trial of
buprenorphine. Two experiments were conducted. First, bupre-
norphine was compared with methadone in the detoxification
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of heroin addicts. This study will delineate the efficacy of
buprenorphine relative to methadone and indicate whether
buprenorphine's withdrawal producing properties will affect
treatment outcomes. Second, an experiment was conducted in
which the opioid blocking properties will affect treatment
outcomes. Second, an experiment was conducted in which the
opioid blocking properties of a range of buprenorphine doses
were examined.
METHODS
General Methods. The basic protocol for these studies will be
described in this section, while any deviations from the basic
protocol will be explained under specific methods for subsequent
studies.
Subjects. Subjects were enrolled in a 90-day (13 week)
detoxification program. Individuals qualified for treatment by
showing physical indications of recent intravenous drug use.
All subjects underwent a standard medical evaluation prior to
enrollment and only healthy individuals were permitted to
participate. In order to obtain a homogenous sample of opioid
addicts, individuals were also excluded from study participation
if there was urinalysis evidence of recent methadone use.
Subjects were instructed to abstain from opioid use for a total
of 10 hrs prior to receiving their first dose of the treatment
drug. All subjects provided written informed consent prior to
participation in the study.
Clinic Procedures. Patients reported to the clinic daily and
ingested their medication under nursing supervision. Urine
samples were collected on Monday, Wednesday and Friday with an
additional urine sample collected every other weekend on either
Saturday or Sunday according to a random schedule. All samples
were collected under staff observation and immediately tested on
site via an Emit system (Syva Corp.) for the presence of opiates
and benzodiazepines. Additionally, randomly selected samples
were sent out each week to an independent laboratory and were
analyzed for a wide variety of both opioid and nonopioid drugs
using thin-layer chromatography (TLC) analysis.
Self-Report Measures. During each clinic visit in which a urine
sample was collected, three self-report questionnaires were
filled out by the patients. The first questionnaire was an
opioid drug effect adjective rating scale composed of 20 times
describing typical opioid drug effects (e.g., nodding, skin
itchy). The second questionnaire was a withdrawal adjective
rating scale composed of 20 items describing common withdrawal
symptoms (e.g., painful joints, hot or cold flashes). On both
scales, patients rated each item on the degree to which they
experienced the symptoms during the past 24 hours on a scale of
0 (not at all) to 9 (severe). The third questionnaire was the
Addiction Research Center (ARC) chronic dosage questionnaire
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composed of a checklist of withdrawal symptoms, a yes-no ques-
tion asking "are you kicking?", and a global question asking
"how do you feel?" which could be answered on a 6 point scale
ranging from very bad to very good.
Experiment I. Comparison of Buprenorphine and Methadone during
the Detoxification of Heroin Addicts.
Subjects. Forty-five males with an average age of 30 yrs were
enrolled in the study. Participants were randomized, strati-
fying for race, to either the buprenorphine or methadone treat-
ment groups. No significant differences were found between the
treatment groups on any demographic variable.
Dosing Procedures. Patients ingested both an oral medication
(methadone or methadone placebo ) and a sublinqual medication
(buprenorphine or buprenbrphine placebo) under nursing super-
vision at each clinic visit. Both the subjects and the nurses
had no information about which medication was active or of the
dose reduction schedule. Patients were stabilized on either 2
mg of buprenorphine or 30 mg of methadone for weeks 1-3 of the
study. After this stabilization period, the doses were reduced
over weeks 4 to 7 with placebo being administered during weeks
8-13. The dose-reduction schedule for buprenorphine during
weeks 4-7 was 1.34, 0.67, 0.34 and 0.17 mg. The methadone dose
reduction schedule for the same period was 20, 10, 5 and 2.5 mg.
Buprenorphine prepared in a 20% ageous alcohol solution and
administered sublingually. Methadone was suspended in cherry
syrup (Methadose) and administered orally. The placebo for each
drug was the same vehicle without the active drug.
Measures. Measures included retention, the number of days of
subject participation prior to the first of three consecutive
absences or the end of the 90 day detoxification period,
attendance, the number of days the subject received scheduled
medication during the retention period, drug positive uriness
and the self-reported measures described above.
Data Analysis. Data were analyzed for the clinical measures of
detoxification which included: (1) opioid positive urines, (2)
benzodiazepine positive urines, (3) clinic attendance, (4)
treatment retention, and (5) self-report measures of opioid drug
effects and withdrawal symptomatology. The mean duration of
treatment retention for the two groups was analyzed including
data from all subjects via a t-test (two-tailed). Only patients
who remained in treatment at least six weeks were included in
the analysis. Additionally, only data obtained during the first
six weeks were analyzed due to subject attrition.
Urinalysis results obtained from the EMIT opiate assay (opiate
positives) were analyzed in two ways; that is, (1) all opiate
positive urines and (2) all opiate positive and missing urines
obtained during the first six weeks were analyzed via a two way
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repeated measures analysis of variance (treatment, time, treat-
ment by time). This latter approach of replacing missing data
makes the conservative assumption that during a clinic absence
patients were taking illicit opioid drugs. Urinalysis from the
Emit benzodiazepines assay, self-report measures of opioid drug
effects, withdrawal symptomatology, and daily clinic attendance
were analyzed via a two way repeated ANOVA (treatment, time,
treatment by time).
Experiment II. Examination of the Opioid Blocking Properties of
Buprenorphine.
Subjects. Five white males served as subjects over a nine month
period with an average age of 32.5 yrs. Patients were told that
they would receive buprenorphine.
Clinic Procedures. Patients received a dose of buprenorphine
(sublingual) at each clinic visit. Both the subjects and the
nurses dispensing the medication were blind to the dose.
Buprenorphine Doses. Patients received first an ascending
series of buprenorphine doses followed by a descending series of
doses. The patients were chronically maintained on each dose of
buprenorphine for a two week interval. The ascending and
descending doses of buprenorphine were 2, 4, 8, 16, 4, and 2 mg,
respectively. Patients were maintained on buprenorphine placebo
during the last week of the study.
Hydromorphone Challenge Session. Between the 10 and 14 day of
chronic administration of each buprenorphine dose, the patient
participated in a 5 hour challenge session approximately 24
hours after the last administration of buprenorphine. During
that session, subjects received three injections administered
intramuscularly. The first injection consisting of saline was
administered after a 30 minute stabilization period. The
remaining two injections consisting of 6 and 12 mg of
hydromorphone, respectively, where administered at 1.5 hr
intervals. The session was terminated 1.5 hours after the last
injection. Physiological measures were taken continuously
throughout the session. Pupil photographs were taken every 30
minutes. Five analog scale self-report questionnaires were
administered every 15 minutes throughout the session. A larger
batter of questions were administered every 30 minutes. The
daily medication was administered to the subject at the
completion of the challenge session. Subjects were paid $25 for
each session they completed and $100 upon completion of all the
challenge sessions.
Measures. The physiological measures consisted of diastolic and
systolic blood pressure, heart rate, respiration rate and skin
temperature, as measured by an Apple II Psychophysiological
Station. Pupil diameter was measured from a photograph taken
with a Polaroid close-up camera with 3X magnification.
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Self-report questions were presented by the Apple II Station.
The five analog scale questions presented the subject with a 100
point line anchored by "not at all" on one end and "extremely"
at the other. The patients moved an arrow to the extent they
felt the drug. The patients were asked to indicate the subject
rates "drug effect", "drug liking", "good" and "bad" effects, as
well as subjective "high." Withdrawal and opiate drug effect
questionnaires, described above, were administered in the larger
battery.
Data Analysis. The self-report and physiological measures were
averaged across the five subjects and presented in a cumulative
dose-effect fashion. A dose effect for each buprenorphine dose
is presented.
RESULTS
Experiment I. Mean duration in treatment was analyzed using a
t-test wit no significant differences being found between the
buprenorphine (N = 22) and methadone (N = 23) groups. The
remaining analyses were conducted on the data obtained from
patients staying in treatment for at least six weeks which was
17 for th buprenorphine group and 14 for the methadone group.
The repeated measures ANOVA failed to reveal any significant
differences between the groups. Only the withdrawal symptoms
from the ARC Cronic Dosage Attitude questionnaire approached
significance [F (1,29) = 3.44, n.s.]. On that measure the
methadone group reported fewer withdrawal symptoms than the
buprenorphine group. Daily attendance, opiate positive urines,
opiate positive or missing urines, benzodiazepine positive
urines, withdrawal symptoms, and global feelings showed
significant time effects. However, significant time effects are
to be expected and reflect the gradual reduction in dose
throughout the detoxification. Only withdrawal symptoms showed
a significant group by time interaction [F (5, 145) = 2.70, p <
.05].
Experiment II. Table 1 presents subject rated high as a
function of the cumulative hydromorphone challenge dose across
the ascending buprenorphine doses. A steep hydromorphone dose
effect curve was obtained on subject rated "high" with subjects
maintained on 2 mg of buprenorphine. Less hydromorphone effect
is seen under the 4 and 8 mg of buprenorphine. Maximal
suppression of hydromorphone's effects occurred when patients
were maintained on the 16 mg dose of buprenorphine.
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Table 1
Subject Rated "High"
DISCUSSION
On the majority of clinic measures from Experiment 1, 2 mg of
buprenorphine is as effective as 30 mg of methadone in the
detoxification of heroin addicts. Overall, the results from
both groups are poor with respect to illicit opioid use and
retention. However, this is not a surprising result since most
studies of detoxification show poor retention and relapse to
opioid use during dose reduction. Nonetheless, buprenorphine is
acceptable to patients and can be used in the treatment of
narcotic addiction. This is remarkable because a drug with
antagonistic properties would not be expected to as effective as
methadone, an opioid agonist, in the treatment of heroin
addicts.
An important result from Experiment I was the lack of
significant group differences on the subject retention
suggesting that buprenorphine precipitated withdrawal may not
have occurred. This may be due to our instruction to patients
that they should remain abstinent from opioids for 10 hr prior
to receiving their first medication; that is, buprenorphine may
be less likely to precipitate withdrawal when the patient is
already experiencing mild withdrawal symptomatology. This view
is supported by a study by Aceto (1984) which examined
buprenorphines ability to precipitate withdrawal in
morphine-dependent monkeys. Buprenorphine was found to
precipitated withdrawal in a dose-related fashion when the
monkeys were administered morphine one-hour prior to the
buprenorphine challenge. Most importantly, buprenorphine was
found to suppress withdrawal in a dose-related fashion when
administered to monkeys who were 15 hr abstinent and already in
withdrawal. The necessity of having patients remain abstinent
to the extent that they experience withdrawal may be necessary
for successful induction onto buprenorphine treatment.
The examination of the opioid blocking properties of
buprenorphine indicates that this drug can produce substantial
blockade. The most efficacious dose appeared to be the 16 mg
dose, which is approximately equivalent to the 8 mg (SC) used by
Jasinski et al., (1978) (R.E. Johnson, personal communication).
Although the 16 mg dose of buprenorphine produced maximal
blockade, the 4 and 8 mg dose may provide clinically significant
blockade.
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In summary, buprenorphine is a drug that can be used to treat
narcotic addiction. Whether buprenorphine will prove to be a
more effective treatment than methadone will require additional
studies in which a variety of doses and buprenorphine's various
properties such as opioid blockade are examined in clinical
trials. Even though Experiment I does not indicate that 2 mg of
buprenorphine is more efficacious than methadone, there are two
other properties of the drug that may favor its use over
methadone. First, buprenorphine is safer than methadone; that
is, buprenorphine overdoses are unlikely to result in death
because there is a ceiling on buprenorphines ability to cause
respiratory depression. Second, buprenorphine is less likely to
be diverted for illicit use than methadone because it will
precipitate withdrawal in addicts not currently in withdrawal,
and therefore, may be less likely diverted for use in that
population.
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Extinction of Conditioned
Responses in Abstinent Cocaine
or Opioid Users
Anna Rose Childress, A. Thomas McLellan, Ronald N.
Ehrman, and Charles P. O’Brien
In 1948, Wikler observed that opioid addicts who had been detoxified and
maintained in a drug-free state would sometimes report symptoms of
opioid withdrawal when talking about drugs during group therapy
sessions, or when they returned to areas where they had previously used
drugs. Wikler labeled this phenomenon “conditioned withdrawal”
speculating that environmental stimuli had acquired the ability (through
classical conditioning) to elicit many of the signs and symptoms of actual
opioid withdrawal. He further hypothesized that these “conditioned
withdrawal” phenomena might play an important role in triggering relapse
to drug use in the abstinent opioid abuser.
In the years since Wikler’s original observations, there have been several
studies demonstrating the existence of conditioned withdrawal in animals
(Wikler & Pescor 1967; Goldberg & Schuster 1970) and in humans (O’Brien
1975; O’Brien et al 1977). We and others have also reported
withdrawal-like symptoms and/or signs in opiate addicts exposed to
drug-related stimuli (Teasdale 1973; Ternes et al 198O; Sideroff & Jarvik
1980). Given this evidence, the existence of conditioned withdrawal is
generally accepted, but its actual clinical importance remains uncertain.
For the past several years our research center has engaged in
treatment-outcome projects to help determine the clinical importance of
conditioned responses such as craving and withdrawal. The general
approach in most of these projects has been to first select conditioned
“trigger’ stimuli (eg. sight of syringe, drug-talk, cook-up paraphernalia)
which reliably elicit conditioned drug responses in the target population,
and then to attempt to reduce these responses through repeated,
non-reinforced exposure (extinction).
In a large scale treatment-outcome study employing extinction trials in
methadone patients (McLellan et al 1986), we found that these
drug-related stimuli were reliable elicitors of conditioned opioid-related
responses, particularly conditioned craving and conditioned withdrawal.
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With 20 or more extinction sessions, conditioned craving was significantly
reduced, but conditioned withdrawal was still in evidence.
In the past year we have been studying conditioned drug-related
responses in abstinent, formerly dependent abusers of either cocaine or
opioids. The two groups of patients were studied following completion of a
30-day in-patient rehabilitation program. As with our previous study in
methadone patients, this project involved extensive pre-treatment,
post-treatment and follow-up measures of the patients’ clinical status. Data
from these sessions has permitted us to examine the question of whether,
and to what extent, conditioned drug-related responses are seen in
abstinent addicts following 30 days of inpatient treatment. The current
paper is an interim report on two sources of data collected in the course of
the long-term treatment outcome study: 1) Pre-treatment laboratory
measurement of the conditioned responses associated with opioid
dependence and 2) attempted extinction of the conditioned responses
associated with either cocaine or opioid use.
METHODS - Study I - Pre-Treatment Assessment of Conditioned
Responses in Abstinent, Opioid-Dependent Subjects
Subjects - for the opioid study were 13 formerly opioid-dependent males
who had just completed at least 30 days of abstinence-oriented
rehabilitation in a therapeutic community. They were then transferred to
the research facility for a three-week inpatient stay, followed by an
eight-week outpatient treatment phase. Interested candidates were
clinically screened to rule out diagnoses of major thought disorder
(schizophrenia) or organic brain syndrome. Patients participated in the
study with the understanding that they would be randomly assigned to one
of four treatment packages: 1) Supportive-expressive psychotherapy-plus
extinction (SE-E), 2) Supportive-expressive psychotherapy plus control
activities (SE-C), 3) Drug counseling plus extinction (DC-E) and 4) Drug
counseling plus control activities (DC-C). Eventual inter-group
comparisons will thus permit assessment of the contribution of professional
psychotherapy and/or extinction to treatment outcome. The average age of
these subjects was 34 years, having an average of 14 years heroin use
and three years of methadone treatment.
Pre-treatment measurements. Prior to treatment each patient’s
responsivity to drug-related stimuli was assessed in a go-minute laboratory
session. These laboratory test sessions were conducted in an environ-
mentally-controlled, electrically-shielded recording chamber. Both
physiological and subjective measures were obtained.
Physiological measures included peripheral skin temperature (TEMP),
galvanic skin resistance (GSR), heart rate (HR), and respiration (RESP).
These physiological measures were simultaneously recorded on a
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polygraph and a Bio-Med computer software package for later analyses.
Subjective measures were obtained by asking each abstinent patient to
rate, on a 1 to 10 scale, the degree of subjective high, craving, or
withdrawal experienced under each set of stimulus conditions. Both
neutral and drug-related stimulus conditions were employed, with each
patient experiencing both conditions, acting as his own control. The
following stimulus sequence was used: 1) Neutral Baseline, 2) Neutral
Videotape (a nature story), 3) Neutral Activity (video pong game), 4) Drug
Baseline, 5) Drug-related Videotape (buy-sell and cook-up-shoot-up
rituals) 6) Drug-related Activity (handling drug paraphernalia and
performing rituals appropriate to the drug e.g., cook-up, tie off or prepare
pipe for free base.) and 7) Recovery Baseline. Both Neutral and
Drug-related stimuli had been developed through our previous large scale
study of conditioned phenomena in a methadone-maintained patient
sample.
RESULTS - Study I
Pretreatment Laboratory Testing. First, mean values for five minute
stimulus periods representing each stimulus period (e.g., Neutral baseline,
Neutral video, Neutral activity, etc.) were determined for each of the
physiological variables (GSR, HR, RESP, and TEMP), for each patient.
Since baseline values on some of these physiological variables
sometimes show drift in the course of a session, we used a difference
score to represent the response to each Neutral or Drug-related stimulus
condition. The difference score was derived by subtracting the appropriate
baseline value from a given stimulus condition, e.g. (Neutral video)  -
(Neutral baseline): (Drug Video) - (Drug baseline) etc. These difference
scores were then compared between Drug and Neutral conditions using
the paired t-test procedures. T-test results for both GSR and TEMP
physiological variables differed significantly for the Drug vs. Neutral activity
(p<.05, one-tailed test). These physiological results, showing greater
arousal (indexed by GSR) and greater reductions in skin temperature to
Drug vs. Neutral activities, parallel our earlier findings in methadone
maintained patients (McLellan et al 1986).
Subjective measures. As with the physiological measures, we first
derived difference scores to represent the change in craving for each
stimulus compared to its baseline and then compared the Neutral vs.
Drug-related conditions using paired t-tests. Results of these comparisons
showed a highly significant difference in craving between Drug vs. Neutral
activity (p<.005, one-tailed test). No significant differences were seen
between neutral and drug-related stimuli on the high or withdrawal
subjective measures. Interestingly, craving increases upon presentation
of drug-related stimuli have occurred in 11 of 13 abstinent patients tested
thus far; markedly greater than the 50% rate shown by methadone
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patients tested under the same conditions (McLellan 1986).
METHODS - Study II - Extinction of conditioned Responses in Abstinent
Opioid-Dependent and Cocaine-Dependent Subjects
Subjects - Opioid subjects were six of the original 13 subjects (described
in Study I) who had been randomly assigned to one of the extinction
groups. Cocaine subjects were six male veterans who had completed
inpatient treatment for cocaine dependence at the same therapeutic
community program described in Study I. These patients were all pilot
subjects in our developing study of conditioned drug responses associated
with cocaine use. They were all males with an average age of 34 and four
years of cocaine use. All cocaine subjects were freebasers.
Extinction Sessions - All subjects in both groups received 20, hour-long
extinction sessions during their three-week inpatient stay. Three types of
conditioned drug stimuli were presented during each session: audiotape
segments of a drug “buy;” videotaped segments of an individual using the
drug; and a drug activity in which the subject actually went through the
drug preparation procedures with paraphernalia identical to those they
had used in their home environment. Each of the three types of stimuli
were repeated three times during each session, thereby providing nine
drug-related stimulus exposures per session for a total of 180 exposures
over the course of 20 sessions. This intensive inpatient extinction offered
four to five times as much drug-related stimulus exposure as our previous
procedures with methadone patients.
The stimuli for the opioid subjects have been described previously
(Mclellan et al., 1986) and the cocaine stimuli were developed in the same
way using language, scenes and paraphernalia directly from the patients’
street experience. Most extinction sessions were conducted on the
inpatient treatment ward. During all sessions subjective measures were
taken at baseline and following stimulus exposure. Data were based on
10-point ratings of the intensity of feelings of high, craving and withdrawal
responses that a patient may experience upon exposure to drug-related
stimuli (CS’s). More detailed measures of the type and intensity of
symptoms was then probed through a list of 48 symptoms.
RESULTS - Study II
Difference scores were calculated for all three rating measures as well as
the two symptom scores for each session, by subtracting the baseline
measure from the post-stimulation score. These difference scores were
examined in a repeated measures ANOVA for both opioid and cocaine
subjects. Despite the small number of subjects there were significant
(p<.01) reductions shown in withdrawal symptoms and in the craving
ratings for both groups. High ratings and high symptom scores were never
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elevated during the intervention and were therefore not significantly
changed over sessions (p>.10). Reduction in craving symptoms as a
function of extinction trials is illustrated for both groups in Figure 1. As
seen, most of the reduction in craving occurs by the tenth session of the
intensive extinction regimen.
FIGURE 1
Extinction of Cocaine & Opioid Craving
SUMMARY AND DISCUSSION
Though data collection in our treatment-outcome study of abstinent former
opioid dependent patients is still in progress and the cocaine study is in an
early stage, two significant findings are already apparent: 1) Drug
dependent patients who have just completed 30 or more days of
abstinence in a therapeutic community setting are extremely vulnerable
when exposed to drug-related stimuli. The opioid patients show
increased arousal (GSR) and decreased peripheral skin temperature
(TEMP) to Drug-Related, as compared to Neutral activities. Our
preliminary evidence suggests similar signs of arousal in abstinent former
cocaine users. Subjectively, 11 of 13 opioid patients showed increased
craving to drug-related stimuli, a rate more than twice that found in
methadone-maintained patients tested under the same conditions.
4) The current extinction procedures were effective in virtually eliminating
both craving and withdrawal symptoms in response to the stimuli within 20
treatment sessions (a 3-week inpatient stay).
Ironically, all these abstinent patients had just finished a “complete” course
(30 days) of therapeutic community (TC) treatment and were considered
ready for discharge. Most of these patients had felt the TC experience was
193
quite beneficial, and had prepared them to stay drug-free. They were
subsequently dismayed to experience intense feelings of craving and
vulnerability upon direct exposure to drug-related stimuli. Several patients
spontaneously commented, “It’s like I was never there (at the TC) - this
(craving) is so strong...” The TC had provided strong support for these
patients’ resolution to remain drug-free, but had left intact the conditioned
responses which could so readily undermine their best intentions.
The results in the cocaine subjects are preliminary, but they represent the
first systematic examination of this aspect of cocaine dependence. Since
results of standard treatment with this powerful drug are poor, the
incorporation of extinction procedures seems to be warranted in a
controlled trial. A procedure similar to our current extinction protocol might
be a particularly useful adjunct to other more standard treatment programs
for the abstinent patient. In its current evolution, our extinction program is
quite intensive, but can easily fit into a 30-day stay. It can be administered
by trained counselors or research assistants and does not require
physician time. The stimuli and procedures are easily adapted to a clinic
setting. Finally it appears to be effective in virtually eliminating
conditioned craving and withdrawal to the drug-related stimuli which we
present. Of course, how-long these reductions will last and how well these
reductions in response will generalize to other drug-related stimuli in the
patient’s post-discharge world remains the crucial question. We hope
generalization will be enhanced by supplemental, outpatient extinction
with individualized conditioned stimuli.
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Source of Income as a Predictor
in Opioid Addicts: 2.5 Year
Follow-Up
Thomas R. Kosten and Bruce J. Rounsaville
INTRODUCTION
Although several studies have suggested that drug abuse treat-
ments have had limited success in helping former addicts become
self supporting (l-3), a more recent study by McLellan et al.
(4) suggested that an inability to become self-supporting during
methadone maintenance treatment may be limited to patients who
are supported by public assistance before applying for treat-
ment. In their study, addicts were grouped according to three
primary sources of pretreatment income - employment, public
assistance and illegal activities - and then analyzed separately
at follow-up. The public assistance group demonstrated not only
an inability to legally support themselves, but globally poor
outcomes with no significant improvements in any area, while the
other two groups made significant improvements in several
psychosocial outcomes including self support through legal
employment. From a recently completed 2.5 year follow-up of
treatment seeking addicts (5,6), we were able to assess the
generalizability of the McLellan study using data from a longer
follow-up that included females, and to compare addicts treated
with detoxification alone to those getting methadone mainte-
nance.
METHODS
Study subjects were opiate-addicted applicants for treatment at
the Substance Abuse Treatment Unit (SATU) of the Connecticut
Mental Health Center and the Yale University Department of
Psychiatry in New Haven, Connecticut. One hundred and fifty-one
out of 204 consecutively admitted subjects participated in a
follow-up evaluation 2.5 years after the initial evaluation
(5,68). Sociodemographic and clinical characteristics of the
subjects lost to follow-up were compared to those interviewed,
and the two groups were demographically comparable, but were
found to differ on several indicators of antisocial behavior.
Fewer of those lost to follow-up had school behavior problems as
children (38% vs 55%) or met DSM-III criteria for antisocial
personality disorder as adults (37% vs 63%). Those lost also
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had fewer arrests (7.5 vs 11.5) and less previous drug abuse
treatment (1.5 vs 2.4 previous predominantly male (76%), 41%
were white, 27% were currently married, 51% were employed, and
the mean age was 28 ± 5 years. They had used opiates for 9.8 ±
4.3 years.
Both the admission and follow-up evaluations included the
Addiction Severity Index (ASI) (7,9), the Social Adjustment
Self-report scale (SAS) (10), Beck Depression Inventory (11) and
Maudslay Personality Inventory (12,13). The AS1 is a structured
interview yielding ten-point clinical ratings of problem severi-
ty in six areas: medical, legal, substance abuse, employment,
family and psychological. On each of these scales higher scores
indicate more impairment.
Patients were classified into three groups based on their
sources of income during the 30 days before seeking treatment,
as described by McLellan et al. (4). This division resulted in
48 employed (E) patients, 46 welfare (W) patients and 57 illegal
income or criminal (C) patients. The three groups differed in
age and the percentage of males. More males were in the em-
ployed group (90%-E vs 65%-W vs 70%-C), and the welfare group
was younger than the other two groups (28-E vs 26.5-W vs 29-C).
Because of these demographic differences, sex stratified and
covariance analyses were also performed. Illegal income and
employment at follow-up were compared within the nine subgroups
formed by "source of income" (employed, welfare, criminal) and
treatment type (methadone, drug-free, detoxification) using
analysis of variance for income change and chi squared for
percent employed.
RESULTS
On the ASI, substance abuse, family, legal and psychological
problems significantly decreased for all three source of income
groups, but the amount of improvement across the three income
groups was significant only for employment and legal problems.
On these two scales the welfare group showed relatively little
change compared to the other two source of income groups. For
employment, the E group went from 2.2 at intake to 2.1 at
follow-up, the W group from 4.0 to 3.2, and the C group from 4.2
to 3.2 (F=7.4, P<0.0001). For legal problems, the E group went
from 3.8 to 2.1, the W group from 3.5 to 2.5, and the C group
from 5.0 to 2.4  (F=5.6, P<O.01).
For the total sample, income from illegal activities was sub-
stantially reduced, but income from other sources did not
significantly change. Illegal income decreased from a mean of
$1058 to $246 monthly during the 2.5 year follow-up (t=5.8,
P<0.0001). Mean employment earnings increased slightly from
$356 to $ 383, and mean welfare income increased from $48 to $79
for the whole sample. Within source of income groups, signifi-
cant changes in income were evident for the employed and crimi-
nal groups, but not for the welfare group. Decreases in
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employment earnings were demonstrated for the employed group
($741 to $483), but no change for the other two groups (F=5.8,
P<0.01). Illegal income substantially decreased for the crimi-
nal group ($2552 to $446), but did not change for the other two
groups (F=25, P<0.0001). Thus, in illegal income and legal
problems, as well as employment, the welfare group showed less
improvement than the other two groups.
To examine whether welfare patients benefited from treatment
with methadone maintenance, we compared methadone maintenance to
detoxification alone. During this 2.5 year follow-up 83 patients
received methadone maintenance, and 40 patients received detoxi-
fication alone. Based on McLellan's findings, we expected that
the welfare patients would do no better with methadone mainte-
nance than with the minimal treatment of detoxification alone.
In comparison, we expected that methadone patients in the other
two income groups would show more improvement than did the
detoxification patients.
The amount of illegal income at intake and follow-up for the
three source of income groups was compared between the methadone
and detoxification patients. For the methadone maintained
subjects, all three income groups reduced their illegal income
at follow-up, although the welfare group had the least percen-
tage reduction (26%-W vs 74%-E and 81%-C). In comparison for
the detoxification alone subjects, the employed group showed an
increase in illegal income of 35% compared to reductions by the
welfare (48%) and criminal groups (84%). In terms of our major
question, welfare predicted a poor illegal activities outcome,
since when treated with methadone maintenance, the welfare group
reduced their illegal income substantially less than the pa-
tients in the other two income groups (F=7.0, P<0.0001).
Furthermore, for the employed group, methadone maintenance had a
substantial impact in reducing illegal income compared the
increase reported by those getting detoxification alone.
In terms of employment status among the methadone maintained
patients, the welfare patients were less often employed at
follow-up (50%) than were the other two groups (E-83% and C-66%)
(chi squared = 3.4, P<0.05, one tailed). Among the detoxifica-
tion patients, employment for the welfare group at follow-up
(50%) did not differ from that for the other two groups (E-60%
and C-33%) (chi squared = 0.03, n.s.). Compared to detoxifica-
tion patients, methadone maintained patients were employed more
often within both the employed (83% vs 60%) (chi squared = 2.6,
P<0.05, one tailed) and criminal groups (66% vs 33%) (chi
squared = 3.9, P<0.05), but not within the welfare group (50% vs
50%) (chi squared = 0.0, n.s.). Thus, as pretreatment source of
income, welfare predicted a relatively poor employment outcome
during methadone maintenance treatment.
DISCUSSION
Treatment outcome 2.5 years after intake was examined within
three subgroups of patients categorized by their primary source
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of income when applying for treatment: employment, welfare and
criminal activities. A wide variety of outcomes were examined
including several psychosocial assessment scales, the Addiction
Severity Index, monthly income from the three primary sources
and employment rates as follow-up. Because the previous short-
term study of this issue included only methadone maintained
patients and did not have a minimal treatment control group (4),
we compared the methadone maintenance patients to those receiv-
ing only detoxification in the present follow-up. Two questions
were addressed: 1. did pretreatment welfare do better with
methadone maintenance than with detoxification alone?
The answer to the first question was that pretreatment welfare
support did not predict globally poor outcome, and the most
striking finding was the general improvement of subjects in all
three "source of income" groups. The differences in outcome
among the three groups were consistent with the areas of iden-
tified problems at intake, and the group with the most severe
problem showed the most improvement in that problem area. In
contrast to the previous six month follow-up by McLellan (4),
our welfare group improved in most areas, and in depressive
symptoms and social adjustment they showed more improvement than
the other two groups. The differences from McLellan et al.
suggest that the previous study of male veterans populations,
and source of income may be much better as a short-term than
long-term predictor of outcome.
In answer to the second question, treatment with methadone
maintenance appeared to have little impact beyond detoxification
in reducing unemployment and illegal income among addicts whose
initial source of income was primarily public assistance (wel-
fare). This finding is consistent with the previous study by
McLellan et al. (4), although McLellan did not have a comparison
group for their methadone maintenance sample in order to control
for non-specific effects of seeking treatment. Future follow-up
studies will need to include minimal treatment or other suitable
comparison groups before we conclude that compared to other
income groups, addicts on welfare obtain minimal benefits from
methadone maintenance, and that they need other forms of treat-
ment such as residental programs.
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AIDS Virus Exposure Behavior
in Long-Term Addicts:
A Preliminary Study
M. Douglas Anglin and Mary-Lynn Brecht
ABSTRACT
Data is presented on the prevalence of clinical AIDS and antibodies to the AIDS
virus in intravenous drug users. In addition, data from subjects followed over
twenty years in a California study on the natural history of narcotics addiction
is reported. Information about AIDS attitudes and high risk behavior is related
to sample characteristics and narcotics use patterns. The possibility for
heterosexual transmission is assessed by report of marital or common-law status
and by the extent of drug use by long-term sexual partners.
INCIDENCE OF AIDS
Through April 7, 1986, 19,181 diagnosed cases of acquired imiunodeficiency
syndrune AIDS) had been reported to the Centers for Disease Control (CDC 1986);
274 of these were children under 13 years of age, and 81 were adolescents
between 13 and 19. The epidemic has grown geunetrically since the first few
cases were identified in 1979-1981. Cases have been reported in 46 states and
the District of Columbia, with the highest prevalence in New York (31% of
cases). California has reported 23% of the cases; Florida and New Jersey
represent 7% and 6%, respectively. Among U.S. cities New York leads with 5,796
cases, followed by San Francisco with 2,014, and Los Angeles with 1,555. When
cases am standardized to a per-million-population rate, New York is first with
573 cases per million, followed by San Francisco (554), Miami (308), Newark
(210), and Los Angeles (185).
AIDS also has been reported in many other countries. By March, 1985, 940 cases
were reported from Europe (CDC 1985a). Although relatively few AIDS cases have
been officially reported in Africa, it is estimated that the incidence is
considerably higher (Piot et al., 1984).  The disease itself appears to follow a
different course in Africa, and understanding that pattern could provide
information important for the rest of the world (Fauci et al., 1985).
DRUG ABUSERS AND AIDS
Intravenous (IV) drug use is the primary risk factor in 17% of the AIDS cases
reported in the United States, and IV drug users constitute the second largest
risk group after homosexual men. IV drug users constitute 14% of male and 53%
of female adult AIDS cases nationwide (CDC 1986). In NEW York 30% of AIDS cases
as of August 1985 had IV drug use as the major risk factor (Bureau of
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Communicable Disease Control 1985). AIDS victims from other risk groups also
have IV drug use as a secondary risk factor; for example, national figures
indicate that 14% of homosexuals with AIDS also have a history of parenteral
drug abuse (Ginzburg 1984; Ginzburg et al., 1985).
Table 1 shows the shows of AIDS cases through about April 6, 1985,
that have IV drug as a contributing or sole risk factor.
Among the 231 pediatric AIDS cases nationwide, 76% are associated with having a
parent with or at risk for AIDS (CDC 1986). Many cases have teen documented in
which one or both parents am IV drug users (Rubinstein et al., 1983; Aleske et
al., 1983; Kaplan et al., 1985).
Isolated studies also show substantial increases in the HTLV-III serum positive
rate  among IV drug users. Weiss et al. (1985) found that 46% of the sample of
56 drug abusers were HILV-III positive in 1982, while Spira et al. (1984) found
at least 58% of a sample of 86 were confirmed positive. Table 2 illustrates the
serious increase in seropositive rates in major cities of the United States and
Europe.
AIDS appears to spread among drug abusers through sharing of needles and drug
paraphernalia. It can also be transmitted from drug abusing mothers to infants.
Furthermore, AIDS can be sexually transmitted by male IV drug users to non-using
females (Pitchenik et al., 1983; Masur et al., 1932; Redfield et al., 1985) or
by incarcerated drug using males to other males by homosexual activity in
institutions.
In a preliminary study, Los Angeles County has reported only 7 of 350 (2.0%) of
admissions to methadone maintenance and methadone detoxification programs to be
positive for HILV-III antibodies (Mascola 1985). This is quite low compared to
the approximately 50% rate reported for homosexual men (Detels 1986). The
potential for a rapid increase in the rate for IV drug users exists because 12%
of the men in the Los Angeles sample reported being gay or bisexual. Thus a
"window" of exposure of a significant size exists between the two highest risk
groups.
Of further concern is the 18% of women in the Los Angeles sample who reported
prostitution. If the HlLV-III exposure rate in IV drug users rises to a high
level, a second window of exposure exists for transmission to the heterosexual
community.
The risk factors within the parenteral substance abusing group affect the
development of the disease after exposure are not known. However, repeated
exposure may be necessary, because few health care workers have contracted AIDS
in spite of needlestick injuries (CDC 1985b). Use of innunosuppressant drugs or
infections such as hepatitis-B or Epstein-Barr Virus (EBV) are possible
cofactors (Marmor et al., 1985). Evidence of immunosuppression has been found
in IV drug users without AIDS (Fiorini et al., 1985).
Opportunistic infections are more common than Kaposi's sarcoma in IV drug users
(Des Jarlais et al., 1984). Shorter survival times are associated with
opportunistic infections than with Kaposi's sarcoma (Riven et al., 1984). IV
drug abuse was the major risk factor in a study of AIDS patients with central
nervous system involvement (Koppel et al., 1985).
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Relatively few data am available on prevalence and transmission of AIDS in
parenteral drug abusers. Studies only recently have progressed from
observations and case studies to more epidemiological ones. More data are
needed to trace the course of AIDS infection and disease in this population.
Such data are critical to public awareness, policy decisions, and provisions for
prevention and treatment resources.
ATTITUDE AND BEHAVIOR SURVEY
An ongoing longitudinal study on the natural history of narcotics addiction gave
us an opportunity to collect attitudinal and behavioral data from 458 heroin
addicts. The original study was designed to evaluate the outccme of treatment
for 581 heroin addicts admitted to the California Civil Addict Program during
1962-1964 (McGlothlin et al., 1977). A  20-year followup is now in progress on
the 458 addicts still alive. Interviewing began for the 20-year postadmission
follwup in November 1985. Because of the increasing prevalence of HTLV-III
antibodies, AIDS-related complex (ARC), and AIDS among the IV drug users, we
included four AIDS-related questions in the natural history interview:
How concerned are you about your physical health?
How many times have your shared a needle with someone in the last five 
years?
How concerned are you that you might have been exposed to AIDS?
How many intravenous drug users do you know who have or had AIDS?
To obtain early information on our findings, we analyzed the first 107
interviews completed as of January 15, 1986. Although this sample is biased
towards subjects who were easy to locate (in prison or with a stable mailing
address), we believe the results provide minimm estimates and am thus
conservatively generalizable to the total sample. The estimte should be
interpreted conservatively since subjects who are still active "street" addicts
are less likely to be represented in these first 107 interviews and are more
likely to be at risk for AIDS exposure.
RESULTS
Table 3 summarizes the results of the AIDS-related and other selected questions
from this preliminary sample. We have divided the sample into a high-AIDS risk
group and a low-AIDS risk group. The high risk group (N = 74) contains those
subjects reporting IV heroin use after January 1, 1980, the date we chose as a
starting point for AIDS exposure risk. The low-risk group (N = 33) reported
their last IV use of heroin as occurring before January 1, 1980. Although 15%
of the high-risk group did not admit to having shared needles in the five years
preceding the interview, we have retained them in the high-risk category because
of possible underreporting of the behavior. We are more confident of the
validity of the report of heroin use since a urine specimen is obtained for
analysis at the time of interview.
Although both high-risk and low-risk groups indicated moderate to very great
concern for personal health (83% and 68%, respectively), only 33% of the
high-risk group and 6% of the low-risk group were personally concerned about
AIDS. Since only 5% of the high-risk group and none of the low-risk group had
personally  know of anyone with AIDS, this lack of concern is not surprising.
On the other hand, the reported level of concern implies either that information
and education efforts directed toward IV drug users, especially those most
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recently involved, are reaching only a minority or that a strung capacity for
denial exists in this group. It is apparent that the high-risk group needs
greater education or other intervention, for 85% of them report having shared
needles with other users in the last five years--55% report having done so 99 or
more times.
The recent and current heroin involvement by the high-risk group is
considerable, because 72% had used heroin and 49% had been addicted in the year
prior to intewiew. Some 23% reported daily use at the tine of interview. As
the general prevalence of AIDS virus increases in the next few years, the risk
to this group will increase in an epidemic manner.
Not only is the high-risk group itself likely to be exposed to the AIDS virus
because of past and current needle sharing, but their sexual partners are also,
especially if they too are addicted. Thirty-one percent of the high risk group
Were married, and 7% were involved with a common-law partner at the tine of
interview. Thirty percent of those reporting themselves married also reported
having wives addicted after January 1, 1980. Sixty-six percent of those
reporting a common-law relationship indicated that their partners had been
addicted after January 1, 1980.
In summary, these results, together with those reported earlier for the Los
Angeles County study, point to the serious AIDS education and prevention needs
in heroin addicts generally, both short-term and long-term. Even 20 years after
admission to treatmant, 69% of our preliminary sample reported heroin
involvement in the AIDS high-risk period after January 1, 1980; 50% reported
heroin involvement in the year before interview. The majority of the sample
exhibited little or no personal concern abort AIDS exposure and reported
extensive needle sharing. Finally, a large number of heterosexual women may
also be at risk for AIDS exposure through sexual contact or neddle sharing
because of marriage or common-law relationships with long-term addicts. More
remotely, but still at risk, are the children of women intimately involved with
long-term addicts.
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TABLE 1. Clinical AIDS and IV Drug Use
Sources: *New York Times, April 6, 1986. New Fear on Drug Use and AIDS
**California Department of Health Services (1986)
TABLE 2. Seroprevalence of AIDS virus antibodies in IV drug users
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TABLE 3. Preliminary results from CAP* followup: AIDS risk,
attitudes, and behaviors
(continued)
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TABLE 3 (continued)
*CAP California Civil Addict Program
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Social Support and Relapse to
Tobacco, Alcohol, and Opiates:
Preliminary Findings
Barbara E. Havassy, Sharon M. Hall, and, Jeanne M. Tschann
Social support is often defined as resources provided by other
persons (Cohen and Syme, 1985). It is described in terms of the
structure and patterns of relationships with others, for exam-
ple, whether one is married, and in terms of its functional
aspects, for example, the extent to which relationships provide
emotional resources (such as a sense of being understood).
Negative qualities of functional support, for example the
constraints supportive relationships may exert over one's
choices, have also been described (see Lehmann et al., 1983,
Schaefer et al., 1981).
Methods of measuring social support as well as the variables
differ depending on which aspect of support is measured.
Despite this variability and a lack of understanding about just
how social support operates, both structural and functional
aspects of support have been shown to play a positive role in
health outcomes. Outcomes of drug treatment especially main-
tenance of abstinence, may also be facilitated by both aspects
of support (see Cohen and Willis, 1985).
Consideration of social support is not common in the drug
treatment literature. When examined, however, social support
has generally predicted outcomes (e.g. Finney et al., 1980;
Foster et al., 1971; Mermelstein et al., in press, Moos et al.,
1979; Orford et al., 1976).
In considering outcomes of drug treatment, it may be important
to distinguish general (or global) social support from support
for cessation of drug use and maintenance of abstinence. The
concept of support specific to drug-use and its potential
relationship to relapse has received little attention.
Mermelstein et al. (in press) attempted to differentiate global
social support from that specific to quitting smoking, however,
results were unclear. Cohen et al. (1985) suggested that
support from intimates rather than from casual acquaintances may
be an important determinant of abstinence.
Several consistencies emerge from the social support, drug
abuse, and treatment literatures. (1) There is evidence of the
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importance of social support in preventing relapse. (2) There
is indication of gender differences in social support (see Cohen
and Willis, 1985) and in relapse rates (for example, see
Davidson, 1976, U.S. Public Health Service 1980). Nevertheless,
knowledge is lacking about processes underlying these diffe-
rences. (3) There is indication that general social support
functions differently from support specific to drug use.
This paper reports the results of a preliminary study about
social support and relapse. The sample consists of the first 77
subjects to enter a study of commonalities in relapse in three
groups of treated drug users: smokers, alcoholic, and opiate
users. (The completed sample consists of 230 subjects in
roughly equal proportions. Data on the 230 are being analyzed
currently.) The work reported here tested two hypotheses on
social support. These hypotheses were: (1) Higher levels of
social support will be related to a lower probability of re-
lapse. (2) Women will receive less social support for maintain-
ing abstinence than men. Relapse was defined as one week of
daily use of the problem drug.
METHOD
Subjects - Subjects were drawn from three drug treatment groups:
opiate addicts completing 21-day methadone assisted detoxifica-
tion or 28 day residential treatment, alcoholics completing 28
day residential treatment, and smokers completing 28 day cessa-
tion treatment. Subjects were employed within the six months
before beginning treatment, were of low to middle socioeconomic
status, and gave data adequate for follow-up contact. Primary
source of income for subjects was legal. Descriptive statistics
for this sample are found in Table 1.
TABLE 1
Descriptive Statistics
Treatment Facilities - The treatment facilities from which
subjects were recruited met the following criteria: 1) The
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treatment goal was abstinence. This goal and the similarity of
goal across sites allowed us to better assess the common effects
of central variables. 2) The treatment episodes were approxi-
mately one month and all episodes had a well-defined ending
date. This similarity eliminated length of treatment as a
confounding variable. 3) The treatment facilities served
clients who were sufficiently representative of the populations
within the drug group so that the data obtained would be mean-
ingful, while allowing us to equate drug groups on demographic
characteristics.
Smokers were recruited from an outpatient smoking treatment
program offered by our research group at San Francisco General
Hospital, a large public teaching hospital. Alcoholics were
recruited mostly from two residential programs. Both used
Alcoholics Anonymous (AA) extensively. Opiate users were
recruited from four sources, three 21 day detoxification clin-
ics, and one 28 day residential facility. The outpatient
clinics provided methadone detoxification and supportive coun-
seling. The inpatient program was based on an adaptation of the
AA model.
Procedures - Subjects were recruited at their treatment site
during the last third of treatment. Only clients who had
acceptable attendance and were abstinent were recruited.
Abstinence was verified by two biochemically validated self-
reports at least 72 hours apart. Clients agreeing to partici-
pate underwent a screening procedure and completed an informed
consent. A study intake assessment battery, including treatment
history, drug and alcohol use, as well as measures of mood,
withdrawal symptoms, and life events, was administered prior to
treatment completion. Follow-up assessments were completed once
a week for 12 weeks (beginning with the first week following
treatment end), or until the subject relapsed. Subjects' drug
and alcohol use, moods, and withdrawal symptoms were monitored
during follow-up assessment. We recognized this procedure could
confound perceived social support with short-term treatment
outcomes. Nevertheless, because all of the alcohol and some of
the opiate subjects were recruited from inpatient facilities
they could not report on social support from their environment
until they returned to it.
Measures - (1) Social Network and Support Inventory (SNSI).
This instrument, developed this study, contains three
measures of social support: functional social support, support
specific to drug use, and structural social support (social
networks). The functional support measure was predominantly
influenced by the work of Sarason et al. (1983). Our measure
taps emotional and instrumental support and negative aspects of
social support. (2) The Interaction Questionnaire (IAQ). This
measure was adapted from the Partner Interaction Questionnaire
(PIQ) originally used with smokers (Mermelstein et al., 1983).
The original questionnaire is a measure of the frequency of
responses by one's spouse about smoking and of the perceived
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helpfulness of these behaviors to the subject in maintaining
abstinence. We revised the questionnaire to be appropriate for
any intimate dyadic relationship between adults who live toge-
ther. (3) Drug-Use. Self-report of abstinence was verified for
smokers by expired air carbon monoxide readings of 9 ppm or
less. Self-report of abstinence for alcoholics was verified by
absence of alcohol in urine specimens. Report of abstinence for
opiate addicts was verified by absence of morphine in urine
specimens. Urinary alcohol and morphine were assayed by a com-
mercial laboratory licensed and monitored by the State of
California. Subjects who were lost to follow-up were coded as
having relapsed.
RESULTS
The small and incomplete sample suggests that a generous
probability level, for example p<.10, would be appropriate. On
the other hand, because of the small sample size, conservative
statistics including hierarchical regression analyses by sets,
could not be used. Data analysis therefore required more tests
than ideal. As a compromise,
cance level.
we retained the p<.05 signifi-
Given these circumstances, interpretation of the
results should be considered tentative. For all of the reported
analyses, save one four-fold chi-square, prototypic analyses are
hierarchical linear regression for continuous dependent varia-
bles and logistic regressions for dichotomous dependent varia-
bles. In all cases the effects of treatment class (TC) were
entered first. We did not include an interaction effect of TC
and the independent variable (IV) of interest when the small and
unbalanced cell sizes led us to expect an interaction would not
be meaningful.
Social Support and Relapse - The hypothesis that greater pet-
ceived social support would predict longer time before relapse
was confirmed. Higher levels of emotional and instrumental sup-
port predicted longer times to relapse for all three drug
groups. The third measure of global social support, negative
support, did not predict relapse. The measure of abstinence
support, IAQ experienced helpfulness scale, only approached sig-
nificance (p>.11). These results are shown in Table 2.
TABLE 2
Measures of Social Support (SS) as Predictors of Time to Relapse
*p<0.5; **p<0.01; ***p<0.001
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Having a "partner" (operationally defined as currently living
with "a spouse, intimate partner, or in a household with someone
you are close to"), predicted weeks to relapse and relapse vs.
not. Those with partners (n=45, 58%) had a longer time to
relapse (mean=10.51 weeks) than those who did not (mean=6.22
weeks). Only 33% of subjects with partners relapsed, while 78%
of subjects without partners relapsed. These data imply the
presence of a partner facilitates abstinence. These results are
shown in Table 3.
TABLE 3
Effects of a Partner as a Predictor of Relapse
**p<0.01; ***p<0.001
Greater drug use of spouses and their encouragement of drug use
predicted shorter time to relapse (spouse drug use and time to
relapse F(1,25)=5.82, p<.05, model F(3,25)=5.68 p<.01, TC
F(2,25)=5.61 p<.01 (spouse encouragement of drug use and time to
relapse F(1,25)=6.79, p<.05; model F(3,25)=6.12, p<.005, TC
F(2,25)=5.79, p<.01).
The drug use of network members and their encouragement of
subjects' drug use also predicted relapse and time to relapse.
Again, greater drug involvement of network members and encour-
agement of drug use predicted shorter time to relapse. These
results are shown in Table 4.
TABLE 4
Social Network (SN) Drug Use and Encouragement for Drug Use
as Predictors of Time to Relapse and Relapse vs. Not
*p<.05; ** p<.01; *** p<.001
Social Support and Gender - Preliminary data confirmed the
hypothesis that women experienced less support for abstinence
than men. On the IAQ, independent of drug group, women reported
they experience less helpfulness in maintaining abstinence than
did men [male mean=.83; female mean=.30]. It is unlikely that
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this difference reflects only a tendency for women to be more
open about negative experience. Independent of drug group,
women reported receiving more instrumental support (male
mean=4.25, female mean=5.05). These results are shown in Table
5. Women also reported receiving more emotional support than
men, regardless of drug group (male mean=4.26, female male=
4.83), but this difference did not achieve accepted levels of
significance.
TABLE 5
Social Support and Gender
IAQ Instrumental Support
Model F(3,41)=2.87* F(3,70)=4.61**
TC F(2,41)=1.98NS F(2,70)=4.59*
Sex F(1,41)=4.64* F(1,70)=4.64*
*p<.05; **p<.01
Independent of drug group, women's networks were different from
men's, though these results narrowly missed p<.05. They were
more likely to have a partner (X (1) = 3.68, p<.06), 75% of
women had partners vs. 52% of men. They were more likely to
have2a best friend [X2 (1)=3.51, p<.07; model X2 (2)=9.05, p<.02;
TC X2 (1)=5.54, p<.021.
DISCUSSION
These data suggest social support aids abstinence across the
three drug groups. They also indicate that sources and types of
support may be different for men and women but that these
differences do not mitigate the value of social support in
preventing relapse.
Several findings of importance emerge. First, general social
support predicts time to relapse. Second, "partners" play a
critical role in early relapse. Subjects with partners were
significantly less prone to relapse in the 12-week post-
treatment period. They also had significantly longer periods of
time before relapse. Among subjects who had partners, relapse
was predicted by partners' behaviors. The greater the experi-
enced helpfulness of the partner the longer was the period
before relapse. Not surprisingly, greater drug involvement of
partners and more encouragement of subjects' drug use predict
relapse and shorter time periods before relapse. These findings
may describe a two-stage risk process: to avoid early relapse,
it is valuable to have a partner, and, given a partner, risk of
relapse is decreased if the partner is not drug-involved and
does not encourage drug use. Third, women reported more general
social support than men. Also, they experienced abstinence-
specific support to be less helpful than did men. It appears
the "paths" to abstinence may be different for men and women.
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Woman appear more likely to have general social support as a
resource. Because of this support, they may not find partner
provided specific support to be helpful. Men may have less
general social support and may find support for abstinence from
their partners to be more helpful than do women.
These data are among the first to indicate that naturally
occurring social support, that is, support available in the
routine of daily life, can help persons who have problem use of
tobacco, alcohol, and opiates to maintain abstinence. General
and drug-use specific social support both appear to influence
abstinence.
Our study is based on the assumption that indentification of
variables associated with relapse that span the addictions is
important. It can lead to better understanding of relapse
processes and to the developments of an integrative and unified
model of relapse. That social support operates across drug
groups to aid abstinence reinforces our research approach. The
findings of sex differences may assist in further articulating a
model of relapse.
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The Discriminative Stimulus Properties of
Histamine H1 Antagonists in d-Amphetamine-
Trained and Midazolam-Trained Pigeons
Suzette M. Evans and C. E. Johanson
Antihistamines, specifically H1 histamine receptor antagonists, have
been shown to have central nervous system (CNS) effects, possessing
both depressant and stimulant properties (Douglas, 1985). Since the
most common side effect of these drugs is drowsiness and sedation,
the majority of studies have focused on the sedative properties of
this drug class, particularly in combination with other sedative
compounds such as barbiturates and ethanol (Winter, 1948; Hughes et
al., 1964; Smith et al., 1974). Despite the fact that H1-antihistamines
are also known to possess CNS stimulant properties, few experimental
studies concerning these actions have been reported (Douglas, 1985;
Wyngarden and Seevers, 1951; Caplan et al., 1982; Poling et al., 1983).
Although as a class, antihistamines have both stimulant and depressant
effects, within the class, there are differences that appear to be
related to the type of antihistamine. For instance, the ethanolamines,
of which diphenhydramine is prototypic, have the greatest sedative
properties. Promethazine (a phenothiazine), chlorcyclizine and
hydroxyzine (piperazines) have sedative properties and hydroxyzine has
been used clinically as an anxiolytic (Rickels, 1978). In contrast, the
alkylamines (e.g., chlorpheniramine) are reported to produce CNS
stimulation (Douglas, 1985) and tripelennamine and pyrilamine
(ethylenediamines) also produce relatively more CNS stimulation.
In spite of the recognition that antihistamines have CNS effects, there
are few laboratory studies on their behavioral effects. One way of
evaluating different Hl-antihistamines with respect to their relative
sedative/stimulant properties is by using drug discrimination methods
which have proven useful in terms of classifying pharmacologically
related drugs (Schuster and Balster, 1978). Although there have been
a few studies on the discriminative stimulus properties of
antihistamines (Overton, 1978; White, 1985; Winter, 1985; Karas et
al., 1985), only one of these studies (Winter, 1985) have not been
designed to evaluate their sedative/stimulant properties. Therefore,
the purpose of the present study was to examine the discriminative
stimulus properties of a wide variety of types of H1-antihistamines
in terms of their ability to substitute for the psychomotor stimulant
&amphetamine or the sedative-hypnotic midazolam in pigeons. The
HI-antihistamines tested were prototypic for their type and care was
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taken to select compounds that were reported to be at the extremes
of the sedative/stimulant continuum. The sedative compounds tested
included diphenhydramine, promethazine, hydroxyzine, and
chlorcyclizine. The less sedative H1-antihistamines tested included
chlorpheniramine, pyrilamine, and tripelennamine. The HZ-antagonist,
cimetidine, which does not act centrally, was also tested as a control.
M E T H O D S
Animals. The animals used in this study were eight white Carneaux
pigeons maintained at 80% of their free-feeding weight and housed
individually with water and grit freely available. To supplement food
obtained during the experimental session, Purina Pigeon Checkers were
provided after the session to maintain reduced weights. Three of the
pigeons (#408 428 and 3380) had previously been trained to
discriminate 2.0 mg/kg intramuscular (i.m.) d-amphetamine from saline
(Evans and Johanson, submitted) and had been tested with a variety
of Drugs. The other five pigeons were trained to discriminate 1.0
(#2779) or 3.0 mg/kg (#1490, 1859, 3315, 7227) midazolam i.m. from
saline and had been tested with a variety of drugs other than
antihistamines.
Apparatus. The experiment was conducted in two ventilated custom-
made operant chambers, each equipped with two translucent response
keys which were transilluminated during the experimental session.
Purina Pigeon Checkers were made available from a food magazine
which was illuminated during food delivery.
Training. The discrimination training procedure used has been
described in detail previously (de la Garza and Johanson, 1985). During
each experimental session each pigeon was injected intramuscularly
with the training drug (d-amphetamine or midazolam) or saline in a
1 ml/kg volume 10 minutes before the session. Following this
pretreatment period, the experimental session began, signalled by the
illumination of both keys and the houselight. Thirty consecutive
responses (fixed-ratio 30; FR 30) on the injection-appropriate key
resulted in 3-see access to food. The left key was correct after drug
administration for 2 d-amphetamine pigeons and 3 midazolam pigeons.
The right key was correct after drug for the remaining pigeons. The
opposite key was designated correct following saline injections. The
drug-key-reinforcer relationship was maintained throughout the
experiment. Responses on the incorrect key reset the fixed-ratio
requirement on the correct key. Each session lasted until 50
reinforcers were delivered or until 30 minutes had elapsed, whichever
occurred first.
Training sessions continued until the percent of total responses on the
correct key was above 90% and the number of responses emitted on
the incorrect key before the first reinforcer was delivered was less
than 30 for seven consecutive sessions. The injection preceding each
session was selected from a pseudorandom sequence, with the
restriction that no condition would occur for three consecutive sessions.
215
Testing. In order to evaluate the stimulus properties of various
antihistamines, these compounds were administered instead of drug
(d-amphetamine or midazolam) or saline during test sessions.
Throughout a test session, 30 consecutive responses on either the drug-
appropriate or saline-appropriate key resulted in food delivery. In all
other respects test sessions were identical to training sessions.
Between test sessions, training sessions continued. The training drug
and saline under training conditions were administered in a double
alternation sequence with test sessions inserted every third session,
i.e., saline, drug, test, drug, saline, test, etc. If an animal failed to
meet the training criteria during a training session, further testing
was postponed until the animal met these criteria on at least two
consecutive training sessions.
Initially a dose-response function for the training drug was established
during test sessions. Subsequently, the discriminative stimulus
properties of several antihistamines were tested in a similar manner.
In general, each dose of a test compound was tested once and three
or four doses of each compound were tested in a mixed order. The
dose-response function for each compound was completed before
another compound was tested. Dose-response functions for each drug
were determined in at least three pigeons. After the completion of
each dose-response function, pigeons were given test sessions with
either the training drug or saline.
Data analyses. A drug was considered to produce discriminative
stimulus effects similar to those of the training drug if at least 80%
of the total responses during the test session were emitted on the
drug-appropriate key. The discrimination data are presented as the
percentage of total responses emitted on the drug key (&amphetamine
or midazolam) for individual pigeons or as the percentage of animals
tested at a particular dose that reached the 80% criterion. In addition,
response rate (resp/sec) on the two keys was determined for each
session. A test compound was tested until a dose was given that
resulted in at least 80% of the responses occurring on the drug-
appropriate key or until a dose was reached which substantially reduced
response rate.
Drugs. The following drugs used in this experiment were gifts: d-
amphetamine sulfate (National Institute on Drug Abuse), tripelennamine
hydrochloride (CIBA-Geigy Corp., Summit, NJ), hydroxyzine
hydrochloride (Pfizer Inc., Brooklyn, NY), cimetidine hydrochloride
(Smith, Kline and French Laboratories, Philadelphia, PA), chlorcyclizine
hydrochloride (Burroughs-Wellcome and Co., Research Triangle Park,
NC), chlorpheniramine maleate (Whitehall Laboratories Inc.,
Hammonton, NJ), midazolam maleate (Hoffman-La Roche, Inc., Nutley,
NJ), diphenhydramine hydrochloride and promethazine hydrochloride
(Wyeth Laboratories, Inc., Philadelphia, PA). The drugs were dissolved
in 0.9% saline and the doses are expressed in terms of the salt.
RESULTS
Control performances. In  the d-amphetamine-trained group, all three
pigeons responded above 90% on the correct key thoughout most of
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the experiment. During test sessions the rate of responding across
the three pigeons ranged from 1.31 to 2.89 resp/sec following saline
and from 1.27 to 2.79 resp/sec following d-amphetamine (2.0 mg/kg).
d-Amphetamine produced a dose-related increase in the percentage of
responses emitted on the d-amphetamine-appropriate key. At the
lowest dose tested (0.3 mg/kg), less than 4% of responding occurred
on the d-amphetamine-appropriate key in all three pigeons whereas
at 1.0 and 3.0 mg/kg more than 90% of responding occurred on the
d-amphetamine-appropriate key. d-Amphetamine also produced a dose-
related decrease in rate of responding.
Similar results were obtained in the midazolam-trained group. All
five pigeons responded above 90% on the correct key throughout most
of the experiment. During test sessions the rate of responding across
the five pigeons ranged from 1.06 to 2.39 resp/sec following saline
and from 0.33 to 1.98 resp/sec following the training dose of
midazolam. Midazolam produced a dose-related increase in the
percentage of responses emitted on the midazolam-appropriate key.
At the lowest dose tested (0.3 mg/kg), less than 25% of responding
occurred on the midazolam-appropriate key in all five pigeons whereas
at the training dose (1.0 or 3.0 mg/kg) more than 95% of responding
occurred on the midazolam-appropriate key. A higher dose (10.0
mg/kg) produced greater than 95% midazolam-appropriate responding
in the 3 pigeons tested. Midazolam also produced a dose-related
decrease in response rate.
Figure 1. The percentage of d-amphetamine-trained pigeons responding
at least 80% on the d-amphetamine-appropriate key when tested with
diprenhydramine ( ), chlorpheniramine ( ), tripelennamine ( )
or test sessions of 2.0 mg/kg d-amphetamine ( ) or saline ( ).
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Antihistamines. Of the seven Hl receptor antagonists tested in the
d-amphetamine group, the ethylenediamine, tripelennamine (1.0 to 3.0
mg/kg), the ethanolamine, diphenhydramine (3.0 to 10.0 mg mg/kg)
and the alkylamine, chlorpheniramine (5.6 mg/kg) substituted for d-
amphetamine in all pigeons tested (Fig. 1). There was little effect
on response rate at doses that substituted for d-amphetamine.
Two other antihistamines did not share discriminative stimulus
properties with d -amphetamine in all pigeons tested (Fig. 2).
Pyrilamine, an ethylenediamine, produced more than 80% d-
amphetamine-appropriate responding in 2 of the 3 pigeons tested at
5.6 or 10.0 mg/kg (Fig. 2). Response rate was substantially reduced
in the pigeon given 10.0 mg/kg whereas 5.6 mg/kg substituted for d-
amphetamine in another pigeon without affecting response rate relative
to d-amphetamine rates. Only partial substitution was observed with
#3380 (57% at 5.6 mg/kg and 54% at 10.0 mg/kg) and these doses
substantially reduced response rate. Chlorcyclizine, a piperazine,
produced greater than 80% d-amphetamine-appropriate responding with
no effect on response rate at 10.0 mg/kg in one pigeon. However,
chlorcyclizine failed to substitute for d-amphetamine in 2 pigeons up
to doses that substantially reduced response rate.
Figure 2. Percent of d-amphetamine responses as a function of dose
during substitution test sessions with pyrilamine and chlorcyclizine for
pigeons #408 ( ), #428 ( ), and #3380 ( ).
In contrast, the phenothiazine, promethazine (1.0-17.0 mg/kg) and
hydroxyzine (10.0-56.0 mg/kg), a piperazine, were not similar to d-
amphetamine since neither of these compounds substituted for d-
amphetamine up to doses that substantially reduced or completely
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suppressed responding. Furthermore, the peripherally acting H2-
receptor antagonist, cimetidine (3.0-100.0 mg/kg), failed to substitute
for d-amphetamine, although response rate was not reduced at 100.0
mg/kg.
Every antihistamine tested in the midazolam-trained group, which
included diphenhydramine (1.0-56.0 mg/kg), hydroxyzine (1.0-56.0
mg/kg), pyrilamine (1.0-17.0 mg/kg) and tripelennamine (0.3-10.0
mg/kg), failed to substitute for midazolam in all pigeons tested. Doses
were tested until response rate was substantially reduced or completely
suppressed. The doses tested in the midazolam-trained group were
comparable to or slightly higher than the doses of these antihistamines
tested in the d-amphetamine-trained group.
DISCUSSION
The results of the present study demonstrate that H1-receptor
antagonists have differential discriminative stimulus properties in the
pigeon. In pigeons trained to discriminate d-amphetamine from saline,
tripelennamine, chlorpheniramine, diphenhydramine and to a certain
extent, pyrilamine, substituted for d-amphetamine. These results are
consistent with other studies indicating that tripelennamine,
chlorpheniramine and pyrilamine have less sedative properties than
other types of antihistamines. In contrast, the antihistamines,
promethazine, hydroxyzine and chlorcyclizine, reported to have more
pronounced sedative properties, failed to substitute for d-amphetamine,
with the exception that chlorcyclizine substituted for d-amphetamine
in one pigeon. Furthermore, the H2-receptor antagonist, cimetidine,
also failed to substitute for d-amphetamine, although this negative
result is most likely due to its inability to penetrate the CNS as
suggested by high doses (100.0 mg/kg) having no effect on response
rate. Interestingly, diphenhydramine, one of the more sedative
antihistamines, also substituted for d-amphetamine. At this time there
is not enough information regarding the discriminative stimulus
properties of antihistamines to adequately interpret this finding.
While the sedative/stimulant properties of H1-antihistamines have not
been previously investigated in groups trained to discriminate a
stimulant (&amphetamine) or a sedative-hypnotic (midazolam), other
studies have demonstrated that H1-antihistamines can serve as
discriminative stimuli. In pigeons trained to discriminate
tripelennamine from saline (Karas et al., 1985) pyrilamine and
diphenhydramine substituted for tripelennamine. Although
chlorpheniramine only showed a partial substitution for tripelennamine,
the authors concluded that higher doses should have been tested. On
the other hand, promethazine only partially substituted and cimetidine
failed to substitute for tripelennamine as did compounds from other
drug classes including diazepam, morphine and phenobarbital. d-
Amphetamine was also tested in this study and a dose of 1.0 mg/kg
produced some tripelennamine-appropriate responding. However since
higher doses were not tested it difficult to interpret these findings.
In summary, the results of Karas et al. (1985) as well as the present
study clearly indicate that within the class of antihistamines there
are differences in discriminative stimulus properties.
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However, in contrast to drug discrimination results in pigeons, other
studies using H1-antihistamines as discriminative stimuli in rats report
that antihistamines do not show differential discriminative stimulus
effects. For instance, promethazine, a more sedative antihistamine,
produced drug-appropriate responding in both diphenhydramine as well
as chlorpheniramine-trained rats, even though chlorpheniramine is a
less sedative antihistamine (Winter, 1985). In addition, H1-receptor
antagonists tested in pyrilamine-trained rats, including
diphenhydramine, promethazine and tripelennamine, substituted for
pyrilamine even though they differ in their ability to induce sedation
in humans (White, 1985).
Although the Hl-antihistamines tested in the midazolam-trained group
varied in their sedative/stimulant properties as well as in their a ability
to substitute for d-amphetamine, none of these compounds substituted
for midazolam. This included hydroxyzine, which was chosen because
of its use clinically as an anxiolytic (Rickels, 1978).
In summary, the present study demonstrated that the antihistamines
known to produce more “CNS stimulation” share discriminative stimulus
properties with &amphetamine in pigeons. With the exception of
diphenhydramine, other sedative H1-antihistamines did not substitute
for d -amphetamine. However, even those more sedative-like H1-
antihistamines tested failed to substitute for midazolam in pigeons.
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The Effects of 12-Hour Limited
Access to Cocaine: Reduction in
Drug Intake and Mortality
Steven I. Dworkin, Nick E. Goeders, John Grabowski, and
James E. Smith
INTRODUCTION
Studies investigating contingent cocaine presentation have
shown the drug to be a very efficacious reinforcer. The drug
is self-administered by a number of species including humans
under both simple and complex schedules of reinforcement.
However, very few studies have reported any toxic consequences
of cocaine administration (for review see Johanson 1984).
Moreover, the primary condition necessary for observing a
severe toxic effect (high subject mortality) appears to be not
restricting access to the drug. Most studies investigating
cocaine self-administration have used limited-access
conditions (i.e. session durations of 6 hours or less).
Limited-access conditions have been favored because they
result in consistent daily-drug intake and little or no signs
of drug toxicity (for review see Pickens, Meisch, and
Thompson 1978). However, parametric investigations of the
effects of experimentor controlled access to the drug with
respect to eliminating or reducing mortality have not been
reported. This study reports the effects of restricting drug
intake to every other hour during 24 hour sessions.
Twelve-hour access to cocaine resulted in a significant
decrease in drug intake and eliminated subject fatality
observed under conditions of unlimited access.
METHOD
Subjects
Male Fisher-344 rats between 90-150 days old at the beginning
of the study were used in these experiments. All twelve
subjects were continuously housed in operant-conditioning
chambers containing three retractable levers and maintained on
a reversed 12 hour light/dark cycle. Each chamber contained a
food dispenser, a water dipper and a motor driven syringe
pump.
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Food and Water
The rats were initially trained on a two, lever concurrent
chained schedule which has been previously described (Dworkin
et al 1984). Briefly, two, levers were made available and a
single response on either lever resulted in the retraction of
the other lever. Nine additional responses resulted in the
presentation of a 45 mg food pellet if the food lever was
selected or 10 s of access to an 0.1 ml dipper of tap water if
the other lever was selected. A 100 s limited hold
contingency timed from the first response and a 30 s time out
after reinforcer presentation or after the elapse of the
limited hold were also scheduled.
Surgical Procedure
Following training on the food and water schedule the rats
were implanted with chronic jugular catheters using previously
described methods (Weeks 1962, 1972). The animals were then
given unrestricted access to food and water and received
hourly 0.2 ml infusions of heparinized saline for 2 days.
Cocaine
Following recovery from the surgical procedure the rats Were
again placed into the three-lever conditioning chambers. A
third lever along with the food and water levers was extended
into the chamber and responses on this lever resulted in
cocaine infusions via the jugular catheter. Cocaine
injections consisted of a 0.5 mg/kg/inj dose administered over
a 4.9 s period with each infusion paired with a 30 s tone.
Limited access to cocaine was scheduled by withdrawing the
cocaine lever for one hour periods every other hour. The food
and water levers were continuously available.
RESULTS
Food and Water Intake before Cocaine
Responding maintained by the food and rater contingencies
before the addition of the cocaine was similar to patterns
previously reported using this schedule (Dworkin et al
1984). Once responding was initiated on either the food or
water lever a high rate of responding was observed until
delivery of the selected reinforcer. A large number of
consecutively completed ratios occurred on both levers. The
mean daily food intake (271 ± 39) was almost 2 1/2 times the
mean daily rater intake (106 ± 41), resulting in a mean daily
intake of 12 gms of food and 11 gms of water which is close to
the 1 to 1 ratio of food to water intake usually observed in
24 hour studies.
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TABLE I
Mean Daily Food, Water and Drug Intake
Values are means ± standard deviation for the last three days
under each condition.
Figure 1. Mean number of reinforcers delivered per day for the
last three sessions before drug was introduced (pre-cocaine),
three sessions <5 days after the drug contingency was added
(early), and the last three sessions (terminal). Vertical Lines
indicate 1 Standard Deviation.
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Continuous Access To Cocaine
Seven subjects rare given continuous access to food, water and
cocaine. Six of these rats (86%) died within 20 days. The
mean food, water and drug intake for these rats are shown in
Figure 1. As show in Table 1 drug intake increased from a
mean daily intake of 18 ± 17 injections (first 3 days of
access) to 84 ± 51 injections (last 3 days before death).
Food intake was also affected by unlimited access to cocaine.
Responding on the food lever decreased 79%, resulting in a
mean daily food intake of 2.6 gms. Continuous access to
cocaine increased water intake in one rat and decreased water
intake in the others.
Limited Access to Cocaine
The access to cocaine for 4 rats was reduced to 12 hours/day.
Responding on the cocaine lever was initially engendered using
unlimited access. However, when significant drug intake was
observed these animals were placed on a schedule allowing
alternate hour access to cocaine. Thus the cocaine lever was
retracted during odd hours and extended during even hours.
All four subjects exposed to this limited access procedure
survived for 90-120 days at which time they were sacrificed.
The limited access to cocaine did not result in significant
changes in responding on either the food or water levers (See
Table 2). however, drug intake was reduced compared to intake
during unlimited access days.
DISCUSSION
Continuous access to cocaine has been reported to result in a
high subject fatality rate in rats (Bozarth and Wise 1985) and
monkeys (Deneau et al 1969; and Johanson et al 1976). This
study further supports these observations. A similar schedule
of food, water and morphine presentation (Dworkin et al 1984)
did not result in any fatalities for up to 6 months of
continuous exposure. Thus, this study further suggest that
the toxicity associated with short-term continuous access to
cocaine is greater than drug toxicity with continuous
1 long-term access to morphine.
Twelve-hour limited access to cocaine did not result in any
fatalities. Cocaine appears to be extremely toxic under
conditions where drug intake is totally under the subject's
control. However, even minimal restraints on drug
availability (access every other hour) severely attenuates the
toxicity associated with the drug.
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Effects of Diazepam and Delta-9-
THC on the Discrimination of
Speech Sounds in the Baboon
Robert D. Hienz and Joseph V. Brady
INTRODUCTION
Numerous studies have documented the effects of drugs
on various aspects of cognition or attention;
relatively little is known, however, about drug
effects on basic sensory processes. An assessment in
terms of sensory function can be important, since
impairment of sensory function may contribute to a
drug's overall abuse liability either directly, or
indirectly through effects on more complex behavioral
processes (Brady and Lukas, 1984). In extending the
assessment of the effects of drugs of abuse on sensory
function in nonhuman primates, we have developed and
applied a psychophysical procedure for evaluating the
discriminability of human speech sounds in baboons.
Speech sound discriminations using periodic,
spectrally complex vowel sounds can provide a
relatively simple method for assessing frequency
resolving power in the auditory system, and deficits
in such discriminations may be readily applicable to
human situations. The present report describes the
results of experiments designed to establish
discriminations between five different vowel sounds,
and to evaluate the effects of two commonly abused
drugs, diazepam and delta-9-THC, on the
discriminability of these vowels.
METHOD
Subjects: The subjects were three dog-faced baboons
( Papio anubis), housed in individual cages and
maintained on a 22-hr restricted feeding schedule with
supplemental monkey chow and fresh fruit provided
daily after each experimental session. Each animal
had a previous drug history with diazepam, but not
with delta-9-THC.
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Apparatus: The testing apparatus consisted of a
modified baboon squeeze cage fitted within a double-
walled sound attenuating chamber (IAC Inc., Model
1201 A). A 76 x 97 cm intelligence panel attached to
one side of the cage contained a primate lever
(BRS/LVE Model PRL-003), a red light-emitting diode
used as a cue light, and a tube feeder for delivery of
banana pellets. Vowel stimuli were delivered through
a wide-range speaker suspended outside the cage and
located directly over the animal's head, approximately
20 cm above ear level.
Steady-state vowels were produced via an Echo ][
speech synthesizer controlled by an Apple IIE
computer. The vowel sounds used were /a/ /ae/,
/U/, and /e/. Fundamental pitch frequency was 122 Hz.
All stimuli were 120 msec in duration, and were
presented at a rate of 2/set. The average intensity
of the vowels was 83 dB.
Procedure: Vowel discriminations were conducted using
a standard reaction time procedure. Throughout the
entire session a background train of sounds of one
vowel was presented (e.g., / / as in "caught"). This
standard vowel was presented at a rate of 2/sec. A
flashing red cue light (5/set) signalled the start of
each trial. In the presence of the cue light a lever
press changed the flashing red light to a continuous
red light which remained steady as feedback as long as
the animal held the lever down. At intervals ranging
from 1.0 to 7.3 sec after initiation of this
maintained holding response, a stimulus change
occurred which consisted of two alternations of the
standard vowel with one of the four comparison vowels.
Release of the lever during this alternation period
was considered a correct detection of the change in
vowel sounds, and resulted in delivery of the
reinforcer (two 190-mg banana-flavored pellets). A 3-
sec intertrial interval (ITI) followed reinforcement;
during this time lever responses re-initiated the ITI.
Lever releases prior to comparison stimulus onset
produced a 3-sec timeout, then reinstated the 3-sec
ITI without reinforcement. If an animal failed to
release the lever during a stimulus change, the red
cue light was turned off following the second
comparison stimulus offset, and lever release then
returned the animal to the ITI. Following the ITI,
the flashing cue light signalled initiation of the
next trial in the series of several hundred which
comprised each daily two to three hour experimental
session.
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Vowel detection scores were determined by randomly
selecting on each trial one of the four comparison
vowel sounds to alternate with the standard vowel
sound, and examining detection frequencies (i.e.,
percent correct lever releases) for each comparison
vowel. To measure the false alarm or "guessing" rate
of each subject, "catch" trials were interspersed
among the normal trials during testing sessions.
During these catch trials no comparison vowel sounds
were presented, and lever releases during catch trials
were punished with a 3-sec timeout.
Test sessions were divided into blocks of 140 trials
with each of the four comparison vowels plus catch
trials presented randomly approximately 28 times
during each block. Four to five such blocks of trials
occurred within each session to provide a number of
separate within-session estimates of detection
frequencies. Performances were considered stable when
false alarm rates were below 30% for each block of
trials within a session, and no systematic changes in
detection frequencies were evident. Each animal was
tested with two different vowel sets; for the first
set / / was the standard vowel, while for the second
set /ae/ was the standard vowel.
Drug Administration, During diazepam testing, a
single i.m. injection was given at the beginning of
each experimental session, immediately after placing
an animal in the chamber. On test days, the animals
received either drug vehicle or one of the doses of
drug; i.m. saline injections were given on all non-
test days. Diazepam was administered i.m. in the
gluteal region at doses of 0.32, 1.0, 3.2, and 10.0
m g / k g . Diazepam was dissolved in a vehicle containing
propylene glycol, polyethoxylated vegetable oil, and
ethanol (20:20:60). The alcohol was evaporated before
injection. All drug doses were prepared immediately
before injection and concentrations were adjusted to
an injectable volume of 0.5 to 1.0 ml. Delta-9-THC
was given orally by injecting the drug into a slice of
orange, and watching the animal consume the orange
slice at the start of the session. Doses of delta-9-
THC given were 0.32, 1.0, 3.2, and 5.6 mg/kg. On non-
drug days animals were given either an orange slice
alone or an orange slice injected with ethanol
(vehicle). Doses of both drugs were given in mixed
order, and subsequent drug administrations were
scheduled only after vowel detection frequencies
returned to baseline values and no further changes
were evident.
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RESULTS
Figure 1 shows the basic effects of diazepam and
delta-9-THC on the discriminability of the four
comparison vowels /a/, /e/, /ae/, and /U/ from
Figure 1. Mean percent changes in vowel
discriminability for diazepam (left) and delta-9-THC
(right) as a function of drug dose. Each curve is for
the indicated comparison vowel, and represents the
mean of three animals.
the standard vowel / / (first vowel set). Plotted are
the percent changes in vowel discriminability as a
function of drug dose averaged across the three
animals. These averages were based on differences
between the peak drug effect and the mean of all
blocks of the preceding saline control day averaged
across replications at each dose, where the peak drug
effect was defined as the lowest percent correct found
across all blocks of a drug session. Vehicle control
data were derived in an identical manner. Diazepam
produced clear decreases in vowel discriminability for
all four comparison vowels, with greater decrements
occurring at the larger diazepam doses (Figure 1,
left). Delta-9-THC, on the other hand, had no effect
on vowel discriminability at any of the doses tested.
Higher doses of both drugs produced cessation of
responding in all animals. Significantly, the effects
of diazepam were most prominent with the vowel /a/,
the vowel that had the smallest changes in formant
frequency structure from the standard vowel / /.
Changes in formant frequency for the 4 comparison
vowels, compared to the standard, were 198, 280, 635,
and 685 Hz for the second formants, and 56, 130, 43,
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and 133 Hz for the first formants of vowels /a/, /U/,
/e/, and /ae/, respectively.
Figure 2 shows the effects of diazepam and delta-9-THC
on vowel discriminability for the second vowel set
(/ae/ as the standard vowel), plotting the mean
percent change in vowel discriminability for each
Figure 2. Comparisons of mean changes in vowel
discriminability for diazepam (filled symbols) and
delta-9-THC (open symbols) for the second set of
vowels, with /ae/ as the standard vowel in each case.
Each data point is a mean for three animals.
comparison vowel averaged across all three animals.
Each comparison vowel is graphed separately to show
more clearly the differences between diazepam and
delta-9-THC. Again, diazepam produced clear, dose-
dependent decreases in vowel discriminability for all
4 comparison vowels, while such changes did not occur
with delta-9-THC. For this second set of vowels,
changes in formant frequency from the standard vowel
were -77, -90, -133, and -203 Hz for first formants,
and -487, -50, -685, and -405 Hz for second formants
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of vowels /a/, /e/, / /, and /U/, respectively. Thus
the smallest formant frequency changes occurred for
/e/ and /a/, the vowels showing the largest decrements
in discriminability following the higher doses of
diazepam.
DISCUSSION
The present results clearly differentiate between the
effects of diazepam and delta-9-THC on the
discrimination of vowel sounds in baboons. Diazepam
produced consistent dose-related decrements in vowel
discriminability, while delta-9-THC did not produce
such consistent changes. These results are in accord
with previous findings that diazepam also affects
auditory function by elevating auditory thresholds
over the same dose range (Lukas et al., 1985). It is
unlikely, however, that the presently observed
decreases in vowel discriminability could be
attributed solely to the concomitant elevations of
only 4 to 8 dB in auditory thresholds that have been
reported to occur at diazepam doses of 3.2 and 10.0
mg/kg, (Lukas et al., 1985). Since auditory
thresholds in the baboon range from 0 to 10 dB SPL for
pure tones between 500 Hz and 2 kHz (Hienz et al.,
1982), the present vowel intensities would have been
73-83 dB above threshold level. Previous studies have
shown that animals can easily make vowel
discriminations with vowel stimuli ranging from 50-70
dB above threshold levels (Dewson et al., 1969; Hienz
et al., 1981). Thus even taking into account the
effects of diazepam on auditory thresholds, the
present stimuli were well within an intensity range
over which such discriminations are readily made.
The lack of consistent changes in the discriminability
of vowels following administration of delta-9-THC
suggests the possibility that the discriminations were
simply not difficult enough to show decrements in
performance following drug administration. Evidence
in favor of this interpretation is suggested by the
fact that delta-9-THC has been previously shown to
produce decrements at similar doses (2 and 4 mg/kg) in
the accuracy of an auditory click frequency
discrimination (click rates of 10.0 Hz vs. 9.4 Hz) in
monkeys when baseline performance levels were less
than 100% (Elsmore, 1972). Thus it may be that delta-
9-THC can be shown to affect more difficult speech
sound discriminations. It is nonetheless clear from
the present data that diazepam more readily affects
these types of discriminations than does delta-9-THC
over the indicated dose ranges.
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Potentiation of Pentobarbital
Sleeping Time by the Acute and
Chronic Administration of
Morphine
Robert N. Pechnick, Gregory W. Terman, and John C.
Liebeskind
INTRODUCTION
During preliminary experiments examining the effects of pento-
barbital anesthesia on morphine-induced analgesia in the rat, it
was noted that pentobarbital sleeping time was greatly length-
ened after the acute administration of morphine. While pre-
vious studies have concluded that the enhancement of barbi-
turate-induced sleeping time is due to inhibition of hepatic
drug metabolizing enzyme activity (Bousquet et al. 1964; Ho et
al. 1976a and 1976b), the exact mechanism of this interaction
is not known. The present study examined the role of opiate
receptors in the mediation of morphine-induced potentiation of
pentobarbital sleeping time by testing two criteria for opiate
receptor involvement: reversal by opiate antagonists, and the
development of tolerance.
METHODS
Male Sprague-Dawley rats (370-420 g; Simonsen Laboratories,
Cilroy, CA) were housed 6 per cage at 22-24ºC under a 12-12
hr light-dark cycle (lights off 08:00-20:00 hr) for at least 14
days prior to the experiment. Standard rat chow and water
were available ad libitum.
The first series of experiments evaluated the effect of acute
morphine administration on pentobarbital sleeping time. Rats
were randomly assigned to treatment groups. All injections
were administered between 11:OO and 12:00 hr with a volume of
1.0 ml/kg. In the first experiment rats were injected S.C.
with either saline (0.9%) or morphine sulfate pentahydrate (5.0
or 10.0 mg/kg), immediately followed by an i.p. injection of
sodium pentobarbital (Nembutal; 50.0 mg/kg). Sleeping time,
defined as the period from the moment of loss of the righting
reflex until its return, was determined. In the second
experiment rats were injected s.c. with either saline, morphine
(10.0 mg/kg), naltrexone hydrochloride (2.0 mg/kg), or both
morphine (10.0 mg/kg) and naltrexone (2.0 mg/kg). All
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groups then received an i.p. injection of pentobarbital (50.0
mg/kg).
The final experiment assessed the effect of chronic morphine
administration on pentobarbital sleeping time. Rats were
anesthetized with halothane and implanted s.c. with either a
placebo pellet, a morphine pellet (75.0 mg base), a naltrexone
pellet (30.0 mg base), or both a morphine and a naltrexone
pellet. Three days later pentobarbital (50.0 mg/kg) was
injected i.p. and sleeping time recorded.
The data were analyzed by one-way analysis of variance fol-
lowed by Student’s t test. The criterion for rejection of the
null hypothesis was p < 0.01.
RESULTS
The acute administration of morphine produced dose-dependent
increases in pentobarbital-induced sleeping time (table 1); the
administration of 10.0 mg/kg of morphine increased the mean
duration of sleep by 73.8%. The acute injection of naltrexone
alone had no effect on pentobarbital-induced sleeping time
(table 2): however, naltrexone pretreatment completely blocked
the acute morphine-induced potentiation of sleeping time.
Table 1
The effect of the acute administration, of morphine on
pentobarbital-induced sleeping time
Group Sleeping Time (min)
Saline 111.5 ± 4.8
Morphine (5.0 mg/kg) 162.7 ± 6.8*
Morphine (10.0 mg/kg) 200.8 ± 15.3*
Values represent means ± the standard errors of the mean
(N=5-6 per group).
*p < 0.01 compared to saline controls.
The mean sleeping time of naltrexone-pelleted rats was the
same as that of placebo-pelleted controls (table 3). Morphine-
pelleted rats showed a 134.0% increase in pentobarbital-induced
sleeping time compared to placebo-pelleted subjects. This
potentiation was not seen in rats that were also implanted with
a naltrexone pellet.
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Table 2
The effect of naltrexone pretreatment on the morphine-induced
increase in pentobarbital sleeping time
Group
Saline
Naltrexone (2.0 mg/kg)
Morphine (10.0 mg/kg)
Morphine (10.0 mg/kg)/
Naltrexone (2.0 mg/kg)
Sleeping Time (min)
99.5 ± 6.6
97.5 ± 5.1
153.7 ± 12.3*
96.3 ± 6.5
Values represent means ± the standard errors of the mean
(N=6 per group).
*p < 0.01 compared to saline controls.
Table 3
The effect of chronic administration of morphine and/or
naltrexone on pentobarbital sleeping time
Group
Placebo Pellet
Naltrexone Pellet (30.0 mg)
Morphine Pellet (75.0 mg)
Morphine Pellet (75.0 mg)/
Naltrexone Pellet (30.0 mg)
Sleeping Time (min)
142.8    ±   11.1
140.5 ±  6.9
342.6 ± 28.5*
156.9 ± 13.7
Values represent means ± the standard errors of the mean
(N=8-11).
*p < 0.01 compared to either placebo-pelleted or morphine-
naltrexone pelleted groups.
DISCUSSION
The results of the present study suggest that the morphine-
induced potentiation of sleeping time is mediated by opiate
receptors. The effect of acute morphine was completely
blocked by the administration of naltrexone, although nal-
trexone alone had no effect on sleeping time. This latter
finding confirms the results of Bhargava (1979) who failed to
observe any effect of naltrexone on pentobarbital sleeping
time; however, Fürst et al. (1977) found that naloxone
decreased the duration of the loss of the righting reflex after
either pentobarbital or methohexital.
While the finding of antagonism of the morphine-induced
potentiation of sleeping time by naltrexone suggests the
involvement of opiate receptors, these receptors do not
necessarily have to be located within the central nervous
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system. Garty et al. (1985) and Hurwitz et al. (1985) have
recently reported the acute administration of opiates can
inhibit the renal clearance as well as the hepatic metabolism of
various drugs, and these effects can be reversed by naloxone.
Thus, opiate effects on hepatic metabolism as well as renal
clearance could be specifically mediated by opiate receptors.
In support of a peripheral mechanism of action, opiate
receptors (Dave et al. 1985) and opiate-like substances (Neidle
et al. 1979) have-been found in the liver and kidney.
However, there are several lines of evidence suggesting that
the potentiation of pentobarbital sleeping time is centrally
mediated. Fatherazi et al. (1985) found that central injections
of morphine into the septal area could increase pentobarbi-
tal-induced sleeping time, and this effect could be antagonized
by intraseptal injections of naloxone. However, Stevenson and
Turnbull (1974) reported that morphine given i. p. did not
potentiate the effects of pentobarbital given directly into the
lateral cerebral ventricles. Cherksey and Altszuler (1974)
found that morphine also potentiated thiopental sleeping time in
rats. Since the termination of action of thiopental is thought
to be due to redistribution out of the brain rather than
peripheral metabolism (Goldstein and Aronow 1960), Cherksey
and Altszuler (1974) concluded that “morphine lowers the brain
threshold for thiopental induced sleep”. Moreover, they also
reported that the injection of nalorphine would block morphine-
induced potentiation of thiopental sleeping time in the dog.
However, Cherksey and Altszuler (1974) noted that the half-
life of thiopental in the brain was increased by morphine
pretreatment; therefore, there may also be a dispositional
component to this phenomenon.
Using a morphine pelleting procedure identical to that utilized
in the present study, Cochin et al. (1979) found that tolerance
to the analgesic effects of morphine is maximal 3 days after
pellet implantation, and Ary and Lomax (1977) reported that
the temperatures of rats return to baseline by 48 hr after
pellet implantation. However, in agreement with previous
reports (Bousquet et al. 1964; Ho et al. 1976a and 1976b;
Lesher and Spratto 1978; Howd and Pryor 1980), the results of
the present study indicate that at this time point no tolerance
is observed to morphine-induced potentiation of pentobarbital
sleeping time. The lack of tolerance to the potentiation of
sleeping time may relate to the inhibition of the expression of
tolerance to the analgesic effect of morphine reported in the
pentobarbital-treated rat (Terman et al. 1985).
The simultaneous implantation of a naltrexone pellet completely
blocked the potentiation of sleeping time in morphine-pelleted
rats, providing further evidence that this phenomenon is
mediated by opiate receptors. Chronic naltrexone treatment
alone did not affect pentobarbital sleeping time in the present
study, although Lehman et al. (1979) found that chronic
naltrexone did potentiate hexobarbital sleeping time in the
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mouse. This discrepancy could be due to the different species
and/or the chronic drug administration procedures used. It is
interesting to note that Axelrod (1956) found that the rats
chronically given nalorphine along with morphine did not show
the depression of hepatic N-demethylation that was observed
during chronic morphine treatment.
In summary, the results of the present study suggest that
morphine-induced potentiation of pentobarbital sleeping time is
mediated by opiate receptors and is still present in mor-
phine-tolerant subjects. It is not clear if this effect is
centrally or peripherally mediated, or if the changes in hepatic
drug metabolizing enzyme activity and drug distribution that
have been observed by other investigators contribute to this
phenomenon or merely correlate with it. However, unless
these differences in metabolism and/or distribution are
mediated by opiate receptors (Carty et al. 1985; Hurwitz et al.
1985), they must play a minor role in morphine-induced poten-
tiation. The finding that the potentiation of pentobarbital
sleeping time is even greater during chronic morphine treat-
ment suggests that the use of barbiturates by individuals
chronically taking opiates may have profound adverse conse-
quences.
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Effects of Chlordiazepoxide on
Intravenous Cocaine Self-
Administration in Rats
Nick E. Goeders and Steven I. Dworkin
The nor-iatrogenic use of cocaine has rapidly increased
during the last decade. Behavioral studies have demon-
strated that the response-contingent administration of
the drug is reinforcing and will maintain long and complex
sequences of behavior by animals including humans under
various schedules of reinforement (Fischmen and Schuster
1982; Goldberg et al.,  1981; Pickens and Thompson 1968).
Although the effects of the drug on neurotransmission are
complex, the primary neurochemical action appears to be an
inhibition of biogenic amine neurotransmitter uptake into
presynaptic nerve endings. While it has not been conclu-
sively elucidated whether or not these neurotransmitters
are involved in the neurobiology of cocaine reinforcement
processes, intravenous self-administration experiments
suggest an important function for dopaminergic neurons.
The administration of pimozide (DeWit and Wise 1977),
haloperidol (de la Garza and Johanson 1982), alha-flu-
penthixol (Ettenburg et al., 1982) and sulpiride Roberts
and Vickers 1984) modulate cocaine-maintained responding by
rats and rhesus monkeys in a dose-related manner suggesting
an attenuation of reinforcing efficacy. Moreover, 6-
hydroxydopamine lesions of the nucleus accumbens disrupt
cocaine self-administration (Roberts et al., 1977; Roberts
et al., 1980) as do similar lesions of the ventral tegmen-
tal area where the cell bodies for the mesolimbic/meso-
cortical dopaminergic neuronal system are localized
(Roberts and Koob 1982).
The pharmacological strategies currently under investiga-
tion for the treatment of the chronic non-medical use of
cocaine have focused almost entirely on direct menipula-
tions of dopaminergic or noradrenergic neuronal activity.
The administration of neuroleptic drugs which attenuate
self-administration in rats and non-human primates has been
reported to be effective in the management of cocaine-
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induced auditory and visual hallucinations and paranoia in
humans (Kleber and Gawin 1984; Wesson and Smith 1985), but
these drugs have no effect or may actually increase subjec-
tive reports of "cocaine craving" (Dackis and Gold 1985).
The most promising pharmacological interventions appear to
involve those drugs which mimic some of the neuropharmaco-
logical properties of cocaine. For example, preliminary
data suggest, that direct receptor stimulation by the
specific dopaminergic agonist, bromocriptine, may allleviate
"cocaine craving" (Dackis and Gold 1985). In addition,
open clinical trials have reported that treatment with
tricyclic antidepressants (e.g., desipramine hydrochloride)
for two to three weeks results in marked decreases in
"cocaine craving" (Baxter 1983) and abstinence from further
cocaine use regardless of whether an affective disorder was
also present (Gawin and Kleber 1984).
The accepted therapeutic value of diazepam or related
benzodiazepines in the treatment of chronic cocaine use has
been limited to the management of seizures and acute
anxiety following a massive overdose (Gay 1982; Wesson end
Smith 1985). However, animal studies have suggested that a
complex behavioral and neuropharmacological interrelation-
ship exists between stimulants and benzodiazepines.
Amphetamine and cocaine have been reported to augment the
effects of diazepam and chlordiazepoxide in conflict and
avoidance paradigms (Sansone 1975; Ford et al., 1979;
Lerner et al., 1986), while diazepam and chlordiazepoxide
can potentiate cocaine and amphetamine-induced increases in
locomotor activity in mice (D'Mello and Stolerman 1977;
Sansone 1980). Recent data suggest that these effects may
be related to interactions between dopaminergic neuronal
activity and brain benzodiazepine receptors. Intraventric-
ular injections of 6-hydroxydopsmine result in significant
reductions in the number of benzodiazepine receptors in
the rat cerebral cortex (Sabato et al., 1980) and cerebel-
lum (Doble et al., 1981) without affecting endogenous
levels of GABA or GABA receptor labeling. In addition, the
administration of buspirone or other neuroleptic agents
results in pronounced increases in benzodiazepine receptor
labeling measured "ex vivo" with flunitrazepam (Oakley and
Jones 1983) or in vivo with Ro 15-1788 (Goeders and Kuhar
1985). This investigation was designed to evaluate the
involvement of benzodiazepines in cocaine reinforcement by
assessing the effects of chlordiazepoxide on intravenous
cocaine self-administration in rats.
M E T H O D S
Male Fischer 344 90 to 150 day old rats were implanted with
chronic jugular catheters using previously described pro-
cedures (Weeks 1962). The catheter was inserted into the
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right posterior facial vein and continued subcutaneously to
the back where it exited immediately behind the scapulae
through a teflon-stainless steel harness. The catheter was
contained within a spring-covered leash and attached to a
leak-proof swivel connected to an infusion pump. The
animals were housed in individual cages in ventilated hous-
ing chambers on a reversed 12 hr light/dark cycle with free
access to food and water. While in the housing chambers,
the animals received 200 ul infusions of heparinized saline
every 2 hours to maintain the patency of the catheters.
The rats were tested for self-administration during daily 3
hour sessions five days a week. The cages were transferred
to sound-attenuating operant conditioning chambers, and a
response lever and stimulus light were installed in each
cage. The animals were initially trained to self-;adminis-
ter cocaine hydrochloride (0.5 mg/kg/200 ul infusion) on a
continuous schedule of reinforcement. The response
requirement was gradually increased to a fixed-ratio 10
limited hold 5 min (FR10 LH5) schedule where the animal had
5 minutes from the first lever-press to complete nine
additional responses. A maximum of 40 infusions were
allowed during each session to minimize the toxic effects
of unlimited drug access. When responding stabilized
(variations < 10%), the rats were tested for self-adminis-
tration with duplicate probes of 0.25 and 1.0 mg/kg/
infusion of cocaine. Each dose was tested during a 3 hour
session with at least three days of baseline responding
allowed between each dose probe.
The effects of chlordiazepoxide (CDP) on cocaine self-
administration were investigated following the completion
of the dose-response gradients. The rats were pretreated
with CDP (3.8, 5.6, 7.5 and 10 mg/kg, i.p.) 15 minutes
before the start of the experimental session and were
allowed to self-administer cocaine (0.5 mg/kg/infusion) as
described above. Each dose was tested twice, and at least
three days of stable baseline responding were required
between each CDP challenge. A separate group of rats were
trained on a discrete trial fixed-ratio 10 schedule of food
presentation with the intertrial interval yoked to the
interinfusion interval of a self-administration animal to
access the non-specific effects of CDP on lever pressing.
RESULTS
Intravenous injections of cocaine rapidly engendered self-
administration in rats, with stable baselines of responding
on the FRlO LH5 schedule of reinforcement obtained within
three to four weeks. Decreasing the dose of the drug
shortened the interinfusion intervals and increased the
number of infusions per session while the higher dose had
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the opposite effect (Figure 1). Pretreatment with the low
dose of CDP (3.8 mg/kg) resulted in moderate decreases in
drug-intake with 0.5 mg/kg cocaine while higher doses (7.5
to 10 mg/kg) virtually eliminated cocaine self-administra-
tion (Figure 1). However, regular patterns of self-admin-
istration were observed in two rats following pretreatment
with 7.5 or 10 mg/kg CDP when the cocaine dose was
increased to 1.0 mg/kg/infusion. Response rates were
increased (+56%) by 3.8 mg/kg CDP in the food reinforcement
animals while only the highest dose (10 mg/kg decreased
responding (-49%).
FIGURE 1. Effects of cocaine dose (mg/kg/infusion) and
chlordiazepoxide (mg/kg) intravenous cocaine self-
administration. Values are the means (± SEM) for double
determinations in 5 rats. The effects of CDP on the self-
administration of 0.5 mg/kg/infusion of cocaine were
assessed following a 15 min pretreatment.
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DISCUSSION
The results of this investigation suggest that chlordiaze-
poxide can influence the reinforcing efficacy of intra-
venous cocaine injections in rats. With the training dose
of cocaine, CDP decreased drug-intake at low doses and
eliminated self-administration at higher doses suggesting
that CDP reduced the reinforcing efficacy of the training
dose of cocaine. However, when the cocaine dose was
increased, regular rates of self-administration were
observed and the patterns of drug-intake indicated that
the effects of CDP had been partially reversed.
The effects of CDP on cocaine self-administration could
have resulted from the actions of the drug on rates of
responding independently of effects on reinforcement.
However, this is unlikely since the animals effectively
completed the response requirement long before the limited
hold had elapsed following pretreatment with CDP. In fact,
low doses of CDP only moderately decreased drug-intake, and
stable rates of responding were even observed with the
higher doses when the cocaine dose was increased. More-
over, the doses of CDP used in this investigation are
consistent with those which increase responding in conflict
or punishment paradigms without affecting performance in
non-punished controls (Rawlins et al., 1980; Sansone 1975)
and which have little or no effect on spontaneous locomotor
activity (D’Mello and Stolerman 1977; Sansone 1980).
Furthermore, the effects of CDP on rats responding on a
food reinforcement schedule yoked for rate with cocaine
self-administration animals demonstrated that only the
highest dose (10 mg/kg) affected the ability of these
animals to respond.
The mechanisms though which CDP produced the effects on
cocaine self-administration reported in this investigation
are not clear, but other data suggest an important role for
dopaminergic neurons. First of all, dopamine receptor
antagonists have been reported to attenuate the reinforcing
efficacy of cocaine (DeWit and Wise 1977; de la Garza and
Johanson 1982; Ettenburg et al., 1982; Roberts and Vickers
1984). In addition, depletion of dopamine with intra-
ventricular injections of 6-hydroxydopamine decreases the
number of benzodiazeoine binding sites in the rat brain
(Doble et al., 1981; Sabato et al., 1980) while neuroleptic
drug which may increase the synthesis and release of
dopamine) increase benzodiazepine “receptor binding in vivo
(Goeders and Kuhar 1985; Oakley and Jones 1983) . These
data suggest that benzodiazepines may influence the rein-
forcing efficacy of cocaine through direct or indirect
interactions with dopaminergic neuronal systems. There-
fore, since a significant proportion of the population
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using cocaine for non-medical purposes may actually be
"self-medicating to regulate painful feelings and psychi-
atric symptoms via their drug use" (Kleber and Gawin 1984),
benzodiazepine therapy may provide a beneficial alternative
strategy for the treatment and management of chronic
cocaine use.
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Diazepam Preference in Subjects
Seeking Treatment for Anxiety
Harriet de Wit, S. M. McCracken, E. H. Uhlenhuth, and
C. E. Johanson
Johanson and Uhlenhuth (1980) reported that diazepam, a commonly-
prescribed tranquilizer, was not preferred over placebo by most normal
healthy subjects in a laboratory test of choice. Low doses of the
drug (2 or 5 mg) were chosen about as often as a placebo, whereas
a higher dose (10 mg) was chosen significantly less often than placebo.
Subjective effects, measured at regular intervals after drug ingestion,
showed that the drug produced predominantly sedative effects.
Similar results were found in subsequent studies using special subject
groups who were thought ‘to be at risk for excessive use of anxiolytics.
For example, older individuals, who represent the highest proportion
of prescription users of tranquilizers, showed no greater preference
for diazepam than a younger comparison group (de Wit et al., 1985).
In addition, anxious subjects, who might be expected to prefer the
drug because of its anxiolytic properties, also did not choose diazepam
over placebo (de Wit et al, 1986). Some of these subjects had anxiety
levels high enough to meet criteria for a diagnosis of Generalized
Anxiety Disorder (GAD; APA, 1980), and showed measurable decreases
in anxiety after diazepam administration. Nevertheless, they did not
prefer the drug.
Thus, even in individuals with high baseline anxiety levels a reduction
in anxiety was not a sufficient condition for the drug to serve as a
positive reinforcer. However, it was observed that most of the
participants in the above study showed little interest in receiving
treatment for their anxiety, suggesting that they were not in severe
distress. The subjects had responded to ads which specified that the
study was research- and not treatment-oriented, and during the
debriefing interview they declined offers of referrals for treatment.
In the present study, therefore, we recruited subjects who were highly
anxious, and, more importantly, were seeking treatment for their
anxiety.
METHOD
Subjects. Thirteen subjects between 21 and 47 participated in this
study. They were recruited from the university and surrounding
community through posters, word-of-mouth referrals and newspaper
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ads. The posters and ads were headed “Are you anxious, tense,
nervous?” and specified that treatment would be offered in return for
participation in a research study. Subjects were accepted if they had
experienced symptoms meeting criteria for GAD for at least one
month prior to the interview. They were not excluded if they also
met criteria for Social Phobia, Panic Disorder, or Obsessive-Compulsive
Disorder, as long as these postdated the GAD. They were excluded
if they had medical problems, if they reported a history of drug abuse
or psychosis, or if they had a concurrent Axis I disorder other than
an anxiety disorder. All subjects reported clinically significant levels
of anxiety. They completed psychiatric self-report questionnaires
including the Hopkins Symptom Checklist (HSCL; Derogatis et al.,
1974), and the Spielberger Trait Anxiety Inventory (STAI; Spielberger,
1970), and were assessed with several clinician rating forms.
Instructions and consent. Prior to participation subjects signed a
consent form which outlined the study in detail and indicated all
possible side effects of any drug they might be given. They were
informed that they would not be told what drug they ingested at the
time, except that it would be either a psychomotor stimulant, a minor
tranquilizer, or a placebo, and that the dose would be within the daily
therapeutic range. Each subject agreed not to take other drugs
except their normal amounts of coffee and cigarettes, 12 hours before
and 6 hours after taking a capsule. Except for the actual drug
ingested, subjects were completely informed of all other procedural
details as outlined below.
Procedure. The 9-session choice experiment was conducted over a
period of 3 weeks. Subjects reported to the laboratory between 9
and 10 am on Mon, Wed and Fri, at which time they completed mood
questionnaires (see below) and ingested a capsule. This took
approximately 5 minutes, after which they were free to leave the
laboratory, taking with them further questionnaires to be completed
1, 3 and 6 hours later. The first four sessions were sampling sessions,
on which the subjects ingested one of two different colored capsules
containing placebo or 10 mg diazepam. Half the subjects received
the drug on sessions 1 and 3 and the placebo on sessions 2 and 4.
The order was reversed for the other half. The last 5 sessions were
choice sessions, on which subjects were allowed to choose the capsule
they preferred. The number of times the drug capsule was chosen
was the primary dependent variable and the measure of the drug’s
reinforcing properties. After completion of the experiment subjects
were debriefed and offered treatment for their anxiety. Response to
treatment was also studied in relation to the subjects’ choice behavior,
and will be reported separately. Drug tablets (Valium 10 mg, Hoffman-
LaRoche) were placed in opaque gelatin capsules (size 00) which were
filled with dextrose powder. Placebo capsules were identical in size
and contained dextrose powder only.
Subjective Effects. The scales used to assess mood were an
experimental version of the Profile of Mood States (POMS; McNair
et al., 1971) a shortened version of the Addiction Research Center
Inventory (ARCI; Haertzen, 1966) and a Visual Analog Scale (VAS).
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For purposes of brevity, only the POMS results will be presented here.
The POMS consists of 72 adjectives commonly used to describe
momentary mood states. Subjects indicate how they feel at the
moment in relation to each of the 72 adjectives on a five-point scale
Figure 1. Number of subjects from previous and current studies who
chose diazepam (10 mg) over placebo 0-5 times. Mean (x) number of
drug choices for each group of subjects is indicated.
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ranging from “not at all” (0) to “extremely” (4). There are eight
clusters of items (subscales) which have been separated empirically
using factor analysis (Anxiety, Depression, Anger, Vigor, Fatigue,
Confusion, Friendliness, and Elation). The value of each subscale is
determined by adding the numbers checked for each adjective in the
cluster and dividing the total by the number of adjectives. Two
additional subscales. Arousal and Positive Mood, were derived from
the other subscales as follows: Arousal = (Anxiety + Vigor) - (Fatigue
+ Confusion): Positive Mood = Elation - Depression. POMS data from
sampling sessions only will be presented: Subjects completed an
additional questionnaire at hour 6 indicating whether they liked the
drug, what they thought it was (stimulant, placebo, tranquilizer) and
whether they had experienced any unusual reactions.
Results. Figure 1 illustrates the frequencies of drug choices (0 through
5 )  f o r  t h e  1 3  s u b j e c t s  i n  t h e  p r e s e n t  s t u d y  a n d ,  f o r
comparison, the results from the previous studies. Whereas in the
previous studies the large majority of subjects preferred placebo over
diazepam, 30 percent of the subjects in the present study chose the
diazepam on all five choice sessions. The average drug choice for
the present group was 2.2 out of 5, while for the previous groups it
was 1.3 or less.
TABLE 1. EXTRA-EXPERIMENTAL VARIABLES
(Mean values (± standard error) or frequencies)
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Figure 2. Average diazepam (solid line) and placebo (dashed line)
POMS scores from sampling sessions only, for subjects who chose
diazepam 0-2 times (N=9) and for subjects who chose diazepam 5
times (N=4).
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Table 1 shows demographic characteristics, questionnaire scores and
drug use histories of the 13 subjects, presented separately for the
nine subjects who chose diazepam 0-2 times and the four who chose
it five times. The groups were similar on all variables except ratio
of males to females.
Liking ratings were consistent with choice behavior. Whereas the
overall difference between placebo liking ratings and drug liking ratings
was -5.7, the difference for low drug choosers was -17.6 (s.d. 5.8)
and for high drug choosers it was +20.8 (s.d. 12.2).
Most of the subjects, regardless of choice behavior, labelled the
diazepam correctly as a tranquilizer (10 out of 13 correct on both
sampling sessions). Less than half of the subjects correctly identified
the placebo. Errors in placebo identifications were about equally
distributed between “stimulant” and “tranquilizer”.
Subjective effects. When data from all 13 subjects were pooled,
typical sedative-like subjective effects were obtained. These effects
included decreased Anxiety and Arousa1, and increased Fatigue and
Confusion. However, when POMS scores were calculated separately
for those subjects who consistently chose the diazepam and those who
chose it infrequently, marked individual differences in mood responses
to the drug became apparent (Figure 2). On Fatigue, Vigor and
Confusion subscales, a sedative-like drug effect was observed in the 0-
2 choice group but not in the 5 choice group. On Anxiety and
Depression subscales the 0-2-time choosers were not affected by the
drug, whereas the 5-time choosers showed decreased scores after
diazepam. Placebo session Anxiety and Depression scores for the 5-
choice group were markedly higher than for the 0-2-choice group.
Finally, Friendliness and Elation scores were elevated on drug sessions
in the 5-time choosers but not the 0-2-time choosers. Pre-drug
differences make the elevations in the 5-time choice group difficult
to interpret, however. Although the small number of subjects precluded
statistical comparisons, these results suggest that diazepam produced
qualitatively different mood effects in the 5-time choosers compared
to the 0-2 time choosers.
DISCUSSION
In contrast to the previously-tested groups of anxious and control
subjects, a sizeable proportion of the subjects in the present experiment
did consistently choose diazepam over piacebo (Figure 1). Thirty
percent of these subjects chose the diazepam on all five choice trials,
whereas in previous studies only 10% (control subjects) and 8% (anxious
subjects) did so. The subjects in the present study differed from
previously-studied anxious subjects in that they were sufficiently
distressed by their level of anxiety to be seeking treatment for it,
although they scored only slightly higher on self-report measures of
anxiety.
The subjective effects of diazepam in the 0-2-time choose 
subjects were similar in quality, magnitude and course to the
effects observed with this drug in previous studies (Johanson and
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Uhlenhuth, 1980; de Wit et al., 1983; 1985). Drug liking scores and
accuracy of drug labelling in this group were also not different from
previous experiments. The 5-time diazepam choosers showed different
subjective responses to the drug, however. They reported relatively
less sedative effects (e.g., on Fatigue and Vigor scales), and did not
report the previously-observed increase in Confusion. Anxiety and
Depression scores were decreased in the 5-time choosers but not in
the 0-2-time choosers in this study. Finally, there was some indication
that Elation and Friendliness scores were higher on drug sessions in
the 5-time choosers, an effect never previously observed (de Wit et
al, 1986), although pre-drug differences between drug and placebo
sessionsmade these findings difficult to interpret. The low and high
choice subjects were similar on most extra-experimental variables,
although proportionately more males chose the diazepam frequently.
Whether this was related to the differences in behavioral and subjective
responses to the drug or due to chance is not clear.
The conclusions that can be drawn from these data are limited because
of the small number of subjects involved. Nevertheless, these findings
suggest a logical relationship between drug preference and mood. In
this and previous studies (de Wit et al, 1986), subjects who experienced
predominantly sedative effects from diazepam were less likely to
choose the drug over a placebo, and reported liking it less than
placebo. The few subjects who did choose the diazepam in this study
reported minimal sedative effects, some decrease in Anxiety and
Depression, and possibly an increase in Friendliness and Elation.
Whether any of these subjective effects play a causal role in the
determination of choice behavior must await further research. Despite
the small number of subjects involved, however, these results suggest
that diazepam can be an effective positive reinforcer in some highly
anxious subjects. As a result, this effect might make these individuals
at risk for excessive of the drug.
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The Dependence Syndrome Across
Different Psychoactive Substances:
Revised DSM-III
Thomas R. Kosten, Bruce J. Rounsaville, Thomas F. Babor,
Robert L. Spitzer, and Janet B. W. Williams
INTRODUCTION
Despite mounting evidence in support of the dependence syndrome
with alcoholism (1-12), there have been no similar investiga-
tions into patterning of the hypothesized syndrome elements
among frequent users of other psychoactive substance. In part,
the lack of empirical work with other substances has been
related to the absence of instruments which tap dependence
syndrome elements for drugs other than alcohol. Recently, the
Substance Dependence Disorders section of the Structured
Clinical Interview for DSM-III-R (SCID) has included a struc-
tured set of questions covering the elements of the dependence
syndrome.
The symptoms hypothesized as clustering together in the
dependence syndrome are the following: 1. narrowing of sub-
stance use repertoire such that substance use becomes stereo-
typed around a regular schedule of almost continuous or daily
consumption; 2. salience of substance taking behavior such that,
despite negative consequences, substance use is given higher
priority than other activities which had previously been impor-
tant; 3. increased tolerance; 4. withdrawal symptoms; 5.
substance use to avoid withdrawal; 6. subjectively experienced
compulsion to use substance; and 7. readdiction liability
(1,13).
In the present study, two postulates of the dependence syndrome
were evaluated: (a) the prediction that syndrome elements
cluster into a unidimensional scale and (b) the relative indepen-
dence of this syndrome from legal, occupational, medical, family
and psychological problems associated with substance use.
METHODS
Subjects were interviewed at two settings: (a) 41 patients from
an inpatient unit of a community mental health center, which
treats patients with a wide range of diagnoses for 28 days, and
(b) 42 patients applying for treatment at an ambulatory
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Substance Abuse Treatment Unit. For the inpatient unit the
sample was predominately male (54%), white (51%) with a high
school education or more (80%) and with an average age of 34
(s.d. 10 years). For the outpatient setting the sample was
predominantly male (74%), white (62%), with a high school
education or more (81%) and with an average age of 29 (s.d. 7
years). Thus, both samples were demographically comparable. As
anticipated, the rates of substance use disorders were consid-
erably higher, particularly for opioids and cocaine, in the
outpatient sample who identified themselves as substance abusers
by seeking specialized treatment. Although the mean number of
drugs abused was 2.3, 14 subjects had no history of drug abuse
and 17 reported abuse of only one type of drug.
Two instruments were employed in the present study: 1. the
Substance Dependence Disorders section of the Structured
Clinical Interview for DSM-III (SCID) (18), and 2. the Addiction
Severity Index (20,21). The SCID provides an interview guide
for determining whether subjects meet DSM-III-R criteria for a
range of psychiatric disorders. In the SCID, subjects were
asked to describe substance using during the most severe episode
in their lifetime, regardless of the presence or absence of a
current episode. The Addiction Severity Index (ASI) was also
completed for all inpatients (one had incomplete data) and a
pilot sample of 15 of the 43 outpatients. The AS1 covers six
major problem areas: legal, employment, medical, family,
psychological, and substance abuse (20,21).
RESULTS
As a test for unidimensionality, the dependence syndrome items
were scored as 0 (not present) and 1 (present) and then added
together for each drug type to form seven dependence syndrome
scales with scored ranging from 0 to 10. The values for
Cronbach's alpha (23) ranged from 0.83 (cannabis) to 0.98
(opiates) indicating excellent internal consistency for all
seven scales, and the item scale correlations were quite good
overall. A second test of unidimensionality involved Guttman
scaling for each type of drug based the 10 items. As indicated
by Guttman reproducability coefficients ranging from 0.85
(alcohol) to 0.97 (opiates), most of the drugs demonstrated good
approximations of "perfectly" unidimensional and cumulative
scales. This suggested that the severity of the dependence
syndrome was indicated by the total number of items endorsed.
To further test for unidimensionality, we factor analyzed the 10
items within each type of drug and found that all 10 items
loaded onto single factors for opiates, cocaine and alcohol.
These single factors accounted for a substantial part of the
variance: 83% for opiates, 68% for cocaine and 56% for alcohol.
Stimulants formed two factors that accounted for 67% of the
variance. The factors were labeled "compulsion" and "problemat-
ic use" based on the items loading above 0.5. Sedatives and
cannabis each had three factors with eigenvalues above 1. Based
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on the items loading on each factor, two common factors were
labeled "can't stop" and "compulsion/salience". The other
factor was different for the two drugs and was labeled "problem-
atic use" for sedatives and "withdrawal consequences" for
cannabis. The three factors accounted for 69% (sedatives) and
58% hallucinogen dependence syndrome items were reported by less
than four respondents, these infrequent items were removed.
Including all 10 items resulted in three factors of which one
included all five infrequent items. When these items were
deleted, the other five items loaded together as a single factor
that accounted for 69% of the variance.
Finally, to test our second postulate, the seven dependence
syndrome scales were correlated with five composite problem
severity scales from the ASI - legal, work, medical, family,
psychological. Five of the 28 correlations between the seven
dependence scales and the ASI scales were significant, but even
for significant associations the shared variance was less than
10%.
DISCUSSION
Based on the newly revised
criteria (15),
DSM-III-R substance dependence
we found that the 10 items in the draft of
DSM-III-R formed internally consistent scales for all seven
drugs under study. For alcohol, opiate and cocaine abusers the
dependence syndrome scale met several criteria for unidimension-
ality including all items loading onto a single factor and
forming good approximations to "perfect" Guttman scales. For
the other drugs - stimulants, sedatives, hallucinogens and
cannabis - a clear unidimensional structure was not confirmed by
every type of analysis, but even for these drugs simple cumula-
tive scales seemed to provide satisfactory measures of a depen-
dence syndrome that was independent of medical-psychosocial
problems. The factor analyses raised the most significant
questions about the unidimensionality of the dependence syndrome
for stimulants, sedatives and cannabis, and these drugs will
need further study in larger samples. Thus, our findings
supported the utility of the dependence syndrome for other drugs
besides alcohol by specifically demonstrating that the syndrome
elements clustered into unidimensional scales for most drugs and
that this syndrome was relatively independent of medical-psycho-
social problems.
The new DSM-III-R substance dependence criteria tested in this
study were designed to solve difficulties in previous criteria.
The increased coherence of using similar criteria across all
substances has great appeal with the general trend toward
polydrug abuse. For every drug examined in this study some
abusers reported most of the 10 criteria for that drug. Fur-
thermore, all of the criteria were useful for at least several
drugs, so that no particular criterion seemed to be so rarely
reported across all seven drugs that it merited being dropped.
In a companion report, we also found that these new criteria
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showed remarkable agreement with the current DSM-III criteria in
identifying substance abusers (19). Thus, it agrees well with
our current system in identifying substance abusers while being
considerably simpler to elsewhere (15) including an ability to
denote distinctions in severity of disorder and the removal of
excessive emphasis of physiological aspects of dependence.
Overall, the present study provides encouragement for undertak-
ing more intensive work with other substances besides alcohol
using the newly revised DSM-III-R.
REFERENCES: May be obtained from the author on request.
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Effects of Marijuana, Cocaine,
and Task Performance on
Cardiovascular Responsivity
Richard W. Foltin, Richard M. Capriotti, Margaret A.
McEntee, Marian W. Fischman, Joseph V. Brady, and
Julia J. Pedroso
Many drugs of abuse have significant effects on the
cardiovascular system. Marijuana has been shown to
produce reliable increases in heart rate with no
change or only small decreases in blood pressure in
humans (e.g., Weiss et al, 1973). Cocaine, on the
other hand reliably increases both heart rate and
blood pressure (e.g., Fischman et al, 1976). Although
many studies have investigated the effects of these
drugs on the cardiovascular system, all have focused
upon drug effects under resting baseline or
nonstressful conditions, and none have investigated
the interactive effects of drug administration and
task performance. This report describes the results
of a study on the interactive effects of task
performance, in combination with either smoked
marijuana or intranasal cocaine, on heart rate and
blood pressure.
M E T H O D S
Subjects. Healthy adult male volunteers, 23 to 38
years of age participated. All subjects were
experienced in the use of both marijuana and cocaine
and had been screened in accordance with extensive
physical and psychological assessment procedures.
Informed consent was obtained and subjects were paid
daily based on their individual task performance.
Additional bonus payments were earned for completion
of a study.
Performance Task. A modified repeated acquisition
task (Fischman, 1978) was presented on a CRT screen
and subjects were provided a 3 button response
manipulandum interfaced with an Apple IIe
microcomputer. A random sequence of up to 25 correct
position responses (left, center, or right) was
possible during each session. The sequence of
correct responses was changed for each session.
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Subjects were required to respond on one of three
response keys (left, center, or right) and each
correct response produced an asterisk on the CRT.
Incorrect responses were followed by a one-second
timeout when the screen was blank. When a correct
sequence was achieved the subject was prompted to
repeat that sequence. Upon completion of the
sequence a second time, a cumulative counter
registered an increment in points earned. Each trial
required the subject to complete a sequence of
responses one response longer than the previous trial
(from 1 to 25). The task ended after 10 minutes.
PROCEDURE. Subjects were seated in a comfortable
reclining chair with one arm kept level with the
heart. Heart rate was continuously monitored via
chest electrodes and both heart rate and blood
pressure (systolic, diastolic and mean arterial) were
recorded every two minutes using a Dinamap 825XT
automated Vital Signs monitor (Critikon Inc., Tampa,
FL).
Subjects remained in the laboratory for at least one
hour after each experimental session to allow drug
effects to dissipate.
Experiment 1 - Marijuana: Nine subjects completed
five consecutive daily sessions. Each session
consisted of: 1) a one hour monitoring period to
insure that no caffeine, nicotine or other drugs were
consumed in association with testing, 2) a 10 minute
rest period, 3) 5 minutes of paced smoking of a
1.84% THC (w/w) or placebo, 1 gram marijuana
cigarette, 4) 10 minutes of post-drug monitoring,
5) 10 minutes of task performance (Group I) or
resting baseline (Group II), and 6) 10 minutes of
resting baseline. All subjects smoked active
marijuana on days 2, 3, and 4 and placebo on days 1
and 5. Group I (n=5) performed the task each day
whereas Group II (n=4) rested during the task period.
Thus, data on cardiovascular changes were collected
under active and placebo marijuana conditions in the
presence (Group I) or absence (Group II) of task
performance. These data were compared with data
collected under baseline conditions prior to drug
administration.
Experiment 2 - Cocaine: Seven subjects completed six
experimental sessions. Each session consisted of: 1)
a one hour monitoring period to insure that no
caffeine, nicotine or other drugs were consumed in
association with testing, 2) a 14 minute rest period,
3) 10 minutes of task performance , 4) administration
of cocaine hydrochloride (4, 48, or 96mg combined
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with lactose to yield a 100 mg of powder which was
inhaled within a two minute period), 5) 14 minutes of
resting baseline, 6) 10 minutes of task performance,
7) 34 minutes of resting baseline, 8) 10 minutes of
task performance and 9) 14 minutes of resting
baseline. Thus, each session consisted of task
performance once prior to drug administration and
then twice (15-25 and 60-70 minutes) after cocaine
administration.
Six of the seven subjects were tested with each of
the three doses of cocaine twice. One subject was
tested only once at each dose level. The first
series of drug doses was administered in ascending
order, while the doses in the second series were
randomly assigned.
RESULTS
task performance
conditions (Group I).
Figure 1. Change from baseline heart rate following marijuana
In the absence of task
alone (n=4) and marijuana + task performance (n=5).
Experiment 1: Figure 1
compares the changes in
heart rate following
active marijuana under
task performance (Group
I) and no task perfor-
mance (Group II)
conditions. Marijuana-
induced heart rate
increases were sustained
at peak levels 10-20
minutes after drug
administration under
produced a small but
Figure 2. Change from baseline mean arterial pressure (MAP) following
consistent increase
marijuana and task performance (Top Panel: Group I and
marijuana (Bottom Panel: Group 2).
(Group II, bottom panel)
performance, peak level
increases were not
sustained (Group II).
After completion of the
task (20-30 minutes post
drug), there was no
difference in heart rate
between the two groups.
Figure 2 summarizes the
effects of active and
placebo marijuana on mean
arterial blood pres-
sure(MAP) under task
performance (Group I)
and no-task performance
(Group II) conditions.
Active marijuana alone
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in MAP (2-3 mm/Hg) compare to placebo. In contrast,
substantial increases in MAP levels (10-12 mm/Hg)
were observed during task performance following
active marijuana administration (10-20 minutes post-
drug) as compared to task performance under placebo
conditions (Group I, top panel). This incremental
increase in MAP with task performance plus active
marijuana was a consistent finding with all five
subjects in Group I. After completion of the task
(20-30 minutes post drug) MAP returned to baseline.
Subjects who performed the task after smoking active
marijuana thus showed substantially elevated blood
pressures and sustained heart rate increases under
such conditions. If an additive model of interaction
is hypothesized and the effect of task alone is added
to the effect of marijuana alone, an expected value
for the effects of marijuana plus task performance
can be derived. Figure 3 presents the results of
subtracting the mathematically derived
expected values from
the observed values
presented in Figures
1 and 2. For all
measures, the observed
values were greater
than the expected values,
indicating that the
response was greater
than that predicted by
an additive model.
Although the differences
were small for both heart Figure 3. Observed expected values for each cardiovascular
rate and systolic blood measure following marijuana administration, HR =
heart rate, SP = systolic  pressure, DP = diastolicpressure, the results
summarized in Figure 3
pressure, MAP = mean arterial pressure
indicate clearly that the effects on diastolic and
mean arterial pressure of marijuana in combination
with task performance were significantly greater than
predicted by an additive model of interaction (DP,
t(5) = 2.61, p < .05; MAP, t(5) = 3.12, p < .05).
Experiment 2: Figure 4 compares the changes in heart
rate following
task performance
alone and task
performance in
combination with
inhaled cocaine
at the indicated
dose levels. The
difference scores
represent changes
from the pre-drug Figure 4. Mean change baseline heart rate after 4,
resting baseline 48, and 96 mg cocaine under task and resting
obtained prior to conditions. Drug adminisrered at 0 minutes.
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the first task performance for the 13 observations at
each dose level, i.e., six subjects tested twice at
each dose and one subject tested once at each dose.
Performance of the task alone (prior to drug
administration) increased heart rate by 8 to 10 beats
per minute, and cocaine alone (O-15 minutes after
drug administration) produced dose-dependent
increases in heart rate. When the task was performed
following cocaine administration (15-25 minutes post-
drug), peak heart rate increases were consistently
sustained above task alone or cocaine alone baseline
levels. Heart rate levels returned immediately to
baseline following the task performance (25-30
minutes after drug administration). The effects of
cocaine interacting with the task-elicited heart rate
response were attenuated 60-70 minutes after drug
administration, as indicated by the smaller changes
in heart rate shown in the right-hand section of
Figure 4.
Figure 5 compares the changes in mean arterial blood
pressure (MAP)
following task
performance alone
and task perfor-
mance in combin-
ation with each
of the administered
doses of cocaine.
Once again, both
task performance
alone (pre-drug) I
and cocaine alone Figure 5. Mean change from baseline blood pressure after
(0-15 minutes after 4, 48, and 96 mg cocaine under task and resting
drug) produced sub- conditions. Drug administered at 0 minutes.
stantial elevations
in blood pressure (10-12 mm/Hg). In combination (15-
25 minutes after drug administration), only the 96mg
dose increased blood pressure above levels produced
by task performance alone. Baselines were again
recovered rapidly (25-30 minutes after drug), and the
interactive effect on blood pressure of cocaine with
task performance were similarly attenuated 60-70
minutes after drug administration (far right section,
Figure 5).
An additive model was hypothesized for the
cardiovascular effect of cocaine in combination with
task performance. For each of four measures (heart
rate, systolic blood pressure, diastolic blood
pressure, and mean arterial pressure), an expected
value was derived by adding the effect of the task
alone to the effect of 4, 48 or 96 mg cocaine alone.
Figure 6 presents the results of subtracting this
mathematically derived expected value from the
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observed values (Figures 4 and 5). Positive values
indicate that the observed response was greater than
predicted by an additive model, while negative
values indicate that the observed response was less
than predicted by an additive model.
cocaine and task
performance had
a greater effect
on heart rate than
predicted by an
additive model of
interaction.
Conversely,
cocaine and
task performance
in combination
had a lesser
effect on blood
pressure than Figure 6. Observed minus expected values for each cardiovascular
predicted by an measure as a function of dose of cocaine. HR = heart rate,
additive model SP = systolic pressure, DP = diastolic pressure, MAP =
of interaction.
mean arterial pressure
DISCUSSION
The results of the present experiments show clearly
that the cardiovascular effects of smoked marijuana
and inhaled cocaine can be substantially exacerbated
by environmental interactions. Task performance
combined with smoked marijuana sustained drug induced
heart rate elevations substantially above control
levels and consistently elevated mean arterial blood
pressure when compared to marijuana or task
performance alone conditions. The substantial
increases in blood pressure during task performance
under active marijuana conditions was greater than
predicted by an additive model of drug-by-task
interaction. Task performance in combination with
inhaled cocaine also sustained drug induced heart
rate and blood pressure elevations substantially
above cocaine alone and task performance alone
conditions. In contrast to the effect of marijuana,
however, only the elevated heart rate values observed
under combined drug and task performance conditions
were greater than those predicted by an additive
model of drug by task interaction.
The finding of increased heart rate and heightened
blood pressure responsivity produced by the
interactive effects of smoked marijuana or inhaled
cocaine and prevailing environmental circumstances
would seem to require reevaluation of the
cardiovascular consequences of such drug use and the
conditions under which it occurs. The present
findings indicate that the potential cardiovascular
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effects of drugs can be exacerbated by a wide range
of circumstances, and these circumstances may include
common stressful events that occur regularly, e.g.,
rush hour driving.
Interestingly, the marijuana and cocaine using
subject population represented in this study was
extensively screened to eliminate all hypertensive
volunteers. Almost 50% of all those volunteering to
participate in this research were rejected because of
elevated pressure levels. Although the relationship
between prior cocaine and/or marijuana use and
hypertension is unknown, the difficulty in obtaining
normotensive marijuana and cocaine experienced
subjects points to the importance of the data
collected in the present study. Further
investigation of the complex interaction between drug
combinations and prevailing environmental
circumstances will provide valuable information on
the adverse health consequences of drug abuse.
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Intravenous Cocaine Self-Admin-
istration by Human Volunteers:
Second-Order Schedules of
Reinforcement
Jack E. Henningfield, Ro Nemeth-Coslett; Jonathan L. Katz,
and Steven R. Goldberg
One effect of cocaine that may contribute to its abuse liability
is its efficacy in establishing previously neutral environmental.
stimuli as both discriminative stimuli and conditioned rein-
forcers. These stimuli can then function to strengthen and
control behavior in their own right (Goldberg, 1973; Goldberg,
Spealman and Kelleher, 1979; Johanson and Schuster, 1981; Katz,
1979; Kelleher, 1966; Katz and Goldberg, 1986). Second-order
schedules of drug injection have been used to systematically study
conditioned reinforcing effects of stimuli associated with drugs
in laboratory animals (cf. Goldberg, Kelleher and Morse, 1975).
Under second-order schedules, responding under one schedule is
treated as a response unit which is reinforced according to
another schedule. Often completion of each response unit produces
a brief stimulus that also accompanies the drug injection.
Second-order schedules can be used to establish and maintain
extended sequences of behavior maintained by relatively inter-
mittent drug injections, and have been used in the experimental
analysis of the degree to which a previously ineffective stimulus
can maintain behavior by virtue of its association with drug
delivery.
For example, in one condition of an earlier study of cocaine
self-administration by squirrel monkeys, every 10 to 30 presses on
a lever produced a brief flash of light; after five minutes had
elapsed from either the start of the session or the last drug
injection, 10 responses again produced the light and also an
intravenous injection of cocaine (Goldberg, Kelleher and Goldberg,
1981). Two functional consequences of the second-order schedule
contingency were that (1) control over behavior was established
that was appropriate to the schedule of presentation of the brief
visual stimulus, and (2) overall rates of responding markedly
increased when the secondary stimuli were omitted although fre-
quency of cocaine injections remained unchanged.
The present report describes the results obtained in a preliminary
study of intravenous cocaine self-administration in two human
volunteers. The purpose of the study was to assess the viability
of maintaining behavior of human subjects under a second-order
schedule in which effects of environmental stimuli associated with
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drug injections could be objectively assessed. Conventional
self-reports of interoceptive drug effects were also assessed
(Jasinski, 1977). The plausibility of using such a procedure was
suggested by the results of earlier studies which had demonstrated
that intravenous drug self-administration by human subjects could
be safely studied under controlled laboratory conditions, and that
such studies could provide data complimentary to conventional
studies of abuse liability and dependence potential (e.g.,
Fischman and Schuster, 1982; Mello, Mendelson and Kuehnle, 1982;
Mello, Mendelson, Kuehnle, and Sellers, 1981; Henningfield,
Miyasato and Jasinski, 1983; Henningfield and Goldberg, 1984).
These studies permit the collection of both self-administration
(i.e., behavioral) data as is typically collected in studies with
animals as well as the collection of self-report data typically
collected in human studies. Thus the present approach provides a
method of comparing the two types of data in addition to infor-
mation not available with either experimental design alone.
METHODS
Two male volunteers, ages 27 (H-743) and 50 (H-689) resided on a
residential research ward for the duration of the study. The
subjects were cigarette smokers who had histories of abuse of a
variety of drugs including opioids, stimulants and sedatives; both
had histories of intravenous cocaine use. Except for one hour
prior to and during experimental sessions, subjects were free to
smoke their usual brand of cigarettes but they were not given
access to illicit or therapeutically used drugs. They were not
permitted to consume caffeinated substances for 12 hours prior to
the start of, or during, sessions.
Experimental sessions were approximately three and one-half hours
in duration and were scheduled one to three days apart. Prior to
a session, a catheter was inserted into a forearm vein and its
patency was maintained with a gravity fed dextrose solution (12 ml
per hr). Subjects were comfortably seated with access to an
operant test panel equipped with two levers and attendant stimulus
lights. Reading materials were also available. The subject's
electrocardiogram was on constant display to a research nurse who
sat out of sight of the subject and also monitored behavior.
The reinforcement schedule was programmed and data were collected
using a PDP8 computer system. Responding on only one of the two
levers on the operant panel had any programmed consequences and
this lever was distinguished by the illumination of a green light
immediately above it. The schedule was as follows: Each 100
responses (lever-presses) on the designated lever produced a 10-
sec illumination of a light (red light over the lever) and
sounding of a tone (fixed-ratio or FR 100 schedule); the first FR
100 completed after the lapse of a one-hour interval (fixed-
interval or FI 60-min schedule) produced the 10-sec light-tone
combination and a 1 ml injection of either cocaine or saline.
During some sessions the light-tone stimulus was only presented
when an injection was obtained, and responding within the one-hour
intervals had no programmed consequences. Sessions were terminated
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when either three injections had been delivered or 3.5 hours had
elapsed. A session light (house light) at the top of the panel
was illuminated for the entire duration of the session, but for
one minute following each injection the stimulus light over the
lever was extinguished and responses had no scheduled consequences
(timeout). During the timeout, subjects were required to rate any
positive and/or negative effects, produced by the injection, on
100 mm visual line analog (VLA) scales.
Immediately following each session, two questionnaires were
administered to quantitate interoceptive effects produced by
injections. The first was a short form (40 items) of the
Addiction Research Center Inventory (ARCI) which contains
empirically derived scales sensitive to the effects of several
classes of psychoactive drugs. The second was the Single Dose
Questionnaire which contains a scale of drug liking, a drug
identification list with the names of 12 commonly used drugs, and
a symptom check list. Additionally, the attending nurse filled
out an observer-version of the Single Dose Questionnaire.
All lever pressing and drug self-administration was "voluntary".
The following instructions were read to the subject immediately
prior to each session:
During this test you are free to press the left lever
as often as you like. Only presses on the left lever
will produce injections; any responses on the right
lever will have no effect. However, you do not have
to press the left lever at all, but you must remain
seated, awake and equipped with the catheter for the
duration of the session. During the session certain
lever presses will turn off the green light, turn on
the red light and sound a tone. Other lever presses
will result in the light, tone, and an i.v. injection
of either some dose of cocaine or placebo. Doses of
cocaine or placebo will remain unchanged throughout an
individual session. After each i.v. injection, the
lights will go out for about a minute and the
equipment will not operate. If you miss an injection,
the lights will also go off for about a minute. When
the lights come back on, you will need to check your
responses on form IVN-5, and then you may continue to
lever press if you like. If you reach the injection
limit programmed into the computer, the lights will go
off until the program decides that it is safe for YOU
to continue. You may end a session or injection
immediately by turning off the AC power switch.
Subject H-689 was the first subject tested in this study. He
was initially tested during 8 sessions in which cocaine
injections (25 mg) were available for self-administration and 7
sessions in which only saline was available for self-adminis-
tration. Subject 743 was tested for a total of 37 sessions
under a variety of conditions in which either cocaine or saline
were presented and in which the secondary stimuli were either
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presented or omitted during the 60-minute intervals. For
H-743, cocaine doses were either 25, 7.9 or 2.5 mg per
injection, and the dose was held constant across sessions until
behavior stabilized for at least three sessions.
RESULTS
Self-report measures indicated that 25 mg cocaine injections
produced interoceptive effects which were reliably different
from those produced by saline. Specifically, scores were
elevated on the Morphine Benzedrine Group (MBG) and Lysergic
Acid Diethylamide (LSD) scales of the Addiction Research Center
Inventory (ARCI), and the Liking scale of the Single Dose
Questionnaire. Observer ratings of drug liking were also
elevated following cocaine injections when compared to placebo.
Scores on the positive VIA scale averaged 28 mm for H-689 and
34 mm for H-743 during their initial series of cocaine injec-
tions. Occasionally, a negative rating of a few mm occurred
after a cocaine injection but the average negative rating was
only 1 mm or less. Saline injections also produced average
ratings of 1 mm or less on either VLA scale. For subject H-743
the lower dose of 7.9 mg produced weak but consistent ratings
of about 3 mm on the positive scale and 0 mm on the negative
scale; at 2.5 mg ratings were 0 mm on either scale after the
first session. Interestingly, VLA scale scores tended to
decline within sessions across the three injections: second
injection scores were about 77% of first injection scores and
third injection scores were about 71% of first injection scores.
Fig. 1. Representative cumulative records from H-689
with cocaine (upper record) and saline (lower record)
injection. The records show that high rates of responding
occurred under both conditions.
As shown in the
Both subjects pressed the active lever and self-administered at
least one injection per session. whether cocaine or saline was
available. Subject H-689 pressed the lever at a high rate
throughout the sessions, pausing only during injections.
Figure 1 shows representative cumulative records of responding
from both a cocaine and a saline sess ion.
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records, saline maintained high and monotonic rates of
responding comparable to those maintained by cocaine and there
was no evidence of a trend in rate of responding across
sessions. Also shown in the figure, there was little evidence
of the development of patterns of responding characteristic of
those obtained in of cocaine self-administration in animal
subjects, or when other reinforcers are used in behavioral
studies with human volunteers. That is, there was no evidence
of the "break and run" responding on the fixed-ratio compo-
nents, nor was there evidence of positively accelerated
response rates ("scalloped" response rate patterns) within the
fixed-interval schedules.
During initial sessions, subject H-743 also pressed the lever
at high rates that did not appear to be under explicit control
of either the stimuli presented according to the fixed-ratio
schedule, or by the injection of cocaine that followed
completion of the fixed-interval schedule. However, by about
the sixth session, the subject began to reliably pause after
each injection, and to develop patterns of responding charac-
teristic of those seen with animal subjects under fixed-
interval schedules of food or drug reinforcement. Furthermore,
the cocaine-paired stimuli appeared to be maintaining patterns
of responding characteristic of those obtained under fixed-
ratio schedules of food or drug reinforcement. These patterns
of responding are illustrated by the representative cumulative
records shown in Figure 2. As shown in the figure, overall
rates of responding were substantially lower when saline was
substituted for cocaine. However, the within-session patterns
of responding were somewhat more interesting. For instance,
during the first interval of each session, there was no
reliable difference between rates of responding when cocaine or
saline were delivered. However, during subsequent intervals,
if cocaine had been delivered at the end of the first fixed-
interval, response rates were similar or somewhat higher; if
saline had been delivered following completion of the first
fixed-interval, response rates generally diminished consid-
erably. Within each fixed-ratio, rates were high and monotonic
and did not vary widely across conditions.
Diminished rates of responding occurred at lower doses of
cocaine; however, on each day that this subject was tested at
the lower doses, all three available injections were self-
administered. When saline was scheduled only the first
injection was taken on one-half of the sessions. Interestingly,
at low doses, VLA scale scores were very low or 0, and no drug
effects were indicated on the Single Dose Questionnaire,
although all available injections were obtained and overall
rates of responding exceeded saline values.
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Fig. 2. Representative cumulative records from H-743
under each of the indicated conditions. The records show
that rates of responding maintained by 25 mg of cocaine
exceeded those maintained by either saline or 7.9 mg.
DISCUSSION
The present results indicate that human subjects can be safely
used to study cocaine self-administration behavior under
second-order schedules of reinforcement. The study also
confirmed that self-administered cocaine produced similar
interoceptive effects as cocaine administered independently of
the behavior of the subject (e.g., Fischman, Schuster,
Resnekov, Shick, Krasnegor, Fennell and Freedman, 1976). For
one subject (H-743), the number of cocaine injections exceeded
the number of saline injections, and response rates maintained
by cocaine exceeded those maintained by saline. These data
suggested that cocaine served as a positive reinforcer relative
to saline. However, subjects always took the first available
injection of the session and there was a tendency to take
injections even in the absence of reliably identified sub-
jective effects. Similarly, whereas rates of lever pressing
were either stable or increasing within the sessions when
cocaine was administered, self-reported effects tended to
diminish across subsequent injections. It is possible that the
stimuli presented according to the second-order schedule contin-
gency contributed to the persistance of the behavior. As
suggested above, the results from procedures most commonly used
to assess abuse liability in humans (self-reported intero-
ceptive effects) did not perfectly correspond to the results
from procedures most commonly used to assess abuse liability in
animals. Identification of the factors that lead to such
behavioral persistence may help to better understand and treat
cocaine dependence; for here, as is the case with other drugs
of abuse, a treatment obstacle is that the degree of behavioral
persistence often appears disproportionate to the effects of
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the drug. Of more theoretical interest, further investigation
will be required to assess the conditions under which patterns
of behavior leading to human drug self-administration are
similar to those which have been obtained with animals. In a
similar vein, it is also important to study the role of the
drug associated stimuli in the mediation of drug self-adminis-
tration behavior as well as the possibility that such stimuli
may come to produce cocaine like interoceptive effects in their
own right.
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The Influence of Pharmacotherapy
on the Neonatal Sleep Patterns
of Infants Born to Opiate-
Addicted Mothers
M. Guilia Torriolo, M. Chiara Steffanini, P. Mariotti,
S. Calzolari, C. Fundaro, and E. Tempesta
The sleep cycles of 24 infants (15 male, 9 female)
born at term (39-41 wks) to opiate-addicted mothers
were studied. All infants weighed >25OO grams and,
with the exception of neonatal abstinence (NAS), were
considered healthy infants. In accordance with the
various pharmacotherapies recommended for withdrawal,
the infants were divided into four groups (6 infants
each): Gr.l-treated with phenobarbital (Pb); Gr.2-
treated with methadone (Me): Gr.3-treated with Pb and
Me: Gr.4-infants without abstinence and needing no
treatment. The NAS Scoring System (Finnegan) was
used to assess severity of withdrawal. Neurological
examinations were performed at one week of age and
upon discharge from the hospital. Sleep studies
consisted of three hour polygraphic recordings
obtained from each infant during the second week of
life and/or following withdrawal. These included 6
EEG channels (Fp2-C4; C4-T4; T4-02; Fp1-C3; C3-T3;
T3-01) and channels of electroculogram (EOG) and
electromyogram (EMG) from the chin surface. Each EEG
polygraphic record was independently evaluated by two
investigators. A two tailed t-test (student's t) was
used for statistical analyses. Findings included 1)
poor sleep organization in infants born to opiate-
addicted mothers: 2) decrease of Quiet Sleep (Q.S.)
in Gr.1 (Pb); 3) alterations in Active Sleep (A.S.)
for all treated groups, but not for the control
infants. The possible mechanisms involved in these
sleep cycle abnormalities are discussed.
Catholic University, Rome, Italy, Department of
Pediatrics, Department of Neurology and the
Department of Psychiatry.
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Contributions of Maternal Alcohol,
Caffeine, and Cigarette Use to
Neonatal Status
Juliana S. Lancaster, Claire D. Coles, Kathleen A.
Platzman, Iris E. Smith, and Arthur Falek
The teratogenic effects of maternal alcohol use on prenatal growth
and neonatal neurobehavioral status have been well documented.
There has been some debate about the real consequences of alcohol
and other drug use when such use is confined to relatively small
amounts or is described as social in nature. Recent work has shown
increased neurobehavioral alterations in the newborns of women who
drank throughout pregnancy as compared to the infants whose mothers
did not drink or stopped mid-pregnancy. The present analysis was
undertaken to examine the individual and/or interactive contribu-
tions of prenatal exposure to alcohol, nicotine, caffeine and
marijuana to neonatal size and neurological status. On the third
day of life, 143 full-term infants were examined by a developmental
psychologist using the Prechtl Neurological Examination for Newborn
Infants. Infants whose mothers drank throughout pregnancy were
smaller and had lower Prechtl scores than did those whose mothers
did not drink or stopped mid-pregnancy. Regression analyses were
conducted on alcohol-exposed and non-exposed infants separately
using measures of maternal health. Other drug use, and alcohol
use were appropriate as predictors of birthweight, head circum-
ference, and Prechtl score. Results showed that roughly 10 percent
of the variance in Prechtl scores was accounted for by the regress-
ions for exposed and non-exposed infants alike. For non-exposed
infants, 3-4 percent of the variance could be accounted for by the
regression. However, for the exposed infants, 20 percent of the
variance in each growth measure could be accounted for by the
regression. Results indicated that neurological status and pre-
natal growth, are measures of different aspects of infant health.
The results strongly support the teaching that pregnant women
should avoid consumption of alcohol and other drugs.
AFFILIATIONS:
Department of Psychiatry, Emory University Medical School and
Human and Behavior Genetics Research Laboratory, Georgia Mental
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Perinatal and Developmental
Outcome of Infants Exposed to
Methadone In-Utero
Karol Kaltenbach and Loretta P. Finnegan
The purpose of this research is to delineate the
effects of methadone exposure in-utero. Subjects
were 141 infants born to drug dependent women
maintained on methadone during pregnancy and 127
non-drug exposed comparison infants matched for
race, maternal age, and socioeconomic status. The
average daily methadone dose for mothers maintained
on methadone was 39 mg. Methadone exposed infants
had smaller birth weights than comparison infants.
The mean birth weight for methadone infants was 2963
gm and the mean birth weight for comparison infants
was 3210 gms (t=4.09, p<.001). Differences were also
found in head circumference. Methadone exposed
infants had a mean head circumference of 33.2 cm and
the mean head circumference found in comparison
infants was 33.94 cm (t=3.23, p<.01). However, this
difference was not clinically significant but rather
reflects the relationship between birth weight and
head circumference. No difference was found between
groups in mental development. One hundred sixty
infants (100 methadone exposed infants and 60
comparison infants) were evaluated with the Bayley
Scale of Mental Development at 6 months of age.
Mean Bayley Mental Development scores for methadone
exposed infants and comparison infants were 103 and
105 respectively. These data suggest that while
methadone exposure in-utero is associated with lower
birth weight, by six months of age, these infants do
not exhibit any remarkable developmental sequelae.
Karol Kaltenbach, Ph.D., Loretta P. Finnegan, M.D.
Jefferson Medical College of Thomas Jefferson
University, Department of Pediatrics, Philadelphia,
PA.
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Prenatal Cocaine Use Associated
With Down Regulation of Receptors
in Human Placenta
Ching H. Wang and Sidney H. Schnoll
Cocaine use during pregnancy has been shown to be associated
with increased risk of abruption placentae and spontaneous abortion.
The effects may be due to its vasoconstrictive action. The vascular
effects may be mediated through the increased in catecholamines
caused by cocaine. Opioid and adrenergic receptors have been
identified on placental tissue, and prenatal exposure to opiates
and ethanol results in a significant decrease in 1 -  and -adrener-
gic receptors. Since cocaine affects catocholamine levels, we studied
whether the transient increase in catecholamines occurring during
cocaine use in pregnancy caused changes in receptor systems in
the human placenta.
Placental tissues were collected from 8 women with histories of
cocaine use during pregnancy and age-matched controls. -adrener-
gic receptors were labeled with 3H-dihydroalprenolol, µ-opiate re-
ceptors with 3H-naloxonc and opiate receptors with 3H-D-ala-D-
leu-onkephalin.
Cocaine users showed a significantly lower number of -adrenergic
receptor  binding s i tes  and µ-  and -opiate binding sites (Bmax).
In 2 patients who were also on methadone during pregnancy, the
changes in µ-opiate receptor binding were abolished. Inclusion of
these two placentas did not alter the significant reduction of µ-opiate
receptor sites among the cocaine users (p<.05). There was no
reduction in binding affinities at the three receptor sites, reflecting
a true down regulation of the receptor population.
Down regulat ion of  adrenergic  receptor  binding s i tes  has been
associated with increased levels of agonists. This would be antici-
pated with cocaine’s blocking of catecholaminc reuptake. Cocaine
may also cause release of endogenous opiates, and the transient
increase in opratc agonists may cause the down regulation of opiate
receptors. Why the patients on methadone did not have an alteration
in the µ-opiate receptors is unknown.
AUTHORS: C. H. Wang, M.D., Ph.D; S. H. Schnoll, M.D.,
Ph.D. : Departments of Pharmacology and Psychiatry, Northwestern
University Medical School, Chicago, IL.
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Cocaine- and Methadone-Exposed
Infants: A Comparison
Ira J. Chasnoff
In conjunction with the increased use of cocaine in the general
population o f  the  Un i t ed  S ta t e s , the number of cocaine-using
pregnant women presenting to the Perinatal Center for Chemical
Dependence at Northwestern University has continued to escalate.
The present study of a population of cocaine-exposed infants was
undertaken to investigate perinatal morbidity and mortality in infants
born to cocaine-using mothers.
From January 1976 to January 1986,  52 infants were born to
cocaine-using women enrolled in the Perinatal Center for Chemical
Dependence. A comparison group (N=73) was selected from the
population of the Perinatal Center representing women of a similar
racial distribution who conceived while addicted to heroin and were
converted to low-dose methadone maintenance for at least the last
two trimesters of their pregnancies. These women had no history
or evidence of  cocaine use. Methadone-maintained women were
selected as a control group in order to be able to compare two
groups of  women who were similar in social, demographic and
environmental backgrounds as well as being comparable for ciga-
rette, alcohol and marijuana use during pregnancy.
As in other substance-abusing populations, the cocaine-addicted
women had a high incidence of infectious disease complications,
especially hepatitis (24%) and venereal disease (10.5%). There
was an increase in complications of labor and delivery (premature
labor, precipitous labor, abruptio placentae and fetal distress) in
cocaine-using women as compared to heroin/methadone-addicted
women. There was no difference in fetal growth parameters between
the two groups. Cocaine-exposed infants showed a greater defi-
ciency in’ state control, and on follow-up there appeared to be an
increased rate of  sudden infant death in the cocaine-exposed
infants.
AUTHOR: I .  J .  Chasnof f ,  M.D. ; Departments of Pediatrics and
Psychiatry, Northwestern University Medical School, Chicago, IL.
Supported by N.I.D.A. Grant 1R01-DA-04103-01.
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Sexual Activities in Drug
Dependent Women
Robert Smith, Dianne Regan, Saundra Ehrlich, and Loretta
P. Finnegan
Drug dependent women tend to lead chaotic lives. No
where is this more evident than in relationships,
particularly with men. Unable to deal with the
conflicts, addicts frequently find solace in drugs.
Since drugs may substitute for sex or be used to
mask feelings of sexual incompetence, a link has
been suggested between sexual activities (behavior,
performance, desire) and the use of such drugs as
heroin, marijuana, opiates, LSD and amphetamines.
To investigate further, 98 women were asked to
complete a Sexuality Questionnaire. Subjects
included 51 drug dependent women (DDW) enrolled in a
methadone program and a group of 47 drug-free
control women (CW) matched for age, race, and
socioeconomic status. The groups were compared on
adolescent and adult sexual parameters. In many
respects, the DDW were similar to the CW in sexual
behaviors, despite high depression scores, lower
self-esteem and sexual and physical abuse.
Differences in the groups included: less frequent
sexual activity than CW following first intercourse
(55 vs 80%); tendency to fewer relationships (76 vs
87%); less current sexual activity (50 vs 60%): and
drug abusing partners with difficulties in sexual
performance. Although first intercourse in both
groups occurred at approximately age 16, for 3 of
the DDW, this event was the result of rape. The
counselors felt that for many of the women, the
drugs were initially used to cope with the trauma of
sexual abuse. First intercourse for the majority of
DDW occurred less as a result of an ongoing
relationship and more as an impulsive event. Fewer
Family Center women reported current sexual
relationships/activities. These findings suggest an
association between drug abuse and difficulty in
forming stable, satisfying sexual relationships.
Jefferson Medical College of Thomas Jefferson
University, Department of Pediatrics, Philadelphia,
PA.
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Cocaine Abuse in Pregnancy:
Effects on the Fetus and Newborn
Lynn Ryan, Saundra Ehrlich, and Loretta P. Finnegan
A dramatic increase in cocaine use is occurring among
pregnant drug-dependent women (DDW), yet few studies
exist regarding the potential effects of this abuse on
the neonate. Within a methadone maintenance program
providing pre- and postnatal services for DDW, the
outcome of infants born to cocaine-using DDW was com-
pared to that of infants of non-cocaine using DDW and
non-DDW. The study population included 150 pregnant
women: 50 women used heroin and methadone plus co-
caine, 50 used heroin and methadone minus cocaine, and
50 were non-DDW. All were matched for age, race, gra-
vidity, parity, socioeconomic status, and cigarette
smoking. Significant differences were found between
the cocaine and drug-free groups in infant birth
weight, length, head circumference, and Apgar scores,
with the cocaine group having lower values for each
variable. Mean gestational age did not vary between
groups. The cocaine group included 1 spontaneous
abortion and 4 fetal deaths; non-cocaine DDW had 2 fe-
tal deaths: there were no fetal deaths in the control
group. Abstinence scores, incorporating 21 parameters
to quantify symptoms in infants born to DDW, were
studied. Mean scores for 19 of the parameters were
lower in the cocaine group than in the non-cocaine
DDW, with the exception of vomiting and convulsions.
These data suggest that: 1) infants born to drug de-
pendent women, both cocaine and non-cocaine users,
have poorer general outcomes than those born to drug
free women; 2) maternal cocaine use does not appear to
increase the incidence of neonatal abstinence: 3)
pregnancies complicated by cocaine abuse are at
greater risk for fetal loss from spontaneous abortions
and later from fetal death; 4) infants born to cocaine
abusing women had infants with decreased birth weight,
head circumference, length and Apgar scores: and 5)
there may be a greater incidence of Sudden Infant
Death Syndrome in infants exposed to cocaine.
Jefferson Medical College of Thomas Jefferson
University, Department of Pediatrics, Phila., PA.
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The Law of Hyperbolas: A Model
of Drug Action Applied to Opiate
Dependence and Abstinence
Julian E. Villarreal, Luis A. Salazar, Jorge E. Herrera,
and Silvia L. Cruz
INTRODUCTION
Experimental ana ly s i s  ha s  p roduced  ev idence  t ha t  op i a t e  depend -
ence  i s  t he  hype r t rophy  o f  a  spec i a l  op i a t e  r ecep to r  sy s t em wh ich
o p e r a t e s  i n  r a t e  m o d e . A formal  defini t ion of  the nature of  such
hypertrophy has been offered (Villarreal et al. 1985 a,b). The altera-
t ions  in function t h a t  c o n s t i t u t e  o p i a t e abs t i nence  a r e  med ia t ed
by the hypertrophied rate-coupled system. Thus,  to  i l lustrate ,  opiate
abs t inence  p rec ip i t a t ed  by  op ia t e antagonists  in  early dependence
occurs  not  when a  given absolute  number  of  receptors  are  occupied
b y  o p i a t e  a n t a g o n i s t  b u t  w h e n  t h e  r a t e  o f  o c c u p a t i o n  b y  a n t a g o -
nist  molecules is  suff icient ly high to reach suprathreshold exci tat ion
in opiate dependent neurons.
A formal model  receptor system capable of  operat ing in rate-coupled
mode, which will be described further on, was studied by mathemati-
cal computer analysis. Our group previously showed that such model
i s  r emarkab ly  adequa t e  t o  r ep roduce the  d ive r s i t y  o f  f ea tu r e s  o f
experimental  opiate  dependence. T h e  p u r p o s e  o f  t h e  p r e s e n t  w o r k
was to  examine,  under  a  complete  range of  condi t ions,  the  quant i ta-
t i ve  r e l a t i onsh ip s  be tween  t he  ma in  va r i ab l e s  o f  t he  r a t e - coup led
sys t em and  t he  cha rac t e r i s t i c s  o f  i t s  r e sponse s . The result is a
ma thema t i ca l  l aw  o f  d rug  ac t i on tha t  p rov ides  a  b road  bas i s  o f
formal theory applicable to the analysis  and descript ion of  the me-
chanisms of  opiate  dependence, spec ia l ly  a s  these  a re  r evea led  in
the complexi ty of  changing act ion pat terns exhibi ted by the abst in-
ence-precipitating actions of opiate antagonists.
T h e  n e w  m a t h e m a t i c a l  f o r m u l a t i o n  i s  c a l l e d  t h e  l a w  o r  t h e  r u l e
of hyperbolas. I t  d e f i n e s  d r u g  p o t e n c y  a n d  m o d e  o f  r e s p o n d i n g
in  s imp le  a lgeb ra i c  t e rms , a s  f u n c t i o n s  o f  t h e  m a i n  v a r i a b l e s  o f
the receptor  system. It applies to any type of drug-receptor-effector
s t ructure  which mediates  the  act ions  of  e i ther  drugs,  hormones or
o t h e r  h u m o r a l  a g e n t s  a c t i n g  u n d e r  t h e  s c h e m e  o f  F i g .  1 . Such
agents  must  only fulf i l l  the fol lowing two condit ions:  1)  they must
b i n d  w i t h  r e c e p t o r s  o b e y i n g  t h e  l a w  o f  m a s s  a c t i o n ;  2 )  t h e y  m u s t
produce primary pharmacologic microevents which have an exponential
decay, statistical or analogic, as an approximation at least.
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Although the law of hyperbolas is  l ikely to have useful  applicat ion
in other  areas of  pharmacology, i t  i s  e x a m i n e d  n o w  m a i n l y  i n  t h e
conc re t e  s ense  o f  a  t heo ry  app l i ed  t o  t he  abs t i nence -p rec ip i t a t i ng
act ions of  opiate  antagonists  in the moving basel ine of  progressive
dependence. Therefore,  a l l  drug act ion t reated in this  paper  should
be  r ega rded  a s  r e f e r r i ng  p r imar i l y  t o  t hose  exc i t a to ry  ac t i ons  o f
antagonists that mediate the precipitation of abstinence. The experi-
men ta l  ev idence  c l ea r l y  demons t r a t e s  t ha t  ab s t i nence  p roduced  by
opiate antagonists is not the result of the simple occlusion of recep-
tors by silent chemical occupation. The onset of antagonist occupa-
tion of receptors causes excitatory subthreshold events which rapidly
fade  away , l eav ing  a f t e rwards  t he  r ecep to r s  chemica l l y  occup ied
but physiologically inactive.
A  d i ag ram o f  t he  mode l  o f  r a t e - coup led  r ecep to r  sys t em employed
is  shown in  f igure  1 . I n  t h i s  t y p e  o f  s y s t e m ,  t h e  d u r a t i o n  o f  t h e
primary pharmacologic s t i m u l u s  i s  d e t e r m i n e d  n o t  b y  t h e  e n t i r e
d u r a t i o n  o f  t h e  c h e m i c a l  b o n d  b e t w e e n  d r u g  a n d  r e c e p t o r  b u t  b y
the  dynamics  o f  t he  p r imary  b io log ica l  e f f ec to r  a s soc i a t ed  wi th
the  p r imary  chemica l  r e cep to r  ( e . g . , b y  t h e  o p e n i n g  a n d  c l o s i n g
of ionic channels  in  exci table  membranes,  or  by s t imulat ion of  en-
z y m e  s y s t e m s  p r o d u c i n g  s e c o n d messenger substances). A  g o o d
example is  given by opiate abst inence precipi tated by the antagonist
naloxone in early dependence. H e r e  t h e  n u m b e r  o f  r e c e p t o r s  t h a t
appea r  t o  be  pa r t i c ipa t i ng  i n  t he  p roces s  o f  neu rona l  exc i t a t i on
( t h e  D R a c t  o f  F i g . 1 )  a t  a n y  m o m e n t  a f t e r  d r u g  a d m i n i s t r a t i o n
is  smaller  than the total  number of  occupied receptors  ( the DRact
plus  the  DRinact) . The dispar i ty  between the number of  receptors
contr ibut ing to cel lular  act ivat ion and the number occupied by drug
molecu le s  l imi t s  pha rmaco log ic  s ens i t i v i t y  w i th  a  ma thema t i ca l ly
predictable temporal course (Pardo, 1959) and gives rise to self-anta-
gonism as  wel l  as  to  the other  features  that  character ize  the beha-
vior of rate-coupled systems (Villarreal, et al., 1985 a,b; Cruz, 1986).
T h e  e x p e r i m e n t a l  e v i d e n c e  i n d i c a t e s  t h a t  t h e  h y p e r t r o p h y  o f  t h e
opiate  rate-coupled system of  opiate  dependence consists  in  an in-
creased durat ion of  the primary pharmacologic microevents  caused
by  t he  onse t  o f  b ind ing  o f  op i a t e  an t agon i s t s  t o  t he i r  r e cep to r s .
T h e s e  c h a n g e s  i n  d u r a t i o n  o f  t h e  p r i m a r y  e x c i t a t o r y  m i c r o e v e n t
were simulated through mathematical means by varying the numerical
value of  the decay rate  constant  kt  of  the act ive s tate  of  the recep-
tor (Vil larreal  et  al . , 1985 a,b; Cruz, 1986). I t  was found that  pro-
g r e s s i v e  d e c r e a s e s  i n  t h e  k t  o f  t h e  s y s t e m  c a u s e  a  h y p e r t r o p h y
of the abst inence response system which reproduces al l  the def ining
phenomeno log i ca l  cha rac t e r i s t i c s  o f  op i a t e  dependence  cons ide red
in specific detail . T h e s e  c h a r a c t e r i s t i c s  a r e :  1 )  t h e  e m e r g e n c e  o f
a capacity of the organism that becomes opiate dependent to produce
abst inence syndromes in  response to  opiate  antagonists ;  2)  the pro-
gressive increase in severity and duration of the abstinence syndromes
that  can be produced in  the  course  of  dependence;  3)  the  response
of precipi tated abst inence requires  antagonist  administrat ion at  high
rates  in early dependence but  this  requirement  is  progressively re-
duced as dependence increases in magnitude; 4) there is a progressive
transformation of  the mode of  responding of  the abst inence receptor
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FIGURE 1. Model receptor system
capable of rate-coupled behavior.
the drug-receptor-effector complex
is initially in a condition of acti-
vation as DRact. Afterwards, the
effector becomes inactivated but
the receptor remains occupied as
DRinact. The rate constant for decay
of  the  act ivated e f fec tor  i s  k t .
Modified from Gosselin (1977).
system from rate-coupled to occupat ion-coupled behavior;  5)  in  the
course of  dependence, there  is  an enormous supersensi t ivi ty  to  the
abst inence-precipi tat ing act ions of  s ingle doses of  antagonists ,  with
paral lel  shif ts  to  the lef t  in  their  dose-abst inence curves,  with very
large changes in their ED50s but without any changes in their chemi-
cal binding properties.
The law of hyperbolas is given as the algebraic equation that relates
kt  and the other  basic variables of  the rate-coupled receptor  system
to: 1) the dose of drug required for the production of a fixed refer-
ence level  of  pharmacologic response ( the ED50 is  employed here) ;
2 )  t h e  m o d e  o f  p h a r m a c o l o g i c  r e s p o n d i n g  ( i . e . ,  w h e t h e r  r a t e -  o r
occupation-coupled). T h e  e q u a t i o n s  d i s c u s s e d  i n  t h i s  p a p e r  r e f e r
on ly  t o  peak  r e sponse s  p roduced  by  t he  i n s t an t aneous  add i t i on  o f
single drug doses. We chose to deal  with these responses f i rs t  be-
cause they are  the most  interest ing par t  of  the abst inence response
and also because peak responses have previously eluded a satisfactory
systematic treatment in any theory of drug action.
I t  m u s t  b e  n o t e d  t h a t  t h e  d e v e l o p m e n t  o f  t h e  l a w  o f  h y p e r b o l a s
i s  a  consequence  o f  t he  fu l l  l og i ca l  and  ma thema t i ca l  de r iva t i on
of propositions that we learned from Pardo (1959) and of the differ-
ential equations elaborated by Cosselin (1977), both of which contribu-
t ions can now be.  amply worked out  because of  the avai labi l i ty of
electronic computers.
METHODS
We studied computer-generated solut ions of  the set  of  s imultaneous
differential equations derived by Gosselin (1977) for receptor systems
ope ra t i ng  a s  i n  F ig .  1 . These solut ions are  formal  s imulat ions of
t h e  t e m p o r a l  c o u r s e  o f  e v e n t s  i n  t h e  r e c e p t o r  s y s t e m  i n  r e s p o n s e
to the administrat ion of  a  s imulated drug dose. Such solutions were
obtained with Gossel in’s  analyt ic  integrat ions and also by numerical
methods of  integrat ion.  Next  are  the s imultaneous different ia l  equa-
tions employed.
d[ACT]/dt = k l (D)[R] - k2[ACT] - k t[ACT] (1)
d[INACT]/dt = kt[ACT] - k4 [INACT] (2)
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W h e r e  [ A C T ]  =  D R a c t , a n d  [ I N A C T ]  =  D R i n a c t ,  a n d  t h e  o t h e r
symbo l s  a s  i n  F ig .  1 . In  actual  computat ion,  the  term k1 (D)[R]
of equation I was transformed to k1 (D)[1 - DRact - DRinact]
b e c a u s e  t h e  t o t a l  o f  t h e  r e c e p t o r s  i s  a s s u m e d  t o  b e  c o n s e r v e d  a s :
R total = 1 = R + DRact + DRinact.
Complete  ser ies  of  s imulated pharmacologic responses to different
values  of  the drug dose parameter  were produced under  each tes ted
se t  o f  cond i t i ons  o f  t he  sy s t em. Dose-response curves  were then
c o n s t r u c t e d  w h e r e  t h e  r e s p o n s e t a k e n  w a s  t h e  p e a k  q u a n t i t y  o f
receptors  in the act ive s tate  generated by each simulat ion of  dose
a d m i n i s t e r e d  ( t h e  p e a k  n u m b e r  o f  D R a c t ) . Final ly,  ED50 values
were  ob t a ined  f rom dose - r e sponse  cu rves  fo r  a  w ide  d ive r s i t y  o f
combinat ions  of  kt ,  k1,  and k2. In a l l  these s tudies ,  the  constant
k4 was fixed at 0.0001. Peak responses are affected only by extreme
values of k4; this constant affects mostly stationary state responses.
RESULTS
For  any  g iven  s imu la t ed  pha rmaco log i c  agen t ,  de f ined  w i th  f i xed
k1 and k2,  var ia t ions in  log kt  produce changes in  log ED50 along
l i ne s  w i th  t he  fo rm  o f  a  hype rbo l a  a s  i n  F ig .  2 . Each hyperbola
represents  a  l ine of  pharmacologic isoact ivi ty (ED50s)  as  a  funct ion
of variations in kt; All drugs can be represented by identical hyper-
bolas. T h e  d r u g s  v a r y  i n  t h e  p o s i t i o n  o f  t h e i r  h y p e r b o l a s  i n  t h e
plane defined by log kt and log ED50.
All  drug hyperbolas have similar  asymptotes. O n e  i s  a  h o r i z o n t a l
asymptote whose numerical value on the y axis corresponds precisely
to  t he  va lue  o f  t he  l og  o f  t he  chemica l  d i s soc i a t i on  cons t an t ,  l og
( k 2 / k 1 ) ,  o f  t h e  d r u g  i n  q u e s t i o n  ( s e e  F i g .  2 ) .  T h u s ,  i n  t h e  s p a c e
of the hyperbolas,  when the act ive s tate  is  long-l ived (with a  small
d e c a y  r a t e  c o n s t a n t  k t ) ,  o c c u p a t i o n  b e c o m e s  t h e  l i m i t i n g  f a c t o r
and the value of  log ED50 is  pr imari ly determined by the horizontal
a sympto t e  l og  (k2 /k1 ) ;  t he  chemica l  d i s soc i a t i on  cons t an t  i s  t hen
the  p r ima ry  de t e rminan t  o f  d rug  po t ency . Fu r the rmore ,  a s  F ig .
2  s h o w s ,  t h e  c h a r a c t e r  o f  t h e  r e s p o n s e s  d e f i n e d  b y  t h e  h o r i z o n t a l
arms of  the hyperbolas  is  that  of  occupat ion-coupled modes of  phar-
macologic behavior. Therefore, w e  c a n  d e s i g n a t e  t h e  h o r i z o n t a l
b r a n c h e s  o f  t h e  h y p e r b o l a s  a s  t h e  d o m a i n  o f  o c c u p a t i o n - c o u p l e d
modes of pharmacologic responding.
When the durat ion of  the pr imary pharmacologic microevent  is  short
( l a r g e  k t ) ,  t h e  d u r a t i o n  o f  t h e  a c t i v e  s t a t e  r a t h e r  t h a n  o c c u p a t i o n
becomes  t he  l im i t i ng  f ac to r  i n  t he  de t e rmina t i on  o f  d rug  po t ency .
With short microevents, the value of log ED50 is primarily determined
by the second,  obl ique, asymptotes of  the hyperbolas. O n e  f o r m
of the equation of the oblique asymptotes is the following:
log ED50 = log kt + log (2/kl) (3)
T h e  o b l i q u e  b r a n c h e s  o f  t h e  h y p e r b o l a s  a r e  t h e  d o m a i n  o f  r a t e -
coupled modes of responding (Fig. 2). As equat ion 3 shows,  in  this
rate-coupled domain, t he  l og  ED50  i s  de t e rmined  by  l og  k t ,  w i th
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FIGURE 2. An example of a hyperbola relating log kt to log EL50 for a drug
with kl = 0.01 and k2 = 0.000l; log (k2/k.l) = -2. One inset shows three sample
simulated responses to each of three points a, b, and c on the
hyperbola. The time bases of the three records are different. The other inset
show the complete  set  of  dose-response curves that  produced the hyperbola.
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a slope of one, a n d  w i t h  t h e  c h e m i c a l  a s s o c i a t i o n  r a t e  c o n s t a n t
k1 playing a role in determining the vertical intercept of the oblique
asymptote, on the plane of log kt vs log ED50.
For any hyperbola in general ,  the point  at  which i ts  two asymptotes
in t e r sec t  i s  c a l l ed  i t s  c en t e r . S u c h  c e n t e r  i s  a  c o n v e n i e n t  p o i n t
to place the borderl ine between the domains of  occupat ion-coupled
behavior  and of  rate-coupled behavior . T h e  x  c o o r d i n a t e  o f  t h e
c e n t e r  o f  a n y  h y p e r b o l a  c o r r e s p o n d s  t o  t h e  v a l u e  o f  l o g  ( k 2 / 2 )
of the drug in question (see for instance Fig. 2 where log (0.0001/2)
= -4.3). It may be said that occupation-coupled modes of respond-
ing  w i l l  be  obse rved  w i th  any  d rug  i n  a  sy s t em whose  k t  f a l l s  t o
the left of k2/2.
Systematic  mathematical  s imulat ions provided the material  to  define
t h e  g e n e r a l  e q u a t i o n o f  t he  pha rmaco log i c  hype rbo l a s . Starting
f r o m  t h e  c a n n o n i c a l  e q u a t i o n  f o r  a  h y p e r b o l a  w i t h  v e r t i c a l  m a j o r
axis, a n  e q u a t i o n  w a s  f o u n d  w i t h  a  r o t a t i o n  a n d  s h a p e  f i t t i n g  t h e
characteristics of the pharmacologic hyperbolas:
y2-xy-0.085=0 (4)
This equation, however, is  centered at  the origin of  the coordinate
axes. The pharmacologic hyperbolas have centers outside the origin,
with coordinates given by x = log (k2/2) and y = log (k2/kl). Equa-
t ion (4)  can then be  rewri t ten , replacing x and y by the correct ion
t e rms  fo r  t r ans l a t i on  o f  t he  o r i g in  i n  t he  p l ane  de f ined  by  l og  k t
and log ED50. Expanding the corrected vers ion of  (4) ,  rearranging
i t  and solving for  log ED50,  we obtain the general  equat ion of  the
pharmacologic hyperbolas:
(5)log ED50=((D+E)/2)+[((D+E)/2)
2-DE+C]1’2
Where D = log (k2/kl), E = log (2kt/kl), and C is a numerical cons-
tan t  equal  to  0 .085. There are only two variable  terms in equat ion
(5). One is “D”, the log of the chemical dissociation constant, KD.
The other  term “E” contains  kt ,  the  decay constant  of  the  pr imary
pharmacologic stimulus. T h e  n e w  t e r m  2 k t / k l  m a y  b e  c a l l e d  t h e
“pharmacologic  evanescence constant” ,  KE. In view of this, we
can rewrite the equation of the oblique asymptotes (3) as follows:
log ED 5 0 = log (2kt)/k1 = log KE (6)
I t  i s  t h e n  w o r t h  n o t i n g  t h a t  j u s t  a s  t h e  h o r i z o n t a l  a s y m p t o t e s  a r e
defined by the chemical dissociation constant KD, the oblique asymp-
totes  are  def ined by a  hybrid pharmacochemical  term KE = 2kt /k1,
which is  the pharmacological  analogue of  the chemical  dissociat ion
constant.
DISCUSSION
The 3-component receptor model presented here is based on Gosselin’s
receptor inactivation model (1977). We chose this model as a starting
po in t  because  i t  i s  t he  s imp les t  cyc l i ca l  r ecep to r  mode l  d i s cus sed
i n  t h e  l i t e r a t u r e  w h i c h  i n c l u d e s  a  r e f r a c t o r y  s t e p  a n d  w h i c h  h a s
formal features of  broad applicabil i ty.  Our model  retains Gossel in’s
equa t i ons  i n t ac t  bu t  r e fo rmu la t e s  i t s  phys io log i c  con t en t  t o  su i t
the demands of the experimental evidence concerning opiate depend-
ence  a s  we l l  a s  t ha t  p roduced  by  d i r ec t  s t ud i e s  on  t he  phys io logy
of excitatory microevents in excitable membranes. The model recep-
tor  system presented in  this  paper  describes our  reformulat ion and
the  i n t e r e s t ed  r eade r  may  consu l t  Gosse l i n ’ s  pape r  fo r  a  de t a i l ed
c o m p a r i s o n  o f  b o t h  m o d e l s . T h e  m a j o r  d i f f e r e n c e  l i e s  w i t h  t h e
variable to which Gosselin attributes the role of primary pharmacolo-
gic s t imulus. I n  o u r  m o d e l  t h e  p r i m a r y  p h a r m a c o l o g i c  s t i m u l u s
is  the total  number of  receptor-effector  uni ts  in  the act ivated s tate
( D R a c t )  a t  a n y  o n e  t i m e . Gossel in ,  however ,  proposes  that  the
primary pharmacologic s t imulus should be proport ional  to  the rate
a t  w h i c h  r e c e p t o r  u n i t s  i n  t h e  a c t i v e  s t a t e  t u r n  t o  t h e  i n a c t i v e
state; quantitatively, t h i s  m e a n s  t h a t  t h e  p h a r m a c o l o g i c  s t i m u l u s
s h o u l d  b e  p r o p o r t i o n a l  t o  t h e  m a t h e m a t i c a l  p r o d u c t  o f  w h a t  w e
h e r e  c a l l  k t  t i m e s  D R a c t . Such proposal  would immediately imply
absurdi t ies  for  our  experimental  problem. To assume with  the  ful l
Gosselin model that the pharmacologic stimulus were kt times DRact
wou ld  mean  t ha t  i n  ve ry  ea r l y  dependence  ( l a rge  k t )  t he r e  wou ld
be large abstinence responses, and that in well developed dependence
(small kt) there would be small abstinence responses. On the  o ther
hand,  this  paper  and previous communicat ions of  our  group provide
abundant evidence of the validity of Gosselin’s mathematical kinetics
in accounting for the processes of opiate abstinence and dependence.
Gosse l in ’ s  k ine t i c s  g ive  ma thema t i ca l  fo rm to  bas i c  p roces se s  i n
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the microphysiology of  excitable membranes. F o r  i n s t a n c e ,  t h e r e
are many recent  reports  showing that  the act ive s tates  of  exci tatory
single ionic channels  in a  variety of  membranes have a s tat is t ical ly
exponential  decay, o r  a t  l e a s t  a  c l o s e  a p p r o x i m a t i o n . W e  h a v e
begun work searching for  a  direct  demonstrat ion of  the equivalence
o f  k t  w i th  t he  r a t e  o f  decay  o f  depo l a r i z i ng  i on i c  channe l s  i n  t he
membranes of opiate-sensitive neurons.
The  l aw  o f  hype rbo la s  i s  spec i a l l y  we l l  su i t ed  a s  a  quan t i t a t i ve
f r a m e w o r k  f o r  t h e  c o m p l e x  s e t  o f  p h e n o m e n a  p r e s e n t e d  b y  o p i a t e
dependence and abstinence. The law is also well suited as a concep-
tua l  ba se  fo r  t he  compara t i ve  ana ly s i s  o f  an t agon i s t s  w i th  r ega rd
to their  abst inence-precipi tat ing act ions. Finally, the law can serve
as the basis for a theory of interactions between antagonists, includ-
ing the cases of  self-antagonism and of  specif ic  cross-antagonism.
The  r e l a t i ve  pos i t i ons  o f  t he  hype rbo l a s  o f  two  an t agon i s t s  w i l l
i n d i c a t e  i f  a n d  w h e n  o n e  o f  t h e m  w i l l  a c t  a s  a n t a g o n i s t  t o  t h e
abstinence-precipitating actions of the other antagonist.
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New Approaches to the Evaluation of Opioid
Agonists and Antagonists Upon the Isolated,
Electrically Stimulated Mouse Vas Deferens
Preparation
Charles B. Smith
INTRODUCTION
Opioid receptors are classified in part by the relative potencies
of agonists and the selectivity of antagonists in a variety of
preparations (Martin et al., 1976; Lord et al, 1977). The iso-
lated, electrically stimulated guinea-pig ileal and mouse vas
deferens preparations have been used widely to evaluate the phar-
macological actions of opioid agonists and antagonists. In the
past a comparison of the actions of such drugs upon the two
preparations has been used to evaluate receptor selectivity. Mu,
kappa and delta receptors are present in the mouse vas deferens
preparation. The development of new, highly selective antago-
nists such as the irreversible mu receptor antagonist beta-funal-
trexamine (beta-FNA, Portoghese et al, 1980; Ward et al., 1982)
and the reversible delta receptor antagonist ICI-l74864 (Cotton
et al ., 1984; Smith et al., 1984) have made possible the evalua-
tion of selectivity of opioid agonists and antagonists by use of
the mouse vas deferens preparation alone. The purpose of this
report is to describe new procedures used by the Drug Evaluation
Unit at the University of Michigan to study opioid agonists and
antagonists upon the mouse vas deferens preparation and to show
results obtained with various standard opioid agonists and
antagonists by the use of these procedures.
M E T H O D S
Male, albino ICR mice, weighing between 25 and 30 g, were used.
The mice were decapitated, the vasa deferentia removed, and 1.5
cm segments were suspended in organ baths which contained 30 ml
of a modified Kreb’s physiological buffer. The buffer contained
the following (mM): NaCl, 118; KCl, 4.75; CaCl2 2.54; MgSO4
1.19; KH2P04, 1.19; glucose, 11; NaHCO3, 25; pargyline HC1, 0.3,
tyrosine, 0.2; ascorbic acid, 0.1; and disodium edetate,0.03.
The buffer was saturated with 95% 02 - 5% CO2 and kept at 37°C.
The segments were attached to strain gauge transducers and sus-
pended between two platinum electrodes. After a 30-min equili-
bration period, the segments were stimulated once every 10 sec
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with pairs of pulses of 2 msec duration, 1 msec apart and at
supramaximal voltage.
The following antagonists were studied: naltrexone HCl, ICI-
174864 [N,N-diallyl-Tyr-Aib-Aib-Phe-Leu-OH] and beta-FNA. Nal-
trexone and ICI-174864 were added to the organ baths 15 minutes
before the determination of cumulative concentration-effect rela-
tionships for the various agonists. beta-FNA was added to the
organ baths after the initial equilibration period. Thirty min
later the beta-FNA was removed from the organ baths by repeated
washings with fresh buffer. The tissues were washed three times
every 5 min for 15 min. Cumulative concentration-effect rela-
tionships for the various agonists were then determined 20 min
after the last wash (i.e. 30 min after the beta-FNA was removed
from the organ baths). The following agonists were studied:
DADLE [D-Ala2-D-leu5 enkephalin], DSLET [Tyr-D-Ser-Gly-Phe-
Leu-Thr], DPDPE [D-pen-D-pen enkephalin], FK-33824 [Tyr-D-Ala-
GlyaePhe-Met-CO)-01], LY-123502 [Tyr-D-Ala-Gly-4-F-Phe-phenyl-
gylcinamide acetate, morphine sulfate, MR-2033 [(±)-5,9-alpha-
dimethyl-2',-hydroxy-2-tetrahydrofurfuryl-6,7-benzomorphan], ti-
fluadom, sufentanil and U50, 488H [trans-3,4-dichloro-N-methyl-
N(2-(l-pyrro-1idinyl)cyclohexyl)benzeneacetamide methanesulfonate
hydrate]. EC 50's were calculated by probit analysis, and pA2
values were determined to assess relative potencies of antag-
onists. All values are the means of at least 6 determinations ±
the standard error of the mean.
All drugs which are submitted for evaluation are studied in the
following manner: 1) the submitted drug is tested on the vas
deferens preparation in the absence and in the presence of
naltrexone. The concentration of the unknown drug is varied from
the lowest with activity to that which is maximally effective.
2) If the submitted drug inhibits the twitch, the ability of
naltrexone to reverse the inhibition is determined. 3) The sub-
mitted drug is assessed for its ability to antagonize the actions
of morphine on the vas deferens. 4) The drug is assessed for
its ability to reverse the inhibition produced by a maximally ef-
fective concentration of morphine. 5) Finally, if the drug has
opioid agonistic activity, studies are conducted to determine the
receptor type upon which it acts. If it has antagonistic
activity upon the vas deferens or upon any of the other
preparations used in the Drug Evaluation Unit, the type of
antagonism (competitive, noncompetitive) and the receptor
selectivity is determined.
The procedure for determining the type of receptor upon which an
agonist might act is outlined in FIGURE 1. A drug which acts
primarily upon delta opioid receptors will be blocked by both
ICI-174864 and beta-FNA. A drug which acts upon kappa receptors
will be blocked by naltrexone, but not by beta-FNA. A drug which
acts primarily upon mu receptors will be blocked by naltrexone
and beta-FNA but not by ICI-174864.
289
DRUG INHIBITS MVD
NALTREXONE BLOCKS NALTREXONE DOES NOT BLOCK
(NON-OPIATE)
BETA-FNA BLOCKS BETA-FNA DOES NOT BLOCK
(KAPPA)
ICI-174864 BLOCKS ICI-174864 DOES NOT BLOCK
(DELTA) (MU)
FIGURE 1. Schematic diagram of procedure for evaluating opioid
agonists.
The procedure for the further evaluation of opioid antagonists is
shown in FIGURE 2. A drug which is selective for mu receptors
will block the actions of morphine or sufentanil. One which is
selective for delta receptors will block the actions of DSLET,
DADLE or DPDPE, and one selective for kappa receptors will block
the actions of U50,488H. A naltrexone-like antagonist which has
activity at all three receptors will block the actions of the
three types of agonist although the pA2 values for the antagonist
will differ when determined with the various receptor-selective
agonists.
UNKNOWN DRUG
BLOCKS ALFENTANIL BLOCKS DSLET BLOCKS U50,488H
(MU) (DELTA) (KAPPA)
FIGURE 2. Schematic diagram of procedure for evaluating opioid
antagonists.
RESULTS
Naltrexone caused parallel shifts to the right in the concentra-
tion-effect curves for mu, kappa and delta receptor agonists.
pA2 values for naltrexone determined with the mu agonists mor-
phine  and sufentanil were 8.59 ± 0.15 and 8.60 ± 0.13 respec-
tively. pA2 values for naltrexone determined with the kappa ago-
nists MR-2033 and tifluadom were 8.20 ± 0.24 and 8.34 ± 0.15, and
pA2 values determined with the delta-agonists DSLET, DADLE and
LYZ-123502 were 7.60 ± 0.10, 7.65 ± 0.05 and 7.57 ± 0.05 respec-
tively. The slopes of the Schild plots did not differ from unity
for any of the agonist-antagonist interactions. These results
indicate that naltrexone has differing affinities for mu, kappa
and delta opioid receptors. This type of analysis, however, is
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not practical in the routine evaluation of new compounds for opi-
oid activity because of the large number of experiments required
to determine individual pA2 values.
As reported previously (Smith et al., 1984), ICI-174864 caused
parallel shifts to the right in the concentration effect curves
FIGURE 3. Antagonism by beta-FNA of the effects of DSLET and
DPDPE upon the isolated, electrically stimulated mouse vas defer-
ens preparation. Ordinate: inhibition expressed as a percent of
the baseline contraction; abscissa: concentration of agonist.
Solid squares: control preparations. Open squares: preparations
were exposed to beta-FNA, 1 microM, for 30 min and then washed
repeatedly with fresh buffer for a further 30 min after which
concentration-effect relationships for the agonists were
determined. Each point represents the mean of at least 6
determinations. Vertical lines represent standard errors of the
mean.
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for delta receptor agonists. pA2 values for ICI-174864 deter-
mined with DSLET, DADLE and LY-123502 were 7.90 ± 0.06, 7.60 ±
0.03 and 7.70 ± 0.51 respectively. ICI-174864 did not shift the
concentration-effect curves for morphine, sufentanil, U50,488H,
Mr-2033 or tifluadom in concentrations as high as 30 uM. Thus,
as reported previously, ICI-174864 is a very selective antagonist
of delta opioid receptors.
In addition to its ability to irreversibly block mu opioid
receptors, beta-FNA antagonized the actions of delta receptor ag-
onists such as DSLET and DPDPE upon the mouse vas deferens prepa-
ration (FIGURE 3). In contrast beta-FNA at a concentration of 1
µM did not alter responses to either U50,488H (FIGURE 4) or to
Mr-2033. Thus, in the mouse vas deferens preparation, beta-FNA
is an irreversible antagonist at delta as well as at mu opioid
receptors.
FIGURE 4. Failure of beta-FNA to antagonize the effects of
U50, 488H upon the isolated, electrically stimulated mouse vas
deferens preparation. See FIGURE 3 for details.
DISCUSSION
In the past it has been difficult to determine upon a single
smooth muscle preparation whether an opioid agonist acted primar-
ily at mu, kappa or delta receptors. In addition, the assessment
of the selectivity of opioid antagonists has been equally diffi-
cult. The development of new and more selective agonists and an-
tagonists has led to new strategies for the evaluation of opioids
upon the isolated, electrically stimulated mouse vas deferens
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preparation. Previously we reported that exposure of the vas
deferens preparation for 15 min to beta-FNA results in a blockade
of both mu and delta opioid receptors (Smith et al., 1984). The
present study shows further that beta-FNA is an irreversible an-
tagonist at both mu and delta receptors, but not at kappa recep-
tors in the vas deferens preparation. Thus, an opioid agonist
which is blocked by naltrexone, but which is not blocked by beta-
FNA would appear to act primarily at kappa opioid receptors.
ICI-174864 is a reversible opioid antagonist which over a wide
range of concentrations only blocks the actions of opioid ago-
nists upon delta receptors. Therefore, this antagonist can be
used to identify drugs which have significant activity upon delta
receptors. An opioid agonist which is blocked by naltrexone,
beta-FNA and ICI-174864 would be likely to act at delta recep-
tors.
A similar approach can be taken to the evaluation of opioid an-
tagonists. A selective delta receptor antagonist will block only
the actions of drugs such as DSLET, DPDPE and DADLE. A selective
mu receptor antagonist will block selectively drugs such as mor-
phine and sufentanil which in the vas deferens appear to act al-
most solely upon mu receptors. Finally, a kappa receptor an-
tagonist would be expected to block the actions of a drug such as
U50, 488H. At this time we have not found an antagonist highly
selective for the kappa receptor. These new procedures for the
evaluation of opioid agonists and antagonists upon the mouse vas
deferens preparation should facilitate greatly the evaluation of
new opioid drugs.
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A Cyclic Somatostatin Analog
That Precipitates Withdrawal
in Morphine-Dependent Mice
J. E. Shook, J. T. Pelton, W. Kazmierski, P. K. Lemcke,
R. G. Villar, V. J. Hruby, and T. F. Burks
ABSTRACT
We evaluated the ability of the mu selective, peptidic, opioid
antagonist CTP to precipitate withdrawal in morphine-dependent
mice after intracerebroventricular (i.c.v.) and subcutaneous
(s.c.) administration. The withdrawal syndrome evoked by i.c.v.
CTP was different in some respects from that observed after
i.c.v. naloxone. Naloxone, given i.c.v., produced shakes and
tremors, defecation, diarrhea, wet dog shakes, jumping and
weight loss. In contrast, the prominent signs following i.c.v.
CTP were grooming, tremors and shakes, defecation, wet dog
shakes and weight loss. CTP treated mice exhibited a greatly
reduced incidence of jumping behaviors and diarrhea. While s.c.
naloxone evoked similar effects to i.c.v. naloxone, CTP given
S.C. stimulated defecation and modest weight loss only. The
differences in the profile of withdrawal signs between naloxone
and CTP may be related to their differences in receptor
selectivity or possibly to their respective alkaloidal and
peptidic natures. The relative lack of behavioral effects seen
after S.C. CTP probably reflects the inability of CTP to pass
through the blood brain barrier, and indicates that although the
majority of withdrawal signs are mediated by centrally located
opioid receptors, the gastrointestinal tract can be withdrawn
independently of the central nervous system.
INTRODUCTION
We have previously reported that the cyclic somatostatin analog
CTP (D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH2), produces selective
opioid mu-receptor antagonism in binding assays with homogenized
rat brain (Pelton et al., 1985; Gulya et al., 1986) as well as
in the guinea pig ileum longitudinal muscle-myenteric plexus and
This work supported by DA02163, NS19972 and AM36289.
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in the mouse vas deferens (Shook et al., 1986a) (delta/mu ratio
6000). In analgesic tests in mice, CTP was found to produce
potent, long-lasting competitive antagonism of mu-selective
agonists and it also antagonized delta selective ligands, but in
a noncompetitive fashion. The mutual antagonism of the
analgesic actions by CTP of both mu and delta ligands probably
reflects a functional coupling of certain analgesic mu and delta
receptors, and does not indicate that CTP loses its mu
selectivity in vivo. This is supported by the finding that CTP
does not block the effects of delta agonists on the
gastrointestinal tract (Shook et al., 1986b). Due to its
peptidic nature, CTP does not readily cross the blood brain
barrier (Shook et al., 1986c). These results indicate that CTP
is an effective mu-receptor antagonist both in vitro and in vivo
which exerts delta analgesic antagonist properties in vivo. In
this study we evaluated the ability of CTP to precipitate
withdrawal in morphine-dependent mice after
intracerebroventricular (i.c.v.) and subcutaneous (s.c.)
administration. Naloxone HCl (given i.c.v. and s.c.) was used
as a standard for comparison.
M E T H O D S
Mice were made morphine dependent and tested for signs of opioid
withdrawal as previously described (Way et al., 1969). Briefly,
male ICR mice weighing 20-25 g were surgically implanted with 75
mg morphine-base pellets or placebo pellets (1 pellet/mouse)
under ether anesthesia. After implantation of pellets, mice
were housed 3 per cage under standard 12 h light, 12 h dark
conditions , and received food and water ad libitum. After 72 h
exposure to the pellets, mice were weighed, and then
administered i.c.v. or S.C. distilled water, CTP or naloxone.
Mice were observed for behavioral and physiological signs of
withdrawal for the 15 min period immediately following i.c.v.
injection, and for 2 consecutive 15 min periods following s.c.
administration. All signs were noted, including the following
characteristic signs of withdrawal: shakes and tremors,
defecation, diarrhea, wet dog shakes and jumping. Body weights
were measured again at 15, 30 and 60 min following injection in
order to determine if weight loss had occurred.
Naloxone HCl was purchased from Sigma (St. Louis, MO.).
Morphine-base pellets (75 mg each) were received from the
National Institute on Drug Abuse. CTP was synthesized by
methods previously described (Pelton et al., 1986).
I.C.V. injections were made in a total volume of 3.0 or 3.3 ul
according to the modified methods of Haley and McCormack (1957)
under light ether anesthesia. S.C. injections were made on a 10
ml/kg basis.
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RESULTS
Administration of naloxone by both i.c.v. (Table 1) and s.c.
(Table 2) routes of administration resulted in distinct opioid
withdrawal syndromes. The syndrome produced by i.c.v. naloxone
was characterized by dose-related increases in the occurrence of
shakes and tremors, defecation, diarrhea, wet dog shakes,
jumping and weight loss. Those mice treated with i.c.v. CTP
exhibited a pronounced withdrawal syndrome which was different
in some respects from that of naloxone (Table 1). Their
withdrawal syndrome was characterized by shakes and tremors,
grooming, defecation, wet dog shakes and weight loss. CTP
(i.c.v.) treated mice showed a greater incidence of wet dog
shakes and a greatly reduced occurrence of diarrhea and jumping
compared to naloxone (i.c.v. or s.c.) treated mice. Grooming
occurred after i.c.v. CTP both in morphine dependent and
morphine naive mice. Administration of s.c. naloxone (Table 2)
elicited effects similar to those produced by i.c.v. naloxone
(Table 1). In contrast, s.c. CTP produced defecation and modest
weight loss only, without causing any behavioral effects
(Table 2).
The results presented in Table 2 include behavioral observations
taken from the first 15 min following s.c. injections only,
because naloxone activity peaked during this time, and there was
no difference in the effects produced by s.c. CTP in either
period. Administration of distilled water to morphine dependent
mice caused no behavioral effects and only minimal weight loss
(mean±sem, % weight loss was 0.7±O.4 g for i.c.v. and 0.3±O.2 g
for s.c.).
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TABLE 1 Occurrence of Withdrawal Signs following intracerebro-
ventricular administration of Naloxone or CTP
Withdrawal Naloxone (ug, i.c.v.)a CTP (ug, i.c.v.)a
Sign 0.1 1.0 10.0 0.1 1.0 10.0
Shakes & Tremors
Grooming
Defecation
Diarrhea
Wet Dog Shakes
(mean±sem)b
Jumping
(mean±sem)b
>3% weight loss
4/8 8/8
0/8 0/8
3/8 8/8
0/8 3/8
1/8 8/8
13 8±3
0/8 0/8
0/8 6/8
8/8
0/8
8/8
8/8
8/8
16±4
8/8
40±12
8/8
7/8
8/8
4/8
0/8
8/8
25±4
0/8
4/9
8/8
8/8
7/8
0/8
8/8
52±8
0/8
6/8
8/8
8/8
8/8
1/8
8/8
48±8
2/8
19±14
8/8
(mean±sem)c 1.2±.2 4.2±.4 5.5±.5 3.3±3.1 4.3±.6 7.8±.5
a number of mice displaying sign/total number of mice tested
b mean±sem, number of times that sign was displayed
within 15 min after injection
(does not include those mice which did not show the sign)
c mean±sem, % weight loss of all mice tested
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TABLE 2 Occurrence of Withdrawal Signs following subcutaneous
administration of Naloxone or CTP
Withdrawal Naloxone (mg/kg, s.c.)a CTP (mg/kg, s.c.)a
Sign 0.01 0.10 1.0 0.01 0.10 1.0
Shakes & Tremors 0/5 3/5 5/5 0/5 0/5 1/5
Grooming 1/5 0/5 1/5 1/5 0/5 0/5
Defecation 5/5 5/5 5/5 3/5 5/5 5/5
Diarrhea 0/5 5/5 5/5 0/5 0/5 1/5
Wet Dog Shakes 1/5 5/5 5/5 0/5 1/5 0/5
(mean±sem)b 2 10±2 25±4 - 2 -
Jumping 0/5 4/5 5/5 0/5 0/5 0/5
(mean±sem)b - 63±20 88±28 - - -
>3% weight loss 0/5 3/5 5/5 1/5 0/5 0/5
(mean*sem)c 1.8±.6 3.2±.2 4.7±.5 3.3±2.2 1.2±.6 1.2±.3
a number of mice displaying sign/total number of mice tested
b mean±sem, number of times that sign was displayed
within 15 min after injection
(does not include those mice which did not show the sign)
c mean±sem, % weight loss of all mice tested
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DISCUSSION
The results presented herein demonstrate that CTP, given i.c.v.,
precipitates withdrawal in morphine-dependent mice, as would be
expected of an opioid receptor antagonist. The differences in
the profile of withdrawal signs elicited by i.c.v. CTP and
naloxone (differential stimulation of diarrhea, wet dog shakes
and jumping) may be explained by differences in their receptor
selectivities. Naloxone can interact with all known opioid
receptors (i.e. mu, delta and kappa). In contrast, CTP has no
kappa antagonist actions and except for analgesia, has no delta
antagonist actions. (CTP blocks delta analgesia through a
noncompetitive mechanism which may reflect a functional link
between certain mu and delta receptors). If CTP retains its
mu-receptor selectivity in the morphine-dependent mouse, then it
should precipitate only those effects associated with the mu
receptor. Due to its relative nonselectivity for the different
types of opiold receptors, naloxone may precipitate effects
associated with all opioid receptors rendered
dependent by chronic morphine treatment. According to this
hypothesis, shakes and tremors, defecation, wet dog shakes and
weight loss may be mu receptor mediated, while diarrhea and
jumping may not be mu mediated. Since it is not clear what
receqtors are effected by this method of inducing
morphine-dependence, it is difficult to determine which
receptors mediate the other effects, but possible candidates may
include the delta, kappa and epsilon receptors. Alternatively,
it is possible that a peptide opioid antagonist, such as CTP,
exhibits a somewhat different spectrum of withdrawal than an
alkaloid type antagonist, such as naloxone.
The relative inability of CTP to cross the blood brain barrier
affords the unique advantage of separating centrally from
peripherally mediated mechanisms. Results from this study
indicate that while the centrally located opioid receptors are
largely responsible for mediating withdrawal responses,
peripherally located opioid receptors can undergo withdrawal
while the brain is not withdrawn.
The grooming seen after i.c.v. CTP (not s.c.) in morphine naive
and dependent mice suggests that this effect is not a withdrawal
sign; its mechanism is unknown.
In summary, CTP, a putative mu receptor antagonist, precipitates
a withdrawal syndrome in morphine-dependent mice which is
somewhat different from that of naloxone. Unlike naloxone, CTP
can be used to separate centrally and peripherally mediated
opioid effects.
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Comparison of the Effects of
Cocaine and D-Amphetamine on the
Pharmacological Actions of
Methadone
Shean-Jang Liu and Richard I. H. Wang
Polydrug abuse and the increasing popularity of cocaine abuse
represent potentially serious clinical problems in the chronic use
of methadone. Our previous studies have shown that many centrally
acting drugs given concurrently with methadone can affect the anal-
gesic response and the development of physical dependence on metha-
done (Liu and Wang 1975, 1978, 1981). Severe side effects and death
among methadone maintenance patients are rarely attributed to metha-
done alone (Concool et al. 1979; Longwell et al. 1979). Indeed,
cocaine has been found to contribute to the death of methadone-
treated patients (Mittleman and Wetli 1984).
It is generally believed that many similarities exist between
cocaine and amphetamine in terms of subjective behavioral, pharmaco-
logical and toxicological effects (Jaffe 1980; Fishman and Schuster
1982). These two central nervous system (CM) stimulants have been
widely abused among drug addicts enrolled in methadone maintenance
programs. Cocaine addicts describe the euphoric effects of cocaine
in terms similar to those used to describe amphetamine effects.
Although there are many similarities of actions, the mechanisms of
actions and toxicity may not be the same. For example, the effects
of cocaine are brief, lasting only a few minutes after iv adminis-
tration, whereas the effects of amphetamine may last for hours
(Jaffe 1980). The phenomenon of increased amphetamine toxicity in
aggregated mice as compared to isolated mice has been well docu-
mented (Gunn and Curd 1940) and was confirmed in our experimental
conditions reported previously (Wang et al. 1969). To our knowledge
no laboratory studies exist demonstrating aggregated toxicity of
cocaine. The mechanisms of cocaine toxicity and lethality, long
considered a safe drug, are poorly understood. One report indicates
hyperthermia as an important contributor to cocaine death in dogs
(Catravas and Waters 1981). The purpose of the present studies was
to compare the effects of cocaine and d-amphetamine administration
on methadone analgesia and withdrawal and to evaluate cocaine toxi-
city and hyperthermic response in rodents.
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M E T H O D S
Animals and Chemicals. Male Swiss Cox mice (Harlan Lab, Indiana-
polis IN) and male Sprague-Dawley rats (Sasco Lab, Madison WI)
were used. The initial body weights of the mouse and rat were 24-
28 g and 100-200 g, respectively. Doses of cocaine·HCl, d-amphet-
amine SO4, dl-methadone·HC1 and naloxone·HCl are expressed in
terms of their salts. The experiments for mortality were carried
out using cages of standard size (24 cm x 18 cm x 18 cm) in air-
conditioned room maintained between 22° and 24°C. Mice were
placed individually for isolation or 9-10 per cage for aggregation
after injection of cocaine. Before the acute experiments, all
animals were fasted for 18 hr with free access to water.
Measurement of Analgesia and Rectal Temperature. Analgesia was
measured by a hot-plate method as described previously (Liu and
Wang 1975). No reaction on the hot plate (maintained at 58 ±
0.5°C) within 30 sec was considered as maximal response. Rectal
temperature was recorded by a thermistemp thermometer (Yellow
Spring Instrument Co, Yellow Spring OH).
Development and Assessment of Physical Dependence on Methadone.
Rats were rendered dependent on methadone by sc implantation for
7 days with an Alzet osmotic minipump (Alza Corp, Palo Alto CA)
containing 200 µ of 180 mg/ml methadone water solution. The
degree of physical dependence was assessed by administering a
challenging dose of naloxone (5 mg/kg, sc) following the 7-day
implantation. The incidences of naloxone-precipitated jumping and
wet-dog shakes were counted for 20 min and the degree of severity
of ptosls and teeth chattering were rated on a scale of 0-4 (with
4 being the most severe) during the 20-min observation period.
Body weight loss was calculated as a percent change of body weight
3 hr after administration of naloxone from the body weight taken
before naloxone injection.
Analysis of the regression line and calculation of LD50 were made
according to the computer programs of Tallarida and Murray (1981)
using an Apple II Computer. Significance was attributed at P<0.05
using Student's  t test.
R E S U L T S
Effect of Acute Cocaine and D-Amphetamine on Methadone Analgesia.
The intensity and duration of methadone analgesia were not affected
by cocaine (20 mg/kg, ip) given 30 min prior to administration of
methadone (4 mg/kg, sc). In both control and cocaine-treated rats
the maximal analgesic effect persisted for 30 min. Methadone anal-
gesia persisted for less than 2 hr in both groups of rats.
Similarly, d-amphetamine (5 mg/kg, ip) given 30 min before adminis-
tration of methadone (4 mg/kg, sc) did not significantly change the
analgesic response to methadone. The intensity and duration of
methadone analgesia in control and acute d-amphetamine-treated
groups were comparable.
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Cocaine Lethality in Isolated and Aggregated Mice. The 0-1 hr
and 0-20 hr mortality data of cocaine are presented in Table 1.
In both aggregated and isolated mice, most deaths occurred within
1 hr after administration of cocaine. Death was preceded by
clonic and tonic convulsions. There was a tendency towards en-
hanced acute lethality under aggregated conditions as compared to
isolated conditions. However, the LD50 of cocaine at 0-1 hr or
0-24 hr in aggregated mice was not significantly different from
the LD50 in isolated mice as shown in Table 1.
TABLE 1. COCAINE MORTALITY IN AGGREGATED AND ISOLATED MICEa
Aggregated Isolated
% Mortality % Mortality
Dose Number Number
mg/kg) of Mice 0-1 hr 0-20 hr of Mice 0-1 hr 0-20 hr
6 0 2 0 10.0 10.0 1 8 11.1 11.1
8 0 21 47.6 47.6 1 8 33.3 44.4
100 22 77.2 86.3 2 0 35.0 50.0
120 24 95.8 95.8 17 82.3 82.3
LD50 and 95% 81.9 80.5 96.6 90.6
confidence (73.9- (73.0- (84.2- (79.5-
limits (mg/kg) 90.7) 88.9) 110.8) 103.4)
a Cocaine·HCl was injected ip. The mortality was counted 1 and
20 hr after administration of cocaine.
Effects of Cocaine and d-Amphetamine on Rectal Temperature of Rats.
Acute cocaine (25 mg/kg, ip) treatment did not induce hyperthermia
during the 2-hr experiment on Day 1 in naive rats. After 7 days
of continuous infusion of cocaine (70 mg/kg/day, ip) through osmo-
tic minipump, there was no effect on rectal temperature. Rectal
temperature remained unchanged from 0-min control value during the
2-hr experiment on Day 8 after administration of cocaine (25 mg/kg,
ip). In contrast, the rectal temperature of naive rats was in-
creased from 0-min control value 15 min after administration of a
single dose of d-amphetamine on Day 1 (Table 2). The rectal tem-
perature stayed high during the 2-hr experiment. After 7-day im-
plantation with d-amphetamine, rats developed tolerance to the
hyperthermic effect of d-amphetamine. This phenomenon was evi-
denced by the fact that the rectal temperature did not go up but
stayed the same as the 0-min control value after the same chal-
lenging dose of d-amphetamine used on Day 1 was given on Day 8
(Table 2).
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TABLE 2. EFFECTS OF ACUTE AND CHRONIC d-AMPHETAMINE ON
RAT RECTAL TEMPERATUREa
Rectal Temperature (°C) After d-Amphetamine Injection
D a y 0-min 15-min 30-min 60-min 90-min
1 37.9±0.33 38.9±0.23* 39.6±0.20** 39.6±0.18** 39.8±0.19**
8 38.1±0.13 38.3±0.07 38.4±0.23 38.3±O.14 38.3±0.19
a Rats were given d-amphetamine (15 mg/kg, is) on days 1 and 8
for measurement of rectal temperature. After the 90-min tem-
perature was taken on Day 1, all rats were implanted ip for
7 days with osmotic minipump containing 200 µl of 150 mg/ml
d-amphetamine. Figures are mean ± S. E. for 7 rats.
* P<0.05; **P<0.01 compared with 0-min value.
Effects of Acute and Chronic Treatment with Cocaine or d-Ampheta-
mine on Naloxone-Precipitated Withdrawal Signs in Methadone-
Dependent Rats. Injection of naloxone to chronic methadone-
implanted rats elicited abstinence signs of precipitated wet-dog
shakes and escape attempts (jumping). Other abstinence signs
included teeth chattering, ptosis, diarrhea and body weight loss.
The effects of acute treatment with cocaine and d-amphetamine on
naloxone-precipitated withdrawal signs are presented in Figure 1.
Acute cocaine treatment did not cause any significant changes on
jumping, wet-dog shake, diarrhea and body weight loss, but signifi-
cantly decreased the degree of teeth chattering and ptosis elicited
by naloxone challenging. In contrast to the effect of cocaine
treatment, acute d-amphetamine treatment greatly increased the num-
ber of jumping and decreased the number of wet-dog shakes. Acute
d-amphetamine treatment also greatly decreased the degree of teeth
chattering, ptosis, diarrhea and body weight loss. When the doses
of d-amphetamine were 10 mg/kg or higher, most of the rats jumped
continuously right after administration of naloxone. The rats
then died preceded with very high rectal temperature and convulsion.
The effects of chronic pretreatment with cocaine and d-amphetamine
on naloxone-precipitated withdrawal signs in methadone-dependent
rats are summarized in Figure 2. Similar to the effect of acute
cocaine treatment, chronic cocaine pretreatment produced no signi-
ficant effects on naloxone-precipitated jumping and wet-dog shake
but decreased the degree of ptosis and diarrhea as compared to
control group. In contrast to the effect of chronic cocaine pre-
treatment, chronic d-amphetamine pretreatment greatly increased
the number of jumping. In addition, chronic d-amphetamine pre-
treatment almost completely abolished teeth chattering and ptosis
precipitated by naloxone. Similar to the effect of chronic co-
caine pretreatment, chronic d-amphetamine pretreatment caused
smaller degree of diarrhea as compared to control group.
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Figure 1. Effect of acute treatment with cocaine or d-amphetamine
on naloxone-precipitated withdrawal signs in methadone-dependent
rats. Rats were made dependent on methadone via sc implantation
for 7 days with osmotic minipump containing 200 µl of 180 mg/ml
methadone water solution. On Day 8, they were injected with
saline (2ml/kg, ip), cocaine (20 mg/kg, ip) or d-amphetamine
(7.5 mg/kg, ip) 30 min before a challenging dose of naloxone
(5 mg/ml, sc) was given. The withdrawal signs were counted or
observed for 10 min. Each bar and vertical line is mean ± S.E.
of at least 6 rats. ** P<0/01 from control.
Figure 2. Effect of chronic pretreatment with cocaine or d-
amphetamine on naloxone-precipitated withdrawal signs in methadone
dependent rats. Rats were implanted for 7 days with osmotic mini-
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pumps containing methadone (200 µl of 180 mg/ml, sc) plus either
cocaine (200 µl of 240 mg/ml, ip) or d-amphetamine (200 µl of 50
mg/ml, ip). Control rats were implanted with methadone and pla-
cebo minipump. After 7 days implantation, all rats were given a
challenging dose of naloxone (5 mg/kg, sc) and withdrawal signs
were counted or observed for 20 min. Each bar and vertical line
is mean ± S.E. of at least 6 rats. *P<0.05 and ** P<0.01 from
control.
DISCUSSION
The results of the present studies indicate some distinguishable
actions of cocaine from d-amphetamine in terms of toxicity and
their effects on methadone withdrawal signs. Amphetamine given
before administration of morphine has been shown to enhance mor-
phine analgesia in rats (Carenzi 1978). Our data showed that acute
administration of d-amphetamine or cocaine shortly before adminis-
tration of methadone exerted no significant effect on methadone
analgesia. Additionally, in a preliminary experiment, we found
that administration of cocaine 20 min before or after administra-
tion of a sublethal dose of methadone (40 mg/kg sc) did not signi-
ficantly change the mortality of methadone in naive rats.
Aggregated toxicity, a phenomenon with amphetamine, was not demon-
strated with cocaine. However, mortalities in the aggregated and
isolated mice tended to be higher than in that of isolated mice
when the doses of cocaine were higher than 60 mg/kg. It is inter-
esting to note that the majority of deaths occurred during the first
1 hr following cocaine administration. All deaths were preceded by
severe tonic and clonic convulsions.
Some investigators (Greenblatt and Osterbert 1981; Askew 1982) have
suggested that amphetamine-induced hyperthermia, causing damage to
the CNS. contributed to the increased lethality of amphetamine in
aggregated mice. It has been reported that tolerance developed to
the hyperthermic effect of the amphetamine in rats (Lewander 1971;
Gotestam 1976). The present studies confirmed this phenomenon and
also showed that acute and chronic administration of cocaine pro-
duced no effect on rectal temperature of rats. This observation
is not in agreement with Catravas and Waters (1981), who found that
acute cocaine administration in dogs produced a severe hyperthermic
response. However, it should be noted that lethal doses of cocaine
were used. Similarly, Wilson et al. (1976) reported that increases
in body temperature, respiratory rate and heart rate were seen only
after large iv doses of cocaine were given to rhesus monkeys. There-
fore, it is not surprising that changes in rectal temperature were
not observed in the present studies since we used nonlethal doses.
Whether cocaine produces hyperthermia in man appears to be contro-
versial. Resnick et al. (1977) reported that 100 mg by insufflation
had no effect on body temperature or respiratory rate but raised
heart rate and blood pressure. Fishman et al. (1976) reported that
core temperature remained constant during the 60-min period follow-
ing iv injection of 25 mg cocaine. Others, however, have reported
that cocaine decreases skin temperature measured by thermocouple
taped on the left index fingertip (Rowbotham et al. 1984).
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Acute administration of cocaine or chronic pretreatment with co-
caine together with methadone did not modify the naloxone-precipi-
tated characteristic methadone withdrawal signs. This result sug-
gests that cocaine neither affected the expression of abstinence
signs nor affected the process of development of physical dependence
to methadone. These results are in agreement with the report of
Steinberg (1978) that previous exposure to cocaine failed to influ-
ence the development of morphine dependence. Contrastly, Steinberg
(1978) showed that d-amphetamine did have an effect on the develop-
ment of morphine dependence. Results of our data indicate an
enhancement of characteristic abstinence signs when rats were given
a single dose of d-amphetamine or pretreated chronically with a com-
bination of d-amphetamine and methadone before administration of
naloxone. We have previously shown that desipramine given to metha-
done-dependent rats also intensified methadone withdrawal jumping
precipitated by naloxone (Liu and Wang 1981). The failure of co-
caine to elicite this response may indicate a difference in mechan-
ism or site of action.
Based on the results of our previous and present studies, it can be
concluded that the following differences exist between cocaine and
d-amphetamine with respect to their mechanisms of toxicities and
their effects on the pharmacological actions of methadone. Cocaine
differs from amphetamine in that there is no increased toxicity of
cocaine in aggregated mice as compared to isolated mice; it does
not produce hyperthermia in rats at nonlethal dose levels; it does
not enhance the naloxone precipitated withdrawal in methadone-
dependent rats; it does not increase the lethality of methadone in
naive rats; it does not increase the incidence of jumping and does
not inhibit wet-dog shakes in methadone-dependent rats; and cocaine
(25 mg/kg, ip) given shortly before a challenging dose of naloxone
does not cause death in methadone-dependent rats whereas all the
rats given d-amphetamine (10 mg/kg, ip) died within 40 min after
administration of naloxone. Cocaine resembles amphetamine in that
both drugs do not affect the analgesic response to methadone.
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Analgesics 4. Studies on the Effects of the Introduction
of Methyl at C-17 of N-Cyclopropylmethyl-Normorphine:
Synthesis, Receptor Binding, In Vivo Activity,
Conformation Energies
John A. Lawson, Lawrence Toll, Gilda H. Loew, Gernot Frenking,
Joseph I. DeGraw, Edward T. Uyeno, Willma Polgar, Norman
Camerman, Arthur Camerman, and D. Adhikesavalu
INTRODOCTION
Our interest in the origins of the antagonist activity that is
introduced when the N-methyl group of morphine is replaced by the
ally1 group of nalorphine (6), Table 1, led us to propose (DeCraw
et al, 1978) that different conformations of the N-ally1 group
could ellicit different receptor responses, i.e., agonism or
antagonism. Thus, if more than one N-ally1 conformation for
nalorphine were energetically available, then the known "mixed"
activity profile might be explained.
Calculations at that time confirmed that, indeed, nalorphine (6 )
has two low energy conformers as the N-ally1 group is rotated. In
order to test our proposal, we decided to replace one hydrogen on
the allyl-methylene carbon with one methyl group, since
conformation energy calculations suggested that, for 3R and 3S
(Table 1), only one low energy rotamer would remain of the two
found for the parent nalorphine (6), and that the single low energy
rotamers for R- and S-configurations would be different, each
corresponding to one of the two found for nalorphine. If
agonism/antagonism activity were modulated by the conformation of
the N-substituent, then perhaps 3R and 3S would no longer
demonstrate "mixed" activities and possibly manifest different
receptor selectivities. Our earlier paper described the subsequent
synthesis of mono-methylated analogs of N-n-propyl-normorphine (2 R,
2 S ) and of nalorphine (3 R, 3S). All were active compounds with
good opiate receptor affinities. We were disappointed to find that
3R and 3S, as well as 2R and 2S, when diastereomerically separated,
demonstrated very little difference in activity and affinity. In
the continued exploration of the effect of methyl addition to C-17
of the N-substituents of morphine, we report here studies of N-
cyclopropylmethyl-normorphine (5) and the two diastereomers 1R and
1S, shown in Table 1.
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M E T H O D S
Chemistry
A diastereomeric mixture of 1R, 1S was prepared in nearly
quantitative yield from N-normorphine and cyclopropyl methyl ketone
under reductive alkylation conditions (Borch 1972) with sodium
cyanoborohydride (Scheme 1). The desired N-alkylated product, as a
diastereomeric mixture 1R, 1S, was recovered as an off-white solid
(92% yield). 1R, 1S could not be separated by chromatography or
crystallization, unlike the related analog mixtures of 2R, 2S and
3R, 3S. However, the bis-benzoate ester derivatives 4R, 4S of 1R, 1S
were separable by both HPLC and fractional crystallization with
better than 99% purity by NMR. A detailed report of this synthesis
and complete high resolution NMR analysis of 1R and 1S will be
reported later, as will the details on the X-ray analysis. The
configuration at C-17 of 4R was confirmed as "r" by X-ray analysis
by Dr. Camerman, see Figure 2.
Scheme 1
Pharmacology
Pure diastereomers 1R and 1S, together with the parent compound N-
cyclopropylmethyl-normorphine (5 ), were tested for analgesic
agonist and narcotic antagonist activities in the mouse tail-flick
test. (Harris et. al., 1969.) For subcutaneous dosing the chemicals
were dissolved in 0.9% saline solution. Morphine sulfate,
nalorphine (6), and cyclaxocine (7) were evaluated as reference
drugs. In a dose-response study, conducted at the peak time,
percent agonism was calculated for each of the three dose levels.
The percentages were plotted against the log-dose to compute the
median effective dose (ED50) and 95% confidence limits. (Litchfield
and Wilcoxon, 1949.) For the evaluation of antagonist activity,
the tail-flick assay developed by Dewey, et al. (1969) was modified
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Fig. 2. X-ray structure for
4 R. (dibenzoate ester
of 1R).
Fig. 1 Rotational energies
(kcal/mol) for a) 1S, b) 1R,
and c) 5 about N-C-17 bond
(as function of , with
Newman projection view along
N-C17 bond for lowest rotamer
minima.
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to include retesting at several intervals.
Conformational Energy Calculations
Energy-conformational analyses of the N-substituents for isomers
1R, 1S and the parent 5 (Fig. 1) have been performed using the
empirical energy program MOLMEC. (Christoffersen, et al, 1981.)
The charges for the coulomb term in the seven-term energy formula
were taken from MNDO calculations. (Dewar and Thiel 1977.)
As shown in Figure 1, two dihedral angles, =C9NC17C19 and
=NC17C19H, define the N-substituent conformation. The energy of
rotation around N-Cl7 was calculated for fixed values of between
0° and 330° at intervals of 30°. For each value of was
optimized, starting with several different values of
Rotational energies reported in Figure 1 were obtained by
constrained optimization of all geometric parameters. holding 
fixed at the lowest energy values for each Minima found by
these constrained optimizations were refined by total geometry
optimization of all bond lengths, bond angles and torsion angles.
Receptor Binding
Binding studies and data analysis were conducted as described
previously. (Toll et al, 1984.) The tissues used were rat whole
brain, and cerebellum from frozen guinea pig brain (Pel Freeze).
Briefly, the tissues were homogenized in Tris buffer and washed
twice by centrifugation. Incubation volumes were 2.0 mL with final
tissue concentrations of 6.0 mg/mL original wet weight for rat
brain and 4.5 mg/mL for guinea pig cerebellum. Incubations were
for 1 h at 25°C prior to filtration and scintillation counting.
Results
Diastereomers 1R and 1S as well as 5 are all pure agonists in the
mouse tail-flick test,as shown in Table 1. An X-ray structure
analysis of the higher affinity diastereomer 1R shown in Figure 2,
indicated it is the C17-R isomer. 1R and 5 are about equally
potent, both being 5-10x more potent analgesics than morphine,
while 1S is about 30 times less potent than 1R and 5, Table 1.
This result is in surprising contrast to the results for the
related analogs cyclazocine (7 ) and nalorphine (6 ), which were
found to be pure antagonists in mice when the tail-flick procedure
was administered.
Studies (Aceto et al., 1968, and Archer et al., 1964) have shown
that both the species and the test used will affect apparent
agonism and antagonism. Analogs 5, 6 and 7 are reported to have
little or no analgesic agonist activity in the rat tail-flick and
be potent antagonists in the same test against meperidine or mor-
phine induced analgesia. Analogs 6 and  7 are also potent agonists
in the mouse writhing test and in humans.
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Table 1
ANALGESIC AGONIST AND NARCOTIC ANTAGONIST POTENCIES
(MOUSE TAIL-FLICK)
Compound Agonism a Antagonism
c of Morphinea
E D 5 0
b A D 5 0
b
1 R 0.57 (0.28 - 1.14)b >213
1 S 15.18 (7.59 - 30.36) >213
5 0.32 (0.13 - 0.80) >221
6 (nalorphine) 828.0 (548.9 - 1,250.36) 2.04 (1.44 - 2.87)
7 (cyclazocine) 294.8 2.84 (1.54 - 5.22)
morphine 2.95 (1.84 - 4.72)
a) subcutaneous, b) µmole/kg (95% confidence limits), c) Antagonism
of mouse tail-flick inhibition which is induced by 21.08 µ mol/kg
(s.c.) of morphine sulfate.
Binding studies were conducted with three [3H] ligands in two
tissues in order to determine affinities at µ-, -, and -receptor
sites. Shown in Table 2 are the affinities of 1R, 1S, 5 and a
number of compounds well characterized at µ, , and sites. The
affinities were obtained by analysis of receptor binding data using
the curve-fitting program LIGAND. (Munson and Rodbard 1980) In
guinea pig cerebellum the [3H] ligands used were [3H]EKC and [3H]
naloxone. In rat brain [3H]EKC, [3H]DADL, [3H]DSLET and [3H]DHM
were used. In both tissues, the data for inhibition for each [3H]
ligand by each of the other compounds listed were analyzed
simultaneously giving self-consistent affinity constants and
maximum binding capacities.
In guinea pig cerebellar membranes, a two site fit was preferred.
One site represents affinities at receptors. This site is
characterized by high affinity for EKC, U-50,488, 1R and 5. The
second site has moderate affinity for all the ligands tested. This
indicates µ and receptors are not present in guinea pig
cerebella. In rat brain membranes, a 3-site fit was preferred.
These sites can best be labeled µ and , and again a low affinity
site possibly unrelated to opioid activity. I f -receptors are
present in rat brain, the number of sites is sufficiently low so
that they were not discerned using these ligands.
KD values shown in Table 2 confirm that 1R and 5 have quite similar
affinity profiles. A 20-30 fold superiosy of 1R and 5 over 1S in
binding is consistently found at all sites. As reflected by their
affinities in rat brain and guinea pig cerebellum, 1R and 5 are
similar to the other cyclopropylmethyl analog (EKC) and have a high
affinity at - as well as at µ-sites.
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Table 2
AFFINITIES OF VARIOUS OPIOIDS
KD nM
Guinea Pig
Cerebellum
Rat Brain
Site 1 Site 2
E K C 4.72 172
N A L 52.6 47.6
DADL ---- ----
DSLET --- ----
D H M 333 52.6
U-50, 1.07 2500
1R 1.10 71.4
1 S 35.7 62.5
5 0.67 66.7
Site 1 Site 2 Site 3
1.32 20.4 164
---- ---- ---
4.35 2.50 23,000
16.1 1.56 12,600
0.53 151 18.2
270 14,900 3030
0.12 9.09 13.3
4.00 164 76.9
0.19 12.0 66.7
Bmax 18.4 93 13.8 8.9 74
(pmol/g)
The rotational profiles found for rotation around N-Cl7 ( ) are
shown in Fig.1. For each isomer the existence of three local
minima indicated by the rotational curves. The resulting local
minima ( A , B, C) are indicated by arrows in Figure 1. The Newman
projections along the N-Cl7 bond for the lowest of these minima are
also shown in fig. 1,
optimized values.
together with the relative energies and
For analog 5, two low-lying minima A and B are found with only 0.8
kcal/mol difference in energy, which; are separated by a rotational
barrier of ˜4 kcal/mol. The third rotamer C is 3.6 kcal/mol higher
in energy than A, and the barrier of rotation towards A and B is >
7 kcal/mol. For 1R and 1S, only one low-lying rotamer for each is
found corresponding to either the minimum B or A of 5,
respectively. We find that all low-lying conformations have trans-
configuration of the hydrogen atoms at nitrogen and C-17 (Figure
1).
For 1R the global minimum B is 2.3 kcal/mol lower in energy than
the next lower A, separated by a barrier of ~4 kcal/mol. The third
rotamer C is 4.4 kcal/mol higher than B. In case of the less
potent isomer 1S, the two higher lying minima B and C are ener-
getically more discriminated from the A minimum. A is 4.0 kcal/mol
lower in energy than than 5.3 kcal/mol lower than B. The X-ray on
the dibenzoate ester of 1R (Fig. 2) shows a value of 186° which
is in good agreement for the calculated value (183°) for 1R.
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Discussion and Conclusions
In the mouse tail-flick test, the N-CPM analog 5 is a pure agonist,
about ten times as potent as morphine. Addition of an -CH3 group,
making the C-17-position of the N-substituent chiral, does not
change this activity profile but appears to negatively affect the
relative receptor-binding affinity and agonist potency of one of
the diastereomers, 1S. The 1R isomer has nearly equal agonist
potency and µ-, -, and -receptor affinity as 5, while both the
agonist activity and -affinity of the 1S isomer is reduced by a
factor of 30. In general, the addition of a methyl group to C-17
does not produce much of a change in receptor selectivity.
Furthermore, relative agonist activity is parallel to both µ- and
-binding affinity. Thus, binding at either or both receptor could
initiate the observed analgesic activity in the mouse.
The addition of a methyl group to C-17 of 5, also affects the
conformational mobility of the N-cyclopropylmethyl substituent. In
compound 5, there are two nearly equi-energy conformers A and B
(Figure 1). Only one of these, B , remains low energy in the potent
1R isomer, while the other minimum, A
active isomer.
, is lowest energy in the less
These results indicate that rotamer B is likely
responsible for high-affinity binding at µ-, -  and -receptors and
for initiation of agonist activity. These results also suggest
that there are similar requirements for binding of the N-
substituent at and -receptors.
Observations of the mice during tail-flick analgesia testing
indicated no Straub-tail response at any dose, and obvious diuresis
at higher doses of 1R. In a preliminary test for addiction
liability, 5 and 1R showed no precipitated withdrawal symptoms in
the mouse-jump test of Saelens et al,(1971.) These observations
are consistent with the -receptor affinity of 1R and 5. More
definitive testing of 1R, both here and through the services of
CPDD is in progress. However, the binding data does suggest that
1R and 5 have good affinity for µ and -receptors, and this dual
mode of binding may explain the high analgesic potency of 1R
apparently free of addiction liability.
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The Effects of Amphetamine-Like
Designer Drugs on Monoaminergic
Systems in Rat Brain
J. W. Gibb, D. M. Stone, D. C. Stahl, and G. R. Hanson
ABSTRACT
The response of brain dopaminergic and serotonergic systems to
the amphetamine-like designer drugs, 3,4-methylenedioxyamp
amphetamine (MDA) and 3,4-methylenedioxymethamphetamine (MDMA),
was investigated and compared to methamphetamine (METH). Like
METH, single or multiple doses of either drug caused marked
reductions in both tryptophan hydroxylase (TPH) activity and
concentrations of 5-hydroxytryptamine (5HT) and 5-hydroxyin-
doleacetic acid (5HIAA) in several brain regions. The reduction
in 5HT content corresponded to the depression of TPH activity in
all regions examined.
In contrast to METH, which induced pronounced deficits in
dopaminergic neuronal markers, repeated doses of MDA or MDMA did
not alter striatal tyrosine hydroxylase (TH) activities or reduce
striatal dopamine concentrations. A single dose of MDA or MDMA
significantly elevated striatal dopamine content; however, after
repeated drug administrations dopamine concentrations were
comparable to control values.
The effects of MDA or MDMA administration in the rat brain are
reminiscent of those elicited by p-chloroamphetamine, a presumed
serotonergic neurotoxin.
INTRODUCTION
The amphetamine-like designer drugs, 3,4-dimethylenedioxyamphet-
amine (MDA) and 3,4-methylenedioxymethamphetamine (MDMA;
"ecstasy") have attracted recent attention by the public and the
scientific community. Because of the potential toxicity of
ecstasy, the DEA declared that MDMA is subject to Schedule I
control as of July 1, 1985. Over the past fifteen years, we have
described the neurochemical effects of toxic doses of methamphet-
amine (1971, 1973, 1976, 1980 and 1985). We now compare the
effects of these amphetamine-like designer drugs on neurochemical
parameters with those previously reported to occur with
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methamphetamine (METH). We observed that single or multiple
doses of MDA or MDMA produce neurochemical deficits in the
serotonergic system which are similar to those induced by METH;
in contrast, the response of dopaminergic pathways to these
agents and METH are very different.
MATERIALS AND METHODS
Drug Administration
Male Sprague-Dawley rats, weighing 200-275 g, were housed 5 per
cage and maintained at 26°C with a 12-hour alternating light-dark
cycle. All drugs were dissolved in 0.9% saline and administered
by subcutaneous injection. MDA and MDMA were hydrochloride salts
of racemic mixtures; doses are expressed in terms of the free
base. Subacute drug treatment consisted of 5 sequential doses at
6-hour intervals of either METH (15 mg/kg), MDA (10 mg/kg), or
MDMA (10 mg/kg). Control animals received similar injections of
saline vehicle alone.
Rats were sacrificed by decapitation 18 hours (subacute) or 3
hours (acute) after the last dose, and brains were immediately
removed and placed on ice. The neostriata, hippocampi, and
frontal cortex regions were removed bilaterally by dissection,
and stored at -70°C until assayed. One of the paired striata,
hippocampi, or cortex regions from each rat was assayed for TPH
and TH (striata only) enzyme activities, while the other was used
in the quantitation of and monoamine metabolite concentrations.
Enzyme Assays
All steps in the preparation of enzymes were performed at 0-5°.
Tissues were weighed and homogenized (1:3) in 50 mM HEPES buffer,
pH 7.4, containing 0.2% Triton X-100 and 5 mM dithiothreitol.
Homogenates were centrifuged at 27,000 x g for 15 minutes.
Duplicate 7.5-µ1 aliquots of the supernatant fraction from each
sample were analyzed for TH activity by a tritium release assay
(Nagatsu et al., 1964) utilizing 3H-tyrosine as substrate.
similar aliquots were assayed for TPH activity using a modified
CO2 -trapping procedure (Ichiyama et al., 1970; Sitaram and
Lees, 1978); details of the assay are described by Hotchkiss et
al. (1979).
Monoamine and Metabolite Assay
Tissue concentrations of dopamine (DA) and its primary metabo-
lites, 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic
acid (HVA), and 5-hydroxytryptamine (5HT) and its major metabo-
lite, 5-hydroxyindoleacetic acid (5HIAA), were measured by
high-performance liquid chromatography (HPLC) with electrochem-
ical detection. Tissues were weighed and homogenized in 0.3-0.5
ml mobile phase buffer containing 0.15 M monochloroacetic acid,
2.0 mM disodium EDTA, and 25 mg/l 1-octane sulfonic acid in 12.5%
methanol at pH 2.9. After centrifugation at 4080 x g for 15
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minutes the supernatant fractions were filtered through a 0.2-µm
Microfilter system (Bioanalytical Systems, Inc West Lafayette,
IN). Fifty-µ1 volumes were injected by a WISP™ automatic sample
processor (Millipore Cor., Millford, MA) onto a 3-µm reverse
samples were run on a LC-154 liquid chromatograph equipped with a
Microsorb C18 column (Rainin Instrument Co., Woburn, MA).
model LC-4B amperometric detector (Bioanalytical Systems, Inc.).
The detector potential was set at +0.73 V. Monoamines and their
metabolites were quantitated by measurement of peak heights and
comparison with those of standards of known concentration
prepared in mobile phase buffer.
RESULTS
Neostriatal TPH activity (Fig. 1) was dramatically depressed (to
less than 25% of control) after subacute administration of
Fig. 1. Effect of subacute drug treatments on neostriatal
tyrosine and tryptophan hydroxylase activities. Treatment
consisted of S.C. injection of MDA (10 mg/kg), MDMA (10 mg/kg),
or METH (15 mg/kg) every 6 hours for 5 doses. Rats were killed
18 hours after the last dose. Combined results from 2 experi-
ments (n 12) are presented as the means ± S.E.M., expressed as
percent control. Control (saline) values (in nmol liberated/g
tissue/h) were: TPH, 45.0; TH: 2645 nmol/g tissue/hr. *p<0.001
versus control, by the two-tailed Student's t test.
MDA (10 mg/kg), MDMA (10 mg/kg) or METH (15 mg/kg). Comparable
decreases were observed in the neurotransmitter, 5-hydroxytrypt-
amine (5HT) and its metabolite, 5-hydroxyindoleacetic acid
(5HIAA) after all three amphetamine analogs (Fig. 2). Similar
responses were observed in the hippocampus and frontal cortex
regions (data not shown).
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Fig. 2 Effect of subacute drug treatments on 5-hydroxytryptamine
(5HT) and 5-hydroxyindoleacetic acid (5HIAA) concentrations.
Results are the means ± S.E.M. from 2 experiments (n 12), express-
ed as percent control. Experimental conditions are described in
fig. 1. Control values (µg/g tissue) were as follows: 5HT,
0.469 and 5HIAA, 0.362.
The effects of each of the three drugs on the dopaminergic system
were examined; there was a major difference observed in the
response to MDA or MDMA compared to that observed after METH.
The characteristic decrease in striatal TH activity was observed
after METH (Fig. l), as has been previously reported (Koda and
Gibb, 1973), but no change was seen in TH activity after MDA nor
MDMA. In contrast to METH, neither MDMA nor MDA significantly
altered the concentrations of neostriatal dopamine but both drugs
elevated HVA concentrations (Table 1) and its metabolites.
Table 1. Effect of subacute drug treatments on neostriatal dopamine and its metabolites
Treatment Group Dopamine DOPAC HVA
Saline Control
MDMA 10 mg/kg
MDA 10 mg/kg
METH 15 mg/kg
8.2 ± .5 1.19 ± .12 .582 ± .032
7.5 ±  .4 1.20 ± .06 .673 ± .028*
8.0 ± .4 1.21 ± .07 .719 ± .026**
2.1 ± .4 ** .47 ± .08 ** .293 ±  .038**
Values represent µg/g tissue ± S.E.M.
n 12, **p< 0.001, * p< 0.02 versus control, by the two-tailed Student's test.
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When rats were administered one acute dose of MDA or MDMA, the
TPH activity was reduced to less than 50% of control 3 h after
receiving the drug. Concentrations of 5HT and 5HIAA were simil-
arly depressed in all three brain regions. Both MDMA and MDA
elevated neostriatal DA concentrations at 3 hr; MDMA, but not
MDA, also elevated HVA concentrations after this one acute dose
of the drug. MDA decreased DOPAC concentrations.
DISCUSSION
The present study provides evidence that both MDA and its
N-methylated derivative, MDMA, are selectively toxic to
serotonergic neurons in the rat brain. Ricaurte et al. (1985)
recently reported MDA-induced neuronal damage in hippocampal and
striatal regions of the rat brain, as well as decreases in
concentrations of 5HT and 5HIAA and in the number of serotonin
uptake sites. This selective effect of the 3,4-methylenedioxy
derivatives of amphetamine and methamphetamine on the sero-
tonergic system is in contradistinction to the effects of the
parent compounds, amphetamine and methamphetamine, which compro-
mise both the serotonergic and the dopaminergic system; neostri-
atal TH activity as well as dopamine, DOPAC and HVA are decreased
by METH and amphetamine.
The selective effect of MDMA and MDA on serotonergic parameters
is reminiscent of the response to p-chloroamphetamine by the
serotonergic system, but no effect is observed on the dopa-
minergic system after administration of this halogenated amphet-
amine. The explanation for this selective response is currently
under investigation.
In summary, administration of either MDA or MDMA caused a marked
decrease in TPH activity in selected brain regions; there is a
parallel decrease in the concentrations of 5HT and 5HIAA. No
change in dopaminergic parameters was observed. The similarity
to the effects of p-chloroamphetamine has interesting toxicologic
and regulatory implications as well as serves as a focal point
for studying the mechanism for this interesting response.
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Apparent Lesser: Physical Depen-
dence Potential of Nor-Diazepam
Compared to Diazepam in the Rat
Norman R. Boisse, John J. Guarino, and Gary M. Samoriski
Diazepam is the most widely prescribed benzodiazepine anxiolytic-
sedative-hypnotic, Its potential to induce chronic physical de-
pendence is now well recognized in man (Owen and Tyrer 1983) and
has been experimentally demonstrated in several animal species
(Lukas and Griffiths 1982; McNicholas and Martin 1982; McNicholas
et al., 1983; Gallaher et al., 1986). Although the nor-metabolite
accumulates more extensively than the parent drug in man, little
is known regarding the relative physical dependence potential of
diazepam and nor-diazepam. Recently, McNicholas et al. (1985)
described a spontaneous withdrawal syndrome for nor-diazepam
chronically treated dogs that was about three times more severe
than their historical standard, diazepam; however, only one chron-
ic dose level was studied for each drug.
To more critically compare the relative physical dependence po-
tential of diazepam and nor-diazepam, the following experimental
strategy was developed. First, the rat was chosen because unlike
man and dog, it eliminates diazepam and nor-diazeoam rapidly (t½=
l-3 hours) and nor-diazepam does not accumulate-(Caccia et al,
1980; Klotz 1979; Klotz et al., 1976; Friedman et al., 1986;
Marcucci et al., 1970). Cocequently, it is the administered
drug that is primarily responsible for dependence induction and
the parent drug/metabolite comparison is not confounded. Secondly,
to evaluate the degree of dependence, withdrawal was precipitated
with the receptor antagonist Ro 15-1788. A comparison of depen-
dence based on spontaneous withdrawal was abandoned because spon-
taneous withdrawal may be confounded by any differences in rates
of drug elimination (Boisse and Okamoto 1978). Finally, a wide
range of final chronic dose levels was studied to achieve a com-
prehensive and balanced comparison.
METHODS
Male Sprague-Dawley rats (350-575 gms, Charles River, Wilmington,
MA) were used and pair housed in an environmentally controlled
facility. Diazepam and nor-diazepam were suspended in 0.4% Agent
K (Bio Serv) and injected intra-gastrically by gavage twice daily
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(8 am, 6 pm); concurrent controls received isovolumic Agent K
(5 ml/kg). Rats were treated bid with diazepam (40 mg/kg or 75
mg/kg) or nor-diazepam (75 mg/kg) for 35 days followed by Ro 15-
1788 withdrawal precipitation 4 hours after the last AM dose.
Following the first precipitation session, chronic treatments
were continued at the same dose level for 4 more days and chronic
doses were progressively increased in a stepwise manner (110,
150, 250 and 400 mg/kg) and rats sequentially precipitated at
weekly intervals.
To test for dependence, rats were challenged with Ro 15-1788 four
hours after the last benzodiazepine dose. The dose 25 mg/kg,
i.p. was previously optimized to precipitate chlordiazepoxide de-
pendence in the rat (Boisse et al., 1982; 1985). The method of
withdrawal evaluation include operationa1 definitions for signs
and each of their grades and inter-observer reliability has been
reported (Ryan and Boisse 1983). Three or four independent
trained observers rated signs just prior to (t=O) and at t=5 and
the treatment. The intensity of individual signs (wd) and of
the syndrome (total WD) was estimated from the average rating of
all co-observers. To compensate for initial baseline differences
in total WD score and to more sensitively quantify the reaction
to Ro 15-1788 challenge, the initial WE score was subtracted
from the WD score obtained after Ro 15-1788 and is called the
delta (A) WD score.
Gross neurological testing included five different ladder and
open-field tests with operationally defined grades (Ryan and
Boisse 1983) which detected CNS depression. All grade points
accrued for these tests were pooled to give a TDP or "total de-
pression point" score.
RESULTS
Both chronic diazepam and nor-diazepam produced dependence in a
dose-dependent fashion. Dose-response analysis for the WD cri-
terion revealed non-parallel curves. The LDR curve calculated by
least squares was more steep for diazepam (slope = 7.3 ±  0.5 SE)
than for nor-diazepam (slope = 3.9 ±  0.7 SE); these slopes were
significantly different (P < .05). The two curves intersected at
the 150 mg/kg dose. For both drugs, maximum precipitated with-
drawal was obtained with the highest final dose studied. For
diazepam (250 mg/kg), the peak WD score was 16.2 (±  1.1 SE); for
nor-diazepam (400 mg/kg), it was 15.8 (±  0.9 SE). The maximum
peak WD score was not different for the two drugs, both drugs
were significantly greater (P < .001) than vehicle control (9.8
± 1.0 SE).
For the peak $WD criterion, maximum
significantly greater (t-test, P<.05)
precipitated withdrawal was
for diazepam (9.5 a 1.2 SE)
than for nor-diazepam (5.8 ±  1.3 SE) and both were significantly
greater (P < .05) than chronic vehicle controls (2.2 ±  0.8 SE).
The discrepancy in outcome for peak WD versus peak A WD criteria
for dependence are largerly due to differences in initial base-
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line WD scores before Ro 15-1788 administration. For nor-diaze-
pam, the initial WD score (9.9 ± 0.9 SE) was significantly greater
(P< .05) than for diazepam (6.7 ± 0.7 SE) or chronic vehicle con-
trol (7.8 ± 1.2 SE). The signs of spontaneous withdrawal for nor-
diazepam were reduced motor activity (1.2 points) and augmented
tactile evoked startle response (0.9 points). Reduced motor
activity is both a withdrawal sign for WD score calculation and
a sign of CNS depression for the TDP criterion. Nor-diazepam and
diazepam treated rats both showed ataxia and significant TDP
scores following the final chronic dose. Initial TDP scores were
significantly reduced following antagonist injection.
Analysis of intensities of individual signs (wd's) for maximal
syndromes (WD's) revealed 7 significant signs for diazepam, 9
signs for nor-diazepam. Both drugs showed curled claw, reduced
spontaneous motor activity, increased struggle on handling, high
step, and muscle hypertonus. Three signs were significantly more
severe for diazepam than for nor-diazepam: curled claw, saliva-
tion and blanced ears. Ear twitches and diarrhea were present
for nor-diazepam but absent for diazepam.
DISCUSSION
This study demonstrates that diazepam and nor-diazepam are cap-
able of inducinq severe physical dependence in the rat. The
failure of previous investigators to precipitate severe diazepam
dependence in the rat (McNicholas and Martin 1982) apparently
reflects inadequate dosing. For both diazepam and nor-diazepam,
a high rate of drug delivery must be maintained to compensate for
the rapid rate of elimination in order to achieve and maintain
dependence inducing tissue levels in the rat.
The maximal precipitated withdrawal syndrome for diazepam and
nor-diazepam was similar in severity based on the withdrawal
directly observed (peak WD criterion). Overall, the signs ex-
pressed were similar except that curled claw, salivation and
blanched ears were more pronounced for diazepam and ear twitches
and diarrhea were present only for nor-diazepam.
The dose-response curve for precipitated withdrawal (WD crite-
rion) was significantly more shallow for nor-diazepam than for
diazepam. For the peak WD criterion, the LDR curve for nor-
diazepam was not only more shallow, but reached a peak value
that was about half that of diazepam. These results suggest
that nor-diazepam may have a lesser apparent physical dependence
potential than diazepam. Coupled with the observation of con-
current spontaneous withdrawal and CNS depression before Ro 15-
1788 for nor-diazepam, these observations suggest that nor-diaze-
pam might be behaving like a partial agonist for dependence in-
duction. Alternatively, nor-diazepam and diazepam may differ in
their affinities and/or intrinsic efficacies to activate benzo-
diazepine receptor sub-types.
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Chronic Nicotine Exposure:
Studies on Water Intake, Body
Weight, Blood Pressure and
Behavior
M. D. Aceto, S. M. Tucker, J. R. Hinson, and G. S. Ferguson
Introduction
There is accumulating evidence that physical dependence plays an
important role in the continuation of the smoking habit, espe-
cially regarding nicotine intake (Pomerleau, et al., 1984,
Russell, 1978). However, a suitable animal model for studying
this phenomenon is lacking. In the hope of remedying this
situation, we have been studying the effects of chronic exposure
to nicotine in rats. In this study, we discuss our preliminary
findings on water intake, body weight, blood pressure and
behavior.
Methods
Adult male Sprague Dawley rats in the weight range 200-280g were
used in these experiments. They were housed individually in
wire mesh cages and had free access to food and water. The
vivarium was temperature controlled (23 ± 2°C) with alternating
light-dark cycles. The rats were allowed to acclimate to their
environment for 1 week before serving as experimental subjects.
The method of Teiger (1974) was used with some modifications.
Male rats were anesthetized and each was fitted with a specially
prepared cannula which was passed subcutaneously from the nape
of the neck to the lateral side of the lower abdomen and then
inserted in the peritoneal cavity. The cannula was attached to
a flow-through swivel mechanism which allowed the animal to move
about in the cage and to eat and drink normally. The swivel was
connected to a syringe pump. When stabilized and recovered,
they received continuous infusions of 8 ml of test solutions
every 24 h for 6 days. Then, nicotine or saline was abruptly
withdrawn and the animals were observed for 1/2 h at 6, 24, 48,
72 and 96 h after abrupt withdrawal.
In the experiments involving direct measurement of blood pres-
sure, the descending aorta was exposed and cannulated according
to the method of Weeks and Jones (1960). All statistical
comparisons were made using the Mann-Whitney U-Test.
Significant when p = 0.05 or less (Siegel , 1956).
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(-)-Nicotine was purchased from Aldrich Chemical Company
(Milwaukee, WI) and converted to the di 1 tartrate salt (Aceto
et al., 1979). All nicotine doses were calculated as base. All
drugs were dissolved in physiological sterile non-pyrogenic
saline solution (Travenol Labs., Dearfield, IL).
Results
As shown in Fig. 1, nicotine, at 10 mg/kg/day, promptly and
drastically curtailed water consumption during the first 24 h.
Thereafter, water intake alternately rose and fell during the
rest of the 6 day infusion period, suggesting that overriding
mechanism(s) were activated. When nicotine was abruptly with-
drawn, water intake rose dramatically and remained elevated
throughout the withdrawal period. Mecamylamine at a dose of 5
mg/kg/day did not block nicotine's hypodipsic effect during the
first 3 days. However, mecamylamine, alone and in combination
with nicotine, significantly increased water consumption begin-
ning on day 4.
Fig. 1. The effects of nicotine (10 mg/kg/day); mecamylamine,
(5 mg/kg/day); nicotine, (10 mg/kg/day); pluse mecamylamine
(5 mg/kg/day), and vehicle (8 ml/day) on water consumption of
rats during the infusion and abrupt withdrawal periods.
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The body weights of all the animals receiving nicotine either
alone or in combination with mecamylamine dropped significantly
(see Fig. 2). Those receiving vehicle or mecamylamine gained
weight throughout the infusion and withdrawal periods. These
results suggest that mecamylamine did not antagonize nicotine.
In turn, this argues against the involvement of cholinergic
mechanisms.
Fig. 2. The effects of nicotine (10 mg/kg/day); mecamylamine,
(5 mg/kg/day); nicotine, (10 mg/kg/day) plus mecamylamine
(5 mg/kg/day), and vehicle, (8 ml/day) on body weight during the
infusion and abrupt withdrawal periods.
In Fig. 3 are illustrated the results of dose response studies.
During the first 24 h, a suppression of drinking was obtained.
Then, alternating increases and decreases in water intake
occurred until day 4 when water consumption for the rats receiv-
ing 20.0 and 10.0 mg/kg/day rose dramatically during the infu-
sion period instead of during the abrupt withdrawal of nicotine.
At the lowest dose, the rise in water intake coincided with the
abrupt withdrawal of nicotine. These results show that increased
water consumption is not necessarily related to abrupt withdraw-
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al. Water consumption remained significantly elevated during
the withdrawal period at the highest dose. Another groups of
rats receiving 10 mg/kg/day of nicotine showed no significant
changes in blood pressure during infusion. However, on days 8,
9 and 10 during withdrawal, blood pressure was elevated
significantly.
In Fig. 4, dose-related decreases in body weight are evident
during the infusion. After abrupt withdrawal, the rats receiv-
ing the low dose showed significantly greater gains in body
weight than the animals receiving vehicle or 10 mg/kg/day of
nicotine. The rats receiving the highest dose of nicotine
rapidly regained weight, so that by day 10 they weighed nearly
as much as the vehicle controls.
Fig. 3. Dose response studies of nicotine (1.0, 10.0 and
20.0 mg/kg/day) and vehicle. (8 ml/day) on water consumption
and of nicotine (10 mg/kg/day) on blood pressure of rats during
the infusion and abrupt withdrawal periods.
In all these experiments no behavioral withdrawal signs were
seen. Instead, the animals were irritable when handled while
receiving nicotine.
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Fig. 4. Body weights of rats infused with nicotine (1.0, 10.0
and 20 mg/kg/day) or vehicle, (8 ml/day) during the infusion and
abrupt withdrawal periods.
Discussion
Apparently, overriding mechanisms are triggered when drinking is
severely restricted. The evidence indicates that this event is
related more to the degree of suppression of drinking than to
the abrupt withdrawal of nicotine and that little tolerance
develops to these effects. Mecamylamine, the nicotine antago-
nist, neither prevented the body weight loss nor blocked the
hypodipsic effect of nicotine during the first three days of
infusion. Afterward, the interpretation of the results is
confounded by the fact that the mecamylamine increased water
intake per se. Although additional doses remain to be tested,
the evidence at hand suggests that cholinergic mechanisms are
not involved in either the body weight or water consumption
changes.
A number of studies involving the chronic administration of
nicotine have reported decreased fluid intake and loss of body
331
weight or failure to gain weight (Falkeborn et al., 1981, Clarke
and Kumar, 1984, Wager-Srdar et al., 1984). However; the
"rebound" phenomenon has not been noted, possibly due to proce-
dural differences.
We believe that the results of this study, may have clinical
relevance. It is known that smokers weigh less than comparable
controls and that cessation of smoking usually results in weight
gain (Schiffman, 1979, Wack and Rodin, 1982). Further, twenty
percent of smokers indicated that control of body weight is an
important reason for smoking (Little, 1964). Neither human nor
animal studies have confirmed the inference that depression of
weight or growth is explained by decreases in food (Wack and
Rodin, 1982). Grunberg (1982) reported that nicotine admini-
stration to humans and rats was accompanied by decreased con-
sumption of sweet, high caloric food. Since specific food
consumption was not a factor in our experiments and since
changes in drinking and body weight occurred within the first 24
h, our results suggest that H20 regulation also plays a signif-
icant role in body weight changes.
Finally, Wenzel and Azmeh (1970) reported that withdrawal of
chronically administered low doses of nicotine produced marked
fluctuating rises in blood pressure of rats. Nicotine was
administered via the drinking water for up to 14 weeks. In our
studies, we showed a significant rise during withdrawal after
only 6 days administration of nicotine. It is clear that
chronically administered nicotine has pronounced effects on
blood pressure and the implications are many. For example, it
is possible that a heavy smoker and/or hypertensive who discon-
tinues smoking may undergo a prolonged period of increased blood
pressure. Obviously, more studies are indicated on this aspect
of nicotine effects.
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Cocaine Inhibition of Locus
Coeruleus Neurons
D. K. Pitts and J. Marwah
The recreational use of cocaine has escalated dramatically over
the past decade (Kozel and Adams 1984). In recent years, concern
has been expressed over the larger doses being self-administered
and the more widespread "destructive" use of the drug (Kozel and
Adams 1984). Although cocaine is known to have both potent local
anesthetic and sympathomimetic properties (Ritchie and Greene
1980), relatively little is known about the mechanisms that
contribute to the central "stimulant" effects at the level of
the single identified neuron. The modulatory action of cocaine
on catecholamine neurotransmission (blocks catecholamine
reuptake) is generally thought to be important in producing the
central stimulant actions of cocaine (Gold and Verebey 1984).
The present study was undertaken to determine the effects of
systemically administered cocaine HCl on the electrical activity
of single spontaneously firing noradrenergic neurons in the rat
locus coeruleus.
M E T H O D S
Male Sprague-Dawley rats (170-280 g) were anesthetized with
urethane (1.25 g/Kg, i.p.), intubated following a tracheotomy,
and allowed to breathe spontaneously. Body temperature was
monitored by a rectal probe and maintained at 37 +/- l°C.
Animals were placed in a Kopf stereotaxic instrument for
extracellular recordings. Glass micropipettes (Radnoti-quikfill)
filled with 2M NaCl and saturated with fast green, tip diameter
1µ were stereotaxically directed toward the locus coeruleus
through a bur hole 1.1 mm posterior to lambda and 1.1 mm lateral
to midline. Noradrenergic LC neurons were generally encountered
at a depth of 5.0-6.0 mm below the skull surface and identified
by the following criteria: a) a characteristic positive-negative
long duration ( 2msec) waveform; b) the presence of cells of
the mesencephalic nucleus of cranial nerve V (trigeminal), which
could be activated by moving the lower mandible and were found
just lateral to the LC recording area; c) acceleration of firing
rate followed by inhibition when pressure was applied to the
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contralateral hindpaw; d) location of cells below a zone of
electrical silence corresponding to the fourth ventricle; e) a
firing rate of 0.5-5.0 Hz and f) inhibition of firing rate
produced by small ( 10 µg/Kg) systemic doses of clonidine. Only
one neuron per animal was studied. Drugs were administered
through a catheter placed in the lateral tail vein (i.v.) or by
the intraperitoneal (i.p.) route. Additional details of the
electrophysiological recording procedure can be obtained from
previous reports (Marwah and Aghajanian 1982; Marwah et al.
1983). Data analysis was accomplished using either the
two-sample t-test or analysis of variance. A "P" value less than
0.05 was considered significant in statistical tests. Data is
expressed as mean ± standard error.
RESULTS
Intravenous cocaine inhibited single identified spontaneously
firing noradrenergic LC neurons. The time course for the
inhibitory effects of 0.25 and 2.0 mg/Kg of cocaine (C) on the
spontaneous activity of LC neurons from two different animals is
shown in Figure 1, panel A and panel B respectively. Prior
administraton of physiological saline (S) did not elicit any
discernable effect on either neuron.
FIGURE 1
Histograms illustrating the effects of intravenous cocaine (C;
0.25mg/Kg-Panel A; 2mg/Kg-Panel B) or physiological saline (S,
0.2ml) administration on the activity of single LC neurons from
two different animals. Each bar represents counts per 10
seconds.
The dose-dependent nature of the cocaine mediated inhibition of
spontaneously firing LC neurons is depicted in Figure 2. The
data is expressed as mean percent inhibition two minutes
following cocaine injection as a function of the mean firing
rate for a two-minute period prior to drug administration. All
of the cocaine doses except the lowest, 0.0625 mg/Kg dose,
produced inhibition of spontaneous LC firing rate significantly
greater than that of saline controls P 0.01.
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Administration of procaine (1mg/Kg i.v.) to individual LC
neurons (see Figure 3A) did not produce any discernable effect
on firing rate or spike amplitude. The effects of intravenous
FIGURE 2
Bar graph depicting the dose-response relationship for the
effects of intravenous cocaine or saline (S) on the activity of
single LC neurons. Each bar represents mean percent inhibition
two minutes after cocaine administration and was expressed as a
function of the mean firing rate for 12 consecutive-ten second
bins prior to drug administration.
procaine were also assessed by constructing a cumulative
dose-response relationship (successive individual doses = 0.25,
0.25, 0.5, 1.0, and 2.0 mg/Kg). Procaine in cumulative doses of
0.25, 0.5, 1.0, 2.0, and 4.0 did not elicit any significant
effects (P .20) on LC neurons (n=4 animals) when compared to
saline controls (see Table 1). Percent inhibition was calculated
as stated above.
The activity of some of the slower firing (<1.5 Hz) LC neurons
was sometimes completely suppressed by cocaine. Figure 3B shows
a single slow spontaneously firing LC neuron that was completely
inhibited by intravenous cocaine (1mg/Kg). Subsequent
administration of the specific alpha-2-adrenoceptor antagonist,
piperoxane (250 µg/Kg, i.v.) reversed the inhibitory effects of
cocaine within one minute following administration. Another
spontaneously firing LC neuron depicted in Figure 3C was also
completely suppressed by intravenous cocaine (1mg/Kg). When
pressure was applied to the contralateral hindpaw (toe pinch;
tp) the cell was activated indicating its continued presence at
the electrode tip. Subsequent administration of the specific
opiate receptor antagonist, naloxone (1mg/Kg, i.v.) did not
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FIGURE 3
Histograms illustrating the effects of various treatments on the
activity of single LC neurons from three different animals (A, B
and C). Each bar represents counts per 10 seconds. Panel A:
effects of intravenous saline (S, 0.2ml) and procaine (Pr, 1
mg/Kg). Panel B: effects of cocaine (C, 1 mg/Kg i.v.) and
piperoxane (Pi, 250 µg/Kg i.v.). Panel C: effects of intravenous
cocaine (C, 1 mg/Kg). pressure on the contralateral hindpaw (toe
pinch; tp). naloxone (N, 1 mg/Kg i.v.) and piperoxane (Pi, 250
µg/Kg i.v.).
reverse the inhibitory effects of cocaine on the LC neuron,
eventhough pressure on the contralateral hindpaw could still
accelerate the cell (tp x 2). The inhibitory effects of cocaine
were, however, reversed by piperoxane (250 µg/Kg, i.v.).
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TREATMENT
TABLE 1
EFFECT OF PROCAINE ON FIRING RATE OF LC NEURONS
SALINE PROCAINE (mg/Kg)
0.25 0.5 1.0 2.0 4.0
± 2.5
1.2 * -6.1 6.4 -6.2 -5.0 -6.4
10.3 6.7 5.3 3.6 19.0
* Mean percent inhibition ± standard error.
The response of LC neurons to cocaine (1mg/Kg) was significantly
(P<0.01) attenuated when animals were pretreated with
yohimbine (n=6; 5mg/Kg, i.p.) twenty minutes prior to cocaine (1
mg/Kg) challenge (data not shown). The mean percent inhibition
of spontaneous activity by cocaine treatment in the presence
(n=6) or absence (n=12) of yohimbine was 29.2 ± 4.3 percent and
61.3 ± 7.7 percent respectively.
D I S C U S S I O N
Our data indicates-that noradrenergic neurons of the rat locus
coeruleus are exquisitively sensitive to systemically
administered cocaine. All of the spontaneously firing LC neurons
receiving doses of cocaine greater than 0.0625 mg/Kg i.v. were
inhibited (n=41). The inhibitory effect of cocaine on LC neurons
was clearly dose dependent for the range of doses employed in
this study (0.0625-2 mg/Kg, i.v.). The mechanism(s) by which
cocaine inhibits LC neurons could encompass either a direct
effect on the LC neurons or indirect effects mediated by other
neurons impinging on the LC. Cardiovascular alterations
(increase in mean arterial pressure) resulting from systemic
cocaine administration were not temporally correlated with the
changes observed in LC neuron firing rate (data not shown). The
local anesthetic properties of cocaine also do not seem to
contribute to the inhibition of spontaneous LC activity
observed, since the structurally related local anesthetic,
procaine, in doses up to 4 mg/Kg i.v. was without significant
effect.
The existence of alpha-2-adrenergic and opiatergic
neuroreceptors on noradrenergic LC neurons has been previously
demonstrated (Bird and Kuhar 1977; Cedarbaum and Aghajanian
1976; Korf et al. 1974; Marwah and Aghajanian 1982). In the
present study reversal of the effects of cocaine on LC neurons
was observed with the specific alpha-2-adrenoceptor antagonist,
piperoxane (i.v.), but not the specific opiate receptor
antagonist, naloxone (i.v.). Furthermore, pretreatment with the
specific alpha-2-adrenoceptor antagonist, yohimbine (i.p.)
significantly attenuated the effects of cocaine on spontaneously
338
firing LC neurons. These results suggest that the inhibition of
LC neurons by cocaine is mediated by alpha-2-adrenoceptors. At
present it is unclear whether an interaction of cocaine with
adrenoceptors may be mediated by a direct or an indirect
mechanism. However, these results are not inconsistent with an
increase in synaptic levels of catecholamines secondary to a
blockade of catecholamine reuptake. Studies employing inhibitors
of catecholamine synthesis and/or storage should clarify this
issue. The source of catecholamines mediating the effects of
cocaine may originate from the LC or other catecholaminergic
neurons that impinge upon the LC.
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Opiate Receptor Mediated Regula-
tion of the Immune Response
In Vivo
R. J. Weber, B. Ikejiri, K. C. Rice, A. Pert, and A. A. Hagan
Evidence has accumulated over the years that the immune and
neuroendocrine systems are interconnected at several levels,
the sharing of specific receptors and their regulatory mole-
cules being among the most notable. The presence of opiate
receptors (Wybran et al., 1979; McDonough et al., 1980; Mehrisi
and Mills, 1983; Johnson et al., 1982; Madden et al., 1982) and
non-opiate like receptors (Hazum et al., 1979; Schweigerer et
al., 1985) on leukocytes, coupled with the identification of
endorphin-like substances being produced by these cells, places
the endogenous opiates and the opiate receptor in an ideal
position to be an internal regulator of the immune system and
to form a portion of a larger neuroimmunoendocrine network. An
increasing number of publications has described the effects of
endogenous opiate peptides on parameters of immunocompetence
and has been reviewed (Weber and Pert, 1984). These parameters
include in vitro antibody (Ab) production, responsiveness  to
mitogenic stimulation, and natural killer (NK) cell activity.
Some of the early suggestions, however, that the immune system
could be affected by opiates were based on studies of the
immunologic status of heroin addicts (Louria et al., 1967;
Sapira, 1968). The peripheral blood lymphocytes from addicts
exhibited decreased proliferative responses to mitogens, though
serum IgM levels were increased. Subsequent studies in mice
injected repeatedly with morphine revealed a similar reduced
ability to respond to concanavalin A, the effect being more
pronounced in females than males (Brown et al., 1974).
Furthermore, it has been shown recently that injection of rats
with 30 to 50 mg/kg of morphine for four days caused
suppression of natural killer cell activity and increased
mortality in rats challenged with a syngeneic tumor (mammary
adenocarcinoma). Suppressed NK cell activity could be observed
three hours after a single injection subcutaneously or
intracerebroventricularly; the morphine effect was reversed in
each case by naltrexone (Shavit et al., 1985). These results
suggested that opiates could be directly involved in altering
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immune responsiveness, although indirect effects mediated
through neuroendocrine pathways or other organ systems affected
by repeated morphine administration are difficult to rule out.
MORPHINE SUPPRESSES ANTIBODY PRODUCTION IN VIVO
We have studied the effects of morphine administration on the
production of antibody in Balb/c mice immunized with
trinitropheny140-ovalbumin (TNP-OVA). Morphine was chronically
infused into animals from an implanted source. Blood was
collected from animals on day 6 following immunization. Serum
Ab levels to trinitrophenyl-bovine serum albumin were
determined using a solid phase enzyme-linked immunosorbent
assay (ELISA). Administration of natural (-)-morphine sup-
pressed the primary response (day 6) to TNP-OVA in vivo (Figure
1).
Figure 1. Morphine-induced suppression of antibody production
in vivo. Mice implanted with a 75 mg morphine pellet and
injected with 100 ug TNP-OVA on day 0 exhibit significant
reduction by day 6 in serum antibody titers to TNP, as assayed
by an ELISA procedure. Antibody levels in sham and control
animals are equivalent, whereas morphine-implanted mice are
significantly depressed (p 0.02). Data represent means ±
standard error (SE) (n=4/group).
MORPHINE-INDUCED IMMUNOSUPPRESSION IS T-DEPENDENT
The generation of an Ab response to TNP-OVA requires the
participation of B cells (Ab-producing cells), T cells (thymus-
derived lymphocytes), and macrophages (antigen processing
cells). The suppression of the Ab response to TNP-OVA could
hypothetically be due to a direct or indirect effect on any or
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all of these cell types. Trinitrophenol, covalently conjugated
to Ficoll (a repeating polymer) , stimulates the production of
antibody without the requirement for accessory cells on T
cells. Therefore, TNP-Ficoll is referred to as a T-independent
antigen, as opposed to TNP-OVA, a T-dependent antigen. This
distinction provides us with a tool through which we can begin
to examine which cell or cells of the system are affected by
morphine (Figure 2). Chronic morphine infusion has no effect
on the Ab response to TNP-Ficoll, suggesting that opiates do
not affect B cells directly but that the suppression is
mediated directly or indirectly through T cells or macrophages.
Figure 2. Lack of morphine-induced suppression in vivo to TNP-
Ficoll. Mice immunized against 1.5 ug TNP-Ficoll fail to
exhibit depressed serum antibody levels on day 6 in response to
an implanted 75 mg morphine pellet. Data represent means ± SE
(n=3/group).
NALOXONE REVERSAL OF MORPHINE-INDUCED IMMUNOSUPPRESSION
In order to determine whether the observed suppression of Ab
production was caused via an interaction of morphine with the
opiate receptor, we examined the effects of an opiate
antagonist on the response. Simultaneous co-implantation of a
(-)-naloxone pellet with the morphine pellet was sufficient to
reverse the morphine-induced suppression of the primary Ab
response to TNP-OVA (Figure 3). Naloxone alone had no effect
when compared to a group of immunized controls.
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Figure 3. Naloxone reversal of morphine-induced antibody
production in vivo. Mice immunized against 100 ug TNP-
ovalbumin were implanted with 75 mg morphine or morphine plus
25 mg naloxone pellets. Serum taken on day 6 shows a
significant reduction (p 0.01) of antibody production in the
morphine-implanted mice, but the effect is reversed in the
morphine-naloxone implanted animals (p 0.05). Data represent
means ± SE (n=5/group).
IMMUNOSUPPRESSION INDUCED BY MORPHINE IS STEREOSPECIFIC
Further experiments were designed to compare the effects of
(-)-morphine with (+)-morphine which does not bind to opiate
receptors. When each compound was administered to different
groups of mice, (-)-morphine demonstrated the expected
suppression of Ab production, whereas the unnatural (+)-
enantiomer of morphine had no significant effect (Figure 4).
These experiments, coupled with naloxone antagonism of the
effect, strongly suggest that morphine induces an in vivo
immunosuppression by acting via the opiate receptor.
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Figure 4. Stereospecificity of morphine-induced antibody
production in vivo. Mice immunized against 100 ug TNP-
ovalbumin were implanted with 75 mg (+)-morphine, the inactive
enantiomer, or (-)-morphine. On day 6, sera were assayed for
antibody levels. The (+)-morphine does not significantly
reduce in vivo antibody production (p 0.051, where as
(-)-morphine does (p 0.01). Data represent means ± SE (n3-
4/group).
LYMPHOKINE ACTIVATED KILLER (LAK) CELL ACTIVITY IS SUPPRESSED
IN MICE INJECTED WITH MORPHINE
Interleukin-2 (IL-21 is a T-lymphocyte derived, hormonal-like
peptide (lymphokine) which stimulates the growth and
differentiation of activated lymphocytes from several species
in vitro and in vivo. Normal lymphocytes when incubated in IL-
2 for several days can be induced to develop into lymphokine
activated killer (LAK) cells (Grimm et al., 1982; Grimm and
Rosenberg, 1984). These cells are capable of lysing tumor cell
lines and fresh tumor targets in vitro and can be used in
adoptive immunotherapy to cause regression of tumors in vivo
(Mazumder and Rosenberg, 1984; Mule' et al., 1984).
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We have investigated the cabability of LAK cells generated from
Balb/cj mice injected with 50 mg/kg of morphine daily for 3
days to lyse a human tumor target (DAUDI) in a short-term
chromium-51 (51Cr) release assay. Table 1 shows the percentage
of total 5lCr released at various effector to target ratios by
LAK cells generated from morphine-injected mice in comparison
to saline-injected mice. These data show a decreased capacity
of LAK cells generated from mice injected with morphine to lyse
a tumor target. These preliminary data suggest that use of
morphine in patients undergoing adoptive immunotherapy may be
contraindicated.
TABLE I
Generation of LAK Cell Activity by Recombinant IL-2 From
BALB/CJ Mice Injected with Morphine
LAK Activity After IL-2 Activation
(% lysis of DAUDI)
Treatment
Morphine
50 mg/kg
80:1 2O:l 5:l
36.7 15.5 -2.7
Saline 47.0 25.5 4.2
In summary, (-)-morphine induces an immunosuppression of an
early event in the T-dependent, primary Ab response to TNP-OVA
in vivo. This opiate-mediated immunosuppression is naloxone
reversible and stereospecific, properties which suggest that it
is mediated through the opiate receptor, which has been
identified on cells of the immune system (see Madden et al.,
this meeting). These results imply that opiates might have
direct influences on the immune system, though in vivo effects
mediated through other organ systems affected by repeated
morphine administration are difficult to rule out. The
findings of Shavit et al., (1985) that ICV administration of
morphine is more effective than a peripheral administration
suggests that morphine may regulate the immune system
indirectly by altering various neuroendocrine mediators of
immunosuppression. Such neuroendocrine factors may also play a
role in the suppression of Ab production and the inability to
generate LAK cells that we observe. In any case, it seems
likely that a network of cells in the brain, glands, and immune
system communicate through shared receptors and regulatory
molecules and that this neuroimmunoendocrine network has a
major role in health and disease. It is applicable to the
subject of this meeting that the study of opium alkaloids
(Rice, 1985), the opiate receptor and endogenous opiate ligands
has contributed greatly to this revelation.
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Novel Biochemical Determinants
in the Preclinical Evaluation
of Opiates
Fedor Medzihradsky
INTRODUCTION
Research in the field of opioid receptors has received a major
impetus by the identification of ligands with high selectivity
toward receptor types, e.g., mu (sufentanil, DAGO), kappa
(U50,488, U69,593), and delta (DSLET, DPDPE). The use of such
compounds has enhanced the classification of opioid receptors in
brain membrane binding assays (Goldstein and James 1984) and in
bioassays with smooth muscle preparations (Gillan and Kosterlitz
1982). We have initially established a procedure for the assay
of opioid receptor binding in brain membranes, based on the
competitive displacement of stereospecifically bound 3H-
etorphine under equilibrium conditions (Medzihradsky 1976).
Using this assay, we have since 1977 determined the opioid
receptor binding of about 600 compounds, tested within their
preclinical evaluation as opiates (e.g., Medzihradsky 1978;
Woods et al. 1986). In the course of these studies, we have
correlated the receptor binding affinity in brain with the
responses elicited in the guinea-pig ileum and mouse vas
deferens preparations (Smith and Medzihradsky 1981, 1986), and
with behavioral characteristics displayed in the rhesus monkey
and pigeon (Woods et al. 1979). In addition to investigating
equilibrium binding (Fischel and Medzihradsky 1981), we have
studied the kinetics of ligand interaction with multiple opioid
receptors (Fischel and Medzihradsky 1986), and have described a
classificaiton of mu and kappa opiates on the basis of their
differential sensitivity toward sodium in binding to opioid
receptors (Medzihradsky et al. 1984). Recently, alkylation of
the membrane preparation with the irreversible opioid antagonist
-CNA in the presence of receptor-selective opiates was used to
investigate the specificity of ligand binding (James and
Goldstein 1984).
However, none of the above outlined approaches provides informa-
tion on the efficacy of ligand binding to opioid receptor. The
assessment of ligand binding to receptor in brain membranes has
to be complemented by a functional assay of effector response.
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We have linked the occupancy of opioid receptor to the stimula-
tion of GTPase in brain membranes (Barchfeld and Medzihradsky
1984; Clark and Medzihradsky 1985), and to the inhibition of
adenylate cyclase in brain slices (Barchfeld et al. 1982). The
assay of opioid receptor coupling to GTPase in isolated brain
membranes can now be carried out under conditions of routine
work, i.e., good precision, sensitivity and capacity. This
functional assay distinguishes between opioid agonists and
antagonists, and has revealed different characteristics of mu,
kappa and delta opiates, particularly pronounced in brain
membranes alkylated to provide specificity for one type of
opioid receptor (Clark and Medzihradsky 1985, 1986; Clark et al.
1986).
METHODS
Membrane preparation (Fischel and Medzihradsky 1981). Membranes
from rat cerebrum and regions of the monkey brain were isolated
by differential centrifugation as described. Aliquots of the
membrane suspension were kept frozen until use.
Receptor alkylation (Clark et al. 1986). Membranes were incuba-
ted at 25° with either -FNA or Superfit, or both. Subse-
quently, the membranes were thoroughly washed by centrifugation
and resuspension. Alternatively, the membranes were incubated
w i t h -CNA in the presence of protecting concentrations of
either sufentanil (mu receptor), U-50, 488 (kappa receptor), or
DSLET (delta receptor).
Binding assay (Medzihradsky et al. 1984). The investigated
opiates compete with 3H-etorphine for bindlng to opioid receptor
in brain membranes. After incubation at 25° to reach binding
equilibrium, the suspension of brain membranes in the assay
medium was quickly filtered and the bound radioactivity
determined. The binding affinity of the tested compound is
expressed as EC50 in displacing specifically bound 
3H-etorphine.
GTPase assay (Clark et al. 1986). The assay is based on the
release of inorganic phosphate from (gamma-32P)GTP in the
presence of different concentrations of opiates. The released
32P-phosphate was separated from nucleotides by adsorption on
charcoal, and the radioactivity determined by liquid
scintillation counting. The results are expressed as
concentration of a compound to produce half-maximal stimulation
of GTPase (KS), and as maximal enzyme stimulation (Smax).
RESULTS AND DISCUSSION
The enhancement of brain GTPase by opiates (Table 1) fulfilled
the criteria for mediation by opioid receptor. The stimulation
was limited to agonists, and blocked by opioid antagonists
(Barchfeld and Medzihradsky 1984; Clark and Medzihradsky 1986).
The rank order of the KS values for various opioid agonists
350
corresponded to that of their binding affinity to opioid
receptor. Except in monkey midbrain (Table l), kappa opiates
stimulated brain GTPase to a lesser extent than mu and delta
ligands of similar binding affinity. Various opioid antagonists
(including naloxone, naltrexone, ICI 174,864 and MR 2266) did
not induce coupling of opioid receptor to GTPase, but displayed
selectivity in inhibiting the effect of agonists. E.g, ICI
174,864 blocked GTPase stimulation by DSLET and DPDPE, but not
by sufentanil or bremazocine (Clark and Medzihradsky 1985).
TABLE 1
Stimulation of GTPase in monkey brain
Opiate
Stimulation of GTPase activity
Brain region KS (µM) Smax (%)
frontal cortex
Levorphanol 20 33
Bremazocine 24
DSLET 4 13
striatum
Levorphanol 27 21
Bremazocine 21 13
DSLET 5 26
midbrain
Levorphanol 30
Bremazocine 31
DSLET
25
24
5 23
In order to study the coupling of individual opioid receptor
types to GTPase, brain membranes were alkylated by two different
approaches. Both direct and protective alkylation conveyed
specificity of brain membranes toward mu, delta or kappa opioid
receptors (Table 2). Direct alkylation with -FNA abolished
GTPase stimulation by mu but not delta, kappa or nonselective
agonists. On the other hand, alkylation with Superfit prevented
the coupling of the delta but not mu or kappa opioid receptor to
GTPase. Finally, successive alkylation with Superfit and -FNA
rendered the brain membranes specific for the kappa receptor.
Alkylation of brain membranes with the irreversible nonselective
opioid antagonist -CNA abolished GTPase stimulation by mu,
delta and kappa agonists. However, protective alkylation with
-CNA in the presence of an excess of mu, delta or kappa ligands
provided specificity in the coupling of the corresponding opioid
receptor to brain GTPase (Table 2). The advantage of protective
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alkylation is the versatility and simplicity of receptor resolu-
tion. Of course, the method depends on the availability of
highly selective protective opioid ligands. The present
disadvantage of the approach is the high cost of -CNA.
TABLE 2
Stimulation of GTPase in alkylated rat brain membranes
Membrane treatment
No treatment
Stimulation of GTPase activity
Opiate Smax (%)
Direct alkylation
Sufentanil
DSLET
Bremazocine
Etorphine
22
26
13
29
-FNA Sufentanil
(blocks mu receptor) DSLET
Bremazocine
Etorphine
Superfit Sufentanil
(blocks delta receptor) DSLET
Bremazocine
Etorphine
-FNA and Superfit Sufentanil
(provides kappa DSLET
Bremazocinespecifically)
Etorphine
Protective alkylation
0
27
 8
20
16
0
12
19
0
0
10
9
-CNA Sufentanil 0
(blocks mu, kappa DSLET 0
and delta receptors) Bremazocine 0
-CNA and Sufentanil Sufentanil 22
(provides mu specifi- DSLET 0
city) Bremazocine 0
-CNA and DSLET (or Sufentanil 0
DPDPE) (provides delta DSLET 26
specificity) Bremazocine 0
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TABLE 3
Evaluation of compounds on the basis of opioid receptor binding and receptor-effector coupling
A. Binding
PHASE 1
Compound
Nonalkylated brain membranes:
displacement of specific 3H-etorphine binding
Results: Opioid character; receptor binding affi-
nity
If the compound is identified as opiate, it enters
Phase 2
PHASE 2
Compound
Receptor alkylation
µ-membranes: -membranes: -membranes:
displacement of specific 3H-etorphine binding
Results: Selectivity and affinity in binding
to specific types of opioid receptors
B. Coupling
PHASE 1
Compound
Nonalkylated brain membranes:
stimulation of low-Km brain GTPase
Results: Functional consequence of
receptor occupancy; agonist/antagonist
character
If the compound stimulates GTPase, it enters
Phase 2
PHASE 2
opioid receptor types
Compound
Receptor alkylation
µ-membranes: -membranes: -membranes:
stimulation of low-km brain GTPase
Results: Selectivity in receptor-effector
coupling; efficacy of ligand binding to
The successful resolution of multiple opioid receptors by the
implemented alkylations was underlined by the results obtained
with the nonselective opiate etorphine: the sum of GTPase
stimulation due to its mu, delta and kappa receptor binding
components (determined in the corresponding alkylated membranes)
equaled maximal enzyme stimulation by etorphine in nonalkylated
membranes (Table 2). The described direct and protective
alkylations can routinely be carried out in batch operation, and
the obtained membranes conveniently kept frozen until use.
Except for decreased concentrations of the alkylators (Clark and
Medzihradsky 1986), identical protocols are followed to treat
brain membranes used in studies on ligand binding to individual
opioid receptor types.
Considering the apparently low efficacy of opioid receptor
binding, i.e., the existence of spare receptors (Clark and
Medzihradsky 1986)
assays is incomplele.
the testing of novel opiates in binding
The availability of a routinely appli-
cable functional assay of receptor-effector coupling (Table 1)
and brain membranes with high selectivity for the mu, delta or
kappa receptor (Table 2), should now benefit the preclinical
evaluation of opiates (Table 3). The two phases of the new
experimental schemes provide for initial screening, i.e., the
identification of the tested compound as an opiate, and subse-
quent determination of binding selectivity, affinity and effi-
cacy, all with the use of just one radiolabeled ligand.
While the assessment of pure antagonists on the basis of their
lacking stimulation of GTPase is unequivocal, the quantitative
responses of mixed agonists-antagonists in the effector assay
have yet to be determined. The described alkylations have been
successfully applied to membranes from monkey brain (Medzihrad-
sky et al., unpublished observations). The use of this tissue
in the biochemical evaluation should further enhance the
correlation with behavioral and physiological findings, and thus
generate a comprehensive profile of the tested compound.
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Synthesis and Biochemical Characterization of
Two Novel Irreversible Ligands Specific for
“Peripheral” Benzodiazepine Receptors
Amy Hauck Newman, Hartmut W. M. Lueddens, Phil
Skolnick, and Kenner C. Rice
Central benzodiazepine (BDZ) receptors were first described by
Squires and Braestrup (1977) and Mohler and Okada (1977) by the
saturable, high affinity, and stereospecific binding of
[3Hldiazepam. Numerous studies have described the pharmaco-
logical, biochemical and physical properties of these receptors
in detail (see Haefly, et al., 1985 for review). Currently,
ligands for BDZ receptors can be classified as agonists,
antagonists, and inverse agonists.
A second type of BDZ receptor was first described in peripheral
tissues (Squires and Braestrup 1977) and in transformed cells of
neural origin (Syapin and Skolnick 1979) and later in the CNS
(shoemaker, et al 1983). These sites have high affinity for
[3Hldiazepam but low affinity for other BDZs such as clonazepam,
Ro 15-1788, and the -carbolines. The physiological function of
these "peripheral" receptors remains elusive and their pharmaco-
logical relevance is currently being studied (Shoemaker, et al.,
1983; Le Fur, et al., 1983). Two ligands, Ro 5-4864 (4'-Cl-
diazepam) and PK 11195 (1-(2-chlorophenyl)-N-methyl-N-(l-methyl-
propyl)-3-isoquinolinecarboxamide), demonstrate high affinity
for these "peripheral" binding sites and define the sites by
showing saturability and selectivity over the central type BDZ
sites, at which these ligands are virtually inert (Le Fur, et
al., 1983). Our goal is to clarify the mechanism of action of
these specific "peripheral" type BDZ ligands and to define the
pharmacological and physiological roles of these sites in the
brain and the periphery. Furthermore it is of interest to
determine the relationship of the "peripheral" type to the
"central" type BDZ receptors on a molecular basis and to discern
whether an association exists with the abuse of centrally active
BDZs.
Irazepine, prepared several years ago, (Rice, et al., 1979) is
an ethylisothiocyanato-derivative of flurazepam, another BDZ
agonist with anxiolytic properties. Irazepine was found to be a
potent, irreversible, ligand for the central BDZ sites.
Consequently, the ethylisothiocyanato-derivatives of Ro
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5-4864; AHN 086 and PK 11195; AHN 070 were prepared. These are
the first potent, irreversible ligands specific for "peripheral"
BDZ receptors.
CHEMISTRY
The synthesis of AHN 086 (1 ), l-(2-isothiocyanatoethyl-7-chloro-
1,3-dihydro-5-(4-chlorophenyl)-2H-1,4-benzodiazepine-2-one, is
shown in Figure 1. It was prepared in three steps from nor-R0
5-4864 (3 ) (a generous gift from Dr. Karl Weber, Boehringer-
Ingelheim).
Racemic 1-(2-chlorophenyl)-N-ethylisothiocyanato-N-(l-methyl-
propyl)-3-isoquinolinecarboxamide, AHN 070 (2a) was prepared in
four steps from PK 11209 (1 1) (a generous gift from Dr. G. Le
Fur, Pharmuka Laboratories shown in Figure 2. The (+)(2b)
and (-)(2c) stereoisomers of AHN 070 were prepared in the same
manner starting with the commercially available (+) and (-)
set-butylamine, respectively. The chemical structures and
purity of AHN 086, (±), (+), and (-) AHN 070 and all inter-
mediates were fully characterized by thin layer chromatography,
melting point, infrared spectroscopy, nuclear magnetic resonance
spectroscopy, mass spectroscopy, combustion analysis, and where
applicable, optical rotation.
BIOCHEMICAL METHODOLOGY
Male Sprague Dawley rats (140-200g) (Taconic Farms, Germantown,
NY) were killed by decapitation. The kidneys or whole brains
were decapsulated, and homogenized in twenty volumes of ice-
cold buffer as specified in a Brinkmann Polytron (setting 6-7
sec) . This tissue homogenate was centrifuged at 23,000 x g for
twenty minutes (4°C) and the resulting pellet resuspended in
100-2000 volumes of buffer, for the kidneys and in 50-200
volumes for the brains. Radioligand binding to this tissue
suspension wasassayed in a volume of 1 ml (2 ml for Scatchard
analysis of [3H]PK 11195 binding) consisting of: 0.25 ml of
tissue suspension, 0.1 ml radioligand [3H]Ro 5-4864 Sp. Act.
78.9 Ci/mmol) or [3H]PK 11195 (Sp. Act. 85 Ci/mmol) (New England
Nuclear, Boston, MA) diluted in assay buffer, drugs, and/or
buffer to final volume. Nonspecific binding was defined using
Ro 5-4864 or PK 11195 (final concentration, 10 µM) for [3H]Ro
5-4864 and [3H]PK 11195, respectively. Incubations were per-
formed at 0-4°C and terminated by rapid filtration over Whatman
GF/B filters, with three washes (5 ml) of assay buffer using a
Brandel M-24R filtering manifold (Brandel Instruments, Gaithers-
burg, MD). Filters were preincubated with 0.1% polgethylenei-
mine in distilled water for Scatchard analysis of [3H]PK 11195
binding. Protein was determined using the Miller modification
(Miller, 1959) of the Lowry (Lowry, et al., 1951) technique.
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FIGURE 1: Synthesis of AHN086
FIGURE 2: Synthesis of ARN070
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RESULTS AND DISCUSSION
The IC50 values for AHN 086 and AHN 070 to inhibit [
3H]Ro 5-4864
binding in the brain and kidney (2.1 ± 0.2 nM and 1.2 0.1  nM,
respectively for AHN 086) and (1.8 ± 0.3 nM and 1.43 ± 0.1 nM,
respectively for AHN 070) were estimated by extrapolating the
observed IC50 at different tissue concentrations to an infinite
tissue dilution {Figure 3). The IC50 values of AHN 086 and AHN
070 to inhibit [3H]PK 11195 binding were identical to the values
obtained for [3H]Ro 5-4864.
Scatchard analysis of [3H]Ro 5-4864 binding to the "peripheral"
BDZ binding sites in kidney membranes, after preincubation with
AHN 086 or AHN 070 followed by extensive washing, revealed a
concentration dependent decrease in the Bmax3 10 between 10 nM and 1
µM, Table 1). In contrast, only the KD of [
3H] PK 11195 was
effected by up to 100 nM of AHN 086 (Table 2). No specific
binding of either radioligand was detectable after preincubation
of the membranes with 1 µM AHN 086 or AHN 070 that could be
displaced by 10 µM PK 11195.
The irreversible nature of AHN 086 and AHN 070 binding to
"perfpheral" BDZ receptors was demonstrated by plotting binding
of [3H]Ro 5-4864 versus receptor concentration at near
saturating concentrations of radioligand (4). In both
cases, the x-axis intercept is significantly different from the
origin, which is strong evidence for an irreversible blockade of
receptors (Rice, et al., 1979). Furthermore, the effects of AHN
086 and AHN 070 on the Bmax of [3H]Ro 5-4864 persisted through
extensive washing of tissues. In contrast, addition of 10 nM Ro
5-4864 elicited an inhibition of radioligand binding that could
be reversed by washing to approximately 98% of control values.
A slight stereoselectivity of the (+) and (-) stereoisomers of
AHN 070 could be observed with the (-) isomer being 2.5-fold
more potent in displacing [3H]PK 11195 as well as [3H]Ro 5-4864.
Therefore both AHN 086, a structural analog of Ro 5-4864, and
AHN 070, a structural analog of PK 11195, are high affinity
ligands that bind specifically and irreversibly to the
"peripheral" BDZ binding sites in brain and kidney. It is hoped
that these two ligands will aid in the purification, isolation
and determination of the amino acid sequence and subsequently
the fractionation of the acylated receptor to confirm the
identity of the amino acid which becomes covalently bonded.
Ultimately this will prove useful for the determination of the
physiological function of these receptors and an improved
understanding of their relationship on a molecular basis to the
central BDZ receptors.
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AHN 070
10 nM 1.43 ± 0.55 4600 ± 547 81 7
100 nM 3.63 ± 0.77* 3901 ± 429* 69 6
TABLE 1:
Effects of AHN 086 and AHN 070 on [3H] RO 5-4864 binding to PBS:
Scatchard Analysis
AHN 086 K D
a B M A X
b %Control n
0 1.23 ± 0.39 5659 ± 554 100 7
10 nM 0.98 ± 0.35 4096 336*± 72 6
100 nM 2.99 ± 0.72* 3100 ± 294* 55 4
TABLE 2:
Effects of AHN 086 and ANH 070 on [3H] PK 11195 binding to PBS:
Scatchard Analysis
AHN 086 K D
a B M A X
b n
0 0.72 ± 0.10 5988 ± 1342 6
10 0.64 ± 0.03 6343 ± 1266 5
100 1.39 ± 0.25* 8049 ± 2728 5
AHN 070
10 0.94 ± 0.21 6853 ± 1096 4
1 0 0 2.05 ± 0.50* 6586 ± 961 4
Kidney membranes prepared in 50 mM potassium phosphate buffer
(pH 7.0) were incubated at a dilution of 1:250 (w/v) with
increasing concentrations of AHN 086 or AHN 070. Scatchard
analyses were performed on these membranes after four washes in
1:250 dilutions. At least eight ligand concentrations (in
triplicate) were used for each determination. Values represent
X ± S.E.M. with the number of determinations as indicated. a:
in nM, b: in fmol/mg protein, *p<0.001 compared to the absence
of AHN 086 or AHN 070.
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Developmental Toxicity of Prenatal
Delta-9-Tetrahydrocannabinol:
Effects of Maternal Nutrition,
Offspring Growth, and Behavior
Donald E. Hutchings, Stephen Brake, Brian Morgan,
Elizabeth Lasalle, and Thomas M. Shi
Animal studies of the neurobehavioral effects following prenatal
exposure to delta-9-tetrahydrocannabinol (THC) have often
yielded ambiguous results. A major problem shared by many of
these studies is that developmental toxicity may not have
resulted from direct drug effects on the embyro and fetus, but
rather, were secondary to THC-induced maternal toxicity (Abel,
1980). For example, one acute effect of THC administration in
rats is a substantial inhibition of food and water intake with
consequent maternal undernutrition and dehydration. Also, THC
can disrupt normal maternal care at parturition and inhibit milk
production and let-down, all with possible negative consequences
for the neurobehavioral development of the offspring (for
discussion, see Hutchings, 1985).
The present study reports on the effects of THC on maternal and
fetal toxicity, and on the growth and behavior of the offspring.
Two dose-levels were administered during the last two weeks of
gestation. To control for the effects of reduced food and water
intake among THC exposed dams, a pair-fed control group was
included. In addition, to obviate possible postnatal effects of
being reared by a drug-treated dam. all experimental and control
litters were reared by surrogate dams. The present study
included a total of 73 treated and control dams and their 932
offspring.
METHOD
Beginning on Day 8 of gestation, either 15 or 50 mg/kg of THC
suspended in sesame oil was administered to two groups of gravid
dams once daily by gastric intubation (THC-15; THC-50). Both
dose-level groups received daily drug administration through Day
22 of gestation, approximately 24 hr prior to expected parturi-
tion. One control group received the vehicle and was pair-fed
to the food and water intake of the 50 mg/kg THC group (PF). A
nontreated control group was left undisturbed throughout preg-
nancy (NT). Within 1-5 hrs of birth, all treated and control
offspring were sexed and weighed and litters culled when
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necessary to 10 pups; litters containing fewer than 8 pups were
also sexed and weighed but excluded from further testing.
Offspring were then fostered to normal mothers of the same
strain that had delivered approximately 24 hrs earlier. All
experimental and control mothers were then sacrificed to deter-
mine the number of implantation sites.
Litters were randomly assigned to either activity or nipple-
attachment testing; none of the litters were tested on both
measures. Activity level testing was carried out using a
6-channel electronic activity monitor with 6 remote sensors.
Eight litters each of treated and control pups were tested.
Treated and control litters were tested for 60 minutes at 3-day
intervals from Day 2 through 32 days of age (day of birth was
designated Day 0). A detailed description of the equipment and
test procedure has been described previously (Hutchings et al,
1980). Individual body weights were measured and recorded.
Offspring from 10 THC-15, 10 THC-50, 9 PF, and 9 NT litters were
tested for nipple attachment on days 2, 5, 8, 11 and 14 of age.
(For a detailed description of the method, see Brake et al, in
press). Approximately 15 min prior to the beginning of testing,
a "test dam" was anesthetized with an intraperitoneal injection
of 50 mg/ml sodium pentobarbital. She was then placed on her
side in a small plastic arena, with the ipsilateral fore and
hindlimbs gently taped to the wall to expose all the nipples.
The liter to be tested was removed from the foster dam and
placed in an incubator maintained at 33-35 C. for five min prior
to the beginning of testing. Then, 2-3 littermates were tested
for a five min session. Pups were placed by hand in the arena
perpendicular to the dam's flank, with their snout in contact
with the ventrum, but not a nipple. If, during testing, pups
moved away from the ventrum or positioned themselves laterally
for more than 10 sec, they were re-started with their snout to
the ventrum. Data collected included the latency to attach to a
nipple and proportion of animals failing to attach.
RESULTS
ANOVA or repeated-measures ANOVA, and Scheffe post hoc tests
were performed on all measures. To analyze offspring effects,
the litter served as the unit of analysis. (All comparisons
characterized below as "significant" denote a probability of
less than .02). There were no maternal deaths among any of the
THC treated or control groups. However, among the dams exposed
to THC, dose-related toxicity was observed. Among the THC-50
dams, there was a substantial reduction in food and water
intake, particularly on the first several days after the initi-
ation of drug treatment. After drug administration of gestation
Day 8, both food and water intake was reduced 75-80% during the
next 24 hr. Over the following 3-4 days, tolerance to the THC
induced inhibition of food and water intake developed and both
food and water intake recovered to approximately 80-85% of that
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displayed by the NT dams. Table 1 shows that the PF, THC-15 and
THC-50 dams failed to gain as much body weight from conception
to term compared with the NT dams, a difference that was highly
significant.
Another major toxic effect observed among the THC treated dams
was in maternal care at parturition. Thirty-five percent (7/20)
of the THC-15 and 45% (9.19) of the THC-50 failed to completely
remove and consume the placental and extra-placental membranes.
This occurred in only 16% (1.17) of the PF dams and in none of
the NT.
Table 1 further shows that mean implantation sites were identi-
cal across all groups, whereas resorptions were slightly higher
for the THC treated groups. Percentages of perinatal mortality
(i.e., non-viable offspring observed at birth) was less than 1%
for the NT and PF groups but 3-4% for the THC groups. Total
perinatal mortality was calculated by combining both perinatal
death and resorptions and dividing by total implantation sites.
Thus, the total proportion of offspring mortality for both THC
groups was approximately double that of either control groups.
Overall, birthweights of the males were higher than the females.
However, the PF, THC-15, and THC-50 groups had significantly
lower birthweights compared with the NT. In addition, there was
a dose-related increase in the proportion of viable male off-
spring at birth.
Though there were no differences in body weight between treated
and control offspring at 32 days of age, rate of postnatal
growth varied as a function of pair-feeding and dose. Body-
weight of the PF control group caught up to the NT controls by
Day 2 of life. The THC-15 group showed a slow rate of growth
during the first five days followed by a more rapid rate, thus
catching up to both control groups by day 11. By comparison,
growth rates were significantly slower over the first 5 days in
the THC-50 group than in the other groups. Further, the THC-50
group never showed a rapid catch-up in growth, although their
weights gradually approached those of the other groups by Day 32.
THC-50 and PF control pups displayed significantly longer
latencies to attach to a nipple. In addition, a significantly
higher proportion of pups from both of these groups failed to
attach during testing. The mean activity data for the THC-
treated and control litters failed to reveal any differences
among any of the groups throughout testing.
The only measure in the study to show a negative dose-response
was postnatal mortality. Among the THC-15 group, 6% of the
males and 4% of the females died after Day 1 of life. Of the
THC-50 group, the proportions were 1% among both the males and
females. There were no deaths among either control groups.
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DISCUSSION
The present study, by virtue of the inclusion of a pair-fed
control and the use of surrogate fostering, clearly distinguish-
es primary developmental toxic effects of THC from secondary
effects mediated by maternal undernutrition. Offspring mortali-
ty did not differ between the NT and PF controls but was sub-
stantially higher among the THC groups, indicating that THC
produces embryotoxicity independent of maternal undernutrition.
In addition, there was a dose-related increase in the sex ratio
of live male to female offspring. A similar increase in sex
ratio favoring males has also been reported for rats exposed
both prior to mating and during pregnancy to marijuana smoke
(Fried and Charlebois, 1979) as well as in a human study of
pregnant marijuana smokers (Tennes et al, 1985). In the present
study, exposure to THC occurred after conception and implanta-
tion, suggesting that female conceptuses have a greater suscep-
tibility to THC embryolethality.
THC was also found to have dose-related effects on rate of
growth independent of maternal undernutrition; whereas the
bodyweights of the PF controls caught up to those of the NT
group within two days, the bodyweights of the THC-50 group were
significantly less than those of the NT group throughout most of
the study. By comparison, the THC-15 group showed inhibited
growth only during the first five days followed by a growth
spurt, so that they caught up to the controls by Day 11 of life.
These dose-related effects on growth may be mediated either by
the persistence of pharmacologically active amounts of the
compound in neonatal tissue and/or inhibition of a hormonally
regulated pathway affecting growth.
THC and maternal nutrition, however, were confounded with
respect to nipple-attachment measures. THC-15 and NT litters
did not differ in their latency to attach while the THC-50
litters took significantly longer and failed to attach more
often. However, similar results were obtained for the PF control
litters. These results suggest that the impaired nipple-attach-
ment observed among the high-dose offspring was not a primary
effect of THC. Rather, these effects may be secondary to the
significant reduction in food and water intake produced among
the THC-50 dams. Offspring activity level, however, was un-
affected by either nutrition or THC.
Considering that the THC nutritional deficit produced in the
dams was most severe during early organogenesis, when the CNS is
particularly susceptible to damage (e.g., see Morgan and Winick,
1985), the effects on nipple attachment are not all surprising.
Moreover, the failure to observe behavioral effects on either
measure for THC alone, agrees with human observations of
neonates. Although Fried (1982) found infants of mothers who
smoked marijuana during pregnancy to be somewhat irritable for
about a month after birth, longterm follow-up to school age
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failed to reveal any persistent behavioral or cognitive defi-
cits. In a similar study, Tennes et al (1985) did not observe
neonatal irritability and, like Fried, found no persistent
neurobehavioral impairment during the first year of life. Thus,
both well-controlled animal studies and human clinical studies
have yet to indicate that exposure to marijuana or THC during
pregnancy produces significant neurobehavioral impairment in the
offspring. However, the embryotoxic properties of THC, with
possible selective effects on females, its postnatal growth
inhibiting effects, as well as reported effects on male re-
productive physiology and performance (e.g. Dalterio et al,
1984) leave little doubt of its potent developmental toxicity.
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LITTERS
MEAN MATERNAL
WT GAIN
MEAN
IMPLICATION
SITES
% RESORPTIONS
% PERINATAL
MORTALITY
TOTAL
OFFSPRING
MORTALITY
NUMBER
BORN LIVE
MALE
FEMALE
MEAN LITTER
SIZE
MEAN BIRTH-
WEIGHT
MALE
FEMALE
TABLE 1
MATERNAL & OFFSPRING EFFECTS
NT PF
17 17
185.5g 135.1g
14 14
5.41% 3.38%
0.65% 0.39%
6.06% 3.77%
104 (47%) 107 (48%)
119 (53%) 115 (52%)
13 13
7.20g 6.80g 6.65g 6.58g
6.83g 6.36g 6.30g 6.20g
THC-15 THC-50
20 19
129.2g 122.8g
14 14
6.30% 7.71%
3.78% 4.58%
10.07% 12.28%
137 (54%) 132 (57%)
117 (46%) 101 (43%)
13 12
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1 7 2 - 6 8 2 0 - 87 - 13
Biological Evaluation of Compounds For Their
Physical Dependence Potential and Abuse
Liability. X. Drug Testing Programs of
The Committee on Problems of
Drug Dependence, Inc. (1986)
Arthur E. Jacobson
The Drug Testing Program of the Committee on Problems of Drug
Dependence (CPDD) was established to evaluate compounds for their
physical dependence potential and abuse liability. Drug testing,
as a public service, represents one of the main purposes of the
CPDD. This work has, in the past, led to our ability to forewarn
the submitters of the compounds, and the public, about a drug’s
potential for abuse. The data which are obtained from this program
also benefit the CPDD and scientific research in other ways. It
serves as a reservoir of information which the CPDD uses to enable
it to enact another of its purposes, to act in an advisory
capacity, providing scientific information to academic,
governmental and industrial groups, on request. The gathered data
have, further, led to basic research into areas which would,
otherwise, have remained unexplored. Several papers have been
published on this work (e.g. Woods et al., 1983; Aceto et al.,
1985; Lessor et al., 1986). The Drug Testing Program of the CPDD
has historically been involved with opioid-like drugs and, also, is
presently obtaining base-line data as a prerequisite to expansion
to the testing of stimulants and depressants.
CONSTITUENCY OF THE DRUG TESTING PROGRAM
The Drug Testing Program on opioid-like compounds has served three
distinct audiences: 1) university researchers who seek rodent
antinociceptive and, perhaps, initial monkey studies (single dose
suppression and precipitated abstinence) for the discernment of the
relationship between the molecular structure of their synthesized
molecules and biological activity, for publication purposes and for
leads to further research in the area; 2) pharmaceutical firms that
generally wish to determine the physical dependence potential and
abuse liability of their compounds before further work, or for
transmission of these data to the FDA to satisfy regulations before
marketing; 3) governmental organizations, such as the DEA, or the
WHO, who desire sufficient data for scheduling purposes, nationally
and/or internationally.
370
This paper serves, mainly, as an introduction to the work, and
summary of the results, of the scientists (see below) involved with
the Drug Testing Program. The opioid-like compounds are classified
in this paper in accord with classical opioid structural types, so
that the changes which are made in these classes can be more easily
observed and compared from year to year (Jacobson 1986, and
previous years).
OPIOID AND STIMULANT/DEPRESSANT TESTING LABORATORIES
There are three groups concerned with the evaluation of compounds
as opioids: the Medical College of Virginia (Drs. M.D. Aceto, L.S.
Harris, E.L. May, E.R. Bowman, R.L. Balster, and P.M. Beardsley),
the University of Michigan (Drs. J.H. Woods, F. Medzihradsky, C.B.
Smith, G.D. Winger, and D.E. Gmerek), and NIDDK, NIH (Dr. A.E.
Jacobson and M. Mattson). The complete work of the MCV and UM
groups is published in this monograph (Aceto et al. 1987; Woods et
al. 1987), and should be consulted for the detailed information on
the evaluated compounds.
Five groups have been involved with the evaluation of the stimulant
and depressant classes of compounds: the University of Chicago
(Drs. C. Johanson and R. Schuster), the Medical College of Virginia
(Drs. Patrick, Yutrzenka, and Harris), the Johns Hopkins University
(Drs. R. Griffiths, N. Ator, R. Lamb, and J. Brady), NIDDK, NIH
(Dr. A. Jacobson, M. Mattson), and NIDA (Dr. E. Cone). Dr. J.
Woods (University of Michigan) has served to coordinate this
program.
SUBMISSION PROCEDURES
The procedure which is followed in both programs is similar.
Compounds are obtained by, or submitted to, Dr. A. E. Jacobson
(NIH, NIDDK) who runs initial mouse antinociceptive tests on
opioid-like compounds, or biochemical assays on benzodiazepines.
The compounds are logged into a computerized system and distributed
to the various groups for evaluation. With the opioids, the
Medical College of Virginia group evaluates the compounds in
various mouse assays for their antinociceptive and narcotic
antagonist activity, as well as in single dose suppression assays
in monkeys. Precipitated withdrawal studies, primary physical
dependence and, occasionally, self-administration data are obtained
in the rhesus monkey. Further, rat infusion methodology is used is
paradigms similar to single-dose suppression, and primary physical
dependence studies in the monkey. Biochemical evaluation,
electrically stimulated mouse vas deferens preparations, most of
the self-administration data and all of the drug discrimination
data are obtained from the University of Michigan, as well as some
single-dose suppression and precipitated withdrawal studies in the
monkey and, occasionally, primary physical dependence in the
monkey. Reports are submitted to Dr. A. E. Jacobson at NIH. Dr.
Jacobson receives written release of the obtained data from the
submitter of the compound, draws the chemical structures of the
released compounds, and sends these to the appropriate laboratory
for inclusion in the Annual Report from the Medical College of
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Virginia and the University of Michigan. The Annual Reports, as
well as a compilation and summary of the data from these reports,
are published as part of the Proceedings of the CPDD in the NIDA
Monograph, from MCV, UM, and NIH.
The stimulant/depressant classes of drugs are handled similarly.
Distribution of a drug is to the Medical College of Virginia for
estimate of potency in rodent tests, to the Addiction Research
Center, NIDA (Dr. E. Cone) for solubility and stability studies,
and then to the University of Chicago for study in pigeons and
monkeys (e.g. self-administration and drug discrimination), and to
the Johns Hopkins University for study in baboons. Reports are
submitted back to Dr. Jacobson and the released data are
incorporated in the Proceedings of the CPDD in the NIDA Monograph.
During this next year, the compounds which will be evaluated will
be chosen from compounds requested by the WHO, or from drugs to be
added to our reference standards list, e.g. deprenyl (or its levo
enantiomer, eldepryl, an antiparkinsonian agent), tranylcypromine
(an anti-depressant), ethchlorvinyl (a sedative-hypnotic),
meprobamate (a sedative), methaqualone, Ro 15-1788, or substances
submitted by industry.
The requirements for submission of compounds for evaluation under
the auspices of the CPDD have been previously discussed (Jacobson,
1981).
CLASSES OF OPIOID-LIKE COMPOUNDS, AND SPECIFIC COMPOUNDS OF
INTEREST AMONG THE EXAMINED OPIOIDS AND STIMULANTS/DEPRESSANTS
The evaluated compounds are listed in 12 tables. Ten 4,5-
epoxymorphinans are listed in tables 1 & 2. Six morphinans and a
phenylmorphan are shown in table 3. There are 23 of the 6,7-
benzomorphans in tables 4 - 6. Table 7 contains eight methadone-
like compounds, and table 8 contains eight pethidine-like compounds
and two compounds based on the fentanyl structure. The remainder
of the tables (9 - 12) concerns 24 compounds which could not be
classified by classical opioid terminology. These are the
miscellaneous compounds.
Qpioid-like Drugs Submitted By A Governmental Unit ("Street" or
"Designer" Drugs)-
Four compounds were submitted by the DEA, through NIDA. Two of
them are extremely potent analogs of fentanyl, the cis and trans 3-
methyl fentanyl (NIH 10456 & 10457, table 8). The more potent cis
compound was found to be 1000 to 2000 times more potent than
morphine in mouse antinociceptive assays (hot plate, PPQ, tail
flick), and was 1000 times more potent than morphine in the single
dose suppression assay in monkeys. Its affinity to opioid
receptors in rat brain membranes and in the mouse vas deferens was
in reasonable accord with the in vivo data. The somewhat less
potent trans compound was 600 times More potent than morphine in
suppressing abstinence in the single dose suppression study. Two
far less potent pethidine-like compounds, NIH 10460 and 10461
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(table 8) also completely suppress abstinence in single dose
suppression studies and were as potent as, or more potent than
morphine in the various antinociceptive studies in rodents.
Priority was given to NIDA and DEA for this work and the evaluation
was accomplished expeditiously.
Two Compounds From Pharmaceutical Industry -
1) Meptazinol
More extensive work was done with a compound which had been
originally evaluated 15 years ago. Meptazinol (NIH 8683, table 9),
which has a structure reminiscent of pethidine, with a T-membered
nitrogen ring, was evaluated by morphine substitution and primary
physical dependence in 1971. In single dose substitution studies
it did not substitute for morphine; it precipitated withdrawal in
withdrawn monkeys, thus apparently acting as a weak narcotic
antagonist. Cur SDS and precipitated withdrawal contemporary data
are in complete accord with the formerly obtained data. The new
primary physical dependence study indicated that the compound was,
essentially, morphine-like from the induced weight loss and
withdrawal syndrome produced on abrupt withdrawal. The original
primary physical dependence study showed mild physiological
dependence following abrupt withdrawal. Further data have been
obtained from antinociceptive studies in rodents (meptazinol is
about 1/2 to 1/5 as potent as morphine), from in vitro experiments
in binding to rat brain membranes (ca. 1/150 the affinity of
morphine), mouse vas deferens (it did not suppress the twitch at
any concentration used, nor reverse the action of morphine on the
twitch), self-injection (rates maintained by meptazinol were
slightly above those maintained by saline at all doses, but the
results were variable), etorphine discrimination (monkeys showed
etorphine-appropriate responding which was suppressed by
preadministration of WIN 4441 (quadazocine)), and ethylketazocine-
discrimination (variable results in two independent studies).
Meptazinol clearly shows some opioid-like activity and some
narcotic antagonist activity in these several assays. It would
appear to be a mixed agonist-antagonist with mu, and perhaps kappa,
opioid receptor mediated effects when evaluated in vivo in rhesus
monkeys.
2) Nalmefene
At one of our previous Annual Meetings, Key Pharmaceutical Company
asked for the opinion of the CPDD on the data obtained by the Drug
Testing Program of the CPDD on nalmefene (17-cyclopropylmethyl-4,5-
epoxy-3,14-dihydroxy-7-methylenemorphinan, NIH 10365). The
evaluative effort was given to a sub-committee, but has not, as
yet, been reported to the CPDD. Cur data have been obtained from
the opioid working groups and compiled by Dr. Harris (MCV). The
data obtained with the compound indicates that it is a potent, pure
narcotic antagonist. It does not substitute for morphine in the
SDS test in monkeys. It has ten times the potency of naloxone in
precipitating withdrawal in non-withdrawn monkeys, and it has a
longer duration of action than naloxone. It was not self-
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administered and it was without morphine like effects in a primary
physical dependence study, in rhesus monkeys. In the latter assay
the drug showed toxicity at the high doses used. The compound has
no dependence potential that can be ascertained in our assays. Key
Pharmaceutical is planning to submit an NDA on this drug for the
management of narcotic overdosage.
Effect of Chiral Center on Biological Activity - "Spiro-epoxides"
Two C-6 Spiro-epoxides based on the 4,5-epoxymorphinans (NIH 10366
and 10367, table 2) were examined and were found to be of interest
from a stereochemical point of view. Our tests clearly indicate
the remarkable ability of the opioid receptor to differentiate
between enantiomers at a somewhat remote chiral center. NIH 10366
is a very potent antinociceptive agent, about 100 times more potent
than morphine. Its isomeric relative, NIH 10367 is inactive as an
antinociceptive, although it appears to have retained reasonable
affinity for the opioid receptors. A somewhat larger ring attached
as a Spiro group to the C-6 position, as seen in NIH 10322 and
10324 (table 2), was much less effective for the retention of
narcotic antagonist or antinociceptive properties. The N-
cyclopropylmethyl derivative, NIH 10322, was found to be
considerably less potent than its molecular parent, naltrexone, as
a narcotic antagonist and showed mixed agonist-antagonist
properties. The Spiro attachment at C-6, as such, appears to have
little apparent effect on in vivo activity, in contrast with the
effect of the chiral center a small distance away, and the effect
of the size and nature of the ring at C-6. These rather complex
molecules can be contrasted with the molecularly simple 6-
oxomorphinan, NIH 10331 (table 3). That morphinan does not have
even a phenolic hydroxyl group and, yet, is three to six times more
potent than morphine in mouse antinociceptive assays. The lack of
the phenolic hydroxyl in NIH 10331 may have militated against the
acquisition of narcotic antagonist activity. Generally, N-
cyclopropylmethyl substituted morphinans are potent antagonists;
the NIH 10331, however, does not have antagonist properties.
Opioid-like Compounds From The University Constituency -
Stimulant Submitted By Governmental - MDMA
Lastly, a stimulant of great interest to the DEA and NIDA was
evaluated by various groups associated with the stimulant/
depressant Drug Testing Program. The drug, (±)-3,4-
methylenedioxymethamphetamine (MDMA) was purported to be a highly
useful psychotherapeutic agent by psychotherapists on the west
coast. It became a “street” drug and was controlled by the DEA
under its new emergency procedures. The compound was examined by
self-administration (i.v.) in cocaine-trained rhesus monkeys, and
rodent infusion, by Drs. Beardsley, Balster and Harris (MCV)
(Beardsley et al., 1986). Three separate studies were carried out
by Dr. Johanson (University of Chicago). In those studies, MDMA
substituted for d-amphetamine in monkeys (i.v., and i.g.) and in
pigeons (i.m.) trained to discriminate d-amphetamine from saline
(Evans and Johanson, 1986; Kamien et al., 1986). In a self-
injection study (i.v.) in baboons by Drs. Lamb and Griffiths (1986)
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(Johns Hopkins University), all three baboons substituted MDMA for
cocaine; the number of injections and response rates maintained by
MDMA were less than those maintained under baseline conditions with
cocaine. The results obtained from the involved groups demonstrated
that MDMA could serve as a reinforcer in various species and, taken
together with other preclinical behavioral studies, suggested a
potential for recreational use of MDMA by humans (Beardsley et al.,
1986).
DRUG TESTING PROGRAM STATISTICS
An arbitrary time period of 5/1 through 4/30 has been used to
relate and compare the intake and output of the Drug Testing
Program and statistical data have been compiled so that comparisons
can be made over an 8 year time span. The mean, and standard
deviation of the mean, of measures of interest have been obtained
from the previous seven years, and observations from this year, the
eighth year in which data have been compiled in this fashion, have
been compared with those data.
The number of compounds which are sent from NIDDK, NIH, to MCV and
UM for evaluation as opioid-like drugs, under the auspices of the
CPDD, shows considerable annual fluctuation. Thus, the mean of
that number is 93; the standard deviation is 30. During the
current year, I sent MCV and UM 63 compounds, the low end of the
deviation of the mean, a statistically insignificant deviation but,
perhaps, somewhat meaningful. Although the number of compounds was
essentially the same as those sent in two of the previous seven
years (1979 and 1983), it must be noted that UM and MCV received a
considerably higher number of compounds during the other five
years.
The reports generated from the data on compounds which have been
released for publication can be observed in this monograph (Aceto
et al., 1987; Woods et al., 1987). There are about 90 of those
reports, consistent with the calculated mean of 95. There is,
generally, only a peripheral relationship between these first two
statistical items. The data generated from the compounds sent to
MCV and UM this year will appear over the next three, or more,
years, due to our allowance of that time period before automatic
publication, and the time necessary to complete work on compounds
which appear scientifically, commercially and/or governmentally
significant. Thus, it can be noted in the reports that we are
still gathering information on, for example, relatively ancient
kappa receptor-selective compounds such as ketocyclazocine and
ethylketocyclazocine. Kappa-selective compounds are, of course, of
considerable scientific interest and, perhaps, commercial
importance.
The sources of the compounds included in this monograph are varied,
as usual. About 13% of these compounds came from industrial
groups. This percentage has remained fairly constant for the past
two or three years, but is appreciably different from earlier years
when about 50% of our compounds came from industry. Universities
provided ca. 59% of our samples this year, and NIH another 18%.
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Thus, over three-quarters of our reports were generated on
compounds from non-commercial sources. We have, also, been
receiving a significantly increased number of compounds for
evaluation from the DEA, through NIDA. Presumably, these
governmental agencies are interested in obtaining data on compounds
illicitly synthesized, the “designer drugs”, with the hope of
adding them to the DEA list of proscribed substances.
ABBREVIATIONS USED IN TAELES 1 - 12.
I = inactive, without a reasonable dose-response relationship,
or insufficiently active for statistical analysis.
ED50 OR AD5Q: Antinociceotive assay (ED50, sc injection except
where noted, mice) [Confidence limits are listed in the MCV and UM
reports (Aceto et al. 1987; Woods et al. 1987)]: HP = hot plate; N
= Nilsen; PPQ = phenylquinone; TF = tail flick; TEA = tail flick
antagonism vs. morphine. These assays are done at MCV, except for
the HP and N which are done at NIDDK, NIH.
EC50 Determinations:
These assays are done at UM. RBH = binding affinity, in the
presence of 150mM NaCl, to rat cerebrum membrane preparations, in
nM (parenthesized number is the +sodium/-sodium [+Na/-Na] ratio).
EC50 was determined by displacement of 0.5nM 3H-etorphine. The
EC50 of morphine, for comparison = 23.6 (1.69). NE = no effect.
NOTE: The present EC50 data cannot be directly compared with those
from my previous reports (Jacobson 1983, and previous years) in
which -Na values were quoted. However, the previously stated
numbers can be recalculated for comparison with those which will be
utilized this year and in the future, through the use of the
+Na/-Na ratio.
GPI = electrically stimulated guinea pig ileum EC50, rounded to
one significant figure, in nM except where noted. (E =
exponential, e.g. 7E-9 M = 7 x 10-g M, where -9 is an exponent
[7E-2 M = 7 x 10-2 M = 0.07 M] (parenthesized numbers are maximum
percent inhibition at EC50); [bracketed letters: A = antagonized
by 10-7M naltrexone; NA = not antagonized by naltrexone; SA =
slight antagonism; NE = no effect on inhibition of twitch]. NOTE:
The GPI assay has been phased out of the normal routine. These data
will not be obtained as part of the general assays. The VD assay
will continue.
VD = electrically stimulated mouse vas deferens EC50 values,
rounded to one significant figure. Agonist activity stated as E =
x10 M, thus: 7E-2 = 0.07 M (parenthesized numbers are maximum
percent inhibition at EC50); [bracketed letters: A = antagonized
by 10-7 M naltrexone; NA = not antagonized by naltrexone; NE = no
effect on inhibition of twitch; SA = slight antagonism by
naltrexone]. Compounds which suppress the twitch and are not
antagonized by naltrexone (noted herein) or UM 979 [NIH 8859,
(-)-5,9-alpha dimethyl-2-(3-furylmethyl-2-(3-furylmethyl)-2’-hydroxy-6,7-
benzomorphan] are said to be non-opioid agonists (e.g. clonidine
can suppress the twitch, but is not antagonized by naltrexone. It
is a non-opioid agonist). (The effect of UM 979 is not noted in
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this report, but see the UM report (Woods et al. 1987) for these
data). Compounds which bind with reasonable affinity in the rat
brain homogenate assay, suppress the twitch in the VD, but are not
blocked by narcotic antagonists may have antagonist properties,
also. This is experimentally determinable by observing their
antagonism to morphine’s suppression of the twitch in the VD
preparation (for these data see Woods et al. 1987).
D ata From Monkey Colonies:
These data are from either MCV or UM. SDS = single dose
suppression: NS = no suppression; CS = complete suppression; PS =
partial suppression. (Parenthesized numbers = dose range studied,
in mg/kg; if CS, then dose at which CS was observed is noted in the
parentheses). Potency comparison with morphine [M] may be stated,
in brackets.
NW = studies in non-withdrawn monkeys. PW = precipitated
withdrawal at dose levels, in mg/kg, indicated in parentheses &/or
comparison with naloxone [N], in brackets; NP = no precipitation;
SP = slight precipitation.
Other Studies (OTHER):
RI = rat infusion (from MCV): NS = no suppression; CS = complete
suppression; PS = partial suppression.
PPD = primary physical dependence.
SA = self-administration (from UM): NE = no effect; High
=codeine-like; IN - intermediate between saline and codeine; SE =
slight effect.
Normal monkeys: M-like = morphine-like effect.
DD = drug discrimination (from UM).
Previous Reports (PR):
A column which relates the titled year (e.g. Problems of Drug
Dependence 1986 - the titled year is 1986) in which previous work
on a compound has been reported. Note that the year of actual
publication generally occurs one year after the titled year. These
data are published in the annual compilations of “Problems of Drug
Dependence”. The data which have been published in previous
reports are shown by a “PR” in the appropriate column (e.g. a PR in
the SDS column would indicate that the SDS work was done in the
year, or one of the years, cited in the PR column).
NOTE: The numbers used in the tables may be rounded. For precise
values, and details of the procedures, see the MCV and UM reports
in these Proceedings (Aceto et al. 1987; Woods et al. 1987).
Abbreviations for structural  formulae: CPM=cyclopropylmethyl;
C B M =cyclobutylmethyl; Me =methyl; Et=ethyl; Pr=propyl.
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TABLE 1 - 4,5-EPOXYMORPHINANSa
a) See text for explanation of column headings.
b) Intravenous route of administration.
c) SDS (1984); SDS & NW (1968 - as NIH 8359).
d) Other assays - PPD (ND), SA (1985).
TABLE 2 - 4,5-EPOXYMORPHINANS (CONTINUED)a
a) See text for explanation of column headings.
b) Insufficiently soluble for assays.
TABLE 3 - MORPHINANS AND PHENYLHORPRANSa
a) See text for explanation of column headings.
b) Antagonism occurs with equimolar concentration of naltrexone.
c) NIH 9975 antagonizes the effects of morphine in the VD assay.
d) Incomplete withdrawal (atypical antagonist); SA (1980).
TABLE 4 - 6,7-BENZOMORPHANSa
a) See text for explanation of column headings.
b) Monkey SDS: NS(l.O-4.0), NW (1969); RI: SDS-nearly CS, PPD-definite PD.
c) SA (1984); SDS (1960, 1969).
TABLE 5 - 6,7-BENZOMORPHANS (CONTINUED)a
a) See text for explanation of column headings.
b) In Vitro - RBH: 1.96, VD: 23-8(93) [Al;
PPD (1981,1982); SDS (1979,198O).
c) RBH, VD, SDS (1983); SDS, NW (1985).
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TABLE 6 - 6,7-BENZOMORPHANS (CONTINUED)a
a) See text for explanation  of column headings.
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TABLE 7 - METHADONE-LIKE COMPOUNDSa
a) See text for explanation of column headings.
386
TABLE 8 - PETHIDINES AND FENTANYLSa
a)  text for explanation  of column headings.
b) Antagonized sulfentanil's agonist  activity.
TABLE 9 - MISCELLANEOUSa
a)  text for explanation of column headings.
b) Other tests - RI: PPD (no overt  effect  on weight;  less spontaneous  activity before
abrupt  withdrawal).
c) Monkeys - SDS: NW - PW(0.005xN). Other  tests  - RI: SDS - NS, PPD (morphine-like);
SA - high; DD - EKC-like  etorphine-like; SDS, PPD (1973); SDS, NW (1984).
d) Antagonized by ICI 174864,  a specific  delta receptor  antagonist.
TABLE 10 - MISCELLANEOUS (CONTINUED)a
a) See text for explanation of column headings.
b) Previous report - 1985
c) Some withdrawal signs noted.
TABLE 11 - MISCELLANEOUS (CONTINUED)a
UM - NS(l-32)(repeat).
c) RBH - NE; MVD - NE; SA - NE; DD - NE.
d) Previous report - 1985(RBH, VD).
a) See text for explanation of column headings.
b) Used cumulative doses for assay at UM; MCV - CS(8) (repeat),
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TABLE 12 - MISCELLANEOUS (CONTINUED)a
a) See text for explanation of column headings.
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Dependence Studies of New
Compounds in the Rhesus Monkey,
Rat and Mouse (1986)
M. D. Aceto, E. R. Bowman, L. S. Harris, and E. L. May
All the drugs, except, cocaine, (+)- and (-)-metazocine,
(+)-cyclazocine, (+)-cyclazocine, (-)-cyclazocine, (+)-ketocy-
clazocine, (-)-ketocyclazocine, and (-)-ethylketocyclazocine were
supplied by Dr. Arthur Jacobson, Medicinal Chemistry Section,
NIADDK, NIH under the auspices of the Committee on Problems of
Drug Dependence, Inc. The chemical structures of the test
compounds were unknown to us when they were originally submitted.
For the most part, the procedures described by Seevers and his
colleagues (1936, 1963) and Deneau (1956) regarding the facili-
ties and training of the monkeys were used and a brief descrip-
tion follows. The monkeys were injected with 3 mg/kg S.C. of
morphine sulfate every 6 hr for at least 90 days before being
used. This dose schedule was reported by Seevers and Deneau
(1963) to produce maximal physical dependence.
Modified procedures for the precipitated withdrawal (PPt-W) and
single-dose suppression (SDS) tests were reported by Aceto and
co-workers (1977 and 1978). The PPt-W test was initiated by the
injection of a test drug 2½ hr after an injection of morphine and
the animals were observed for signs of withdrawal. The SDS test
was started approximately 15 hr after the last dose of morphine
at which time the animals were showing withdrawal signs. The
onset and duration of action of the test drug were noted. In
both tests, a vehicle control and an appropriate positive control
(naloxone·HCl 0.05 mg/kg or morphine sulfate, 3.0 mg/kg) along
with 3 different treatments (doses) of a test compound were
randomly allocated to the 5 monkeys of a group. Occasionally 4
monkeys comprised a group and 2 doses of test compound were
studied. Usually, 3 or 4 groups per compound were used. All
drugs were given subcutaneously (1 ml/kg) or intravenously (1-2
ml) and the vehicle used is indicated for each compound. The
observer was "blind" with regard to the treatment given. A
minimal 2-week washout and recuperation period between tests was
allowed. In the primary physical dependence (PPD) tests, the
animals of a group received the drug every 4-6 hr for 30-50 days.
They were placed in abrupt withdrawal and challenged with nalox-
one periodically, then observed for signs of physical dependence.
All potency estimates are rough approximations only.
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The rat-infusion method was reported by Teiger (1974) and certain
modifications are indicated as follows. Semi-restrained, male,
Sprague-Dawley rats were medicated by continuous infusion through
indwelling intraperitoneal cannulas for 6 days with a drug. Rats
were anesthetized after which each was fitted with a specially
prepared cannula which was passed subcutaneoulsy from the nape of
the neck to the lateral side of the lower abdomen and then
inserted into the peritoneal cavity. The cannula was anchored at
both ends with silk sutures and attached to a flow-through,
swivel mechanism which allowed the animal to move about in the
cage and eat and drink normally. The swivel was connected to a
syringe which was attached to a syringe pump. The animals
received 7-10 ml of solution every 24 hr.
In the substitution for morphine (SM) test, the animals first
received morphine (50 mg/kg/24 hr on the first day, 100 mg/kg/24
hr on the second day, and 200 mg/kg/24 hr from days 3-6). Then,
a test drug was substituted for 2 days. The morphine controls
received an infusion of water. The animals were observed for
changes in body weight and for behavioral-withdrawal signs for ½
hr at 24,48,72 and/or 96 hr after stopping the infusion of
morphine.
In the primary physical dependence (PPD) study, the rats received
test compound for 6 days and then were placed in abrupt with-
drawal and observed as above. Occasionally a drug was given
along with morphine.
Table I
Comparative Data-ED50, mg/kg S.C. (95% C.L.) of Selected
Standards in 3 Mouse Agonist-Antagonist Tests
Drug Tail-Flick Tail-Flick Phenylquinone
Test Antagonism Test Test
Pentazocine 15% at 10.0 18 (12.4-26) 1.65
Cyclazocine 17% at l.Oa 0.03 (0.02-.78) 0.011 (0.0046-
0.03)
Nalorphine*HCl None at 10.0 2.6 (0.69-9.75) 0.6 (0.025-
1.44)
Naloxone*HCl None at 10.0 0.035 (0.010- No Activity
0.93)
Naltrexone •HCl None at 10.0 0.007 (0.002- No Activity
0.02)
Morphine Sulfate 5.8 (5.7-5.9) ---- 0.23 (0.20-
0.25)
aMice were ataxic at 3.0 and 10.0 mg/kg but no further increase
in reaction time was seen.
Three mouse tests were used in our laboratory to provide a
preliminary estimate of the potency and profile of activity of
each test compound. The tests were the tail-flick agonist (TF)
393
and the morphine antagonist (TF vs M) tests and the phenylquinone
(PPQ) test (Dewey et al., 1970; Dewey and Harris, 1971).
Reference-standard data for these tests are shown in Table 1. In
addition, Dr. Jacobson provided us with estimated starting doses.
These doses were based on results obtained from the mouse-hot
plate (HP) (Eddy and Leimbach, 1953; Jacobson and May, 1965;
Atwell and Jacobson, 1978) and Nilsen (N) (Perrine et al., 1972)
tests from his laboratory. Reference data for these tests are
shown in Table 2.
Table 2
Comparative Data (ED50 mg/kg s.c.) [95% S.E.] from the Hot
Plate and Nilsen Test
Compound Hot Plate Test Nilsen Test
Subcutaneous Subcutaneous
Oral Oral
Morphine Sulfate
Codeine Phosphate
Levorphanol Tartrate
Meperidines·HCl
(-)-Metazocines·HBr
Dihydromorphinone·HCl
Nalorphine·HCl
Cyclazocine
Pentazocine
Chlorpromazine·HCl
0.98(0.83-1.1)
6.3(4.7-8.3)
6.8(4.5-10.2)
13.5(9.7-18.7)
0.2(0.1-0.3)
-
5.3(4.0-7.1)
-
0.6(0.5-0.9)
10.6(8.0-14.1)
0.19(0.15-0.25)
0.9(0.7-1.2)
9.9(5.7-2.1)
-
1.5(1.1-2.1)
-
9.3(6.7-12.8)
-
1.1(0.9-1.5)
-
1.3(1.0-1.7)
8.3(6.0-11.4)
7.4(4.9-11.0)
14.7(9.2-23.3)
0.2(0.16-0.3)
2.5(1.7-3.7)
-
-
0.5(0.3-0.7)
26.0(21.0-33.0)
0.2(0.15-0.3)
1.8(1.5-2.1)
23.0(16.2-32.7)
-
0.1(0.07-0.16)
-
6.5(4.4-8.8)
-
-
-
Naloxone·HCl and Naltrexone·HCl, no dose response.
Phenobarbital, Amobarbital, Valium, Oxazepam, Flurazepam,
Mepromate and Mescaline are inactive on the hot plate test.
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SUMMARY OF COMPOUNDS TESTED
COMPOUND #
NIH MCV
7569
7571
7981
8211
8374
8683
10093
10124
10165
10249
10253
10258
10274
(8359)
10275 4386 butorphanol
4501, 4430
4502, 4431
4510
4526
4480
4403
4438
4336
4348
4388
4389
4390
4385
CHEMICAL CLASS
OR GENERIC NAME
(-)-metazocine
(+)-metazocine
(±)-cyclazocine
cocaine
6.7-benzomorphan
meptazinol
endoethenotetrahydrooripavine
nalorphine
(±)-ethylketocyclazocine
6,7-benzomorphan
6,7-benzomorphan
quinuclidine
nalbuphine
MOUSE RAT MONKEY
TF, TFvsM, PPQ, HP, N SM, PPD SDS, PPt-W, PPD
+ + + + + + +
+ + + + +
+ + + a , b + +
+
+ + + + +
+ + + + + +
+ c
+ c
+ + +
a , b
+
+ + + +
+ + + +
+ + + +
+ + + +
+ + + + + + +
COMPOUND # CHEMICAL CLASS
NIH MCV OR GENERIC NAME
10319
(10455)
10322
10324
10331
10333
10334
10335
10346
10347
10348
10349
10357
10362
10363
4400, 4521 piperazined
4404 14-hydroxydihydromorphinone
4408 14-hydroxydihydromorphinone
4465 6-morphinone
(6-oxomorphinan)
4409 dihydrocarbostyril
4410 dihydrocarbostyril
4411 dihydrocarbostyril
4414 (±)-ketocyclazocine
4417 quinuclidine
4418 methyleneoxy-6,7-benzomorphan
4419 methyleneoxy-6,7-benzomorphan
4433 14-hydroxydihydromorphinone
4422 quinuclidine
4425 14-hydroxydihydromorphinone
MOUSE RAT MONKEY
TF, TFvsM, PPQ, HP, N SM, PPD SDS, PPt-W, PPD
+ + + + +
+ + + + +
+ + + +
+ + + +
+ + + + + +
+ + + + +
+ + + + +
+ +
a , b +
+ + + +
+ + + +
+ + + +
+ + + + + +
+ + + +
+ + + + + +
COMPOUND #
NIH MCV
10365
10366
10367
10368
10369
10370
10371
10372
10379
10380
10385
(2820)
10386
10387
10388
10389
4426
4423
4424
4434
4435
4436
4466
4437
4455
4456
4457
4458 diphenylhexan-3-one
4459 diphenylhexan-3-one
4460 diphenylhexan-3-one
4467 diphenylhexan-3-one
CHEMICAL CLASS MOUSE RAT MONKEY
OR GENERIC NAME TF, TFvsM, PPQ, HP, N SM,PPD SDS, PPt-W, PPD
nalmefene
14-hydroxydihydromorphinone
14-hydroxydihydromorphinone
methyleneoxy-6,7-benzomorphan
methyleneoxy-6,7-benzomorphan
methyleneoxy-6,7-benzomorphan
4,14-dimethoxymorphinan-6-one
tetrahydronaphthalene
methyleneoxy-6,7-benzomorphan
methyleneoxy-6,7-benzomorphan
diphenylhexan-3-one
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+ +
+
+
+
+
+
+
+ +
+
+
+
+
+
+
COMPOUND #
NIH MCV
10391
10393
10396
10398
10408
10409
10413
10416
10421
4464
4462
4463
4481
4482
4483
4476
4477
4484
10422 4485
10423 4486
10425 4488
10429 4475
10432 4493
10433 4494
CHEMICAL CLASS MOUSE RAT MONKEY
OR GENERIC NAME TF, TFvsM, PPQ, HP, N SM, PPD SDS, PPt-W, PPD
diphenylhexan-3-one
cyclohexylphenylhexan-3-one
diphenylhexan-3-one
(-)-eseroline
5-methoxyindoline
5-methoxyindoline
methyleneoxy-6,7-benzomorphan
6,7-benzomorphan
(-)-eserine
(physostigmine)
(-)-eseroline
5-hydroxyindoline
5-hydroxyindoline
4-tryptophan
4-phenylpiperidine
4-phenylpiperidine
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
-I-
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
COMPOUND #
N I H MCV
CHEMICAL CLASS
OR GENERIC NAME
MOUSE RAT MONKEY
TF, TFvsM, PPQ, HP, N SM, PPD SDS, PPt-W, PPD
10434
10439
10440
10449
10450
10451
10452
10453
10454
10455
10456
10457
10460
10461
4495 4-phenylpiperidine
4504 (+)-eseroline
4503 4-phenylpiperidine
4511 (+)-cyclazocine
4512 (-)-cyclazocine
4513 (-)-ketocyclazocine
4515 (-)-ethylketocyclazocine
4519 4-phenylpiperidine
4520 4-phenylpiperidine
10319 piperazined
4522 4-anilinopiperidine
4523 4-anilinopiperidine
4527 4-anilinopiperidine
4528 4-anilinopiperidine
+ +
+ +
+ +
+ +
+ +
+ + +
+ + +
+ + +
+ + +
+ +
+ +
+ +
+
+
+ a , b
+ a , b
+ a , b
+ +
+ +
+ +
+ +
+ +
+ +
+ + +
aNaloxone AD50 vs. ED80, bYohimbine AD50 vs. ED80, cSpecial i.v. study, dSubmitted twice under
different code numbers
NIH 7569, MCV 4430, 4501, UM 743 (-)-2'-Hydroxy-2,5,9a-trimethyl-
6,7-benzomorphan hydrobromide [(-)-metazocine]
MOUSE DATA ED50 or AD50 (95% C.L.)
(mg/kg s.c.)
1) TF- 0.81 (0.33 - 1.98)
2) TF vs. M - Inactive at 1.0,
10.0 and 30.0
3) PPQ - 0.3 (0.1 - 0.91)
4) H P - 0.62 (0.45 - 0.91)
5) N - 0.40 (0.32 - 0.67)
Rodent data reported previously
RAT INFUSION
(SM and PPD)
As shown in the figure and table (-)-metazocine nearly substitu-
ted for morphine. Note that when it was withdrawn at the end of
day 8, the rats promptly went into complete withdrawal. When
given alone for 6 days, it produced physical dependence as evi-
denced by the loss of body weight and the development of typical
behavioral withdrawal signs. Control vehicle and morphine-
treated rats behaved as expected.
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1 7 2 - 6 8 2 0 - 87 - 14
NIH 7569, MCV 4430, 4501, UM 743 (-)-2'-Hydroxy-2,5,9a-trimethyl-
6,7-benzomorphan hydrobromide [(-)-metazocine]
(cont...)
Substitution for morphine and primary physical dependence
studies in the rat with (-)-metazocine
Treatment Hour after termination of infusion
24 48 72 96
H2O Control
a
N=4
Morphine Infusionb
N=4
Morphine Infusion
plus (-)-Metazocinec
substitution (SDS)
N=4
2.3 1.0 0.8 0.5
7.5 6.5 5.5 2.0
0.8 1.5 5.0 1.8
0.20 0.50 0.02 0.34
(-)-Metasocine
Infusiond (PPD) 8.6 5.2 1.4 2.6
N=5 0.008 0.03 0.06 0.09
Mean number of withdrawal signs (hypersensitivity, squeaking,
aggression, wet-dog shakes, rubbing and chewing) noted during
1/2-hr observation periods at specified intervals and calculated
probability values (one-tailed Mann-Whitney U-test) when com-
pared with H2O controls.
a8ml/24 hr
b50 mg/kg/24 hr on day 1, 100 mg/kg/24 hr on day 2; 200 mg/kg/24
hr on days 3-6;
c50 mg/kg/24 hr days 7-8
d25 mg/kg/24 hr day 1; 50 mg/kg/24 hr on day 2, 24 mg/kg/24 hr
on days 3-6.
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NIH 7571, MCV 4431, 4502. UM 744 (+)-2'Hydroxy-2,5,9a-trimethyl-
6,7-benzomorphan hydrobromide [(+)-Metazocine]
MOUSE DATA ED50 or AD50 (95% C.L.)
(mg/kg s.c.)
See optical isomer
NIH 7569
1) TF- Inactive at 1.0, 10.0 and
30.0
2) TF vs. M - 0% at 15; 23% at
20.0; 56% at 30.0; 68% at 60.0
3) PPQ -
4) H P - Inactive at 20.0
5) N - Inactive at 20.0
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NIH 7981, MCV 4510 (±)-2-Cyclopropylmethyl-5,9a-dimethyl-2'-
hydroxy-6,7-benzomorphan [(±)-Cyclazocine]
MOUSE DATA ED50 or AD50 (95% C.L.)
mg/kg s.c.)
1) TF- 17% at 10.0
a
2) TF vs. M -
3) PPQ - 0.05 (0.03 - 0.11)b,c
0.03 (0.2-0.78)
4) HP - 1.5 (0.7 - 0.16)
5) N - 0.11 (0.07 - 016)
Reported previously
Naloxone AD50 vs ED80 of NIH 7981
= 0.3 (0.09 - 0.85)
CYohimbine inactive vs ED80 of NIH
7981
NIH 8211, MCV 4526 Cocaine hydrochloride
Rat Infusion (PPD)
When given to rats continuously either at a dose of 50 mg/kg/day
for 6 days, or at a dose regimen of 10 mg/kg/day on days l-3 and
100 mg/kg/day on days 4-6. cocaine did not significantly affect
either body weight, water consumption or overt behavior during
drug administration and during abrupt withdrawal in sharp con-
tract with morphine (see Fig. and Table). However, at both dose
regimens the animals showed significantly less spontaneous
activity in the photocell activity cages just before the initia-
tion of abrupt withdrawal of drug on day 6, but not during abrupt
withdrawal.
404
NIH 8211, MCV 4526 Cocaine hydrochloride
(cont....)
Table (Cocaine)
Meansa of Withdrawal Signsb of Morphine-Treated and
Cocaine-Treated Rats Compared With H2O Controls
HOURS IN WITHDRAWAL
Treatment 0 24 48 72 96
H2O Controls
C 0.5 0 0 0 0
Cocained 1.3 0 1.0 0 0.3
Cocainee
Morphine Controlsf
4.0 0 0 0 0
1.2 5.3a 13.3a 13.7a 14.0a
a Significant at p < 0.05, one-tailed test (Mann Whitney U-test)
b Hypersensitivity, squeaking, aggression, wet-dog shakes, rub-
bing, chewing
c N=4, 7m1/24 hr
d N=4, 50 mg/kg/day (days 1-6)
e N=2, 10 mg/kg/day (days 1-3), 100 mg/kg/day (days 4-6)
f N=3, 50 mg/kg 1st day, 100 mg/kg 2nd day, 200 mg/kg days 3-5.
H2O days 7-10
405
NIH 8374, MCV 4480, UM 696 (+)-2,9 -Dimethyl-2'-hydroxy-5-
propyl-6,7-benzomorphan hydrochloride
MOUSE DATA ED or AD50 (95% C-L.)
(mg/kg s.c.)
1) TF- Inactive at 1.0, 10.0
and 30.0
2) TF vs. M - 21.5 (13.4 - 34.5)
3) PPQ - 3.1 (0.9 - 10.7)
HP - 12.3 (10.0 - 15.2)
NIH 8683, MVC 4403, UM 888 m-(3-Ethyl-1-methylhexahydro-1H-
azepine-3-yl) phenol hydrochloride (Meptazinol hydrochloride)
MOUSE DATA ED or AD50 (95% C.L.)
(mg/kg i.v.)
1) TF - 12.8 (5.8 - 28.3)
2) TF vs. M - Inactive at 1.0,
10.0 and 30.0
3) PPQ - 1.6 (0.5 - 5.1)
4) HP - 5.3 (4.0 - 7.1)
MONKEY DATA
A. (SDS) # Animals , 3 , 3 , 2
a,
Dose (mg/kg s.c.) 3.2 0.8 0.2
3(Morphine), 3(H2O)
3.0 1 ml/kg
As shown in the figure, NIH 8683 did not substitute for morphine
in the dose range studied. Tremors were noted at the 2 higher
doses.
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NIH 8683, MVC 4403, UM 888 m-(3-Ethyl-1-methylhexahydro-1H-
azepine-3-yl) phenol hydrochloride (Meptazinol hydrochloride)
NIH 8683 precipitated some withdrawal signs at the highest dose.
Although the drug acted promptly, it had a short duration of
action (approx. 1 hr, see figure).
aNot plotted, N=2.
RAT DATA
A. Substitution for morphine study: As shown in the first
figure at doses of 100 or 200 mg/kg/24 hr, NIH 8683 did not sub-
stitute for morphine. The animals receiving both dose regimens
lost as much body weight as the morphine controls. In addition,
as shown in Table 1, the animals receiving the lower dose also
manifested opioid-like withdrawal signs. At the highest dose,
although the means at 48 and 72 hr appear large and approach sta-
tistical significance when compared to the water controls, most
of the withdrawal signs were generated by only 2 rats. It is
also possible that higher doses might have substituted.
407
B. (PPt-W) # Animals 2a , 4 , 3 ,
Dose (mg/kg s.c.) 6.4 3.2 0.8
2a , 4 (Naloxone), 4(H2O)
0.2 0.05 1 ml/kg
NIH 8683, MVC 4403, UM 888 m-(3-Ethyl-1-methylhexahydro-1H-
azepine-3-yl) phenol hydrochloride (Meptazinol hydrochloride)
(cont....)
FIGURE 1
B. Primary Physical Dependence Study (PPD): In the second
figure and table are shown the results of the PPD study. NIH
dependence study. At both dose schedules, the drug produced
physical dependence indistinguishable from that observed in the
morphine controls as evidenced by loss of body weight and deve-
lopment of withdrawal syndrome after NIH 8683 was abruptly with-
drawn. We recently reconfirmed these results using the lower
dose regimen.
408
NIH 8683, MVC 4403, M 888 m-(3-Ethyl-l-methylhexahydro-1H-
azepine-3-yl) phenol hydrocfhloride (Meptazinol hydrochloride)
(cont....)
FIGURE 2
General Conclusions and Recommendations
NIH 8683 (racemate) is showing an unusual profile of activity.
In the mouse, the compound has an antinociceptive profile of
activity similar to that of morphine. In the morphine-dependent
rhesus monkey, it appears to be a weak morphine antagonist.
Finally, in the rat, the drug does not substitute for morphine
but produces morphine-like physical dependence. This compound
is related structurally to certain N-methyl benzomorphans and
homobenzomorphans. Extensive studies of the optical isomers of
these N-methyl derivatives revealed a remarkable separation of
agonist-antagonist properties among several species. Similar
studies of the optical isomers of NIH 8683 are recommended. In
addition, PPD studies of the racemate in rhesus monkeys are
urged.
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NIH 8683 TABLE 1
MEAN WITHDRAWAL SCORES1 AND PROBABILITY VALUES2 CALCULATED DURING 1 HOUR OBSERVATION PERIODS
AT SPECIFIED INTERVALS FOR COMPARIONS BETWEEN H2O ONLY GROUP AND NIH 8683 OR MORPHINE
CONTROLS IN A SUBSTITUTION FOR MORPHINE STUDY IN CONTINUOUSLY-INFUSED RATS
Treatment/24 hr
24
Hours in Withdrawal
48 72 96
H2O Only x = 0.8 x = 1.2 x = 1.4 x = 1.4
N=5 ------- ------- ------- -------
Morphine Sulfate Infusion3 x = 9.3 x = 12.3 x = 5.0 x = 4.0
p = 0.008 p = 0.008 p = 0.016 p = 0.076
Morphine Infusion4 x = 6.4 x = 12.4 x = 13.2 x = 6.4
8683C Substition p = 0.016 p = 0.048 p = 0.004 p = 0.012
Morphine Infusoin5 x = 10.6 x = 8.0 x = 10.4 x = 8.0
8683C Substitution p = 0.004 p = 0.155 p = 0.133 p = 0.274
1Hypersensitivity, 1 squealing, aggression, wet-dog shakes, rubbing and chewing
2One-tailed test (Mann-Whitney U-Test)
350 mg/kg - day 1, 100 mg/kg - day 2, 200 mg/kg - days 3-6, N=4
4100 mg/kg - days 7 and 8, N-5
5200 mg/kg - days 7 and 8, N=5
NIH 8683 TABLE 2
MEAN WITHDRAWAL SCORES1 AND PROBABILITY VALUES2 CALCULATED DURING ½ HOUR OBSERVATION PERIODS
AT SPECIFIED INTERVALS FOR COMPARIONS BETWEEN H2O ONLY GROUP AND NIH 8683 OR MORPHINE
CONTROLS IN A PRIMARY PHYSICAL DEPENDENCE STUDY IN CONTINUOUSLY-INFUSED RATS
Treatment/24 hr
24
Hours in Withdrawal
48 72 96
H2O Only
3 x = 0.8 x = 1.2 x = 1.4 x = 1.4
N=5 ------- ------- ------- -------
Morphine Sulfate Infusion4 x = 9.3 x = 12.3 x = 5.0 x = 4.0
p = 0.008 p = 0.008 p = 0.016 p = 0.076
NIH 8683C Infusion5
NIH 8683C Infusion6
p = 0.016 p = 0
x = 13.2 x = 1
p = 0.004 p = 0
1.8
.004
x = 2.8 x = 2.0
p = 0.111 p = 0.383
x = 4.4 x = 3.6
p = 0.0274 p = 0.0461
x = 11.8 x = 7.0
.075
3Studies shown in Tables 1 and 2 for NIH 8683 were done at same time. H2O and morphine controls
are the same and are listed each time to facilitate comparisons
4550 mg/kg - day 1, 100 mg/kg - day 2, 200 mg/kg - days 3-6, N-4
5650 mg/kg - day 1, 100 mg/kg - day 2, 200 mg/kg - days 3-6, N-5
100 mg/kg - day 1, 200 mg/kg - days 2-6, N=5
1Hypersensitivity, squealing, aggressor, wet-dog shakes, rubbing and chewing
20ne-tailed test (Mann-Whitney U-Test)
NIH 10093, MCV 4438 7 -Amino-6,14-endoethenotetrahydrooripavine
3) PPQ -
4) HP-
aVehicle - lactic acid plus H2O
MOUSE DATA ED50 or AD50 (95% C.L.)
(mg/kg i.v.)
1) TF -
2) TF vs. M - Inactive at 0.1,
1.0, 10.0 and 20.0a
Special i.v. study
NIH 10124, MCV 4436 Nalorphine hydrochloride
MOUSE DATA ED50 or
(mg/kg i.v.)
1) TF -
AD50 (95% C.L.)
2) TF vs. M - 0.8 (0.3 - 2.0)
3) PPQ -
4) H P -
Special i.v. study
zocine)
NIH 10165, 8848, MCV 4348, UM975 (±)-2-Cyclopropylmethyl-5-ethyl-
8-oxo-9 -methyl-6,7-benaomorphan methanesulfonate (Ethylketocycla-
MOUSE DATA ED50 or AD50 (95% C.L.)
(mg/kg s.c.)
3) PPQ - 0.05 (0.03 - 0.10)
b,c
4) HP - 0.09 (0.07 - 0.120)
a
aReported previously
bNaloxone AD50 vs ED80 of
NIH 8858 = 0.23 (0.12 - 0.46)
1.0)a
2) TF vs. M - Inactive at 1.0,
10.0 and 30.0a
1) TF - Inactive at 0.4 (0.1 -
cYohimbine inactive vs ED80 of NIH
8848 at 0.1, 1.0, 10.0 and 20.0
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NIH 10249, MCV 4388 N-(2,3-Epoxypropyl)normetazocine
MOUSE DATA ED50 or AD50 (95% C.L.)
(mg/kg s.c.)
1) TF- Inactive at 1.0, 10.0
and 30.0
2) TF vs. M - 9% at 1.0, 14% at
10.0 and 30% at 30.0
3) PPQ - 18.1 (11.7 - 28.0)
4) HP - Inactive at 20.0
NIH 10253, MCV 4389 N-(N-Phenylguanidino)-5,9-dimethyl-6,7-
benzomorphan hydrochloride
NIH 10258, MCV 4390
chloride
MOUSE DATA ED50 or AD50 (95% C.L.)
(mg/kg s.c.)
1) TF- Inactive at 1.0, 10.0
and 30.0
2) TF vs. M- 0% at 0.1, 24% at
1.0, 0% at 10.0 and 2% at 30.03)
PPQ - 15.6 (6.4 - 38.2)a
4) HP - Inactive at 50.0
Vehicle (assays 1,2,3) Tween 80 +
EtOH + H2O
al of 6 died of convulsions at 60.0
Ataxia also noted
3-(N-Propionyl)anilinoquinuclidine hydro-
1) TF - Inactive at 1.0, 10.0
and 30.0a
2) TF vs. M - Inactive at 1.0,
10.0 and 30.0
3) PPQ - 4.6 (1.6 - 13.6)
4) HP - Inactive at 50.0, 40% at
MOUSE DATA ED50 or AD50 (95% C.L.)
(mg/kg s.c.)
100.0
aStimulation at 30.0
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NIH 10274, 8359, MCV 4385, UM 686 Nalbuphine hydrochloride
MOUSE DATA ED50 or AD50 (95% C.L.)
(mg/kg s.c.)
1) TF - 10% at 1.0, 22% at 10.0,
and 15% at 30.0
2) TF vs. M - 20% at 1.0, 69%
at 3.0, 63% at 10.0 and 57% at
30.0
3) PPQ - 0.26 (0.09 - 0.81)
4) H P -
Rodent data reported previously.
MONKEY DATA # Animals , 3 , 3 , 3 (Morphine) ,
S D S Dose (mg/kg s.c.) 20.0 10.0 3.0
3(H2O)
1ml/kg
NIH 8359 partly suppressed withdrawal in withdrawn morphine-
dependent monkeys at the 2 higher doses. The drug has a quick
onset but a shorter duration of action than morphine (see
figure).
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NIH 10275, 8791, MCV 4386, UM 941 Butorphanol Tartrate
MOUSE DATA ED50
(mg/kg s.c.)
MONKEY DATA
1)
2)
3)
4)
5)
or AD50 (95% C.L.)
TF - Inactive at 1.0, 10.0
and 30.0
TF vs. M - Inactive at 1.0,
10.0 and 30.0
PPQ - a) Inactive at 1.0,
10.0 and 30.0
b) 15.0 (5.9 - 38.0)a
HP - 0.78 (0.6 - 1.0)
N - 0.09 (0.06 - 0.4)
aRepeated all other rodent
data reported previously.
A. (SDS) # Animals 3 , 3 ,
Dose (mg/kg s.c.) 0.5 0.05
3(Morphine), 3(H2O)
3.0 1 ml/kg
The drug did not substitute for morphine and may have exacerbated
withdrawal, (see figure).
B. (PPt-W) # Animals 1
a , 3 , 3 ,
Dose (mg/kg s.c.) 9.0 6.0 3.0
2a , 3 , 3(Naloxone), 3(H2O)
1.5 0.5 0.05 1 ml/kg
NIH 10275 did not precipitate a full withdrawal syndrome up to
the convulsive dose of 9.0 mg/kg. Some withdrawal signs were
noted namely, salivation, tremors, contact avoidance, pacing,
drowsiness and wet-dog shakes. Most of these signs were observed
at the 6.0 mg/kg dose. Only one monkey in the entire study
retched, vomitted, and vocalized when its abdomen was palpated.
Onset of action was rapid but duration was shorter than naloxone
(90 min). This drug appears to be an atypical antagonist.
a Not plotted, N less than 3.
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NIH 10275, 8791, MCV 4386, UM 941 Butorphanol Tartrate
(cont)....
NIH 10319, 10455, MCV 4400, 4521 N-Propargyl-N'-(3-trifluoro-
methylphenyl)piperazine hydrochloride
MOUSE DATA ED or AD50 (95% C.L.)
(mg/kg s.c.)
1)
2)
3)
4)
TF - Inactive at 1.0, 10.0
and 30.0
TF vs. M - Inactive at 1.0,
10.0 and 30.0
PPQ - 5.8 (1.5 - 22.0)
HP - 50% at 15. 50% at 20.0
MONKEY DATA
(SDS) # Animals 3 , 4 , 4 ,
Dose (mg/kg s.c.) 20.0 10.0 2.5
4(Morphine), 4(H2O)
3.0 1 ml/kg
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NIH 10319, 10455, MCV 4521, 4400 N-Propargyl-N'-(3-trifluoro-
methylphenyl)piperazine hydrochloride
(cont)....
NIH 10319 produced a dose-related suppression of withdrawal
signs. At the highest dose, it completely suppressed withdrawal
in 2 of 3 animals. Onset of action is rapid and duration of
action is shorter than that of morphine.
NIH 10322, MCV 4404 6 -(2-Carboxy-1-propenyl)-naltrex-6 -ol-
lactone
MOUSE DATA ED50 or AD50 (95% C.L.)
mg/kg s.c.)
1) TF- Inactive at 1.0, 10.0
and 30.0
2) TF vs. M - 1.6 (0.9 - 2.7)
a
3) PPQ - 11.7 (6.5 - 22.0)
a
4) HP- 50% at 20.0
5) N - 50% at 20.0
aVehicle - Tween80 + H2O
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NIH 10324, MCV 4408 6 -(2-Carboxy-1-propenyl)-oxymorph-6 -ol-
-lactone)
MOUSE DATA ED50 or AD50 (95% C.L.)
(mg/kg s.c.)
3) PPQ - 2.4 (1.1 - 5.3)
4) HP - 3.5 (2.4 - 5.3)
1) TF- 18.6 (12.5 - 27.8)
2) TF vs. M - Inactive at 1.0,
10.0 and 30.0
NIH 10331, MCV 4465 (-)-N-Cyclopropylmethylmorphinan-6-one
salicylate
MOUSE DATA ED50 or AD50 (95% C.L.)
(mg/kg s.c.)
1) TF - 0.9 (0.4 - 2.3)
2) TF vs. M - Inactive at 1.0,
10.0 and 30.0
3) PPQ - 0.2 (0.07 - 0.3)
4) HP - 0.4 (0.3 - 0.6)
NIH 10333, MCV 4409 (+)-7-Chloro-3-dimethylamino-1-methyl-3,4-
dihydrocarbostyril hydrochloride
MOUSE DATA ED50 or AD50 (95% C.L.)
(mg/kg s.c.)
1) TF- Inactive at 1.0, 10.0
and 30.0
2) TF vs. M - Inactive at 1.0,
10.0 and 30.0
3) PPQ - 10.1 (5.3 - 19.3)
4) HP- 40% at 50 mg/kg,
60% at 100 mg/kg
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NIH 10333, MCV 4409 (+)-7-Chloro-3-dimethylamino-1-methyl-3,4-
dihydrocarbostyril hydrochloride
(cont....)
MONKEY DATA
A. (SDS) # Animals 3 , 2 , 2 ,
Dose (mg/kg s.c.) 16.0 4.0 1.0
3(Morphine), 3(H2O)
3.0 1 ml/kg
As shown in the figure, this drug did not substitute for morphine
at 1.0 - 16.0 mg/kg and may have exacerbated withdrawal at the
highest dose.
B. (PPt-W) # Animals 2a , 3 , 3 ,
Dose (mg/kg s.c.) 32.0 16.0 4.0
3(Naloxone), 3(H2O)
0.05 1 ml/kg
This compound produced some withdrawal signs designated, pacing,
drowsiness, tremors, wet-dog shakes, and one animal retched at
the highest dose. The drug did not precipitate a full withdrawal
syndrome. In fact, at the highest dose, it also produced ataxia
and jaw sag in one animal (see figure).
aNot plotted N less than 3
419
NIH 10334, MCV 4410 (-)-7-Chloro-3-dimethylamino-1-methyl-3,4-
dihydrocarbostyril hydrochloride
MOUSE DATA ED50 or AD50 (95% C.L.)
(mg/kg s.c.)
See racemate NIH 10333 1)
2)
3)
4)
TF - Inactive at 1.0, 10.0
and 30.0
TF vs. M - Inactive at 1.0,
10.0 and 30.0
PPQ - 25.9 (11.9 - 56.3)
HP - 30% at 50 mg/kg
MONKEY DATA # Animals 3 , 3 , 2 ,
(SDS) Dose (mg/kg s.c.) 32.0 8.0 2.0
3(Morphine), 3(Morphine),
1 ml/kg 3.0
NIH 10334 did not substitute for morphine in the dose range 2.0 -
32.0 mg/kg. At the highest dose, some ataxia, jaw sag and saliva-
tion was noted.
NIH 10335, MCV 4411 (+)-7-Chloro-3-dimethylamino-1-methyl-3,4-
dihydrocarbostyril hydrochloride
MOUSE DATA ED50 or AD50 (95% C.L.)
(mg/kg s.c.)
see racemate NIH 10333 1) TF - Inactive at 1.0, 10.0
and 30.0
2) TF vs. M - Inactive at 1.0,
10.0 and 30.0
3) PPQ - 3.0 (1.2 - 7.0)
4) HP - 0% at 20 or 50 mg/kg
MONKEY DATA # Animals 2 , 3 , 2 ,
(SDS) Dose (mg/kg s.c.) 32.0 16.0 4.0
3 ( H 2 O ) 3(Morphine)
1 ml/kg 3.0
In the dose range of 1.0 - 32.0 mg/kg, NIH 10335 did not substi-
tute for morphine.
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NIH 10346, 8847, MCV 4414, UM 974 (±)-Ketocyclasocine
NIH 10347, MCV 4417
hydrochloride
MOUSE DATA ED50 or AD50 (95% C.L.)
(mg/kg s.c.)
1) TF - Inactive at 0.5, 5.0 and
20.0
2) TF vs. M-
3) PPQ - 0.1 (0.08 - 0.2)a'b
4) H P - a) 0.42 (0.32 - 0.56)
b) 0.65 (0.50 - 0.84)
aNaloxone AD50 vs ED80 of NIH
8847 is 0.5 (0.2 - 1.4)
bYohimbine AD50 vs ED80 of NIH
8847 is inactive at 0.1, 1.0,
10.0 and 20.0
2-Benzyl-3-phenyl- 2,3-quinuclidine
MOUSE DATA ED50 or AD50 (95% C.L.)
(mg/kg s.c.)
1) TF - Inactive at 1.0, 10.0
and 30.0
2) TF vs. M - Inactive at 1.0,
10.0 and 30.0
3) PPQ - Inactive at 1.0, 10.0
and 30.0
4) HP - Inactive up to 50.0,
convulsions
NIH 10348, MCV 4418 (-)-9 -(2-Carbethoxyethyl)-2'-methoxy-2-
methyl-5,1'-methyleneoxy-6,7-benzomorphan hydrochloride
MOUSE DATA ED50 or AD50 (95% C.L.)
(mg/kg s.c.)
1) TF - Inactive at 1.0, 10.0
and 30.0
2) TF vs. M - Inactive at 1.0,
10.0 and 30.0
3) PPQ - 0% at 1.0, 26% at 10.0,
43% at 30.0 and 54% at 60.0
4) HP- Inactive up to 50.0,
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NIH 10349, MCV 4419 (-)-9 -(3-hydroxypropyl)-2'-methoxy-2-methyl-
5,1'-methyleneoxy-6,7-benzomorphan hydrochloride
MOUSE DATA ED50 or AD50 (95% C.L.)
(mg/kg s.c.)
1) TF- Inactive at 1.0, 10.0
20% at 30.0
2) TF vs. M - 22% at 0.1, 35% at
1.0, 35% at 30.0 and 20% at
60.0
3) PPQ - Inactive at 1.0 and
30.0, 23% at 10.0
4) HP - Inactive at 5.0 and 20.0
NIH 10357, MCV 4433 17-Cyclopropylmethyl-3,14-dihydroxy-4,5
epoxy-68-fluoromorphinan hydrochloride
MOUSE DATA ED50 or AD50 (95% C.L.)
(mg/kg s.c.)
1) TF - Inactive at 1.0, 10.0,
and 30.0
2) TF vs. M - 0.003 (0.001 -
0.008)
3) PPQ - 16% at 0.5, 34% at 1.0,
61% at 10.0, 47% at 20.0 and
58% at 30.0
4) HP - Inactive
MONKEY DATA
A. (SDS) # Animals 3 , 3 ,
Dose (mg/kg s.c.) 0.01 0.001
3(Morphine), 3(H2O)
3.0 1 ml/kg
This compound did not substitute for morphine, instead, it
appeared to exacerbate withdrawal at the lowest dose (see
figure).
B. (PPt-W) # Animals 1
a , 3 , 3 ,
Dose (mg/kg s.c.) 0.001 0.01 0.05
3(Naloxone), 3(H2O)
0.05 1 ml/kg
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NIH 10357, MCV, 4433 17-Cyclopropylmethyl-3,14-dihydroxy-4,5
epoxy-6 -fluoromorphinan hydrochloride
(cont)....
As illustrated in the figure, NIH 10357 promptly precipitated
withdrawal. The action was dose related. The drug appears to be
similiar to naloxone.
aNot plotted in Figure, N=1.
NIH 10362, MCV 4422 2-Benzyl-3-phenyl-3-acetoxyquinuclidine
hydrochloride
MOUSE DATA ED50 or AD50 (95% C.L.)
1) TF- Inactive at 1.0, 10.0
and 30.0
2) TF vs. M - 34% at 1.0, 2% at
10.0 and 23% at 30.0
3) PPQ - Inactive at 1.0 and
10.0, 14% at 30.0
4) HP- Inactive at 5.0 and 20.0
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NIH 10363, MCV 4425 7 -(1-Carboxyvinyl)-6 -naltrexal lactone
MOUSE DATA ED50 or AD50 (95% C.L.)
(mg/kg s.c.)
1) TFa - Inactive at 1.0, 10.0
and 30.0
2) TF vs. Ma - 0.01 (0.03 -
0.03)
3) PPQ -
4) HP - Inactive at 20.0
aVehicle - Tween 80 + H2O
MONKEY DATA
A. (SDS) # Animals 3, 3,
Dose (mg/kg s.c.) 0.02 0.005
3(Morphine), 4 (Tween 80 + H2O)
3.0 1 ml/kg
As shown in the figure, a dose of 0.02 mg/kg exacerbated
withdrawal, whereas the 0.005 dose was inactive. Morphine
substituted completely.
B. PPt-W - 2 hr after morphine (nonwithdrawn animals)
# Animals 3 , 4 , (Morphine),
Dose (mg/kg s.c.) 0.12 0.08 3.0
4 (Tween 80 + H2O)
1 ml/kg
because N=1. The action resembles that of naloxone.
NIH 10363 promptly precipitated withdrawal at
0.12 mg/kg. The data for the 0.02 mg.kg dose
doses of 0.08 and
was not plotted
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NIH 10363, MCV 4425 7 -(1-Carboxyvinyl)-6 -naltrexal lactone
(cont....)
NIH 10365, MCV 4422 17-Cyclopropylmethyl-3,14-dihydroxy-4,5-
epoxy-7-methylenemorphinan hydrochloride (Nalmefene)
MOUSE DATA ED50 (95% C.L.)
1) TF - Inactive at 1.0,
10.0 and 30.0
2) TF vs M - 0.001 (0.002 -
0.004)
3) PPQ - Inactive at 0.003,
0.03, 1.0, 10.0 and 30.0
4) HP - Inactive
MONKEY DATA
(PPD)
The experimental details and summary are presented in the accom-
panying table. Three experimentally naive rhesus monkeys (2
males and 1 female) weighing 2.1 - 2.8 kg at the start of the
study were injected as indicated below and observed for ½ hr once
a day (a.m.) shortly after drug was administered.
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TABLE 1
Summary of a primary physical dependence study in rhesus monkeys with NIH 10365.
Day Dose  (mg/kg)
4-6 times a day
1. . . . . . . . . . O.la
2. . . . . . . . . . 0.2a
3. . . . ...... 0.4a
4 . . . . . . . . . . 0.8a
5 . . . . . . . . . . 1.6a
6-8......... 1.6b
9-l0........ 3.2a
ll-12........ 6.4a
13-16........ 6.4a
17 day Abrupt Withdrawal
18-22 ........ 6.4b
9.6b
Throughout the rest of study, the main signs observed were restlessness.
23-25 ........ By day 25, l/3 was slow and 3/3 were slow on days 26-29. On day 29, one
26-29 ........ 6.4b monkey had a swollen scrotum and moved about very slowly.
Comments
Although restlessness and fighting were the main signs noted during the first
10 days, these signs are not necessarily drug effects and may simply reflect
normal behavior while being observed. Drowsiness was noted in all the animals
on day 11. In addition, slowing was noted in all three subjects on day 12.
Salivation and scratching were the only signs observed on days 13 and 14.
On day 15, one monkey developed severe diarrhea and was treated accordingly.
Some slowing, restlessness and drowsiness were noted thru day 16.
Thirteen to fourteen hrs into abrupt withdrawal, the signs designated as
extreme restlessness (2/3)c, wet-dog shakes (2/3) and vocalization (2/3)
were seen.
TABLE 1
( . . . .cont)
30 day Abrupt Withdrawal
and Naloxone
Challenge
Conclusion
Severe slowing in 1 monkey and some restlessness (2/3) and drowsiness (3/3)
were noted. Nineteen hrs after abrupt withdrawal of NIH 10365, a naloxone
challenge of 1.0 mg/kg s.C. to 2 monkeys did not produce any remarkable signs.
During the afternoon, one male animal expired, and the following day the other
male was found dead. A gross autopsy was performed by a university veteri-
narian. Fluid retention in the thoracic and abdominal cavities and
gastrointestinal tract was observed. Some hemorraghic areas were observed on
the lungs of both animals.
NIH 10365 does not seem to have a significant opioid physical dependence
liability However, chronic and high doses of the drug apparently cause
fluid retention, and male monkeys seem to be more susceptible.
a 6 times a day at 6 a.m., 9 a.m., noon, 3 p.m., 6 p.m. and midnight.
b 4 times a day at 6 a.m., noon, 6 p.m. and midnight.
c Ratios refer to the number of animals showing a sign over the total number of subjects.
NIH 10366, MCV 4423 E-6-Carboethoxymethylene-6 -oxido-oxymorphone
MOUSE DATA ED50 or AD50 (95% C.L.)
(mg/kg s.c.)
1)
2)
3)
4)
TF - Inactive at 1.0, 10.0
and 30.0
TF vs. M - 0-29% from 0.1 to
30.0
PPQ - O-23% at 1.0, 10.0 and
30.0
HP - Inactive at 5.0 and 20.0
Vehicle - Tween 80 + H2O
NIH 10367, MCV 4424 Z-6-Carboethoxymethylene-6B-oxido-oxymorphone
acetate
MOUSE DATA ED50 or AD50 (95% C.L.)
mg/kg s.c.)
1) TF - 0.1 (0.04 - 0.3)
2) TF vs. M - Inactive at 1.0,
10.0 and 30.0
3) PPQ - 0.02 (0.09-0.05)
4) HP - 0.08 (0.06 - 0.1)
Vehicle - Tween 80 + H2O
NIH 10368, MCV 4434 (-)-2'-Methoxy-2-methyl-5,1'-methyleneoxy-9
propyl-6,7-benzomorphan hydrochloride
MOUSE DATA ED50 or AD50 (95% C.L.)
(mg/kg s.c.)
1) TF - 8.1 (2.3 - 28.2)
2) TF vs. M - Inactive at 1.0,
10.0 and 30.0
3) PPQ - 0.8 (0.3 - 2.8)
4) HP- Inactive up to 20.0
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NIH 10369, MCV 4435 (-)-2'-Hydroxy-2-methyl-5,1'-methyleneoxy-9
propyl-6,7-benzomorphan hydrochloride
MOUSE DATA ED50 or AD50 (95% C.L.)
(mg/kg s.c.)
1) TF - 0.4 (0.2 - 0.8)
2) TF vs. M - Inactive at 1.0,
10.0 and 30.0
3) PPQ - 0.1 (0.06 - 0.2)
4) HP - 1.8 (1.3 - 2.6)
NIH 10370, MCV 4436 (-)-2'-Acetoxy-2-methyl-5,l'-methyleneoxy-9
propyl-6,7-benzomorphan hydrochloride
MOUSE DATA ED50 or AD50 (95% C.L.)
(mg/kg s.c.)
4) HP - 30%  5.0, 20% at 20.0
3) PPO - 0.2 (0.1 - 0.3)
1) TF - 0.7 (0.5 - 1.0)
2) TF vs. - Inactive at 1.0,
10.0 and 30.0
NIH 10371, MCV 4466
mide
(-)-4,14-Dimethoxymorphinan-6-one hydrobro-
MOUSE DATA ED50 or AD50 (95% C.L.)
(mg/kg s.c.)
1) TF- 3.9 (1.5 - 10.3)
2) TF vs. M - Inactive at 1.0,
10.0 and 30.0
3) PPQ - 0.3 (0.1 - 0.8)
4) HP - Inactive up to 20.0, 10%
at 20.0
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NIH 10372, MCV 4437 2,2-Dimethyl-3-Dimethylamino-7-hydroxy-
1-tetralone hydrobromide
MOUSE DATA ED50 or AD50 (95% C.L.)
(mg/kg s.c.)
1) TF- 6.2 (2.2 - 17.6)
2) TF vs. M - Inactive at 1.0,
10.0 and 30.0
3) PPQ - 9.9 (5.7 - 17.3)
4) HP- Inactive at 5.0 and 20.0
Rodent data reported previously
MONKEY DATA
A. (SDS) # Animals 1
a , 4 , 3 ,
Dose (mg/kg s.c.) 1.5 6.0 12.0
4(Morphine), 4(H2O)
3.0 1 ml/kg
NIH 10372 produced a dose-related reduction in withdrawal signs
at 1.5-12.0 mg/kg (see figure). However, the drug did not
totally suppress the withdrawal signs. Lack of sufficient
compound precluded further testing at higher doses. Two animals
receiving the highest dose died approximately 3 weeks after
receiving drug. Gross autopsy did not reveal any abnormalities.
aNot plotted, N=1.
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NIH 10379, MCV 4455 (-)-2-Allyl-2'-hydroxy-5,1'methyleneoxy-9
propyl-6,7-benzomorphan hydrochloride
MOUSE DATA ED50 or AD50 (95% C.L.)
(mg/kg s.c.)
1) TF - Inactive at 1.0, 10.0
and 30.0
2) TF vs. M - 0.4 (0.1 - 1.0)
3) PPQ - 17% at 1.0 and 10.0,
40% at 30.0
4) HP - 20% at 20.0
NIH 10380, MCV 4456 (-)-2'-Hydroxy-5,1'methyleneoxy-2-phenethyl-
9 -propyl-6,7-benzomorphan hydrochloride
MOUSE DATA ED50 or AD50 (95% C.L.)
(mg/kg s.c.)
1) TF - 1.4 (0.9 - 2.4)
2) TF vs. M - Inactive at 1.0,
10.0 and 30.0
3) PPQ - 0.2 (0.1 - 0.4)
4) HP -
NIH 10385, MCV 4457, 2820, UM 118 6-Dimethylamino-4,4-diphenyl-
hexan-3-one hydrochloride
MOUSE DATA ED50 or AD5O (95% C.L.)
(mg/kg s.c.)
1) TF - 5.1 (3.1 - 8.4)
2) TF vs. M - Inactive at 1.0,
10.0 and 30.0
3) PPQ - 1.0 (0.3 - 3.0)
4) HP - 2.4 (1.7 - 3.3)
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NIH 10386, MCV 4458 6-Dimethylamino-4-(4-fluorophenyl)-4-phenyl-
hexan-3-one hydrochloride
MOUSE DATA ED50 or AD50 (95% C.L.)
(mg/kg s.c.)
1) TF - 30.0 (19.5 - 48.9)
2) TF vs. M - Inactive at 1.0,
10.0 and 30.0
3) PPQ - 9.2 (5.3 - 15.8)
4) HP - Inactive at 5.0 and 20.0
NIH 10387, MCV 4459 6-Dimethylamino-4-(4-chlorophenyl)-4-phenyl-
hexan-3-one hydrochloride
MOUSE DATA ED50 or AD50 (95% C.L.)
(mg/kg s.c.)
2) TF vs. M - Inactive at 1.0,
10.0 and 30.0
1) TF - Inactive at 1.0, 10.0
and 30.0
3) PPQ - 11% at 1.0, 17% at 10.0
and 14% at 30.0
4) HP - Inactive at 5.0 and 20.0
NIH 10388, MCV 4460 6-Dimethylamino-4-(4-bromophenyl)-4-phenyl-
hexan-3-one hydrochloride
MOUSE DATA ED50 or AD50 (95% C.L.)
mg/kg s.c.)
1) TF - Inactive at 1.0, 10.0 and
30.0
2) TF vs. M - Inactive at 1.0,
10.0 and 30.0
3) PPQ - 23% at 1.0, 19% at 10.0
and 16% at 30.0
4) HP - Inactive at at 5.0 and
20.0
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NIH 10389, MCV 4467 6-Dimethylamino-4-(4-methoxyphenyl)-4-phenyl-
hexan-3-one hydrochloride
MOUSE DATA ED50 or AD50 (95% C.L.)
(mg/kg s.c.)
1) TF - Inactive at 1.0, 10.0 and
30.0
2) TF vs. M - Inactive at 1.0,
10.0 and 30.0
3) PPQ - 19% at 1.0, 11% at 10.0
and 36% at 30.0
4) HP - Inactive at 5.0 and 20.0
NIH 10391, MCV 4464 6-Dimethylamino-4-(4-methylphenyl)-4-phenyl-
hexan-3-one hydrochloride
NIH 10393, MCV 4462
one hydrochloride
MOUSE DATA ED50 or AD50 (95% C.L.)
(mg/kg s.c.)
1) TF - 3.4 (1.7 - 7.1)
2) TF vs. M - Inactive at 1.0,
10.0 and 30.0
3) PPQ - 1.4 (0.7 - 2.8)
4) HP -
6-Dimethylamino-4-cyclohexyl-4-phenylhexan-3-
MOUSE DATA ED50 or AD50 (95% C.L.)
(mg/kg s.C.)
30.0
2) TF vs. M - 7.7 (3.0 - 20.2)
3) PPQ - 13.7 (12.5 - 15.1)
4) HP - Inactive at 5.0 and 20.0a
1) TF- Inactive at 1.0, 10.0 and
aWalked backward in circles
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NIH 10396, MCV 4463 6-Dimethylamino-4,4-(4,4'-difluorodiphenyl-
hexan-3-one hydrochloride
MOUSE DATA ED50 or AD50 (95% C.L.)
(mg/kg s.c.)
1)
2)
3)
4)
TF - Inactive at 1.0, 10.0 and
30.0
TF vs. M - 3% at 1.0, 23% at .
10.0 and 2% at 30.0
PPQ - Inactive at 1.0 and
10.0, 43% at 30.0
HP - Inactive at 5.0 and 20.0
NIH 10398;MCV 4481 (-)-Eseroline
MOUSE DATA ED50 or AD50 (95% C.L.)
(mg/kg s.c.)
1) TF - 2.3 (1.0 - 5.3)
2) TF vs. M - Inactive at 1.0,
10.0 and 30.0
3) PPQ - 0.7 (0.3 - 1.7)
4) HP - 1.6 (1.1 - 2.2)
NIH 10408, MCV 4482 (3S)-1,3-Dimethyl-3-(2-methylaminoethyl)-5-
methoxyindoline oxalate
MOUSE DATA ED50 or AD50 (95% C.L.)
(mg/kg s.c.)
1) TF - Inactive at 1.0, 10.0
and 30.0
2) TF vs. M - 18% at 0.3, 58% at
1.0, 31% at 3.0, 20% at 10.0
and 40% at 30.0
3) PPQ - 2.9 (0.9 - 9.3)
4) HP - Inactive at 5.0 and 20.0
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NIH 10409, MCV 4483 (3S)-1,3-Dimethyl-3-(2-dimethylaminoethyl)-5-
methoxyindoline oxalate
MOUSE DATA ED50 or AD50 (95% C.L.)
(mg/kg s.c.)
1) TF - Inactive 1.0, at 10.0
a n d  3 0 . 0
2) TF vs. M - 0% at 1.0, 54% at
3.0. 30% at 10.0 and 0% at
30.0
3) PPQ - 17% at 1.0, 66% at 3.0,
43% at 10.0 and 51% at 30.0
4) HP - Inactive at 5.0 and 20.0
NIH 10413, MCV 4476 (-)-2-Methyl-5,1' -methyleneoxy-9 -propyl-6,7-
benzomorphan hydrochloride
MOUSE DATA ED50 or AD50 (95% C.L.)
(mg/kg s.c.)
1) TF  -20.7 (14.3  30.1)
2) TF vs. M - Inactive at 1.0,
10.0 and 30.0
3) PPQ - 2.9 (1.3 - 6.3)
4) HP- Inactive at 5.0 and 20.0
NIH 10416 MCV 4477 (-)-2,5-Dimethyl-1'-hydroxy-9 -propyl-6,7-
benzomorphan hydrochloride
MOUSE DATA ED50 or AD50 (95% C.L.)
(mg/kg s.c.)
1) TF - Inactive at 1.0, 10.0 and
30.0a
2) TF vs. M - Inactive at 1.0,
10.0 and 30.0a
3) PPQ - 3.9 (1.8 - 8.7)
4) H P - Inactive at 5.0 and 20.0b
aConvulsions and lethality at 30.0
bTremors and convulsions
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NIH 10421 MCV 4484 (-)-Eserine (Physostigmine)
MOUSE DATA ED50 or AD50 (95% C.L.)
(mg/kg s.c.) Vehicle (Lactic acid
and H2O)
1) TF - 0.06 (0.05 - 0.08)
2) TF vs. M - Inactive at 0.5 and
1 . 0
3) PPQ - 0.05 (0.02 - 0.16) 1/6
died at 0.25 mg/kg
4) HP - Toxic at 0.5
NIH 10422 MCV 4485 (-)-Eseroline methylmethosulfate
MOUSE DATA ED50 or AD50 (95% C.L.)
(mg/kg s.c.)
1) TF - Inactive at 1.0, 10.0 and
30.0
2) TF vs. M - 11% at 1.0, 32% at
10.0 and 26% at 30.0
3) PPQ - 33% at 0.001, 47% at
0.01, 67% at 0.1, 55% at 1.0,
43% at 10.0 and 11% at 30.0
4) HP - Inactive at 5.0 and 20.0
NIH 10423 MCV 4486 (3S)-1,3-Dimethyl-3-(2-dimethylaminoethyl)-5-
hydroxyindoline hydrochloride
MOUSE DATA ED50 or AD50 (95% C.L.)
(mg/kg s.c.)
1) TF - Inactive at 0.1, 1.0,
10.0 and 30.0
2) TF vs. M - Inactive at 0.1,
10.0 and 30.0
3) PPQ - 9% at .O.l, 17% at 1.0,
29% at 10.0 and 11% at 30.0
4) HP- Inactive at 5.0 and 20.0
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NIH 10425 MCV 4488 (3S)-1,3-Dimethyl-3-(2-methylaminoethyl)-5-
hydroxyindoline hydrochloride
MOUSE DATA ED50 or AD50 (95% C.L.)
(mg/kg s.c.)
1) TF - Inactive at 0.1, 1.0,
10.0 and 18% at 20.0
2) TF vs. M - Inactive at 0.1,
1.0, 10.0 and 16% at 30.0
3) PPQ - 1.7 (0.1 - 27.7)
4) HP - Inactive at 5.0 and 20.0
TLC indicates major impurities
NIH 10429 MCV 4475 L-Tryptophan tartrate
MOUSE DATA
(mg/kg s.c.)
ED50 or AD50 (95% C.L.)
1) TF -
2) TF vs. M - 0% at 1.0, 26% at
10.0 and 30.0, 6% at 40.0
3) PPQ -
4) HP -
Vehicle - Tween 80 + H2O
MONKEY DATA # Animals 1
a , 3 , 3 ,
(SDS) Dose (mg/kg s.c.) 32.0 64.0 128.0
3(H2O+Tween 80) 3(Morphine)
1 ml/kg 3.0
As shown in the accompanying figure, tryptophan neither substi-
tuted for morphine nor exacerbated withdrawal.
aThis dose not plotted, N=1.
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NIH 10429 MCV 4475 L-Tryptophan tartrate
(cont....)
NIH 10432, MCV 4493 (±)-4-Phenyl-4-propionoxy-1,2,6-trimethyl-
piperidine hydrochloride
MOUSE DATA ED50 or AD50 (95% C.L.)
(mg/kg s.c.)
1) TF - 2.7 (1.0 - 7.5)
2) TF vs. M - Inactive at 1.0,
10.0 and 30.0
3) PPQ - 0.1 (0.03 - 0.5)
4) HP - 1.5 (1.1 - 2.1)
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NIH 10433, MCV 4494 (+)-4-Phenyl-4-propionoxy-1,2,6-trimethyl-
piperidine hydrochloride
MOUSE DATA ED50 or AD50 (95% C.L.)
(mg/kg s.c.)
See NIH 10432 1) TF- 0.7 (0.2 - 2.0)
2) TF vs. M - 0% at 1.0, 12% at
10.0 and 56% 30.0
3) PPQ - 0.2 (0.07 - 0.7)
4) HP - 1.1 (0.9 - 1.3)
NIH 10434, MCV 4495 (-)-4-Phenyl-4-propionoxy-1,2,6-trimethyl-
piperidine hydrochloride
See NIH 10432
MOUSE DATA ED50 or AD50 (95% C.L.)
(mg/kg s.c.)
1) TF - 11.0 (6.8 - 17.8)
2) TF vs. M - 0% at 0.1, 14% at
0.5, 8% at 1.0, 10% at 5.0,
12% at 10.0 and 0% at 25.0
3) PPQ - 3.0 (1.9 - 4.7)
4) HP - Inactive at 5.0 to 20.0
NIH 10439, MCV 4504 (+)-Eseroline sulfate
See optical isomer
NIH 10422
MOUSE DATA ED50 or AD50 (95% C.L.)
(mg/kg s.c.)
1) TF - 0% at 1.0, 14% at 10.0
and 13% at 30.0
2) TF vs. M - Inactive at 0.1,
1.0, 10.0 and 30.0
3) PPQ - 2.3 (0.5 - 9.6)
4) HP - Inactive at 5.0 to 20.0
TLC indicated major impurities
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NIH 10440, MCV 4503 N-(2-Carbethoxyethyl)-N-norketobemidone
hydrobromide
MOUSE DATA ED50 or AD50 (95% C.L.)
(mg/kg s.c.)
1) TF - Inactive at 0.1, 1.0,
10.0 and 30.0
2) TF vs. M - 10% at 0.01, 31% at
0.1, 0% at 1.0, 0% at 10.0 and
10% at 30.0
3) PPQ - Inactive at 0.1, 1.0,
10.0 and 30:0
NIH 10449, MCV 4511 (+)-Cyclazocine
MOUSE DATA
(mg/kg s.c.)
ED50 or AD50 (95% C.L.)
See racemate NIH 7981 1) TF -
2) TF vs. M -
3) PPQ - Inactive at 0.1 and 1.0
4) HP -
NIH 10450, MCV 4512 (-)-Cyclazocine
MOUSE DATA ED50 or AD50 (95% C-L.)
(mg/kg s.c.)
See racemate NIH 7981 1) TF -
2) TF vs. M -
3)
0.046)a,b
PPQ - 0 .014 (0.0045 -
4) HP -
aNaloxone AD50 vs ED80 of
(-)-cyclazocine = 0.7 (0.2 - 2.3)
bYohimbine inactive vs ED80 of
(-)-cyclazocine as an antagonist at
0.1, 1.0 and 10.0
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NIH 10451, MCV 4513 (-)-Ketocyclazocine
MOUSE DATA ED50 or AD50 (95% C.L.)
(mg/kg s.c.)
See racemate NIH 10346 1) TF -
2) TF vs. M -
3) PPQ - 0.06 (0.02 - 0.2)
a'b
4) HP -
aNaloxone AD50 vs ED80 of
(-)-ketocyclazocine = 0.15 (0.06 -
0.35)
bYohimbine inactive vs ED80 of
(-)-ketocyclazocine at 1.0, 10.0
and 20.0
NIH 10452, MCV 4515 (-)-Ethylketocyclazocine
MOUSE DATA ED50 or AD50 (95% C.L.)
(mg/kg s.c.)
See racemate NIH 10165 1) TF -
2) TF vs. M -
3) PPQ - 0.005 (0.002 - 0.011)
a'b
4) HP -
aNaloxone AD50 vs ED80 of
(-)-ethylketocyclazocine
ED80 = 0.9 (0.2 - 3.7)
bYohimbine inactive as an antago-
nist vs ED80 of (-)-ethylketocy-
clazocine at 10.0
NIH 10453, MCV 4519 N-(Carboethoxypropyl)-N-norketobemidone
oxalate
MOUSE DATA ED50 or AD50 (95% C.L.)
(mg/kg s.c.)
1) TF -
2) TF vs. M - Inactive at 1.0,
10.0 and 30.0
3) PPQ -
4) H P -
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NIH 10454, MCV 4520 N-(Carboethoxymethyl)-N-norketobemidone
oxalate
MOUSE DATA ED50 or AD50 (95% C.L.)
(mg/kg s.c.)
1) TF - Inactive at 1.0, 10.0 and
30.0
2) TF vs. M - Inactive at 1.0,
10.0 and 30.0
3) PPQ - 17% at 0.1, 20% at 1.0,
43% at 10.0 and 40% at 30.0
4) HP - Inactive at 20.0
NIH 10455a, 10319, MCV 4521, 4400 N-propargyl-N'-(3-trifluro-
methylphenyl)piperazine hydrochloride
MOUSE DATA ED50 or AD50 (95% C.L.)
(mg/kg s.c.)
See NIH 10319 1) TF- Inactive at 1.0, 10.0 and
30.0
2) TF vs. M - Inactive at 1.0,
10.0 and 30.0
3) PPQ - 3.3 (0.34 - 32.54)
4) HP - 50% at 15, 50% at 20.0
5) N -
MONKEY DATA # Animals , 3 , 3 ,
(SDS) Dose (mg.kg s.c.) 8.0 2.0
3(Morphine) 3(H2O)
3.0 1 ml/kg
At the highest dose, NIH 10455 substituted quickly, completely
but briefly for morphine. At the peak effect, the drug is
approximately 1/3 as potent as morphine (see figure). Some
eyelid ptosis and slowing were also observed at the highest dose.
aThis compound was submitted twice under different code numbers
and rodent and monkey studies were conducted each time in blind
studies.
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NIH 10455a, 10319, MCV 4521, 4400 N-propargyl-N'-(3-trifluro-
methylphenyl)piperazine hydrochloride
(cont)....
NIH 10456, MCV 4522 (±)-cis-3-Methylfentanyl hydrochloride
MOUSE DATA ED50 or AD50 (95% C.L.)
(mg/kg s.c.)
1) TF - 0.002 (0.001 - 0.006)
2) TF vs. M Inactive  at 0.0001,
0.01 and 0.1a
3) PPQ - 0.0001 (0.00008 -
0.00003)
4) HP - 0.0005 (0.0003 - 0.0007)
MONKEY DATA # Animals 3 , 3 ,
(SDS) Dose (mg/kg s.c.) 0.003 0.0005
3(Morphine), 3(H2O)
3.0 1 ml/kg
At the highest dose, NIH 10456 substituted completely for
morphine (see Figure). In addition, the animals developed body
sag and scratched themselves frequently. These signs are usually
seen when narcotics are given to non-tolerant monkeys. The drug
acted promptly and its duration of action was at least 2 1/2 hr.
Its potency is estimated to be 1000 x that of morphine.
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NIH 10456, MCV 4522 (±)-cis-3-Methylfentanyl hydrochloride
oxalate
(cont)....
NIH 10457, MCV 4523 (±)-trans-3-Methylfentanyl hydrochloride
MOUSE DATA ED50 or AD50 (95% C.L.)
mg/kg s.c.)
1) TF- 0.01 (0.005 - 0.03)
2) TF vs. M - Inactive at 0.005,
0.05 and 0.5
3) PPQ - 0.002 (0.001 - 0.003)
4) HP - 0.009 (0.006 - 0.013)
MONKEY DATA # Animals 3 , 3 ,
(SDS) Dose (mg/kg s.c.) 0.003 0.0005
3(Morphine), 3(H2O)
3.0 1 ml/kg
Dose-related suppression of withdrawal signs was observed (see
figure). At the highest dose, the drug substituted completely
for morphine. The drug acted promptly but its duration of action
was relatively short (about 90-120 min) compared with morphine.
Potency estimate is 600 x morphine at peak effect.
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NIH 10457, MCV 4523 (+)-trans-3-Methylfentanyl hydrochloride
(cont)....
NIH 10460, MCV 4527 1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine
(PEPAP)
MOUSE DATA ED50 or AD50 (95% C.L.)
(mg/kg s.c.)
1) TF- 0.83 (0.35 - 1.97)
2) TF vs. M - Inactive at 1.0,
10.0 and 30.0
3) PPQ - 0.04 (0.01 - 0.16)
4) HP- 0.74 (0.53 - 1.04)
MONKEY DATA # Animals 4 , 3 ,
(SDS) Dose (mg/kg s.c,) 1.0 0.25
3(Morphine), 3(H2O)
3.0 1 ml/kg
NIH 10460 substituted completely for morphine. The drug acted
promptly and its duration of action was about 2 hr (see figure).
Its potency is 10 x morphine. Body sag and frequent scratching
were seen at the highest dose. In the preliminary study in which
the animal received a cummulative dose of 3.0 mg/kg in l/2 hr,
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NIH 10460, MCV 4527 1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine
(PEPAP)
(cont)....
the animal was ataxic and did not require the usual injection of
morphine at noon.
NIH 10461, MCV 4528 1-Methyl-4-phenyl-4-propionoxypiperidine
hydrochloride (MPPP)
MOUSE DATA ED50 or AD50 (95% C.L.)
(mg/kg s.c.)
1) TF - 0.70 (0.34 - 1.43)
2) TF vs. M - Inactive at 1.0,
10.0 and 30.0
3) PPQ - 0.18 (0.01 - 0.23)
4) H P -
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NIH 10461, MCV 4528 1-Methyl-4-phenyl-4-propionoxypiperidine
hydrochloride (MPPP)
(cont)....
MONKEY DATA # Animals 4 , 3 ,
(SDS) Dose (mg/kg s.c.) 1.0 0.25
3 (Morphine), 3(H2O)
3.0 1 ml/kg
NIH 10461 promptly substituted completely for morphine but its
duration of action was only 60-90 min (see figure). Scratching
was observed at both doses. At its peak effect the drug is
approximately 10 times more potent than morphine. In the
preliminary study, after a cummulative dose of 3.0 mg/kg in 1/2
hr, ataxia, slowing, scratching and eyelid ptosis were observed.
A naloxone challenge (0.04 mg/kg) to this animal precipitated
withdrawal. A bloody ejaculate was noted. However, the urine
stream was clear.
447
Evaluation of New Compounds for
Opioid Activity: 1986 Annual Report
James H. Woods, Charles B. Smith, Fedor Medzihradsky,
Gail D. Winger, and Debra E. Gmerek
The evaluation of new compounds by the programs at the Univer-
sity of Michigan and the Medical College of Virginia is coordi-
nated by Dr. Arthur E. Jacobson, Medicinal Chemistry Section,
NIAKDD, National Institutes of Health, Bethesda, MD. The drugs,
which come originally from pharmaceutical companies, univer-
sities, and government laboratories, are submitted to Dr.
Jacobson, who performs the MOUSE ANALGESIA tests. Values
obtained in these tests for some representative opioid drugs are
given in Table I.
At the UM and MCV laboratories, drug samples arrive from Dr.
Jacobson with only the following information: (1) an identifying
NIH number, (2) molecular weight, (3) solubility information and
(4) a recommended starting dose. After the evaluation is
complete and the report submitted to Dr. Jacobson, the
mouse-analgesia data is released to the evaluating laboratory,
and the submitter is requested to release the chemical structure
within three years.
DRUG DISCRIMINATION IN RHESUS MONKEYS
We currently use two groups of monkeys to test the discrimina-
tive effects of submitted drugs. One of these groups are
trained to discriminate the administration of the kappa agonist
ethylketazocine (EKC). The other groups are trained to
discriminate the mu agonists, codeine or etorphine.
The procedures used with the EKC-trained monkeys have been
described in Bertalmio et al. 1982. The monkeys are removed
from their home cages each day and seated in primate restraining
chairs. These chairs are placed in isolation chambers equipped
with two response levers, several stimulus lights and a cup to
receive Noyes, banana-flavored pellets. These monkeys are
required to make 100 consecutive responses on the correct one of
the two levers and receive ten 300-mg food pellets. The right
lever is correct if they were given a subcutaneous injection of
0.0032 mg/kg EKC immediately prior to the start of the trial.
The left lever is designated correct if they were given a sham
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injection before the start of the trial. Each trial lasts
15-min and consists of an initial 10-min, black-out period
followed by a period of as long as 5 min, during which a blue
light is illuminated in the chamber and the monkey can respond
for food. If the food pellets are earned before the 5 min
period is completed, the lights are extinguished for the re-
mainder of this time. Typically, a daily session consists of
several 15 min trials. During a training session, if EKC is
given, it is given on the penultimate trial of that session.
Responding on the drug-appropriate lever is reinforced during
that trial and on the subsequent, final trial of the day. These
last two trials may be preceded by from zero to four sham trials
on a training day. A training session of six sham trials is
also scheduled from time to time.
With this type of multiple discrete trial training, the animals
can be tested with a cumulative dosing procedure. On a test
session, the first trial is preceded by an injection of saline,
and prior to subsequent trials, increasing, cumulative doses of
the test drug are administered. One hundred consecutive re-
sponses on either lever are reinforced throughout the test
session. The test drug is administered in increasing doses
until the monkey either responds on the drug-appropriate lever,
the response rate falls to less than half of the saline-control
rate, or six trials are given. In the latter situation, it is
assumed that the selected dose range is too low, and the test is
continued at higher doses on the next test session. Each test
session is preceded and followed by a training session. The
criterion for satisfactory performance must be met on each
training session that is followed by a test session. This
criterion is that at least 90% of the responses during each
trial of a training session must be on the injection appropriate
lever, either sham or EKC.
The procedure for the codeine-trained (or etorphine-trained)
monkeys is similar, but not identical. For simplicity, only the
codeine training procedure is described here. These animals are
also trained and tested in a discrete, multiple-trial paradigm.
The main difference between the codeine procedure and the EKC
procedure is that the codeine monkeys are on a fixed-ratio 20
schedule rather than a fixed-ratio 100 schedule and they receive
a single pellet for correct responses. They can earn as many as
10 pellets during the five minute, food-availability period of
each trial, but each pellet is earned by making 20 responses.
Because in this procedure, monkeys can switch from one lever to
another following the delivery of food, an additional criterion
is added for satisfactory performance. In addition to making
90% or more of their responses on the correct lever, the monkeys
must make fewer than 40 total responses prior to earning the
first food pellet of each trial. Tests of the discriminative
effects of submitted drugs in the codeine-trained monkeys are
also done using a cumulative dosing procedure with dosing
criteria identical to those used in the EKC-trained monkeys.
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DEPENDENCE EVALUATION IN RHESUS MONKEYS
The single-dose suppression (SDS) test determines the ability of
a drug to suppress the signs of withdrawal in monkeys which have
been made dependent by the chronic administration of morphine (3
mg/kg every six hours). Compounds suspected of having morphine-
antagonist properties are tested for their ability to precipi-
tate the withdrawal syndrome in nonwithdrawn (NW) morphine-
dependent monkeys. Nondependent monkeys (Normals) are used to
determine whether the acute effects of the test drug are rever-
sible by nalorphine or naloxone. In a primary dependence (PDS)
study, non-dependent monkeys receive the test drug every six
hours for 30 days to determine whether withdrawal signs will
appear when the animals are challenged with an antagonist or
when drug administration is discontinued.
Details of these techniques have been presented in the ANNUAL
REPORT to the Committee in 1963 (Minutes of the 25th Meeting) by
Deneau and Seevers (1963) and by Villarreal (1973).
SELF-ADMINISTRATION BY MONKEYS
Tests of self-administration determine the ability of the drug
to maintain responding in monkeys trained to self-inject co-
deine. Each of at least three monkeys is studied with saline as
a negative control and a number of doses of the test compound
until a maximum rate of responding was obtained or until, in the
absence of evidence of a reinforcing effect, observable changes
in behavior are produced by the compound.
The schedule of intravenous drug delivery is a fixed-ratio 30;
when a light above a lever was illuminated, the 30th response
produced a five-sec intravenous drug injection accompanied by
another light that is illuminated during drug delivery. After
each injection, a ten-min timeout condition was in effect during
which responses have no scheduled consequence and neither light
is illuminated. Each of the two daily sessions consist of 13
injections or 130 min, whichever occur first. Other details of
the procedure and initial findings with a variety of narcotics
are given in previous reports (Woods, 1977; 1980).
Doses of the drugs are typically described in terms of mg/kg/
injection (inj). Duplicate observations of codeine (0.32
mg/kg/inj) and of saline were obtained for each monkey. A
saline substitution was conducted before and after the series of
observations on a test drug; the control rates of codeine-rein-
forced responding were obtained by a random sampling of two
sessions interpolated between the drug-substitution sessions.
These data are represented in the following graphs with indivi-
dual symbols for each of the monkeys; each symbol is the mean of
duplicate observations for a given dose in each monkey. The
closed circles indicate the averaged data for observations on
the subset of monkeys used to study each drug under each of
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the experimental conditions. In all cases, the rates of res-
ponding given are those calculated during only the fixed-ratio
portion of each session.
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
Details of the binding assay have been described previously
(Woods et al., 1979; Medzihradsky et al., 1984). Briefly,
aliquots of a membrane preparation from rat cerebrum were
incubated with 3H-etorphine in the presence of 150 mM NaCl, and
in the presence of different concentrations of the drug under
investigation. Specific, i.e., opioid-receptor-related
interaction of 3H-etorphine was determined as the difference in
binding obtained in the absence and presence of an appropriate
excess of unlabeled etorphine. The potency of the drugs in
displacing the specific binding of H-etorphine was determined
from log-probit plots of the data. It should be noted that since
April 1982 the concentration of 3H-etorphine in the binding
assay was reduced from 3.0 nM to 0.5 nM, a concentration
approaching the KD of the radiolabeled opioid. This change was
implemented in order to let the determined EC50 approximate the 
true Kj of a given drug. However, due to the different concen-
trations of the radiolabeled ligand the EC50 determined since
April, 1982 are lower than those obtained previously. For the
purpose of reference, Table II contains EC50 values of represen-
tative opiates determined in binding assays using 0.5 nM 3H-
etorphine. Unless specifically noted in the Report, it should
be assumed that 0.5 nM etorphine was used in the binding assays.
INHIBITION OF TWITCH IN ELECTRICALLY-DRIVEN GUINEA PIG ILEUM AND
MOUSE VAS DEFERENS PREPARATIONS.
Currently, submitted drugs are evaluated only on the mouse vas
deferens preparation. See previous Annual Reports by us to the
Committee for details of procedure used in the assessment of
some of the drugs reported here. For details, see accompanying
article (Smith, C.B. this volume).
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TABLE I
MOUSE ANALGESIA. Before submission to The University of Michigan, all compounds are evaluated for
analgesic activity by Dr. Arthur E. Jacobson. Shown below are comparative data (
(95% Confidence Interval) from Hot Plate
ED 50mg/kq)
and Nilsena assays. umol/kg
Compound
HOT PLATE
(sc/mg/kg) (oral, mg/kg)
-------------- --------------
NILSEN
(SC, mg/kg) (oral, mg/kg)
-------------- --------------
NIH # (SC, umol/kg) (oral, umol/kg) (SC. umol/kg), (oral, umol/kg)
Morphine sulfate
NIH 0001, 9929
Codeine phosphate
NIH 0002
Levorphanol tartrate
NIH 4590
Meperidine.HCl
NIH 5221
(-)-Metazocine.HBr
NIH 7569
0.98 (0.83-1.1) 6.3 (4.7-8.3)
--------------- ----------------
2.9 (2.5-3.3) 18.9 (14.1-24.9)
6.8 (4.5-10.2)
----------------
17.1 (11.3-25.7)
13.5 (9.7-18.7)
---------------
34.0 (24.4-47.1)
0.2 (0.1-0.3) -
--------------
0.5 (0.2-0.7) -
5.3 (4.0-7.1) - - -
---------------- - - -
18.7 (14.1-25.0)
0.6 (0.5-0.9)
-------------
1.9 (1.4-2.8)
10.6 (8.0-14.1)
---------------
34.1 (25.7-45.3)
1.3 (1.0-1.7)
-------------
3.9 (3.0-5.1)
7.4 (4.9-11.0)
--------------
18.6 (12.3-27.7)
0.2 (0.16-0.3)
--------------
0.5 (0.4-0.7)
0.5 (0.3-0.7)
-------------
1.6 (1.0-2.3)
8.3 (6.0-11.4)
--------------
24.9 (18.0-34.1)
14.7 (9.2-23.3)
-------------
37.0 (23.2-58.7)
2.5 (1.7-3.7)
--------------
6.2 (4.2-9.1)
26.0 (21.0-33.0)
---------------
83.6 (67.5-106.1)
TABLE I Continued
Dihydromorphinone.HCl
NIH 0123
Nalorphine.HCl
NIH 2105
Cyclazocine
NIH 7981
Pentazocine
NIH 7958
Naltrexone.HCl
NIH 8503
Naloxone.HCl
NIH 7890
0.19 (0.15-0.25) 0.9 (0.7-1.2)
---------------- -------------
0.6 (0.5-0.8) 2.8 (2.2-3.7)
9.9 (5.7-17.1) -
----------------
28.4 (16.4-49.1) -
1.5 (1.1-2.1) -
------------- -
5.5 (4.1-7.7) -
9.3 (6.7-12.8) -
---------------
32.6 (23.5-44.9)
0.2 (0.15-0.3)
--------------
0.6 (0.5-0.9)
23.0 (16.2-32.7)
----------------
66.1 (46.6-94.0.)
0.1 (0.07-0.16)
---------------
0.4 (0.3-0.6)
6.5 (4.4-8.8)
----------------
22.8 (15.4-30.9)
No dose response
No dose response
1.8 (1.5-2.1)
--------------
5.6 (4.7-6.5)
-
-
-
-
-
-
-
-
- -
--------------------------------------------------------------------------------------------------------------
No antinociceptive activity in hot plate assay: Phenobarbital, amobarbital, diazepam, meprobamate,
mescaline, oxazepam, flurazepam.
Chloropromazine.HCl 1.1 (0.9-1.5)
---------------
3.2 (2.4-4.2)
a) Eddy and Leimbach (1953); b) Jacobson and May (1965); c) Atwell and Jacobson (1978); d) Perrine,
Atwell, Tice, Jacobson and May (1972).
EC50 (nM)
+NaClCompound
TABLE II
EC50 of representative opioids in displacing
the specific binding of 0.5 nM 3H-etorphine
in a membrane preparation from rat cerebrum
-NaCl +Na/-Na
UM 911* 14.6 28.3 1.94
Morphine 14.0 23.6 1.69
Dextrorphan 6180 9820 1.59
UM 1071R* 1.14 1.55 1.36
Ketazocine 10.7 14.1 1.32
Ethylketazocine 5.22 6.60 1.26
(-)SKF 10047 4.09 3.93 0.96
Etorphine 0.47 0.37 0.79
(-)Cyclazocine 0.85 0.53 0.63
Naltrexone 1.43 0.63 0.44
NOTE: Binding data for these and other compounds, determined in
binding assays using 3.0 nM 3H-etorphine, are included in the
1978 and 1981 ANNUAL REPORTS.
*2-(3-methylfurfuryl)-2'-hydroxy-5,9a-dimethyl-6,7-benzomorphon
methane sulfanate.
** IR-5R-9R-2"R-5,9-dimethyl-2'-hydroxy-2-tetrahydrofurfuryl-
6,7- benzomorphan hydrochloride
SUMMARY OF TESTS PERFORMED
The compounds which were evaluated at the University of Michigan
during the past year, and the individual tests which were per-
formed are shown in Table III. Also shown are dates of Annual
Reports in which results are reported of earlier tests on those
compounds conducted at Michigan.
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UM NIH
0888 8683
1401 9625
1313 9931
9935
9947
9948
9949
9950
9955
1347 9975
1399 10036
10157
10158
10319
10333
10334
10335
10363
10366
10367
10368
10369
10370
MCV SDS NW N SA GPI MVD BIND PDS
4176
4271
4272
4273
4274
4275
4296
4349
4346
4440
4409
4410
4411
4425
4423
4424
4434
4435
4436
TABLE III
SUMMARY OF TESTS PERFORMED
CHEMICAL CLASS AND/OR
GENERIC NAME
Meptazinol
Benzomorphan
Morphinan
Morphinan
Peptide
Peptide
Peptide
Peptide
Phenylmorphan
Morphinan
Benzazocine
Benzomorphan
Benzomorphan
Phenylpiperazine
Dihydrocarbosytril
Dihydrocarbosytril
Dihydrocarbosytril
Oxymorphone
Oxymorphone
Oxymorphone
Benzomorphan
Benzomorphan
Benzomorphan
1973 1973 - + - + + 1973
- - - + _ 1982- -
- 1982 - - - + + -
- - - - + - + -
- - - - + + + -
- - - - + + + -
- - - - = = + -
- - - - = = + -
- - - - - + + -
1982 - - - - + + -
+ - 1985 1985- - - -
+ - - 1985- - 1985 -
- - - - - + + -
- - - - 1985 1985 - -
- - - - - + - -
- - - - - + + -
- - - - - + + -
- - - - - + + -
+ - - - - + + -
+ - - - - + + -
- - - - - + + -
- - - - - + + -
- - - - - + + -
UM NIH
10384 4448 Codeine
10440 4503 Phenylpiperidine
10453 4519 Phenylpiperidine
10454 4520 Phenylpiperidine
10456 4522 Methylfentanyl
10457 4523 Methylfentanyl
10460 4527 Phenylpiperidine
10461 4528 Phenylpiperidine
MCV
TABLE III (continued)
SUMMARY OF TESTS PERFORMED
CHEMICAL CLASS AND/OR
GENERIC NAME SDS NW N SA GPI MVD BIND PDS
- - - - - + + -
- - - - - + + +
- - - - - + + -
- - - - - + + -
- - - - + + - -
- - - - - + + -
- - - - - + + -
- - - - - + + -
1NIH 8683 3-(3-Ethylhexahydro-1-methyl-1 H-azepin-3-yl)pheno
hydrochloride (Meptazinol hydrochloride)
MOUSE ANALGESIA, ED50, (mg/kg)
Hot Plate: 5.3 (4.0 - 7.1)
This is an update of our previous report and includes a summary
of data obtained to date.
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of 1600 nanoM in the presence of 150 milliM NaCl.
MOUSE VAS DEFERENS PREPARATION
NIH 8683 was studied on the isolated, electrically stimulated
mouse vas deferens preparation in concentrations which ranged
from 10-8 M to 3 x 10-5 M. The EC50 for this drug was not
determinable since it did not suppress the twitch at any
concentration. In an equimolar concentration NIH 8683 did not
reverse the inhibitory action of a maximally effective
concentration of morphine (10 microM).
SELF-INJECTION STUDY
Self-administration of NIH 8683 was evaluated in seven rhesus
monkeys trained to respond for 0.32 mg/kg/inj codeine (Woods,
J.H., Drug and Alcohol Dependence, 1980, 8:233-230). Data from
one animal was discarded due to its high rates of
saline-maintained responding. Doses of 0.03, 0.10, 0.32 and 1.0
mg/kg/inj NIH 8683 were substituted for codeine during single
130 min sessions. Each dose was tested twice in at least four
of the six subjects. Rates maintained by NIH 8683 were slightly
above those maintained by saline at all doses. This is
illustrated in the accompanying figure, which shows the data
from the individual monkeys who are identified by number or by
name. There was more variability in the rates of responding
maintained by NIH 8683 than is generally the case in this type
of test. For this reason, the typical inverted-U shaped
function relating dose per injection to rate of responding did
not appear with NIH 8683.
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NIH 8683 3-(3-Ethylhexahydro-1-methyl-1 H-azepin-3-yl)phenol
hydrochloride (Meptazinol hydrochloride)
...(continued)
CODEINE DISCRIMINATION STUDY
Cumulative doses of from 0.1 to 5.6 mg/kg NIH 8683 were
administered to two rhesus monkeys trained to discriminate
0.00032 mg/kg etorphine from saline. The procedure has been
described (Bertalmio et al., J. Pharmacol. Meth., 7:289-299,
1982). NIH 8683 was tested four times in each monkey. One
monkey indicated that NIH 8683 had stimulus properties in common
with etorphine on all four occasions, at a dose of 1.0, 1.8 or
3.2. mg/kg. The second monkey indicated that NIH 8683 had
stimulus properties in common with etorphine on two of the four
occasions, and made the majority of his responses on the
etorphine-appropriate lever (65%) on a third occasion. This
monkey also showed etorphine-appropriate responding at doses of
1.0 mg/kg or above. Neither monkey responded on the
etorphine-appropriate lever with cumulative administration of
NIH 8683 following
44441 (quadazocine). Response rates were suppressed by doses of
presession administration of 1.0 mg/kg/Win
NIH 8683 of 3.2 or 5.6 mg/kg, and this was not modified by prior
administration of quadazocine.
ETHYLKETAZOCINE-DISCRIMINATION STUDY
Four monkeys trained to discriminate 0.0032 or 0.0056 mg/kg EKC
from sham injections were given increasing doses of NIH 8683 is
a procedure
discriminative
identical to that used to evaluate the
effects of etorphine. NIH 8683 produced
EKC-appropriate responding in each of the four monkeys at doses
of 0.1, 1.0, 3.2 or 10 mg/kg. Response rates were quite
suppressed at 10 mg/kg in all monkeys. The evaluation of NIH
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NIH 8683 3-(3-Ethylhexahydro-1-methyl-1 H -azepin-3-yl)phenol
hydrochlride (Meptazinol hydrochloride)
....(continued)
8683 was replicated in two of these monkeys and, on the second
occasion, EKC-appropriate responding did not develop.
MORPHINE-DEPENDENT MONKEYS
Doses of 3.0, 6.0 and 12.0 mg/kg were administered to
morphine-dependent rhesus monkeys. Increasing doses led to
increased severity of the withdrawal signs. (Reported
previously.)
PRIMARY DEPENDENCE STUDY
Doses of 8 and then 16 mg/kg NIH 8683 were administered every
six hours to rhesus monkeys. Doses of 24 and 32 mg/kg every six
hours produced convulsions, as did 16 mg/kg every four hours.
Both 8 and 16 mg/kg every six hours produced signs of mild CNS
depression mixed with signs of mild CNS stimulation. Chronic
administration of 16 mg/kg every six hours resulted in mild
physiological dependence demonstrated by withdrawal signs of
grade 0-1 on day 42 following nalorphine administration, and
withdrawal signs of grade 1-2 on day 33 following naloxone
administration. Abrupt withdrawal of NIH 8683 on day 48 re-
sulted in withdrawal signs of grade 0-1. (Reported previously.)
SUMMARY
NIH 8683 displaced etorphine only at very high concentrations.
It was neither an opioid agonist nor an antagonist in the mouse
vas deferens at the concentrations evaluated.
NIH 8683 did have opioid activity in vivo however. It produced
a quadazocine-reversible generalization to etorphine in two
rhesus monkeys, a mild degree of opioid-like physiological
dependence, and had a weak reinforcing effect. It also
generalized to EKC in four rhesus monkeys on initial evaluation,
but not on repeat evaluation in two of these animals. It is
most unusual to have a drug that produced both EKC and
etorphine-like discriminative effects.
NIH 8683 was a clear opioid antagonist in monkeys
physiologically dependent to morphine. It was approximately
1/40th the potency of nalorphine in this regard.
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NIH 9625 1-[2 ,6 ,11S)-(±)-1-(1,2,3,4,5,6-hexahydro-8-hydroxy-
3,6,11-trimethyl-2,6,methano-3-benzazocin-11-yl]-6-methyl-3-
heptanone methanesulfonate
MOUSE ANALGESIA, ED50, 
Hot Plate: 1.1 (0.8-1.3)
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of 1.96 nanoM in presence of 150 milliM NaCl
MOUSE VAS DEFERENS PREPARATION
Inhibitory
EC50 (M) Maximum Response
Drug alone
After naltrexone
With equimolar concentration
of naltrexone
Equimolar concentration
with morphine
SUMMARY
1.94 x 10-8 93.0 ± 6.3%
2.60 x 10-7 92.7 ± 2.0%
Reversal
No antagonism
NIH 9625 is a morphine-like agonist without antagonistic
activity. It is both equipotent and equi-effective when
compared with morphine. It is more potent than morphine in the
binding assay.
NIH 9931 (-)-N-Cyclopropylmethyl-4-methoxymorphinan-6-one
MOUSE ANALGESIA, ED50, (mg/kg)
Hot Plate: 21.7 (17.9-26.3)
 A s s a y : 0% at 10, 40% at 20
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NIH 9931 (-)-N-Cyclopropylmethyl-4-methoxymorphinan-6-one
....(continued)
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of 23.9 nanoM
MOUSE VAS DEFERENS
Drug alone
After naltrexone
in presence of 150 milliM NaCl.
PREPARATION
Inhibitory
EC50 (M) Maximum Response
3.55 x 10-7
3.81 x 10-8
38.8 ± 4.5%
10.6 ± 0.6%
With equimolar concentration
of naltrexone
Equimolar concentration
with morphine
SUMMARY
Reversal
Partial reversal
NIH 9931 appears to be a complex opiate agonist-antagonist upon
the isolated mouse vas deferens preparation. It is significan-
tly more potent in the binding assay than in the mouse vas
deferens.
NIH 9935 1-Bromo-4-hydroxy-6-keto-N-methylmorphinan hydrobro-
mide
M O U S E  A N A L G E S I A ,   
Hot Plate: 14.8 (11.3-19.3)
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of 459 nanoM in presence of 150 milliM NaCl.
MOUSE VAS DEFERENS PREPARATION
NIH 9935 did not alter the twitch of the mouse vas deferens
preparation at any concentration.
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NIH 9935 1-Bromo-4-hydroxy-6-keto-N-methylmorphinan hydrobro-
mide
. . . .(continued)
SUMMARY
NIH 9935 possesses weak opioid actions in either preparation.
NIH 9947 L-Tyrosyl-D-alanylglycyl-L-4-fluorophenylalanyl-L-phe-
nylglycinamide acetate
M O U S E  A N A L G E S I A ,   
Hot Plate: 2.1 (1.5-3.0)
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of 0.53 nanoM in presence of 150 milliM NaCl.
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN GUINEA PIG ILEUM
Drug alone
After naltrexone
After UM 979
Inhibitory
EC50 (M)  Maximum Response
5.32 x 10-10 64.8 ± 9.2%
6.72 x 1O-8 43.8 ± 10.3%
2.39 x 10-g 78.6 ± 11.1%
MOUSE VAS DEFERENS PREPARATION
Drug alone 2.61 x 10
-11
100%
After naltrexone 3.94 x 10
-11
99.2 ± 0.8%
After UM 979 2.07 x 10-11 100%
After ICI-174-864 3.51 x 10-9 95.5%
Inhibitory
EC50 (M) Maximum Response
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NIH 9947
nylglycinamide acetate
. . . .(continued)
SUMMARY
NIH 9947 is morphine-like upon the guinea pig ileum and is more
sensitive to antagonism by naltrexone than by UM 979. NIH 9947
is a very potent delta receptor agonist upon the mouse vas
deferens which is antagonized by ICI-174864, but not by UM 979
and only slightly by naltrexone. It is also a very potent
displacer of etorphine.
NIH 9948 L-Tyrosyl-D-alanylglycyl-N- -ethyl-1- m-bromophenyla-
lanine amide acetate
M O U S E  A N A L G E S I A ,   
Hot Plate: 3.3 (2.3-4.9)
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of 1.23 nanoM in presence of 150 milliM NaCl.
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN GUINEA PIG ILEUM
Inhibitory
EC50 (M)
Drug alone 1.06 x 1O-8
After naltrexone 5.72 x 1O-8
After UM 979 4.05 x 10-9
MOUSE VAS DEFERENS PREPARATION
Inhibitory
EC50 (M)
Drug alone
After naltrexone
After UM 979
Maximum Response
36.7 ± 4.5%
67.1 ± 6.4%
46.8 ± 9.0%
Maximum Response
2.47 x 10-10 100%
4.42 x 10-9 100%
5.24 x 10-10 100%
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NIH 9948 L-Tyrosyl-D-alanylglycyl-N-a-ethyl-1- m -bromopheny-
lalanine amide acetate
. . . .(continued)
SUMMARY
NIH 9948 is morphine-like upon both the guinea pig ileum and the
mouse vas deferens. It is much more potent than morphine upon
the vas deferens, and much less efficacious than morphine upon
the ileum.
assay; consistent with actions on the smooth muscle
It is a potent displacer of etorphine in the binding
preparation.
NIH 9949 N- -Methyl-L-tyrosyl-D-alanylglycyl-N- -ethyl-L-p-
fluorophenylalanine amide acetate
M O U S E  A N A L G E S I A ,   
Hot Plate: 0.07 (0.50-0.97)
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of 1.5 nanoM in presence of 150 milliM NaCl.
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN GUINEA PIG ILEUM
Drug alone 8.94 x 10
-12
After naltrexone 2.59 x 10
-8
After UM 979 2.50 x 10-9
Inhibitory
EC50 (M) Maximum Response
44.9 ± 5.6%
70.6 ± 2.7%
61.4 ± 1.8%
464
NIH 9949 N- -Methyl-L-tyrosyl-D-alanylglycyl-N- -ethyl-L-p -
fluorophenylalanine amide acetate
. . . .(continued)
MOUSE VAS DEFERENS PREPARATION
Drug alone
After naltrexone
After UM 979
Inhibitory
EC50 (M) Maximum Response
6.66 x 10-11 100%
5.96 x 10-9 100%
3.51 x 10-10 100%
SUMMARY
NIH 9949 is morphine-like upon both the guinea pig ileum and the
mouse vas deferens. It is much more
each of the preparations.
potent than morphine upon
It displaced 3H-etorphine in rat
brain membranes with high potency.
NIH 9950 N- -Methyl-L-tyrosyl-D-alanylglycyl-N- -cyclopropyl-
methyl-L- m-bromophenylalanine amide acetate
M O U S E  A N A L G E S I A ,   
Hot Plate: 2.1(1.1-4.2)
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of 0.33 nanoM in presence of 150 milliM NaCl.
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN GUINEA PIG ILEUM
Drug alone
After naltrexone
After UM 979
Inhibitory
EC50 (M) Maximum Response
9.58 x 10-11 36.8 ± 9.7%
1.75 x 10-8 51.6 ± 8.3%
1.35 x 10-9 46.2 ± 13.9%
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NIH 9950 N- -Methyl-L-tyrosyl-D-alanylglycyl-N- -cyclopropyl-
methyl-L- m-bromophenylalanine amide acetate
....(continued)
MOUSE VAS DEFERENS PREPARATION
Drug alone
After naltrexone
After UM 979
SUMMARY
Inhibitory
EC50 (M) Maximum Response
1.03 x 10-9 100%
3.79 x 10-8 100%
7. 43 x 10-10 100%
NIH 9950 is morphine-like upon both the guinea pig ileum and the
mouse vas deferens. It is more potent than morphine in each of
the three preparations and is markedly more potent in the
binding assay.
NIH 9955 (±)-2,9 -Dimethyl-5-(m-hydroxyphenyl)morpian hydro-
chloride
M O U S E  A N A L G E S I A ,   
Hot Plate: 10.0 (6.0-16.8*
Inactive
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of 292 nanoM in presence of 150 milliM NaCl
MOUSE VAS DEFERENS PREPARATION
NIH 9955 caused no inhibition of the twitch either with control
preparations or in the presence of naltrexone, 10-7 M. At a
concentration of 3 x 10-5 M, NIH 9955 caused an increase in the
magnitude of the twitch.
SUMMARY
This compound may have some opioid activity based only on the
findings from the binding assay. This was not corraborated by
the findings from the mouse vas deferens.
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NIH 9975 (-)-N-Allyl-14-hydroxy-4-methoxymorphinan-6-one
M O U S E  A N A L G E S I A ,   
Hot Plate: 0% at 20, 20% at 50
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of 194 nanoM in the presence of 150 milliM NaCl.
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
Inhibitory
EC50 (nM) Maximum Response
Drug alone 3.98 ± 1.03 40.0 ± 3.2%
After naltrexone 3.81 ± 0.75 39.5 ± 3.1%
With equimolar concentration
of naltrexone
Equimolar concentration
with morphine
SUMMARY
Slight reversal
Partial reversal
The findings from both preparations indicate opioid activity.
The compound may not have strong agonist actions; based on the
relatively low potency in the binding assay and lack of activity
in the mouse vas deferens.
NIH 10036 1,2,3,4,5,6-Hexahydro-9-methoxy-1,6-methano-3-benza-
zocine oxalate
M O U S E  A N A L G E S I A ,   
Hot Plate: 1.8 (1.1-2.7)
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NIH 10036 1,2,3,4,5,6-Hexahydro-9-methoxy-1,6-methano-3-benza-
zocine oxalate
. . . .(continued)
See 1985 Annual Report for in vitro studies.
SINGLE-DOSE SUPPRESSION STUDY
NIH 10036 was given cumulatively to 14-hr withdrawn morphine-
dependent monkeys (n=5) in doses of 1.0, 3.0 and 1.9 mg/kg.
There was a possible slight exacerbation of withdrawal observed
at 3.0 mg/kg, otherwise, no effects at the other doses.
NIH 10157 2'-Hydroxy-5-methyl-9 -(3-methyl)butyl-2-phenethyl-
6,7-benzomorphan oxalate
M O U S E  A N A L G E S I A ,   
Hot Plate: 50% at 50
See 1985 Annual Report for in vitro studies.
SINGLE-DOSE SUPPRESSION STUDY
NIH 10157 was given cumulatively to 14-hr withdrawn
morphine-dependent rhesus monkeys (n=3) at doses of 5.6 and 10.0
mg/kg. At these doses, NIH 10157 failed to alter withdrawal
signs.
NIH 10158 2'-Hydroxy-5-methyl-9 -(3-methyl)butyl-2-propyl-6,7-
benzomorphan oxalate
M O U S E  A N A L G E S I A ,   
Hot Plate: No dose response
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NIH 10158 2'-Hydroxy-5-methyl-9 -(3-methyl)butyl-2-propyl-6,7-
benzomorphan oxalate
. . . .(continued)
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of 165 nanoM in presence of 150 milliM NaCl.
MOUSE VAS DEFERENS PREPARATION
NIH 10158 did not inhibit the contraction of this preparation at
any concentration. Concentrations of 10
-6 M and higher
increased markedly the magnitude of the twitch. In a
concentration of 10-7 M, NIH 10158 did not reverse the
inhibition produced by an equimolar concentration of morphine
sulfate.
SUMMARY
NIH 10158 is devoid of opiate agonistic or antagonistic actions
upon the isolated mouse vas deferens preparation. This compound
is quite unusual in having a moderately high affinity for the
etorphine binding site without having significant opioid
activity in the mouse vas deferens.
NIH 10319 N-Propargyl-N'(3-trifluoromethylphenyl)piperazine.HCl
M O U S E  A N A L G E S I A ,   
Hot Plate: 60% at 100
See 1985 Annual Report for in vitro studies.
SINGLE-DOSE SUPPRESSION STUDY
NIH 10319 was given cumulatively to 14-hr withdrawn
morphine-dependent rhesus monkeys (n=6) at the following doses:
1.0, 3.2, 10, 18, 32. No effect was observed until 1 hr
following 32 mg/kg NIH 10319. At this point there was
mydriosis, slight muscle relaxation and decreased abdominal
defense reactions to palpitation. However, the monkeys
continued to sit on the floor of their cages, showed
irritability towards each other and pronounced apprehension
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NIH 10319 N-Propargyl-N'(3-trifluoromethylphenyl)piperazine.HCl
. . .(continued)
towards handling. NIH 10319 does not suppress withdrawal in a
morphine like manner.
NIH 10333 (±)-7-Chloro-3-dimethylamino-1-methyl-3,4-dihyrocar-
bostyril hydrochloride.
M O U S E  A N A L G E S I A ,   
Hot Plate: Inactive (60% at 100)
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of > 100 microM in the presence of 150 milliM NaCl (18%
displacement at 100 microM).
MOUSE VAS DEFERENS PREPARATION
Inhibitory
EC50 (M) Maximum Response
Drug alone 1.25 x 1O-5 39.3 ± 8.5%
After naltrexone 1.89 x 10-5 42.3 ± 3.3
With equimolar concentration
of naltrexone No reversal
Equimolar concentration
of morphine No reversal
SUMMARY
NIH 10333 is devoid of significant opiate agonist or antagonist
activity upon the isolated mouse vas deferens preparation. It
also failed to displace etorphine at a significant potency.
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NIH 10334 (-)-7-Chloro-3-dimethylamino-1-methyl-3,4-dihyrdocar-
bostyril hydrochloride
M O U S E  A N A L G E S I A ,   
Hot Plate: Inactive (30% at 50)
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of > 10 microM in the presence of NaCl (20% displacement at
6 microM).
MOUSE VAS DEFERENS PREPARATION
Inhibitory
EC50 (M) Maximum Response
Drug alone 5.47 x 10-5
5.29 x 10-5
34.6 ± 6.7%
After naltrexone 30.6 ± 5.0%
With equimolar concentration
of naltrexone No reversal
Equimolar concentration
with morphine No reversal
SUMMARY
NIH 10334 is devoid of opiate agonistic or antagonistic activity
upon the isolated mouse vas deferens preparation nor did it
possess significant potency in displacing etorphine in the
binding assay.
NIH 10335 (±)-7-Chloro-3-dimethylamino-1-methyl-3,4-dihydro-
carbostyril hydrochloride
M O U S E  A N A L G E S I A ,   
Hot Plate: Inactive (to 50)
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NIH 10335 (±)-7-Chloro-3-dimethylamino-1-methyl-3,4-dihydro-
carbostyril hydrochloride
. . . .(continued)
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of 6
MOUSE VAS
microM in the presence of NaCl.
DEFERENS PREPARATION
Inhibitory
EC50 (M) Maximum Response
Drug alone 1.38 x 1O-4
After naltrexone 1.36 x 1O-4
64.8 ± 3.3%
58.2 ± 4.2%
With equimolar concentration
of naltrexone
Equimolar concentration
No reversal
with morphine No reversal
SUMMARY
NIH 10335 was without significant opioid activity in either of
the in vitro assays.
NIH 10363 7 -(1-Carboxyvinyl)-6 -naltrexal lactone
M O U S E  A N A L G E S I A ,   
Hot Plate: Inactive (at 20)
Using H2O, ethanol, dimethyl sulfoxide and diluted HCl (pH 3),
NIH 10383 was found to be insoluble in both in vitro assays.
NIH 10366 -oxido-oxymorphone
M O U S E  A N A L G E S I A ,   
Hot Plate: Inactive (to 20)
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NIH 10366 E-6-Carboethoxymethylene-6B-oxido-oxymorphone
. . . .(continued)
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
IC50 of 40.5 nanoM in presence of NaCl.
MOUSE VAS DEFERENS PREPARATION
Inhibitory
EC50 (M) Maximum Response
Drug alone 8.11 x 1O-7
2.11 x 10-6
94.3 ± 11.9%
After naltrexone 91.8 ± 6.7%
With equimolar concentration
of naltrexone Partial reversal
Equimolar concentration
with morphine Increased inhibitory action
ASSESSMENT IN WITHDRAWN, MORPHINE-DEPENDENT RHESUS MONKEYS
NIH 10366 was given cumulatively (0.03, 0.1, 0.3, 1.0  mg/kg) to
withdrawn morphine-dependent monkeys (n=3). There was no
observable effect.
SUMMARY
The in vitro findings suggest that NIH 10366 is a morphine-like
agonist with a comparable potency. At the doses examined in
vivo (too small), morphine did not suppress withdrawal.
NIH 10367 Z-6-Carboethoxymethylene-6 -oxido-oxymorphone acetate
M O U S E  A N A L G E S I A ,   
Hot Plate: 0.08 (0.06-0.10)
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
IC50 of 15.4 nanoM in presence of NaCl.
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NIH 10367 Z-6-Carboethoxymethylene-6B-oxido-oxymorphone acetate
. . . .(continued)
MOUSE VAS DEFERENS PREPARATION
Inhibitory
EC50 (M) Maximum Response
Drug alone 1.23 x 1O-7
1O-6
96.1 ± 9.5%
After naltrexone 2.68 x 95.9 ± 11.1%
With equimolar concentration
of naltrexone
Equimolar concentration
with morphine
Complete reversal
Increased inhibitory effect
ASSESSMENT IN WITHDRAWN, MORPHINE-DEPENDENT RHESUS MONKEYS
NIH 10367 completely suppressed the intermediately severe
withdrawal produced by 14-hrs of deprivation. It was more
potent than morphine in this regard, and it has a short duration
of action (2 hrs at a dose of 1 mg/kg).
SUMMARY
NIH 10367 is a morphine-like agonist with greater potency in the
dependent monkey and in the binding assay, but approximately the
same potency as morphine in the vas deferens preparation.
NIH 10368 (-)-2'-Methoxy-2-methyl-5,1'-methyleneoxy-9 -propyl-6,
7-benzomorphan hydrochloride
M O U S E  A N A L G E S I A ,   
Hot Plate: Inactive
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of 2.8 microM in presence of NaCl
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NIH 10368 (-)-2'-Methoxy-2-methyl-5,1'-methyleneoxy-9a-propyl-6,
7-benzomorphan hydrochloride
. . . (continued)
MOUSE VAS DEFERENS PREPARATION
NIH 10368 did not suppress the twitch at any concentration. At
a concentration of 10
magnitude of the twitch.
M this drug increased markedly the NIH
NIH 10368 at a concentration of 10-7M
did not block responses to morphine. NIH 10368 at a
concentration of 10 M did not reverse the inhibitory effect of
an equivalent concentration of morphine.
SUMMARY
NIH 10368 is devoid of opiate agonistic or antagonistic activity
upon the isolated mouse vas deferens preparation. In addition,
it displaced etorphine with only very low affinity.
NIH 10369 (-)-2'-Hydroxy-2-methyl-5,1'-methyleneoxy-9 -propyl-
6,7-benzomorphan hydrochloride
M O U S E  A N A L G E S I A ,   
Hot Plate: 1.8 (1.3-2.6)
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of 39 nanoM in presence of NaCl.
MOUSE VAS DEFERENS PREPARATION
Drug alone
After naltrexone
Inhibitory
EC50 (M) Maximum Response
3.50 x 10-7
3.32 x 10-6
77.1 ± 8.0%
43.4 ± 8.1%
With equimolar concentration
of naltrexone
Equimolar concentration
with morphine
Marked reversal
Did not alter effect
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NIH 10369 (-)-2'-Hydroxy-2-methyl-5,l'-methyleneoxy-9 -propyl-
6,7-benzomorphan hydrochloride
. . . .(continued)
SUMMARY
NIH 10369 has significant opiate activity in both preparations.
NIH 10370 (-)-2'-Acetoxy-2-methyl-5,1'-methyleneoxy-9 -propyl-
6,7-benzomorphan hydrochloride
M O U S E  A N A L G E S I A ,   
Hot Plate: Inactive (20% at 20)
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of 133 nanoM in the presence of NaCl.
MOUSE VAS DEFERENS PREPARATION
Inhibitory
EC50 (M) Maximum Response
Drug alone 8.52 x 1O-8
4.22 x 1O-7
80.6 ± 4.0%
After naltrexone 61.6 ± 2.8%
With equimolar concentration
of naltrexone Marked reversal
Equimolar concentration
with morphine Did not alter effect
SUMMARY
NIH 10370 is a morphine-like "mu" opiate agonist upon the
isolated mouse vas deferens preparation. Its potency in the
binding assay is consistent with its action on the vas deferens.
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NIH 10384 Codeine succinate
M O U S E  A N A L G E S I A ,   
Hot Plate: Inactive (to 20)
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
IC50 of 19 microM in the presence of NaCl.
MOUSE VAS DEFERENS PREPARATION
Inhibitory
EC50 (M) Maximum Response
Drug alone 4.51 x 10-6 98.2 ± 0.9%
After naltrexone 8.09 x 10-5 86.9 ± 3.2%
With equimolar concentration
of naltrexone Reversal
Equimolar concentration
with morphine Did not alter effect
SUMMARY
NIH 10440 N-(2-Carbethoxyethyl)-N-norketobemidone hydrobromide
M O U S E  A N A L G E S I A ,   
Hot Plate: Inactive (to 20)
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
IC50 of 235 nanoM in the presence of NaCl.
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NIH 10440 N-(2-Carbethoxyethyl)-N-norketobemidone hydrobromide
. . . .(continued)
MOUSE VAS DEFERENS PREPARATION
NIH 10440 did not inhibit the twitch of the vas deferens at any
concentration studied. Concentrations of 1 microM to 10 microM
caused increases in the magnitude of the twitch above basal
levels. In the presence of naltrexone, 100 nanoM, there was no
appreciable differences in the responses of this preparation to
NIH 10440. NIH 10440, 100 nanoM, did not alter responses to
concentrations of morphine from 10 nanoM to 10 microM. IN the
presence of a maximally effective concentration of morphine (10
microM) an equimolar concentration of NIH 10440 produced the
same increase in the magnitude of the twitch as seen in control
experiments.
SUMMARY
NIH 10440 appears to be devoid of opioid activity on the mouse
vas deferens preparation and has a very low potency in the
binding assay. It is unlikely that this compound has
significant opiate activity.
NIH 10453 N-(Carboethoxypropyl)-N-norketobemidone oxalate
M O U S E  A N A L G E S I A ,   
Hot Plate: Inactive (to 20)
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of 440 nanoM in the presence of NaCl.
MOUSE VAS DEFERENS PREPARATION
In concentrations of 10-10 M to 10-4 M NIH 10454 produced no
significant inhibition of the twitch. At a concentration of
10-7 M, it caused a 7-fold shift to the right in the sufentanil
concentration-effect curve. The data suggest that NIH 10454 is
an opiate antagonist approximately one-third as potent as
naltrexone.
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NIH 10453 N-(Carboethoxypropyl)-N-norketobemidone oxalate
. . . .(continued)
SUMMARY
The binding data on NIH 10453 suggest that the compound will be
significantly less potent than naloxone and naltrexone. The
relative potency of NIH 10453 cannot be determined with the
current information on the mouse vas deferens.
NIH 10454 N-Carbethoxy-methyl-N-norketobemidone oxalate
M O U S E  A N A L G E S I A ,   
Hot Plate: Inactive (16% at 20)
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of 1.7 microM in the presence of NaCl.
MOUSE VAS DEFERENS PREPARATION
In concentrations of 10-10 M to 10-4 M NIH 10454 produced no
siqnificant inhibition of the twitch. At a concentration of
10-7 M, it caused a 7-fold shift to the right in the sufentanil
concentration-effect curve. The data suggest that NIH 10454 is
an opiate antagonist approximately one-third as potent as
naltrexone.
SUMMARY
This compound has lower affinity for the opiate binding site
than standards (e.g., naloxone, naltrexone), but appears to have
antagonist activity in the vas deferens. Its relative potency
in the latter preparation cannot be determined with the current
protocol.
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NIH 10456 (±)-cis-3-Methylfentanyl hydrochloride
M O U S E  A N A L G E S I A ,   
Hot Plate: 0.0005 (0.0003-0.0007)
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of 5.8 nanoM in the presence of NaCl.
MOUSE VAS DEFERENS PREPARATION
Inhibitory
EC50 (nanoM) Maximum Response
Drug alone 0.62 ± 0.16 100%
After naltrexone 9.75 ± 38.5 100%
With ICI 174,864 1.72 ± 0.66 100%
With equimolar concentration
of naltrexone Complete reversal
Equimolar concentration
with ICI 174,864 Slight rightward shift
SUMMARY
Both preparations demonstrate that NIH 10456 has potent opioid
activity. In the vas deferens, NIH 10456 may have
both mu and delta receptors. We have not as
experience with the current protocol to know if
unusual finding.
activity at
yet enough
this is an
NIH 10457 (±)-trans-3-Methylfentanyl hydrochloride
M O U S E  A N A L G E S I A ,   
Hot Plate: 0.009 (0.006-0.013)
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NIH 10457 (±)-trans-3-Methylfentanyl hydrochloride
....(continued)
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of 24 nanoM in the presence of NaCl.
MOUSE VAS DEFERENS PREPARATION
Inhibitory
EC50 (nanoM) Maximum Response
Drug alone 69.2 ± 66.1 100%
After naltrexone 733.0 ± 203.0 100%
With equimolar concentration
of naltrexone Complete reversal
Equimolar concentration
with ICI 174,864 No shift
SUMMARY
The assays demonstrate NIH 10457 to be a potent opioid. Its
action upon the vas deferens appears to be quite complex; this
is a novel pattern of activity upon this preparation.
NIH 10460 1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine
(PEPAP)
M O U S E  A N A L G E S I A ,   
Hot Plate: 0.74 (0.53-1.04)
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of 160 nanoM in the presence of NaCl.
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NIH 10460 1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine
(PEPAP)
....(continued)
MOUSE VAS DEFERENS PREPARATION
Inhibitory
EC50 (M) Maximum Response
Drug alone 3 x 10-9 52.8%
After naltrexone 6 x 10 15.8%
With equimolar cncentration
of naltrexone Complete reversal
Equimolar concentration
with sufentanil Slight reversal
SUMMARY
On the mouse vas deferens preparation, NIH 10460 appears to be
an opiate agonist/antagonist more potent but less efficacious
than morphine. The slight reversal of sufentanil suggests some
antagonist activity. The potency estimate of 10460 in both
preparations suggest that it is less potent than morphine.
NIH 10461 1-Methyl-4-phenyl-4-propionoxypiperidine hydrochlo-
ride (MPPP)
MOUSE ANALGESIA, ED50 (mg/kg)
Hot plate: 0.90 (0.66-1.23)
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of 1110 nanoM in the presence of NaCl.
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NIH 10461 1-Methyl-4-phenyl-4-propionoxypiperidine hydrochlo-
ride (MPPP)
....(continued)
MOUSE VAS DEFERENS PREPARATION
NIH 10461 did not significantly inhibit the twitch at any
concentration studied. NIH 10461, 100 nanoM, did not shift the
sufentanil concentration-effect curve. NIH 10461, 10 microM,
did not reverse the inhibitory action of a maximally effective
concentration of sufentanil.
SUMMARY
The binding assay suggests that NIH 10461 might have opioid
activity at high concentrations. This was not confirmed in the
mouse vas deferens. Therefore, the compound is not likely to
have significant opioid activity.
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Abstinence
as defined by the law of hyperbolas, 281-287
(-)-2’-Acetoxy-2-metyl-5,1'-methyleneoxy-9 -propyl-6,7-benzomorphan
hydrochloride (NIH 10370; MCV 4436)
biological evaluation of dependence liability, 385
depression of smooth muscle twitch, 476
displacement of stereospecific 3H-etorphine binding, 476
mouse analgesia, 429, 476
Addiction
See Drug dependence
Adinazolam
comparative evaluation of acute behavioral and subjective effects, 71
ß-Adrenergic receptors
in human placenta, effect of cocaine on, 277
Adrenocorticotropin hormone
effects of methadone on abnormalities in opiate addicts, 58
AHN 070 [(±)-1-(2-Chlorophenyl)-N-ethylisothiocyanato-N-(methylpropyl)-3-
isoquinolinecarboxamide]
synthesis and binding characteristics to benzodiazepine receptors,
356-362
AHN 086 [1-(2-Isothiocyanatoethyl-7-chloro-1,3-dihydro-5-(4-chlorophenyl)-
2H-1,4-benzodiazepine-2-one]
synthesis and binding characteristics to benzodiazepine receptors,
356-362
AIDS
exposure behavior in long-term addicts, 200-206
incidence in heroin addicts, 94
D-Ala2-D-leu5-enkephalin
See DADLE
Alcohol
contribution of maternal use to neonatal status, 275
dependence syndrome, 255-258
effects on human aggressive behavior, 109-115
effects on LHRH stimulated release of LH and FSH in monkeys,
124-130
effects on naltrexone stimulation of neuroendocrine function in women,
116-123
physiological and subjective responses to alcohol-related stimuli, 131-136
significance of tolerance in development of dependence, 9-19
social support and relapse to use of, 207-213
Alcoholics
physiological and subjective responses to alcohol-related stimuli, 131-136
role of temptation in reactivity to alcohol stimuli, 102- 108
Alfentanil
doses used in cardiac surgery, 31
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(-)-2-AIlyl-2’-hydroxy-5,1’-methyleneoxy-9 -propyl-6,7-benzomorphan
hydrochloride (NE-I 10379; MCV 4455)
biological evaluation of dependence liability, 385
mouse analgesia, 431
(-)-N-Allyl-14-hydroxy-4-methoxymorphinan-6-one (NIH 9975)
biological evaluation of dependence liability, 382
depression of smooth muscle twitch, 467
displacement of stereospecific 3H-etorphine binding, 467
mouse analgesia, 467
(-)-N-Allylnormetazocine (SKF 10047)
depression of smooth muscle twitch, 454
7 -Amino-6,14-endoethenotetrahydrooripavine  (NIH 10093, MCV 4438)
biological evaluation of dependence liability, 380
mouse analgesia, 412
Amobarbital
mouse analgesia, 394, 453
d-Amphetamine
contribution of personality variables to subjective effects, 80
effects on pharmacological actions of methadone, 302-308
evaluation of discriminative stimulus properties of antihistamines in
d-amphetamine-trained pigeons, 214-220
Antinociception
morphine in the chronic spinal rat, 69
Anxiety
diazepan preference in subjects seeking treatment for, 248-254
2-Benzyl-3-phenyl-3-acetoxyquinuclidine hydrochloride (NIH 10362; MCV
4422)
biological evaluation of dependence liability, 390
mouse analgesia, 423
2-Benzyl-3-phenyl- 2,3-quinuclidine hydrochloride (NIH 10347, MCV 4417)
mouse analgesia, 421
Bremazocine
stimulation of GTPase in brain, 351-352
1-Bromo4-hydroxy-6-keto-N-methylmorphinan hydrobromide (NIH 9935)
biological evaluation of dependence liability, 382
depression of smooth muscle twitch, 461
displacement of stereospecific 3H-etorphine binding, 461
mouse analgesia, 461
Buprenorphine
abuse liability in combination with naloxone, 145-156
precipitation of withdrawal in addicts, 182-188
use in detoxification of heroin addicts, 182-188
Butorphanol tartrate (NIH 8791; NIH 10275; MCV 4386; UM 941)
biological evaluation of dependence liability, 382
dependence studies in monkeys, 415, 416
mouse analgesia, 415
precipitated withdrawal in opioid-dependent humans, 157-161
BW942C
opioid profile in man, 81
Caffeine
contribution of maternal use to neonatal status, 275
reinforcing and physical dependence producing properties, 75
486
Cannabis
See Marihuana
(-)-9a-(2-Carbethoxyethyl)-2'-methoxy-2-methyl-5,1'-methyleneoxy-6,7-
benzomorphan hydrochloride (NIH 10348; MCV 4418)
biological evaluation of dependence liability, 385
mouse analgesia, 421
N-(2-Carbethoxyetbyl)-N-norketobemidone hydrobromide (NIH 10440; MCV
4503)
biological evaluation of dependence liability, 387
depression of smooth muscle twitch, 478
displacement of stereospecific 3H-etorphine binding, 477
mouse analgesia, 440, 477
E-6-Carboethoxymethylene-6p-oxido-oxymorphone (NIH 10366; MCV 4423)
biological evaluation of dependence liability, 381
dependence studies in monkeys, 473
depression of smooth muscle twitch, 473
displacement of stereospecific 3H-etorphine binding, 473
mouse analgesia, 428, 472
Z-6-Carboethoxymethylene-6ß-oxide-oxymorphone acetate (NIH 10367; MCV
4424)
biological evaluation of dependence liability, 381
dependence studies in monkeys, 474
depression of smooth muscle twitch, 474
displacement of stereospecific 3H-etorphine binding, 473
mouse analgesia, 428, 473
N-(Carboethoxymethyl)-N-norketobemidone oxalate (NIH 10454; MCV 4520)
biological evaluation of dependence liability, 387
depression of smooth muscle twitch, 479
displacement of stereospecific 3H-etorphine binding, 479
mouse analgesia, 442, 479
N-(Carboethoxypropyl)-N-norketobemidone oxalate (NIH 10453; MCV 4519)
biological evaluation of dependence liability, 387
depression of smooth muscle twitch, 478
displacement of stereospecific 3H-etorphine binding, 478
mouse analgesia, 441, 478
1 1-Nor-9-Carboxy- 9-tetrahydrocannabinol
placental transfer in monkeys near term, 88
Carbon monoxide
marker for assessing and treating tobacco dependence in pulmonary
disease, 73
6a-(2-Carboxy-1-propenyl)-naltrex-6 b -ol-g -lactone (NIH 10322, MCV 4404)
biological evaluation of dependence liability, 381
mouse analgesia, 417
6a-(2-Carboxy-1-propenyl)-oxymorph-6 b -ol- g -lactone (NIH 10324; MCV
4408)
biological evaluation of dependence liability, 381
mouse analgesia, 418
7a-(1-Carboxyvinyl)-6 a-naltrexal lactone (NIH 10363; MCV 4425)
biological evaluation of dependence liability, 381
dependence studies in monkeys, 424-425
depression of smooth muscle twitch, 472
487
displacement of stereospecific 3Hetorphine binding, 472
mouse analgesia, 424,472
Cblorcydizine
discriminative stimulus properties in d-amphetamine- and
midazolam-trained pigeons, 214-220
Chlordiazpoxide
effects on cocaine self-administration in rata, 240-247
b-Chlornaltrexamine
See b-CNA
(±)-7-Chloro-3-dimethylamino-1-methyl-3,4dihydrccarbostyril    hydrochloride
(NIH 10333; MCV 4409)
biological evaluation of dependence liability, 389
dependence studies in monkeys, 419
depression of smooth muscle twitch, 419
displacement of stereospecific 3H-etorphine binding, 470
mouse analgesia, 418,470
(-)-7-Chlor-3-dimethylamino-1-methyl-3,4-dihydrocarbostyril hydrochloride
(NIH 10334; MCV 4410)
biological evaluation of dependence liability, 389
dependence studies in monkeys, 420
depression of smooth muscle twitch, 471
displacement of stereospecific 3H-etorphine binding, 471
mouse analgesia, 420, 471
(+)-7-Chloxo-3-dimethylamino-1-methyl-3,4dihydrocarbostyril  hydrochloride
(NIH 10335; MCV 4411)
biological evaluation of dependence liability, 389
dependence studies in monkeys, 420
depression of smooth muscle twitch, 472
displacement of stereospecific 3H-etorphine binding, 472
mouse analgesia, 420, 471
(±)-1-(2-Chlorophenyl)-N-ethylisothiocyanato-N-(methylpropyl)-3-
isoquinolinecarboxamide
See AHN 070
Chlorpheniramine
discriminative stimulus properties in d-amphetamine- and
midazolam-trained pigeons, 214-220
Chlorpromazine
mouse analgesia, 394, 453
Cimetidine
discriminative stimulus properties in d-amphetamine- and
midazolam-trained pigeons, 214-220
Cigarette
contribution of maternal use to neonatal status, 275
effect of rod length on smoking topography, 93
See also Tobacco
b-CNA
affinity labels for studying opioid tolerance and dependence, 42-45
alkylation of GTPase in brain, 351-352
Cocaine (NIH 8211; MCV 4526)
abuse in pregnancy, effects on the fetus and newborn, 280
biological evaluation of dependence liability, 388
dependence studies in rats, 404, 405
488
dependence syndrome, 255-258
effects on b-adrenergic, µ-and d -opioid receptors in human placenta, 277
effects on cardiovascular responsivity, 259-265
effects on local cerebral glucose utilization, 89
effects on pharmacological actions of methadone, 302-308
extinction of conditioned responses in abstinence, 189-195
inhibition of locus coeruleus neurons, 334-340
limited access reduces intake and mortality, 221-225
perinatal morbidity and mortality in infants exposed to cocaine in utero,
278
self-administration by human volunteers, 266-273
self-administration in rats, effects of chlordiazepoxide on, 240-247
Codeine phosphate (NIH 0002)
mouse analgesia, 394, 452
Codeine succinate (NIH 10384; MCV 4448; 6-Succinylcodeine)
biological evaluation of dependence liability, 380
depression of smooth muscle twitch, 477
displacement of stereospecific 3H-etorphine binding, 477
mouse analgesia, 477
Coffee
reinforcing and physical dependence producing properties, 75
See also Caffeine
Cortisol
effects of alcohol and naltrexone on levels in women, 116-123
effects of methadone on abnormalities in opiate addicts, 58
CPT [D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH2]
precipitates withdrawal in morphine-dependent mice, 195-301
(-)-Cyclazocine (NIH 10450; MCV 4512)
biological evaluation of dependence liability, 383
depression of smooth muscle twitch, 454
mouse analgesia, 440
(+)-Cyclazocine (NIH 10449; MCV 4511)
biological evaluation of dependence liability, 383
mouse analgesia, 440
(±)-Cyclazocine [NIH 7981; MCV 4510; (±)-2-Cyclopropylmethyl-5,9a -
dimethyl-2'-hydroxy-6,7-benzomorphan]
biological evaluation of dependence liability, 383
mouse analgesia, 393, 394 ,404, 453
17-Cyclopropylmethyl-3,14-dihydroxy-4,5 a-epoxy-6 b-fluoromorphinan
hydrochloride (NIH 10357; MCV 4433)
biological evaluation of dependence liability, 380
dependence studies in monkeys, 422-423
mouse analgesia, 422
17-Cyclopropylmethyl-3,14-dihydroxy-4,5-epoxy-7-methylenemorphinan
hydrochloride (NIH 10365; MCV 4426)
See Nalmefene
(±)-2-Cyclopropylmethyl-5-ethyl-8-oxo-9a-methyl-6,7-benzomorphan methane
sulfonate (NIH 8848; NIH 10165; MCV 4348; UM 975)
See Ethylketocyclazocine
(-)-N-Cyclopropylmethyl-4-methoxymorphinan-6-one (NIH 9931)
biological evaluation of dependence liability, 382
depression of smooth muscle twitch, 460
489
displacement of stereospecific 3H-etorphine binding, 460
mouse analgesia, 460
(-)-N-Cyclopropylmethylmorphinan-6-one salicylate (NIH 10331; MCV 4465)
biological evaluation of dependence liability, 382
mouse analgesia, 418
N-Cyclopropylmethylnormorphine
effect of methyl at C-17 on pharmacological activity, 309-315
DADLE [D-Ala2-D-leu5-enkephalin]
evaluation of agonistic activity in the isolated, electrically stimulated
mouse vas deferens, 288-294
Dependence
See Drug dependence
Dextrorphan (NIH 4591; MCV 4473; UM 380)
depression of smooth muscle twitch, 454
N,N-Diallyl-Try-Aib-Aib-Phe-Lue-OH
See ICI 174864
Diazepm
comparison of physical dependence potential to that of nor-diazepam in
rat, 322-326
effects on discrimination of speech sounds in the baboon, 226-232
effects on human laboratory aggression, 101
mouse analgesia, 394, 453
preference in subjects seeking treatment for anxiety, 248-254
subjective effects of withdrawal, 76
nor-Diazepam
comparison of physical dependence potential to diazepam in rat, 322-326
trans-3,4-Dichlor-N-methyt-N(2-(1-pyrrolidinyl)cyclohexyl)-
benzeneacetamide methanesulfonate hydrate
See U50,488H
Dihydromorphinone (NIH 0123)
mouse analgesia, 394,453
(-)-4,14-Dimethoxymorphinan-6-one hydrobromide (NIH 10371; MCV 4466)
biological evaluation of dependence liability, 382
mouse analgesia, 429
6-Dimethylamin-4-(4-bromophenyl)-4phenylhexan-3-one hydrochloride (NIH
10388; MCV 4460)
biological evaluation of dependence liability, 386
mouse analgesia, 432
6-Dimethylamino-4-(4-chlorophenyl)4phenylhexan-3-one hydrochloride (NIH
10387; MCV 4459)
biological evaluation of dependence liability, 386
mouse analgesia, 432
6-Dimethylaminc-4-cyclohexy-4-phenylhexa-3-one hydrochloride (NIH
10393; MCV 4462)
biological evaluation of dependence liability, 386
mouse analgesia, 433
6-Dimethylamino-4,4-(4,4'-difluoro)diphenylhexan-3-one hydrochloride (NIH
10396; MCV 4463)
biological evaluation of dependence liability, 386
mouse analgesia, 434
6-Dimethylamino-4,14-diphenylhexan-3-one hydrochloride (NIH 10385; MCV
2820; MCV 4457; UM 118)
biological evaluation of dependence liability, 386
490
mouse analgesia, 431
6-Dimethylamino-4-(4-fluorophenyl)-4-phenylhexan-3-one hydrochloride (NIH
10386; MCV 4458)
biological evaluation of dependence liability, 386
mouse analgesia, 432
6-Dimethylamino-4-(4-methoxyphenyl)-4-phenylhexan-3-one hydrochloride
(NIH 10389; MCV 4467)
biological evaluation of dependence liability, 386
mouse analgesia, 433
6-Dimethylamino-4-(4-methylphenyl)-4-phenylhexan-3-one hydrochloride
(NIH 10391; MCV 4464)
biological evaluation of dependence liability, 386
mouse analgesia, 433
(3S)-1,3-Dimethyl-3-(2-dimethylaminoethyl)-5-hydroxyindoline hydrochloride
(NIH 10423; MCV 4486)
biological evaluation of dependence liability, 391
mouse analgesia, 436
(3S)-1,3-Dimethyl-3-(2-dimethylaminoethyl)-5-methoxyindoline oxalate (NIH
10409; MCV 4483)
biological evaluation of dependence liability, 391
mouse analgesia, 435
2,2-Dimethyl-3-dimethylamino-7-hydroxy-1-tetralone hydrobromide (NIH
10372; MCV 4437)
biological evaluation of dependence liability, 389
dependence studies in monkeys, 430
mouse analgesia, 430
(±)-2,9a-Dimethyl-5-( m-hydroxyphenyl)morphan hydrochloride (NIH 9955)
biological evaluation of dependence liability, 382
depression of smooth muscle twitch, 466
displacement of stereospecific 3H-etorphine binding, 466
mouse analgesia, 466
(-)-2,5-Dimethyl-1'-hydroxy-9 a-propyl-6,7-benzomorphan hydrochloride (NIH
10416; MCV 4477)
biological evaluation of dependence liability, 384
mouse analgesia, 435
(+)-2,9a-Dimethyl-2’-hydroxy-5-propyl-6,7-benzomorphan hydrochloride
(NIH 8374; MCV 4480; UM 696)
biological evaluation of dependence liability, 383
mouse analgesia, 406
lR-5R-9R-2"R-5,9-Dimethyl-2’-hydroxy-2-tetrahydrofurful-6,7-
benzomorphan hydrochloride (UM 1071R)
depression of smooth muscle twitch, 454
(±)-5,9a-Dimethyl-2'-hydroxy-2-tetrahydrofurfuryl-6,7-benzomorphan
See Mr-2033
(3S)-1,3-Dimethyl-3-(2-metylaminoethyl)-5-hydroxyindoline hydrochloride
(NIH 10425; MCV 4488)
biological evaluation of dependence liability, 391
mouse analgesia, 437
(3S)-1,3-Dimethyl-3-(2-methylaminoethyl)-5-methoxyindobine oxalate (NIH
10408; MCV 4482)
biological evaluation of dependence liability, 391
mouse analgesia, 434
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Diphenhydramine
discriminative stimulus properties in d-amphetamine- and
midazolam-trained pigeons, 214-220
effects on reinforcing brain stimulation, 92
Drug dependence
as defined by the law of hyperbolas, 281-287
AIDS virus exposure behavior in long-term addicts, 200-206
butorphanol-precipitated withdrawal in opioid dependence, 157-161
carbon monoxide for assessing and treating tobacco dependence in
pulmonary disease, 73
comparison of physical dependence potential of diazepam and
nor-diazepam in rat, 322-326
coffee and caffeine dependence properties, 75
dependence syndrome in alcohol, marijuana, opioid and cocaine users,
255-258
development to pentobarbital, role of genetic differences in, 91
effects of altered dose incentive procedures on polydrug use in methadone
maintenance patients, 162-167
effects of pentobarbital and methadone on neonatal sleep patterns of
infants born to opioid-addicted mothers, 274
effect on placental xenobiotic metabolism, 86
implications for the pharmacological treatment of addiction, 53-62
incidence of split-like ventricles in infants born to addicts, 87
mechanism for development of opioid dependence, 63-68
resuscitation of infants born to drug-dependent women, 70
role of endorphins in opioid addiction, 59-60
role of neural substrates in development of, 46-52
role of spinal cord in development of opiate dependence, 42-45
role of temptation in reactivity to alcohol stimuli in alcoholics, 102-108
sexual activity in dependent women, 279
significance of tolerance in, 9-19
social support and relapse to tobacco, alcohol and opiates, 207-213
source of income as a predictor of opioid addiction, 196-199
tolerance and dependence: implications for the pharmacological treatment
of addiction, 53-62
use of buprenorphine in detoxification of heroin addicts, 182-188
DPDPE [D-Pen-D-pen-enkephalin]
evaluation of agonistic activity in the isolated, electrically stimulated
mouse vas defer-ens, 288-294
DSLET [Tyr-D-Ser-Gly-Phe-Leu-Thr]
evaluation of agonistic activity in the isolated, electrically stimulated
mouse vas deferens, 288-294
stimulation of GTPase in brain, 351-352
Ecstasy (Methylenedioxymethamphetamine (MDMA)
See MDMA, 74, 78-79
Endorphins
role in opioid addiction, 59-60
N-(2,3-Epoxypropyl)nonnetazocine (NIH 10249; MCV 4388)
biological evaluation of dependence liability, 383
mouse analgesia, 413
(-)-Eserine (NIH 10421; MCV 4484; physostigmine)
biological evaluation of dependence liability, 391
mouse analgesia, 436
(-)-Eseroline (NIH 10398; MCV 4481)
492
biological evaluation of dependence liability, 391
mouse analgesia, 434
(-)-Eseroline methylmethosulfate (NIH 10422; MCV 4485)
biological evaluation of dependence liability, 391
mouse analgesia, 436
(+)-Eseroline sulfate (NIH 10439; MCV 4504)
biological evaluation of dependence liability, 391
mouse analgesia, 439
Estradiol
effects of alcohol and nakrexone on levels in women, 116-123
Ethyl-N-[2-amino-6-(4-fluorphenylmethylamino)-pyridin-3-yl]carbamate
See Flupirtine, 84
(±)-Ethylketocyclazocine [NIH 8848; NIH 10165; MCV 4348; UM 975;
(±)-2-Cyclopropylmethyl-5-ethyl-8-oxo-9 a-methyl-6,7-benzomorphan methane
sulfonate]
biological evaluation of dependence liability, 384
mouse analgesia, 412
(-)-Ethylketccyclazocine (NIH 10452; MCV 4515)
biological evaluation of dependence liability, 384
mouse analgesia, 441
m -(3-Ethyl-l-methylhexahydro-lH-azepine-3-yl)phenol hydrochloride (NIH
8683; MCV 4403; UM 888)
See Meptazinol hydrochloride
Etorphine
depression of smooth muscle twitch, 454
stimulation of GTPase in rat brain, 351
Fentanyl
doses used in cardiac surgery, 3 1
FK-33824 [Tyr-D-Ala-Gly-MePhe-Met-(O)-ol]
evaluation of agonistic activity in the isolated, electrically stimulated
mouse vas deferens, 288-294
Flupirtine
discriminative properties in rats, 84
pharmacological profile of activity, 85
Fhurazepam
mouse analgesia, 394, 453
b -FNA
affinity labels for studying opioid tolerance and dependence, 42-45
alkylation GTPase in brain, 351-352
evaluation of antagonistic activity in the isolated, electrically stimulated
mouse vas deferens, 288-294
Follicle-stimulating hormone (FSH)
effects of alcohol on LHRH-stimulated release in monkeys, 124-130
effects of methadone on abnormalities in opiate addicts, 58
b-Funaltrexamine
See b-FNA
Genetics
role in development of physical dependence to pentobarbital, 91
Glucose utilization
effects of cocaine on, 89
Heroin
development of dependence to, 47-50
methylnaloxonium hydrochloride effects on self administration of, 49-50
493
172-682 0 - 87 - 18
use of buprenorphine in detoxification of heroin addicts, 182-188
Heroin addicts
mortality rate and incidence of AIDS, 94
See also Opioids
1-(2a,6a,11S)-(±)-1-(1,2,3,4,5,6-Hexahydro-8-hydroxy-3,6,11-trimethyl-2,6-
methano-3-benzazocin-11-yl]-6-methyl-3-heptanone methanesulfonate (NIH
9625)
biological evaluation of dependence liability, 384
depression of smooth muscle twitch, 460
displacement of stereospecific 3H-etorphine binding, 460
mouse analgesia, 460
1,2,3,4,5,6-Hexahydro-9-methoxy-1,6-methano-3-benzazocine oxalate (NIH
10036; UM 1399)
biological evaluation of dependence liability, 389
dependence studies in monkeys, 468
depression of smooth muscle twitch, 468
displacement of stereospecific 3H-etorphine binding, 468
mouse analgesia, 467
Histamine
involvement in tripelennamine potentiation of opioid reinforcement, 92
Hydromorphone
abuse liability assessment in man, 145-149
(-)-2'-Hydroxyd-5,1'-methyleneoxy-2-phenethyl-9 a-propyl-6,7-benzomo
hydrochloride (NIH 10380; MCV 4456)
biological evaluation of dependence liability, 385
mouse analgesia, 431
2'-Hydroxy-5-methyl-9 a-(3-methyl)butyl-2-phenethyl-6,7-benzomorphan
(NIH 10157; MCV 4349)
biological evaluation of dependence liability, 383
dependence studies in monkeys, 468
depression of smooth muscle twitch, 468
displacement of stereospecific 3H-etorphine binding, 468
mouse analgesia, 468
2'-Hydroxy-5-methyl-9 a-(3-methyl)butyl-2-propyl-6,7-benzomorphan (NIH
10158)
biological evaluation of dependence liability, 383
depression of smooth muscle twitch, 469
displacement of stereospecific 3H-etorphine binding, 469
mouse analgesia, 468
(-)-2'-Hydroxy-2-metyl-5,1'-methyleneoxy-9 a-propyl-6,7-benzomorphan
hydrochloride (NIH 10369; MCV 4435)
biological evaluation of dependence liability, 385
depression of smooth muscle twitch, 475
displacement of stereospecific ‘H-etorphine binding, 475
mouse analgesia, 429, 475
(-)-9a-(3-Hydroxypropyl)-2’-methoxy-2-methyl-5,1’-methyleneoxy-6,7-
benzomorphan hydrochloride (NIH 10349; MCV 4419)
biological evaluation of dependence liability, 385
mouse analgesia, 422
Hydroxyzine
discriminative stimulus properties in d-Amphetamine- and
midazolam-trained pigeons, 214-220
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ICI-174864
evaluation of antagonistic activity in the isolated, electrically stimulated
mouse vas deferens, 288-294
Immune response
opioid receptor-mediated regulation of, 341-348
Income
source as a predictor of opioid addiction, 196-199
Infants
incidence of split-like ventricles in infants born to addicts, 87
1-(2-Isothiocyanatoethyl-7-chloro-1,3-dihydro-5-(4-chlorophenyl)-2H-1,4-
benzodiazepine-2-one
See AHN 086
J. Michael Morrison Award
introduction of recipient, 2-3
J. Michael Morrison Award Lecture, 4-6
(±)-Ketocyclazocine (NIH 10364; NIH 8847; MCV 4414; UM 974)
biological evaluation of dependence liability, 384
depression of smooth muscle twitch, 454
mouse analgesia, 421
subjective, physiologic and discriminative effects in drug abusers, 77
(-)-Ketocyclazocine (NIH 10451; MCV 4513)
biological evaluation of dependence liability, 384
mouse analgesia, 441
Law of Hyperbolas
model of drug action applied to opioid dependence and abstinence,
281-287
Levorphanol (NEI 4590; NIH 10123; MCV 4474; UM 510)
mouse analgesia, 394, 452
stimulation of GTPase in monkey brain, 351
Lorazepam
comparative evaluation of acute behavioral and subjective effects, 71
Luteinizing hormone (LH)
effects of alcohol and nahrexone on levels in women, 116-123
effects of alcohol on LHRH-stimulated release in monkeys, 124-130
effects of methadone on abnormalities in opiate addicts, 58
Luteinizing hormone releasing hormone (LHRH)
effects of alcohol on stimulated release of LH and FSH in monkeys,
124-130
effects of methadone on abnormalities in opiate addicts, 58
LY-123502 [Tyr-D-Ala-Gly-4-F-Phe-phenylgylcinamide acetate]
evaluation of agonistic activity in the isolated, electrically stimulated
mouse vas deferens, 288-294
Marijuana
contribution of maternal use to neonatal status, 275
effects on cardiovascular responsivity, 259-265
dependence syndrome, 255-258
effects of passive smoke exposure, 150-156
MCV 2820 (NIH 10385; MCV 4457; UM 118)
See 6-Dimethylamino-4,14diphenylhexan-3-one hydrochloride
MCV 4400 (NIH 10455; NIH 10319; MCV 4521)
See N-Propargyl-N'-(3-trifluoromethylphenyl)piperazine hydrochloride
MCV 4002 (NIH 8503; NIH 9930; UM 1312)
See Naltrexone
MCV 4268 (NIH 7958; UM 381)
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See Pentazocine
MCV 4336 (NIH 2105; NIH 10124; UM 1411)
See Nalorphine
MCV 4348 [NIH 8848; NIH 10165; UM 975; (±)-2-Cyclopropylmethyl-
5-ethyl-8-oxo-9 a-methyl-6,7-benzomorphan methane sulfonate]
See Ethylketocyclazocine
MCV 4349 (NIH 10157)
See 2'-Hydroxy-5-methyl-9 a -(3-methyl)butyl-2-phenethyl-6,7-
benzomorphan
MCV 4385 (NIH 8359; NIH 10274; UM 686)
See Nalbuphine hydrochloride
MCV 4386 (NIH 8791; NIH 10275; UM 941)
See Butorphanol tartrate
MCV 4388 (NIH 10249)
See N-(2,3-Epoxypropyl)normetazocine
MCV 4389 (NIH 10253)
See N-(N-Phenylguanidino)-5,9-dimethyl-6,7-benzomorphan
hydrochloride
MCV 4390 (NIH 10258)
See 3-(N-Propionyl)anilinoquinuclidine hydrochloride
MCV 4403 [NIH 8683; UM 888; m-(3-Ethyl-l-methylhexahydro-lH-
azepine-3-yl)phenol hydrochloride]
See Meptazinol hydrochloride
MCV 4404 (NIH 10322)
See 6a-(2-Carboxy-1-propcnyl)-naltrex-6 b-o l -g -lactone
MCV 4408 (NIH 10324)
See 6a -(2-Carboxy-l-propcnyl)-oxymorph-6 b-ol-y-lactone
MCV 4409 (NIH 10333)
See (±)-7-Chloro-3-dimetylamino-l-methyl-3,4-dihydrocarbostyri1
hydrochloride
MCV 4410 (NIH 10334)
See (-)-7-Chloro-3-dimethylamino-l-methyl-3,4-dihydrocarbostyri1
hydrochloride
MCV 4411 (NIH 10335)
See (+)-7-Chloro-3-dimethylamino-l-methyl-3,4-dihydrocarbostyril
hydrochloride
MCV 4414 (NIH 8847; NIH 10364; UM 974)
See (±)-Ketocyclazocine
MCV 4417 (NIH 10347)
See 2-Benzyl-3-phenyl- D 2,3-quinuclidine hydrochloride
MCV 4418 (NIH 10348)
See (-)-9 a-(2-Carbethoxyethyl)-2'-methoxy-2-methyl-5,1'-
methylencoxy-6,7-benzomorphan hydrochloride
MCV 4419 (NIH 10349)
See (-)-9 a-(3-Hydroxypropyl)-2'-methoxy-2-methyl-5,1’-
methylencoxya-6,7-benzomorphan hydrochloride
MCV 4422 (NIH 10362)
See 2-Benzyl-3-phenyl-3-acetoxyquinuclidine hydrochloride
MCV 4423 (NIH 10366)
See E-6-Carbocthoxymethylene-6 b-oxido-oxymorphone
MCV 4424 (NIH 10367)
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See Z-6-Carbethoxymethylene-6 b-oxido-oxymorphone acetate
MCV 4425 (NIH 10363)
See 7a-(1-Carboxyvinyl)-6 a -naltrexal lactone
MCV 4426 (NIH 10365; 17-cyclopropylmethyl-3,14-dihydroxy-4,5-epoxy-
7-methylenemorphinan hydrochloride)
See Nalmefene
MCV 4430 [NIH 7569; MCV 4501; UM 743; (-)-2'-Hydroxy-2,5,9a-trimethyl-
6,7-benzomorphan hydrobremide]
See (-)-Metazocine
MCV 4431 [NIH 7571; MCV 4502; UM 744; (+)-2'-Hydroxy-2,5,9a -
trimethyl-6,7-benzomolphan hydrobromide]
See (+)-Metazocine
MCV 4433 (NIH 10357)
See 17-Cyclopropylmethyl-3,14-dihydroxy-4,5a-epoxy-6ß-
fluoromorphinan hydrochloride
MCV 4434 (NIH 10368)
See (-)-2'-Methoxy-2-methyl-5,1'-methyleneoxy-9a -propyl-
6,7-benzomorphan hydrochloride
MCV 4435 (NIH 10369)
See (-)-2'-Hydroxy-2-methyl-5,1'-methyleneoxy-9a-propyl-
6,7-benzomorphan hydrochloride
MCV 4436 (NIH 10370)
See (-)-2'-Acetoxy-2-methyl-5,1'-methyleneoxy-9 a -propyl-
6,7-benzomorphan hydrochloride
MCV 4437 (NIH 10372)
See 2,2-Dimethyl-3-dimethylamino-7-hydroxy-1-tetralone hydrobromide
MCV 4438 (NIH 10093)
See 7a-Amino-6,14-endoethenotetrahydrooripavine, 412, 380
MCV 4457 (NIH 10385; MCV 2820; UM 118)
See 6-Dimethylamino-4,14-diphenylhexan-3-one hydrochloride
MCV 4458 (NIH 10386)
See 6-Dimethylamino-C(4-fluorophenyl)-4-phenylhexan-3-one
hydrochloride
MCV 4459 (NIH 10387)
See 6-Dimethylamino-4-(4-chlorophenyl)-4-phenylhexan-3-one
hydrochloride
MCV 4460 (NIH 10388)
See 6-Dimethylamino-4-(4-bromophenyl)-4-phenylhexan-3-one
hydrochloride
MCV 4462 (NIH 10393)
See 6-Dimethylamino-4-cyclohexyl-4-phenylhexan-3-one hydrochloride
MCV 4463 (NIH 10396)
See 6-Dimethylamino-4,4-(4,4’-difluoro)diphenylhexan-3-one
hydrochloride
MCV 44604 (NIH 10391)
See 6-Dimethylamino-4-(4-methylphenyl)-4-phenylhexan-3-one
hydrochloride
MCV 4467 (NIH 10389)
See 6-Dimethylamino-4-(4-methoxyphenyl)-4-phenylhexan-3-one
hydrochloride
MCV 4475 (NIH 10429)
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See L-Tryptophan tartrate
MCV 4448 (NIH 10384; 6-Succinylcodeine)
See Codeine succinate
MCV 4449 (NIH 7890; UM 426)
See Naloxone
MCV 4455 (NIH 10379)
See (-)-2-Allyl-2'-hydroxy-5,1'-methyleneoxy-9a-propyl-
6,7-benzomorphan hydrochloride
MCV 4456 (NIH 10380)
See (-)-2'-Hydroxy-5,1'-methyleneoxy-2-phenethyl-9 a-propyl-
6,7-benzomorphan hydrochloride
MCV 4465 (NIH 10331)
See (-)-N-Cyclopropylmethylmorphinan-6-one salicylate
MCV 4466 (NIH 10371)
See (-)-4,14-Dimethoxymorphinan-6-one hydrobromide
MCV 4473 (NIH 4591;UM380)
See Dextrorphan
MCV 4474 (NIH 4590; NIH 10123; UM 510)
See Levorphanol
MCV 4476 (NIH 10413)
See (-)-2-Methyl-5,1'-methyleneoxy-9 a -prpyl-6,7-benzomorpha
hydrochloride
MCV 4477 (NIH 10416)
See (-)-2,5-Dimethyl-1'-hydroxy-9a -propyl-6,7-benzomorphan
hydrochloride
MCV 4480 (NIH 8374; UM 696)
See (+)-2,9 a-Dimethyl-2'-hydroxy-5-propyl-6,7-benzomorphan
hydrochloride
MCV 4481 (NIH 10398)
See (-)-Eseroline
MCV 4482 (NIH 10408)
See (3S)-1,3-Dimethyl-3-(2-methylaminoethyl)-5-methoxyindoline
oxalate
MCV 4483 (NIH 10409)
See (3S)-1,3-Dimethyl-3-(2-dimethylaminoethyl)-5-methoxyindoline
oxalate
MCV 4484 (NIH 10421; physostigmine)
See (-)-Eserine
MCV 4485 (NIH 10422)
See (-)-Eseroline methylmethosulfate
MCV 4486 (NIH 10423)
See (3S)-1,3-Dimethyl-3-(2-dimethylaminoethyl)-5-hydroxyindoline
hydrochloride
MCV 4488 (NIH 10425)
See (3S)-1,3-Dimethyl-3-(2-methylaminoethyl)-5-hydroxyindoline
hydrochloride
MCV 4493 (NIH 10432)
See (±)-4-Phenyl-4-propionoxy-1,2,6-trimethylpiperidine hydrochloride
MCV 4494 (NIH 10433)
See (+)-4-Phenyl4propionoxy- 1,2,6-trimethylpiperidine hydrochloride
MCV 4495 (NIH 10434)
See (-)-4-Phenyl-4-propionoxy-1,2,6-trimethylpiperidine hydrochloride
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MCV 4501 [NIH 7569; MCV 4430; UM 743; (-)-2'-Hydroxy-2,5,9a-trimethyl-
6,7-benzomorphan hydrobromide]
See (-)-Metazocine
MCV 4502 [NIH 7571; MCV 4431; UM 744; (+)-2'-Hydroxy-2,5,9a-
trimethyl-6,7-benzomorphan hydrobromide]
See (+)-Metazocine
MCV 4503 (NIH 10440)
See N-(2-Carbethoxyethyl)-N-norketobemidone hydrobromide
MCV 4504 (NIH 104390)
See (+)-Eseroline sulfate
MCV 4510 [NIH 7981; (±)-2-Cyclopropylmethyl-5,9 a -dimethyl-2'-hydroxy-
6,7-benzomorphan]
See (±)-Cyclazocine
MCV 4511 (NIH 10449)
See (+)-Cyclazocine
MCV 4512 (NIH 10450)
See (-)-Cyclazocine
MCV 45 13 (NIH 1045 1)
See (-)-Ketocyclazocine
MCV 4515 (NIH 10452)
See (-)-Ethylketocyclazocine
MCV 4519 (NIH 10453)
See N-(Carboethoxypropyl)-N-norketobemidone oxalate
MCV 4521 (NIH 10455; NIH 10319; MCV 4400)
See N-Propargyl-N'-(3-trifluoromethylphenyl)piperazine hydrochloride
MCV 4522 (NIH 10456)
See (±)-cisS-Methylfentanyl hydrochloride
MCV 4523 (NIH 10457)
See (±)-trans-3-Methylfentanyl hydrochloride
MCV 4526 (NIH 8211)
See Cocaine hydrochloride
MCV 4527 (NIH 10460; PEPAP)
See 1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine
MCV 4528 (NIH 10461: MPPP)
See 1-Methyl-4-phenyl-4:propionoxypiperidine hydrochloride
MDA (3,4-methylenedioxyamphetamine)
effects on monoaminergic systems in rat brain, 316-321
effects on neurotensin and Substance P in rat basal ganglia, 74
MDMA (methylenedioxymethamphetamine, Ecstasy)
effects on brain-stimulation reward and detection thresholds, 78-79
effects on monoaminergic systems in rat brain, 316-321
effects on neurotensin and Substance P in rat basal ganglia, 74
Meperidine (NIH 5221)
mouse analgesia, 394, 452
Meprobamate
mouse analgesia, 394, 453
Meptazinol hydrochloride [m-(3-Ethyl-1-methylhexahydro-1H-azepine-3-yl)-
phenol hydrochloride; NIH 8683; MCV 4403; UM 888]
biological evaluation of dependence liability, 388
codeine discrimination study, 458
dependence studies in monkeys, 406-407, 457-459
dependence studies in rats, 407-411
depression of smooth muscle twitch, 457
499
displacement of stereospecific 3H-etorphine binding, 457
ethylketocyclazocine discrimination study, 458
mouse analgesia, 406, 457
use in postoperative pain, 168-174
Mescaline
mouse analgesia, 394, 453
Metabolism
in placenta, effect of drug addiction on, 86
(-)-Metazocine [NIH 7569; MCV 4430; MCV 4501; UM 743; (-)-2'-Hydroxy-
2,5,9a-trimethyl-6,7-benzomorphan hydrobromide]
biological evaluation of dependence liability, 383
dependence studies in rats, 401-402
mouse analgesia, 394, 452
(+)-Metazocine [NIH 7571; MCV 4431; MCV 4502; UM 744; (+)-2'-Hydroxy-
2,5,9a-trimethyl-6,7-benzomorphan hydrobromide]
biological evaluation of dependence liability, 383
mouse analgesia, 403
Methadone
effects of altered dose incentive procedures on polydrug use in methadone
patients, 162-167
effects of cocaine and d-amphetamine on pharmacological actions of,
302-308
effects on body temperature in rats, assessed by calorimetric analysis, 82
effects on neuroendocrine abnormalities in opiate addicts, 58
exposure to infants in utero, perinatal and developmental outcome, 276
influence on neonatal sleep patterns of infants born to opioid-addicted
mothers, 274
mortality rate and incidence of AIDS in methadone patients, 94
perinatal morbidity and mortality in infants exposed to methadone in
utero, 278
treatment effectiveness of medical staff and services in methadone
programs, 175-181
use in treatment of opiate addiction, 55-58
Methamphetamine
effects on monoaminergic systems in rat brain, 316-321
Methaqualone
contribution of personality variables to subjective effects, 80
(-)-2'-Methoxy-2-metyl-5,1'-methyleneoxy-9 a-propyl-6,7-benzomorpha
hydrochloride (NIH 10368; MCV 4434)
biological evaluation of dependence liability, 385
depression of smooth muscle twitch, 474
displacement of stereospecific 3H-etorphine binding, 474
mouse analgesia, 428,474
3,4-Methylenedioxyamphetamine (MDA)
effects on neurotensin and Substance P in rat basal ganglia, 74
Methylenedioxymethamphetamine (MDMA, Ecstasy)
effects on brain-stimulation reward and detection thresholds, 78-79
effects on neurotensin and Substance P in rat basal ganglia, 74
(±)-cis-3-Methylfentanyl hydrochloride (NIH: 10456; MCV 4522)
biological evaluation of dependence liability, 387
dependence studies in monkeys, 443-444
depression of smooth muscle twitch, 480
displacement of stereospecific 3H-etorphine binding, 480
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mouse analgesia, 443, 480
(±)-trans-3-Methylfentanyl hydrochloride (NIH 10457; MCV 4523)
biological evaluation of dependence liability, 387
dependence studies in monkeys, 444-445
depression of smooth muscle twitch, 481
displacement of stereospecific 3H-etorphine binding, 481
mouse analgesia, 444,480
2-(3-Methylfurfuryl)-2'-hydroxy-5,9 a-dimethyl-6,7-benzomorphan methane
sulfanate (UM 911)
depression of smooth muscle twitch, 454
(-)-2-Methyl-5,1'-methyleneoxy-9 a-propyl-6,7-benzomorphan hydrochloride
(NIH 10413; MCV 4476)
biological evaluation for dependence liability, 385
mouse analgesia, 435
Methylnaloxonium hydrochloride
effect on heroin self administration, 49-50
1-Methyl-4-phenyl-4-propionoxypiperidine hydrochloride (NIH 10461; MCV
4528; MPPP)
biological evaluation of dependence liability, 387
dependence studies in monkeys, 447
depression of smooth muscle twitch, 483
displacement of stereospecific 3H-etorphine binding, 482
mouse analgesia, 446,482
N-a-Methyl-L-tyrosyl-D-alanylglycyl-N- a -cyclopropylmethyl-L-m-bromo-
phenylalanine amide acetate (NIH 9950)
biological evaluation of dependence liability, 388
depression of smooth muscle twitch, 464
displacement of stereospecific 3H-etorphine binding, 464
mouse analgesia, 464
N-a -Methyl-L-tyrosyl-D-alanylglycyl-N- a-ethyl-L-p -fluorophenyl amide
acetate (NIH 9949)
biological evaluation of dependence liability, 388
depression of smooth muscle twitch, 465-466
displacement of stereospecific 3H-etorphine binding, 465
mouse analgesia, 464
Midazolam
evaluation of discriminative stimulus properties of antihistamines in
midazolam-trained pigeons, 214-220
dependence studies in the rat, 90
Mood states
elicit withdrawal in opiate addicts, 137-144
Morphine (NIH 0001; NIH 9929)
antinociception in the chronic spinal rat, 69
effects on body temperature in rats, assessed by calorimetric analysis, 82
effects on the immune system in vivo, 341-348
evaluation of agonistic activity in the isolated, electrically stimulated
mouse vas deferens, 288-294
depression of smooth muscle twitch, 454
development of dependence, 47
development of tolerance, 20-28
mouse analgesia, 393, 394, 452
potentiation of pentobarbital sleeping times, 233-239
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subjective, physiologic and discriminative effects in drug abusers, 77
use in postoperative pain, 168-174
Morpholinobutryl-D8-tetrahydrocannabinol
pharmacological and radioligand binding studies of, 72
MPPP (NIH 10461; MCV 4528)
See 1-Methyl-4-phenyl-4-propionoxypiperidine hydrochloride
Mr-2033 [(±)-5,9a-Dimethyl-2'-hydroxy-2-tetrahydrofufuryl-6,7-
benzomorphan]
evaluation of agonistic activity in the isolated, electrically stimulated
mouse vas deferens, 288-294
Nalbuphine hydrochloride (NIH 10274; NIH 8359; MCV 4385; UM 686)
biological evaluation of dependence liability, 380
dependence studies in monkeys, 414
mouse analgesia, 414
Nahnefene (NIH 10365; MCV 4426; 17-Cyclopropylmethyl-3,14-dihydroxy-
4,5-epoxy-7-methylenemorphinan hydrochloride)
biological evaluation of dependence liability, 380
dependence studies in monkeys, 425-427
mouse analgesia, 425
Nalorphine (NIH 2105; NIH 10124; MCV 4336; UM 1411)
mouse analgesia, 393, 394, 412, 453
Naloxone (NIH 7980; MCV 4449; UM 426)
effect on abuse liability of buprenorphine, 145-149
effects on cocaine inhibition of locus coeruleus neurons, 336-337
interaction with T-lymphocytes, 83
mouse analgesia, 393, 394, 453
reversal of morphine-induced effects on the immune system, 341-348
subjective, physiologic and discriminative effects in drug abusers, 77
Naltrexone (NIH 8503; NIH 9930; MCV 4002; UM 1312)
depression of smooth muscle twitch, 454
evaluation of antagonistic activity in the isolated, electrically stimulated
mouse vas deferens, 288-294
mouse analgesia, 393, 394, 453
stimulation of neuroendccrine function in women, effects of alcohol on,
116-123
Nathan B. Eddy Memorial Award
introduction of recipient, 7-8
Nathan B. Eddy Memorial Award Lecture, 9-19
Neuroendocrine function
methadone-induced changes in opioid addicts, 58
Neurotensin Methylenedioxymethamphetamine (MDMA, ecstasy)
effects of MDMA and MDA on neurotensin in rat basal ganglia, 74
Nicotine
effect of chronic exposure on water intake, body weight, blood pressure
and behavior in rat, 327-333
NIH 0001 (NIH 9929)
See Morphine sulfate, 393, 394, 452, 454
NIH0002
See Codeine phosphate, 394, 452
NIH 0123
See Dihydromorphinone, 394, 453
NIH 2105 (NIH 10124; MCV 4336; UM 1411)
See Nalorphine, 393, 394, 412, 453
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NIH 4590 (NIH 10123; MCV 4474; UM 510)
See Levorphanol, 394, 452
NIH 4591 (MCV 4473; UM 380)
See Dextrorphan, 454
NIH 5221
See Meperidine, 394, 452
NIH 7569 [MCV 4430; MCV 4501; UM 743; (-)-2'-Hydroxy-2,5,9a-trimethyl-
6,7-benzomorphan hydrobromide]
See (-)-Metazocine, 383, 394, 401-402, 452
NIH 7571 [MCV 4431; MCV 4502; UM 744; (+)-2'-Hydroxy-2,5,9 a -
trimethyl-6,7benzomorphan hydrobromide]
See (+)-Metazocine, 383, 403
NIH 7890 (MCV 4449; UM 426)
See Naloxone, 393, 394, 453
NIH 7958 (MCV 4268; UM 381)
See Pentazocine, 393, 394, 453
NIH 7980
See Naloxone, 393, 394, 453
NIH 7981 MCV 4510; (±)-2-Cyclopropylmethyl-5,9a-d imethyl-2 ' -hydroxy-
6,7-benzomorphan]
See (±)-Cyclazocine, 383, 393, 394, 404, 453
NIH 8211 (MCV 4526)
See Cocaine hydrochloride, 388, 404, 405
NIH 8359 (NIH 10274; MCV 4385; UM 686)
See Nalbuphine hydrochloride, 380, 414
NIH 8374 (MCV 4480; UM 696)
See (+)-2,9 a-Dimethyl-2’-hydroxy-5-propy1-6,7-benzomorphan
hydrochloride, 383, 406
NIH 8503 (NIH 9930; MCV 4002; UM 1312)
See Naltrexone, 393, 394, 453, 454
NIH 8683[MCV 4403; UM 888; m- (3-Ethyl - l -methylhexahydro-1H-
azepine-3-yl)phenol hydrochloride]
See Meptazinol hydrochloride, 388, 406-411, 457-459
NIH 8791 (NIH 10275; MCV 4386; UM 941)
See Butorphanol tartrate, 382, 415, 416
NIH 8847 (NIH 10364; MCV 4414; UM 974)
See (±)-Ketocyclazocine, 384, 421, 454
NIH 8848 [NIH 10165; MCV 4348; UM 975; (±)-2-Cyclopropylmethyl-
5-e thy l-8-oxo-9a -methyl-6,7-benzomorphan methane sulfonate]
See Ethylketocyclazocine, 384, 412
NIH 9625
See 1-[(2a , 6a ,11S)-(±)-1-(1,2,3,4,5,6-Hexahydro-8-hydroxy-3,6,11-
trimethyl-2,6-methano-3-benzazocin-11-yl)]-6-methyl-3-heptanone
methanesulfonate, 384, 460
NIH 9929 (NIH 0001)
See Morphine sulfate, 393, 394, 452, 454
NIH 9930 (NIH 8503; MCV 4002; UM 1312)
See Naltrexone, 393, 394, 453, 454
NIH 9931
See (-)-N-Cyclopropylmethy1-4-methoxymorphinan-6-one, 382, 460
NIH 9935
See 1-Bromo-4-hydroxy-6-keto-N-methylmorphinan hydrobromide,
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382, 461
NIH 9947
See L-Tyrosyl-D-alanylglycyl-L-4-fluorophenylalanyl-L-
phenylglycinamide acetate, 388, 462
NIH 9948
See L-Tyrosyl-D-alanylglycyl-N-a-ethyl-L- m -bromophenylalanine amide
acetate, 388, 463
NIH 9949
See N-a-Methyl-L-tyrosyl-D-alanylglycyl-N- a -ethyl-L- p
fluorophenylalanine amide acetate, 388, 464-466
NIH 9955
See (±)-2,9a-Dimethyl-5-( m-hydroxyphenyl)morphan hydrochloride,
382,466
NIH 10036 (UM 1399)
See 1,2,3,4,5,6-Hexahydro-9-methoxy-1,6-methano-3-benzazocine
oxalate, 389, 467, 468
NIH 10093 (MCV 4438)
See 7a-Amino-6,14-endoethenotetrahydrooripavine, 380, 412
NIH 10123 (NIH 4590; MCV 4474; UM 510)
See Levorphanol, 394, 452
NIH 10124 (NIH 2105; MCV 4336; UM 1411)
See Nalorphine, 393, 394, 412, 453
NIH 10157 (MCV 4349)
See 2'-Hydroxy-5-methyl-9a -(3-methyl)butyl-2-phenethyl-6,7-
benzomorphan, 383, 468
NIH 10158
See 2'-Hydroxy-5-methyl-9 a-(3-methyl)butyl-2-propyl-6,7-
benzomorphan, 383, 468, 469
NIH 10165 [NIH 8848; MCV 4348; UM 975; (±)-2-Cyclopropylmethyl-
5-ethyl-8-oxo-9a -methyl-6,7-benzomorphan methane sulfonate]
See (±)-Ethylketocyclazocine, 384, 412
NIH 10249 (MCV 4388)
See N-(2,3-Epoxypropyl)normetazocine, 383, 413
NIH 10253 (MCV 4389)
See N-(N-Phenylguanidino)-5,9-dimethyl-6,7-benzomorphan
hydrochloride, 384, 413
NIH 10258 (MCV 4390)
See 3-(N-Propionyl)anilinoquinuclidine hydrochloride, 390, 413
NIH 10274 (NIH 8359; MCV 4385; UM 686)
See Nalbuphine hydrochloride, 380, 414
NIH 10275 (NIH 8791; MCV 4386; UM 941)
See Butorphanol tartrate, 382, 415, 416
NIH 10319 (NIH 10455; MCV 4400; MCV 4521)
See N-Propargyl-N’-(3-trifluoromethylphenyl)piperazine hydrochloride,
390, 416-417, 442-443, 469-470
NIH 10322 (MCV 4404)
See 6a-(2-Carboxy-1-propenyl)-naltrex-6 b -ol-g -lactone, 381, 417
NIH 10324 (MCV 4408)
See 6a-(2-Carboxy-1-propenyl)-oxymorph-6 b -ol-g -lactone, 381, 418
NIH 10331 (MCV 4465)
See (-)-N-Cyclopropylmethylmorphinan-6-one salicylate, 382, 418
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NIH 10333 (MCV 4409)
See (±)-7-Chloro-3-dimethylamino-1-methyl-3,4-dihydrocarbostyril
hydrochloride, 389, 418, 419, 470
NIH 10334 (MCV 4410)
See (-)-7-Chloro-3-dimetylamino-1-methyl-3,4-dihydrocarbostyril
hydrochloride, 389, 420, 471
NIH 10335 (MCV 4411)
See (+)-7-Chloro-3-dimetylamino-1-methyl-3,4-dihydrocarbostyril
hydrochloride, 389, 420, 471, 472
NIH 10347 (MCV 4417)
See 2-Benzyl-3-phenyl-D2,3-quinuclidine hydrochloride, 390, 421
NIH 10348 (MCV 4418)
See (-)-9a-(2-Carbethoxyethyl)-2'-methoxy-2-methyl-5,1'-
methyleneoxy-6,7-benzomorphan hydrochloride, 385, 421
NIH 10349 (MCV 4419)
See (-)-9a-(3-Hydroxypropyl)-2'-methoxy-2-methyl-5,1'-
methyleneoxy-6,7-benzomorphan hydrochloride, 385, 422
NIH 10357 (MCV 4433)
See 17-Cyclopropylmethyl-3,14-dihydroxy-4,5 a -epoxy-6b-
fluoromorphinan hydrochloride, 380, 422, 423
NIH 10362 (MCV 4422)
See 2-Benzyl-3-phenyl-3-acetoxyquinuclidine hydrochloride, 390, 423
NIH 10363 (MCV 4425)
See 7a -(1-Carboxyvinyl)-6 a-naltrexal lactone, 381, 424, 425, 472
NIH 10364; NIH 8847; MCV 4414; UM 974)
See (±)-Ketocyclazocine, 384, 421, 454
NIH 10365 (MCV 4426; 17-cyclopropylmethyl-3,14-dihydroxy-4,5-epoxy-
7-methylenemorphinan hydrochloride)
See Nalmefene, 380, 425-427
NIH 10366 (MCV 4423)
See E-6-Carboethoxymethylene-6/3-oxido-oxymorphone, 381, 428, 472,
473
NIH 10367 (MCV 4424)
See Z-6-Carboethoxymethylene-6p-oxido-oxymorphone acetate, 381,
428, 473, 474
NIH 10368 (MCV 4434)
See (-)-2'-Methoxy-2-methyl-5,1'-methyleneoxy-9 a -propyl-
6,7-benzomorphan hydrochloride, 385, 428, 474
NIH 10369 (MCV 4435)
See (-)-2'-Hydroxy-2-methyl-5,1'-methyleneoxy-9 a -propyl-
6,7-benzomorphan hydrochloride, 385, 429, 475
NIH 10370 (MCV 4436)
See (-)-2'-Acetoxy-2-methyl-5,1'-methyleneoxy-9a-propyl-
6,7-benzomorphan hydrochloride, 385, 429, 476
NIH 10371 (MCV 4466)
See (-)-4,14-Dimethoxymorphinan-6-one hydrobromide, 382, 429
NIH 10372 (MCV 4437)
See 2,2-Dimethyl-3-dimethylamino-7-hydroxy-1-tetralone
hydrobromide, 389, 430
NIH 10379 (MCV 4455)
See (-)-2-Allyl-2'-hydroxy-5,1'-methyleneoxy-9 a -propyl-
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6,7-benzomorphan hydrochloride, 385, 431
NIH 10380 (MCV 4456)
See (-)-2'-Hydroxy-5,1’-methyleneoxy-2-phenethyl-9 a-propyl-
6,7-benzomorphan hydrochloride, 385, 431
NIH 10384 (MCV 4448; 6-Succinylcodeine)
See Codeine succinate, 380, 477
NIH 10385 (MCV 2820; MCV 4457; UM 118)
See 6-Dimethylamino-4,14-diphenylhexan-3-one hydrochloride,
386,431
NIH 10386 (MCV 4458)
See 6-Dimethylamino-4-(4-fluorophenyl)-4-phenylhexan-3-one
hydrochloride, 386, 432
NIH 10387 (MCV 4459)
See 6-Dimethylamino-4-(4-chlorophenyl)-4-phenylhexan-3-one
hydrochloride, 386, 432
NIH 10388 (MCV 4460)
See 6-Dimethylamino-4-(4-bromophenyl)-4-phenylhexan-3-one
hydrochloride, 386, 432
NIH 10389 (MCV 4467)
See 6-Dimethylamino4(4-methoxyphenyl)-4-phenylhexan-3-one
hydrochloride, 386, 433
NIH 10391 (MCV 4464)
See 6-Dimethylamino-4-(4-methylphenyl)4phenylhexan-3-one
hydrochloride, 386, 433
NIH 10393 (MCV 4462)
See 6-Dimethylaminwl-cyclohexyl-4-phenylhexan-3-one hydrochloride,
386, 433
NIH 10396 (MCV 4463)
See 6-Dimethylamino-4,4-(4,4’-difluoro)diphenylhexan-3-one
hydrochloride, 386, 434
NIH 10398 (MCV 4481)
See (-)-Eseroline, 391, 434
NIH 10408 (MCV 4482)
See (3S)-1,3-Dimethyl-3-(2-methylaminoethyl)-5-methoxyindoline
oxalate, 391, 434
NIH 10409 (MCV 4483)
See (3S)-1,3-Dimethyl-3-(2-dimethylaminoethy1)-5-methoxyindoline
oxalate, 391, 435
NIH 10413 (MCV 4476)
See (-)-2-Methyl-5,1'-methyleneoxy-9a-prpyl-6,7-benzomorpha
hydrochloride, 385, 435
NIH 10416 (MCV 4477)
See (-)-2,5-Dimethyl-1’-hydroxy-9 a-propyl-6,7-benzomorphan
hydrochloride, 384, 435
NIH 10421 (MCV 4484; Physostigmine)
See (-)-Eserine, 391, 436
NIH 10422 (MCV 4485)
See (-)-Eseroline methyhnethosulfate, 391, 436
NIH 10423 (MCV 4486)
See (3S)-1,3-Dimethyl-3-(2dimethylaminoethyl)-5-hydroxyindoline
hydrochloride, 391, 436
NIH 10425 (MCV 4488)
See (3S)-1,3-Dimethyl-3-(2-methylaminoethyl)-5-hydroxyindoline
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hydrochloride, 391, 437
NIH 10429 (MCV 4475)
See L-Tryptophan tartrate, 391, 437, 438
NlH 10432 (MCV 4493)
See (±)-4-Phenyl-4-propionoxy-1,2,6-trimethylpiperidine hydrochloride,
NIH 10433 (MCV 4494)
See (+)-4-Phenyl-4-propionoxy-1,2,6-trimethylpiperidine hydrochloride,
387, 439
NIH 10434 (MCV 4495)
See (-)-4-Phenyl-4-propionoxy-1,2,6-trimetbylpiperidine hydrochloride,
387, 439
NIH 10439 (MCV 4504)
See (+)-Eseroline sulfate, 391, 439
NIH 10440 (MCV 4503)
See N-(2-Carbethoxyethyl)-N-norketobemidone hydrobromide, 387,
440, 477, 478
NIH 10449 (MCV 4511)
See (+)-Cyclazocine, 383, 440
NIH 10450 (MCV 4512)
See (-)-Cyclazocine, 383, 440, 454
NIH 10451 (MCV 4513)
See (-)-Ketocyclazocine, 384, 441
NIH 10452 (MCV 4515)
See (-)-Ethylketocyclazocine, 384, 441
NIH 10453 (MCV 45 19)
See N-(Carboethoxypropyl)-N-norketobemidone oxalate, 387, 441, 478
NIH 10454 (MCV 4520)
See N-(Carboethoxymethyl)-N-norketobemidone oxalate, 387, 442, 479
NIH 10455 (NIH 10319; MCV 4400; MCV 4521)
See N-Propargyl-N'-(3-trifluoromethylphenyl)piperazine hydrochloride,
390, 416-417, 442-443, 469-470
NIH 10456 (MCV 4522)
See (±)-cis-3-Methylfentanyl hydrochloride, 387, 443, 444, 480
NIH 10457 (MCV 4523)
See (±)-truns-3-Methylfentanyl hydrochloride, 387, 444, 445, 480, 481,
NIH 10460 (MCV 4527; PEPAP)
See 1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine, 387, 445, 446,
481, 482
NIH 10461 (MCV 4528; MPPP)
See 1-Methyl-4-phenyl-4-propionoxypiperidine hydrochloride, 387,
446, 447, 482, 483
Opioids
dependence syndrome, 255-258
evaluation of agonistic and antagonistic activity in the isolated, electrically
stimulated mouse vas deferens, 288-294
extinction of conditioned responses in users, 189-195
influence of pentobarbital and methadone on neonatal sleep patterns of
infants born to opioid-addicted mothers, 274
mechanism for tolerance and dependence, 63-68
methadone in treatment of addiction, 55-58
mood states elicit withdrawal in addicts, 137-144
social support and relapse to use of, 207-213
receptor heterogeneity and isolation, 35-41
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receptors in human placenta, effect of cocaine on, 277
relevance of tolerance for clinical practice, 29-34
role of endorphins in addiction to, 59
role of neural substrates in development of dependence and tolerance to,
46-52
role of spinal cord in development of tolerance and dependence, 42-45
source of income as a predictor of addiction, 196-199
Oxazepam
mouse analgesia, 394, 453
Patient-controlled analgesia
as an effective treatment modality, 32
D-Pen-D-pen-enkephalin
See DPDPE
Pentazocine (NIH 7958; MCV 4268; UM 381)
comparison of pharmacological profile to flupirtine, 85
drug discrimination studies with flupirtine, 84
mouse analgesia, 393, 394, 453
Pentobarbital
genetic differences in the development of physical dependence to, 91
influence on neonatal sleep patterns of infants born to opioid-addicted
mothers, 274
morphine potentiation of sleeping times, 233-239
Pentylenetetrazol discrimination
a sensitive assay for diazepam withdrawal, 76
PEPAP (NIH 10460; MCV 4527)
See 1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine
D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH2 (CPT)
precipitates withdrawal in morphine-dependent mice, 195-301
Phenobarbital
mouse analgesia, 394, 453
1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine (NIH 10460; MCV 4527;
PEPAP)
biological evaluation of dependence liability, 387
dependence studies in monkeys, 445-446
depression of smooth muscle twitch, 482
displacement of stereospecific 3H-etorphine binding, 48 1
mouse analeesia. 445, 481
N-(N-Phenylguanidino)-5,9-dimethyl-6,7-benzomorphan hydrochloride (NIH
10253: MCV 4389)
biological evaluation of dependence liability, 384
mouse analgesia, 413
(±)-4-Phenyl-4-propionoxy-1,2,6-trimethylpiperidine hydrochloride (NIH
10432. MCV 4493)
biological evaluation of dependence liability, 387
mouse analgesia. 438
(+)-4-Phenyl-4-propionoxy-1,2,6-trimethylpiperidine hydrochloride (NIH
10433. MCV 4494)
biological evaluation of dependence liability, 387
mouse analgesia, 439
(-)-4-Phenyl-4-propionoxy-1,2,6-trimethylpiperidine hydrochloride (NIH
10434, MCV 4495)
biological evaluation of dependence liability, 387
mouse analgesia, 439
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Physostigmine (NIH 10421; MCV 4484)
See (-)-Eserine
Piperoxane
effects on cocaine inhibition of locus coeruleus neurons, 336-337
Placenta
effect of drug addiction on xenobiotic metabolism in, 86
placental transfer of cannabinoids in monkeys near term, 88
Postoperative pain
comparison of meptazinol and morphine in, 168-174
Procaine
effects on locus coeruleus neurons, 334-340
effects on reinforcing brain stimulation, 92
Progesterone
effects of alcohol and naltrexone on levels in women, 116-123
Prolactin
effects of alcohol and nahrexone on levels in women, 116-123
effects of methadone on abnormalities in opiate addicts, 58
Promethazine
discriminative stimulus properties in d-amphetamine- and
midazolam-trained pigeons, 214-220
N-Propargyl-N’-(3-trifluoromethylphenyl)piperazine hydrochloride (NIH
10319; NIH 10455; MCV 4400; MCV 4521)
biological evaluation of dependence liability, 390
dependence studies in monkeys, 416-417, 442-443, 469-470
mouse analgesia, 416, 442, 469
3-(N-Propionyl)anilinoquinuclidine hydrochloride (NIH 10258; MCV 4390)
biological evaluation of dependence liability, 390
mouse analgesia, 413
Pyrilamine
discriminative stimulus properties in d-amphetamine- and
midazolam-trained pigeons, 214-220
Resuscitation
of infants born to drug-dependent women, 70
SKF 10047
See N-Allylnormetazocine
Split-like ventricles
incidence in infants born to addicts, 87
Substance P
effects of MDMA and MDA on Substance P in rat basal ganglia, 74
6-Succinylcodeine (NIH 10384; MCV 4448)
See Codeine succinate
Sufentanil
evaluation of agonistic activity in the isolated, electrically stimulated
mouse vas deferens, 288-294
doses used in cardiac surgery, 31
Testosterone
effects of methadone on abnormalities in opiate addicts, 58
D9-Tetrahydrocannabinol
effects on discrimination of speech sounds in the baboon, 226-232
effects on maternal nutrition, offspring growth and behavior, 363-369
placental transfer in monkeys near term, 88
Tetrahydrocannabinols
pharmacological and radioligand binding studies of water-soluble
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derivatives, 72
Tifluadom
evaluation of agonistic activity in the isolated, electrically stimulated
mouse vas deferens, 288-294
T-lymphocytes
interaction with naloxone, 83
Tobacco
carbon monoxide as a marker for assessing and treating tobacco
dependence in pulmonary disease, 73
effect of cigarette rod length on smoking topography, 93
social support and relapse to use of, 207-213
See also Cigarettes
Tolerance
mechanism for development of opioid tolerance, 63-68
implications for the pharmacological treatment of addiction, 53-62
relevance for clinical practice, 29-34
role of neural substrates in development of opioid tolerance, 46-52
role of spinal cord in development of opiate tolerance, 42-45
significance for drug and alcohol dependence, 9-19
to morphine, 20-28
Tramadol
drug discrimination studies with flupirtine, 84
5'-Trimethylammonium- D 8-tetrahydrocannabinol phenolate
pharmacological and radioligand binding studies of, 72
Tripelennamine
discriminative stimulus properties in d-amphetamine- and
midazolam-trained pigeons, 214-220
potentiation of opioid reinforcement, involvement of histamine, 92
L-Tryptophan tartrate (NIH 10429; MCV 4475)
biological evaluation of dependence liability, 391
dependence studies in monkeys, 431-438
mouse analgesia, 437
T’s and Blues
See Tripelennamine, 92
Tyr-D-Ala-Gly-MePhe-Met-(O)-ol
See FK-33824
Tyr-D-Ala-Gly-4-F-Phe-phenylglycinamide acetate
See LY-123502
L-Tyrosyl-D-alanylglycyl-N- a-ethyl-L- m-bromophenylalanine amide acetate
(NIH 9948)
biological evaluation of dependence liability, 388
depression of smooth muscle twitch, 463
displacement of stereospecific 3H-etorphine binding, 463
mouse analgesia, 463
L-Tyrosyl-D-alanylglycyl-L-4-fluorophenylalanyl-L-phenylglycinamidea acetate
(NIH 9947)
biological evaluation of dependence liability, 388
depression of smooth muscle twitch, 462
displacement of stereospecific 3H-etorphine binding, 462
mouse analgesia, 462
Tyr-D-Ser-Gly-Phe-Leu-Thr
See DSLET
U50,488H [trans-3,4-Dichloro-N-methyl-N(2-(1-pyrrolidinyl)cyclohexyl)-
510
benzeneacetamide methanesulfonate hydrate]
effects on body temperature in rats, assessed by calorimetric analysis, 82
evaluation of agonistic activity in the isolated, electrically stimulated
mouse vas deferens, 288-294
UM 380 (NIH 4591; MCV 4473)
See Dextrorphan
UM 118 (NIH 10385; MCV 2820; MCV 4457)
See 6-Dimethylamino-4,14-diphenylhexan-3-one hydrochloride
UM 381 (NIH 7958; MCV 4268)
See Pentazocine
UM 426 (NIH 7890; MCV 4449)
See Naloxone
UM 510 (NIH 4590; NIH 10123; MCV 4474)
See Levorphanol
UM 686 (NIH 8359; NIH 10274; MCV 4385)
See Nalbuphine hydrochloride
UM 696 (NIH 8374; MCV 4480)
See (+)-2,9a-Dimethyl-2’-hydroxy-5-propyl-6,7-benzomorphan
hydrochloride
UM 743 [NIH 7569; MCV 4430; MCV 4501; (-)-2’-Hydroxy-2,5,9a -trimethyl-
6,7-benzomorphan hydrobromide]
See (-)-Metazocine
UM 744 [NIH 7571; MCV 4431; MCV 4502; (+)-2’-Hydroxy-2,5,9 a-
trimethyl-6,7-benzomorphan hydrobromide]
See (+)-Metazocine
UM 888 [NIH 8683; MCV 4403; m-(3-Ethyl-l-methylhexahydro-1H-
azepine-3-yl)phenol hydrochloride]
See Meptazinol hydrochloride
UM 941 (NIH 8791; NIH 10275; MCV 4386)
See Butorphanol tartrate
UM 974 (NIH8847; NIH10364; MCV4414)
See (±)-Ketocyclazocine
UM 975 [NIH 8848; NIH 10165; MCV 4348; (±)-2-Cyclopropylmethyl-
5-ethyl-8-oxo-9 a -methyl-6,7-benzomorphan methane sulfonate]
See Ethylketocyclazocine
UM 1071R
See 1R-5R-9R-2"R-5,9-Dimethyl-2’-hydroxy-2-tetrahydrofurfury1-6,7-
benzomorphan hydrochloride
UM 1312 (NIH 8503; NIH 9930; MCV 4002)
See Naltrexone
UM 1399 (NIH 10036)
See 1,2,3,4,5,6-Hexahydro-9-methoxy-1,6-methano-3-benzazocine
oxalate
UM 1411 (NIH 2105; NIH 10124; MCV 4336)
See Nalorphipe
Valium
See Diazepam
Withdrawal
buprenorphine precipitation of withdrawal in addicts, 182-188
precipitated by butorphanol in opioid-dependent humans, 157-161
precipitated by mood states in opiate addicts, 137-144
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